In O
the O
8 O
patients O
the O
difference O
betweent O
he O
mean O
diastolic O
values O
of O
delta O
PU O
and O
delta O
PM O
was O
- O
0 O
. O
54 O
+ O
/ O
- O
1 O
. O
0 O
( O
SD O
) O
mmHg O
. O

The O
biochemistry O
of O
amniotic O
fluid O
with O
poor O
fetal O
growth O
. O

Resistance O
to O
the O
simulated O
physiologic O
environment O
was O
tested O
by O
measured O
retention O
of O
mechanical O
properties O
after O
immersion O
times O
in O
pseudo O
- O
extracellular O
fluid O
( O
PECF O
) O
at O
37 O
degrees O
C O
for O
as O
long O
as O
three O
years O
. O

This O
expression O
assumes O
: O
( O
1 O
) O
a O
laminar O
flow O
regimen O
during O
expiration O
, O
and O
( O
2 O
) O
a O
constant O
CT O
value O
over O
the O
range O
of O
VT O
. O

Their O
conduction O
velocity O
ranged O
from O
0 O
. O
23 O
to O
0 O
. O
98 O
m O
/ O
sec O
( O
group O
C O
) O
. O

The O
major O
urinary O
metabolites O
were O
3 O
- O
( O
3 O
- O
carboxyphenyl O
) O
- O
5 O
- O
hydroxymethyl O
- O
2 O
- O
oxazolidinone O
and O
a O
glucuronide O
of O
toloxatone O
. O

The O
ventilation O
did O
not O
increase O
when O
PACO2 O
was O
increased O
. O

Changes O
of O
thirtynine O
serum O
protein O
components O
following O
surgical O
stress O
. O

These O
differences O
are O
smaller O
than O
those O
described O
in O
standard O
textbooks O
. O

The O
present O
study O
examined O
the O
dependence O
of O
difference O
tone O
level O
[ O
L O
( O
f2 O
- O
f1 O
) O
] O
on O
the O
following O
parameters O
of O
the O
two O
- O
tone O
input O
: O
f1 O
, O
f2 O
/ O
f1 O
( O
f2 O
greater O
than O
f1 O
) O
, O
L1 O
, O
L2 O
, O
and O
L1 O
= O
L2 O
. O

With O
certain O
exceptions O
the O
method O
was O
considered O
suitable O
in O
the O
routine O
intravenous O
cholangiography O
. O

Delayed O
mortality O
of O
mice O
following O
inhalation O
of O
acute O
doses O
of O
CH2O O
, O
SO2Cl2 O
, O
and O
Br2 O
. O

Guinea O
pigs O
weighing O
300 O
approximately O
350 O
g O
were O
used O
. O

None O
of O
the O
cystometrograms O
showed O
uninhibited O
detrusor O
contractions O
. O

Treatment O
of O
Graves O
' O
disease O
. O

Allergic O
reaction O
to O
Patent O
Blue O
Violet O
during O
lymphography O
. O

One O
- O
third O
of O
the O
men O
with O
azoospermia O
and O
with O
sperm O
density O
of O
less O
than O
10 O
million O
had O
marked O
FSH B-GENE
elevation O
and O
our O
experience O
confirms O
the O
work O
of O
others O
that O
this O
indicates O
a O
poor O
prognosis O
. O

It O
was O
concluded O
that O
both O
of O
these O
surgical O
procedures O
were O
as O
effective O
as O
pinealectomy O
in O
reversing O
the O
pineal O
- O
induced O
alterations O
in O
the O
reproductive O
physiology O
of O
the O
blind O
- O
anosmic O
female O
rat O
. O

This O
implies O
that O
the O
groups O
do O
not O
just O
differ O
along O
one O
dimension O
, O
but O
along O
three O
dimensions O
. O

Deep O
tans O
were O
induced O
over O
the O
backs O
of O
volunteers O
with O
repeated O
exposure O
to O
longwave O
ultraviolet O
radiation O
( O
UV O
- O
A O
) O
. O

Elimination O
of O
bagassosis O
in O
Louisiana O
paper O
manufacturing O
plant O
workers O
. O

Evaluation O
of O
the O
Du O
Pont O
aca O
ammonia O
procedure O
. O

2 O
) O
The O
time O
- O
sharing O
principle O
was O
applied O
to O
gain O
high O
stability O
. O

In O
three O
of O
the O
seven O
, O
inhalation O
of O
2 O
ml O
normal O
saline O
produced O
FEV1 O
falls O
of O
25 O
% O
to O
30 O
% O
, O
but O
these O
falls O
were O
not O
as O
great O
as O
each O
subject O
' O
s O
reactions O
to O
the O
test O
solutions O
. O

Potency O
of O
enflurane O
in O
dogs O
: O
comparison O
with O
halothane O
and O
isoflurane O
. O

Measurement O
of O
magnesium O
absorption O
in O
man O
using O
stable O
26Mg O
as O
a O
tracer O
. O

Female O
mice O
were O
significantly O
more O
resistant O
to O
infection O
than O
males O
. O

During O
the O
following O
9 O
1 O
/ O
2 O
years O
three O
sequential O
liver O
biopsies O
were O
performed O
. O

Thromboplastic O
and O
fibrynolytic O
activity O
of O
the O
blood O
after O
administration O
of O
intralipid O
in O
men O
with O
history O
of O
myocardial O
infarction O
up O
to O
45 O
year O
of O
life O

The O
authors O
report O
the O
clinicopathologic O
findings O
in O
four O
cases O
of O
adult O
women O
with O
rhabdomyosarcomas O
that O
originated O
in O
the O
endometrium O
or O
cervix O
, O
or O
both O
. O

Urine O
antibodies O
could O
not O
be O
demonstrated O
in O
any O
other O
cases O
. O

99mTc O
phytate O
, O
198Au O
colloid O
, O
and O
99mTc O
antimony O
sulfide O
have O
been O
used O
; O
the O
last O
appears O
to O
have O
been O
the O
most O
satisfactory O
. O

A O
suspected O
hypothalamic O
dysfunction O
and O
a O
slightly O
impaired O
pituitary O
function O
manifested O
as O
GH B-GENE
deficiency O
were O
their O
common O
endocrinological O
features O
. O

A O
one O
- O
way O
analysis O
of O
variance O
, O
performed O
separately O
for O
men O
and O
women O
for O
differences O
among O
the O
three O
phobic O
groups O
on O
field O
dependence O
, O
showed O
significance O
( O
rho O
less O
than O
. O
05 O
) O
for O
the O
females O
, O
with O
the O
famale O
agoraphobic O
being O
more O
field O
dependent O
than O
the O
female O
simple O
phobic O
groups O
, O
but O
not O
for O
the O
males O
. O

Residues O
removed O
from O
transcripts O
by O
splicing O
were O
identified O
. O

The O
histochemistry O
and O
ultrastructure O
of O
calcified O
cerebellar O
deposits O
described O
by O
Tonge O
et O
al O
. O

A O
36 O
year O
- O
old O
woman O
was O
given O
Ergotamine O
Tartrate O
4 O
. O
5 O
mg O
p O
. O
d O
. O
during O
seven O
days O
, O
after O
an O
abortion O
( O
a O
still O
birth O
) O
. O

As O
expected O
, O
the O
heparin O
did O
produce O
increased O
recalcification O
times O
and O
the O
development O
of O
occasional O
subcutaneous O
hematomas O
. O

The O
overall O
incidence O
of O
SIDS O
was O
1 O
. O
43 O
per O
1 O
, O
000 O
live O
births O
. O

Significant O
increases O
in O
mean O
serum O
E2 O
concentration O
( O
100 O
to O
150 O
pg O
/ O
ml O
) O
were O
noted O
at O
6 O
and O
8 O
hours O
after O
administration O
on O
day O
1 O
and O
at O
8 O
hours O
on O
day O
4 O
. O

We O
remain O
convinced O
that O
antilymphocyte B-GENE
globulin I-GENE
( O
ALG B-GENE
) O
is O
a O
potent O
immunosuppressive O
agent O
in O
humans O
. O

Patients O
were O
subclassified O
into O
age O
- O
matched O
groups O
of O
primary O
untreated O
cancer O
( O
21 O
) O
, O
recurrent O
cancer O
( O
18 O
) O
, O
and O
" O
cured O
" O
patients O
who O
had O
been O
free O
of O
disease O
for O
at O
least O
9 O
months O
( O
16 O
) O
. O

Bacteriostatic O
and O
bacteriacidal O
activity O
of O
hydroxy O
- O
9 O
ellipticine O
in O
vitro O

Personal O
satisfaction O
in O
nursing O
: O
an O
encounter O
with O
extremely O
hostile O
patients O

The O
effect O
of O
hydrostatic O
pressure O
on O
the O
swimming O
activity O
of O
three O
hyponeustonic O
crustacea O
, O
Anomalocera O
patersoni O
, O
Pontella O
mediterranea O
, O
Labidocera O
wollastoni O

Abnormal O
calcium O
metabolism O
in O
normocalcaemic O
sarcoidosis O
. O

A O
five O
- O
phase O
experiment O
was O
designed O
to O
investigate O
( O
a O
) O
whether O
contingent O
music O
- O
listening O
would O
act O
as O
a O
reinforcer O
to O
increase O
arithmetic O
performance O
of O
EMR O
children O
and O
( O
b O
) O
whether O
this O
contingent O
reinforcement O
would O
affect O
preference O
for O
that O
reinforcer O
. O

The O
responsiveness O
of O
visual O
cortex O
( O
VC O
) O
and O
superior O
colliculus O
( O
SC O
) O
was O
simultaneously O
compared O
following O
conditioning O
" O
ON O
" O
or O
" O
OFF O
" O
stimulation O
, O
in O
the O
rabbit O
. O

During O
activity O
III O
, O
one O
patient O
developed O
angina O
. O

Estimation O
of O
L O
- O
alanine O
in O
serum O
or O
plasma O
using O
the O
LKB O
reaction O
rate O
analyser O
. O

Infants O
who O
died O
in O
the O
first O
12 O
hours O
from O
' O
IVH O
only O
' O
had O
suffered O
severe O
birth O
asphyxia O
but O
in O
those O
who O
died O
later O
the O
main O
symptom O
was O
recurrent O
apnoea O
. O

Wherever O
the O
site O
of O
the O
conditioning O
stimulation O
, O
these O
modifications O
disappeared O
after O
ischaemia O
of O
the O
leg O
. O

Near O
term O
, O
under O
experimental O
conditions O
, O
maternal O
and O
fetal O
blood O
gases O
, O
pH O
, O
uterine O
and O
umbilical O
blood O
flows O
were O
measured O
or O
calculated O
. O

It O
was O
concluded O
that O
patients O
with O
acute O
respiratory O
failure O
requiring O
artificial O
ventilation O
have O
two O
componenents O
of O
the O
pulmonary O
shunt O
, O
one O
parallel O
with O
and O
the O
other O
inversely O
related O
with O
the O
PAO2 O
. O

The O
most O
common O
cause O
of O
renal O
deterioration O
in O
the O
spinal O
cord O
injured O
patient O
is O
irreversible O
vesicoureteral O
reflux O
. O

Circulatory O
arrest O
in O
the O
operating O
room O
. O

Iodine O
- O
123 O
was O
satisfactorily O
imaged O
only O
with O
the O
MEC O
and O
pinhole O
collimators O
, O
which O
in O
turn O
yielded O
MTF O
values O
comparable O
to O
those O
measured O
for O
99mTc O
. O

Petrous O
meningioma O
en O
plaque O
presenting O
as O
a O
right O
middle O
ear O
tumor O
. O

The O
difficulties O
to O
analyse O
prostaglandins O
( O
PG O
) O
by O
gas O
- O
liquid O
chromatography O
are O
mainly O
due O
to O
the O
lack O
of O
sensitivity O
of O
the O
gas O
- O
chromatograph O
itself O
( O
higher O
than O
200 O
ng O
) O
and O
to O
the O
poor O
resolution O
of O
the O
packed O
columns O
. O

Also O
, O
samples O
of O
serum O
were O
absorbed O
with O
the O
various O
solid O
- O
phase O
allergens O
and O
the O
reactivity O
of O
the O
remaining O
IgE B-GENE
antibodies I-GENE
was O
determined O
. O

Extramedullary O
plasmacytoma O
of O
the O
parotid O
gland O

The O
recovered O
calves O
were O
tested O
for O
immunity O
to O
homologous O
severe O
challenge O
, O
50 O
or O
73 O
days O
after O
the O
first O
infection O
. O

Oxygen O
tension O
of O
the O
small O
lymph O
vessels O
( O
PLO2 O
) O
of O
the O
rabbit O
hind O
limb O
was O
measured O
with O
both O
a O
flow O
- O
through O
micro O
chamber O
and O
a O
polarographic O
catheter O
- O
tip O
oxygen O
electrode O
to O
obtain O
experimental O
data O
on O
the O
source O
of O
oxygen O
in O
the O
lymph O
. O

I O
. O

Since O
1968 O
, O
a O
steep O
decrease O
in O
the O
number O
of O
strains O
resistant O
to O
three O
or O
more O
antibiotics O
( O
multiple O
- O
resistant O
) O
and O
in O
strains O
of O
the O
83A O
complex O
was O
noticed O
. O

The O
contraceptive O
pattern O
of O
157 O
women O
was O
analysed O
and O
13 O
. O
8 O
percent O
were O
using O
inefficient O
methods O
. O

I O
. O

Nerve O
stimulation O
( O
1 O
. O
5 O
- O
12 O
cycles O
/ O
s O
) O
produced O
frequency O
- O
dependent O
reductions O
in O
CBF O
, O
a O
decrease O
of O
50 O
percent O
occurring O
with O
the O
highest O
frequency O
. O

Risk O
of O
infection O
in O
the O
treatment O
of O
fractures O

Prolonged O
heavy O
work O
effected O
an O
increase O
of O
10 O
. O
3 O
plus O
or O
minus O
0 O
. O
9 O
mmHg O
in O
in O
vivo O
P50 O
( O
7 O
. O
30 O
PH O
- O
v O
, O
41 O
degrees O
C O
- O
v O
, O
and O
45 O
Pv O
- O
CO2 O
) O
; O
due O
entirely O
to O
the O
additive O
effects O
of O
increased O
venous O
temperature O
and O
[ O
H O
+ O
] O
. O

This O
sequence O
is O
almost O
identical O
with O
that O
of O
human B-GENE
luteinizing I-GENE
hormone I-GENE
( O
Sairam O
, O
M O
. O

At O
the O
very O
high O
dose O
levels O
used O
, O
sodium O
saccharin O
and O
sodium O
cyclamate O
were O
weak O
solitary O
carcinogens O
producing O
4 O
/ O
253 O
and O
3 O
/ O
228 O
bladder O
tumours O
respectively O
, O
and O
the O
first O
of O
these O
tumours O
did O
not O
appear O
for O
more O
than O
80 O
weeks O
. O

However O
, O
a O
10 O
- O
- O
15 O
% O
lengthening O
of O
the O
partial O
thromboplastin B-GENE
time O
is O
evident O
after O
24 O
hours O
of O
storage O
. O

No O
evidence O
of O
either O
positive O
or O
negative O
chemography O
was O
found O
. O

A O
study O
of O
chromosomes O
of O
lymphocytes O
from O
patients O
treated O
with O
hycanthone O
. O

Study O
of O
the O
physico O
- O
chemical O
state O
of O
plutonium O
- O
239 O
in O
a O
citrate O
solution O
- O
blood O
system O

Maternal O
lactation O

In O
both O
cases O
, O
at O
the O
end O
of O
exposure O
the O
same O
level O
of O
blood B-GENE
carboxyhemoglobin I-GENE
( O
COHb B-GENE
) O
( O
about O
50 O
% O
) O
was O
reached O
. O

The O
results O
indicate O
that O
increased O
pulmonary O
blood O
flow O
and O
decreased O
pulmonary O
vascular O
resistance O
with O
advancing O
gestation O
are O
due O
to O
an O
increase O
in O
the O
total O
number O
of O
vessels O
and O
increased O
vasomotor O
reactivity O
is O
related O
to O
an O
increase O
in O
the O
total O
amount O
of O
smooth O
muscle O
while O
the O
thickness O
of O
muscle O
in O
individual O
vessels O
remains O
constant O
. O

Reduction O
in O
dosage O
restored O
normal O
taste O
sense O
in O
all O
three O
, O
but O
in O
two O
the O
drug O
had O
to O
be O
discontinued O
because O
of O
persisting O
high O
transaminase O
levels O
. O

A O
late O
diagnosis O
of O
retinoblastoma O
is O
an O
unquestionable O
fact O
that O
allows O
its O
growth O
and O
leads O
to O
a O
deterioration O
in O
the O
outlook O
. O

The O
concept O
of O
" O
structural O
identifiability O
" O
is O
employed O
in O
this O
analysis O
to O
determine O
which O
model O
parameters O
can O
be O
and O
which O
cannot O
be O
determined O
" O
uniquely O
" O
from O
given O
input O
- O
output O
data O
; O
a O
step O
- O
by O
- O
step O
procedure O
based O
on O
an O
extension O
of O
this O
concept O
is O
presented O
for O
adapting O
the O
overall O
approach O
to O
the O
experimental O
design O
problem O
. O

Acquired O
factor B-GENE
VIII I-GENE
inhibitor O
in O
non O
- O
hemophilic O
patients O

The O
study O
of O
calcium O
metabolism O
in O
ten O
thalassaemic O
children O
comperatively O
with O
controls O
after O
oral O
administration O
of O
47Ca O
has O
shown O
diminished O
intestinal O
absorption O
. O

AP O
was O
induced O
by O
intraductal O
infusion O
of O
two O
different O
concentrations O
of O
glycodeoxycholic O
acid O
( O
GDOC O
17 O
mmol O
and O
34 O
mmol O
) O
. O

Tissue B-GENE
plasminogen I-GENE
activator I-GENE
, O
its O
inhibitor O
and O
other O
parameters O
of O
fibrinolysis O
in O
blood O
of O
patients O
operated O
for O
mild O
hypertrophy O
of O
the O
prostate O

The O
mean O
( O
+ O
/ O
- O
SD O
) O
PaO2 O
increased O
from O
80 O
. O
8 O
+ O
/ O
- O
26 O
. O
9 O
mmHg O
before O
to O
89 O
. O
8 O
+ O
/ O
- O
27 O
. O
3 O
mmHg O
after O
the O
infusion O
( O
P O
< O
0 O
. O
05 O
) O
and O
the O
PaCO2 O
decreased O
from O
42 O
. O
4 O
+ O
/ O
- O
8 O
. O
3 O
to O
39 O
. O
6 O
+ O
/ O
- O
7 O
. O
9 O
mmHg O
( O
P O
< O
0 O
. O
05 O
) O
. O

The O
two O
drugs O
increase O
the O
rate O
of O
early O
diastolic O
filling O
. O

We O
cloned O
the O
third O
human O
gene O
for O
the O
LD78 B-GENE
, O
termed O
LD78 B-GENE
gamma I-GENE
and O
the O
sequence O
analysis O
showed O
that O
it O
is O
a O
5 O
' O
- O
truncated O
pseudogene O
. O

In O
the O
absence O
of O
histological O
criteria O
, O
which O
it O
is O
difficult O
to O
demand O
in O
view O
of O
the O
variability O
of O
results O
and O
potential O
dangers O
of O
endomyocardial O
biopsy O
involving O
such O
thin O
and O
fragile O
ventricular O
walls O
, O
the O
diagnosis O
of O
ACRV O
is O
based O
upon O
the O
concomitant O
existence O
of O
: O
( O
1 O
) O
electrophysiological O
criteria O
: O
ventricular O
arrhythmias O
, O
in O
particular O
sustained O
monomorphous O
VT O
, O
with O
the O
particular O
feature O
of O
a O
very O
high O
degree O
of O
sensitivity O
to O
adrenergic O
stimulation O
( O
exercise O
) O
, O
the O
existence O
of O
late O
potentials O
on O
the O
high O
amplification O
ECG O
, O
a O
highly O
specific O
sign O
, O
though O
unfortunately O
of O
poor O
sensitivity O
in O
localized O
froms O
, O
those O
which O
are O
most O
difficult O
to O
identify O
( O
2 O
) O
; O
segmentary O
morphological O
and O
kinetic O
RV O
abnormalities O
, O
most O
often O
resulting O
in O
localized O
akinetic O
or O
dyskinetic O
parietal O
vaulting O
, O
with O
stasis O
" O
in O
situ O
" O
. O

66 O
: O
469 O
- O
479 O
, O
1992 O
) O
. O

Possibly O
, O
the O
scr1 B-GENE
- I-GENE
1 I-GENE
mutation I-GENE
does O
not O
affect O
signal O
recognition O
or O
translational O
arrest O
but O
instead O
results O
in O
maintenance O
of O
translational O
arrest O
of O
AEP B-GENE
synthesis O
. O

Both O
Rep78 B-GENE
and O
Rep68 B-GENE
cut O
the O
terminal O
AAV O
sequence O
at O
the O
same O
site O
( O
nucleotide O
124 O
) O
. O

Nucleotide O
sequence O
analysis O
revealed O
that O
TAR B-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
very O
similar O
to O
the O
CREB2 B-GENE
protein I-GENE
. O

A O
patient O
suffering O
from O
heparin O
- O
associated O
thrombocytopenia O
( O
HAT O
) O
, O
recurrent O
arteriothromboses O
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin O
is O
described O
. O

Comparison O
with O
the O
sequence O
databanks O
show O
that O
Tactile B-GENE
is O
a O
member O
of O
the O
immunoglobulin B-GENE
gene I-GENE
superfamily I-GENE
, O
with O
similarity O
to O
Drosophila B-GENE
amalgam I-GENE
, O
the O
melanoma B-GENE
Ag I-GENE
MUC I-GENE
- I-GENE
18 I-GENE
, O
members O
of O
the O
carcinoembryonic B-GENE
Ag I-GENE
family I-GENE
, O
the O
poliovirus B-GENE
receptor I-GENE
, O
and O
the O
neural B-GENE
cell I-GENE
adhesion I-GENE
molecule I-GENE
. O

The O
phenotypes O
of O
the O
ICP0 B-GENE
nonsense O
mutants O
were O
intermediate O
between O
those O
of O
the O
wild O
- O
type O
virus O
and O
7134 O
in O
that O
the O
more O
ICP0 B-GENE
- I-GENE
coding I-GENE
sequence I-GENE
expressed O
by O
a O
given O
nonsense O
mutant O
, O
the O
more O
wild O
type O
- O
like O
was O
its O
phenotype O
. O

In O
contrast O
, O
gel O
mobility O
shift O
experiments O
have O
failed O
to O
reveal O
that O
HAP2 B-GENE
or O
HAP3 B-GENE
binds O
to O
domain O
1 O
or O
that O
hap3 B-GENE
mutations O
affect O
the O
complexes O
bound O
to O
it O
. O

The O
experiment O
results O
showed O
: O
( O
i O
) O
not O
only O
1O2 O
, O
but O
also O
free O
radicals O
( O
O2 O
- O
. O
. O
OH O
and O
YHPD O
- O
. O
) O
can O
be O
formed O
by O
the O
aid O
of O
YHPD O
; O
and O
( O
ii O
) O
as O
to O
the O
ability O
of O
producing O
1O2 O
, O
YHPD O
less O
than O
BHPD O
, O
while O
for O
generating O
O2 O
- O
. O
and O
. O
OH O
, O
YHPD O
greater O
than O
BHPD O
. O

Two O
points O
are O
indicated O
: O
first O
, O
the O
photosensitized O
damage O
of O
YHPD O
is O
interrelated O
to O
not O
only O
1O2 O
, O
but O
also O
free O
radicals O
( O
O2 O
- O
. O
. O
OH O
and O
YHPD O
- O
. O
) O
; O
second O
, O
although O
the O
photosensitized O
damage O
of O
YHPD O
is O
stronger O
than O
that O
of O
BHPD O
, O
yet O
the O
photosensitized O
damage O
is O
negatively O
correlated O
to O
the O
yield O
of O
1O2 O
but O
positively O
correlated O
to O
those O
of O
O2 O
- O
. O
and O
OH O
. O

The O
unphosphorylated O
form O
of O
RNA B-GENE
polymerase I-GENE
II I-GENE
is O
designated O
IIA O
, O
whereas O
the O
phosphorylated O
form O
is O
designated O
IIO O
. O

RNA B-GENE
polymerase I-GENE
IIA I-GENE
was O
recovered O
in O
transcriptionally O
active O
complexes O
in O
reactions O
in O
which O
the O
input O
enzyme O
was O
RNA B-GENE
polymerase I-GENE
IIA I-GENE
. O

Fructokinase B-GENE
activity O
is O
elevated O
up O
to O
twofold O
when O
Z O
. O
mobilis O
was O
grown O
on O
fructose O
instead O
of O
glucose O
, O
and O
there O
was O
a O
parallel O
increase O
in O
frk B-GENE
mRNA I-GENE
levels O
. O

The O
enhancer O
region O
of O
Akv O
murine O
leukemia O
virus O
contains O
the O
sequence O
motif O
ACAGATGG O
. O

Two O
splice O
variants O
of O
ALF1 B-GENE
cDNA I-GENE
have O
been O
found O
, O
differing O
by O
a O
72 O
- O
bp O
insertion O
, O
coding O
for O
putative O
proteins O
of O
682 O
and O
706 O
amino O
acids O
. O

Cloning O
and O
primary O
structure O
of O
neurocan O
, O
a O
developmentally O
regulated O
, O
aggregating O
chondroitin O
sulfate O
proteoglycan O
of O
brain O
. O

The O
- O
64 O
/ O
- O
37 O
region O
interacted O
with O
purified O
Sp1 B-GENE
and O
an O
unidentified O
protein O
( O
s O
) O
, O
proximal B-GENE
regulatory I-GENE
factor I-GENE
( I-GENE
s I-GENE
) I-GENE
I I-GENE
( O
PRF B-GENE
- I-GENE
I I-GENE
) O
. O

This O
soluble O
form O
of O
the O
HGFr B-GENE
( O
sHGFr B-GENE
) O
bound O
HGF B-GENE
with O
an O
affinity O
similar O
to O
that O
of O
the O
authentic O
, O
membrane O
- O
associated O
receptor O
. O

Also O
, O
the O
human B-GENE
glycoprotein I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
promoter I-GENE
was O
induced O
10 O
- O
fold O
by O
FSK B-GENE
in O
GH4 O
rat O
pituitary O
cells O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Some O
research O
studies O
have O
related O
this O
kind O
of O
tumors O
with O
prolonged O
ingestion O
of O
H2 O
inhibitors O
and O
others O
antacid O
. O

The O
rationale O
for O
continuous O
dopaminergic O
stimulation O
in O
patients O
with O
Parkinson O
' O
s O
disease O
. O

Amino O
acid O
sequence O
comparison O
revealed O
significant O
homology O
between O
the O
yeast B-GENE
and I-GENE
Escherichia I-GENE
coli I-GENE
gamma I-GENE
- I-GENE
glutamyl I-GENE
kinases I-GENE
throughout O
their O
lengths O
. O

This O
computation O
is O
performed O
by O
a O
parallel O
network O
of O
locally O
connected O
neuron O
- O
like O
elements O
. O

Neither O
gene O
possesses O
a O
distinct O
transcriptional O
start O
site O
as O
shown O
by O
nuclease B-GENE
S1 I-GENE
analysis O
. O

Gene O
and O
pseudogene O
of O
the O
mouse O
cation O
- O
dependent O
mannose B-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
receptor I-GENE
. O

The O
chick O
axon O
- O
associated O
surface O
glycoprotein O
neurofascin B-GENE
is O
implicated O
in O
axonal O
growth O
and O
fasciculation O
as O
revealed O
by O
antibody O
perturbation O
experiments O
. O

Entry O
of O
yeast O
cells O
into O
the O
mitotic O
cell O
cycle O
( O
Start O
) O
involves O
a O
form O
of O
the O
CDC28 B-GENE
kinase I-GENE
that O
associates O
with O
G1 O
- O
specific O
cyclins B-GENE
encoded O
by O
CLN1 B-GENE
and O
CLN2 B-GENE
( O
ref O
. O

From O
all O
clinically O
important O
yeasts O
species O
, O
a O
total O
of O
96 O
% O
were O
identified O
by O
ATB O
method O
according O
to O
conventional O
methods O
. O

Consequently O
, O
significant O
differences O
between O
the O
measured O
and O
calculated O
methods O
were O
noted O
in O
oxygen O
uptake O
( O
213 O
+ O
/ O
- O
41 O
ml O
/ O
min O
vs O
193 O
+ O
/ O
- O
25 O
ml O
/ O
min O
, O
p O
< O
0 O
. O
001 O
) O
, O
oxygen O
delivery O
( O
780 O
+ O
/ O
- O
297 O
ml O
/ O
min O
vs O
716 O
+ O
/ O
- O
296 O
ml O
/ O
min O
, O
p O
< O
0 O
. O
001 O
) O
, O
and O
cardiac O
output O
( O
5 O
. O
8 O
+ O
/ O
- O
2 O
. O
2 O
L O
/ O
min O
vs O
5 O
. O
3 O
+ O
/ O
- O
1 O
. O
8 O
L O
/ O
min O
, O
p O
< O
0 O
. O
001 O
) O
. O

Negatively O
supercoiled O
plasmid O
pUC19 O
did O
not O
compete O
, O
whereas O
an O
otherwise O
identical O
plasmid O
pUC19 O
( O
CG O
) O
, O
which O
contained O
a O
( O
dG O
- O
dC O
) O
7 O
segment O
in O
the O
Z O
- O
form O
was O
an O
excellent O
competitor O
. O

In O
contrast O
, O
the O
lumenal O
domains O
of O
Sec12p B-GENE
, O
Stl1p B-GENE
and O
Stl2p B-GENE
are O
very O
different O
in O
size O
and O
do O
not O
show O
any O
appreciable O
homology O
. O

The O
gene O
sequence O
also O
identified O
a O
340 O
- O
nucleotide O
RNA O
in O
total O
yeast O
RNA O
and O
in O
purified O
RNase B-GENE
MRP I-GENE
enzyme I-GENE
preparations O
. O

The O
RNase B-GENE
MRP I-GENE
RNA I-GENE
gene I-GENE
was O
deleted O
by O
insertional O
replacement O
and O
found O
to O
be O
essential O
for O
cellular O
viability O
, O
indicating O
a O
critical O
nuclear O
role O
for O
RNase B-GENE
MRP I-GENE
. O

Mutational O
analysis O
of O
essential O
IncP O
alpha O
plasmid O
transfer O
genes O
traF B-GENE
and O
traG B-GENE
and O
involvement O
of O
traF B-GENE
in O
phage O
sensitivity O
. O

The O
promoter O
was O
stimulated O
8 O
- O
20 O
- O
fold O
by O
phorbol O
esters O
accounting O
for O
the O
previously O
observed O
transcriptional O
activation O
of O
protein B-GENE
kinase I-GENE
C I-GENE
beta I-GENE
. O

In O
the O
eight O
patients O
with O
persistent O
generalized O
lymph O
- O
adenopathy O
( O
PGL O
) O
and O
nontender O
, O
nonenlarging O
nodes O
, O
pathologic O
analysis O
revealed O
lymphoid O
hyperplasia O
. O

We O
found O
that O
both O
the O
E26 O
virus O
- O
encoded O
v B-GENE
- I-GENE
ets I-GENE
and O
the O
myeloid B-GENE
/ I-GENE
B I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
factor I-GENE
PU I-GENE
. I-GENE
1 I-GENE
bind O
efficiently O
to O
this O
site O
in O
vitro O
. O

Localization O
of O
the O
brachial O
plexus O
with O
the O
nerve O
stimulator O
is O
equally O
effective O
at O
the O
interscalene O
, O
supraclavicular O
, O
and O
axillary O
sites O
. O

The O
second O
method O
, O
the O
" O
macro O
" O
assay O
, O
has O
a O
sensitivity O
range O
of O
0 O
. O
03 O
- O
5 O
. O
0 O
micrograms O
phosphorus O
with O
100 O
- O
500 O
microliters O
HClO4 O
. O

Anti B-GENE
- I-GENE
CRK I-GENE
antibodies I-GENE
detect O
a O
53kDa O
protein O
in O
extracts O
of O
C O
. O
fasciculata O
in O
agreement O
with O
the O
size O
predicted O
from O
the O
nucleotide O
sequence O
of O
the O
cloned O
gene O
. O

Use O
of O
free O
- O
access O
minerals O
. O

Respiratory O
interaction O
after O
spinal O
anesthesia O
and O
sedation O
with O
midazolam O
. O

V O
. O

Rice B-GENE
dwarf I-GENE
phytoreovirus I-GENE
segment I-GENE
S12 I-GENE
transcript I-GENE
is O
tricistronic O
in O
vitro O
. O

Cold O
cardioplegia O
was O
administered O
at O
45 O
mm O
Hg O
every O
20 O
minutes O
for O
2 O
hours O
. O

Comparable O
amounts O
of O
alpha B-GENE
5 I-GENE
beta I-GENE
1 I-GENE
integrin I-GENE
were O
isolated O
from O
these O
cells O
by O
chromatography O
of O
detergent O
extracts O
on O
a O
fibronectin B-GENE
cell O
- O
binding O
fragment O
affinity O
column O
and O
elution O
with O
EDTA O
. O

From O
this O
library O
, O
LEU2 B-GENE
and O
HIS3 B-GENE
cDNAs O
were O
recovered O
at O
a O
frequency O
of O
about O
1 O
in O
10 O
( O
4 O
) O
and O
in O
12 O
out O
of O
13 O
cases O
these O
were O
expressed O
in O
a O
galactose O
- O
dependent O
manner O
. O

Among O
these O
, O
ACT1 B-GENE
was O
isolated O
four O
times O
, O
and O
NSR1 B-GENE
three O
times O
. O

BiP670 B-GENE
retains O
basal O
and O
Ca2 O
+ O
ionophore O
A23187 O
- O
inducible O
activities O
. O

As O
a O
part O
of O
a O
large O
examination O
, O
total O
and O
free O
serum O
cholesterol O
, O
total O
lipid O
and O
triglyceride O
levels O
were O
determined O
. O

DIBA O
was O
more O
sensitive O
and O
had O
a O
better O
negative O
predictive O
value O
and O
a O
lower O
false O
negative O
percentage O
than O
DFAT O
. O

Caries O
and O
parodontitis O
have O
been O
one O
of O
the O
most O
spread O
diseases O
of O
mankind O
. O

ME1a1 B-GENE
, O
a O
16 O
- O
base O
- O
pair O
nuclear O
factor O
binding O
site O
residing O
between O
the O
c B-GENE
- I-GENE
MYC I-GENE
P1 I-GENE
and I-GENE
P2 I-GENE
transcription I-GENE
initiation I-GENE
sites I-GENE
, O
is O
required O
for O
P2 O
activity O
. O

The O
next O
twenty O
years O
of O
prevention O
in O
Indian O
country O
: O
visionary O
, O
complex O
, O
and O
practical O
. O

The O
cDNA O
has O
an O
open O
reading O
frame O
of O
900 O
amino O
acids O
capable O
of O
encoding O
a O
97 O
- O
kDa O
protein O
. O

The O
gene O
encoding O
TRP B-GENE
- I-GENE
2 I-GENE
maps O
to O
mouse O
chromosome O
14 O
, O
in O
the O
region O
of O
the O
coat B-GENE
colour I-GENE
mutation I-GENE
slaty I-GENE
. O

A O
comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
T O
. O
thermophilus O
enzyme O
with O
that O
of O
the O
Escherichia O
coli O
enzyme O
showed O
( O
i O
) O
a O
37 O
% O
overall O
similarity O
; O
( O
ii O
) O
the O
conservation O
of O
the O
Ser O
residue O
, O
which O
is O
known O
to O
be O
phosphorylated O
in O
the O
E O
. O
coli O
enzyme O
, O
and O
of O
the O
surrounding O
sequence O
; O
and O
( O
iii O
) O
the O
presence O
of O
141 O
extra O
residues O
at O
the O
C O
terminus O
of O
the O
T O
. O
thermophilus O
enzyme O
. O

Because O
single O
- O
chamber O
rate O
- O
adaptive O
atrial O
pacing O
leaves O
the O
patient O
exposed O
to O
the O
risk O
of O
future O
development O
of O
AV O
block O
and O
DDD O
pacing O
does O
not O
provide O
chronotropic O
support O
, O
it O
is O
likely O
that O
the O
new O
rate O
- O
adaptive O
dual O
- O
chamber O
( O
DDDR O
) O
devices O
will O
be O
used O
in O
a O
significant O
number O
of O
these O
patients O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

When O
transiently O
transfected O
into O
K562 O
cells O
, O
this O
Lg B-GENE
genomic O
clone O
is O
actively O
transcribed O
, O
suggesting O
that O
, O
although O
it O
possesses O
the O
characteristics O
of O
a O
processed O
pseudogene O
, O
it O
is O
likely O
to O
correspond O
to O
the O
gene O
encoding O
this O
new O
ferritin B-GENE
subunit I-GENE
. O

The O
p130 B-GENE
and O
p62 B-GENE
tyrosine O
- O
phosphorylated O
proteins O
that O
complexed O
v B-GENE
- I-GENE
Src I-GENE
SH2 B-GENE
in O
vitro O
also O
associated O
with O
v B-GENE
- I-GENE
Src I-GENE
in O
v B-GENE
- I-GENE
src I-GENE
- O
transformed O
Rat O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v B-GENE
- I-GENE
Src I-GENE
SH2 B-GENE
domain O
. O

These O
data O
support O
a O
possible O
biological O
significance O
of O
the O
frameshift O
to O
occur O
at O
this O
position O
of O
the O
large O
overlap O
by O
including O
the O
putative O
RNA O
template O
- O
binding O
site O
of O
the O
PLRV B-GENE
replicase I-GENE
in O
the O
ORF2a B-GENE
/ I-GENE
ORF2b I-GENE
transframe I-GENE
protein I-GENE
. O

The O
MET4 B-GENE
gene O
was O
cloned O
, O
and O
its O
sequence O
reveals O
that O
it O
encodes O
a O
protein O
related O
to O
the O
family O
of O
the O
bZIP B-GENE
transcriptional I-GENE
activators I-GENE
. O

It O
is O
believed O
that O
these O
domains O
are O
important O
for O
directing O
specific O
protein O
- O
protein O
interactions O
necessary O
for O
the O
proper O
functioning O
of O
Src B-GENE
. O

The O
recently O
developed O
gamma B-GENE
- I-GENE
interferon I-GENE
( O
IFN B-GENE
- I-GENE
gamma I-GENE
) O
assay O
system O
for O
the O
diagnosis O
of O
bovine O
tuberculosis O
in O
cattle O
has O
been O
accredited O
by O
the O
Standing O
Committee O
on O
Agriculture O
for O
use O
in O
Australia O
. O

Control O
Tmuscle O
was O
35 O
. O
8 O
+ O
/ O
- O
0 O
. O
7 O
degrees O
C O
, O
with O
control O
Wi O
, O
max O
being O
51 O
. O
6 O
( O
SD O
8 O
. O
7 O
) O
W O
. O
kg O
- O
1 O
. O

However O
, O
other O
regions O
of O
the O
plasmid O
are O
also O
efficiently O
repaired O
. O

Thus O
, O
the O
human B-GENE
D1A I-GENE
gene I-GENE
belongs O
to O
the O
category O
of O
tissue O
- O
specific O
, O
regulated O
genes O
that O
have O
housekeeping O
- O
type O
promoters O
. O

Computer O
- O
aided O
" O
FRAME O
" O
analysis O
revealed O
four O
possible O
open O
reading O
frames O
( O
ORFs O
) O
, O
three O
in O
one O
direction O
and O
one O
in O
the O
opposite O
direction O
. O

Domain O
II O
is O
highly O
homologous O
to O
the O
LDL B-GENE
receptor I-GENE
and O
contains O
four O
repeats O
with O
perfect O
conservation O
of O
all O
6 O
consecutive O
cysteines O
. O

Here O
, O
we O
present O
evidence O
for O
a O
model O
in O
which O
mRNA O
sequences O
up O
to O
around O
100 O
nucleotides O
downstream O
from O
the O
start O
codon O
of O
21K O
fold O
back O
and O
base O
- O
pair O
to O
the O
21K O
translation O
initiation O
region O
, O
thereby O
decreasing O
the O
translation O
initiation O
frequency O
. O

In O
the O
last O
20 O
years O
, O
the O
therapeutic O
uses O
of O
botulinum B-GENE
toxin I-GENE
, O
a O
potent O
neurotoxin O
, O
have O
been O
investigated O
. O

At O
the O
C O
- O
terminus O
of O
the O
protein O
is O
a O
domain O
that O
contains O
sequences O
very O
similar O
to O
those O
found O
in O
the O
breakpoint O
cluster O
region O
gene O
product O
, O
n B-GENE
- I-GENE
chimerin I-GENE
, O
and O
rho B-GENE
GAP I-GENE
, O
all O
of O
which O
have O
been O
shown O
to O
possess O
intrinsic O
GAP B-GENE
activity O
on O
small B-GENE
GTPases I-GENE
. O

The O
circadian O
rhythmicity O
of O
sleep O
was O
pronounced O
. O

The O
sequence O
data O
now O
permit O
a O
detailed O
interpretation O
of O
the O
X O
- O
ray O
crystallographic O
structure O
of O
the O
enzyme O
and O
the O
cloning O
and O
expression O
of O
the O
clostridial O
gene O
will O
facilitate O
site O
- O
directed O
mutagenesis O
. O

AgMNPV O
and O
Orgyia O
pseudotsugata O
MNPV O
( O
OpMNPV O
) O
are O
similar O
in O
terms O
of O
promoter O
structure O
and O
polyhedrin B-GENE
primary I-GENE
sequence I-GENE
, O
and O
the O
polyhedrin B-GENE
gene I-GENE
of O
both O
viruses O
is O
transcribed O
in O
the O
anti O
- O
clockwise O
direction O
in O
relation O
to O
their O
physical O
maps O
. O

These O
results O
are O
consistent O
with O
the O
roles O
that O
CCK B-GENE
and O
trypsin B-GENE
inhibitors O
are O
believed O
to O
play O
in O
the O
negative O
feedback O
control O
of O
pancreatic O
exocrine O
function O
. O

A O
724 O
- O
bp O
segment O
of O
the O
5 O
' O
- O
flanking O
region O
consisting O
of O
the O
proximal O
E O
- O
box O
flanked O
upstream O
by O
a O
mammalian O
- O
specific O
352 O
- O
bp O
region O
was O
sufficient O
for O
maximal O
transcriptional O
activation O
in O
postconfluent O
BC3H1 O
myoblasts O
. O

These O
results O
indicate O
that O
baculovirus O
- O
expressed O
TR B-GENE
mediates O
transcriptional O
activation O
and O
repression O
in O
a O
promoter O
- O
specific O
manner O
in O
vitro O
. O

The O
serum O
erythropoietin B-GENE
( O
EPO B-GENE
) O
concentrations O
of O
15 O
male O
triathletes O
( O
26 O
. O
3 O
U O
. O
ml O
- O
1 O
) O
were O
significantly O
lower O
than O
those O
of O
45 O
male O
distance O
runners O
( O
31 O
. O
6 O
U O
. O
ml O
- O
1 O
; O
P O
less O
than O
0 O
. O
05 O
) O
. O

These O
results O
support O
the O
diagnostic O
validity O
of O
NFPD O
in O
CP O
/ O
NCA O
patients O
, O
because O
such O
patients O
had O
a O
family O
history O
of O
panic O
disorder O
similar O
to O
patients O
with O
a O
more O
classical O
panic O
disorder O
presentation O
. O

FDA O
regulations O
for O
growth O
factors O
and O
related O
products O
. O

DESIGN O
: O
Serum O
aldosterone O
and O
plasma B-GENE
renin I-GENE
activity O
were O
measured O
supine O
prior O
to O
and O
60 O
, O
90 O
, O
120 O
minutes O
after O
oral O
captopril O
, O
25 O
mg O
. O

Both O
parents O
are O
clinically O
normal O
and O
unrelated O
. O

UF O
- O
021 O
ophthalmic O
solution O
( O
0 O
. O
03 O
to O
0 O
. O
24 O
% O
) O
, O
when O
topically O
applied O
to O
the O
eyes O
of O
rabbits O
, O
caused O
dose O
- O
dependent O
IOP O
reduction O
( O
2 O
. O
8 O
to O
5 O
. O
2 O
mmHg O
) O
, O
without O
transient O
IOP O
rise O
. O

This O
is O
in O
contrast O
with O
the O
classical O
' O
oxygen O
debt O
hypothesis O
' O
, O
which O
states O
that O
the O
oxygen O
debt O
and O
lactate O
clearance O
are O
linked O
. O

In O
addition O
a O
greater O
proportion O
of O
women O
in O
the O
sweeping O
group O
had O
a O
cervical O
dilatation O
of O
4 O
cm O
or O
more O
at O
the O
first O
vaginal O
examination O
in O
the O
labour O
ward O
( O
16 O
/ O
33 O
( O
49 O
% O
) O
vs O
5 O
/ O
32 O
( O
16 O
% O
) O
; O
OR O
4 O
. O
39 O
; O
95 O
% O
CI O
1 O
. O
56 O
to O
12 O
. O
32 O
; O
P O
= O
0 O
. O
005 O
) O
. O

A O
control O
group O
of O
nine O
women O
( O
age O
23 O
- O
40 O
years O
) O
on O
oral O
contraceptives O
( O
Nordette O
- O
28 O
) O
was O
also O
studied O
four O
times O
during O
a O
pill O
cycle O
. O

Patients O
with O
an O
enzymatic O
activity O
below O
X O
- O
- O
1 O
manifested O
a O
decrease O
of O
the O
content O
of O
IgA B-GENE
, O
IgG B-GENE
, O
IgM B-GENE
, O
T O
and O
B O
lymphocytes O
, O
and O
of O
phagocytic O
activity O
of O
neutrophils O
as O
compared O
to O
patients O
exhibiting O
a O
high O
enzymatic O
activity O
. O

The O
relation O
between O
myocardial B-GENE
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
and O
left O
ventricular O
( O
LV O
) O
function O
was O
studied O
in O
10 O
patients O
, O
aged O
41 O
to O
61 O
years O
( O
average O
51 O
) O
, O
with O
LV O
volume O
overload O
mainly O
due O
to O
chronic O
mitral O
regurgitation O
. O

axl O
, O
a O
transforming O
gene O
isolated O
from O
primary O
human O
myeloid O
leukemia O
cells O
, O
encodes O
a O
novel O
receptor B-GENE
tyrosine I-GENE
kinase I-GENE
. O

The O
single O
most O
important O
element O
, O
by O
linker O
- O
scanning O
analysis O
, O
is O
a O
10 O
- O
bp O
region O
that O
contains O
a O
CCAAT O
motif O
. O

Capnography O
curves O
of O
40 O
HVS O
patients O
, O
40 O
non O
- O
HVS O
patients O
with O
psycho O
- O
somatic O
complaints O
and O
26 O
healthy O
controls O
were O
analyzed O
. O

However O
, O
alterations O
in O
electrostatic O
and O
hydrophobic O
interactions O
created O
by O
the O
three O
amino O
acid O
substitutions O
prevent O
the O
conformational O
change O
in O
the O
enzyme O
usually O
produced O
by O
calmodulin B-GENE
binding O
. O

Transfer O
RNA O
genes O
from O
Dictyostelium O
discoideum O
are O
frequently O
associated O
with O
repetitive O
elements O
and O
contain O
consensus O
boxes O
in O
their O
5 O
' O
and O
3 O
' O
- O
flanking O
regions O
. O

Histamine O
- O
2 O
blockade O
in O
psoriasis O

A O
third O
is O
a O
partial O
element O
terminating O
at O
a O
probable O
internal O
restriction O
site O
used O
for O
cloning O
. O

No O
such O
benefits O
were O
seen O
for O
children O
with O
CD4 B-GENE
+ I-GENE
counts O
below O
0 O
. O
2 O
x O
10 O
( O
9 O
) O
per O
liter O
at O
entry O
. O

Because O
the O
human B-GENE
Antp I-GENE
TATAA I-GENE
binding I-GENE
protein I-GENE
is O
expressed O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
we O
suggest O
that O
this O
homeobox B-GENE
gene I-GENE
has O
evolved O
a O
more O
general O
transcriptional O
regulatory O
function O
in O
higher O
eukaryotic O
cells O
. O

Venkatesan O
, O
and O
D O
. O

Stable O
expression O
of O
the O
chimeric O
alpha B-GENE
i I-GENE
( I-GENE
54 I-GENE
) I-GENE
/ I-GENE
s I-GENE
polypeptide O
in O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
constitutively O
increased O
both O
cAMP O
synthesis O
and O
cAMP B-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
activity O
. O

Surprisingly O
, O
there O
is O
no O
sequence O
homology O
between O
this O
region O
of O
Ly B-GENE
- I-GENE
6E I-GENE
and O
the O
established O
consensus O
for O
the O
interferon B-GENE
- I-GENE
stimulated I-GENE
response I-GENE
element I-GENE
, O
which O
has O
been O
shown O
functionally O
important O
to O
all O
previously O
characterized O
alpha B-GENE
/ I-GENE
beta I-GENE
interferon I-GENE
- O
inducible O
promoters O
. O

Relatively O
large O
DNA O
rearrangements O
spanning O
the O
region O
with O
tandem O
direct O
repeats O
encoding O
the O
carboxy O
- O
terminal O
histone B-GENE
H1 I-GENE
- I-GENE
like I-GENE
structure O
of O
AlgP B-GENE
were O
detected O
in O
several O
strains O
upon O
conversion O
from O
the O
mucoid O
to O
the O
nonmucoid O
phenotype O
. O

It O
is O
, O
however O
, O
extremely O
homologous O
to O
a O
third O
' O
non O
- O
classical O
' O
gene O
, O
HLA B-GENE
- I-GENE
5 I-GENE
. I-GENE
4 I-GENE
, O
and O
to O
the O
chimpanzee O
gene O
, O
Ch28 B-GENE
. O

Although O
the O
N13 O
- O
N20 O
interpeak O
interval O
remained O
stable O
because O
of O
the O
parallel O
shift O
of O
the O
2 O
peaks O
, O
the O
central O
conduction O
time O
measured O
from O
onset O
latencies O
of O
N11 O
and O
N20 O
significantly O
increased O
. O

Isolation O
and O
characterization O
of O
the O
rat O
chromosomal O
gene O
for O
a O
polypeptide O
( O
pS1 B-GENE
) O
antigenically O
related O
to O
statin B-GENE
. O

Chem O
. O

This O
report O
substantiates O
that O
at O
least O
two O
of O
the O
18 O
kDa O
hsps B-GENE
in O
maize O
are O
products O
of O
different O
but O
related O
genes O
. O

Finally O
, O
some O
point O
mutations O
in O
the O
Gag B-GENE
- O
Pol B-GENE
PR O
domain O
inhibited O
activation O
of O
RT B-GENE
in O
trans O
by O
a O
wild O
- O
type O
PR B-GENE
, O
suggesting O
that O
the O
correct O
conformation O
of O
the O
PR B-GENE
domain O
in O
Gag B-GENE
- O
Pol B-GENE
is O
prerequisite O
for O
activation O
of O
RT B-GENE
. O

Cloning O
of O
a O
human O
cDNA O
encoding O
a O
CDC2 B-GENE
- I-GENE
related I-GENE
kinase I-GENE
by O
complementation O
of O
a O
budding B-GENE
yeast I-GENE
cdc28 I-GENE
mutation O
. O

E O
. O
, O
Hession O
, O
C O
. O
, O
Goff O
, O
D O
. O
, O
Griffiths O
, O
B O
. O
, O
Tizard O
, O
R O
. O
, O
Newman O
, O
B O
. O
, O
Chi O
- O
Rosso O
, O
G O
. O
, O
and O
Lobb O
, O
R O
. O
, O
( O
1990 O
) O
Cell O
63 O
, O
1349 O
- O
1356 O
) O
. O

The O
above O
results O
mean O
that O
the O
increase O
in O
alpha B-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
makes O
the O
prostate O
, O
which O
has O
been O
already O
hypertrophied O
, O
less O
elastic O
, O
inhibiting O
external O
urinary O
sphincter O
function O
. O

An O
approximately O
2 B-GENE
- I-GENE
kilobase I-GENE
B2 I-GENE
transcript I-GENE
was O
expressed O
in O
all O
alfalfa O
organs O
tested O
. O

In O
some O
early O
B O
cells O
and O
Abelson O
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
- O
cell O
lines O
, O
LT B-GENE
mRNA I-GENE
is O
constitutively O
expressed O
. O

Testosterone O
, O
free O
testosterone O
, O
non B-GENE
- I-GENE
sex I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
- O
bound O
testosterone O
, O
and O
free O
androgen O
index O
: O
which O
testosterone O
measurement O
is O
most O
relevant O
to O
reproductive O
and O
sexual O
function O
in O
men O
with O
epilepsy O
? O

One O
patients O
had O
plasma B-GENE
C I-GENE
- I-GENE
peptide I-GENE
greater O
than O
3 O
pM O
and O
was O
therefore O
excluded O
from O
analysis O
. O

Complex O
repetitive O
discharges O
were O
observed O
in O
muscles O
of O
mdx O
mice O
but O
no O
complex O
repetitive O
discharges O
or O
other O
abnormalities O
were O
observed O
in O
muscles O
of O
normal O
control O
mice O
. O

W O
. O
G O
. O

A O
mouse B-GENE
brain I-GENE
beta I-GENE
- I-GENE
spectrin I-GENE
of O
cDNA O
was O
identified O
within O
a O
lambda O
Gt11 O
expression O
library O
using O
an O
antibody O
which O
specifically O
binds O
with O
the O
235 B-GENE
kDa I-GENE
spectrin I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
. O

We O
obtained O
quantitative O
evidence O
on O
the O
coding O
of O
interaural O
time O
differences O
( O
ITDs O
) O
of O
click O
stimuli O
by O
40 O
single O
neurons O
in O
the O
auditory O
cortex O
of O
anesthetized O
albino O
rats O
. O

Pulmonary O
hypertension O
, O
with O
or O
without O
coronary O
arterial O
narrowing O
, O
is O
the O
major O
condition O
leading O
to O
isolated O
atrial O
infarction O
. O

Diltiazem O
decreased O
the O
total O
body O
clearance O
from O
34 O
. O
0 O
+ O
/ O
- O
8 O
. O
0 O
to O
28 O
. O
6 O
+ O
/ O
- O
6 O
. O
1 O
mL O
/ O
min O
( O
P O
less O
than O
. O
01 O
) O
, O
and O
prolonged O
the O
elimination O
half O
- O
life O
from O
12 O
. O
6 O
+ O
/ O
- O
3 O
. O
0 O
to O
14 O
. O
3 O
+ O
/ O
- O
2 O
. O
5 O
hours O
( O
P O
less O
than O
. O
01 O
) O
of O
antipyrine O
without O
any O
changes O
in O
volume O
of O
distribution O
. O

The O
model O
is O
able O
to O
anticipate O
why O
the O
effect O
of O
water O
fluoridation O
on O
caries O
prevalence O
is O
most O
pronounced O
when O
caries O
is O
diagnosed O
at O
cavity O
level O
. O

An O
8 O
- O
h O
exposure O
to O
10 O
mg O
DMEA O
/ O
m3 O
corresponds O
to O
a O
postexposure O
plasma O
concentration O
and O
2 O
- O
h O
postexposure O
urinary O
excretion O
of O
4 O
. O
9 O
mumol O
/ O
l O
and O
75 O
mmol O
/ O
mol O
creatinine O
, O
respectively O
. O

Marked O
thrombocytopenia O
, O
depletion O
of O
serum B-GENE
fibrinogen I-GENE
and O
prolonged O
prothrombin B-GENE
and O
activated O
partial O
thromboplastin B-GENE
time O
, O
were O
recorded O
at O
5 O
to O
10 O
and O
30 O
to O
40 O
minutes O
after O
intravenous O
envenomation O
. O

Auditory O
threshold O
shifts O
, O
as O
measured O
by O
the O
auditory O
evoked O
brainstem O
response O
, O
were O
measured O
at O
2 O
, O
4 O
, O
8 O
, O
12 O
, O
16 O
, O
20 O
and O
24 O
kHz O
. O

Interspecific O
backcross O
analysis O
using O
progeny O
derived O
from O
matings O
of O
( O
C57BL O
/ O
6J O
x O
Mus O
spretus O
) O
F1 O
x O
C57BL O
/ O
6J O
mice O
indicates O
that O
the O
thrombospondin B-GENE
gene I-GENE
is O
tightly O
linked O
to O
the O
Fshb B-GENE
, O
Actcl B-GENE
, O
Ltk B-GENE
, O
and O
B2M B-GENE
loci I-GENE
on O
murine O
chromosome O
2 O
. O

If O
delay O
has O
occurred O
between O
centrifugation O
and O
the O
measurement O
, O
causing O
substantial O
loss O
of O
CO2 O
, O
equilibration O
of O
the O
sample O
with O
a O
gas O
mixture O
corresponding O
to O
PCO2 O
= O
5 O
. O
3 O
kPa O
prior O
to O
the O
measurement O
is O
recommended O
. O

The O
EPO B-GENE
levels O
were O
distinctly O
increased O
before O
transfusion O
; O
they O
did O
not O
significantly O
change O
just O
after O
transfusion O
, O
but O
subsequently O
decreased O
. O

Felodipine O
did O
not O
alter O
the O
baseline O
FEV1 O
, O
but O
showed O
a O
small O
significant O
inhibitory O
effect O
upon O
histamine O
and O
AMP O
induced O
bronchoconstriction O
. O

Relatively O
little O
is O
known O
regarding O
the O
role O
of O
5 B-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
activity O
in O
male O
rat O
sexual O
behavior O
. O

The O
present O
study O
reports O
visual O
evoked O
potential O
responses O
to O
pattern O
reversal O
( O
VEP O
- O
P O
) O
in O
ten O
third O
trimester O
pregnant O
women O
and O
changes O
in O
latency O
of O
NPN O
complex O
when O
compared O
with O
these O
responses O
in O
the O
non O
pregnant O
state O
. O

In O
all O
instances O
the O
apparent O
alcohol O
responses O
were O
very O
small O
and O
never O
exceeded O
a O
reading O
of O
1 O
microgram O
/ O
100ml O
for O
breath O
samples O
more O
than O
10min O
post O
- O
exposure O
. O

The O
gene O
is O
1 O
, O
139 O
base O
pairs O
( O
bp O
) O
long O
, O
and O
, O
like O
other O
members O
of O
the O
SIG B-GENE
family I-GENE
, O
the O
beta B-GENE
TG I-GENE
gene I-GENE
is O
divided O
into O
3 O
exons O
. O

Thus O
, O
the O
positive O
effect O
of O
NS1 B-GENE
on O
the O
steady O
- O
state O
levels O
of O
P4 B-GENE
transcripts I-GENE
depends O
on O
the O
amplification O
of O
gene O
copy O
number O
and O
the O
integrity O
of O
the O
terminal O
repeats O
. O

It O
is O
transparent O
, O
cheap O
to O
be O
made O
, O
and O
easy O
to O
empty O
and O
was O
tested O
in O
118 O
animals O
for O
two O
and O
four O
weeks O
. O

The O
Thr161Val O
mutation O
causes O
a O
lethal O
phenotype O
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
, O
while O
replacement O
of O
Thr161 O
with O
glutamic O
acid O
, O
potentially O
mimicking O
phosphorylation O
, O
causes O
uncoordination O
of O
mitosis O
and O
multiple O
cytokinesis O
. O

Deregulation O
of O
their O
expression O
may O
contribute O
to O
malignant O
transformation O
associated O
with O
HTLV O
- O
1 O
infection O
. O

In O
conclusion O
, O
we O
observed O
a O
great O
regeneration O
ability O
following O
mechanical O
injury O
in O
the O
nasal O
mucosa O
. O

There O
occurred O
a O
linear O
relationship O
between O
the O
drop O
in O
glucose B-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphatase I-GENE
dehydrogenase I-GENE
activity O
and O
in O
vitamin O
E O
level O
, O
on O
one O
hand O
, O
and O
the O
duration O
of O
poisoning O
with O
sodium O
nitrite O
. O

A O
vector O
containing O
a O
transcriptionally O
inactive O
neomycin B-GENE
phosphotransferase I-GENE
II I-GENE
gene I-GENE
was O
used O
to O
select O
promoter O
sequences O
from O
a O
pool O
of O
random O
genomic O
DNA O
fragments O
. O

Previous O
analysis O
of O
the O
98 O
- O
bp O
sequence O
has O
delineated O
several O
protein O
- O
binding O
domains O
that O
are O
recognized O
by O
nuclear O
factors O
present O
in O
human O
brain O
cells O
. O

Naturally O
acquired O
antibodies O
were O
demonstrated O
in O
some O
rabbits O
kept O
on O
commercial O
farms O
. O

Biol O
. O

Nucleotide O
sequences O
between O
the O
env B-GENE
gene I-GENE
and O
the O
LTR B-GENE
of I-GENE
SFV I-GENE
- I-GENE
1 I-GENE
were O
determined O
. O

The O
human O
cDNA O
was O
used O
to O
demonstrate O
that O
tumor B-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
could O
rapidly O
stimulate O
MARCKS B-GENE
gene I-GENE
transcription O
in O
the O
human O
promyelocytic O
leukemia O
cell O
line O
HL60 O
. O

Dd B-GENE
PK1 I-GENE
RNA I-GENE
decreases O
after O
6 O
h O
of O
starvation O
to O
re O
- O
accumulate O
once O
the O
cells O
have O
aggregated O
. O

Young O
CD O
- O
1 O
mice O
, O
4 O
days O
old O
, O
exposed O
to O
0 O
. O
1 O
% O
nicotine O
sulfate O
on O
gestational O
days O
6 O
- O
20 O
were O
compared O
with O
untreated O
pups O
of O
the O
same O
age O
to O
determine O
its O
effect O
on O
the O
development O
of O
mandibular O
first O
molars O
. O

USF B-GENE
synthesized O
in O
an O
in O
vitro O
transcription O
and O
translation O
system O
also O
binds O
to O
the O
ADH B-GENE
promoter I-GENE
as O
well O
as O
to O
the O
MLP O
. O

Arterial O
radioactivity O
content O
after O
the O
intravenous O
administration O
of O
HMPAO O
in O
seven O
human O
subjects O
was O
analyzed O
. O

Linear O
regression O
analysis O
was O
performed O
and O
the O
following O
result O
was O
obtained O
: O
clearance O
( O
HMPAO O
) O
= O
0 O
. O
07 O
+ O
0 O
. O
43 O
. O
rCBF O
with O
a O
high O
significance O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

Saccharomyces O
cerevisiae O
has O
been O
used O
widely O
both O
as O
a O
model O
system O
for O
unraveling O
the O
biochemical O
, O
genetic O
, O
and O
molecular O
details O
of O
gene O
expression O
and O
the O
secretion O
process O
, O
and O
as O
a O
host O
for O
the O
production O
of O
heterologous O
proteins O
of O
biotechnological O
interest O
. O

Formalin O
activated O
both O
SNO O
NS O
and O
NnS O
neurones O
, O
but O
, O
when O
they O
responded O
, O
NS O
neurones O
( O
n O
= O
5 O
) O
showed O
only O
the O
first O
phase O
of O
activity O
while O
NnS O
neurones O
showed O
either O
one O
( O
n O
= O
13 O
) O
or O
two O
phases O
( O
n O
= O
6 O
) O
. O

Uptake O
of O
ofloxacin O
by O
Escherichia O
coli O

A O
deletion O
series O
of O
the O
5 O
' O
flanking O
region O
was O
created O
from O
position O
- O
1329 O
to O
- O
74 O
relative O
to O
the O
transcriptional O
initiation O
site O
and O
similarly O
examined O
in O
transgenic O
tobacco O
. O

Toxicity O
was O
very O
mild O
with O
both O
regimens O
, O
although O
sedation O
was O
significantly O
higher O
in O
arm O
B O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

Limits O
of O
energy O
turnover O
in O
relation O
to O
physical O
performance O
were O
addressed O
in O
terms O
of O
upper O
and O
lower O
limit O
, O
changes O
during O
a O
training O
programme O
and O
how O
to O
regulate O
energy O
balance O
at O
a O
changing O
energy O
turnover O
. O

Moreover O
, O
promoters O
containing O
a O
TATA O
box O
in O
the O
absence O
of O
Sp1 B-GENE
sites I-GENE
or O
Sp1 B-GENE
sites I-GENE
in O
the O
absence O
of O
a O
TATA O
box O
were O
equally O
inducible O
in O
vitro O
, O
as O
was O
an O
RNA B-GENE
polymerase I-GENE
III I-GENE
promoter I-GENE
. O

Ivermectin O
uptake O
and O
distribution O
in O
the O
plasma O
and O
tissue O
of O
Sudanese O
and O
Mexican O
patients O
infected O
with O
Onchocerca O
volvulus O
. O

The O
currently O
proposed O
extended O
arch O
repair O
should O
be O
reserved O
for O
the O
small O
group O
of O
infants O
with O
transverse O
aortic O
arch O
to O
ascending O
aorta O
diameter O
ratios O
( O
arch O
indices O
) O
of O
less O
than O
0 O
. O
25 O
. O

DNA O
hybridization O
analysis O
revealed O
that O
both O
pigmented O
and O
nonpigmented O
cells O
of O
Y O
. O
pestis O
possess O
a O
DNA O
locus O
homologous O
to O
the O
Escherichia B-GENE
coli I-GENE
fur I-GENE
gene I-GENE
. O

We O
report O
two O
patients O
receiving O
maintenance O
valproate O
, O
one O
with O
resolving O
acute O
hepatitis O
C O
and O
the O
other O
with O
chronic O
persistent O
hepatitis O
C O
, O
with O
incidental O
microvesicular O
steatosis O
demonstrated O
on O
oil O
- O
red O
O O
stains O
. O

UDP B-GENE
- I-GENE
Gal I-GENE
: I-GENE
Gal I-GENE
beta I-GENE
1 I-GENE
- I-GENE
- I-GENE
- I-GENE
- I-GENE
4GlcNAc I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
- I-GENE
- I-GENE
- I-GENE
3 I-GENE
- I-GENE
galactosyltransferase I-GENE
is O
a O
terminal B-GENE
glycosyltransferase I-GENE
that O
is O
widely O
expressed O
in O
a O
variety O
of O
mammalian O
species O
, O
with O
the O
notable O
exception O
of O
man O
, O
apes O
, O
and O
Old O
World O
monkeys O
. O

A O
synthetic O
oligonucleotide O
containing O
the O
SRE O
sequence O
from O
the O
mouse B-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
promoter I-GENE
( O
- O
299 O
to O
- O
322 O
) O
was O
radioactively O
labeled O
, O
used O
as O
a O
probe O
for O
the O
mobility O
shift O
assay O
and O
Southwestern O
( O
DNA O
- O
protein O
) O
blotting O
, O
and O
also O
used O
for O
sequence O
- O
specific O
affinity O
chromatography O
. O

This O
study O
indicates O
that O
this O
dose O
- O
intense O
regimen O
can O
be O
safely O
administered O
, O
even O
with O
the O
use O
of O
purged O
marrow O
, O
with O
an O
acceptable O
toxicity O
profile O
. O

INTERVENTIONS O
: O
Patients O
received O
rt B-GENE
- I-GENE
PA I-GENE
, O
heparin O
, O
and O
aspirin O
. O

Sequence O
analysis O
of O
the O
sMtCK B-GENE
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
TATAA O
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol B-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

Sequence O
analysis O
of O
the O
sMtCK B-GENE
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
TATAA O
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol B-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

The O
cDNA O
segment O
is O
flanked O
by O
the O
immunoglobulin B-GENE
gene I-GENE
recombination I-GENE
signal I-GENE
sequences I-GENE
so O
that O
the O
cDNA O
segment O
can O
invert O
and O
the O
human B-GENE
IL I-GENE
- I-GENE
2R I-GENE
L I-GENE
chain I-GENE
is O
subsequently O
expressed O
under O
the O
control O
of O
the O
SV40 B-GENE
promoter I-GENE
. O

Habituation O
of O
completely O
isolated O
neurons O
of O
the O
edible O
snail O
to O
electrical O
stimulation O
. O

Insulin B-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
1 I-GENE
( O
IGF B-GENE
- I-GENE
1 I-GENE
) O
in O
burn O
patients O
. O

The O
suppression O
was O
also O
demonstrated O
in O
a O
transient O
expression O
assay O
in O
vivo O
using O
isolated O
barley O
endosperms O
. O

RNA O
gel O
retardation O
and O
competition O
analyses O
indicate O
that O
TRP B-GENE
- I-GENE
185 I-GENE
binding O
is O
strongly O
dependent O
on O
the O
TAR O
RNA O
loop O
sequences O
. O

This O
generalization O
of O
MFP O
involves O
defining O
an O
appropriate O
high O
- O
resolution O
cost O
function O
, O
parametrizing O
the O
search O
space O
of O
the O
environment O
and O
source O
, O
constructing O
solutions O
of O
the O
wave O
equation O
, O
and O
utilizing O
a O
nonlinear O
optimization O
method O
to O
search O
the O
parameter O
landscape O
for O
the O
global O
minimum O
of O
the O
cost O
function O
. O

The O
original O
technique O
was O
developed O
in O
the O
1960 O
' O
s O
to O
analyze O
the O
inner O
ear O
fluid O
as O
a O
diagnostic O
procedure O
( O
i O
. O
e O
. O
, O
diagnostic O
labyrinthotomy O
) O
in O
acoustic O
neuroma O
suspects O
. O

Evolution O
of O
lesions O
did O
not O
necessarily O
follow O
a O
regular O
progression O
through O
the O
later O
stages O
of O
the O
vitelliform O
classification O
. O

Urine O
specimens O
containing O
either O
phencyclidine O
( O
PCP O
) O
or O
11 O
- O
nor O
- O
delta O
9 O
- O
tetrahydrocannabinol O
- O
9 O
- O
carboxylic O
acid O
( O
9 O
- O
THC O
- O
COOH O
) O
were O
adulterated O
with O
sodium O
chloride O
, O
bleach O
, O
vinegar O
, O
potassium O
hydroxide O
, O
liquid O
soap O
, O
2 O
- O
propanol O
, O
and O
ammonia O
. O

Along O
with O
previously O
mapped O
genes O
including O
Ly B-GENE
- I-GENE
1 I-GENE
and O
CD20 B-GENE
, O
OSBP B-GENE
defines O
a O
new O
conserved O
syntenic O
group O
on O
the O
long O
arm O
of O
chromosome O
11 O
in O
the O
human O
and O
the O
proximal O
end O
of O
chromosome O
19 O
in O
the O
mouse O
. O

Here O
we O
show O
that O
these O
synthetic O
binding O
sites O
have O
a O
more O
restricted O
and O
specific O
ability O
to O
enhance O
transcription O
when O
assayed O
in O
transformed O
embryos O
. O

After O
base O
- O
line O
CBF O
was O
established O
, O
hexamethonium O
bromide O
( O
2 O
mg O
/ O
kg O
iv O
) O
, O
ipratropium O
bromide O
( O
0 O
. O
5 O
microgram O
/ O
kg O
iv O
) O
, O
indomethacin O
( O
2 O
mg O
/ O
kg O
iv O
) O
, O
or O
intravenous O
0 O
. O
9 O
% O
saline O
was O
administered O
. O

This O
study O
suggests O
that O
BSPMs O
are O
useful O
in O
the O
assessment O
of O
AMI O
in O
terms O
of O
diagnosis O
, O
location O
and O
extent O
of O
myocardial O
infarct O
. O

Examination O
of O
immediate B-GENE
- I-GENE
early I-GENE
transcription I-GENE
factor I-GENE
expression O
during O
the O
MDI O
regimen O
revealed O
that O
RA O
mediated O
an O
elevated O
, O
prolonged O
expression O
of O
c B-GENE
- I-GENE
Jun I-GENE
mRNA I-GENE
accompanied O
by O
diminished O
expression O
of O
c B-GENE
- I-GENE
Fos I-GENE
and O
Jun B-GENE
- I-GENE
B I-GENE
mRNAs I-GENE
. O

Although O
heart O
rate O
and O
diastolic O
pressure O
rose O
in O
some O
degree O
1 O
min O
after O
intubation O
, O
free O
and O
total O
CA O
concentrations O
did O
not O
increase O
during O
study O
period O
. O

Processing O
, O
secretion O
, O
and O
immunoreactivity O
of O
carboxy B-GENE
terminally I-GENE
truncated I-GENE
dengue I-GENE
- I-GENE
2 I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
expressed O
in O
insect O
cells O
by O
recombinant O
baculoviruses O
. O

Seven O
clones O
encoding O
interferon B-GENE
response I-GENE
element I-GENE
binding I-GENE
factors I-GENE
have O
been O
isolated O
from O
a O
mouse O
fibroblast O
lambda O
gt11 O
cDNA O
library O
by O
using O
a O
32P O
end O
- O
labeled O
tandem O
trimer O
of O
the O
mouse B-GENE
( I-GENE
2 I-GENE
' I-GENE
- I-GENE
5 I-GENE
' I-GENE
) I-GENE
oligoadenylate I-GENE
synthetase I-GENE
gene I-GENE
interferon O
response O
element O
as O
a O
probe O
. O

DNA O
- O
protein O
UV O
cross O
- O
linking O
studies O
indicated O
that O
UHF B-GENE
- I-GENE
1 I-GENE
has O
an O
electrophoretic O
mobility O
on O
sodium O
dodecyl O
sulfate O
- O
acrylamide O
gels O
of O
approximately O
85 O
kDa O
and O
suggested O
that O
additional O
proteins O
, O
specific O
to O
each O
promoter O
, O
bind O
to O
each O
site O
. O

The O
specific O
interaction O
between O
a O
defined O
structural O
element O
of O
the O
human O
immunodeficiency O
virus O
mRNA O
( O
RRE B-GENE
, O
the O
Rev B-GENE
response I-GENE
element I-GENE
) O
and O
the O
virus B-GENE
- I-GENE
encoded I-GENE
protein I-GENE
Rev I-GENE
has O
been O
implicated O
in O
the O
regulation O
of O
the O
export O
of O
unspliced O
or O
singly O
spliced O
mRNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

Radiation O
- O
induced O
changes O
in O
the O
area O
of O
alveoli O
and O
septa O
as O
well O
as O
collagen B-GENE
content O
were O
seen O
11 O
weeks O
after O
irradiation O
. O

The O
first O
follow O
- O
up O
was O
at O
a O
nearly O
constant O
interval O
of O
5 O
. O
1 O
years O
in O
Caerphilly O
and O
3 O
. O
2 O
years O
in O
Speedwell O
; O
251 O
major O
IHD O
events O
had O
occurred O
. O

Once O
the O
proliferation O
of O
fibroblasts O
and O
collagen B-GENE
synthesis O
had O
led O
to O
an O
increase O
of O
mechanical O
strength O
, O
no O
negative O
effect O
on O
wound O
healing O
could O
be O
detected O
applying O
the O
same O
chemotherapeutic O
agents O
. O

During O
the O
years O
1980 O
- O
87 O
a O
total O
of O
287 O
persons O
received O
disability O
pensions O
in O
the O
municipality O
of O
Nordreisa O
in O
northern O
Norway O
. O

HeLa O
and O
Jurkat O
cell O
lines O
carrying O
the O
nef B-GENE
gene I-GENE
linked O
to O
the O
CMV O
promoter O
or O
the O
HIV B-GENE
- I-GENE
1 I-GENE
LTR I-GENE
were O
isolated O
by O
coselection O
for O
neomycin O
resistance O
. O

Two O
patients O
had O
immediate O
adverse O
effects O
from O
NMF O
; O
one O
had O
a O
grand O
mal O
seizure O
and O
the O
other O
developed O
severe O
abdominal O
pain O
. O

The O
muscles O
from O
the O
ischemic O
group O
had O
significantly O
lower O
( O
P O
less O
than O
. O
05 O
) O
values O
for O
capillary O
density O
and O
capillary O
to O
fiber O
ratio O
and O
significantly O
higher O
intercapillary O
distance O
than O
those O
from O
the O
normal O
group O
. O

Serum B-GENE
TNF I-GENE
concentrations O
were O
elevated O
at O
diagnosis O
and O
gradually O
decreased O
toward O
the O
reference O
limits O
by O
week O
16 O
. O

Conclusion O
: O
inlet O
type O
VSD O
and O
perimembranous O
type O
TOF O
have O
anatomic O
features O
in O
which O
the O
proximal O
His O
bundle O
tends O
to O
be O
jeopardized O
by O
suturing O
for O
VSD O
closure O
. O

The O
remainder O
( O
18 O
. O
4 O
% O
) O
was O
with O
IgA B-GENE
nephropathy O
, O
which O
was O
histologically O
mild O
. O

Grossly O
, O
the O
experimental O
vulvitis O
was O
identical O
to O
the O
field O
condition O
, O
and O
bacteria O
indistinguishable O
from O
the O
inoculated O
strains O
were O
reisolated O
. O

3 O
. O

Hemorrhagic O
shock O
and O
bacterial O
translocation O
in O
a O
swine O
model O
. O

A O
method O
for O
establishing O
stimulus O
control O
of O
ethanol O
responding O
was O
developed O
. O

In O
all O
cases O
, O
high O
- O
level O
expression O
of O
the O
truncated B-GENE
avian I-GENE
integrins I-GENE
was O
obtained O
. O

In O
adulthood O
these O
rats O
were O
hyperactive O
and O
learned O
the O
active O
avoidance O
response O
later O
than O
the O
controls O
. O

The O
N O
- O
terminal O
115 O
amino O
acids O
correspond O
to O
a O
putative O
DNA O
- O
binding O
domain O
and O
show O
significant O
sequence O
similarity O
with O
other O
cloned O
IFN B-GENE
response I-GENE
factors I-GENE
( O
IRF B-GENE
- I-GENE
1 I-GENE
and O
IRF B-GENE
- I-GENE
2 I-GENE
) O
. O

The O
patients O
were O
divided O
into O
3 O
subgroups O
: O
1 O
) O
13 O
N O
+ O
patients O
with O
multiple O
hot O
spots O
( O
greater O
than O
2 O
) O
( O
N O
+ O
IM O
) O
; O
2 O
) O
24 O
N O
+ O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
+ O
IS O
) O
; O
3 O
) O
12 O
N O
- O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
- O
IS O
) O
. O

Further O
, O
they O
are O
consistent O
with O
the O
suggestion O
that O
sites O
homologous O
to O
the O
CAR1 B-GENE
URS I-GENE
may O
be O
situated O
in O
the O
5 O
' O
- O
flanking O
regions O
of O
multiple O
unrelated O
yeast O
genes O
. O

Uses O
of O
orthoclone O
OKT3 B-GENE
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
nonfunction O
in O
kidney O
transplantation O
. O

Uses O
of O
orthoclone O
OKT3 O
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
nonfunction O
in O
kidney O
transplantation O
. O

In O
Denmark O
only O
1 O
- O
3 O
cases O
of O
transfusion O
- O
associated O
hepatitis O
NANB O
( O
TAH O
- O
NANB O
) O
are O
registered O
annually O
or O
about O
1 O
case O
per O
100 O
, O
000 O
units O
transfused O
. O

Hence O
, O
the O
replacement O
of O
Phe O
- O
62 O
with O
Ser O
specifically O
affects O
a O
determinant O
on O
the O
lambda B-GENE
I I-GENE
light I-GENE
chain I-GENE
that O
is O
necessary O
for O
the O
intracellular O
transport O
of O
this O
molecule O
. O

The O
deduced O
amino O
acid O
sequence O
has O
the O
greatest O
homology O
( O
61 O
% O
) O
to O
the O
green B-GENE
alga I-GENE
Scenedemus I-GENE
obliquus I-GENE
plastocyanin I-GENE
. O

Higher O
fasting O
serum O
gastrin B-GENE
concentration O
( O
102 O
. O
0 O
+ O
/ O
- O
21 O
. O
1 O
vs O
63 O
. O
3 O
+ O
/ O
- O
8 O
. O
3 O
ng O
. O
l O
- O
1 O
) O
, O
and O
greater O
postprandial O
gastrin B-GENE
release O
( O
AUC0 O
- O
120 O
: O
16690 O
+ O
/ O
- O
2648 O
vs O
10654 O
+ O
/ O
- O
1283 O
ng O
. O
l O
- O
1 O
min O
) O
were O
observed O
after O
VTP O
- O
HM O
than O
after O
VTP O
- O
Cas O
. O

The O
experimental O
group O
consisted O
of O
61 O
examinees O
class O
II O
/ O
2 O
orthodontic O
anomalies O
. O

Subjects O
were O
16 O
male O
chronic O
schizophrenics O
consisting O
of O
8 O
DST O
suppressors O
and O
8 O
nonsuppressors O
. O

In O
this O
article O
we O
propose O
to O
find O
out O
the O
percentage O
of O
normal O
occlusion O
and O
the O
distribution O
of O
maloclusions O
, O
according O
to O
the O
anteroposterior O
relationship O
between O
the O
dental O
archs O
( O
following O
the O
ANGLE3 O
classification O
) O
. O

We O
have O
previously O
identified O
, O
by O
screening O
a O
lambda O
gt11 O
expression O
library O
, O
murine B-GENE
protein I-GENE
mXBP I-GENE
, O
which O
binds O
to O
a O
sequence O
which O
overlaps O
the O
3 O
' O
end O
of O
the O
murine B-GENE
class I-GENE
II I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
A I-GENE
alpha I-GENE
gene I-GENE
X I-GENE
box I-GENE
, O
a O
conserved O
transcription O
element O
found O
upstream O
of O
all O
class O
II O
genes O
. O

A O
contiguous O
and O
sequentially O
occupied O
secondary O
Fur B-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
entC B-GENE
was O
protected O
at O
higher O
Fur B-GENE
concentrations O
, O
extending O
the O
protected O
region O
to O
+ O
49 O
, O
and O
sequestering O
the O
putative O
Shine O
- O
Dalgarno O
sequence O
. O

The O
major O
promoter O
responds O
strongly O
to O
virus O
- O
encoded O
trans O
activators O
EIA B-GENE
and O
EIV B-GENE
and O
contains O
four O
elements O
: O
a O
TAGA O
motif O
analogous O
to O
the O
TATA O
box O
, O
two O
EIIF B-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
, O
and O
an O
ATF B-GENE
/ O
CREB B-GENE
site O
. O

Luteinizing B-GENE
hormone I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
analog O
therapy O
of O
uterine O
fibroid O
: O
analysis O
of O
results O
obtained O
with O
buserelin O
administered O
intranasally O
and O
goserelin O
administered O
subcutaneously O
as O
a O
monthly O
depot O
. O

Although O
there O
are O
no O
octamer O
elements O
in O
the O
adenovirus O
genome O
that O
are O
known O
to O
be O
important O
for O
transcription O
, O
there O
are O
octamer O
elements O
in O
the O
viral O
terminal O
repeat O
sequences O
. O

A O
4 O
. O
8 O
- O
kilobase O
BamHI B-GENE
- O
HindIII B-GENE
fragment O
encoding O
the O
entire B-GENE
Neurospora I-GENE
crassa I-GENE
CuZn I-GENE
superoxide I-GENE
dismutase I-GENE
gene I-GENE
( O
herein O
designated O
sod B-GENE
- I-GENE
1 I-GENE
) O
was O
isolated O
from O
a O
genomic O
library O
using O
two O
60 O
- O
base O
deoxyoligonucleotide O
probes O
corresponding O
to O
the O
published O
N O
. O
crassa O
amino O
acid O
sequence O
. O

Using O
appropriate O
synthetic O
HSE O
oligonucleotides O
, O
three O
types O
of O
clones O
with O
potential O
HSE O
binding O
domains O
were O
isolated O
from O
a O
tomato O
lambda O
gt11 O
expression O
library O
by O
DNA O
- O
ligand O
screening O
. O

This O
result O
indicates O
that O
separate O
complexes O
exist O
containing O
ankyrin B-GENE
and O
fodrin B-GENE
with O
either O
uvomorulin B-GENE
or O
Na B-GENE
+ I-GENE
, I-GENE
K I-GENE
+ I-GENE
- I-GENE
ATPase I-GENE
. O

These O
genes O
are O
expressed O
within O
a O
few O
hours O
of O
the O
initiation O
of O
development O
; O
their O
mRNAs O
accumulate O
to O
a O
peak O
at O
12 O
hr O
and O
persist O
until O
culmination O
. O

In O
transient O
cotransfection O
assays O
using O
Chang O
liver O
cells O
( O
CCL O
13 O
) O
, O
pM1 O
DNA O
exerts O
a O
6 O
- O
to O
10 O
- O
fold O
trans O
- O
activating O
effect O
on O
the O
expression O
of O
the O
pSV2CAT O
reporter O
plasmid O
. O

We O
have O
determined O
the O
nucleotide O
( O
nt O
) O
sequence O
of O
the O
7 B-GENE
. I-GENE
5 I-GENE
- I-GENE
kb I-GENE
COR I-GENE
segment I-GENE
that O
encompasses O
a O
cluster O
of O
six O
genes O
( O
CYC1 B-GENE
, O
UTR1 B-GENE
, O
UTR3 B-GENE
, O
OSM1 B-GENE
, O
tRNA B-GENE
( I-GENE
Gly I-GENE
) I-GENE
and O
RAD7 B-GENE
) O
located O
on O
chromosome O
X O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

No O
recombination O
signal O
sequences O
have O
been O
found O
contiguous O
to O
the O
recombination O
point O
. O

The O
antinociceptive O
properties O
, O
as O
measured O
by O
the O
tail O
- O
flick O
and O
hot O
- O
plate O
tests O
, O
and O
the O
motor O
effects O
of O
an O
intrathecally O
- O
administered O
benzodiazepine O
agonist O
midazolam O
, O
alone O
, O
and O
in O
combination O
with O
morphine O
, O
was O
examined O
in O
rats O
. O

To O
identify O
these O
sites O
, O
the O
deduced O
amino O
acid O
sequence O
of O
the O
3T3 O
- O
L1 O
adipocyte B-GENE
insulin I-GENE
receptor I-GENE
of O
the O
mouse O
was O
determined O
. O

PAO O
blocks O
turnover O
of O
the O
phosphoryl O
group O
of O
pp15 B-GENE
, O
causing O
its O
accumulation O
, O
and O
thereby O
appears O
to O
interrupt O
signal O
transmission O
from O
the O
receptor O
to O
the O
glucose O
- O
transport O
system O
. O

It O
is O
likely O
that O
the O
sequence O
similarities O
reflect O
a O
common O
molecular O
architecture O
of O
the O
two O
heme O
binding O
sites O
and O
of O
a O
copper O
binding O
site O
in O
these O
enzymes O
. O

The O
TraD B-GENE
protein I-GENE
( I-GENE
83 I-GENE
, I-GENE
899 I-GENE
Da I-GENE
) I-GENE
contains O
three O
hydrophobic O
regions O
, O
of O
which O
two O
are O
located O
near O
the O
amino O
- O
terminal O
region O
. O

The O
protein O
product O
of O
orfD B-GENE
, O
which O
is O
probably O
a O
new O
tra B-GENE
gene I-GENE
( O
named O
traX B-GENE
) O
, O
contains O
65 O
% O
hydrophobic O
amino O
acids O
, O
especially O
rich O
in O
alanine O
and O
leucine O
. O

A O
gene O
in O
Drosophila O
melanogaster O
that O
maps O
cytologically O
to O
2C1 O
- O
3 O
on O
the O
distal O
portion O
of O
the O
X O
- O
chromosome O
encodes O
a O
member O
of O
the O
steroid B-GENE
/ I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

A O
portion O
of O
Region O
II O
also O
resembles O
part O
of O
the O
human O
c B-GENE
- I-GENE
jun I-GENE
oncoprotein O
' O
s O
leucine O
zipper O
, O
which O
in O
turn O
, O
has O
been O
demonstrated O
to O
be O
the O
heterodimerization O
site O
between O
the O
jun B-GENE
and O
fos B-GENE
oncoproteins I-GENE
. O

To O
determine O
whether O
vanadate O
could O
inhibit O
PEPCK B-GENE
gene I-GENE
transcription O
, O
a O
series O
of O
chimeric O
genes O
containing O
several O
deletions O
in O
the O
P B-GENE
- I-GENE
enolypyruvate I-GENE
carboxykinase I-GENE
promoter I-GENE
between O
- O
550 O
and O
- O
68 O
was O
linked O
to O
the O
structural O
genes O
for O
either O
amino B-GENE
- I-GENE
3 I-GENE
- I-GENE
glycosyl I-GENE
phosphotransferase I-GENE
( O
neo B-GENE
) O
or O
chloramphenicol B-GENE
acetyltransferase I-GENE
and O
introduced O
into O
hepatoma O
cells O
using O
three O
methods O
: O
( O
a O
) O
infection O
with O
a O
Moloney O
murine O
leukemia O
virus O
- O
based O
retrovirus O
, O
( O
b O
) O
transfection O
and O
stable O
selection O
for O
neo B-GENE
expression O
, O
or O
( O
c O
) O
transient O
expression O
of O
chloroamphenicol B-GENE
acetyltransferase I-GENE
. O

Significant O
correlations O
were O
obtained O
between O
changes O
in O
SSEP O
in O
response O
to O
AS O
and O
the O
presence O
of O
not O
deep O
residual O
- O
organic O
disturbances O
, O
so O
- O
called O
" O
ground O
" O
in O
psychogenic O
disorders O
. O

Both O
strains O
grew O
very O
poorly O
, O
or O
not O
at O
all O
, O
on O
nonfermentable O
carbon O
sources O
and O
exhibited O
, O
at O
most O
, O
only O
5 O
% O
of O
wild B-GENE
- I-GENE
type I-GENE
ubiquinol I-GENE
- I-GENE
cytochrome I-GENE
c I-GENE
oxidoreductase I-GENE
activity O
. O

Regulation O
of O
irgA B-GENE
by O
iron O
in O
V O
. O
cholerae O
occurs O
at O
the O
transcriptional O
level O
, O
and O
there O
is O
an O
interrupted O
dyad O
symmetric O
sequence O
in O
the O
vicinity O
of O
the O
promoter O
that O
is O
homologous O
to O
Fur B-GENE
binding I-GENE
sites I-GENE
of O
E O
. O
coli O
. O

The O
recombinant O
contains O
the O
normal O
beta B-GENE
A I-GENE
- I-GENE
globin I-GENE
gene I-GENE
, O
the O
mutant O
gene O
and O
Ylp O
vector O
sequences O
between O
the O
two O
copies O
. O

The O
characterized O
Y B-GENE
' I-GENE
repeated I-GENE
sequence I-GENE
families I-GENE
provide O
an O
experimental O
system O
in O
which O
repeated O
sequence O
interactions O
and O
subsequent O
evolution O
can O
be O
studied O
. O

However O
, O
primary O
transcripts O
of O
a O
variant B-GENE
tRNA I-GENE
( I-GENE
Val I-GENE
) I-GENE
( I-GENE
UAC I-GENE
) I-GENE
gene I-GENE
are O
processing O
deficient O
under O
standard O
growth O
conditions O
( O
30 O
degrees O
C O
) O
, O
due O
to O
a O
slightly O
altered O
5 O
' O
flanking O
region O
. O

Three O
of O
the O
short O
ORFs O
in O
the O
central O
region O
of O
BIV O
have O
been O
identified O
by O
location O
and O
structural O
similarity O
to O
the O
nonstructural O
/ O
regulatory O
genes O
( O
vif B-GENE
, O
tat B-GENE
, O
and O
rev B-GENE
) O
of O
other O
lentiviruses O
; O
we O
also O
discovered O
two O
unique O
ORFs O
, O
termed O
W O
and O
Y O
, O
which O
may O
serve O
as O
exons O
for O
novel O
genes O
. O

The O
contribution O
that O
alternative O
splicing O
events O
in O
c B-GENE
- I-GENE
myb I-GENE
expression O
may O
make O
on O
c B-GENE
- I-GENE
myb I-GENE
function O
remains O
to O
be O
elucidated O
. O

IgG B-GENE
and O
IgM B-GENE
antibody O
activity O
was O
determined O
by O
adding O
a O
1 O
: O
100 O
dilution O
of O
serum O
to O
plates O
coated O
with O
A60 B-GENE
antigen I-GENE
. O

1 O
, O
among O
which O
nine O
have O
been O
cloned O
and O
two O
( O
potentially O
functional O
) O
sequenced O
. O

The O
urinary O
protein O
, O
serum O
albumin B-GENE
, O
BUN O
and O
SCr O
all O
had O
very O
significant O
improvement O
. O

Patients O
with O
detectable O
serum O
TNF B-GENE
levels O
had O
significantly O
lower O
serum O
T3 O
concentrations O
compared O
to O
those O
with O
undetectable O
levels O
[ O
1 O
. O
072 O
+ O
/ O
- O
0 O
. O
588 O
vs O
. O

Rats O
with O
one O
olfactory O
bulb O
removed O
and O
the O
contralateral O
naris O
closed O
can O
detect O
odors O
. O

Expression O
of O
the O
human O
T B-GENE
cell I-GENE
receptor I-GENE
( I-GENE
TCR I-GENE
) I-GENE
alpha I-GENE
gene I-GENE
is O
regulated O
by O
a O
T O
cell O
- O
specific O
transcriptional O
enhancer O
that O
is O
located O
4 O
. O
5 O
kilobases O
( O
kb O
) O
3 O
' O
to O
the O
C B-GENE
alpha I-GENE
gene I-GENE
segment I-GENE
. O

The O
Ets B-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
was O
localized O
to O
a O
17 O
- O
base O
pair O
( O
bp O
) O
region O
from O
the O
3 O
' O
end O
of O
T B-GENE
alpha I-GENE
2 I-GENE
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
encodes O
a O
40 O
- O
kDa O
nuclear O
protein O
, O
Tax B-GENE
, O
which O
stimulates O
transcription O
from O
three O
21 O
- O
base O
pair O
( O
bp O
) O
repeats O
in O
its O
U3 O
region O
. O

We O
have O
now O
identified O
, O
after O
21 O
serial O
undiluted O
passages O
of O
MHV O
, O
a O
small B-GENE
DI I-GENE
RNA I-GENE
, O
DIssF B-GENE
, O
which O
is O
efficiently O
packaged O
into O
virions O
. O

This O
, O
together O
with O
the O
data O
obtained O
with O
haloperidol O
, O
suggests O
that O
a O
minimal O
increase O
in O
the O
firing O
rate O
of O
LC O
cells O
( O
+ O
140 O
% O
) O
is O
required O
before O
it O
could O
influence O
the O
turnover O
of O
NA O
, O
as O
measured O
by O
DOPAC O
changes O
. O

The O
Mauriceville O
and O
Varkud O
mitochondrial O
plasmids O
are O
closely O
related O
, O
closed O
- O
circular O
DNAs O
( O
3 O
. O
6 O
and O
3 O
. O
7 O
kb O
, O
respectively O
) O
that O
have O
characteristics O
of O
mtDNA O
introns O
and O
retroid O
elements O
. O

The O
circadian O
rhythm O
, O
however O
, O
was O
not O
affected O
and O
the O
difference O
between O
minimum O
( O
12 O
. O
00 O
h O
) O
and O
maximum O
( O
18 O
. O
50 O
h O
) O
serum O
concentrations O
was O
31 O
. O
3 O
% O
. O

Most O
strains O
( O
95 O
% O
) O
of O
S O
. O
lugdunensis O
produced O
a O
delta B-GENE
hemolysin I-GENE
like O
that O
seen O
with O
nine O
other O
species O
of O
CNS O
. O

Experiments O
showed O
that O
temporary O
arrest O
of O
pulmonary O
circulation O
under O
conditions O
of O
extracorporeal O
circulation O
is O
attended O
by O
the O
development O
of O
ischemia O
of O
the O
respiratory O
pulmonary O
tissue O
. O

Taste O
reactivity O
tests O
were O
used O
to O
examine O
the O
orofacial O
responses O
of O
alcohol O
preferring O
( O
P O
) O
rats O
and O
alcohol O
nonpreferring O
( O
NP O
) O
rats O
to O
the O
taste O
of O
alcohol O
. O

1 O
( O
" O
long O
method O
" O
) O
and O
the O
HML O
method O
. O

No O
causal O
relations O
may O
be O
inferred O
from O
the O
correlation O
between O
the O
level O
of O
trapezius O
activity O
and O
complaints O
, O
though O
it O
indicates O
that O
individual O
, O
inexpedient O
muscle O
activity O
patterns O
may O
constitute O
an O
important O
risk O
factor O
for O
development O
of O
musculo O
- O
skeletal O
complaints O
. O

Analysis O
with O
additional O
anti O
- O
peptide O
antibodies O
specific O
for O
alpha B-GENE
, I-GENE
beta I-GENE
, I-GENE
or I-GENE
gamma I-GENE
PKC I-GENE
indicated O
that O
all O
three O
types O
of O
PKC B-GENE
are O
expressed O
in O
JK O
cells O
; O
however O
, O
JKPE O
cells O
lost O
a O
major O
approximately O
82 O
kDa O
immunoreactive O
cytosolic O
protein O
detectable O
with O
anti B-GENE
- I-GENE
PKC I-GENE
alpha I-GENE
antibody I-GENE
. O

Erythrocyte O
protoporphyrin O
concentration O
increased O
significantly O
( O
P O
less O
than O
0 O
. O
05 O
) O
by O
14 O
days O
in O
dogs O
fed O
the O
basal O
diet O
, O
and O
remained O
significantly O
high O
relative O
to O
that O
in O
dogs O
of O
the O
other O
dietary O
groups O
for O
the O
remainder O
of O
the O
study O
. O

The O
coding O
sequences O
of O
the O
Crry B-GENE
gene I-GENE
encompass O
over O
25 O
kb O
of O
DNA O
, O
whereas O
the O
Crry B-GENE
- O
ps B-GENE
sequences O
are O
included O
within O
a O
single O
5 B-GENE
. I-GENE
6 I-GENE
- I-GENE
kb I-GENE
Eco I-GENE
- I-GENE
R1 I-GENE
fragment I-GENE
. O

The O
genomic O
and O
transcriptional O
complexity O
of O
the O
Crry B-GENE
and O
Crry B-GENE
- O
ps B-GENE
genes O
. O

Determination O
of O
three O
- O
dimensional O
imaging O
properties O
of O
a O
light O
microscope O
system O
. O

Methods O
used O
include O
Cobb O
angle O
and O
a O
segmental O
evaluation O
( O
T7 O
- O
T12 O
) O
of O
each O
of O
convex O
and O
concave O
rib O
- O
vertebra O
angles O
( O
RVAs O
) O
, O
rib O
- O
vertebra O
angle O
differences O
( O
RVADs O
) O
, O
vertebral O
rotation O
, O
tilt O
and O
displacement O
. O

Lars O
has O
AIDS O
- O
- O
a O
more O
dignified O
life O
with O
care O
at O
home O
. O

Accumulations O
of O
Tl O
+ O
1 O
( O
202Tl O
label O
) O
were O
6 O
times O
those O
for O
Ga O
or O
In O
in O
the O
brain O
and O
muscles O
, O
and O
. O
1 O
times O
in O
plasma O
. O

A O
poor O
correlation O
was O
also O
observed O
between O
PbB O
and O
ALAD B-GENE
activity O
of O
the O
stearate O
workers O
. O

Since O
the O
UfAP B-GENE
and O
UTMP B-GENE
share O
many O
biosynthetic O
and O
structural O
features O
that O
include O
site O
of O
biosynthesis O
in O
the O
endometrium O
, O
P4 O
- O
responsiveness O
, O
the O
presence O
of O
the O
mannose O
6 O
- O
phosphate O
lysosomal O
recognition O
marker O
, O
and O
considerable O
sequence O
similarity O
, O
the O
UfAP B-GENE
and O
the O
UTMP B-GENE
may O
have O
homologous O
function O
which O
for O
both O
still O
remains O
obscure O
. O

Fifteen O
light O
for O
dates O
infants O
and O
their O
placentae O
were O
compared O
to O
15 O
well O
- O
grown O
infants O
and O
their O
placentae O
. O

Treating O
renal O
anaemia O
with O
recombinant O
human O
erythropoietin B-GENE
. O

Basing O
on O
experimental O
toxicity O
research O
it O
was O
established O
that O
, O
out O
of O
50 O
atmosphere O
metal O
corrosion O
inhibitors O
, O
some O
14 O
per O
cent O
were O
found O
extremely O
hazardous O
, O
42 O
per O
cent O
- O
- O
of O
high O
level O
hazardous O
, O
33 O
percent O
- O
- O
of O
moderate O
and O
11 O
per O
cent O
- O
- O
of O
low O
hazardous O
. O

The O
effects O
on O
reflex O
latencies O
but O
not O
on O
paCO2 O
or O
pHa O
were O
blocked O
by O
naloxone O
( O
2 O
mg O
/ O
kg O
) O
, O
and O
were O
not O
present O
in O
morphine O
- O
tolerant O
animals O
. O

Of O
the O
remaining O
seven O
, O
five O
reacted O
either O
with O
immediate O
and O
strong O
symptoms O
or O
had O
spontaneously O
reduced O
gluten B-GENE
intake O
, O
or O
had O
an O
acquired O
IgA B-GENE
deficiency O
. O

In O
addition O
serum B-GENE
IgE I-GENE
concentrations O
were O
not O
statistically O
different O
. O

The O
findings O
suggest O
that O
, O
although O
iodine O
deficiency O
is O
the O
most O
probable O
cause O
of O
goiter O
among O
immigrants O
of O
the O
1928 O
cohort O
, O
where O
the O
native O
population O
is O
concerned O
( O
both O
men O
and O
women O
) O
, O
some O
other O
goitrogenic O
factor O
( O
s O
) O
must O
be O
involved O
. O

Co O
- O
administration O
of O
5FU O
, O
angiotensin B-GENE
II I-GENE
and O
microspheres O
via O
the O
hepatic O
artery O
may O
reduce O
drug O
exposure O
in O
the O
systemic O
compartment O
and O
therefore O
may O
increase O
the O
therapeutic O
ratio O
of O
5FU O
administration O
via O
the O
hepatic O
artery O
. O

In O
contrast O
, O
2 O
, O
397 O
( O
74 O
% O
) O
had O
one O
or O
more O
risk O
factors O
( O
not O
low O
risk O
) O
; O
of O
these O
, O
5 O
. O
3 O
% O
died O
in O
6 O
weeks O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

Comparison O
of O
propofol O
and O
thiopentone O
as O
anaesthetic O
agents O
for O
electroconvulsive O
therapy O
. O

Nonvascular O
ophthalmic O
and O
neurologic O
disorders O
that O
can O
be O
confused O
with O
amaurosis O
fugax O
are O
listed O
, O
and O
an O
algorithm O
for O
evaluation O
( O
which O
includes O
ophthalmic O
examination O
, O
laboratory O
studies O
, O
and O
noninvasive O
carotid O
artery O
studies O
) O
is O
given O
. O

These O
characteristics O
of O
N22 O
/ O
P22 O
indicate O
that O
it O
is O
a O
localized O
synaptically O
dependent O
event O
conforming O
to O
a O
transverse O
dipole O
with O
dorsal O
negativity O
and O
a O
simultaneous O
anterior O
positivity O
. O

We O
evaluated O
the O
likelihood O
of O
tissues O
to O
be O
positive O
for O
carcinoembryonic B-GENE
antigen I-GENE
and O
the O
intensity O
of O
carcinoembryonic B-GENE
antigen I-GENE
staining O
in O
specimens O
of O
villous O
adenomas O
, O
mixed O
polypoid O
villous O
adenomas O
, O
polypoid O
adenomas O
, O
and O
diverticulitis O
using O
the O
peroxidase B-GENE
- O
antiperoxidase B-GENE
technique O
. O

These O
results O
support O
the O
view O
that O
clonidine O
and O
6 O
- O
OHDA O
, O
but O
not O
alpha O
- O
MD O
, O
have O
central O
pressor O
actions O
in O
the O
rat O
that O
oppose O
their O
antihypertensive O
action O
. O

We O
conclude O
that O
Hansel O
' O
s O
stain O
substantially O
improves O
the O
recognition O
of O
eosinophiluria O
as O
compared O
with O
Wright O
' O
s O
stain O
. O

The O
study O
included O
139 O
eyes O
with O
presumed O
ocular O
histoplasmosis O
syndrome O
( O
POHS O
) O
and O
age O
- O
related O
macular O
degeneration O
( O
AMD O
) O
. O

Rarely O
, O
patients O
with O
locally O
advanced O
, O
uncontrollable O
, O
non O
- O
metastatic O
prostatic O
cancer O
enjoy O
prolonged O
survival O
. O

ATP O
gamma O
S O
inhibition O
can O
be O
overcome O
by O
high O
concentrations O
of O
ATP O
, O
dATP O
, O
araATP O
, O
or O
ddATP O
. O

Enhancer O
and O
promoter O
elements O
directing O
activation O
and O
glucocorticoid O
repression O
of O
the O
alpha B-GENE
1 I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
in O
hepatocytes O
. O

The O
gene O
is O
contained O
within O
a O
1 O
. O
8 O
- O
kilobase O
AccI B-GENE
- O
EcoRI B-GENE
restriction O
fragment O
mapping O
at O
map O
coordinates O
0 O
. O
136 O
to O
0 O
. O
148 O
in O
the O
UL O
region O
of O
the O
EHV O
- O
1 O
genome O
and O
is O
transcribed O
from O
right O
to O
left O
. O

Spontaneous O
sensitization O
to O
cross O
- O
reacting O
chemicals O
in O
a O
proportion O
of O
control O
animals O
is O
strongly O
suggested O
, O
somewhat O
akin O
to O
spontaneous O
sensitization O
in O
patients O
with O
anaphylactoid O
reactions O
to O
neuromuscular O
blockers O
on O
first O
exposure O
, O
and O
in O
whom O
IgE B-GENE
antibodies I-GENE
are O
detected O
. O

The O
84 B-GENE
. I-GENE
1C I-GENE
mAb I-GENE
recognizes O
a O
site O
on O
IgE B-GENE
which O
is O
identical O
or O
very O
close O
to O
the O
Fc B-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
, O
and O
95 O
. O
3 O
recognizes O
a O
site O
on O
IgE B-GENE
which O
is O
related O
, O
but O
not O
identical O
to O
the O
Fc B-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
. O

Endocrine O
cells O
were O
studied O
by O
means O
of O
Grimelius O
' O
silver O
staining O
and O
immunostaining O
for O
chromogranin B-GENE
, O
a O
general O
marker O
of O
endocrine O
cells O
. O

A O
potential O
TATA O
box O
is O
located O
29 O
base O
pairs O
upstream O
of O
the O
first O
transcription O
initiation O
site O
. O

In O
76 O
% O
of O
59 O
lead O
- O
toxic O
children O
, O
bone O
lead O
values O
measured O
by O
LXRF O
were O
equal O
to O
or O
greater O
than O
those O
measured O
in O
normal O
and O
industrially O
exposed O
adults O
. O

When O
considered O
with O
the O
known O
neurotoxic O
effects O
on O
children O
of O
" O
low O
levels O
" O
of O
exposure O
to O
lead O
, O
these O
results O
also O
suggest O
that O
either O
an O
excessively O
narrow O
margin O
of O
safety O
or O
insufficient O
safety O
is O
provided O
by O
present O
U O
. O
S O
. O
guidelines O
, O
which O
classify O
an O
elevated O
blood O
lead O
concentration O
as O
25 O
micrograms O
/ O
dl O
or O
greater O
. O

In O
resting O
3T3 O
cells O
, O
jun B-GENE
- I-GENE
D I-GENE
is O
expressed O
at O
a O
higher O
level O
compared O
to O
c B-GENE
- I-GENE
jun I-GENE
and O
jun B-GENE
- I-GENE
B I-GENE
, O
and O
its O
transcription O
is O
stimulated O
only O
slightly O
by O
serum O
growth O
factors O
. O

Functional O
rearranged O
antibody O
genes O
were O
detected O
with O
JH B-GENE
and O
VH B-GENE
heavy I-GENE
chain I-GENE
probes O
and O
with O
Jk B-GENE
and O
Vk B-GENE
light I-GENE
chain I-GENE
probes O
. O

Isolation O
of O
Weeksella O
virosa O
( O
formerly O
CDC O
group O
IIf O
) O
from O
a O
vaginal O
sample O
. O

Growth O
of O
tracheal O
anastomoses O
in O
growing O
animals O

The O
ORF1 O
product O
was O
required O
for O
competence O
, O
while O
ORF2 O
, O
which O
was O
cotranscribed O
with O
ORF1 O
and O
encoded O
a O
predicted O
protein O
of O
126 O
amino O
acids O
, O
was O
not O
. O

In O
all O
sessions O
under O
IFN B-GENE
, O
the O
latency O
of O
the O
P100 O
component O
of O
the O
VEP O
was O
shortened O
as O
compared O
to O
baseline O
conditions O
. O

This O
paper O
presents O
the O
reasons O
why O
countries O
to O
which O
Chagas O
disease O
is O
endemic O
should O
carry O
out O
the O
relevant O
research O
themselves O
. O

The O
PETCO2 O
measurement O
during O
precordial O
compression O
predicted O
the O
success O
of O
defibrillation O
with O
return O
of O
spontaneous O
circulation O
. O

Gastric O
CO2 O
/ O
HCO3 O
was O
determined O
in O
absence O
of O
simultaneous O
inhibition O
of O
acid O
secretion O
by O
intra O
- O
and O
extragastric O
pCO2 O
/ O
pH O
measurements O
in O
23 O
persons O
and O
calculated O
using O
the O
equation O
of O
Henderson O
- O
Hasselbalch O
. O
pCO2 O
was O
measured O
with O
use O
of O
a O
new O
electrode O
. O

Inefficacy O
of O
phosphine O
fumigation O
against O
ticks O
. O

According O
to O
the O
published O
sequence O
of O
the O
CHS1 B-GENE
gene I-GENE
, O
this O
fragment O
contains O
four O
repeats O
of O
a O
TGAAACA O
consensus O
sequence O
previously O
identified O
in O
the O
alpha B-GENE
- I-GENE
factor I-GENE
- O
inducible O
BAR1 B-GENE
promoter I-GENE
[ O
Kronstad O
, O
J O
. O

Xenopus B-GENE
homolog I-GENE
of I-GENE
the I-GENE
mos I-GENE
protooncogene I-GENE
transforms O
mammalian O
fibroblasts O
and O
induces O
maturation O
of O
Xenopus O
oocytes O
. O

Southern O
blot O
analyses O
demonstrated O
a O
low O
, O
if O
not O
single O
, O
copy O
number O
for O
this O
gene O
and O
conservation O
of O
this O
domain O
in O
other O
vertebrates O
. O

We O
conclude O
that O
( O
a O
) O
the O
likelihood O
of O
detecting O
carcinoma O
or O
atypical O
hyperplasia O
exclusively O
in O
the O
adipose O
tissue O
component O
of O
grossly O
benign O
breast O
biopsies O
is O
extremely O
low O
, O
and O
( O
b O
) O
a O
possible O
cost O
- O
effective O
method O
of O
sampling O
grossly O
benign O
breast O
biopsies O
consists O
of O
initially O
submitting O
a O
maximum O
of O
10 O
blocks O
of O
fibrous O
parenchyma O
for O
each O
case O
, O
then O
examining O
the O
remaining O
tissue O
histologically O
only O
if O
carcinoma O
or O
atypical O
hyperplasia O
is O
found O
among O
these O
blocks O
. O

A O
brief O
account O
of O
the O
1988 O
seminar O
in O
Shanghai O
on O
viral O
hepatitis O
A O

Erythrocytic O
stages O
of O
mammalian O
malarial O
parasites O
contain O
acristate O
mitochondria O
whose O
functions O
are O
not O
well O
understood O
. O

Restriction O
maps O
of O
the O
cloned O
plasmids O
revealed O
that O
their O
chromosomal O
inserts O
consisted O
of O
overlapping O
fragments O
. O

In O
contrast O
, O
a O
similar O
fragment O
lacking O
the O
38 O
- O
base O
- O
pair O
region O
had O
no O
such O
stabilizing O
effect O
. O

This O
TC B-GENE
- I-GENE
II I-GENE
enhanson I-GENE
, O
which O
is O
identical O
to O
the O
kappa B-GENE
B I-GENE
motif I-GENE
from O
the O
kappa B-GENE
chain I-GENE
enhancer I-GENE
, O
was O
active O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
which O
contrasts O
with O
the O
previously O
reported O
lymphoid O
cell O
specificity O
of O
the O
kappa B-GENE
B I-GENE
motif I-GENE
. O

The O
DNA O
sequences O
predict O
proteins O
for O
SRP54sc B-GENE
and O
SRP54sp B-GENE
that O
are O
47 O
% O
and O
52 O
% O
identical O
to O
SRP54mam B-GENE
, O
respectively O
. O

Antihistamines O
in O
asthma O
. O

We O
have O
therefore O
evaluated O
the O
efficacy O
and O
safety O
of O
doxazosin O
, O
a O
new O
orally O
active O
selective O
alpha B-GENE
1 I-GENE
blocker O
, O
in O
patients O
with O
systemic O
hypertension O
with O
concomitant O
airflow O
limitation O
. O

The O
discussion O
focuses O
primarily O
on O
the O
newer O
drugs O
like O
angiotensin B-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
, O
alpha B-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockers O
, O
and O
calcium O
antagonists O
. O

A O
736 O
- O
bp O
sequence O
of O
the O
5 O
' O
flanking O
region O
adjacent O
to O
the O
cap O
site O
of O
the O
human B-GENE
AFP I-GENE
gene I-GENE
shows O
a O
61 O
% O
similarity O
with O
the O
corresponding O
region O
of O
the O
mouse B-GENE
AFP I-GENE
gene I-GENE
. O

Nodular O
involvement O
of O
the O
left O
lung O
and O
infiltration O
of O
the O
mucosa O
of O
the O
left O
lower O
lobe O
bronchus O
followed O
very O
gradually O
and O
a O
monoclonal O
gammopathy O
( O
IgA B-GENE
- I-GENE
- I-GENE
Type I-GENE
Kappa I-GENE
) O
was O
demonstrated O
. O

These O
data O
locate O
the O
aniridia B-GENE
gene I-GENE
( O
AN2 B-GENE
) O
and O
a O
recurrent O
T B-GENE
- I-GENE
cell I-GENE
leukemia I-GENE
breakpoint I-GENE
( O
TCL2 B-GENE
) O
in O
the O
marker O
sequence O
, O
on O
opposite O
sides O
of O
MIC1 B-GENE
. O

A O
fine O
- O
structure O
deletion O
map O
of O
human O
chromosome O
11p O
: O
analysis O
of O
J1 O
series O
hybrids O
. O

Most O
of O
them O
were O
situated O
at O
Sylvius O
fissure O
( O
13 O
cases O
) O
. O

Intracellular O
activity O
studies O
indicated O
that O
, O
at O
ten O
times O
MBC O
, O
only O
penicillin O
had O
any O
significant O
activity O
against O
intracellular O
staphylococci O
, O
reducing O
survival O
by O
28 O
% O
. O

The O
lowest O
detectable O
concentration O
was O
1 O
. O
0 O
ng O
/ O
ml O
in O
the O
serum O
. O

The O
antigen B-GENE
- I-GENE
specific I-GENE
IgG4 I-GENE
antibody I-GENE
seems O
to O
be O
an O
index O
in O
evaluating O
immunotherapy O
objectively O
. O

The O
differential O
diagnosis O
of O
both O
affections O
is O
based O
on O
the O
clinical O
course O
, O
sialography O
and O
CT O
examination O
which O
along O
with O
modern O
ATB O
treatment O
significantly O
modify O
hitherto O
used O
surgical O
therapy O
. O

An O
FP B-GENE
mutant I-GENE
, O
AcFP875 B-GENE
- I-GENE
2 I-GENE
, O
had O
a O
1 O
. O
6 O
- O
kbp O
insertion O
of O
S O
. O
frugiperda O
DNA O
near O
the O
5 O
' O
end O
of O
these O
transcripts O
which O
by O
S1 B-GENE
analysis O
were O
shown O
to O
initiate O
within O
the O
host O
cell O
sequence O
. O

Postcoital O
contraception O
: O
a O
family O
planning O
study O
. O

A O
0 O
. O
5 O
rating O
was O
intended O
to O
characterize O
subjects O
in O
whom O
mild O
cognitive O
impairment O
due O
to O
senile O
dementia O
of O
the O
Alzheimer O
type O
was O
suspected O
but O
was O
insufficient O
in O
degree O
to O
warrant O
a O
diagnosis O
of O
definite O
dementia O
. O

An O
implant O
may O
release O
a O
drug O
either O
by O
diffusion O
concurrent O
with O
dissolution O
of O
the O
polymeric O
implant O
material O
without O
depolymerization O
( O
Type O
A O
) O
or O
by O
bioerosion O
involving O
depolymerization O
( O
Type O
B O
) O
. O

Improved O
cosmesis O
, O
extension O
of O
the O
scope O
of O
the O
problems O
that O
can O
be O
addressed O
with O
this O
repair O
( O
including O
treatment O
of O
a O
distal O
urethrocutaneous O
fistula O
) O
and O
the O
ease O
with O
which O
the O
Arap O
procedure O
can O
be O
performed O
are O
the O
advantages O
that O
this O
operation O
has O
over O
other O
1 O
- O
stage O
distal O
hypospadias O
repairs O
. O

The O
galactose B-GENE
transporter I-GENE
shows O
both O
sequence O
and O
structural O
homology O
with O
a O
superfamily O
of O
sugar B-GENE
transporters I-GENE
which O
includes O
the O
human B-GENE
HepG2 I-GENE
- I-GENE
erythrocyte I-GENE
and I-GENE
fetal I-GENE
muscle I-GENE
glucose I-GENE
transporters I-GENE
, O
the O
rat B-GENE
brain I-GENE
and I-GENE
liver I-GENE
glucose I-GENE
transporters I-GENE
, O
the O
Escherichia B-GENE
coli I-GENE
xylose I-GENE
and I-GENE
arabinose I-GENE
permeases I-GENE
, O
and O
the O
S B-GENE
. I-GENE
cerevisiae I-GENE
glucose I-GENE
, I-GENE
maltose I-GENE
, I-GENE
and I-GENE
galactose I-GENE
transporters I-GENE
. O

The O
calcium O
requirement O
for O
hypothermic O
storage O
of O
the O
cardiac O
explant O
. O

The O
seventh O
cysteine O
residue O
of O
CTSE B-GENE
is O
located O
within O
the O
activation O
peptide O
region O
of O
the O
proenzyme O
. O

With O
both O
wild O
- O
type O
and O
the O
mutant O
enzymes O
, O
ATP O
activates O
both O
[ O
14C O
] O
Asp O
in O
equilibrium O
N O
- O
carbamyl O
- O
L O
- O
aspartate O
( O
C O
- O
Asp O
) O
and O
the O
[ O
32P O
] O
carbamyl O
phosphate O
( O
C O
- O
P O
) O
in O
equilibrium O
Pi O
exchanges O
. O

Mapping O
results O
suggested O
that O
the O
complementation O
group O
identified O
by O
these O
mutants O
is O
allelic O
to O
the O
ag B-GENE
alpha I-GENE
1 I-GENE
mutation O
identified O
previously O
. O

Recently O
, O
an O
alternatively O
spliced O
form O
of O
c B-GENE
- I-GENE
myb I-GENE
- I-GENE
encoded I-GENE
mRNA I-GENE
has O
been O
identified O
in O
murine O
cells O
containing O
either O
normal O
or O
rearranged O
c B-GENE
- I-GENE
myb I-GENE
genes I-GENE
. O

Metformin O
plasma O
concentrations O
remained O
unchanged O
except O
for O
patients O
transferred O
from O
1 O
. O
5 O
to O
2 O
. O
0 O
g O
daily O
to O
850 O
mg O
twice O
daily O
; O
in O
these O
patients O
plasma O
concentrations O
increased O
from O
1 O
. O
83 O
+ O
/ O
- O
0 O
. O
87 O
to O
2 O
. O
50 O
+ O
/ O
- O
0 O
. O
89 O
micrograms O
/ O
l O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

A O
significant O
relationship O
existed O
during O
the O
evolution O
of O
the O
disease O
between O
CRS O
/ O
BW O
and O
gas O
exchange O
parameters O
( O
FIO2 O
and O
a O
/ O
AO2 O
ratio O
) O
( O
P O
less O
than O
0 O
. O
01 O
) O
, O
but O
gas O
exchange O
improved O
earlier O
than O
lung O
mechanics O
. O

Liquid O
chromatography O
with O
amperometric O
detection O
( O
LC O
/ O
AD O
) O
is O
used O
to O
determine O
fluazifop O
acid O
produced O
from O
the O
metabolism O
or O
base O
hydrolysis O
of O
fluazifop O
- O
butyl O
in O
soybeans O
and O
soybean O
oil O
. O

The O
dichloromethane O
is O
removed O
, O
mobile O
phase O
solvent O
is O
added O
, O
and O
aliquots O
are O
injected O
onto O
a O
PRP O
- O
1 O
liquid O
chromatographic O
column O
; O
fluazifop O
acid O
is O
separated O
from O
coextracted O
compounds O
and O
detected O
at O
an O
applied O
potential O
of O
+ O
1 O
. O
25 O
V O
, O
using O
an O
amperometric O
electrochemical O
detector O
in O
the O
oxidation O
mode O
. O

The O
titer O
of O
anti B-GENE
HSV I-GENE
type I-GENE
1 I-GENE
and O
anti B-GENE
HSV I-GENE
type I-GENE
2 I-GENE
antibodies I-GENE
in O
the O
mothers O
' O
and O
cord O
blood O
was O
determined O
and O
compared O
. O

Kidney O
weight O
and O
kidney O
- O
to O
- O
body O
weight O
ratio O
were O
significantly O
elevated O
at O
the O
highest O
dose O
level O
after O
10 O
weeks O
and O
at O
the O
two O
higher O
dose O
levels O
after O
15 O
weeks O
of O
exposure O
. O

Swim O
- O
over O
: O
an O
alternative O
method O
for O
harvesting O
motile O
spermatozoa O
. O

A O
raised O
amplitude O
of O
the O
aggregation O
of O
plates O
and O
a O
decrease O
in O
the O
threshold O
of O
their O
sensitivity O
to O
ADP O
were O
established O
in O
the O
persons O
with O
types O
IIa O
and O
IIb O
HLP O
and O
in O
CHD O
without O
HLP O
. O

In O
Experiment O
2 O
, O
we O
again O
used O
classification O
, O
but O
the O
fixed O
standard O
75 O
was O
not O
at O
the O
center O
of O
the O
range O
of O
target O
numbers O
( O
20 O
, O
21 O
, O
. O
. O
. O

Among O
booked O
patients O
the O
maternal O
mortality O
rate O
was O
0 O
. O
32 O
and O
among O
unbooked O
patients O
11 O
. O
13 O
per O
1000 O
deliveries O
. O

Evidence O
from O
the O
structure O
of O
a O
number O
of O
cDNA O
clones O
, O
as O
well O
as O
S1 B-GENE
nuclease I-GENE
and O
primer O
extension O
studies O
supports O
the O
hypothesis O
that O
the O
PTHrP B-GENE
gene I-GENE
contains O
at O
least O
two O
mRNA O
transcription O
start O
points O
that O
define O
two O
putative O
regulatory O
domains O
. O

The O
transcription O
initiation O
site O
was O
determined O
by O
S1 B-GENE
nuclease I-GENE
mapping O
. O

A O
larval B-GENE
albumin I-GENE
- I-GENE
like I-GENE
protein I-GENE
was O
not O
detectable O
by O
silver O
staining O
in O
serum O
of O
tadpoles O
before O
the O
beginning O
of O
metamorphosis O
at O
stage O
48 O
. O

Behaviorally O
, O
a O
pain O
- O
tolerant O
group O
( O
PT O
= O
29 O
Ss O
) O
tolerated O
the O
entire O
3 O
- O
min O
test O
( O
means O
= O
180 O
+ O
/ O
- O
0 O
sec O
) O
, O
while O
a O
pain O
- O
sensitive O
group O
( O
PS O
= O
13 O
Ss O
) O
averaged O
only O
50 O
. O
31 O
+ O
/ O
- O
20 O
. O
81 O
sec O
of O
the O
cold O
- O
pressor O
test O
( O
t O
= O
16 O
. O
75 O
, O
P O
less O
than O
0 O
. O
0001 O
) O
, O
replicating O
our O
earlier O
studies O
. O

Isolated O
proteinuria O
( O
i O
. O
e O
. O
without O
hematuria O
and O
/ O
or O
pyuria O
) O
is O
a O
frequent O
finding O
. O

Lithium O
delays O
the O
circadian O
rhythm O
of O
wheel O
- O
running O
in O
Syrian O
hamsters O
at O
plasma O
concentrations O
( O
0 O
. O
59 O
- O
0 O
. O
74 O
mM O
) O
that O
also O
cause O
toxic O
weight O
loss O
. O

When O
two O
- O
dimensional O
polyacrylamide O
gel O
electrophoretic O
patterns O
of O
[ O
35S O
] O
methionine O
- O
labeled O
proteins O
secreted O
from O
cells O
infected O
with O
parental O
and O
recombinant O
viruses O
were O
compared O
, O
a O
spot O
missing O
from O
the O
latter O
corresponded O
in O
molecular O
weigh O
and O
isoelectric O
point O
with O
that O
predicted O
from O
the O
N1L B-GENE
ORF I-GENE
. O

Buflomedil O
( O
i O
. O
v O
. O
) O
induced O
a O
dose O
- O
dependent O
increase O
of O
cardiac O
output O
at O
0 O
. O
16 O
- O
0 O
. O
64 O
mg O
/ O
kg O
, O
biphasic O
changes O
at O
1 O
. O
28 O
and O
2 O
. O
56 O
mg O
/ O
kg O
and O
a O
marked O
decrease O
and O
subsequent O
slight O
increase O
at O
a O
large O
dose O
of O
5 O
. O
12 O
mg O
/ O
kg O
. O

We O
use O
the O
term O
corticosteroid O
- O
dependent O
IA O
to O
refer O
to O
the O
serious O
problem O
of O
chronic O
IA O
requiring O
maintenance O
prednisone O
therapy O
. O

The O
two O
IL6 B-GENE
mRNA I-GENE
species O
are O
generated O
by O
alternative O
polyadenylation O
at O
sites O
separated O
by O
a O
distance O
of O
1 O
. O
2 O
kilobases O
. O

In O
one O
acromegalic O
patient O
visual O
improvement O
was O
obtained O
while O
the O
abnormal O
GH B-GENE
secretion O
remained O
unaltered O
. O

In O
contrast O
, O
the O
PPSF O
+ O
DBP O
side O
showed O
large O
amounts O
of O
bone O
formation O
, O
and O
bone O
almost O
covered O
the O
implant O
. O

In O
44 O
evaluable O
patients O
the O
response O
rate O
was O
50 O
% O
, O
with O
one O
complete O
response O
. O

Thus O
, O
multiple O
myogenic O
factors O
that O
vary O
qualitatively O
and O
quantitatively O
may O
be O
responsible O
for O
the O
different O
and O
complex O
modulatory O
programs O
of O
actin B-GENE
gene I-GENE
expression O
observed O
during O
in O
vivo O
muscle O
differentiation O
. O

The O
effect O
of O
acetazolamide O
( O
ACZ O
) O
on O
HCO3 O
- O
and O
Cl O
- O
activities O
in O
inner O
ear O
fluid O
was O
investigated O
by O
ion O
- O
selective O
microelectrode O
methods O
. O

The O
predicted O
L B-GENE
mRNA I-GENE
was O
6398 O
nucleotides O
long O
and O
contained O
a O
single O
open O
reading O
frame O
corresponding O
to O
an O
L B-GENE
protein I-GENE
encompassing I-GENE
2109 I-GENE
amino I-GENE
acids I-GENE
with O
a O
MW O
of O
241 O
, O
546 O
. O

Aplastic O
crisis O
in O
sickle O
cell O
disorders O
: O
bone O
marrow O
necrosis O
and O
human O
parvovirus O
infection O
. O

The O
bactericidal O
activity O
of O
six O
new O
rifamycin O
derivatives O
- O
- O
rifabutin O
( O
RBU O
) O
, O
FCE O
22250 O
( O
F22 O
) O
, O
rifapentine O
( O
RPE O
) O
, O
CGP O
29861 O
( O
C29 O
) O
, O
CGP O
7040 O
( O
C70 O
) O
and O
CGP O
27557 O
( O
C27 O
) O
and O
rifampicin O
( O
RMP O
) O
- O
- O
have O
been O
measured O
against O
log O
phase O
and O
, O
as O
a O
better O
test O
of O
sterilising O
activity O
, O
against O
stationary O
phase O
cultures O
of O
Mycobacterium O
tuberculosis O
, O
H37Rv O
. O

Mo O
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
moribund O
at O
3 O
to O
13 O
months O
postinoculation O
, O
whereas O
delta O
Mo O
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
moribund O
at O
6 O
to O
24 O
months O
postinoculation O
. O

RVEF O
and O
LVEF O
both O
increased O
by O
about O
14 O
% O
( O
p O
less O
than O
0 O
. O
05 O
and O
p O
less O
than O
0 O
. O
01 O
) O
. O

The O
levels O
of O
NPY B-GENE
- O
ir O
in O
the O
rat O
vas O
deferens O
were O
not O
affected O
by O
either O
surgical O
or O
pharmacological O
treatment O
. O

The O
primary O
structure O
and O
cotranscription O
of O
the O
petCA B-GENE
genes I-GENE
encoding O
the O
Rieske B-GENE
- I-GENE
FeS I-GENE
( O
nuclear B-GENE
encoded I-GENE
in I-GENE
plants I-GENE
) O
and O
apocytochrome B-GENE
f I-GENE
proteins I-GENE
has O
been O
described O
previously O
( O
Kallas O
, O
T O
. O
, O
Spiller O
, O
S O
. O
, O
and O
Malkin O
, O
R O
. O

The O
Nostoc O
petBD B-GENE
genes I-GENE
are O
not O
closely O
linked O
to O
the O
psbB B-GENE
gene I-GENE
( O
encoding O
the O
51 O
- O
kDa O
photosystem B-GENE
II I-GENE
polypeptide I-GENE
) O
and O
do O
not O
contain O
introns O
as O
do O
the O
closely O
related O
chloroplast O
genes O
. O

RNA O
blot O
hybridizations O
identified O
an O
1 O
. O
8 O
- O
kb O
mRNA O
common O
to O
cytochrome B-GENE
b6 I-GENE
and O
subunit O
IV O
, O
and O
an O
intensely O
hybridizing O
0 O
. O
8 O
- O
kb O
mRNA O
specific O
to O
the O
subunit O
IV O
gene O
probe O
. O

All O
of O
the O
indigo O
- O
producing O
bacteria O
had O
an O
indoxyl B-GENE
phosphatase I-GENE
with O
a O
pI O
of O
6 O
. O
4 O
. O

The O
number O
of O
polymerases O
active O
in O
vitro O
at O
the O
E O
strand O
promoter O
was O
similar O
to O
the O
number O
of O
polymerases O
at O
the O
L O
strand O
promoter O
. O

A O
family O
of O
RNA O
molecules O
in O
the O
2 O
. O
0 O
- O
2 O
. O
2 O
- O
kilobase O
range O
identified O
with O
a O
probe O
from O
this O
gene O
was O
overexpressed O
in O
the O
resistant O
cells O
. O

Intravesical O
chemotherapy O
. O

Studies O
were O
performed O
on O
several O
superficial O
veins O
from O
the O
rabbit O
face O
to O
examine O
the O
relationship O
between O
beta B-GENE
adrenoceptor I-GENE
subtype I-GENE
distribution O
, O
intrinsic O
myogenic O
tone O
and O
sympathetic O
nerve O
innervation O
. O

Two O
polyadenylation O
sites O
were O
used O
, O
one O
at O
the O
end O
of O
the O
early B-GENE
( I-GENE
E I-GENE
) I-GENE
region I-GENE
of O
the O
viral O
DNA O
, O
the O
other O
at O
the O
end O
of O
the O
late B-GENE
( I-GENE
L I-GENE
) I-GENE
region I-GENE
. O

We O
propose O
that O
the O
technique O
of O
low O
- O
frequency O
kindling O
is O
a O
useful O
experimental O
model O
in O
assessing O
the O
effects O
of O
antipsychotic O
or O
antiepileptic O
drugs O
on O
the O
excitability O
of O
the O
limbic O
regions O
. O

The O
biosynthesis O
and O
stability O
of O
the O
three O
mutant O
proteins O
were O
similar O
to O
those O
of O
the O
wild B-GENE
- I-GENE
type I-GENE
erbB I-GENE
protein I-GENE
, O
and O
all O
three O
retained O
the O
ability O
to O
transform O
chicken O
embryo O
fibroblasts O
. O

Codon O
usage O
in O
C O
. O
reinhardtii O
mitochondria O
is O
highly O
biased O
, O
with O
eight O
codons O
entirely O
absent O
from O
all O
protein O
- O
coding O
genes O
; O
however O
, O
even O
though O
codon O
usage O
is O
restricted O
, O
it O
appears O
that O
C O
. O
reinhardtii O
mtDNA O
cannot O
encode O
the O
minimum O
number O
of O
tRNAs O
needed O
to O
support O
mitochondrial O
protein O
synthesis O
. O

Like O
scrotal O
testes O
, O
undescended O
testes O
were O
hypointense O
to O
fat O
on O
sequences O
with O
a O
short O
repetition O
time O
( O
TR O
) O
and O
echo O
time O
( O
TE O
) O
in O
all O
cases O
, O
and O
hyperintense O
or O
isointense O
to O
fat O
on O
long O
TR O
/ O
TE O
sequences O
in O
all O
but O
two O
cases O
. O

The O
East O
African O
dik O
- O
dik O
antelope O
represents O
a O
miniature O
model O
ruminant O
for O
comparative O
studies O
. O

Efficacy O
and O
field O
evaluation O
of O
Bacillus O
thuringiensis O
( O
H O
- O
14 O
) O
and O
B O
. O
sphaericus O
against O
floodwater O
mosquitoes O
in O
California O
. O

2 O
cases O
of O
type O
II O
tyrosinosis O
( O
Richner O
- O
Hanhart O
syndrome O
) O

This O
loss O
was O
independent O
of O
drug O
concentration O
and O
a O
correction O
factor O
was O
employed O
to O
calculate O
the O
true O
free O
diazepam O
concentration O
. O

Effects O
of O
a O
perfluorochemical O
blood O
substitute O
on O
diazepam O
binding O
by O
human B-GENE
albumin I-GENE
. O

A O
second O
promoter O
activity O
was O
identified O
in O
the O
region O
between O
the O
two O
major O
transcriptional O
start O
sites O
. O

Computer O
analysis O
included O
digital O
averaging O
, O
followed O
by O
digital O
filtering O
in O
different O
frequency O
bands O
in O
order O
to O
determine O
the O
frequency O
range O
corresponding O
to O
notches O
and O
slurs O
. O

We O
also O
examined O
the O
relationship O
between O
the O
side O
of O
sinusitis O
and O
the O
cleft O
side O
in O
patients O
with O
unilateral O
cleft O
palate O
. O

Successful O
use O
of O
transureteroureterostomy O
to O
salvage O
ureterosigmoidostomy O
after O
anastomotic O
failure O
. O

We O
have O
identified O
and O
characterized O
the O
structure O
of O
the O
Spec1 B-GENE
gene I-GENE
in O
the O
sea O
urchin O
Strongylocentrotus O
purpuratus O
. O

Functional O
flow O
was O
evaluated O
using O
laser O
Doppler O
flowmetry O
( O
LDF O
) O
, O
for O
which O
the O
output O
signal O
, O
blood O
cell O
flux O
( O
BCF O
) O
, O
is O
expressed O
in O
terms O
of O
volts O
. O

Our O
data O
, O
however O
, O
did O
not O
suggest O
the O
existence O
of O
a O
conversion O
factor O
for O
LDF O
signal O
to O
absolute O
flow O
values O
from O
experiment O
to O
experiment O
. O

Quantitative O
analysis O
of O
the O
coronary O
stenosis O
was O
assessed O
before O
and O
after O
PTCA O
, O
and O
the O
dilatation O
resulted O
in O
an O
increase O
in O
minimal O
luminal O
cross O
- O
sectional O
area O
from O
1 O
. O
1 O
+ O
/ O
- O
0 O
. O
8 O
to O
2 O
. O
7 O
+ O
/ O
- O
1 O
. O
2 O
mm2 O
. O

In O
a O
previous O
study O
( O
Brandl O
, O
C O
. O

The O
seco O
- O
steroid O
hormone O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
is O
known O
to O
induce O
the O
expression O
of O
a O
calcium O
binding O
protein O
termed O
calbindin B-GENE
- I-GENE
D28K I-GENE
in O
a O
variety O
of O
target O
tissues O
. O

In O
addition O
, O
the O
calbindin B-GENE
- I-GENE
D28K I-GENE
promoter I-GENE
is O
composed O
of O
a O
variety O
of O
simple O
repeated O
sequences O
, O
some O
of O
which O
are O
components O
of O
putative O
regulatory O
signals O
. O

Organ O
transplantation O
in O
Denmark O
. O

A O
114 O
- O
base O
pair O
sequence O
of O
predominantly O
repeating O
purine O
- O
pyrimidine O
nucleotides O
separates O
these O
two O
d O
( O
AC O
) O
repeats O
. O

Evidence O
for O
a O
role O
of O
endogenous B-GENE
corticotropin I-GENE
- I-GENE
releasing I-GENE
factor I-GENE
in O
cold O
, O
ether O
, O
immobilization O
, O
and O
traumatic O
stress O
. O

The O
210 O
kDa O
precursor O
is O
converted O
slowly O
( O
t O
1 O
/ O
2 O
= O
2 O
h O
) O
by O
proteolytic O
processing O
into O
a O
125 O
kDa O
( O
alpha O
' O
) O
and O
83 O
kDa O
( O
beta O
' O
) O
species O
. O

Its O
predicted O
amino O
acid O
sequence O
shows O
extensive O
homology O
to O
those O
of O
Drosophila B-GENE
hsp70 I-GENE
, O
trout B-GENE
hsp70 I-GENE
, O
Xenopus B-GENE
hsp70 I-GENE
, O
yeast B-GENE
hsp70 I-GENE
, O
and O
some O
homology O
to O
the O
heat B-GENE
- I-GENE
inducible I-GENE
dnaK I-GENE
gene I-GENE
product I-GENE
of O
Escherichia O
coli O
. O

At O
temperatures O
permissive O
for O
transformation O
, O
6m2 O
cells O
contain O
P58gag B-GENE
produced O
from O
the O
4 O
. O
0 O
- O
kilobase O
( O
kb O
) O
viral O
RNA O
genome O
and O
P85gag B-GENE
- O
mos B-GENE
translated O
from O
a O
3 O
. O
5 O
- O
kb O
spliced O
mRNA O
. O

Multistep O
transformation O
by O
defined O
fragments O
of O
herpes O
simplex O
virus O
type O
2 O
DNA O
: O
oncogenic O
region O
and O
its O
gene O
product O
. O

One O
group O
( O
n O
= O
9 O
) O
was O
premedicated O
with O
midazolam O
, O
0 O
. O
1 O
mg O
kg O
- O
1 O
, O
and O
atropine O
0 O
. O
2 O
- O
0 O
. O
4 O
mg O
i O
. O
m O
. O

In O
order O
to O
study O
the O
influence O
of O
iron O
overload O
on O
the O
polymorphonuclear O
leucocyte O
( O
PMN O
) O
metabolism O
of O
patients O
on O
chronic O
hemodialysis O
, O
generation O
of O
superoxide O
anion O
( O
O2 O
- O
) O
by O
PMN O
in O
whole O
blood O
was O
compared O
in O
two O
groups O
of O
hemodialyzed O
patients O
: O
group O
A O
consisted O
of O
twenty O
- O
one O
individuals O
with O
serum O
ferritin B-GENE
levels O
above O
1000 O
ng O
/ O
ml O
and O
group O
B O
of O
nineteen O
individuals O
with O
serum O
ferritin B-GENE
levels O
below O
1000 O
ng O
/ O
ml O
. O

Diazepam O
( O
3 O
mg O
/ O
kg O
) O
generalized O
to O
Ro O
11 O
- O
6896 O
whereas O
the O
structurally O
related O
Ro O
5 O
- O
4864 O
( O
3 O
mg O
/ O
kg O
and O
30 O
mg O
/ O
kg O
) O
did O
not O
. O

Five O
patients O
developed O
metastatic O
spread O
, O
and O
all O
of O
them O
died O
of O
tumor O
. O

There O
were O
no O
interfering O
peaks O
in O
the O
quantitation O
of O
sulbactam O
. O

Translation O
of O
specific O
cellular O
genes O
from O
the O
chimeric O
viral O
- O
cellular O
transcripts O
seems O
to O
be O
unlikely O
. O

Two O
mutants O
, O
each O
representative O
of O
a O
separate O
pet B-GENE
complementation O
group O
, O
have O
been O
analyzed O
. O

A O
centromere O
in O
S O
. O
cerevisiae O
consists O
of O
a O
region O
of O
DNA O
, O
approximately O
150 O
bp O
in O
length O
, O
containing O
three O
important O
sequence O
elements O
, O
which O
are O
folded O
with O
proteins O
into O
a O
specific O
conformation O
in O
the O
chromatin O
( O
the O
yeast O
kinetochore O
) O
. O

Two O
separate O
NF1 B-GENE
- I-GENE
binding I-GENE
loci I-GENE
were O
also O
found O
in O
the O
equivalent O
IE68 B-GENE
gene I-GENE
of O
HCMV O
( O
Towne O
) O
DNA O
, O
but O
in O
this O
case O
the O
DNA O
sequence O
and O
competition O
filter O
binding O
experiments O
indicated O
a O
maximum O
of O
only O
four O
to O
five O
consensus O
binding O
sites O
encompassing O
the O
promoter O
- O
enhancer O
region O
. O

The O
previously O
described O
four O
sets O
of O
13 O
- O
to O
18 O
- O
base O
- O
pair O
interspersed O
repeat O
elements O
between O
- O
55 O
and O
- O
580 O
provide O
most O
of O
the O
high O
basal O
transcriptional O
strength O
, O
whereas O
the O
arrangement O
of O
further O
upstream O
tandemly O
repeated O
NF1 B-GENE
- I-GENE
binding I-GENE
sites I-GENE
may O
contribute O
significantly O
to O
the O
expanded O
biological O
host O
range O
for O
expression O
of O
SCMV B-GENE
IE94 I-GENE
compared O
with O
HCMV B-GENE
IE68 I-GENE
. O

Active O
lambda B-GENE
and I-GENE
kappa I-GENE
antibody I-GENE
gene I-GENE
rearrangement O
in O
Abelson O
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
cell O
lines O
. O

Influence O
of O
cyclo B-GENE
- I-GENE
oxygenase I-GENE
inhibition O
and O
of O
leukotriene B-GENE
receptor I-GENE
blockade O
on O
pulmonary O
vascular O
pressure O
/ O
cardiac O
index O
relationships O
in O
hyperoxic O
and O
in O
hypoxic O
dogs O
. O

Northern O
analyses O
of O
RNAs O
from O
mouse O
tissues O
and O
cell O
lines O
indicated O
that O
p11 B-GENE
mRNA I-GENE
levels O
vary O
widely O
. O

Morphine O
produced O
a O
dose O
- O
dependent O
bradycardia O
followed O
by O
tachycardia O
. O

The O
PSS B-GENE
gene I-GENE
was O
subcloned O
into O
a O
1 O
. O
1 O
- O
kb O
fragment O
of O
the O
yeast O
DNA O
on O
the O
YEp13 O
vector O
. O

The O
gene O
is O
essential O
for O
yeast O
vegetative O
growth O
. O

Bacteriologic O
culture O
of O
pancreatic O
tissue O
was O
positive O
in O
6 O
/ O
8 O
IB O
and O
3 O
/ O
17 O
NIB O
rats O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

These O
similarities O
suggest O
that O
these O
E2 B-GENE
proteins I-GENE
are O
structurally O
and O
evolutionarily O
related O
. O

Histological O
examination O
revealed O
a O
small O
simple O
renal O
cyst O
associated O
with O
renal O
cell O
carcinoma O
. O

Thus O
, O
prostacyclin O
enhanced O
the O
autoregulative O
property O
of O
the O
inner O
ear O
vessels O
. O

The O
method O
is O
accurate O
, O
with O
good O
precision O
and O
adequate O
sensitivity O
. O

Factors O
influencing O
the O
bond O
strength O
between O
glass O
polyalkenoate O
( O
ionomer O
) O
cements O
and O
dentine O
. O

Van O
der O
Ende O
, O
R O
. O

Clinical O
findings O
were O
: O
height O
183 O
cm O
, O
weight O
62 O
kg O
, O
increased O
length O
of O
lower O
limbs O
, O
P2 O
- O
A2 O
pilosity O
and O
micropenis O
. O

The O
8 O
patients O
receiving O
Ir192 O
implant O
in O
addition O
to O
external O
radiation O
showed O
improved O
( O
p O
= O
0 O
. O
06 O
) O
survival O
compared O
to O
the O
9 O
receiving O
external O
only O
: O
median O
15 O
months O
( O
range O
1 O
. O
5 O
- O
34 O
+ O
months O
) O
versus O
7 O
months O
( O
range O
2 O
. O
5 O
- O
21 O
months O
) O
. O

No O
effect O
was O
found O
on O
grooming O
behavior O
. O

Clinical O
and O
biological O
correlates O
of O
panic O
states O
. O

Effects O
of O
long O
- O
term O
parenteral O
nutrition O
on O
gastrin B-GENE
release O
in O
dogs O
. O

The O
mean O
weight O
and O
height O
velocities O
were O
148 O
% O
and O
122 O
% O
of O
the O
standard O
, O
respectively O
. O

In O
64 O
% O
a O
small O
cardiac O
vein O
does O
not O
exist O
, O
but O
its O
origin O
, O
the O
right O
marginal O
vein O
, O
joins O
the O
system O
of O
anterior O
cardiac O
veins O
. O

The O
results O
of O
these O
experiments O
indicate O
that O
at O
least O
two O
upstream O
activator O
sequences O
( O
UAS O
) O
mediate O
maximum O
induction O
by O
galactose O
. O

Reversal O
of O
the O
increase O
in O
apomorphine O
- O
induced O
stereotypy O
and O
aggression O
in O
REM O
sleep O
deprived O
rats O
by O
dopamine O
agonist O
pretreatments O
. O

The O
genetic O
basis O
for O
the O
expression O
of O
a O
latent O
VH B-GENE
allotype I-GENE
in O
the O
rabbit O
was O
investigated O
. O

Potentiation O
of O
the O
thrombolytic O
efficacy O
of O
single B-GENE
- I-GENE
chain I-GENE
urokinase I-GENE
( O
Pro B-GENE
- I-GENE
urokinase I-GENE
) O
by O
heparin O
. O

The O
variability O
is O
most O
likely O
a O
result O
of O
alternative O
splicing O
of O
exons O
from O
the O
primary O
elastin B-GENE
transcripts I-GENE
. O

This O
led O
to O
the O
conclusion O
that O
the O
metatarsal O
artery O
should O
be O
used O
for O
toe O
MP O
joint O
grafts O
, O
while O
the O
unilateral O
proper O
digital O
artery O
is O
suitable O
for O
toe O
PIP O
joint O
grafts O
, O
together O
with O
concomitant O
or O
dorsal O
cutaneous O
vein O
. O

Factors O
involved O
in O
specific O
transcription O
by O
mammalian O
RNA B-GENE
polymerase I-GENE
II I-GENE
: O
purification O
, O
genetic O
specificity O
, O
and O
TATA O
box O
- O
promoter O
interactions O
of O
TFIID B-GENE
. O

You O
make O
the O
diagnosis O
. O

Conservative O
treatment O
of O
bladder O
carcinoma O
by O
partial O
cystectomy O
and O
interstitial O
iridium O
192 O
. O

The O
results O
presented O
suggest O
that O
TIQ O
reduces O
the O
turnover O
rate O
of O
the O
nigrostriatal O
dopamine O
neurons O
after O
repeated O
administration O
for O
a O
long O
period O
in O
mice O
. O

During O
a O
28 O
- O
week O
promotion O
bioassay O
, O
groups O
of O
30 O
male O
CD O
- O
1 O
mice O
were O
treated O
once O
with O
50 O
microliter O
of O
either O
DMBA O
( O
1 O
. O
0 O
mg O
/ O
ml O
) O
or O
acetone O
, O
rested O
for O
2 O
weeks O
, O
and O
then O
treated O
twice O
per O
week O
with O
test O
material O
for O
the O
remaining O
25 O
weeks O
. O

An O
11 O
- O
month O
- O
old O
girl O
suffering O
from O
Dandy O
- O
Walker O
malformation O
( O
DWM O
) O
associated O
with O
tetralogy O
of O
Fallot O
( O
TOF O
) O
is O
presented O
. O

The O
median O
survival O
is O
not O
reached O
with O
a O
median O
follow O
- O
up O
time O
of O
9 O
. O
6 O
years O
. O

Critical O
evaluation O
of O
various O
methods O
of O
determining O
markers O
of O
fetal O
maturity O
in O
amniotic O
fluid O

Neuromyelitis O
optica O
( O
Devic O
' O
s O
syndrome O
) O
: O
not O
always O
multiple O
sclerosis O
. O

Effect O
of O
the O
methods O
of O
cutaneous O
administration O
of O
methyl O
isobutyl O
ketone O
on O
its O
toxicity O

The O
temporal O
and O
static O
plasma O
concentration O
- O
effect O
relationships O
were O
evaluated O
by O
pharmacodynamic O
modeling O
and O
linear O
regression O
. O

Fourteen O
patients O
were O
in O
the O
multifocal O
disease O
group O
; O
13 O
were O
detected O
by O
SPECT O
and O
10 O
by O
TCT O
. O

The O
SSB B-GENE
- O
poly O
( O
dT O
) O
affinity O
is O
too O
high O
to O
measure O
in O
buffers O
containing O
even O
5 O
M O
NaCl O
; O
however O
, O
in O
1 O
. O
8 O
- O
2 O
. O
5 O
M O
NaBr O
, O
we O
measure O
alpha O
log O
Kobsd O
/ O
alpha O
log O
[ O
NaBr O
] O
= O
- O
5 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
, O
with O
a O
lower O
value O
of O
omega O
T O
/ O
O O
= O
130 O
+ O
/ O
- O
70 O
. O

Minor O
differences O
were O
noted O
with O
latamoxef O
producing O
mild O
persistant O
elevation O
of O
prothrombin B-GENE
time O
( O
0 O
. O
7 O
second O
) O
associated O
with O
depression O
of O
factor B-GENE
II I-GENE
and O
factor B-GENE
VII I-GENE
. O

Plasma B-GENE
renin I-GENE
activity O
does O
not O
predict O
the O
antihypertensive O
efficacy O
of O
chlorthalidone O
. O

Cephradine O
250 O
mg O
at O
night O
for O
12 O
months O
was O
given O
as O
a O
prophylactic O
measure O
to O
33 O
female O
patients O
of O
mean O
age O
41 O
. O
6 O
years O
, O
who O
had O
a O
history O
in O
the O
preceding O
12 O
months O
of O
between O
three O
and O
24 O
( O
median O
= O
7 O
) O
episodes O
of O
frequency O
and O
/ O
or O
dysuria O
. O

The O
activity O
of O
the O
EGF B-GENE
receptor I-GENE
promoter I-GENE
can O
be O
modulated O
by O
E1A B-GENE
protein I-GENE
and O
receptor O
RNA O
levels O
increased O
by O
stimulation O
with O
phorbol O
ester O
or O
fetal O
calf O
serum O
. O

By O
Felix O
Lagrange O
, O
1918 O
. O

The O
epidermal B-GENE
growth I-GENE
factor I-GENE
( I-GENE
EGF I-GENE
) I-GENE
receptor I-GENE
, O
which O
exhibits O
intrinsic O
protein B-GENE
tyrosine I-GENE
kinase I-GENE
activity O
, O
undergoes O
a O
rapid O
, O
intramolecular O
self O
- O
phosphorylation O
reaction O
following O
EGF B-GENE
activation O
. O

A O
case O
of O
AIDS O
- O
related O
complex O
( O
ARC O
/ O
LAS O
) O
in O
a O
health O
worker O

Vimentin B-GENE
positivity O
was O
noted O
in O
the O
undifferentiated O
and O
fibroblastic O
components O
. O

The O
spermicide O
nonoxynol O
- O
9 O
is O
a O
member O
of O
a O
homologous O
series O
of O
alkylphenol O
- O
ethoxylates O
( O
polyethoxyethanols O
) O
of O
general O
formula O
C9H19 O
- O
C6H6 O
- O
O O
- O
( O
CH2CH2O O
) O
n O
- O
1 O
CH2CH2OH O
. O

Depending O
on O
the O
location O
and O
size O
of O
the O
mass O
, O
a O
wide O
range O
of O
clinical O
presentations O
is O
associated O
with O
the O
lesion O
. O

The O
development O
and O
distribution O
of O
Trypanosoma O
congolense O
, O
T O
vivax O
and O
T O
brucei O
in O
the O
skin O
of O
goats O
was O
examined O
after O
the O
animals O
were O
bitten O
by O
infected O
Glossina O
morsitans O
centralis O
. O

During O
the O
observation O
period O
of O
0 O
. O
4 O
- O
30 O
weeks O
, O
cardiac O
white O
spots O
on O
the O
right O
ventricle O
of O
BALB O
/ O
c O
mice O
were O
first O
detected O
at O
three O
weeks O
( O
6 O
of O
20 O
mice O
; O
30 O
% O
) O
, O
and O
the O
maximal O
incidence O
of O
cardiac O
white O
spots O
was O
obtained O
at O
nine O
weeks O
( O
39 O
of O
44 O
mice O
; O
88 O
% O
) O
. O

Increasing O
the O
RH O
beyond O
32 O
% O
resulted O
in O
solvation O
of O
the O
peroxy O
radical O
, O
sterically O
hindering O
the O
radical O
from O
entering O
the O
propagation O
transition O
state O
. O

PATIENTS O
and O
METHODS O
: O
Thallium O
- O
201 O
myocardial O
scintigraphy O
was O
performed O
at O
rest O
and O
after O
0 O
. O
56 O
mg O
/ O
kg O
intravenous O
dipyridamole O
during O
four O
minutes O
in O
16 O
patients O
with O
sarcoidosis O
. O

Which O
cineangiographically O
assessed O
anatomic O
variable O
correlates O
best O
with O
functional O
measurements O
of O
stenosis O
severity O
? O
A O
comparison O
of O
quantitative O
analysis O
of O
the O
coronary O
cineangiogram O
with O
measured O
coronary O
flow O
reserve O
and O
exercise O
/ O
redistribution O
thallium O
- O
201 O
scintigraphy O
. O

Water O
content O
and O
equilibrium O
water O
partition O
in O
immature O
cartilage O
. O

Ischemic O
heart O
disease O
, O
age O
of O
more O
than O
75 O
years O
, O
and O
the O
fact O
that O
the O
patient O
was O
a O
woman O
were O
independent O
predictors O
of O
poor O
cardiac O
function O
. O

Liquid O
chromatographic O
method O
for O
determination O
of O
citreoviridin O
in O
corn O
and O
rice O
. O

The O
incidence O
of O
cryptosporidiosis O
in O
young O
children O
was O
determined O
by O
staining O
of O
faecal O
specimens O
with O
a O
modified O
Kinyoun O
stain O
. O

The O
4 O
degrees O
stimuli O
were O
found O
to O
elicit O
scalp O
distributions O
for O
the O
pattern O
reversal O
P100 O
and O
the O
pattern O
onset O
C1 O
consistent O
with O
striate O
and O
extrastriate O
visual O
cortical O
origins O
respectively O
. O

A O
Golgi O
study O
of O
the O
sixth O
layer O
of O
the O
cerebral O
cortex O
. O

Man O
and O
insect O
, O
past O
, O
present O
, O
future O

Mean O
fluorosis O
scores O
, O
however O
, O
were O
similar O
. O

Autonomic O
dysfunctions O
were O
restricted O
to O
tonic O
pupils O
. O

On O
the O
other O
hand O
, O
if O
the O
measured O
angle O
ANB O
is O
smaller O
than O
the O
calculated O
angle O
, O
the O
skeletal O
relation O
is O
Class O
III O
. O

These O
data O
should O
be O
useful O
in O
developing O
reagents O
for O
heterozygote O
detection O
and O
prenatal O
diagnosis O
of O
11 B-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
deficiency O
, O
the O
second O
most O
frequent O
cause O
of O
congenital O
adrenal O
hyperplasia O
. O

Neither O
ethanol O
nor O
estrogen O
has O
been O
shown O
to O
cause O
UROD B-GENE
- O
deficiency O
in O
animals O
. O

Although O
not O
common O
, O
the O
disorder O
is O
the O
most O
frequently O
diagnosed O
disturbance O
of O
porphyrin O
metabolism O
in O
many O
countries O
, O
and O
further O
insight O
into O
its O
unusual O
pathogenesis O
may O
clarify O
the O
hepatotoxic O
effects O
of O
the O
4 O
etiologic O
agents O
. O

This O
means O
that O
the O
loss O
of O
recessives O
must O
be O
calculated O
by O
using O
a O
hypergeometric O
and O
not O
a O
binomial O
model O
as O
Fisher O
did O
. O

The O
poly O
( O
A O
) O
segment O
of O
the O
RNA O
was O
selectively O
cross O
- O
linked O
to O
the O
72 O
, O
000 O
- O
molecular O
- O
weight O
protein O
( O
72K O
protein O
) O
. O

Possible O
pathogenetic O
mechanisms O
of O
hemopoietic O
changes O
in O
response O
to O
space O
flight O
effects O
are O
described O
. O

Development O
of O
a O
yeast O
system O
to O
assay O
mutational O
specificity O
. O

As O
a O
last O
resort O
, O
it O
may O
be O
possible O
to O
maintain O
a O
patient O
on O
dialysis O
in O
reasonable O
health O
with O
a O
DiaTAP O
button O
graft O
complex O
infected O
with O
Staphylococcus O
epidermidis O
and O
intermittent O
positive O
blood O
cultures O
using O
long O
term O
vancomycin O
therapy O
. O

Reward O
value O
of O
prosodic O
features O
of O
language O
for O
autistic O
, O
mentally O
retarded O
, O
and O
normal O
children O
. O

Due O
to O
its O
relatively O
soluble O
chemical O
form O
, O
90Sr O
was O
rapidly O
translocated O
from O
lung O
to O
bone O
where O
a O
substantial O
portion O
was O
retained O
for O
a O
long O
period O
of O
time O
. O

Artificial O
ventilation O
was O
conducted O
using O
a O
tidal O
volume O
of O
10 O
ml O
X O
kg O
- O
1 O
and O
a O
rate O
of O
10 O
to O
12 O
c O
X O
min O
- O
1 O
. O

Significantly O
lower O
heart O
rate O
reactivity O
and O
significantly O
less O
pronounced O
left O
temporal O
artery O
pulse O
amplitude O
responses O
were O
found O
in O
non O
- O
medicated O
TH O
subjects O
than O
in O
controls O
. O

An O
epidemiological O
survey O
of O
rheumatic O
valve O
disease O
and O
rheumatic O
fever O
in O
primary O
and O
secondary O
school O
students O
in O
Jiangxi O
Province O

Heat O
- O
labile O
- O
like O
enterotoxin O
( O
LT B-GENE
) O
was O
produced O
by O
26 O
of O
42 O
stool O
isolates O
( O
62 O
% O
) O
, O
while O
only O
1 O
of O
the O
42 O
isolates O
( O
2 O
% O
) O
produced O
enterotoxinlike O
activity O
in O
suckling O
mice O
; O
65 O
% O
of O
the O
cytotoxin O
- O
producing O
strains O
also O
produced O
an O
LT B-GENE
- I-GENE
like I-GENE
material O
. O

The O
nucleotide O
sequences O
of O
the O
human B-GENE
and I-GENE
murine I-GENE
ornithine I-GENE
decarboxylase I-GENE
mRNAs I-GENE
share O
an O
85 O
% O
homology O
, O
even O
in O
their O
3 O
' O
- O
noncoding O
regions O
. O

The O
absolute O
concentrations O
of O
alpha B-GENE
2 I-GENE
- I-GENE
plasmin I-GENE
inhibitor O
, O
alpha B-GENE
2 I-GENE
- I-GENE
macroglobulin I-GENE
, O
and O
antithrombin B-GENE
III I-GENE
increased O
with O
exercise O
( O
all O
P O
less O
than O
0 O
. O
005 O
) O
, O
but O
when O
concentrations O
were O
corrected O
for O
acute O
shifts O
of O
plasma O
water O
during O
exercise O
, O
the O
quantity O
of O
these O
inhibitors O
actually O
decreased O
( O
all O
P O
less O
than O
0 O
. O
005 O
) O
. O

In O
the O
normal O
, O
basal O
( O
unstimulated O
) O
condition O
there O
were O
no O
significant O
correlations O
( O
p O
greater O
than O
0 O
. O
05 O
) O
between O
the O
systolic O
blood O
pressure O
and O
dopamine O
( O
r O
= O
0 O
. O
09 O
) O
, O
norepinephrine O
( O
r O
= O
0 O
. O
26 O
) O
, O
or O
epinephrine O
( O
r O
= O
0 O
. O
27 O
) O
, O
nor O
were O
there O
significant O
correlations O
between O
melatonin O
and O
dopamine O
( O
r O
= O
- O
0 O
. O
01 O
) O
, O
norepinephrine O
( O
r O
= O
- O
0 O
. O
26 O
) O
, O
or O
growth B-GENE
hormone I-GENE
( O
r O
= O
0 O
. O
17 O
) O
. O

In O
cases O
of O
1 O
degrees O
HPT O
, O
the O
plasma O
1 O
, O
25 O
- O
( O
OH O
) O
2D O
level O
rose O
significantly O
in O
all O
cases O
( O
P O
less O
than O
0 O
. O
05 O
) O
, O
although O
the O
pattern O
of O
the O
increase O
was O
not O
uniform O
. O

It O
is O
largely O
predicted O
by O
lupus O
anticoagulant O
( O
estimated O
by O
activated O
partial O
thromboplastin B-GENE
time O
) O
and O
/ O
or O
antibody O
to O
cardiolipin O
. O

Data O
from O
119 O
men O
and O
40 O
women O
undergoing O
coronary O
angiography O
provide O
an O
opportunity O
to O
compare O
these O
associations O
in O
relation O
to O
a O
direct O
and O
continuous O
measure O
of O
atherosclerosis O
while O
controlling O
for O
age O
, O
sex O
, O
income O
, O
hypertension O
, O
serum O
cholesterol O
, O
smoking O
, O
angina O
, O
diabetes O
, O
family O
history O
of O
heart O
disease O
, O
Type O
A O
behavior O
pattern O
, O
and O
hostility O
. O

The O
presence O
in O
such O
patients O
of O
antibodies O
to O
adrenaline O
and O
noradrenaline O
is O
indicative O
of O
considerable O
disruption O
of O
catecholamine O
biotransformation O
. O

Effects O
of O
a O
low O
- O
energy O
laser O
beam O
on O
the O
cells O
of O
the O
newt O
embryo O

Samples O
from O
1415 O
neurological O
patients O
were O
used O
to O
study O
the O
diagnostic O
value O
of O
acid B-GENE
alpha I-GENE
1 I-GENE
- I-GENE
glycoprotein I-GENE
in O
the O
lumbar O
cerebrospinal O
fluid O
. O

Comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
M B-GENE
RNA I-GENE
product I-GENE
of I-GENE
Uukuniemi I-GENE
virus I-GENE
with O
that O
of O
Punta O
Toro O
and O
Rift O
Valley O
fever O
viruses O
showed O
in O
both O
cases O
a O
weak O
homology O
that O
was O
more O
pronounced O
for O
the O
proteins O
located O
at O
the O
COOH O
- O
terminal O
end O
of O
the O
precursor O
. O

The O
purpose O
of O
this O
study O
is O
twofold O
: O
( O
1 O
) O
to O
present O
a O
parallel O
form O
of O
the O
Gudjonsson O
Suggestibility O
Scale O
( O
GSS O
, O
Form O
1 O
) O
; O
( O
2 O
) O
to O
study O
test O
- O
retest O
reliabilities O
of O
interrogative O
suggestibility O
. O

The O
average O
deviations O
in O
the O
X O
- O
ray O
counts O
of O
the O
constant O
elements O
from O
the O
series O
means O
were O
used O
to O
correct O
the O
recorded O
count O
of O
the O
variable O
element O
in O
each O
block O
. O

To O
evaluate O
the O
relative O
accuracy O
of O
continuous O
wave O
( O
CW O
) O
and O
high O
pulse O
repetition O
frequency O
( O
HPRF O
) O
Doppler O
for O
estimating O
aortic O
transvalvular O
pressure O
gradients O
, O
Doppler O
examinations O
with O
both O
devices O
were O
obtained O
in O
87 O
consecutive O
patients O
with O
aortic O
valve O
disease O
. O

The O
number O
of O
fecal O
pellets O
ingested O
peaked O
at O
5 O
to O
6 O
weeks O
old O
( O
13 O
pellets O
/ O
day O
) O
and O
gradually O
decreased O
, O
thereafter O
( O
2 O
. O
1 O
pellets O
at O
78 O
weeks O
old O
, O
1 O
. O
5 O
pellets O
at O
104 O
weeks O
old O
) O
. O

Two O
of O
these O
six O
cases O
showed O
mucosal O
spread O
without O
stromal O
invasion O
( O
type O
A O
) O
; O
the O
remaining O
four O
cases O
presented O
a O
direct O
extension O
( O
type O
B O
) O
from O
muscle O
- O
invasive O
carcinomas O
of O
the O
bladder O
. O

The O
development O
of O
a O
data O
base O
is O
described O
which O
can O
be O
used O
as O
common O
reference O
for O
ECG O
computer O
programs O
analyzing O
12 O
or O
15 O
simultaneously O
recorded O
leads O
. O

Contraction O
of O
the O
tracheal O
muscle O
and O
the O
activity O
of O
stretch O
receptors O
in O
the O
trachea O

The O
selenium O
level O
and O
glutathione B-GENE
peroxidase I-GENE
activity O
in O
the O
blood O
, O
liver O
, O
and O
stomach O
mucosa O
were O
significantly O
higher O
in O
the O
high O
- O
selenium O
diet O
group O
than O
in O
the O
low O
- O
selenium O
diet O
group O
. O

Amikacin O
was O
the O
most O
stable O
and O
tobramycin O
was O
the O
least O
stable O
aminoglycoside O
under O
the O
conditions O
tested O
. O

This O
may O
explain O
in O
part O
a O
secular O
trend O
towards O
reduced O
birthweight O
for O
gestation O
in O
preterm O
infants O
. O

Nickel O
is O
the O
most O
common O
cause O
of O
allergic O
contact O
dermatitis O
in O
Singapore O
, O
resulting O
in O
positive O
reactions O
in O
patch O
tests O
between O
7 O
and O
14 O
% O
. O

Findings O
of O
positive O
potentials O
showed O
that O
N1 O
originated O
in O
the O
area O
of O
ventral O
gray O
matter O
through O
the O
ventro O
- O
lateral O
column O
and O
N2 O
through O
the O
dorsal O
column O
. O

Splenectomized O
patients O
are O
predisposed O
toward O
developing O
overwhelming O
bacterial O
infections O
. O

The O
rats O
were O
used O
for O
the O
study O
of O
the O
effects O
of O
sepsis O
on O
the O
utilization O
of O
exogenous O
fat O
emulsion O
. O

The O
possibility O
of O
a O
hereditary O
disorder O
leading O
to O
a O
minor O
defect O
in O
elastic O
fibre O
structure O
which O
could O
be O
responsible O
for O
the O
spontaneous O
lesions O
is O
discussed O
. O

N O
- O
Substituted O
trimethylsilylcarbamates O
were O
tested O
as O
derivatizing O
reagents O
for O
gas O
chromatographic O
analysis O
. O

The O
growing O
drug O
problem O
is O
also O
reflected O
in O
the O
increasing O
number O
of O
cases O
of O
hepatitis O
B O
and O
of O
drug O
- O
related O
deaths O
. O

Under O
the O
same O
hematocrit O
and O
flow O
conditions O
, O
the O
rate O
of O
oxygen O
saturation O
decrease O
was O
significantly O
higher O
for O
the O
sickle O
cells O
than O
for O
normal O
cells O
. O

The O
risk O
for O
these O
complications O
is O
increased O
by O
the O
following O
factors O
: O
multiple O
gestation O
, O
the O
combination O
of O
magnesium O
sulfate O
and O
beta O
- O
adrenergic O
agonist O
, O
and O
the O
use O
of O
adrenocortico O
- O
steroids O
to O
hasten O
fetal O
pulmonary O
maturity O
. O

Intensification O
of O
human O
myocardial O
contractile O
activity O
as O
affected O
by O
blood O
serum O

Inhibition O
of O
histalog O
- O
stimulated O
gastric O
secretion O
by O
40 O
749 O
RP O
, O
a O
new O
long O
- O
acting O
gastric O
antisecretory O
agent O
. O

Five O
- O
year O
prospective O
study O
of O
peripheral O
white O
blood O
cells O
in O
infectious O
mononucleosis O
. O

Novel O
multigene O
families O
encoding O
highly O
repetitive O
peptide O
sequences O
. O

The O
M O
- O
3 O
subtype O
was O
an O
adverse O
prognostic O
factor O
. O

In O
addition O
, O
marked O
hypertension O
accompanied O
this O
disorder O
and O
all O
abnormalities O
, O
including O
the O
hypertension O
, O
responded O
to O
1 B-GENE
- I-GENE
desamino I-GENE
- I-GENE
8 I-GENE
- I-GENE
D I-GENE
- I-GENE
arginine I-GENE
vasopressin I-GENE
therapy O
. O

In O
19 O
patients O
vagotomy O
not O
only O
curbed O
the O
bleeding O
but O
provided O
definitive O
therapy O
( O
Visick O
I O
- O
II O
) O
; O
4 O
patients O
died O
( O
mortality O
rate O
16 O
% O
) O
. O

A O
yeast O
DNA O
fragment O
carrying O
the O
gene B-GENE
CP I-GENE
A1 I-GENE
encoding O
the O
small O
subunit O
of O
the O
arginine O
pathway O
carbamoyl B-GENE
- I-GENE
phosphate I-GENE
synthetase I-GENE
has O
been O
sequenced O
. O

The O
H2 B-GENE
receptor I-GENE
antagonists O
and O
sucralfate O
cost O
about O
the O
same O
and O
have O
few O
side O
effects O
. O

Such O
studied O
acquired O
with O
low O
energy O
or O
medium O
energy O
collimation O
and O
a O
window O
centered O
on O
the O
159 O
keV O
123I O
photopeak O
contain O
appreciable O
septal O
breakthrough O
signals O
originating O
from O
Compton O
scatter O
of O
high O
energy O
photons O
primarily O
from O
124I O
. O

The O
concentrations O
of O
apo B-GENE
A I-GENE
- I-GENE
I I-GENE
and O
apo B-GENE
A I-GENE
- I-GENE
II I-GENE
of O
abstainers O
decreased O
significantly O
compared O
with O
the O
corresponding O
changes O
in O
controls O
. O

Thyrotropin B-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
- O
induced O
contraction O
of O
urethral O
and O
vaginal O
muscle O
. O

Results O
of O
this O
study O
indicate O
that O
GLC O
of O
short O
chain O
fatty O
acids O
produced O
on O
agar O
medium O
by O
anaerobes O
, O
combined O
with O
simple O
tests O
such O
as O
Gram O
' O
s O
stain O
and O
colonial O
morphology O
, O
may O
allow O
fir O
direct O
presumptive O
genus O
identification O
from O
an O
initial O
pure O
agar O
culture O
. O

Tissue O
pressure O
, O
rCBF O
, O
and O
water O
content O
were O
measured O
from O
gray O
matter O
in O
the O
central O
core O
and O
the O
peripheral O
margin O
of O
the O
MCA O
territory O
over O
6 O
h O
after O
MCAO O
. O

Dissolution O
of O
the O
Pt O
- O
30 O
% O
Ir O
microelectrode O
tip O
was O
observed O
by O
scanning O
electron O
microscopy O
at O
charge O
densities O
as O
low O
as O
200 O
microC O
/ O
cm2 O
X O
ph O
( O
1 O
A O
/ O
cm2 O
) O
, O
whereas O
erosion O
of O
activated O
iridium O
microelectrodes O
occurred O
only O
at O
the O
highest O
charge O
and O
current O
densities O
( O
3200 O
microC O
/ O
cm2 O
X O
ph O
, O
16 O
A O
/ O
cm2 O
) O
. O

The O
results O
from O
the O
first O
five O
years O
of O
follow O
up O
in O
1972 O
showed O
a O
4 O
. O
7 O
- O
fold O
excess O
mortality O
for O
ischaemic O
and O
other O
heart O
diseases O
( O
ICD O
A83 O
- O
A84 O
) O
compared O
with O
a O
comparable O
reference O
cohort O
of O
paper O
mill O
workers O
. O

The O
primary O
CT O
findings O
were O
misinterpreted O
as O
a O
brain O
infarct O
or O
possibly O
a O
tumour O
. O

However O
, O
kidneys O
perfused O
for O
72 O
hr O
demonstrated O
more O
similar O
renal O
functions O
when O
tested O
by O
either O
IMPK O
or O
IBPK O
. O

It O
has O
been O
reported O
that O
rat O
blood O
chloroform O
levels O
were O
significantly O
decreased O
after O
treatment O
with O
ClO2 O
. O

For O
this O
purpose O
, O
a O
simple O
respiration O
- O
control O
device O
has O
been O
developed O
that O
enables O
the O
patient O
to O
monitor O
breath O
- O
holding O
during O
successive O
scans O
. O

In O
the O
10 O
patients O
with O
a O
more O
severe O
degree O
of O
steatorrhea O
the O
decrease O
in O
fat O
loss O
approached O
20 O
% O
and O
a O
close O
relationship O
was O
found O
( O
r O
= O
0 O
. O
84 O
, O
p O
less O
than O
0 O
. O
01 O
) O
between O
the O
extent O
of O
the O
fatty O
acid O
loss O
on O
placebo O
and O
the O
decrease O
of O
this O
loss O
on O
taurine O
. O

Polysorbate O
80 O
did O
not O
have O
a O
direct O
stimulant O
or O
relaxant O
effect O
on O
either O
guinea O
pig O
ileum O
or O
rat O
uterus O
, O
however O
, O
it O
antagonised O
the O
contractions O
induced O
by O
acetylcholine O
, O
histamine O
, O
barium O
, O
5 O
- O
hydroxytryptamine O
and O
carbachol O
in O
a O
dose O
- O
dependent O
manner O
. O

Either O
a O
UV O
detector O
set O
at O
268 O
nm O
or O
an O
electrochemical O
( O
EC O
) O
detector O
set O
at O
a O
potential O
of O
+ O
0 O
. O
9 O
V O
( O
versus O
Ag O
/ O
AgCl O
/ O
3 O
M O
NaCl O
) O
was O
used O
to O
monitor O
the O
drug O
. O

The O
mean O
transfer O
ratios O
of O
the O
drug O
into O
the O
genital O
tissues O
to O
the O
concentration O
in O
the O
uterine O
arterial O
blood O
were O
such O
that O
the O
transfer O
ratio O
into O
the O
portio O
vaginalis O
was O
the O
highest O
, O
followed O
by O
the O
uterine O
cervix O
and O
the O
myometrium O
, O
and O
that O
into O
the O
oviduct O
was O
the O
lowest O
with O
about O
1 O
/ O
2 O
that O
into O
the O
portio O
vaginalis O
. O

Lower O
extremity O
weight O
bearing O
under O
various O
standing O
conditions O
in O
independently O
ambulatory O
patients O
with O
hemiparesis O
. O

These O
results O
were O
compared O
with O
those O
obtained O
in O
- O
D O
mothers O
and O
pups O
, O
after O
giving O
the O
mothers O
an O
oral O
supplement O
( O
10 O
i O
. O
u O
. O
vitamin O
D3 O
/ O
day O
) O
during O
the O
period O
of O
lactation O
( O
20 O
days O
) O
. O

Treatment O
with O
oxyphenylbutazone O
and O
hydrocortisone O
failed O
to O
inhibit O
the O
raised O
serum B-GENE
CPN I-GENE
levels O
. O

40 O
, O
000 O
) O
. O

Duration O
of O
remission O
in O
advanced O
gastric O
cancer O
patients O
responding O
to O
sequential O
dose O
of O
MTX O
and O
5 O
- O
FU O

The O
fast O
real O
- O
time O
digital O
processing O
of O
the O
N2 O
and O
flow O
signals O
incorporated O
filtering O
, O
delay O
compensation O
, O
and O
corrections O
for O
the O
effects O
of O
changes O
in O
gas O
composition O
and O
temperature O
. O

National O
Institutes O
of O
Health O
Consensus O
Development O
Conference O
Statement O
. O

Diagnosis O
: O
progressive O
multifocal O
leukoencephalopathy O
. O

The O
imino O
proton O
of O
T3 O
in O
the O
O6meG O
. O
T O
12 O
- O
mer O
and O
G3 O
in O
the O
O6meG O
. O
N O
12 O
- O
mer O
helix O
, O
which O
are O
associated O
with O
the O
modification O
site O
, O
resonate O
at O
unusually O
high O
field O
( O
8 O
. O
5 O
to O
9 O
. O
0 O
ppm O
) O
compared O
to O
imino O
protons O
in O
Watson O
- O
Crick O
base O
pairs O
( O
12 O
. O
5 O
to O
14 O
. O
5 O
ppm O
) O
. O

Postnatal O
volumetric O
development O
of O
the O
prefrontal O
cortex O
in O
the O
rat O
. O

We O
also O
observed O
that O
the O
predictive O
ability O
of O
the O
selected O
attitudes O
and O
orientations O
increased O
considerably O
from O
1975 O
to O
1982 O
. O

They O
also O
discuss O
the O
existing O
nomenclature O
. O

Estral O
cycle O
in O
white O
rats O
in O
the O
low O
and O
high O
mountains O
of O
Kirghizia O

Studies O
on O
the O
organic O
matrix O
of O
human O
ear O
ossicles O

Sensitization O
to O
hyperlactatemia O
induced O
by O
phenformin O
after O
subtotal O
ablation O
of O
the O
pancreas O
. O

Effect O
of O
variations O
in O
time O
interval O
between O
treatment O
with O
BCG O
and O
quartz O
dust O
on O
translocation O
of O
quartz O
dust O
from O
the O
lungs O
to O
their O
regional O
lymph O
nodes O
. O

Metastasis O
of O
colon O
carcinoma O
to O
the O
lip O
. O

Pre B-GENE
- I-GENE
beta I-GENE
- I-GENE
1 I-GENE
lipoprotein I-GENE
and O
early O
detection O
of O
risk O
factors O
for O
coronary O
heart O
disease O
. O

I O
. O

A O
study O
in O
vivo O
of O
adrenergic B-GENE
receptors I-GENE
in O
the O
rectum O
and O
in O
the O
internal O
and O
sphincter O
of O
the O
cat O
. O

Problems O
common O
to O
pediatrics O
and O
anesthesiology O

Clinical O
course O
and O
nursing O
care O
of O
patients O
with O
decubitus O
ulcer O
- O
- O
use O
of O
pillows O
stuffed O
with O
buckwheat O
chaff O

Re O
- O
examining O
methylbenzene O
( O
toluene O
) O
as O
a O
treatment O
for O
Ancylostomum O
caninum O
. O

Teratological O
studies O
on O
SF O
- O
837 O
. O

60th O
birthday O
of O
colonel O
prof O
. O
e O
. O
cerny O
m O
. O
d O
. O

Morphology O
of O
bacteriophages O
of O
Klebsiella O
bacilli O
. O

Benign O
intramural O
tumors O
of O
the O
esophagus O

Methyl O
mercury O
intoxication O
in O
rat O
kidneys O
. O

Disability O
insurance O
under O
social O
security O
. O

Polycythemia O
- O
1973 O
. O

Analysis O
of O
clearance O
curve O
of O
rose O
bengal O
- O
I O
- O
131 O

VII O
. O

Effect O
of O
a O
high O
- O
intensity O
SHF O
field O
on O
the O
blood O
coagulation O
system O

Plastic O
solution O
of O
elbow O
joint O
ankylosis O
with O
a O
decorticated O
cylindrical O
flap O

Effects O
of O
ionizing O
radiation O
in O
the O
human O
oral O
cavity O
and O
oropharynx O
: O
results O
of O
a O
survey O
. O

The O
Twentieth O
Anniversary O
of O
the O
Pomeranian O
Medical O
Academy O
. O

Study O
of O
antinuclear O
autoantibodies O
by O
immunofluorescence O
technic O
in O
collagen B-GENE
diseases O

Some O
reflexions O
apropos O
of O
a O
personal O
statistical O
study O
of O
513 O
arterial O
embolisms O

Reactivities O
to O
horse B-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
. O

The O
effect O
of O
osmotic O
flow O
on O
the O
distribution O
of O
horseradish B-GENE
peroxidase I-GENE
within O
the O
intercellular O
spaces O
of O
toad O
bladder O
epithelium O
. O

Nitrogen O
- O
hydrogen O
tautomerism O
in O
porphyrins O
and O
chlorins O
. O

A O
possible O
role O
for O
the O
mixed O
function O
oxidase B-GENE
enzyme O
system O
in O
the O
requirement O
for O
selenium O
in O
the O
rat O
. O

Periodic O
breathing O
and O
apnea O
in O
preterm O
infants O
. O

Working O
session O
report O
: O
in O
vivo O
- O
in O
vitro O
screening O
. O

Dynamics O
of O
hospital O
stay O
in O
peptic O
ulcer O
patients O

A O
case O
of O
M O
hemoglobinosis O

Results O
of O
the O
official O
inspection O
of O
the O
commercial O
anti O
- O
inflammatory O
enzyme O
preparations O
containing O
chymotrypsin B-GENE
and O
trypsin B-GENE
by O
means O
of O
modified O
NF O
13 O
methods O

The O
content O
of O
glucosamine O
and O
galactosamine O
in O
tartar O

The O
non O
- O
role O
of O
fluoride O
in O
the O
control O
of O
plasma O
calcium O
in O
the O
parathyroidectomized O
rat O
. O

Modification O
of O
the O
growth O
of O
Tetrahymena O
by O
compounds O
which O
affect O
the O
adrenergic O
mechanism O
. O

Factors O
influencing O
in O
vitro O
skin B-GENE
permeability I-GENE
factor I-GENE
production O
by O
Vibrio O
cholerae O
. O

Midge O
control O
in O
flood O
channels O
. O

Tolerance O
test O
of O
HB O
419 O
in O
animal O
experiments O

The O
distribution O
of O
body O
fluids O
following O
hemorrhage O
and O
resuscitation O
in O
combat O
casualties O
. O

Once O
more O
Hong O
Kong O
influenza O
in O
the O
Netherlands O

Early O
disagnosis O
of O
cancer O
- O
- O
50 O
per O
cent O
of O
all O
patients O
could O
be O
cured O

Difficulties O
bound O
to O
measuring O
of O
sputum O
viscosity O

The O
absolute O
configuration O
at O
C O
- O
2 O
in O
monocrotalic O
acid O
. O

CO2 O
assimilation O
by O
chloroplasts O
illuminated O
on O
filter O
paper O
. O

The O
effect O
of O
low O
dosage O
radiation O
on O
metabolism O
and O
function O
of O
the O
rat O
kidney O
damaged O
by O
ischemia O

Quantitation O
of O
exocrine B-GENE
IgA I-GENE
in O
human O
serum O
in O
health O
and O
disease O
. O

Iodine O
metabolism O
in O
chronic O
thyroiditis O
. O

Propagation O
and O
hormone O
production O
by O
human O
normal O
and O
malignant O
trophoblast O
in O
rats O
. O

Morphogenesis O
of O
the O
trochanter O
produced O
by O
femoral O
regeneration O
in O
the O
phasmid O
Carausius O
morosus O
Br O

3 O
. O

Nephrectomy O
applied O
to O
cattle O

Evaluation O
of O
automatic O
blood O
cell O
counters O
. O

The O
effect O
of O
a O
constant O
magnetic O
field O
on O
the O
phagocytic O
activity O
of O
Paramecia O

Relations O
between O
adrenergic O
mechanisms O
and O
analgesic O
effects O

The O
bearing O
of O
season O
and O
sequence O
of O
calving O
on O
frequency O
of O
male O
, O
female O
and O
total O
calvings O
in O
Hariana O
cows O
. O

Effect O
of O
castration O
on O
pituitary B-GENE
and I-GENE
serum I-GENE
LH I-GENE
and O
FSH B-GENE
in O
testosterone O
- O
sterilized O
rats O
. O

The O
significance O
of O
the O
phenolphthalein B-GENE
sulphatase I-GENE
test O
for O
the O
differentiation O
and O
identification O
of O
Nocardia O
species O
. O

Effect O
of O
heparin O
on O
the O
inactivation O
of O
serum B-GENE
lipoprotein I-GENE
lipase I-GENE
by O
the O
liver O
in O
unanesthetized O
dogs O
. O

Experimental O
chlorpromazine O
cataracts O
. O

The O
need O
in O
the O
small O
hospital O
. O

Statistics O
of O
the O
past O
5 O
years O

Naphthalene O
and O
paradichlorobenzene O
in O
clinical O
toxicology O

Story O
of O
a O
hospital O
that O
filmed O
its O
employee O
orientation O
program O
. O

Value O
of O
the O
method O
of O
passive O
hemagglutination O
with O
polysaccharide O
C O
in O
detecting O
C B-GENE
- I-GENE
reactive I-GENE
protein I-GENE
as O
compared O
to O
precipitation O
in O
capillaries O
and O
slide O
latex O
test O
with O
anti B-GENE
- I-GENE
CRP I-GENE
serum O

Antimicrobial O
substance O
isolated O
from O
an O
acorn O
extract O
. O

On O
the O
amount O
and O
significance O
of O
the O
effective O
glucose O
level O
in O
tumors O
. O

The O
immuno O
- O
purified O
mRNA O
in O
the O
polysome O
complex O
was O
used O
to O
prepare O
cDNA O
with O
which O
to O
probe O
a O
D O
. O
melanogaster O
genomic O
library O
. O

Eight O
recombinant O
DNA O
clones O
of O
endogenous O
murine O
leukemia O
virus O
( O
MuLV O
) O
- O
related O
DNA O
sequences O
have O
been O
isolated O
from O
a O
lambdaphage O
genomic O
library O
of O
Balb O
/ O
c O
mouse O
DNA O
. O

Mature O
mRNA O
for O
cytosolic B-GENE
phosphoenolpyruvate I-GENE
carboxykinase I-GENE
of I-GENE
the I-GENE
chicken I-GENE
is O
2 O
. O
8 O
kilobases O
in O
length O
, O
similar O
to O
that O
previously O
noted O
for O
mRNA O
coding O
for O
the O
same O
enzyme O
in O
the O
rat O
. O

Upstream O
activation O
sites O
of O
the O
CYC1 B-GENE
gene I-GENE
of O
Saccharomyces O
cerevisiae O
are O
active O
when O
inverted O
but O
not O
when O
placed O
downstream O
of O
the O
" O
TATA O
box O
" O
. O

Plasma O
and O
erthrocyte O
lipid O
profile O
and O
lipoprotein B-GENE
lipase I-GENE
activity O
in O
postheparin O
plasma O
on O
vasectomized O
rabbits O
were O
studied O
and O
also O
the O
incidence O
of O
atherosclerosis O
in O
different O
arterial O
beds O
. O

Propranolol O
also O
effectively O
controlled O
her O
familial O
tremor O
. O

The O
distribution O
phase O
is O
followed O
by O
an O
elimination O
phase O
with O
a O
much O
longer O
half O
- O
life O
( O
mean O
value O
375 O
min O
) O
and O
a O
volume O
of O
distribution O
of O
approximately O
200 O
- O
400 O
l O
. O

Plasma B-GENE
secretin I-GENE
, O
pancreozymin B-GENE
, O
and O
somatostatin B-GENE
- I-GENE
like I-GENE
hormone I-GENE
in O
chronic O
renal O
failure O
patients O
. O

We O
have O
followed O
37 O
phenytoin O
- O
treated O
patients O
with O
reduced O
serum B-GENE
IgA I-GENE
concentrations O
for O
2 O
- O
7 O
years O
. O

Unusual O
course O
of O
plasmocytosis O
. O

Toxicity O
was O
significant O
in O
selected O
cases O
; O
three O
patients O
developed O
WBC O
counts O
less O
than O
1 O
, O
000 O
/ O
mm3 O
and O
one O
of O
these O
patients O
died O
with O
sepsis O
. O

At O
Cabras O
( O
Oristano O
) O
, O
a O
town O
characterized O
by O
a O
high O
incidence O
of O
thalassaemia O
and O
G6PD B-GENE
deficiency O
less O
than O
half O
the O
people O
between O
18 O
and O
35 O
have O
a O
fair O
knowledge O
of O
genetic O
diseases O
and O
of O
their O
prevention O
. O

Experience O
with O
the O
tensor O
fasciae O
latae O
free O
flap O
. O

The O
abluminal O
surface O
is O
often O
almost O
entirely O
encircled O
by O
a O
thick O
layer O
of O
fibrillary O
connective O
tissue O
. O

The O
customary O
coupling O
reagent O
sulfanilic O
acid O
has O
been O
replaced O
by O
1 O
, O
3 O
- O
dimethylbarbituric O
acid O
; O
CNCl O
is O
produced O
in O
the O
flow O
through O
system O
directly O
from O
KCN O
and O
chloramine O
T O
. O

Among O
six O
different O
library O
isolates O
containing O
6 B-GENE
. I-GENE
5 I-GENE
- I-GENE
to I-GENE
7 I-GENE
- I-GENE
kb I-GENE
IAP I-GENE
units I-GENE
, O
some O
restriction O
sites O
were O
highly O
conserved O
whereas O
others O
varied O
in O
both O
occurrence O
and O
position O
. O

During O
the O
period O
from O
May O
to O
August O
, O
1978 O
, O
an O
epidemic O
of O
hand O
, O
foot O
and O
mouth O
disease O
( O
HFMD O
) O
occurred O
in O
Gifu O
prefecture O
. O

We O
have O
investigated O
the O
requirements O
of O
the O
CH B-GENE
gene I-GENE
switch O
by O
characterizing O
two O
rearranged B-GENE
gamma I-GENE
2b I-GENE
genes I-GENE
from O
a O
gamma B-GENE
2b I-GENE
producing O
mouse O
myeloma O
( O
MPC O
- O
11 O
) O
. O

WR O
- O
2721 O
( O
S O
- O
2 O
- O
( O
3 O
aminopropylamino O
) O
ethylphosphorothioic O
acid O
) O
has O
been O
investigated O
for O
its O
ability O
to O
protect O
gut O
, O
lung O
, O
and O
testis O
, O
as O
well O
as O
fibrosarcoma O
( O
FSa O
) O
tumor O
nodules O
, O
in O
the O
lungs O
of O
mice O
from O
gamma O
- O
radiation O
injury O
. O

The O
ensembles O
are O
considered O
to O
be O
one O
of O
the O
forms O
of O
activity O
of O
the O
structured O
morphofunctional O
cortical O
units O
, O
i O
. O
e O
. O
the O
columns O
. O

The O
strong O
conservation O
of O
the O
inverted O
terminal O
repeat O
sequence O
may O
reflect O
a O
common O
integration O
mechanism O
for O
VL30 B-GENE
elements I-GENE
and O
MuLV O
proviruses O
. O

In O
conclusion O
, O
these O
studies O
indicate O
that O
LiCl O
( O
1 O
) O
decreases O
histamine O
- O
stimulated O
gastric O
acid O
secretion O
, O
and O
( O
2 O
) O
diminishes O
bile O
- O
induced O
disruption O
of O
the O
gastric O
mucosal O
barrier O
in O
the O
canine O
Heidenhain O
pouch O
. O

Gel O
route O
preparation O
of O
low O
fusing O
dental O
porcelain O
frit O
. O

The O
dnaQ B-GENE
- O
lacZ B-GENE
and O
the O
rnh B-GENE
- O
lacZ B-GENE
fused O
genes O
were O
constructed O
and O
hybrid O
proteins O
with O
beta B-GENE
- I-GENE
galactosidase I-GENE
activity O
were O
produced O
. O

The O
primary O
structure O
of O
the O
GAL7 B-GENE
5 I-GENE
' I-GENE
flanking I-GENE
region I-GENE
has O
many O
features O
common O
to O
those O
of O
multicellular O
eukaryotic O
genes O
. O

Sweet O
oranges O
, O
mandarin O
, O
grapefruit O
, O
lemon O
, O
and O
lime O
are O
generally O
used O
for O
processing O
. O

Bepridil O
, O
a O
calcium O
antagonist O
with O
a O
half O
- O
life O
of O
approximately O
42 O
hours O
, O
was O
compared O
with O
placebo O
in O
a O
double O
- O
blind O
, O
randomized O
, O
crossover O
trial O
. O

Climatic O
treatment O
of O
children O
with O
respiratory O
allergy O

The O
susceptibility O
of O
the O
PPNG O
strains O
to O
clinically O
relevant O
antibiotics O
varied O
with O
the O
plasmid O
pattern O
; O
this O
stresses O
the O
necessity O
of O
permanent O
surveillance O
of O
gonococcal O
infections O
and O
of O
regular O
evaluation O
of O
the O
recommendations O
for O
antimicrobial O
treatment O
. O

If O
facilities O
for O
measurements O
of O
O2 O
consumption O
and O
hence O
metabolic O
rate O
are O
available O
, O
these O
should O
be O
utilized O
. O

This O
generally O
means O
an O
energy O
intake O
of O
1 O
. O
4 O
to O
1 O
. O
6 O
times O
the O
energy O
expenditure O
, O
with O
a O
N O
intake O
of O
250 O
to O
400 O
mg O
/ O
kg O
/ O
day O
. O

The O
statistical O
analysis O
of O
data O
of O
TRH B-GENE
test O
on O
a O
sample O
of O
57 O
healthy O
volunteers O
has O
permitted O
an O
evaluation O
of O
the O
upper O
limits O
of O
the O
normal O
thyrotropin B-GENE
response O
; O
the O
secretory O
area O
( O
As O
) O
was O
shown O
to O
be O
more O
discriminating O
. O

Transitory O
subclinical O
and O
permanent O
hypothyroidism O
in O
the O
course O
of O
subacute O
thyroiditis O
( O
de O
Quervain O
) O
. O

It O
is O
concluded O
that O
axillo O
- O
axillary O
by O
- O
pass O
is O
a O
simple O
solution O
for O
a O
complex O
haemodynamic O
, O
clinical O
and O
therapeutic O
problem O
. O

Endothelium O
of O
the O
central O
ear O
artery O
of O
an O
anesthetized O
rabbit O
is O
damaged O
by O
placing O
artery O
forceps O
on O
the O
ear O
directly O
over O
the O
vessel O
. O

Hydrocortisone O
seems O
to O
be O
unable O
to O
hinder O
the O
postdenervation O
changes O
in O
the O
muscle O
membrane O
whereas O
high O
doses O
of O
the O
hormone O
are O
able O
to O
induce O
changes O
in O
the O
muscle O
membrane O
. O

Significant O
clinical O
differences O
between O
the O
patients O
treated O
with O
and O
without O
AMB O
were O
longer O
survival O
time O
following O
diagnosis O
of O
illness O
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
more O
frequent O
cranial O
nerve O
signs O
in O
the O
treated O
patients O
( O
P O
= O
0 O
. O
089 O
) O
. O

Catch O
- O
up O
growth O
was O
observed O
only O
for O
a O
12 O
- O
month O
period O
in O
4 O
children O
with O
a O
bone O
age O
of O
7 O
to O
8 O
years O
. O

The O
present O
paper O
elucidates O
the O
existing O
discrepancies O
, O
and O
offers O
a O
consistent O
terminology O
incorporating O
also O
such O
terms O
as O
" O
additivity O
" O
, O
" O
potentiation O
" O
, O
and O
" O
simple O
similarity O
" O
. O

Brainstem O
auditory O
evoked O
responses O
( O
BAERs O
) O
and O
quantitative O
saccadic O
eye O
movement O
studies O
provide O
information O
on O
the O
integrity O
of O
pathways O
traversing O
the O
brainstem O
. O

The O
salient O
clinical O
features O
, O
the O
problems O
of O
management O
and O
the O
modern O
approaches O
to O
the O
reconstruction O
of O
facial O
deformities O
seen O
in O
this O
disease O
are O
described O
. O

The O
rational O
for O
the O
prophylactic O
treatment O
, O
the O
therapy O
of O
the O
meningopathy O
and O
AIL O
- O
AIEOP O
protocols O
are O
exposed O
. O

Hepatitis O
B O
vaccine O

The O
Sarns O
51F O
cavoatrial O
cannula O
decompressed O
the O
venous O
system O
as O
efficiently O
as O
the O
double O
caval O
cannulas O
. O

Three O
experiments O
contrasted O
the O
effects O
of O
6 O
- O
hydroxydopamine O
- O
induced O
lesions O
of O
the O
ventral O
noradrenergic O
and O
dorsal O
noradrenergic O
projections O
, O
predominantly O
to O
hypothalamus O
and O
cortex O
, O
respectively O
, O
upon O
body O
weight O
changes O
and O
food O
- O
related O
behaviour O
in O
the O
rat O
. O

Female O
Wistar O
rats O
were O
fed O
a O
liquid O
diet O
, O
Sustacal O
, O
which O
contained O
ethanol O
( O
40 O
% O
of O
calories O
) O
or O
isocaloric O
sucrose O
. O

Introductory O
remarks O
. O

Combination O
of O
a O
Shwachman O
syndrome O
and O
a O
complex O
granulocyte O
function O
disorder O
in O
a O
girl O

Trial O
3 O
broiler O
chickens O
were O
maintained O
on O
control O
feed O
until O
they O
reached O
3 O
weeks O
of O
age O
at O
which O
time O
they O
were O
taken O
off O
of O
feed O
for O
2 O
. O
5 O
hr O
and O
then O
placed O
on O
either O
control O
feed O
or O
feed O
containing O
4 O
. O
0 O
ppm O
ochratoxin O
A O
, O
and O
heart O
rate O
and O
blood O
pressure O
were O
measured O
every O
half O
hour O
through O
7 O
hr O
. O

While O
these O
findings O
may O
reflect O
the O
sensitivity O
of O
a O
thick O
myocardial O
wall O
to O
ischaemia O
during O
surgery O
, O
the O
postoperative O
recovery O
was O
not O
related O
to O
the O
serum B-GENE
CK I-GENE
- I-GENE
MB I-GENE
level O
. O

Using O
a O
MOS O
- O
Hypersil O
reversed O
- O
phase O
column O
with O
a O
phosphate O
buffer O
- O
- O
acetonitrile O
mobile O
phase O
, O
baseline O
separation O
of O
antipyrine O
, O
its O
metabolites O
3 O
- O
hydroxymethylantipyrine O
, O
norantipyrine O
and O
4 O
- O
hydroxyantipyrine O
, O
and O
the O
internal O
standard O
, O
phenacetin O
, O
was O
achieved O
within O
6 O
min O
. O

Serum O
lipids O
and O
lipoproteins O
of O
29 O
insulin B-GENE
dependent O
diabetic O
children O
have O
been O
determined O
and O
related O
to O
the O
metabolic O
status O
of O
the O
patients O
. O

The O
AD O
components O
were O
markedly O
more O
dependent O
on O
the O
affective O
state O
of O
the O
rat O
then O
was O
the O
V1 O
component O
. O

HBB O
concentration O
in O
the O
fetuses O
indicated O
little O
, O
if O
any O
accumulation O
. O

All O
samples O
exhibited O
a O
decline O
in O
ethanol O
concentration O
, O
with O
most O
losses O
falling O
within O
the O
expected O
20 O
to O
40 O
mg O
% O
range O
. O

Pilot O
study O
of O
blood O
coagulation O
in O
gout O
patients O
. O

Further O
, O
the O
reduction O
in O
5 O
- O
hydroxytryptophan O
( O
5 O
- O
HTP O
) O
accumulation O
by O
LSD O
showed O
regional O
differences O
in O
inhibition O
by O
methiothepin O
( O
hypothalamus O
greater O
than O
cortex O
greater O
than O
striatum O
) O
which O
paralleled O
the O
autoreceptor O
antagonist O
activity O
of O
methiothepin O
in O
vitro O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Effects O
of O
methiothepin O
and O
lysergic O
acid O
diethylamide O
on O
serotonin O
release O
in O
vitro O
and O
serotonin O
synthesis O
in O
vivo O
: O
possible O
relation O
to O
serotonin B-GENE
autoreceptor I-GENE
function O
. O

In O
a O
recent O
measles O
epidemic O
in O
El O
Paso O
, O
TX O
, O
120 O
, O
000 O
records O
were O
screened O
using O
these O
criteria O
, O
and O
as O
a O
result O
13 O
, O
000 O
students O
were O
vaccinated O
. O

Twenty O
- O
one O
percent O
of O
these O
patients O
had O
neurologic O
disease O
that O
appeared O
to O
be O
responsible O
for O
the O
tinnitus O
. O

Bullous O
angiolymphoid O
hyperplasia O
with O
eosinophilia O

The O
hypertension O
with O
elevated O
PRA O
, O
however O
, O
was O
resistant O
to O
the O
angiotensin B-GENE
II I-GENE
( O
AII B-GENE
) O
analog O
[ O
Sar1 O
, O
Ile8 O
] O
ALL O
. O

Volume O
of O
distribution O
of O
total O
DMDZ O
( O
range O
, O
1 O
. O
33 O
to O
6 O
. O
30 O
l O
/ O
kg O
) O
and O
of O
unbound O
DMDZ O
after O
correction O
for O
protein O
binding O
( O
range O
, O
43 O
to O
243 O
l O
/ O
kg O
) O
was O
larger O
in O
women O
than O
in O
men O
of O
all O
ages O
, O
and O
in O
the O
elderly O
as O
opposed O
to O
the O
young O
. O

Effects O
of O
dopamine O
and O
of O
a O
dopaminergic O
blocker O
, O
haloperidol O
, O
on O
the O
responses O
of O
carotid O
body O
chemoreceptors O
to O
hypoxia O
and O
hypercapnia O
were O
investigated O
in O
16 O
anesthetized O
cats O
. O

1 O
. O

The O
alterations O
in O
differentiation O
of O
osteoprogenitor O
cells O
, O
together O
with O
the O
failure O
of O
mineralization O
, O
resulted O
in O
significantly O
lower O
rates O
of O
bone O
formation O
( O
as O
measured O
by O
fluorochrome O
labeling O
) O
in O
the O
magnesium O
- O
deficient O
rats O
. O

The O
role O
of O
DNA O
rearrangement O
and O
alternative O
RNA O
processing O
in O
the O
expression O
of O
immunoglobulin B-GENE
delta I-GENE
genes I-GENE
. O

There O
is O
now O
a O
significative O
difference O
between O
age O
group O
1 O
- O
5 O
and O
the O
others O
( O
p O
Less O
Than O
0 O
, O
02 O
) O
. O

Factor B-GENE
VIII I-GENE
procoagulant O
activity O
, O
antigen O
concentration O
and O
von B-GENE
Willebrand I-GENE
activity O
as O
ristocetin B-GENE
cofactor I-GENE
were O
determined O
several O
times O
in O
10 O
patients O
with O
DIC O
. O

In O
silicosis O
, O
significant O
relationships O
between O
patients O
and O
sons O
were O
not O
seen O
with O
respect O
to O
arterial O
blood O
gas O
determinations O
and O
ventilatory O
responses O
except O
for O
Paco2 O
of O
patients O
and O
hypercapnic O
ventilatory O
responses O
of O
sons O
. O

For O
steers O
the O
urinary O
N O
values O
were O
403 O
and O
295 O
mg O
/ O
kg O
W0 O
. O
75 O
at O
200 O
and O
350 O
kg O
live O
weight O
respectively O
and O
total O
N O
excretion O
including O
faecal O
N O
was O
408 O
and O
320 O
mg O
/ O
kg O
W0 O
. O
75 O
. O

TEMTU O
and O
DPTU O
were O
the O
most O
potent O
teratogens O
. O

Similar O
observations O
were O
made O
with O
unilateral O
pneumothorax O
of O
15 O
cmH2O O
for O
30 O
min O
. O

Fibromuscular O
intimal O
thickening O
was O
seen O
in O
the O
ascending O
and O
thoracic O
aorta O
of O
the O
swine O
fed O
62 O
, O
500 O
IU O
of O
vitamin O
D3 O
/ O
kg O
of O
diet O
for O
three O
months O
duration O
; O
and O
after O
3 O
months O
of O
vitamin O
D3 O
withdrawal O
, O
atherosclerotic O
lesions O
were O
found O
. O

Detection O
of O
exercise O
- O
induced O
asynergy O
by O
M O
- O
mode O
echocardiography O
. O

Both O
groups O
were O
subjected O
to O
tests O
of O
delayed O
hypersensitivity O
with O
Candidin B-GENE
, O
Trycophytin B-GENE
and O
Tuberculin B-GENE
. O

Efficacy O
of O
cervical O
spine O
immobilization O
methods O
. O

Circulating O
platelets O
may O
be O
activated O
by O
exposed O
triple O
- O
helical O
collagen B-GENE
in O
atherosclerotic O
lesions O
in O
Mg O
- O
deficient O
ruminants O
. O

In O
the O
ultramarathon O
runner O
the O
testosterone O
levels O
sharply O
rose O
at O
the O
beginning O
of O
the O
training O
session O
( O
from O
the O
7 O
, O
20 O
ng O
/ O
ml O
to O
11 O
, O
50 O
ng O
/ O
ml O
after O
20 O
' O
training O
) O
, O
and O
subsequently O
decrease O
after O
3 O
hours O
( O
9 O
, O
20 O
ng O
/ O
ml O
) O
and O
at O
the O
end O
of O
the O
6 O
hours O
training O
( O
4 O
, O
60 O
ng O
/ O
ml O
) O
. O

Terbutaline O
; O
a O
beta2 O
- O
adrenergic O
agonist O
, O
and O
aminophyllin O
, O
a O
phosphodiesterase O
inhibitor O
, O
were O
given O
separately O
, O
or O
in O
combination O
, O
to O
rabbit O
fetuses O
on O
the O
28th O
day O
of O
gestation O
. O

The O
hyperacute O
phase O
of O
posterolateral O
myocardial O
infarction O
. O

After O
a O
year O
of O
planning O
in O
the O
Laboratory O
Assistants O
' O
School O
in O
Stockholm O
: O
new O
education O
for O
laboratory O
assistants O
is O
now O
arranged O

The O
electrocardiogram O
. O

The O
Authors O
have O
proposed O
to O
develop O
this O
research O
employing O
a O
preparation O
containing O
exclusively O
a O
cortisonic O
, O
the O
desametazone O
, O
in O
order O
to O
evaluate O
the O
alterations O
of O
the O
dentinogenesis O
to O
be O
attributed O
to O
such O
component O
. O

Secretory B-GENE
IgA I-GENE
and O
serum B-GENE
immunoglobulins I-GENE
as O
indices O
of O
the O
local O
immunity O
of O
the O
intestinal O
mucosa O
in O
acute O
leukemias O

Fluorometric O
methods O
can O
also O
provide O
information O
about O
porphyrin O
binding O
sites O
that O
is O
useful O
in O
understanding O
porphyrin O
transport O
and O
clearance O
. O

The O
monoexponential O
rate O
of O
clearance O
of O
tracer O
- O
- O
obtained O
from O
the O
portion O
of O
the O
residue O
- O
detection O
curve O
reflecting O
metabolism O
of O
fatty O
acid O
incorporated O
into O
neutral O
lipids O
- O
- O
correlated O
directly O
with O
induced O
changes O
in O
tension O
- O
time O
index O
after O
injections O
into O
the O
left O
atrium O
( O
r O
= O
0 O
. O
96 O
, O
n O
= O
12 O
) O
, O
right O
atrium O
( O
r O
= O
0 O
. O
86 O
, O
n O
= O
14 O
) O
, O
and O
ear O
vein O
( O
r O
= O
0 O
. O
93 O
, O
n O
= O
14 O
) O
. O

Specific O
IgE B-GENE
levels O
decreased O
slightly O
, O
but O
always O
remained O
within O
the O
pathological O
range O
. O

Correlation O
between O
intraocular O
involvement O
and O
systemic O
outcome O
was O
poor O
. O

The O
results O
indicate O
that O
folate O
compounds O
decrease O
formate O
accumulation O
after O
methanol O
by O
stimulating O
formate O
oxidation O
or O
utilization O
and O
suggest O
a O
possible O
use O
for O
folates O
in O
the O
treatment O
of O
certain O
cases O
of O
human O
methanol O
poisoning O
. O

The O
" O
cracked O
- O
tooth O
" O
syndrome O
. O

The O
foregoing O
results O
show O
that O
CXD O
has O
high O
efficacy O
and O
safety O
and O
it O
can O
be O
said O
that O
it O
is O
a O
drug O
required O
in O
the O
pediatric O
field O
. O

Based O
on O
peptide O
map O
similarities O
, O
partial O
amino O
- O
terminal O
sequence O
data O
, O
and O
common O
genetic O
origin O
, O
it O
is O
suggested O
that O
p60 B-GENE
and O
p62 B-GENE
have O
identical O
amino O
acid O
sequences O
carboxy O
- O
terminal O
to O
the O
p60 B-GENE
initiator O
methionine O
( O
residue O
21 O
of O
p62 B-GENE
) O
. O

Diagnosis O
of O
phenylalanine B-GENE
hydroxylase I-GENE
deficiency O
( O
phenylketonuria O
) O
. O

The O
uncomplicated O
cases O
of O
typhoid O
fever O
were O
found O
to O
have O
an O
intact O
CMIR O
as O
compared O
to O
the O
complicated O
cases O
. O

There O
was O
a O
significant O
correlation O
between O
tubular O
diameter O
and O
spg O
( O
r O
= O
0 O
. O
68 O
, O
P O
less O
than O
0 O
. O
001 O
) O
suggesting O
that O
tubular O
diameter O
measurements O
in O
histological O
sections O
could O
be O
used O
to O
predict O
sperm O
production O
. O

The O
differential O
investigation O
of O
lipoproteins O
, O
however O
, O
showed O
that O
the O
high B-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
( O
HDL B-GENE
) O
fractions O
are O
absolutely O
or O
relatively O
decreased O
with O
respect O
to O
low B-GENE
- I-GENE
density I-GENE
lipoproteins I-GENE
( O
LDL B-GENE
) O
in O
cerebral O
infarcts O
and O
in O
transient O
ischaemic O
attacks O
. O

A O
note O
on O
some O
consequences O
of O
UV O
vision O
in O
birds O
. O

Parasitological O
and O
pathological O
findings O
in O
capuchin O
monkeys O
infected O
with O
Schistosoma O
japonicum O
or O
Schistosoma O
mansoni O
. O

In O
the O
past O
, O
immunology O
in O
Singapore O
was O
mainly O
confined O
to O
serology O
for O
the O
diagnosis O
of O
certain O
infectious O
diseases O
. O

Modification O
of O
enteral O
resorption O
by O
cytostatic O
therapy O

In O
vitro O
penetration O
tests O
of O
human O
sperm O
into O
cervical O
mucus O
were O
introduced O
in O
order O
to O
study O
the O
interaction O
between O
sperm O
and O
cervical O
mucus O
. O

Vibrio O
fluvialis O
( O
group O
F O
vibrio O
) O
in O
Maharashtra O
. O

The O
hormonal O
response O
to O
a O
standardized O
bicycle O
exercise O
test O
was O
studied O
in O
11 O
male O
cadets O
exposed O
to O
a O
course O
of O
107 O
h O
of O
continuous O
activity O
with O
less O
than O
2 O
h O
sleep O
. O

At O
an O
ambient O
temperature O
of O
25 O
degrees O
C O
, O
the O
responses O
to O
spinal O
cooling O
are O
reduced O
during O
the O
dark O
phase O
. O

Ulcer O
appeared O
on O
the O
angulus O
of O
the O
stomach O
at O
the O
28th O
week O
and O
resulted O
in O
ulcer O
scar O
at O
the O
42nd O
week O
. O

Results O
of O
the O
recognition O
task O
revealed O
significant O
effects O
of O
consonant O
voicing O
, O
position O
and O
vowel O
context O
on O
syllable O
recognition O
. O

Visual O
response O
properties O
of O
neurons O
in O
four O
extrastriate O
visual O
areas O
of O
the O
owl O
monkey O
( O
Aotus O
trivirgatus O
) O
: O
a O
quantitative O
comparison O
of O
medial O
, O
dorsomedial O
, O
dorsolateral O
, O
and O
middle O
temporal O
areas O
. O

A O
unified O
approach O
to O
the O
standardization O
of O
allergens O
. O

A O
dose O
- O
dependent O
fall O
in O
GABA O
content O
was O
observed O
; O
GABA O
decrease O
was O
evident O
15 O
min O
after O
the O
administration O
, O
reached O
its O
nadir O
at O
60 O
min O
and O
disappeared O
at O
120 O
minutes O
. O

For O
monocytes O
, O
as O
measured O
on O
the O
Hematrak O
, O
it O
was O
13 O
. O
4 O
% O
. O

Evoked O
potential O
and O
single O
unit O
responses O
to O
olfactory O
nerve O
volleys O
in O
the O
isolated O
turtle O
olfactory O
bulb O
. O

While O
all O
deletions O
within O
the O
sequence O
coding O
for O
the O
mature O
tRNA O
led O
to O
inactivity O
of O
the O
mutated O
genes O
, O
substitution O
of O
the O
central O
portion O
by O
concatenated B-GENE
Hind I-GENE
III I-GENE
linkers I-GENE
produced O
gene O
units O
active O
in O
transcription O
. O

Survival O
was O
calculated O
both O
from O
the O
date O
of O
onset O
and O
from O
the O
date O
of O
diagnosis O
. O

With O
Sair O
and O
So2 O
, O
mean O
vital O
capacity O
was O
reduced O
by O
44 O
% O
from O
control O
. O

Of O
the O
117 O
patients O
( O
out O
of O
the O
136 O
) O
with O
serologic O
evidence O
of O
chronic O
thyroiditis O
who O
could O
be O
studied O
, O
eight O
( O
7 O
% O
) O
had O
hyperthyroidism O
and O
45 O
( O
38 O
% O
) O
were O
hypothyroid O
. O

The O
new O
semi O
- O
synthetic O
oral O
cephalosporin O
, O
CGP O
9 O
, O
000 O
, O
has O
been O
evaluated O
in O
a O
large O
number O
of O
hospitalized O
patients O
with O
urinary O
infections O
. O

Current O
status O
of O
chemotherapy O
for O
Hodgkin O
' O
s O
disease O

Over O
a O
period O
of O
15 O
days O
16 O
% O
of O
the O
dose O
administered O
was O
excreted O
with O
faeces O
and O
0 O
. O
9 O
% O
in O
the O
urine O
. O

Electron O
microscopic O
picture O
of O
the O
cerebral O
cortex O
in O
rats O
cooled O
to O
22 O
degrees O
C O

Thirty O
- O
one O
age O
- O
matched O
, O
conscious O
, O
virgin O
, O
male O
Sprague O
- O
Dawley O
rats O
and O
spontaneously O
hypertensive O
rats O
( O
SHRs O
) O
were O
individually O
injected O
with O
a O
single O
subcutaneous O
dose O
of O
85 O
mg O
/ O
kg O
dl O
- O
isoproterenol O
to O
determine O
the O
degree O
and O
time O
course O
of O
drug O
- O
induced O
cardiac O
failure O
and O
functional O
recovery O
. O

Prevention O
of O
transfusion O
reactions O
by O
the O
use O
of O
saline O
washed O
red O
blood O
cells O
. O

The O
geometric O
mean O
hemagglutination O
- O
inhibition O
antibody O
titers O
( O
GMT O
) O
of O
non O
- O
immunized O
, O
once O
- O
immunized O
, O
and O
twice O
- O
immunized O
chickens O
were O
compared O
at O
2 O
- O
week O
intervals O
following O
primary O
immunization O
, O
secondary O
immunization O
, O
and O
challenge O
. O

100 O
more O
than O
in O
the O
summer O
coat O
) O
. O

Two O
new O
artifacts O
in O
automated O
coagulation O
testing O
. O

This O
relatively O
simple O
and O
easily O
performed O
technique O
of O
measuring O
deep O
muscle O
temperature O
appears O
to O
be O
a O
useful O
adjunct O
in O
choosing O
the O
amputation O
level O
. O

Changes O
in O
immunologic O
reactivity O
in O
subjects O
receiving O
transfer B-GENE
factor I-GENE
could O
not O
be O
distinguished O
from O
those O
in O
subjects O
receiving O
placebo O
. O

Charcoal O
- O
facilitated O
dialysis O
. O

Retinal O
changes O
in O
pigmentary O
retinopathy O
in O
children O

As O
a O
result O
, O
beta O
- O
apo O
- O
8 O
' O
- O
carotenoic O
acid O
ethyl O
ester O
( O
apo O
- O
EE O
) O
was O
used O
as O
a O
reference O
standard O
in O
Experiments O
4 O
to O
6 O
. O

Six O
hours O
after O
the O
last O
administration O
, O
uterus O
of O
Gf O
and O
Cv O
mice O
were O
weight O
337 O
. O
6 O
mg O
% O
and O
423 O
. O
5 O
mg O
% O
respectively O
, O
the O
difference O
was O
statistically O
significant O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

Analysis O
of O
an O
autopsy O
population O
. O

Autoradiographic O
localisation O
of O
its O
cellular O
distribution O
in O
the O
kidney O
. O

Microscopic O
anatomy O
and O
cell O
population O
dynamics O
. O

In O
11 O
patients O
with O
Horton O
' O
s O
headache O
morphological O
investigations O
( O
differential O
white O
blood O
cell O
count O
) O
, O
cytoenzymatic O
determinations O
( O
alkaline B-GENE
and I-GENE
acid I-GENE
phosphatase I-GENE
, O
non B-GENE
- I-GENE
specific I-GENE
esterase I-GENE
) O
and O
cytoimmunological O
tests O
( O
IgM B-GENE
and O
IgG B-GENE
binding O
) O
were O
carried O
out O
on O
capillary O
blood O
neutrophils O
obtained O
from O
the O
area O
of O
pain O
, O
non O
- O
painful O
area O
of O
the O
skin O
on O
the O
head O
on O
the O
contralateral O
side O
, O
and O
from O
the O
finger O
. O

The O
resulting O
R B-GENE
protein I-GENE
terminates O
five O
codons O
downstream O
of O
the O
frameshift O
site O
at O
the O
V B-GENE
protein I-GENE
stop O
codon O
. O

BSE O
and O
farmworkers O
. O

Peroxisome B-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPARs B-GENE
) O
and O
retinoid B-GENE
X I-GENE
receptors I-GENE
( O
RXRs B-GENE
) O
are O
nuclear B-GENE
hormone I-GENE
receptors I-GENE
that O
are O
activated O
by O
fatty O
acids O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
respectively O
. O

The O
number O
of O
lactotropes O
, O
somatotropes O
, O
thyrotropes O
, O
and O
gonadotropes O
was O
not O
altered O
compared O
with O
controls O
, O
indicating O
that O
in O
the O
adult O
pituitary O
, O
POMC B-GENE
products I-GENE
are O
not O
required O
to O
maintain O
the O
distribution O
of O
cell O
types O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
the O
PERE B-GENE
formed O
three O
major O
complexes O
( O
P1 O
, O
P2 O
and O
P3 O
) O
with O
proteins O
in O
nuclear O
extracts O
from O
HeLa O
or O
293 O
cells O
. O

That O
sequence O
strongly O
promoted O
the O
transcription O
of O
the O
promotorless O
chloramphenicol B-GENE
acetyltranferase I-GENE
( O
CAT B-GENE
) O
gene O
in O
cells O
of O
pancreatic O
origin O
( O
AR O
- O
42J O
) O
but O
not O
in O
cells O
of O
non O
- O
pancreatic O
origin O
( O
Rat O
2 O
and O
IEC O
6 O
) O
. O

In O
the O
absence O
of O
E1A243 B-GENE
, O
YY1 B-GENE
represses O
CRE O
- O
dependent O
transcription O
of O
c B-GENE
- I-GENE
fos I-GENE
by O
physically O
interacting O
with O
ATF B-GENE
/ O
CREB B-GENE
proteins O
bound O
to O
the O
- O
67 O
CRE O
. O

TPBF B-GENE
has O
two O
potential O
coiled O
- O
coil O
regions O
, O
a O
basic O
region O
, O
a O
proline O
- O
rich O
region O
, O
a O
histidine O
- O
rich O
N O
terminus O
, O
and O
a O
nuclear O
targeting O
sequence O
. O

To O
confirm O
the O
GapIII B-GENE
protein I-GENE
activity O
, O
constructs O
containing O
different O
GapIII B-GENE
- O
GRD B-GENE
domains O
were O
transformed O
into O
iral B-GENE
mutant O
yeast O
to O
determine O
their O
relative O
ability O
to O
replace O
IRA1 B-GENE
functionally O
. O

A O
water O
- O
vapour O
giga O
- O
maser O
in O
the O
active O
galaxy O
TXFS2226 O
- O
184 O
. O

These O
incisors O
were O
studied O
by O
scanning O
electron O
microscopy O
- O
energy O
dispersive O
spectroscopy O
analysis O
( O
SEM O
- O
EDS O
) O
and O
light O
microscopy O
to O
examine O
the O
calciotraumatic O
lines O
of O
strontium O
in O
the O
rat O
incisor O
labial O
dentin O
. O

Mechanism O
of O
enhancement O
of O
DNA O
expression O
consequent O
to O
cointernalization O
of O
a O
replication O
- O
deficient O
adenovirus O
and O
unmodified O
plasmid O
DNA O
. O

Hepatitis B-GENE
B I-GENE
surface I-GENE
antigen I-GENE
was O
detected O
in O
2 O
patients O
, O
with O
negative O
hepatitis B-GENE
C I-GENE
virus I-GENE
antibody I-GENE
. O

Liver O
transplantation O
in O
one O
patient O
resolved O
metabolic O
complications O
but O
did O
not O
improve O
PMN O
count O
or O
the O
infectious O
status O
, O
while O
neutropenia O
was O
corrected O
by O
G B-GENE
- I-GENE
CSF I-GENE
. O

Joys O
and O
F O
. O

Tyrosine O
phosphorylation O
of O
cellular O
proteins O
is O
the O
earliest O
identifiable O
event O
following O
T B-GENE
- I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
TCR B-GENE
) O
stimulation O
and O
is O
essential O
for O
activating O
downstream O
signaling O
machinery O
. O

The O
interferon B-GENE
- O
induced O
RNA B-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKR B-GENE
) O
is O
considered O
to O
play O
an O
important O
role O
in O
the O
cellular O
defense O
against O
viral O
infection O
and O
, O
in O
addition O
, O
has O
been O
suggested O
to O
be O
a O
tumor O
suppressor O
gene O
because O
of O
its O
growth O
- O
suppressive O
properties O
. O

Moreover O
, O
Lck B-GENE
was O
reversibly O
co O
- O
immunoprecipitated O
with O
p95Vav B-GENE
, O
and O
the O
stoichiometry O
of O
binding O
increased O
in O
anti B-GENE
- I-GENE
CD3 I-GENE
- O
treated O
Jurkat O
cells O
. O

Interleukin B-GENE
- I-GENE
8 I-GENE
( O
IL B-GENE
- I-GENE
8 I-GENE
) O
is O
a O
potent O
inflammatory O
mediator O
that O
belongs O
to O
the O
family O
of O
C B-GENE
- I-GENE
X I-GENE
- I-GENE
C I-GENE
chemokines I-GENE
. O

Three O
mutants O
( O
pms1 B-GENE
, O
pms2 B-GENE
and O
pms3 B-GENE
) O
isolated O
earlier O
from O
MW104 O
- O
1B O
were O
shown O
to O
correct O
in O
vitro O
constructed O
plasmids O
with O
defined O
DNA O
mismatches O
( O
G O
/ O
T O
, O
A O
/ O
C O
, O
G O
/ O
G O
, O
etc O
. O
) O
poorly O
( O
Kramer O
et O
al O
. O
, O
1989a O
) O
. O

Hematopoietic B-GENE
growth I-GENE
factors I-GENE
are O
being O
used O
to O
accelerate O
the O
recovery O
of O
myelopoiesis O
following O
high O
- O
dose O
chemotherapy O
in O
cancer O
patients O
. O

A O
particularly O
striking O
HpaII B-GENE
tiny O
fragment O
island O
, O
extending O
over O
nearly O
2 O
, O
000 O
base O
pairs O
, O
surrounds O
the O
USF2 B-GENE
translation I-GENE
initiation I-GENE
site I-GENE
. O

Dilutions O
of O
H B-GENE
- I-GENE
2b I-GENE
or I-GENE
H I-GENE
- I-GENE
2d I-GENE
NP I-GENE
peptides I-GENE
indicated O
that O
3 O
- O
4 O
logs O
less O
H B-GENE
- I-GENE
2b I-GENE
NP I-GENE
peptide I-GENE
was O
required O
to O
sensitize O
syngeneic O
target O
cells O
for O
CTL O
- O
specific O
lysis O
, O
suggesting O
that O
the O
differing O
affinities O
of O
H O
- O
2b O
and O
H O
- O
2d O
major B-GENE
histocompatibility I-GENE
complex I-GENE
molecules I-GENE
for O
their O
peptides O
likely O
account O
for O
the O
total O
removal O
of O
NP O
CTL O
in O
the O
H O
- O
2b O
mice O
but O
only O
partial O
removal O
in O
H O
- O
2d O
mice O
made O
to O
express O
thymic O
NP O
. O

Although O
both O
transfected O
cell O
lines O
contain O
FGF B-GENE
- I-GENE
1 I-GENE
cell I-GENE
surface I-GENE
receptors I-GENE
as O
judged O
by O
crosslinking O
studies O
, O
the O
wild O
- O
type O
transfectants O
are O
refractory O
to O
exogenous O
FGF B-GENE
- I-GENE
1 I-GENE
, O
whereas O
the O
mutant O
transfectants O
respond O
normally O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
median O
post O
- O
treatment O
, O
pre O
- O
operative O
serum B-GENE
PSA I-GENE
was O
0 O
. O
4 O
ng O
/ O
ml O
. O

The O
amino O
acid O
sequences O
of O
the O
predicted O
RfbA B-GENE
and O
RfbB B-GENE
homologs I-GENE
showed O
identities O
of O
75 O
. O
7 O
% O
( O
87 O
. O
9 O
% O
total O
similarity O
) O
and O
78 O
. O
0 O
% O
( O
86 O
. O
5 O
% O
total O
similarity O
) O
, O
respectively O
. O

In O
this O
paper O
we O
report O
that O
ligand O
binding O
induced O
tyrosine O
phosphorylation O
in O
BaF3 O
cells O
engineered O
to O
express O
the O
murine B-GENE
Mpl I-GENE
receptor I-GENE
( O
BaF3 O
/ O
mMpl B-GENE
) O
. O

A O
chicken B-GENE
paxillin I-GENE
cDNA I-GENE
was O
also O
cloned O
and O
is O
predicted O
to O
encode O
a O
protein O
approximately O
90 O
% O
identical O
to O
human B-GENE
paxil I-GENE
- I-GENE
lin I-GENE
. O

In O
vivo O
association O
between O
Shb B-GENE
- O
SH3 B-GENE
domain O
proteins O
v B-GENE
- I-GENE
Src I-GENE
and O
Eps8 B-GENE
was O
detected O
by O
coimmunoprecipitation O
. O

As O
expected O
, O
the O
insulin B-GENE
effect O
to O
increase O
ras B-GENE
GTP I-GENE
formation O
and O
MAP B-GENE
kinase I-GENE
activity O
was O
negligible O
in O
A O
/ O
K1018 O
cells O
but O
normal O
, O
or O
supernormal O
, O
in O
Y O
/ O
F2 O
cells O
. O

Appropriate O
restriction O
sites O
allow O
one O
to O
insert O
virtually O
any O
desired O
cDNA O
fragment O
directly O
behind O
the O
epitope O
- O
specific O
sequence O
and O
before O
a O
long O
poly O
( O
A O
) O
tail O
. O

The O
gene O
product O
of O
cotS B-GENE
was O
confirmed O
to O
be O
identical O
to O
Cot40 B-GENE
- I-GENE
2 I-GENE
by O
SDS O
- O
PAGE O
and O
immunoblotting O
from O
Escherichia O
coli O
transformed O
with O
a O
plasmid O
containing O
the O
cotS B-GENE
region I-GENE
. O

The O
optimal O
care O
of O
CHF O
patient O
includes O
the O
recognition O
and O
management O
of O
these O
electrolyte O
disturbances O
. O

METHODS O
: O
rHb1 B-GENE
. I-GENE
1 I-GENE
or O
human B-GENE
serum I-GENE
albumin I-GENE
was O
administered O
intravenously O
to O
fasting O
male O
volunteers O
. O

A O
mutant O
( O
residues O
1 O
- O
332 O
) O
showed O
complete O
Ca2 O
+ O
/ O
CaM B-GENE
- O
dependent O
activity O
. O

The O
two O
bases O
immediately O
flanking O
the O
5 O
' O
end O
of O
the O
element O
proved O
to O
be O
very O
important O
to O
its O
function O
as O
a O
UAS O
element O
as O
did O
the O
two O
bases O
immediately O
3 O
' O
of O
the O
bHLH O
core O
motif O
. O

These O
results O
indicate O
that O
the O
PCNA B-GENE
gene I-GENE
is O
a O
likely O
target O
gene O
of O
E2F B-GENE
. O

Differential O
sensitivity O
of O
the O
MMPI O
- O
2 O
depression O
scales O
and O
subscales O
. O

The O
chloramphenicol B-GENE
- I-GENE
resistance I-GENE
transposon I-GENE
Tn4451 B-GENE
undergoes O
precise O
conjugative O
deletion O
from O
its O
parent O
plasmid O
plP401 O
in O
Clostridium O
perfringens O
and O
precise O
spontaneous O
excision O
from O
multicopy O
plasmids O
in O
Escherichia O
coli O
. O

A O
general O
model O
for O
ARE O
- O
mediated O
mRNA O
degradation O
involving O
a O
potential O
role O
for O
certain O
heterogeneous O
nuclear O
ribonucleoproteins O
and O
ARE B-GENE
- I-GENE
binding I-GENE
proteins I-GENE
is O
proposed O
. O

Individual O
mutations O
in O
motifs O
III O
, O
IV O
, O
and O
V O
had O
distinctive O
effects O
on O
the O
affinity O
of O
enzyme O
for O
GTP O
, O
the O
rate O
of O
covalent O
catalysis O
( O
EpG O
formation O
) O
, O
or O
the O
transfer O
of O
GMP O
from O
enzyme O
to O
RNA O
. O

Mutational O
analysis O
of O
mRNA B-GENE
capping I-GENE
enzyme I-GENE
identifies O
amino O
acids O
involved O
in O
GTP O
binding O
, O
enzyme O
- O
guanylate O
formation O
, O
and O
GMP O
transfer O
to O
RNA O
. O

Staphylococcal B-GENE
enterotoxin I-GENE
A I-GENE
involvement O
in O
the O
illness O
of O
a O
20 O
- O
month O
- O
old O
burn O
patient O
. O

These O
results O
suggest O
that O
G B-GENE
beta I-GENE
gamma I-GENE
- O
stimulated O
Shc B-GENE
phosphorylation O
represents O
an O
early O
step O
in O
the O
pathway O
leading O
to O
p21ras B-GENE
activation O
, O
similar O
to O
the O
mechanism O
utilized O
by O
growth B-GENE
factor I-GENE
tyrosine I-GENE
kinase I-GENE
receptors I-GENE
. O

Negative O
- O
staining O
, O
refractile O
mycobacteria O
in O
Romanowsky O
- O
stained O
smears O
. O

Here O
we O
focused O
on O
the O
role O
of O
the O
5 O
' O
proximal O
regulatory O
cassette O
( O
- O
190 O
; O
+ O
53 O
bp O
) O
of O
the O
rat B-GENE
enkephalin I-GENE
( O
rENK B-GENE
) O
gene O
in O
the O
developmental O
regulation O
of O
the O
enkephalin B-GENE
phenotype O
. O

Unexpectedly O
, O
all O
ENK B-GENE
- I-GENE
specific I-GENE
motifs I-GENE
formed O
specific O
and O
highly O
abundant O
protein O
- O
DNA O
complexes O
when O
nuclear O
extracts O
from O
the O
human O
tumor O
cell O
line O
( O
HeLa O
) O
, O
which O
does O
not O
express O
ENK B-GENE
, O
were O
used O
. O

Infant O
aged O
3 O
. O
5 O
years O
presents O
persistence O
of O
primordial O
vitreous O
body O
with O
crystalline O
dislocation O
in O
the O
camera O
aquosa O
and O
secondary O
buphthalmos O
of O
the O
left O
eye O
and O
microphthalmos O
with O
dislocation O
of O
the O
crystalline O
in O
the O
vitreous O
body O
of O
the O
right O
eye O
. O

Imaging O
features O
of O
splenic O
epidermoid O
cyst O
with O
pathologic O
correlation O
. O

SL1 B-GENE
trans O
- O
splicing O
specified O
by O
AU O
- O
rich O
synthetic O
RNA O
inserted O
at O
the O
5 O
' O
end O
of O
Caenorhabditis O
elegans O
pre O
- O
mRNA O
. O

Overexpression O
of O
wild B-GENE
- I-GENE
type I-GENE
p53 I-GENE
also O
induces O
apoptosis O
in O
an O
LCL O
. O

These O
observations O
lead O
to O
the O
proposal O
that O
the O
RNAP B-GENE
II I-GENE
CTD I-GENE
might O
be O
an O
in O
vivo O
target O
for O
the O
activated O
p42mapk B-GENE
and O
p44mapk B-GENE
MAP I-GENE
kinases I-GENE
. O

We O
also O
isolated O
two O
alternatively O
spliced O
forms O
of O
human B-GENE
CD6 I-GENE
cDNA I-GENE
lacking O
sequences O
encoding O
membrane O
- O
proximal O
regions O
of O
the O
cytoplasmic O
domain O
which O
maintain O
the O
same O
reading O
frame O
as O
CD6 B-GENE
- O
PB1 B-GENE
. O

We O
have O
isolated O
a O
Drosophila O
melanogaster O
( O
Dm O
) O
cDNA O
encoding O
a O
polypeptide O
that O
has O
extensive O
sequence O
similarity O
to O
the O
mammalian B-GENE
MAPKAPK I-GENE
- I-GENE
2 I-GENE
. O

A O
2 B-GENE
. I-GENE
4 I-GENE
- I-GENE
kb I-GENE
MAPKAPK I-GENE
- I-GENE
2 I-GENE
message I-GENE
is O
expressed O
throughout O
development O
, O
while O
two O
shorter O
transcripts O
of O
2 O
. O
3 O
and O
1 O
. O
8 O
kb O
appear O
to O
be O
specifically O
expressed O
in O
the O
germline O
. O

The O
integrity O
of O
the O
cDNA O
sequence O
was O
confirmed O
by O
analysis O
of O
several O
overlapping O
genomic O
clones O
that O
span O
the O
GAR1 B-GENE
gene I-GENE
. O

Phorbol O
esters O
stimulated O
phosphorylation O
of O
CSK B-GENE
35H I-GENE
proteins I-GENE
, O
thus O
emphasizing O
that O
sequences O
isolated O
according O
to O
PKC B-GENE
binding O
activity O
in O
vitro O
are O
also O
PKC B-GENE
substrates O
in O
vivo O
. O

One O
of O
these O
is O
surrounded O
by O
an O
adenine O
- O
uridine O
rich O
region O
that O
can O
form O
an O
11 O
- O
base O
pair O
stem O
structure O
. O

Additionally O
, O
the O
enzyme O
shows O
activity O
towards O
triglycerides O
such O
as O
olive O
oil O
and O
tributyrin O
and O
towards O
egg O
- O
yolk O
emulsions O
. O

The O
nucleotide O
sequence O
directly O
upstream O
of O
fimA B-GENE
contains O
two O
open O
reading O
frames O
, O
ORF5 O
and O
ORF1 O
, O
whose O
deduced O
protein O
products O
are O
homologous O
to O
members O
of O
a O
superfamily O
of O
ATP B-GENE
- I-GENE
binding I-GENE
cassette I-GENE
membrane I-GENE
transport I-GENE
proteins I-GENE
, O
including O
both O
prokaryotic O
and O
eukaryotic O
uptake O
and O
export O
systems O
. O

The O
ORF3 O
probe O
also O
hybridized O
to O
a O
540 O
bp O
transcript O
consistent O
with O
the O
size O
of O
ORF3 O
alone O
and O
supportive O
of O
the O
mutagenesis O
data O
of O
non O
- O
linkage O
. O

Mean O
growth O
changes O
in O
this O
Class O
II O
sample O
were O
comparable O
to O
those O
previously O
reported O
for O
male O
subjects O
with O
Class O
I O
malocclusions O
over O
the O
same O
age O
period O
, O
suggesting O
a O
similarity O
in O
postpubertal O
development O
between O
these O
two O
groups O
. O

By O
in O
vitro O
immunoprecipitations O
and O
gel O
shift O
assays O
, O
we O
identified O
two O
classes O
of O
high O
affinity O
Engrailed B-GENE
- I-GENE
binding I-GENE
sites I-GENE
upstream O
of O
each O
of O
the O
two O
polyhomeotic O
transcription O
units O
. O

Subjects O
with O
a O
short O
postexposure O
time O
and O
a O
dioxin O
burden O
> O
0 O
. O
6 O
pg O
/ O
m3 O
had O
a O
significantly O
higher O
risk O
of O
hypoergy O
than O
unexposed O
subjects O
( O
hypoergy O
I O
: O
OR O
= O
9 O
. O
51 O
, O
95 O
% O
CI O
= O
1 O
. O
96 O
- O
42 O
. O
02 O
; O
hypoergy O
II O
: O
OR O
= O
2 O
. O
92 O
, O
95 O
% O
CI O
= O
1 O
. O
14 O
- O
7 O
. O
5 O
) O
. O

Analysis O
of O
this O
sequence O
combined O
with O
that O
previously O
reported O
for O
the O
5 O
' O
- O
flanking O
region O
directly O
proximal O
to O
the O
start O
of O
transcription O
revealed O
several O
putative O
regulatory O
sequences O
. O

The O
experimental O
design O
represents O
a O
2 O
x O
3 O
factorial O
arrangement O
of O
treatments O
with O
three O
dietary O
levels O
of O
incorporation O
of O
RSB O
( O
0 O
, O
50 O
, O
and O
100 O
% O
) O
, O
and O
chickens O
either O
infected O
or O
uninfected O
. O

A O
cDNA O
clone O
corresponding O
to O
the O
putative O
GA B-GENE
20 I-GENE
- O
oxidase B-GENE
genomic O
sequence O
was O
constructed O
with O
the O
reverse O
transcription O
- O
PCR O
method O
, O
and O
the O
identity O
of O
the O
cDNA O
clone O
was O
confirmed O
by O
analyzing O
the O
capability O
of O
the O
fusion O
protein O
expressed O
in O
Escherichia O
coli O
to O
convert O
GA53 B-GENE
to O
GA44 B-GENE
and O
GA19 B-GENE
to O
GA20 B-GENE
. O

Total O
cholesterol O
was O
also O
reduced O
at O
week O
12 O
by O
17 O
. O
0 O
% O
( O
20 O
mg O
/ O
day O
) O
and O
15 O
. O
7 O
% O
( O
20 O
- O
30 O
mg O
/ O
day O
) O
, O
and O
at O
week O
52 O
by O
20 O
. O
4 O
% O
( O
< O
or O
= O
20 O
mg O
/ O
day O
) O
and O
19 O
. O
2 O
% O
( O
> O
or O
= O
30 O
mg O
/ O
day O
) O
. O

Piperacillin O
- O
tazobactam O
can O
be O
used O
for O
the O
treatment O
of O
infections O
caused O
by O
gram O
- O
negative O
, O
gram O
- O
positive O
, O
aerobic O
, O
and O
anaerobic O
bacteria O
. O

This O
apparently O
anomalous O
structure O
/ O
activity O
relationship O
raises O
important O
issues O
for O
understanding O
the O
evolution O
of O
regulatory O
peptides O
and O
the O
mechanisms O
that O
control O
their O
expression O
. O

This O
paper O
summarises O
the O
experimental O
evidence O
upon O
which O
the O
clinical O
trials O
of O
aldose B-GENE
reductase I-GENE
inhibitors O
in O
diabetic O
patients O
have O
been O
initiated O
and O
the O
results O
of O
published O
drug O
trials O
in O
these O
patients O
. O

Increase O
in O
urinary O
calcium O
and O
oxalate O
after O
fructose O
infusion O
. O

The O
Babcock O
Surgical O
Clinic O
. O

Histopathological O
features O
of O
relapsed O
leprosy O
. O

One O
of O
these O
factors O
, O
HRF B-GENE
- I-GENE
1 I-GENE
, O
recognizes O
a O
cis O
element O
consisting O
of O
an O
inverted O
palindromic O
motif O
. O

Regulation O
of O
Gax B-GENE
homeobox B-GENE
gene I-GENE
transcription O
by O
a O
combination O
of O
positive O
factors O
including O
myocyte B-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
factor I-GENE
2 I-GENE
. O

The O
carboxyl O
- O
terminal O
transactivation O
domain O
of O
heat B-GENE
shock I-GENE
factor I-GENE
1 I-GENE
is O
negatively O
regulated O
and O
stress O
responsive O
. O

The O
RAT3 B-GENE
gene I-GENE
encodes O
an O
1157 O
- O
amino O
acid O
protein O
without O
similarity O
to O
other O
known O
proteins O
. O

CCAAT B-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
isoforms I-GENE
beta I-GENE
and I-GENE
delta I-GENE
are O
expressed O
in O
mammary O
epithelial O
cells O
and O
bind O
to O
multiple O
sites O
in O
the O
beta B-GENE
- I-GENE
casein I-GENE
gene I-GENE
promoter I-GENE
. O

We O
have O
found O
that O
the O
expression O
of O
GTPase B-GENE
- O
deficient O
mutants O
of O
alpha B-GENE
12 I-GENE
( O
alpha B-GENE
12Q229L I-GENE
) O
or O
alpha B-GENE
13 I-GENE
( O
alpha B-GENE
13Q226L I-GENE
) O
leads O
to O
robust O
activation O
of O
the O
Jun B-GENE
kinase I-GENE
/ O
stress B-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK B-GENE
/ O
SAPK B-GENE
) O
pathway O
. O

Using O
mutagenesis O
, O
we O
have O
identified O
two O
mutations O
of O
the O
second O
actin B-GENE
- I-GENE
binding I-GENE
domain I-GENE
that O
can O
also O
suppress O
the O
act1 B-GENE
mutations O
of O
interest O
. O

The O
normal O
cell O
cycle O
is O
regulated O
by O
several O
molecules O
, O
such O
as O
the O
tumor B-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
pRb I-GENE
, O
the O
G1 B-GENE
cyclins I-GENE
, O
the O
cyclin B-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
and O
their O
inhibitors O
. O

These O
results O
are O
very O
useful O
for O
deciding O
on O
the O
doses O
of O
hormones O
and O
the O
expected O
serum O
estradiol O
level O
in O
HRT O
for O
Japanese O
women O
. O

Comparison O
of O
1 O
. O
5 O
Tesla O
and O
0 O
. O
35 O
Tesla O
field O
strength O
magnetic O
resonance O
imaging O
scans O
in O
the O
morphometric O
evaluation O
of O
the O
lumbar O
intervertebral O
foramina O
. O

A O
new O
vector O
, O
pHBK280 O
, O
was O
designed O
to O
facilitate O
this O
analysis O
. O

Here O
we O
describe O
an O
in O
vitro O
assay O
where O
the O
NS3 B-GENE
- I-GENE
4A I-GENE
polyprotein I-GENE
, O
NS3 B-GENE
, O
the O
serine B-GENE
proteinase I-GENE
domain I-GENE
( I-GENE
the I-GENE
N I-GENE
- I-GENE
terminal I-GENE
181 I-GENE
residues I-GENE
of I-GENE
NS3 I-GENE
) I-GENE
, O
and O
the O
NS4A B-GENE
cofactor I-GENE
were O
produced O
by O
cell O
- O
free O
translation O
and O
tested O
for O
trans O
- O
processing O
of O
radiolabeled O
substrates O
. O

In O
contrast O
, O
over O
- O
expression O
of O
RAR B-GENE
beta I-GENE
only O
poorly O
restored O
differentiation O
, O
although O
it O
could O
replace O
RAR B-GENE
gamma I-GENE
for O
the O
activation O
of O
target O
genes O
. O

The O
5 O
' O
- O
terminus O
of O
the O
p B-GENE
- I-GENE
gvpF I-GENE
- I-GENE
M I-GENE
mRNA I-GENE
was O
located O
169 O
nucleotides O
upstream O
of O
p B-GENE
- I-GENE
gvpF I-GENE
within O
p B-GENE
- I-GENE
gvpE I-GENE
. O

However O
, O
the O
relative O
binding O
affinity O
for O
the O
motifs O
is O
different O
. O

The O
transport O
of O
a O
genetically O
engineered O
chimeric O
transmembrane O
protein O
connected O
to O
this O
ER O
leader O
sequence O
was O
as O
efficient O
as O
that O
of O
the O
original O
protein O
from O
which O
the O
ER O
sequence O
has O
been O
derived O
. O

A O
polymorphic O
bipartite O
motif O
signals O
nuclear O
targeting O
of O
early O
auxin O
- O
inducible O
proteins O
related O
to O
PS B-GENE
- I-GENE
IAA4 I-GENE
from I-GENE
pea I-GENE
( I-GENE
Pisum I-GENE
sativum I-GENE
) I-GENE
. O

The O
plant O
hormone O
auxin O
transcriptionally O
activates O
early B-GENE
genes I-GENE
. O

A O
new O
non O
- O
LTR O
retrotransposon O
provides O
evidence O
for O
multiple O
distinct O
site O
- O
specific O
elements O
in O
Crithidia O
fasciculata O
miniexon O
arrays O
. O

The O
CVA16 B-GENE
. I-GENE
4 I-GENE
proteolipid I-GENE
transcript I-GENE
is O
the O
most O
prevalent O
of O
the O
two O
proteolipid O
messages O
in O
expanding O
ovules O
harvested O
10 O
d O
post O
- O
anthesis O
. O

The O
synthetic O
DNA O
sequence O
was O
constructed O
to O
achieve O
efficient O
base O
pairing O
with O
Escherichia B-GENE
coli I-GENE
16S I-GENE
ribosomal I-GENE
RNA I-GENE
, O
avoidance O
of O
internal O
secondary O
structure O
, O
and O
optimal O
codon O
usage O
for O
high O
- O
level O
protein O
expression O
in O
accord O
with O
the O
known O
preferences O
in O
E O
. O
coli O
. O

Transcription O
factors O
containing O
a O
basic O
helix O
- O
loop O
- O
helix O
( O
bHLH O
) O
motif O
regulate O
the O
expression O
of O
tissue O
- O
specific O
genes O
in O
a O
number O
of O
mammalian O
and O
insect O
systems O
. O

EsaR B-GENE
can O
repress O
its O
own O
expression O
but O
seems O
not O
to O
regulate O
the O
expression O
of O
esaI B-GENE
. O

We O
conclude O
that O
, O
in O
comparison O
to O
reports O
from O
other O
regions O
, O
Scandinavian O
renal O
transplant O
recipients O
are O
at O
high O
risk O
of O
dying O
of O
IHD O
. O

Veterinary O
certification O
for O
livestock O
export O
. O

Diffuse O
white O
matter O
injury O
can O
be O
attributed O
to O
radiation O
and O
associated O
with O
neurological O
deficits O
, O
but O
leukoencephalopathy O
is O
rarely O
observed O
in O
the O
absence O
of O
chemotherapy O
. O

The O
ectopic O
expression O
of O
Oct B-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
in O
hybrid O
cells O
under O
a O
constitutive O
promoter O
is O
sufficient O
for O
transcriptional O
activation O
of O
an O
octamer O
- O
dependent O
promoter O
. O

We O
here O
demonstrate O
that O
a O
temperature O
- O
sensitive O
fission O
yeast O
mutant O
which O
has O
a O
mutation O
in O
a O
homologous O
gene O
, O
and O
two O
of O
three O
additional O
( O
mtr1 B-GENE
/ O
prp20 B-GENE
/ O
srm1 B-GENE
) O
mutants O
accumulate O
nuclear O
poly O
( O
A O
) O
+ O
RNA O
at O
37 O
degrees O
C O
. O

Since O
RCC1p B-GENE
acts O
as O
GNRP B-GENE
for O
Ran B-GENE
, O
a O
small B-GENE
nuclear I-GENE
GTPase I-GENE
of O
the O
ras B-GENE
superfamily I-GENE
, O
we O
have O
identified O
two O
homologs O
of O
Ran B-GENE
in O
S O
. O
cerevisiae O
( O
CNR1 B-GENE
and O
CNR2 B-GENE
) O
. O

Prostate B-GENE
specific I-GENE
antigen I-GENE
shows O
the O
metastatic O
cases O
better O
[ O
correction O
of O
worse O
] O
than O
prostatic B-GENE
acid I-GENE
phosphatase I-GENE
. O

Of O
these O
carriers O
149 O
were O
diagnosed O
to O
be O
asymptomatic O
clinically O
, O
biochemically O
and O
echographically O
. O

Identification O
of O
mutations O
in O
the O
coding O
sequence O
of O
the O
proto B-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
kit I-GENE
in O
a O
human O
mast O
cell O
leukemia O
cell O
line O
causing O
ligand O
- O
independent O
activation O
of O
c B-GENE
- I-GENE
kit I-GENE
product I-GENE
. O

Insulin B-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
IGF B-GENE
- I-GENE
BP I-GENE
- I-GENE
2 I-GENE
) O
transcription O
in O
rat O
liver O
varies O
with O
developmental O
age O
and O
fasting O
. O

The O
presence O
of O
the O
RV O
5 O
' O
( O
+ O
) O
SL O
sequence O
had O
the O
primary O
enhancing O
effect O
on O
translation O
. O

By O
contrast O
, O
all O
proteins O
initiated O
with O
a O
methionine O
placed O
one O
residue O
upstream O
of O
the O
natural O
N O
terminus O
of O
PR B-GENE
failed O
to O
show O
specific O
proteolysis O
. O

Reverse B-GENE
transcriptase I-GENE
and O
protease O
activities O
of O
avian O
leukosis O
virus O
Gag B-GENE
- O
Pol B-GENE
fusion O
proteins O
expressed O
in O
insect O
cells O
. O

PATIENTS O
AND O
METHODS O
: O
We O
report O
our O
experience O
with O
seven O
children O
with O
active O
small O
bowel O
Crohn O
' O
s O
disease O
given O
a O
casein B-GENE
- O
based O
, O
polymeric O
feed O
rich O
in O
TGF B-GENE
- I-GENE
beta I-GENE
2 I-GENE
( O
Specific O
Polymeric O
Diet O
; O
Nestle O
- O
Clintec O
; O
Vevey O
, O
Switzerland O
) O
as O
complete O
nutrition O
for O
8 O
weeks O
. O

The O
leader O
sequence O
of O
the O
isolated O
cDNA O
clone O
contains O
several O
small O
open O
reading O
frames O
upstream O
of O
the O
initiation O
codon O
of O
the O
largest O
open O
reading O
frame O
coding O
for O
the O
homeodomain B-GENE
protein I-GENE
. O

Experimental O
adhesion O
prophylaxis O
with O
recombinant B-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
. O

To O
determine O
which O
sequences O
in O
the O
rat B-GENE
P450c17 I-GENE
promoter I-GENE
may O
be O
responsible O
for O
basal O
and O
cAMP O
- O
stimulated O
gene O
transcription O
, O
deletion O
constructs O
containing O
between O
- O
1 O
, O
560 O
and O
- O
53 O
base O
pairs O
of O
5 O
' O
- O
flanking O
DNA O
from O
the O
rat B-GENE
P450c17 I-GENE
gene I-GENE
were O
ligated O
to O
plasmids O
expressing O
the O
reporter O
gene O
luciferase B-GENE
and O
transfected O
into O
two O
mouse O
cell O
lines O
, O
adrenal O
Y O
- O
1 O
cells O
, O
and O
testicular O
Leydig O
MA O
- O
10 O
cells O
. O

We O
have O
cloned O
and O
sequenced O
the O
mouse B-GENE
NMO1 I-GENE
cDNA I-GENE
, O
which O
encodes O
the O
NAD B-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
: I-GENE
menadione I-GENE
oxidoreductase I-GENE
[ O
also O
called O
NAD B-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
: I-GENE
( I-GENE
quinone I-GENE
acceptor I-GENE
) I-GENE
oxidoreductase I-GENE
; O
quinone B-GENE
reductase I-GENE
; O
azo B-GENE
dye I-GENE
reductase I-GENE
; O
DT B-GENE
diaphorase I-GENE
; O
EC B-GENE
1 I-GENE
. I-GENE
6 I-GENE
. I-GENE
99 I-GENE
. I-GENE
2 I-GENE
] O
. O

Mutations O
in O
the O
VPS45 B-GENE
gene I-GENE
, O
a O
SEC1 B-GENE
homologue O
, O
result O
in O
vacuolar O
protein O
sorting O
defects O
and O
accumulation O
of O
membrane O
vesicles O
. O

In O
293 O
cells O
, O
expression O
of O
the O
NF B-GENE
- I-GENE
kappa I-GENE
B I-GENE
inhibitor O
, O
I B-GENE
kappa I-GENE
B I-GENE
- I-GENE
alpha I-GENE
, O
reduced O
the O
stimulatory O
activity O
of O
LMP B-GENE
. O

Binding O
of O
meAda B-GENE
is O
necessary O
to O
activate O
transcription O
of O
the O
adaptive O
response O
genes O
; O
accordingly O
, O
in O
vitro O
transcription O
of O
aidB B-GENE
is O
dependent O
on O
the O
presence O
of O
meAda B-GENE
. O

No O
significant O
differences O
were O
identified O
between O
groups O
for O
pH O
, O
PaCO2 O
, O
intracranial O
pressure O
, O
heart O
rate O
, O
brain O
temperature O
, O
or O
glucose O
levels O
. O

Weak O
allergenicity O
of O
recombinant B-GENE
hirudin I-GENE
CGP I-GENE
39393 I-GENE
( O
REVASC O
) O
in O
immunocompetent O
volunteers O
. O

Each O
dietary O
treatment O
was O
fed O
to O
six O
pen O
replicates O
of O
five O
chicks O
per O
pen O
for O
21 O
d O
. O

The O
NarX B-GENE
and O
NarQ B-GENE
proteins I-GENE
with O
amino O
acid O
substitutions O
at O
the O
first O
conserved O
histidine O
position O
were O
also O
unable O
to O
dephosphorylate O
NarL B-GENE
- O
phosphate O
in O
vitro O
. O

The O
Ng B-GENE
/ I-GENE
RC3 I-GENE
and O
PKC B-GENE
- I-GENE
gamma I-GENE
genes I-GENE
have O
a O
similar O
expression O
pattern O
in O
the O
brain O
during O
development O
. O

Structure O
and O
regulation O
of O
the O
gene O
encoding O
the O
neuron O
- O
specific O
protein B-GENE
kinase I-GENE
C I-GENE
substrate O
neurogranin B-GENE
( O
RC3 B-GENE
protein I-GENE
) O
. O

As O
in O
Tb O
, O
U6 B-GENE
is O
a O
single O
- O
copy O
gene O
and O
two O
tRNA O
genes O
, O
tRNAGln B-GENE
and O
tRNAIle B-GENE
, O
are O
found O
upstream O
to O
the O
gene O
. O

2 O
. O

Two O
mammalian O
enzymes O
, O
the O
haem B-GENE
- I-GENE
controlled I-GENE
repressor I-GENE
( O
HCR B-GENE
) O
and O
the O
double B-GENE
- I-GENE
stranded I-GENE
RNA I-GENE
- I-GENE
activated I-GENE
inhibitor I-GENE
( O
dsI B-GENE
) O
, O
phosphorylate O
Ser O
- O
51 O
of O
the O
alpha O
subunit O
, O
thereby O
inhibiting O
the O
exchange O
of O
bound O
nucleotides O
on O
, O
and O
thus O
the O
recycling O
of O
, O
eIF B-GENE
- I-GENE
2 I-GENE
. O

A O
triple O
Ser O
- O
- O
> O
Ala O
mutant O
form O
of O
yeast O
eIF B-GENE
- I-GENE
2 I-GENE
alpha I-GENE
was O
found O
to O
be O
no O
longer O
phosphorylated O
by O
either O
of O
the O
yeast O
( O
or O
mammalian O
) O
casein B-GENE
kinase I-GENE
activities O
in O
vitro O
. O

Binding O
activity O
in O
rat O
liver O
nuclear O
extracts O
includes O
these O
orphan O
receptors O
as O
judged O
from O
electromobility O
supershift O
experiments O
and O
from O
results O
obtained O
with O
expressed O
receptors O
, O
although O
the O
element O
in O
CYP2C11 B-GENE
did O
not O
bind O
HNF B-GENE
- I-GENE
4 I-GENE
. O

Transcript O
analysis O
reveals O
that O
lethal O
B B-GENE
block I-GENE
substitutions O
reduce O
U6 B-GENE
RNA I-GENE
synthesis O
at O
least O
10 O
- O
fold O
in O
vivo O
and O
20 O
- O
fold O
in O
vitro O
. O

Lung O
function O
tests O
( O
EFR O
) O
were O
performed O
on O
these O
patients O
for O
a O
period O
of O
19 O
. O
2 O
+ O
/ O
- O
3 O
. O
4 O
months O
. O

Staphylococcus O
aureus O
and O
CNS O
showed O
high O
or O
moderate O
resistance O
rates O
to O
methicillin O
( O
DMPPC O
) O
. O

Hybridization O
signals O
were O
also O
detected O
with O
total O
DNAs O
of O
Rhizobium O
leguminosarum O
bv O
. O
phaseoli O
, O
Rhodobacter O
capsulatus O
and O
Escherichia O
coli O
, O
but O
not O
those O
of O
Xanthomonas O
campestris O
pv O
. O
campestris O
and O
Pseudomonas O
putida O
. O

Serum O
induction O
of O
a O
MEF2 B-GENE
reporter I-GENE
gene I-GENE
was O
not O
observed O
in O
a O
line O
of O
NIH O
3T3 O
cells O
which O
contain O
low O
MEF2 B-GENE
site I-GENE
binding O
activity O
. O

Since O
AP B-GENE
- I-GENE
1 I-GENE
is O
an O
important O
mediator O
of O
tumor O
promoter O
action O
, O
these O
findings O
may O
explain O
the O
anti O
- O
tumor O
- O
promoting O
activity O
of O
phenolic O
antioxidants O
. O

The O
second O
complex O
, O
when O
purified O
, O
contained O
four O
protein O
components O
including O
the O
36 O
- O
kDa O
protein O
. O

The O
study O
was O
repeated O
after O
administration O
of O
oral O
amiodarone O
, O
50 O
mg O
/ O
kg O
/ O
day O
for O
2 O
days O
in O
8 O
divided O
doses O
( O
mean O
dose O
6 O
. O
9 O
+ O
/ O
- O
0 O
. O
4 O
g O
) O
. O

The O
other O
two O
clones O
, O
Ash B-GENE
- I-GENE
m I-GENE
and I-GENE
- I-GENE
s I-GENE
, O
had O
nucleotide O
sequences O
identical O
with O
Ash B-GENE
- I-GENE
l I-GENE
cDNA O
in O
the O
amino O
- O
terminal O
region O
. O

MATERIAL O
AND O
METHODS O
: O
Of O
the O
17 O
men O
and O
17 O
women O
, O
who O
were O
21 O
to O
80 O
years O
of O
age O
, O
27 O
had O
hereditary O
motor O
and O
sensory O
neuropathy O
type O
I O
and O
7 O
had O
acquired O
demyelinating O
polyneuropathy O
. O

Muscle B-GENE
GSH I-GENE
- I-GENE
Px I-GENE
activity O
after O
prolonged O
exercise O
, O
training O
, O
and O
selenium O
supplementation O
. O

We O
found O
that O
PML B-GENE
was O
expressed O
at O
a O
lower O
level O
in O
S O
, O
G2 O
, O
and O
M O
phases O
and O
at O
a O
significantly O
higher O
level O
in O
G1 O
phase O
. O

The O
roxithromycin O
doses O
that O
were O
chosen O
for O
these O
studies O
were O
less O
than O
achievable O
blood O
levels O
. O

We O
demonstrate O
here O
that O
the O
- O
DEDDDL O
sequence O
stabilizes O
GDP O
binding O
to O
Ran B-GENE
, O
and O
that O
the O
domain O
is O
required O
for O
high O
affinity O
interaction O
with O
a O
Ran B-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
HTF9A B-GENE
/ O
RanBP1 B-GENE
. O

Serial O
followup O
strength O
data O
for O
2 O
patients O
were O
compared O
to O
change O
in O
creatinine B-GENE
kinase I-GENE
( O
CK B-GENE
) O
levels O
. O

Transfection O
of O
non O
- O
deleted O
expression O
vector O
into O
NIH3T3 O
cells O
results O
in O
acquisition O
of O
focus O
- O
forming O
activity O
while O
a O
deleted O
form O
of O
expression O
vector O
fails O
to O
show O
this O
activity O
even O
in O
the O
presence O
of O
basic B-GENE
FGF I-GENE
. O

All O
ribosomal B-GENE
protein I-GENE
( O
rp B-GENE
) O
gene O
promoters O
from O
Saccharomyces O
cerevisiae O
studied O
so O
far O
contain O
either O
( O
usually O
two O
) O
binding O
sites O
for O
the O
global O
gene O
regulator O
Rap1p B-GENE
or O
one O
binding O
site O
for O
another O
global O
factor O
, O
Abf1p B-GENE
. O

CONCLUSION O
: O
The O
MTD O
for O
CPT O
- O
11 O
administered O
in O
a O
3 O
consecutive O
- O
days O
- O
every O
- O
3 O
weeks O
schedule O
in O
this O
patient O
population O
is O
115 O
mg O
/ O
m2 O
/ O
day O
. O

Otte O
, O
Mol O
. O

A O
secondary O
phosphorylation O
of O
CREB341 B-GENE
at O
Ser129 O
is O
required O
for O
the O
cAMP O
- O
mediated O
control O
of O
gene O
expression O
. O

A O
role O
for O
glycogen B-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
in O
the O
control O
of O
gene O
expression O
. O

Reconstitution O
of O
complexes O
containing O
p62 B-GENE
and O
the O
src B-GENE
family I-GENE
kinase I-GENE
p59fyn B-GENE
in O
HeLa O
cells O
demonstrated O
that O
complex O
formation O
resulted O
in O
tyrosine O
phosphorylation O
of O
p62 B-GENE
and O
was O
mediated O
by O
both O
the O
SH3 B-GENE
and O
SH2 B-GENE
domains I-GENE
of O
p59fyn B-GENE
. O

Protein B-GENE
cHMGI I-GENE
binds O
preferentially O
to O
AT O
- O
rich O
DNA O
with O
a O
half O
- O
saturation O
value O
of O
1 O
. O
1 O
nM O
. O

The O
U14 B-GENE
genes I-GENE
of O
mouse O
as O
well O
as O
rat O
, O
hamster O
, O
human O
, O
Xenopus O
and O
trout O
are O
encoded O
within O
introns O
of O
the O
constitutively O
expressed O
70 B-GENE
- I-GENE
kDa I-GENE
- I-GENE
cognate I-GENE
- I-GENE
heat I-GENE
- I-GENE
shock I-GENE
protein I-GENE
gene I-GENE
( O
hsc70 B-GENE
) O
. O

Inclusion O
in O
this O
family O
of O
proteins O
suggests O
that O
FliQ B-GENE
and O
FliR B-GENE
may O
participate O
in O
an O
export O
pathway O
required O
for O
flagellum O
assembly O
. O

Coronary O
vasoconstriction O
caused O
by O
endothelin B-GENE
- I-GENE
1 I-GENE
is O
enhanced O
by O
ischemia O
- O
reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

Atcys1 B-GENE
, O
Athyp1 B-GENE
, O
AKin10 B-GENE
and O
the O
ORF O
are O
very O
close O
to O
each O
other O
and O
organized O
in O
the O
same O
polarity O
; O
hence O
, O
the O
intergenic O
regions O
probably O
contain O
, O
within O
less O
than O
0 O
. O
5 O
kb O
, O
all O
the O
regulatory O
elements O
necessary O
to O
govern O
initiation O
and O
termination O
of O
transcription O
. O

Southern O
blot O
hybridization O
experiments O
suggest O
the O
presence O
of O
one O
copy O
of O
Atcys1 B-GENE
, O
Athyp1 B-GENE
and O
AKin10 B-GENE
per O
haploid O
genome O
, O
and O
Northern O
blot O
analysis O
demonstrates O
that O
the O
three O
genes O
are O
differentially O
expressed O
in O
roots O
, O
shoots O
and O
leaves O
. O

Between O
the O
subgroups O
of O
dementia O
disorders O
there O
were O
no O
significant O
differences O
in O
basal O
cortisol O
levels O
. O

Basal O
components O
of O
the O
transcription O
apparatus O
( O
RNA B-GENE
polymerase I-GENE
II I-GENE
, O
TATA B-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
contain O
activation O
domains O
: O
is O
the O
repetitive O
C O
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA B-GENE
polymerase I-GENE
II I-GENE
a O
" O
portable O
enhancer O
domain O
" O
? O
Regions O
rich O
in O
serine O
, O
threonine O
, O
and O
proline O
residues O
can O
be O
found O
in O
transcriptional O
activation O
domains O
, O
as O
well O
as O
in O
the O
N O
- O
terminal O
parts O
of O
mammalian B-GENE
TATA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
where O
they O
are O
interrupted O
by O
polyglutamine O
stretches O
. O

Mutagenesis O
of O
IM1 B-GENE
enhances O
the O
ability O
of O
c B-GENE
- I-GENE
Fos I-GENE
to O
activate O
an O
AP1 B-GENE
bearing I-GENE
promoter I-GENE
. O

Self O
or O
foreign O
cellular O
proteins O
provide O
peptides O
for O
presentation O
by O
major B-GENE
histocompatibility I-GENE
complex I-GENE
( I-GENE
MHC I-GENE
) I-GENE
class I-GENE
I I-GENE
molecules I-GENE
on O
the O
surface O
of O
antigen O
presenting O
cells O
( O
APC O
) O
. O

However O
, O
cotransfection O
studies O
indicate O
that O
RVR B-GENE
does O
not O
activate O
transcription O
when O
this O
hormone O
response O
element O
is O
linked O
to O
a O
reporter O
gene O
but O
rather O
acts O
as O
a O
potent O
competitive O
repressor O
of O
ROR B-GENE
alpha I-GENE
function O
. O

Molecular O
cloning O
and O
sequencing O
of O
a O
cDNA O
encoding O
SR B-GENE
beta I-GENE
revealed O
that O
SR B-GENE
beta I-GENE
is O
a O
transmembrane O
protein O
and O
, O
like O
SR B-GENE
alpha I-GENE
and O
SRP54 B-GENE
, O
is O
a O
member O
of O
the O
GTPase B-GENE
superfamily I-GENE
. O

To O
understand O
the O
function O
of O
receptor B-GENE
- I-GENE
linked I-GENE
tyrosine I-GENE
phosphatases I-GENE
in O
neural O
development O
, O
we O
sought O
to O
identify O
LAR B-GENE
isoforms I-GENE
preferentially O
expressed O
in O
the O
nervous O
system O
and O
cellular O
processes O
regulating O
LAR B-GENE
alternative O
splicing O
. O

135 O
students O
had O
a O
count O
of O
less O
than O
50 O
eggs O
/ O
10 O
ml O
. O
urine O
and O
56 O
had O
more O
than O
50 O
eggs O
/ O
10ml O
. O

Chrispeels O
[ O
1993 O
] O
EMBO O
J O
12 O
: O
2241 O
- O
2247 O
) O
. O

The O
mRNAs O
of O
the O
GRF B-GENE
genes I-GENE
are O
encoded O
by O
six O
exons O
interrupted O
by O
five O
introns O
. O

A O
major O
task O
for O
sports O
scientists O
may O
be O
to O
verify O
empirically O
the O
nature O
of O
an O
integrated O
model O
of O
the O
sport O
performer O
. O

Removal O
of O
the O
GST B-GENE
domain I-GENE
from O
GST B-GENE
- O
Tax B-GENE
by O
thrombin B-GENE
restores O
Tax B-GENE
' O
s O
ability O
to O
assemble O
a O
ternary O
Tax B-GENE
- O
CREB B-GENE
- O
21 O
- O
bp O
- O
repeat O
complex O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Specific O
binding O
was O
not O
observed O
with O
either O
the O
orthologous O
rat O
or O
mouse O
fragments O
using O
human O
or O
rodent O
extracts O
. O

We O
have O
attempted O
to O
clone O
two O
recessive O
extragenic O
suppressors O
of O
such O
ts O
mutants O
( O
sdp1 B-GENE
for O
mutation B-GENE
pol3 I-GENE
- I-GENE
14 I-GENE
and O
sdp5 B-GENE
- I-GENE
1 I-GENE
for O
mutation B-GENE
pol3 I-GENE
- I-GENE
11 I-GENE
) O
by O
transforming O
thermoresistant O
haploid O
strains O
pol3 B-GENE
- I-GENE
14 I-GENE
sdp1 I-GENE
and O
pol3 B-GENE
- I-GENE
11 I-GENE
sdp5 I-GENE
- I-GENE
1 I-GENE
with O
wild O
- O
type O
genomic O
libraries O
in O
singlecopy O
or O
multicopy O
vectors O
. O

In O
acute O
- O
phase O
livers O
, O
we O
observed O
a O
dramatic O
reduction O
in O
HNF B-GENE
- I-GENE
3 I-GENE
alpha I-GENE
expression O
which O
correlates O
with O
a O
decrease O
in O
the O
expression O
of O
its O
target O
gene O
, O
the O
TTR B-GENE
gene I-GENE
. O

Similarly O
, O
in O
mammalian O
cells O
PBP74 B-GENE
is O
synthesized O
as O
a O
pre O
- O
protein O
that O
requires O
membrane O
potential O
- O
dependent O
import O
into O
mitochondria O
for O
its O
maturation O
. O

The O
first O
open O
reading O
frame O
of O
the O
blueberry O
scorch O
carlavirus O
( O
BBScV O
) O
genome O
encodes O
a O
putative O
replication O
- O
associated O
protein O
of O
223 O
kDa O
( O
p223 B-GENE
) O
. O

From O
sequence O
alignments O
with O
phylogenetically O
related O
viruses O
, O
including O
tymoviruses O
, O
we O
predicted O
that O
p223 B-GENE
contained O
a O
papain B-GENE
- I-GENE
like I-GENE
proteinase I-GENE
domain I-GENE
with O
a O
putative O
catalytic O
cysteine994 O
and O
histidine1075 O
. O

The O
p97 B-GENE
- O
depleted O
nuclei O
remained O
largely O
competent O
for O
nuclear O
protein O
import O
. O

Using O
gel O
retardation O
assays O
with O
HepG2 O
nuclear O
extract O
, O
we O
demonstrated O
the O
presence O
of O
a O
specific O
protein O
which O
bound O
to O
the O
NRE O
fragment O
. O

Twenty O
- O
two O
consecutive O
patients O
with O
ischaemic O
ulcers O
had O
tcPO2 O
measured O
and O
the O
ankle O
/ O
brachial O
( O
ABI O
) O
and O
toe O
/ O
brachial O
( O
TBI O
) O
indices O
calculated O
. O

TcPO2 O
measurement O
appears O
to O
be O
a O
reliable O
technique O
that O
can O
influence O
ischaemic O
ulcer O
management O
. O

Expression O
of O
h6 O
. O
1 O
in O
COS O
- O
1 O
cells O
led O
to O
the O
production O
of O
a O
typical O
type B-GENE
IV I-GENE
PDE I-GENE
activity O
in O
that O
cAMP O
, O
but O
not O
cGMP O
, O
served O
as O
substrate O
and O
its O
activity O
was O
insensitive O
to O
either O
Ca2 O
+ O
/ O
CaM B-GENE
or O
cGMP O
but O
was O
inhibited O
by O
low O
concentrations O
of O
rolipram O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
PSD2 B-GENE
gene I-GENE
was O
heterologously O
expressed O
by O
infection O
of O
Sf O
- O
9 O
insect O
cells O
with O
recombinant O
baculovirus O
, O
resulting O
in O
a O
10 O
- O
fold O
increase O
in O
PSD B-GENE
activity O
. O

Like O
Epo B-GENE
, O
HNF B-GENE
- I-GENE
4 I-GENE
is O
expressed O
in O
kidney O
, O
liver O
, O
and O
Hep3B O
cells O
but O
not O
in O
HeLa O
cells O
. O

Moreover O
, O
the O
hypoxia O
- O
induced O
expression O
of O
the O
endogenous O
Epo B-GENE
gene I-GENE
was O
significantly O
inhibited O
in O
Hep3B O
cells O
stably O
transfected O
with O
HNF B-GENE
- I-GENE
4 I-GENE
delta I-GENE
C I-GENE
. O

These O
observations O
indicate O
that O
there O
are O
multiple O
mechanisms O
by O
which O
an O
individual O
transcript O
can O
be O
degraded O
following O
deadenylation O
. O

Small B-GENE
Maf I-GENE
proteins I-GENE
heterodimerize O
with O
Fos B-GENE
and O
may O
act O
as O
competitive O
repressors O
of O
the O
NF B-GENE
- I-GENE
E2 I-GENE
transcription I-GENE
factor I-GENE
. O

Both O
factors O
demonstrated O
significant O
correlations O
with O
rCBF O
in O
the O
medial O
prefrontal O
cortex O
and O
frontal O
polar O
cortex O
while O
for O
each O
factor O
there O
were O
also O
unique O
patterns O
of O
correlations O
with O
posterior O
brain O
regions O
. O

The O
resulting O
integrated O
physical O
, O
genetic O
, O
and O
cytogenetic O
map O
constitutes O
a O
resource O
for O
the O
characterization O
of O
genes O
that O
may O
be O
involved O
in O
the O
WAGR O
syndrome O
. O

Three O
classes O
of O
test O
objects O
were O
considered O
: O
( O
1 O
) O
a O
multicompartment O
test O
object O
for O
31P O
MRS O
measurements O
performed O
with O
slice O
- O
selective O
sequences O
; O
( O
2 O
) O
a O
two O
- O
compartment O
test O
object O
for O
volume O
- O
selection O
1H O
MRS O
; O
and O
( O
3 O
) O
two O
- O
compartment O
test O
objects O
for O
assessing O
the O
performance O
of O
experimental O
systems O
using O
ISIS O
as O
volume O
localization O
sequence O
in O
31P O
MRS O
. O

Pregnancy O
screening O
by O
uterine O
artery O
Doppler O
velocimetry O
- O
- O
which O
criterion O
performs O
best O
? O
OBJECTIVE O
: O
To O
test O
whether O
repeating O
Doppler O
studies O
of O
the O
uteroplacental O
circulation O
late O
in O
gestation O
will O
improve O
the O
test O
' O
s O
power O
for O
predicting O
pregnancy O
- O
induced O
hypertension O
and O
fetal O
growth O
restriction O
( O
FGR O
) O
, O
and O
whether O
analysis O
based O
on O
a O
combination O
of O
quantitative O
and O
qualitative O
assessments O
of O
the O
uterine O
arterial O
waveforms O
will O
yield O
better O
results O
than O
analysis O
based O
on O
either O
alone O
. O

Analysis O
of O
disassociation O
rates O
indicates O
that O
the O
Grf10 B-GENE
- O
Swi5 B-GENE
- O
DNA O
complex O
has O
a O
longer O
half O
- O
life O
than O
protein O
- O
DNA O
complexes O
that O
contain O
only O
Swi5 B-GENE
or O
Grf10 B-GENE
. O

The O
mutant O
allele O
of O
the O
alpha B-GENE
1 I-GENE
- I-GENE
tubulin I-GENE
gene I-GENE
was O
designated O
tua1 B-GENE
- I-GENE
1 I-GENE
. O

Analysis O
of O
a O
set O
of O
deletion O
constructs O
in O
transient O
transfection O
assays O
measuring O
heterologous O
reporter O
gene O
( O
luciferase B-GENE
) O
activity O
demonstrated O
that O
the O
182 O
- O
bp O
5 O
' O
- O
flanking O
region O
provides O
full O
promoter O
activity O
in O
IL B-GENE
- I-GENE
2 I-GENE
- O
stimulated O
L2 O
cells O
. O

Northern O
analysis O
of O
RNA O
samples O
isolated O
from O
ammonium O
- O
grown O
cultures O
of O
the O
ntcA B-GENE
mutant I-GENE
showed O
reduced O
amounts O
of O
glnA B-GENE
message I-GENE
and O
the O
absence O
of O
a O
1 O
. O
7 O
- O
kb O
transcript O
. O

In O
order O
to O
define O
potential O
candidate O
genes O
for O
inherited O
disorders O
characterized O
by O
aberrant O
gene O
expression O
, O
we O
utilized O
Kruppel B-GENE
- I-GENE
related I-GENE
sequences I-GENE
to O
isolate O
zinc O
finger O
- O
containing O
cDNAs O
. O

The O
isolated O
POT1 B-GENE
clones O
hybridized O
to O
a O
1 O
. O
4 O
kb O
RNA O
species O
, O
which O
was O
induced O
approximately O
30 O
- O
fold O
when O
oleate O
was O
the O
carbon O
source O
. O

The O
Y O
. O
lipolytica O
genomic O
POT1 B-GENE
gene O
was O
disrupted O
by O
replacing O
120 O
bp O
of O
its O
coding O
sequence O
with O
2 O
. O
7 O
kbp O
of O
DNA O
including O
the O
Y O
. O
lipolytica O
LEU2 B-GENE
gene I-GENE
. O

The O
novel O
Notch B-GENE
homologue I-GENE
mouse B-GENE
Notch I-GENE
3 I-GENE
lacks O
specific O
epidermal B-GENE
growth I-GENE
factor I-GENE
- I-GENE
repeats I-GENE
and O
is O
expressed O
in O
proliferating O
neuroepithelium O
. O

Immunoreactive O
AR B-GENE
content O
in O
transfected O
COS O
- O
1 O
cells O
was O
not O
influenced O
by O
exposure O
to O
8 O
- O
Br O
- O
cAMP O
. O

Internal O
biliary O
drainage O
, O
unlike O
external O
drainage O
, O
does O
not O
suppress O
the O
regeneration O
of O
cholestatic O
rat O
liver O
after O
partial O
hepatectomy O
. O

ORF O
2 O
potentially O
encoded O
a O
hydrophobic O
protein O
of O
29 O
, O
705 O
Da O
with O
six O
potential O
membrane O
- O
spanning O
regions O
. O

Plasmids O
were O
constructed O
with O
the O
mouse O
promoter O
region O
linked O
to O
the O
reporter B-GENE
gene I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT B-GENE
) O
, O
and O
transiently O
and O
stably O
transfected O
in O
the O
INS O
- O
1 O
cells O
. O

Specifically O
, O
this O
study O
determined O
the O
influence O
of O
: O
( O
1 O
) O
an O
awareness O
strategy O
, O
( O
2 O
) O
a O
non O
- O
awareness O
strategy O
, O
( O
3 O
) O
a O
Five O
- O
Step O
Approach O
strategy O
and O
( O
4 O
) O
a O
control O
condition O
. O

Mutually O
exclusive O
interaction O
of O
the O
adenovirus B-GENE
E4 I-GENE
- I-GENE
6 I-GENE
/ I-GENE
7 I-GENE
protein I-GENE
and O
the O
retinoblastoma B-GENE
gene I-GENE
product I-GENE
with O
internal O
domains O
of O
E2F B-GENE
- I-GENE
1 I-GENE
and O
DP B-GENE
- I-GENE
1 I-GENE
. O

The O
transverse O
magnetization O
decays O
mentioned O
above O
exhibited O
two O
components O
, O
a O
T2 O
fast O
( O
T2f O
) O
and O
a O
T2 O
slow O
( O
T2s O
) O
component O
. O

Expression O
of O
a O
dominant B-GENE
- I-GENE
negative I-GENE
ras I-GENE
gene I-GENE
also O
blocks O
TIS10 B-GENE
/ O
PGS2 B-GENE
induction O
by O
v B-GENE
- I-GENE
src I-GENE
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B-GENE
activation O
of O
NF B-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ O
Rel B-GENE
involves O
phosphorylation O
and O
degradation O
of O
I B-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
and O
RelA B-GENE
( I-GENE
p65 I-GENE
) I-GENE
- O
mediated O
induction O
of O
the O
c B-GENE
- I-GENE
rel I-GENE
gene I-GENE
. O

These O
RZR B-GENE
subtypes O
represent O
members O
of O
a O
new O
family O
of O
orphan B-GENE
nuclear I-GENE
receptors I-GENE
that O
most O
likely O
regulate O
specific O
gene O
expression O
. O

Interestingly O
, O
these O
response O
elements O
display O
dramatically O
reduced O
affinity O
for O
retinoic B-GENE
acid I-GENE
receptor I-GENE
- O
retinoid B-GENE
- I-GENE
X I-GENE
receptor I-GENE
heterodimers O
. O

Remarkably O
, O
U21 B-GENE
contains O
a O
long O
stretch O
( O
13 O
nt O
. O
) O
of O
complementarity O
to O
a O
highly O
conserved O
sequence O
in O
28S B-GENE
rRNA I-GENE
. O

These O
results O
provide O
evidence O
of O
a O
bypass O
of O
p53 B-GENE
- O
induced O
Waf1 B-GENE
/ O
Cip1 B-GENE
- O
mediated O
cell O
cycle O
regulatory O
pathways O
by O
a O
member O
of O
the O
myb B-GENE
oncogene I-GENE
family I-GENE
. O

All O
groups O
were O
challenged O
subsequently O
with O
naloxone O
( O
0 O
. O
4 O
mg O
/ O
kg O
) O
in O
the O
distinctive O
environment O
and O
then O
observed O
for O
signs O
of O
opiate O
withdrawal O
. O

There O
were O
9 O
patients O
in O
NYHA O
class O
III O
and O
8 O
in O
class O
IV O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

TG O
- O
day O
and O
TG O
- O
night O
were O
19 O
. O
4 O
+ O
/ O
- O
6 O
. O
1 O
% O
, O
26 O
. O
6 O
+ O
/ O
- O
5 O
. O
3 O
% O
, O
( O
750 O
mm3 O
< O
T O
. O

Ten O
volunteers O
were O
tested O
at O
18 O
, O
000 O
ft O
( O
5 O
, O
486 O
m O
) O
, O
and O
through O
12 O
, O
000 O
, O
8 O
, O
000 O
, O
and O
5 O
, O
000 O
ft O
( O
3 O
, O
657 O
, O
2 O
, O
438 O
, O
and O
1 O
, O
524 O
m O
) O
with O
directional O
sounds O
recorded O
via O
a O
dummy O
head O
microphone O
and O
presented O
binaurally O
. O

Upon O
differentiation O
with O
retinoic O
acid O
( O
RA O
) O
, O
transcription O
of O
the O
Rex B-GENE
- I-GENE
1 I-GENE
gene I-GENE
decreases O
rapidly O
. O

In O
general O
, O
the O
filtration O
rate O
in O
relevant O
areas O
appears O
to O
be O
an O
integrative O
and O
easily O
determined O
parameter O
, O
reflecting O
hormonal O
and O
neurogenic O
vascular O
as O
well O
as O
local O
interstitial O
control O
of O
the O
Starling O
forces O
. O

Homozygous O
null O
embryos O
also O
displayed O
abnormalities O
in O
heart O
development O
, O
consistent O
with O
the O
conclusion O
that O
Tek B-GENE
is O
necessary O
for O
endocardial O
/ O
myocardial O
interactions O
during O
development O
. O

A O
strong O
trithorax B-GENE
binding I-GENE
site I-GENE
was O
found O
at O
the O
cytological O
location O
of O
the O
fork B-GENE
head I-GENE
gene I-GENE
, O
a O
region O
- O
specific O
homeotic B-GENE
gene I-GENE
not O
located O
within O
a O
homeotic B-GENE
complex I-GENE
. O

C B-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat B-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
[ O
Potter O
et O
al O
. O
, O
Arch O
. O

C B-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat B-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
[ O
Potter O
et O
al O
. O
, O
Arch O
. O

Segments O
with O
more O
reduced O
BMIPP O
uptake O
than O
MIBI O
uptake O
( O
mismatching O
) O
showed O
either O
normal O
wall O
motion O
or O
demonstrated O
inotropic O
reserve O
during O
dobutamine O
stimulation O
. O

The O
present O
data O
also O
indicate O
that O
patients O
with O
TGBM O
nephropathy O
often O
have O
concomitant O
IgA B-GENE
nephropathy O
and O
mesangial O
proliferative O
glomerulonephritis O
. O

A O
full O
- O
length O
cDNA O
clone O
isolated O
from O
a O
rat O
lung O
library O
was O
predicted O
to O
encode O
a O
55 O
- O
kDa O
protein O
containing O
at O
its O
amino O
terminus O
a O
targeting O
domain O
that O
binds O
to O
the O
ANP B-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
- I-GENE
like I-GENE
domain I-GENE
and O
containing O
at O
its O
carboxyl O
terminus O
a O
putative O
protein B-GENE
- I-GENE
serine I-GENE
phosphatase I-GENE
domain O
. O

A O
high O
- O
resolution O
restriction O
map O
of O
over O
200 O
kb O
of O
contiguous O
DNA O
containing O
N B-GENE
- I-GENE
myc I-GENE
has O
been O
generated O
by O
subcloning O
YACs O
into O
cosmids O
. O

In O
the O
present O
article O
, O
the O
causes O
of O
death O
or O
ill O
- O
being O
as O
found O
in O
10 O
consecutive O
carcinogenicity O
studies O
- O
- O
5 O
studies O
with O
2400 O
OFA O
( O
Sprague O
- O
Dawley O
- O
derived O
) O
and O
Wistar O
rats O
and O
5 O
studies O
with O
2400 O
OF1 O
and O
NMRI O
mice O
- O
- O
were O
re O
- O
examined O
. O

Surprisingly O
, O
Northern O
( O
RNA O
) O
blot O
analysis O
and O
reverse B-GENE
transcriptase I-GENE
- O
PCRs O
performed O
after O
transfection O
of O
COS O
- O
7 O
or O
HeLa O
cells O
with O
these O
viral O
RNAs O
revealed O
that O
Y88S B-GENE
and O
Y88L B-GENE
RNAs I-GENE
replicated O
at O
only O
very O
low O
levels O
. O

Moreover O
, O
the O
ability O
to O
selectivity O
arrest O
elongation O
by O
polIII B-GENE
at O
defined O
positions O
within O
the O
tRNA O
gene O
transcription O
unit O
has O
permitted O
the O
identification O
of O
discrete O
functional O
properties O
of O
paused O
mammalian B-GENE
polIII I-GENE
ternary I-GENE
complexes I-GENE
. O

A O
recent O
index O
( O
Fluorosis O
Risk O
Index O
) O
developed O
by O
Pendrys O
( O
1990 O
) O
is O
also O
included O
in O
this O
review O
. O

The O
role O
of O
HIV B-GENE
tat I-GENE
, O
which O
is O
the O
main O
enhancing O
factor O
for O
viral B-GENE
LTR I-GENE
, O
in O
the O
regulation O
of O
IL B-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription O
has O
been O
studied O
following O
transient O
expression O
of O
the O
tat B-GENE
gene I-GENE
in O
phorbol O
ester O
and O
calcium O
ionophore O
- O
activated O
Jurkat O
cells O
transfected O
with O
IL B-GENE
- I-GENE
2 I-GENE
promoter O
- O
chloramphenicol B-GENE
acetyltransferase I-GENE
reporter O
constructs O
. O

Splice O
variations O
in O
genes O
coding O
for O
the O
transmembrane B-GENE
FGF I-GENE
receptor I-GENE
( O
FGFR B-GENE
) O
result O
in O
isoforms O
that O
vary O
in O
the O
ectodomain O
, O
intracellular O
juxtamembrane O
domain O
, O
and O
the O
intracellular O
kinase O
domain O
. O

The O
git1 B-GENE
, O
git3 B-GENE
, O
git5 B-GENE
, O
git7 B-GENE
, O
git8 B-GENE
and O
git10 B-GENE
genes I-GENE
act O
upstream O
of O
adenylate B-GENE
cyclase I-GENE
, O
presumably O
encoding O
an O
adenylate B-GENE
cyclase I-GENE
activation O
pathway O
. O

Deletion O
studies O
identified O
a O
distal O
response O
element O
that O
is O
responsible O
for O
the O
cytokine O
response O
and O
has O
properties O
of O
an O
inducible O
transcriptional O
enhancer O
. O

No O
drop O
in O
oxygen O
saturation O
( O
SaO2 O
) O
or O
visual O
evidence O
of O
transient O
electroencephalographic O
( O
EEG O
) O
arousals O
can O
be O
found O
at O
repeat O
polysomnography O
. O

This O
sequenced O
region O
of O
the O
V O
beta O
locus O
contains O
an O
average O
number O
of O
repetitive O
DNA O
elements O
( O
21 O
Alu B-GENE
, O
three O
L1 B-GENE
, O
three O
MER O
, O
and O
three O
retrovirus O
- O
related O
elements O
. O

However O
, O
by O
an O
NS35 B-GENE
- I-GENE
specific I-GENE
RNA I-GENE
capture O
assay O
, O
the O
multimers O
were O
shown O
to O
possess O
the O
RNA O
- O
binding O
activity O
previously O
demonstrated O
for O
NS35 B-GENE
. O

Ketamine O
in O
the O
treatment O
of O
bronchospasm O
during O
mechanical O
ventilation O
. O

The O
molecular O
basis O
for O
commitment O
of O
progenitors O
to O
the O
eosinophil O
lineage O
and O
mechanisms O
by O
which O
eosinophil O
- O
specific O
genes O
are O
expressed O
and O
regulated O
during O
differentiation O
is O
unknown O
. O

Thus O
, O
YMIP B-GENE
is O
a O
functional O
homolog O
of O
RMIP B-GENE
and O
represents O
a O
new O
component O
of O
the O
yeast O
mitochondrial O
import O
machinery O
. O

Tryptic O
cleavage O
and O
peptide O
sequence O
analysis O
demonstrated O
that O
the O
98 O
- O
kD O
protein O
is O
identical O
to O
a O
recently O
cloned O
protein O
, O
special B-GENE
A I-GENE
- I-GENE
T I-GENE
- I-GENE
rich I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
SATB1 B-GENE
) O
, O
that O
binds O
selectively O
to O
nuclear O
matrix O
/ O
scaffold O
- O
associated O
regions O
of O
DNA O
( O
MARs O
/ O
SARs O
) O
. O

Heparin O
had O
no O
effect O
on O
rAC B-GENE
- I-GENE
st I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
phosphatase I-GENE
activity O
, O
while O
the O
B O
subunit O
- O
containing O
forms O
were O
stimulated O
2 O
- O
3 O
- O
fold O
. O

BACKGROUND O
AND O
DESIGN O
: O
Fifty O
- O
nine O
melanocytic O
nevi O
with O
eccentric O
foci O
of O
hyperpigmentation O
( O
" O
small O
dark O
dots O
" O
) O
that O
measured O
primarily O
1 O
to O
2 O
mm O
in O
diameter O
were O
prospectively O
examined O
to O
determine O
the O
histologic O
correlates O
of O
the O
dark O
dots O
. O

A O
single O
NMSC O
was O
present O
in O
69 O
. O
4 O
% O
, O
two O
in O
16 O
% O
, O
three O
in O
6 O
. O
4 O
% O
, O
four O
in O
3 O
. O
5 O
% O
, O
five O
to O
nine O
in O
4 O
. O
2 O
% O
, O
and O
0 O
. O
5 O
% O
had O
ten O
or O
more O
. O

The O
two O
ParA B-GENE
proteins I-GENE
that O
are O
produced O
as O
a O
result O
of O
independent O
translation O
initiation O
at O
two O
different O
start O
codons O
within O
the O
same O
open O
reading O
frame O
were O
overexpressed O
in O
Escherichia O
coli O
and O
partially O
purified O
. O

To O
get O
further O
insights O
into O
the O
molecular O
mechanisms O
that O
control O
tal B-GENE
- I-GENE
1 I-GENE
expression O
, O
we O
have O
isolated O
5 O
' O
sequences O
of O
the O
murine O
gene O
and O
compared O
them O
to O
their O
human O
counterparts O
. O

These O
results O
demonstrate O
that O
a O
diverse O
set O
of O
carboxyl O
- O
terminal O
sequence O
motifs O
and O
posttranslational O
modifications O
lead O
to O
functional O
Ras B-GENE
proteins I-GENE
in O
yeast O
. O

Binding O
of O
U2 B-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( O
snRNP O
) O
to O
the O
pre O
- O
mRNA O
is O
an O
early O
and O
important O
step O
in O
spliceosome O
assembly O
. O

Our O
results O
indicate O
that O
the O
KRAB B-GENE
domain I-GENE
present O
in O
the O
non O
- O
finger O
region O
of O
many O
ZFP B-GENE
genes I-GENE
quenches O
transcription O
possibly O
due O
to O
specific O
protein O
- O
protein O
interactions O
between O
the O
KRAB B-GENE
- I-GENE
A I-GENE
domain I-GENE
and O
components O
of O
the O
proximal O
transcriptional O
apparatus O
. O

Marine O
oils O
and O
cardiovascular O
reactivity O
. O

Significant O
alterations O
in O
CBC O
results O
and O
serum B-GENE
CRP I-GENE
concentration O
, O
compared O
with O
baseline O
values O
, O
were O
lacking O
in O
dogs O
of O
the O
control O
group O
. O

The O
newly O
recognised O
skeletogenital O
syndrome O
. O

Ras B-GENE
- I-GENE
and I-GENE
ultra I-GENE
- I-GENE
violet I-GENE
- I-GENE
responsive I-GENE
protein I-GENE
kinases I-GENE
that O
phosphorylate O
c B-GENE
- I-GENE
Jun I-GENE
on O
serine O
residues O
at O
positions O
63 O
and O
73 O
and O
stimulate O
its O
transcriptional O
activity O
have O
been O
identified O
. O

A O
short O
sequence O
surrounding O
the O
major O
JNK B-GENE
phosphorylation O
site O
of O
c B-GENE
- I-GENE
Jun I-GENE
is O
conserved O
in O
c B-GENE
- I-GENE
Fos I-GENE
and O
is O
part O
of O
its O
activation O
domain O
, O
suggesting O
that O
c B-GENE
- I-GENE
Fos I-GENE
may O
be O
similarly O
regulated O
. O

c B-GENE
- I-GENE
Fos I-GENE
transcriptional O
activity O
stimulated O
by O
H B-GENE
- I-GENE
Ras I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
distinct O
from O
JNK B-GENE
and O
ERK B-GENE
. O

Essential O
features O
of O
this O
model O
are O
bending O
of O
the O
DNA O
double O
helix O
and O
contact O
of O
operator O
sites O
with O
repressor O
domains O
bearing O
sequence O
homologies O
with O
the O
helix O
- O
turn O
- O
helix O
( O
HTH O
) O
motifs O
of O
other O
DNA O
- O
binding O
proteins O
. O

The O
binding O
of O
transcription O
factor O
AP B-GENE
- I-GENE
1 I-GENE
and O
vitamin B-GENE
D I-GENE
receptor I-GENE
( O
VDR B-GENE
) O
to O
the O
composite O
AP B-GENE
- I-GENE
1 I-GENE
plus I-GENE
vitamin I-GENE
- I-GENE
D I-GENE
- I-GENE
responsive I-GENE
promoter I-GENE
region O
( O
AP B-GENE
- I-GENE
1 I-GENE
+ I-GENE
VDRE I-GENE
) O
of O
the O
human B-GENE
osteocalcin I-GENE
gene I-GENE
was O
characterized O
in O
osteocalcin B-GENE
- O
producing O
( O
MG O
- O
63 O
) O
and O
non O
- O
producing O
( O
U2 O
- O
Os O
, O
SaOs O
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

2 O
. O

The O
LTR O
- O
binding O
activities O
of O
VBP B-GENE
, O
a1 B-GENE
/ I-GENE
EBP I-GENE
, O
and O
B B-GENE
- I-GENE
cell I-GENE
nuclear I-GENE
extract I-GENE
protein I-GENE
were O
compared O
and O
mapped O
by O
gel O
shift O
, O
DNase B-GENE
I I-GENE
footprinting O
, O
and O
methylation O
interference O
assays O
. O

These O
results O
suggest O
that O
leader O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
complementary O
sequences O
. O

These O
results O
suggest O
that O
leader O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
complementary O
sequences O
. O

To O
determine O
whether O
P35 B-GENE
could O
activate O
the O
39k O
promoter O
in O
the O
absence O
of O
IE1 B-GENE
, O
the O
p35 B-GENE
open O
reading O
frame O
was O
cloned O
under O
the O
control O
of O
the O
ie1 B-GENE
promoter I-GENE
. O

In O
addition O
, O
a O
microsatellite O
repeat O
polymorphism O
with O
a O
heterozygosity O
of O
71 O
% O
at O
the O
RET B-GENE
locus I-GENE
and O
a O
restriction O
fragment O
length O
polymorphism O
with O
a O
heterozygosity O
of O
42 O
% O
detected O
by O
a O
lambda O
clone O
from O
the O
D10S94 B-GENE
locus I-GENE
have O
been O
developed O
for O
high O
- O
resolution O
genetic O
linkage O
mapping O
and O
predictive O
diagnostic O
testing O
. O

However O
, O
tyrA B-GENE
can O
be O
expressed O
efficiently O
from O
an O
internal O
promoter O
which O
appears O
to O
lie O
within O
the O
3 O
' O
portion O
of O
aroF B-GENE
. O

Within O
the O
span O
of O
attenuator O
region O
encoding O
the O
three O
stem O
- O
loop O
structures O
of O
mRNA O
secondary O
configuration O
, O
hot O
spots O
of O
base O
- O
residue O
divergence O
were O
localized O
to O
looped O
- O
out O
regions O
. O

Previous O
studies O
showed O
that O
mutations O
in O
the O
6K O
protein O
led O
to O
the O
slow O
release O
of O
aberrant O
, O
multi O
- O
cored O
infectious O
virions O
. O

The O
RFLP O
patterns O
of O
the O
isolates O
from O
six O
of O
these O
patients O
remained O
essentially O
unchanged O
( O
two O
strains O
showed O
one O
additional O
band O
) O
despite O
the O
development O
of O
drug O
resistance O
. O

Southern O
analysis O
on O
genomic O
DNA O
isolated O
from O
tissues O
and O
cell O
lines O
from O
several O
mouse O
strains O
using O
mCD22 B-GENE
cDNA I-GENE
demonstrated O
that O
the O
Cd22 B-GENE
locus I-GENE
encoding O
mCD22 B-GENE
is O
a O
single O
copy O
gene O
of O
< O
or O
= O
30 O
kb O
. O

The O
tyrosine B-GENE
hydroxylase I-GENE
gene I-GENE
( O
TH B-GENE
) O
contains O
a O
single O
copy O
of O
a O
consensus O
CRE O
at O
- O
45 O
to O
- O
38 O
base O
pair O
( O
bp O
) O
upstream O
of O
the O
transcription O
initiation O
site O
. O

Fenoldopam O
, O
a O
dopamine B-GENE
receptor I-GENE
agonist O
, O
has O
been O
shown O
, O
in O
animal O
experiments O
, O
to O
improve O
renal O
perfusion O
. O

The O
results O
indicate O
that O
hrpRS B-GENE
and O
hrpL B-GENE
are O
part O
of O
a O
regulatory O
cascade O
in O
which O
HrpR B-GENE
and O
HrpS B-GENE
activate O
expression O
of O
hrpL B-GENE
and O
HrpL B-GENE
, O
a O
putative O
sigma B-GENE
factor I-GENE
, O
induces O
expression O
of O
HrpL B-GENE
- I-GENE
responsive I-GENE
genes I-GENE
. O

All O
other O
normal O
and O
transformed O
lymphoid O
and O
nonlymphoid O
cell O
lines O
and O
normal O
tissues O
were O
negative O
for O
PANG B-GENE
expression O
except O
for O
the O
brain O
, O
wherein O
unique O
4 O
. O
0 O
- O
and O
6 O
. O
1 O
- O
kb O
transcripts O
were O
detected O
. O

L O
. O
, O
Greer O
, O
J O
. O
& O
Carter O
, O
G O
. O

Western O
blotting O
( O
immunoblotting O
) O
with O
an O
antiserum O
to O
a O
partial O
SOD B-GENE
expressed O
in O
Escherichia O
coli O
revealed O
two O
proteins O
with O
estimated O
molecular O
masses O
of O
19 O
and O
29 O
kDa O
. O

Members O
of O
the O
myocyte B-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
2 I-GENE
( O
MEF2 B-GENE
) O
family O
of O
transcription O
factors O
bind O
a O
conserved O
A O
/ O
T O
- O
rich O
sequence O
in O
the O
control O
regions O
of O
numerous O
muscle O
- O
specific O
genes O
. O

Seven O
of O
these O
had O
counterparts O
in O
the O
US O
of O
herpes O
simplex O
type O
1 O
( O
HSV O
- O
1 O
) O
, O
pseudorabies O
virus O
( O
PRV O
) O
, O
and O
equine O
herpesvirus O
type O
1 O
( O
EHV O
- O
1 O
) O
. O

The O
previously O
described O
enhanced O
translation O
of O
spinach O
L12 B-GENE
mRNA I-GENE
from O
its O
two O
tandem O
AUG O
codons O
and O
the O
two O
functional O
rpl12 B-GENE
genes I-GENE
in O
Arabidopsis O
probably O
provide O
two O
mechanisms O
for O
generating O
the O
four O
copies O
of O
L12 B-GENE
/ I-GENE
chloroplast I-GENE
ribosome I-GENE
, O
qualitatively O
different O
from O
those O
attempted O
in O
eubacteria O
. O

Genomic O
DNA O
clones O
containing O
the O
T B-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
human I-GENE
MAL I-GENE
gene I-GENE
were O
isolated O
. O

Expression O
of O
the O
dibasic O
proprotein O
processing O
enzyme O
furin B-GENE
is O
directed O
by O
multiple O
promoters O
. O

Certain O
spt10 B-GENE
spontaneous O
alleles O
are O
good O
suppressors O
but O
have O
a O
normal O
growth O
rate O
, O
suggesting O
that O
the O
SPT10 B-GENE
protein I-GENE
may O
have O
two O
distinct O
functions O
. O

In O
Rat O
1a O
cells O
, O
m1R B-GENE
stimulation O
of O
phospholipase B-GENE
C I-GENE
beta I-GENE
and O
the O
marked O
rise O
in O
intracellular O
calcium O
stimulated O
cyclic O
AMP O
( O
cAMP O
) O
synthesis O
, O
resulting O
in O
the O
activation O
of O
protein B-GENE
kinase I-GENE
A I-GENE
. O

The O
mutations O
did O
not O
affect O
the O
repression O
of O
CPA1 B-GENE
by O
arginine O
. O

A O
segment O
of O
mRNA O
encoding O
the O
leader O
peptide O
of O
the O
CPA1 B-GENE
gene I-GENE
confers O
repression O
by O
arginine O
on O
a O
heterologous O
yeast O
gene O
transcript O
. O

Structure O
and O
expression O
of O
the O
alternative O
sigma B-GENE
factor I-GENE
, O
RpoN B-GENE
, O
in O
Rhodobacter O
capsulatus O
; O
physiological O
relevance O
of O
an O
autoactivated O
nifU2 B-GENE
- O
rpoN B-GENE
superoperon O
. O

Insertion O
of O
short O
oligonucleotides O
encoding O
the O
basic O
amino O
acid O
motifs O
726 O
- O
GRKRKSP O
- O
732 O
from O
IE175 B-GENE
and O
500 O
- O
VRPRKRR O
- O
506 O
from O
IE110 B-GENE
into O
deleted O
cytoplasmic O
forms O
of O
the O
two O
proteins O
restored O
the O
karyophilic O
phenotype O
and O
confirmed O
that O
these O
motifs O
are O
both O
necessary O
and O
sufficient O
for O
proper O
nuclear O
localization O
. O

Mapping O
of O
intracellular O
localization O
domains O
and O
evidence O
for O
colocalization O
interactions O
between O
the O
IE110 B-GENE
and O
IE175 B-GENE
nuclear O
transactivator O
proteins O
of O
herpes O
simplex O
virus O
. O

The O
revertant O
TATA O
boxes O
accelerated O
the O
kinetics O
of O
HIV O
replication O
when O
present O
in O
the O
context O
of O
an O
LTR O
containing O
a O
Sp1 B-GENE
mutation O
( O
deletion O
or O
site O
specific O
) O
; O
no O
effect O
was O
observed O
on O
the O
infectivity O
of O
wild O
- O
type O
HIV O
. O

Mitochondrial B-GENE
Mas70p I-GENE
signal I-GENE
anchor I-GENE
sequence I-GENE
. O

Response O
to O
treatment O
was O
better O
in O
patients O
with O
less O
pretreatment O
( O
one O
- O
two O
prior O
treatments O
) O
than O
in O
heavily O
pretreated O
ones O
( O
more O
than O
three O
) O
and O
this O
relation O
was O
found O
to O
be O
statistically O
significant O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
class B-GENE
II I-GENE
Escherichia I-GENE
coli I-GENE
alanine I-GENE
tRNA I-GENE
synthetase I-GENE
aminoacylates I-GENE
RNA I-GENE
miniduplexes I-GENE
, O
which O
reconstruct O
the O
acceptor O
end O
of O
alanine B-GENE
tRNA I-GENE
with O
the O
critical O
G3 O
: O
U70 O
base O
pair O
. O

A O
second O
study O
group O
, O
with O
intact O
cardiac O
innervation O
, O
consisted O
of O
19 O
patients O
with O
stable O
angina O
pectoris O
class O
I O
to O
III O
. O

Thus O
, O
we O
have O
separated O
the O
signal O
function O
from O
the O
anchor O
function O
of O
the O
6 O
. O
7K O
SA O
domain O
. O

Exposure O
to O
higher O
TPA O
concentrations O
decreased O
the O
content O
of O
these O
transcripts O
. O

Our O
results O
indicate O
that O
the O
minimal O
requirements O
for O
induction O
of O
PEPCK B-GENE
by O
PKA B-GENE
and O
inhibition O
by O
insulin B-GENE
include O
: O
1 O
) O
the O
CREB B-GENE
activation I-GENE
domain I-GENE
, O
2 O
) O
the O
PEPCK B-GENE
TATA I-GENE
sequence I-GENE
, O
and O
3 O
) O
insulin B-GENE
- O
responsive O
hepatoma O
cells O
. O

Topical O
L O
- O
NNA O
attenuated O
the O
hypercapnic O
increase O
of O
CoBF O
by O
52 O
+ O
/ O
- O
6 O
% O
and O
CeBF O
by O
29 O
+ O
/ O
- O
5 O
% O
after O
45 O
- O
min O
exposure O
. O

Restriction O
analysis O
and O
Southern O
hybridization O
revealed O
the O
presence O
of O
Tn5422 B-GENE
in O
all O
the O
plasmid O
- O
mediated O
cadmium O
- O
resistant O
L O
. O
monocytogenes O
strains O
tested O
but O
not O
in O
strains O
encoding O
cadmium O
resistance O
on O
the O
chromosome O
. O

The O
7 O
- O
day O
treatment O
resulted O
in O
a O
decrease O
in O
mitochondrial O
uptake O
of O
Rh123 O
and O
an O
increase O
in O
NAO O
uptake O
. O

Thrombotic O
thrombocytopenic O
purpura O
in O
systemic O
lupus O
erythematosus O
. O

Women O
' O
s O
opportunities O
for O
paid O
work O
outside O
the O
home O
are O
constrained O
by O
their O
role O
as O
primary O
carer O
within O
the O
family O
, O
writes O
Trudy O
Wynne O
. O

Interestingly O
, O
the O
interaction O
of O
ZAP B-GENE
- I-GENE
70 I-GENE
with O
the O
motif O
was O
dependent O
on O
the O
presence O
of O
both O
ZAP B-GENE
- I-GENE
70 I-GENE
SH2 B-GENE
domains I-GENE
and O
both O
of O
the O
tyrosine O
residues O
in O
the O
motif O
, O
suggesting O
that O
ZAP B-GENE
- I-GENE
70 I-GENE
interacts O
with O
two O
phosphotyrosine O
residues O
and O
that O
the O
binding O
of O
the O
two O
SH2 B-GENE
domains I-GENE
is O
cooperative O
. O

PRL B-GENE
- I-GENE
1 I-GENE
is O
able O
to O
dephosphorylate O
phosphotyrosine O
substrates O
, O
and O
mutation O
of O
the O
active O
- O
site O
cysteine O
residue O
abolishes O
this O
activity O
. O

50 O
kDa O
and O
130 O
- O
170 O
kDa O
were O
detected O
. O

This O
strategy O
was O
used O
to O
place O
both O
the O
Tn903 B-GENE
neo I-GENE
gene I-GENE
and O
the O
Rhodosporidium B-GENE
toruloides I-GENE
phenylalanine I-GENE
ammonia I-GENE
lyase I-GENE
( O
PAL B-GENE
) O
- O
encoding O
gene O
under O
the O
transcriptional O
control O
of O
pPGK B-GENE
: O
: O
REP2 B-GENE
. O

In O
the O
case O
of O
congenital O
protein B-GENE
C I-GENE
deficiency O
, O
vitamin O
K O
antagonists O
must O
be O
started O
cautiously O
due O
to O
the O
risk O
of O
skin O
necrosis O
. O

In O
addition O
, O
we O
observe O
that O
the O
hUBF B-GENE
- I-GENE
promoter I-GENE
interaction O
is O
highly O
sensitive O
to O
the O
antagonistic O
effects O
of O
cisplatin O
- O
DNA O
adducts O
. O

Simultaneous O
, O
bilateral O
and O
permanent O
ventilation O
with O
a O
diaphragm O
pacing O
in O
childhood O
: O
the O
implantation O
technique O
and O
indications O

The O
pyrR B-GENE
and O
pyrP B-GENE
genes I-GENE
encoded O
polypeptides O
with O
calculated O
molecular O
masses O
of O
19 O
. O
9 O
and O
45 O
. O
2 O
kDa O
, O
respectively O
. O

To O
identify O
the O
precise O
location O
of O
the O
phosphorylation O
site O
on O
the O
64 O
- O
kDa O
protein O
, O
a O
step O
- O
by O
- O
step O
mutagenesis O
procedures O
was O
followed O
. O

Co O
- O
transfection O
of O
a O
tat B-GENE
expressing O
plasmid O
with O
these O
viruses O
containing O
the O
tat B-GENE
ORF I-GENE
mutations O
resulted O
in O
higher O
levels O
of O
virus O
production O
demonstrating O
that O
the O
effects O
of O
both O
mutants O
are O
tat B-GENE
specific O
. O

Analysis O
of O
the O
gag B-GENE
and O
rev B-GENE
proteins I-GENE
in O
the O
transfected O
cells O
demonstrated O
that O
these O
proteins O
were O
not O
detectable O
in O
cells O
transfected O
with O
the O
tat B-GENE
mutants I-GENE
but O
could O
be O
readily O
detected O
when O
the O
mutations O
were O
complemented O
in O
trans O
with O
a O
tat B-GENE
expression O
vector O
. O

SIN O
- O
1 O
had O
no O
influence O
on O
either O
the O
ischemic O
parameters O
in O
the O
surface O
electrocardiogram O
( O
ECG O
) O
or O
the O
intracoronary O
ECG O
. O

Stimulation O
of O
[ O
3H O
] O
PA O
production O
upon O
CD3 B-GENE
cross O
- O
linking O
was O
77 O
% O
lower O
in O
permeabilized O
CD45 B-GENE
- I-GENE
cells O
than O
in O
CD45 B-GENE
+ I-GENE
cells O
, O
consistent O
with O
the O
reduced O
activity O
of O
p59fyn B-GENE
in O
CD45 B-GENE
- I-GENE
cells O
. O

A O
Dictyostelium O
transformant O
overexpressing O
DdPTPa B-GENE
does O
not O
develop O
normally O
. O

We O
postulate O
that O
CaM B-GENE
binding O
by O
HIV B-GENE
envelope I-GENE
proteins I-GENE
is O
likely O
to O
exert O
diverse O
modulatory O
effects O
, O
and O
the O
mechanism O
for O
HIV O
- O
induced O
cytotoxicity O
may O
involve O
, O
in O
part O
, O
inhibition O
of O
CaM B-GENE
- O
regulated O
cellular O
functions O
. O

There O
was O
no O
apparent O
effect O
of O
growth O
temperature O
on O
the O
steady O
- O
state O
levels O
of O
fad7 B-GENE
mRNA I-GENE
in O
wild O
type O
plants O
. O

A O
second O
important O
molecule O
in O
TCR B-GENE
signal O
transduction O
is O
the O
guanine B-GENE
nucleotide I-GENE
binding I-GENE
protein I-GENE
, O
p21ras B-GENE
, O
which O
is O
coupled O
to O
the O
TCR B-GENE
by O
a O
protein B-GENE
tyrosine I-GENE
kinase I-GENE
dependent O
mechanism O
. O

A O
series O
of O
5 O
' O
- O
deletions O
revealed O
that O
the O
fragment O
- O
218 O
to O
+ O
4 O
from O
the O
TSS O
had O
the O
highest O
promoter O
activity O
, O
nearly O
1000 O
- O
fold O
greater O
than O
the O
promoterless O
chloramphenicol B-GENE
acetyltransferase I-GENE
construct I-GENE
. O

The O
lemdr1 B-GENE
gene I-GENE
was O
cloned O
in O
the O
expression O
vector O
pALTNEO O
and O
transfected O
into O
wild O
- O
type O
L O
. O
enriettii O
and O
the O
resulting O
transfected O
cells O
were O
resistant O
to O
vinblastine O
but O
at O
lower O
levels O
than O
in O
the O
selected O
mutant O
cells O
. O

The O
bioavailability O
of O
etodolac O
from O
capsules O
exposed O
to O
stressed O
conditions O
was O
compared O
in O
both O
dogs O
and O
humans O
to O
capsules O
stored O
at O
RT O
conditions O
. O

As O
regards O
lipid O
metabolism O
, O
the O
mean O
values O
for O
total O
triglycerides O
, O
cholesterol O
, O
LDL B-GENE
- I-GENE
cholesterol I-GENE
and O
HDL B-GENE
- I-GENE
cholesterol I-GENE
seen O
at O
the O
end O
of O
five O
years O
of O
Norplant O
- O
2 O
rod O
use O
and O
six O
months O
postremoval O
were O
similar O
to O
the O
preinsertion O
mean O
. O

To O
our O
knowledge O
this O
is O
the O
first O
case O
in O
which O
a O
probable O
association O
between O
cholelithiasis O
and O
Wildervanck O
' O
s O
syndrome O
has O
been O
recorded O
. O

Addition O
of O
phalloidin O
- O
stabilized O
F B-GENE
- I-GENE
actin I-GENE
nuclei O
and O
phalloidin O
restored O
L266D O
actin B-GENE
' O
s O
ability O
to O
polymerize O
at O
4 O
degrees O
C O
. O

Northern O
( O
RNA O
) O
analysis O
demonstrated O
expression O
of O
human O
PI B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
all O
tissues O
and O
cell O
lines O
tested O
. O

These O
results O
demonstrate O
the O
existence O
of O
different O
PI B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
isoforms I-GENE
and O
define O
a O
family O
of O
genes O
encoding O
distinct O
PI B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic I-GENE
subunits I-GENE
that O
can O
associate O
with O
p85 B-GENE
. O

One O
complex O
most O
likely O
contained O
Sp1 B-GENE
, O
and O
another O
complex O
showed O
S O
- O
phase O
- O
specific O
binding O
, O
suggesting O
a O
direct O
role O
in O
the O
cell O
- O
cycle O
- O
dependent O
R1 B-GENE
gene I-GENE
expression O
. O

The O
rate O
of O
enzymic O
stimulation O
induced O
by O
a O
given O
nitrate O
correlates O
closely O
with O
the O
rate O
of O
measured O
NO O
production O
from O
the O
nitrate O
molecule O
. O

Two O
patients O
were O
treated O
successfully O
with O
a O
combination O
of O
metronidazole O
( O
a O
tissue O
amoebicide O
) O
and O
diloxanide O
( O
a O
lumenal O
amoebicide O
) O
. O

We O
have O
identified O
in O
the O
5 O
' O
untranslated O
region O
of O
the O
Drosophila B-GENE
copia I-GENE
retrotransposon I-GENE
, O
3 O
' O
to O
the O
left O
LTR O
, O
a O
sequence O
for O
transcriptional O
regulation O
by O
homeoproteins O
. O

By O
using O
the O
full O
- O
length O
cytoplasmic O
domain O
and O
mutants O
with O
progressive O
carboxy O
- O
terminal O
deletions O
, O
internal O
deletions O
, O
or O
point O
mutations O
, O
we O
identified O
the O
first O
150 O
amino O
acid O
residues O
of O
LIFR B-GENE
as O
the O
minimal O
region O
necessary O
for O
signaling O
. O

Oligonucleotide O
competitors O
were O
used O
to O
evaluate O
the O
accessibility O
of O
the O
TATA O
- O
binding O
site O
in O
TIF B-GENE
- I-GENE
IB I-GENE
, O
TFIID B-GENE
, O
and O
TFIIIB B-GENE
. O

The O
227 O
- O
to O
- O
239 O
region O
blocked O
ADR1 B-GENE
activity O
independently O
of O
the O
TAD B-GENE
present O
on O
ADR1 B-GENE
, O
ADR1 B-GENE
DNA O
binding O
, O
and O
specific O
ADH2 B-GENE
promoter I-GENE
sequences I-GENE
. O

TGF B-GENE
beta I-GENE
1 I-GENE
expression O
is O
largely O
governed O
by O
three O
AP B-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
located O
in O
two O
different O
promoters O
of O
this O
gene O
. O

Repeated O
administration O
of O
GRg2 O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
significantly O
improved O
the O
CYP O
- O
induced O
recognitional O
deficits O
by O
increasing O
the O
CYP O
- O
decreased O
rate O
from O
55 O
. O
8 O
+ O
/ O
- O
9 O
. O
6 O
to O
80 O
. O
8 O
+ O
/ O
- O
4 O
. O
2 O
in O
d O
3 O
learning O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
5 O
. O
6 O
, O
p O
< O
0 O
. O
05 O
) O
, O
from O
53 O
. O
4 O
+ O
/ O
- O
8 O
. O
4 O
to O
60 O
. O
0 O
+ O
/ O
- O
8 O
. O
2 O
in O
48 O
h O
memory O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
7 O
. O
5 O
, O
p O
< O
0 O
. O
05 O
) O
and O
from O
55 O
. O
0 O
+ O
/ O
- O
5 O
. O
5 O
to O
88 O
. O
3 O
+ O
/ O
- O
2 O
. O
5 O
in O
24 O
h O
memory O
retention O
( O
F O
( O
1 O
, O
12 O
) O
27 O
. O
5 O
, O
p O
< O
0 O
. O
01 O
) O
as O
well O
as O
from O
60 O
. O
0 O
+ O
/ O
- O
6 O
. O
8 O
to O
85 O
. O
6 O
+ O
/ O
- O
6 O
. O
9 O
in O
48 O
h O
memory O
retrieval O
( O
F O
( O
1 O
, O
12 O
) O
= O
5 O
. O
2 O
, O
p O
< O
0 O
. O
05 O
) O
, O
respectively O
. O

The O
therapeutic O
action O
of O
cyclosporin O
A O
( O
Sandimmun O
) O
: O
its O
application O
in O
rheumatoid O
arthritis O
. O

Pentazocine O
analgesia O
: O
is O
there O
a O
niche O
for O
Talwin O
Nx O
? O
Pentazocine O
can O
be O
a O
useful O
analgesic O
agent O
for O
the O
management O
of O
acute O
dental O
pain O
. O

In O
addition O
, O
REP21 O
plants O
were O
resistant O
to O
an O
unusually O
broad O
range O
of O
tobamoviruses O
including O
tomato O
mosaic O
virus O
, O
tobacco O
mild O
green O
mosaic O
virus O
, O
TMV O
- O
U5 O
, O
green O
tomato O
atypical O
mosaic O
virus O
, O
and O
ribgrass O
mosaic O
virus O
. O

In O
our O
studies O
, O
we O
utilized O
HIV O
- O
1 O
HXB2 B-GENE
and O
HIV O
- O
1 O
Z2Z6 B-GENE
core I-GENE
enhancers I-GENE
because O
the O
Z2Z6 B-GENE
strain O
has O
a O
single O
point O
mutation O
flanking O
the O
right O
ETS B-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

Because O
of O
the O
small O
number O
of O
visceral O
angiography O
procedures O
performed O
( O
38 O
) O
, O
no O
definitive O
conclusions O
could O
be O
drawn O
as O
to O
the O
differences O
between O
ionic O
and O
nonionic O
agents O
regarding O
grade O
- O
2 O
and O
grade O
- O
3 O
adverse O
events O
. O

The O
Stryker O
frame O
modification O
to O
the O
standard O
Dornier O
HM3 O
lithotriptor O
allows O
for O
improved O
visualization O
and O
easier O
localization O
of O
distal O
ureteral O
calculi O
compared O
to O
the O
standard O
gantry O
. O

Glomerular O
mesangial O
cells O
expressed O
an O
abundant O
1 O
. O
1 O
kb O
mRNA O
transcript O
for O
Id1 B-GENE
, O
but O
in O
contrast O
to O
other O
cell O
types O
Id1 B-GENE
mRNA I-GENE
was O
expressed O
in O
both O
randomly O
cycling O
cells O
and O
in O
serum O
- O
deprived O
, O
quiescent O
cultures O
. O

A O
single O
1 O
. O
8 O
- O
kb O
transcript O
mRNA O
was O
detected O
by O
Northern O
( O
RNA O
) O
blot O
analysis O
, O
and O
its O
5 O
' O
end O
maps O
to O
a O
position O
51 O
bp O
upstream O
from O
the O
site O
of O
initiation O
of O
protein O
synthesis O
. O

The O
sequence O
similarity O
has O
suggested O
that O
SCG10 B-GENE
and O
stathmin B-GENE
have O
been O
derived O
from O
structurally O
and O
evolutionarily O
related O
genes O
. O

These O
data O
are O
consistent O
with O
the O
idea O
that O
the O
neuron B-GENE
- I-GENE
specific I-GENE
SCG10 I-GENE
gene I-GENE
evolved O
by O
duplication O
and O
modification O
of O
the O
more O
broadly O
expressed O
stathmin B-GENE
/ O
Lap18 B-GENE
gene O
. O

We O
found O
that O
T3 O
( O
10 O
( O
- O
8 O
) O
M O
) O
selectively O
stimulates O
transcription O
from O
rGH B-GENE
- O
TRE O
- O
and O
TREpal O
- O
, O
but O
not O
ME O
- O
TRE O
- O
and O
F2 O
- O
TRE O
- O
, O
containing O
templates O
in O
which O
these O
TREs O
are O
linked O
in O
front O
of O
the O
rGH B-GENE
minimal I-GENE
promoter I-GENE
containing O
only O
the O
TATA B-GENE
box I-GENE
binding I-GENE
protein I-GENE
, O
but O
not O
any O
other O
proximal O
binding O
protein O
, O
sequence O
. O

However O
, O
artificially O
ventilated O
rats O
, O
pretreated O
with O
MK O
- O
801 O
, O
were O
more O
sensitive O
( O
lethal O
cocaine O
dose O
, O
76 O
. O
6 O
+ O
/ O
- O
8 O
. O
0 O
mg O
/ O
kg O
, O
n O
= O
5 O
) O
than O
vehicle O
pretreated O
rats O
( O
129 O
. O
4 O
+ O
/ O
- O
15 O
. O
8 O
mg O
/ O
kg O
, O
n O
= O
6 O
) O
, O
indicating O
that O
MK O
- O
801 O
may O
increase O
both O
the O
respiratory O
and O
the O
cardiac O
toxicity O
of O
cocaine O
in O
urethane O
anesthetized O
rats O
. O

ENV B-GENE
also O
was O
secreted O
from O
P O
. O
pastoris O
using O
the O
S B-GENE
. I-GENE
cerevisiae I-GENE
alpha I-GENE
- I-GENE
factor I-GENE
prepro I-GENE
secretion I-GENE
leader I-GENE
and O
the O
S B-GENE
. I-GENE
cerevisiae I-GENE
invertase I-GENE
signal I-GENE
sequence I-GENE
. O

The O
following O
evidence O
indicates O
that O
the O
69 O
- O
kD O
protein O
is O
a O
common O
, O
rather O
than O
a O
U1 B-GENE
- O
specific O
, O
protein O
, O
possibly O
associating O
with O
the O
snRNP O
core O
particles O
by O
protein O
- O
protein O
interaction O
. O

Praziquantel O
and O
Albendazole O
were O
found O
effective O
in O
the O
treatment O
of O
neurocysticercosis O
, O
but O
because O
of O
serious O
side O
effects O
encountered O
in O
some O
cases O
, O
the O
drugs O
should O
be O
used O
cautiously O
in O
selected O
cases O
only O
. O

Transcriptional O
analysis O
of O
a O
series O
of O
deletion O
mutants O
of O
the O
gene O
in O
the O
nuclear O
extracts O
prepared O
from O
the O
middle O
silk O
gland O
of O
2 O
- O
day O
- O
old O
fifth O
instar O
larvae O
revealed O
the O
presence O
of O
multiple O
cis O
- O
regulatory O
elements O
located O
both O
upstream O
and O
downstream O
of O
the O
initiation O
site O
. O

One O
of O
these O
elements O
, O
the O
homeodomain B-GENE
- I-GENE
binding I-GENE
element I-GENE
, O
was O
identified O
to O
mediate O
negative O
regulation O
. O

Monospecific O
antibodies O
raised O
against O
rat B-GENE
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
1A1 I-GENE
recognized O
a O
protein O
in O
the O
hepatic O
microsomes O
of O
the O
double O
- O
crested O
cormorant O
, O
and O
also O
in O
those O
of O
the O
great O
blue O
heron O
( O
Ardea O
herodias O
) O
, O
using O
immunoblotting O
. O

Mutations O
in O
the O
nuclear B-GENE
gene I-GENE
CBP1 I-GENE
of I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
result O
in O
degradation O
of O
mitochondrially B-GENE
encoded I-GENE
cytochrome I-GENE
b I-GENE
( O
cob B-GENE
) O
RNA O
; O
thus O
, O
the O
cells O
are O
unable O
to O
respire O
. O

The O
5 O
' O
ends O
of O
F3R B-GENE
late O
transcripts O
were O
located O
to O
an O
A O
within O
the O
sequence O
5 O
' O
- O
TAAAG O
, O
41 O
nt O
downstream O
from O
the O
early O
promoter O
and O
17 O
nt O
upstream O
from O
the O
initiation O
codon O
. O

NF B-GENE
- I-GENE
kappa I-GENE
B I-GENE
p65 B-GENE
, O
p50 B-GENE
, O
and O
Rel B-GENE
functionally O
synergize O
with O
C B-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
, O
C B-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
, O
and O
C B-GENE
/ I-GENE
EBP I-GENE
delta I-GENE
. O

It O
could O
be O
detected O
exclusively O
in O
the O
culture O
medium O
of O
cDNA O
- O
transfected O
COS O
cells O
. O

The O
first O
group O
of O
sequential O
BMB O
showed O
a O
significant O
progress O
to O
myelofibrosis O
in O
so O
- O
called O
" O
Chronic O
Megakaryocytic O
- O
Granulocytic O
Myelosis O
" O
- O
- O
CMGM O
- O
, O
which O
corresponds O
to O
Agnogenic O
Myeloid O
Metaplasia O
- O
AMM O
- O
in O
72 O
. O
4 O
% O
( O
21 O
/ O
29 O
patients O
) O
, O
as O
well O
as O
in O
CML O
with O
megakaryocytic O
increase O
- O
CML O
. O
MI O
- O
in O
39 O
. O
2 O
% O
( O
20 O
/ O
51 O
) O
. O

These O
lesions O
were O
asymptomatic O
, O
but O
both O
were O
characterized O
clinically O
by O
central O
ulceration O
. O

Release O
of O
this O
selective O
pressure O
, O
however O
, O
gave O
way O
to O
homologous O
resolution O
of O
the O
cointegrate O
structures O
. O

The O
equivalent O
of O
the O
third O
ligand O
, O
H O
- O
87 O
, O
is O
T O
- O
47 O
in O
the O
PSTAIRE O
sequence O
motif O
. O

Botulinum B-GENE
toxin I-GENE
: O
preferred O
treatment O
for O
hemifacial O
spasm O
. O

2 O
- O
AP O
induced O
marked O
, O
steady O
rises O
in O
mRNA O
accumulation O
from O
both O
transfected O
and O
chromosomally O
integrated O
HIV O
- O
1 O
constructs O
but O
no O
increases O
from O
an O
endogenous O
gene O
encoding O
gamma B-GENE
- I-GENE
actin I-GENE
or O
glucose B-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
. O

On O
the O
other O
hand O
, O
the O
structures O
of O
the O
b O
- O
Zip O
domain O
are O
well O
conserved O
among O
these O
Maf B-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

The O
Functional O
Independence O
Measure O
: O
a O
comparative O
study O
of O
clinician O
and O
self O
ratings O
. O

Polymyxin O
B O
was O
given O
intravenously O
for O
1 O
week O
postburn O
in O
doses O
designed O
to O
neutralize O
circulating O
endotoxemia O
. O

SvO2 O
can O
be O
determined O
in O
vitro O
and O
in O
vivo O
. O

The O
transverse O
relaxation O
time O
( O
T2 O
) O
and O
apparent O
diffusion O
coefficient O
of O
water O
were O
determined O
. O

These O
findings O
suggest O
a O
functional O
cross O
- O
talk O
between O
RB B-GENE
protein I-GENE
and O
p21ras B-GENE
, O
which O
balances O
the O
cell O
phenotype O
between O
normal O
and O
transformed O
states O
. O

The O
other O
transmembrane O
regions O
as O
well O
as O
the O
nucleoplasmic O
domain O
are O
not O
required O
for O
sorting O
. O

These O
cell O
lines O
, O
selected O
for O
the O
ability O
to O
support O
the O
replication O
of O
a O
temperature O
- O
sensitive O
VP5 B-GENE
mutant I-GENE
, O
were O
used O
to O
isolate O
VP5 B-GENE
and O
VP23 B-GENE
null O
mutants O
. O

The O
E1 B-GENE
nuclear I-GENE
transport I-GENE
motif I-GENE
is O
highly O
conserved O
in O
the O
animal O
and O
human O
papillomaviruses O
and O
is O
encoded O
in O
a O
similar O
region O
in O
the O
related O
E1 B-GENE
genes I-GENE
. O

The O
E1 B-GENE
replication I-GENE
protein I-GENE
of O
bovine O
papillomavirus O
type O
1 O
contains O
an O
extended O
nuclear O
localization O
signal O
that O
includes O
a O
p34cdc2 B-GENE
phosphorylation O
site O
. O

In O
the O
present O
study O
, O
beta O
- O
funaltrexamine O
( O
beta O
- O
FNA O
) O
and O
naltrindole O
( O
NTI O
) O
( O
nonequilibrium O
mu O
- O
and O
delta O
- O
antagonist O
, O
respectively O
) O
were O
used O
to O
precipitate O
withdrawal O
in O
butorphanol O
- O
dependent O
rats O
. O

Mutations O
at O
the O
extreme O
C O
- O
terminus O
of O
EIAV B-GENE
Tat I-GENE
impaired O
both O
RNA O
binding O
and O
activation O
domain O
functions O
, O
suggesting O
effects O
on O
secondary O
or O
tertiary O
structure O
. O

This O
observation O
suggests O
that O
the O
methyl O
- O
directed O
repair O
system O
utilizes O
the O
proximal O
d O
( O
GATC O
) O
sequence O
to O
direct O
correction O
. O

Lithium O
phthalocyanine O
( O
LiPc O
) O
is O
a O
prototype O
of O
another O
generation O
of O
synthetic O
, O
metallic O
- O
organic O
, O
paramagnetic O
crystallites O
that O
appear O
very O
useful O
for O
in O
vitro O
and O
in O
vivo O
electron O
paramagnetic O
resonance O
oximetry O
. O

IE2 B-GENE
- O
IE2 B-GENE
interactions O
were O
mapped O
to O
a O
domain O
containing O
a O
putative O
helix O
- O
turn O
- O
helix O
motif O
located O
near O
the O
C O
terminus O
of O
IE2 B-GENE
, O
between O
amino O
acids O
456 O
and O
539 O
. O

Precipitation O
using O
GST B-GENE
fusion I-GENE
proteins I-GENE
containing O
Fyn B-GENE
SH2 B-GENE
, O
SH3 B-GENE
, O
and O
SH2 B-GENE
/ O
SH3 B-GENE
domains O
revealed O
that O
PI B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
bound O
principally O
to O
the O
SH3 B-GENE
domain I-GENE
of O
Fyn B-GENE
. O

A O
sheep O
testicular O
cDNA O
library O
constructed O
in O
pcDNA1 O
vector O
was O
screened O
with O
a O
probe O
generated O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
corresponding O
to O
a O
1 O
. O
6 O
kb O
fragment O
of O
the O
rat B-GENE
luteinizing I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
. O

Two O
putative O
Rev B-GENE
proteins I-GENE
with O
apparent O
molecular O
masses O
of O
18 O
and O
16 O
kDa O
were O
expressed O
by O
p2 B-GENE
/ I-GENE
2 I-GENE
and O
p176 B-GENE
, O
while O
p20 B-GENE
expressed O
only O
a O
16 O
- O
kDa O
species O
. O

Defects O
of O
fibrillin B-GENE
( O
FBN1 B-GENE
) O
, O
a O
glycoprotein O
component O
of O
the O
extracellular O
microfibril O
, O
cause O
Marfan O
syndrome O
. O

A O
region O
approximately O
100 O
bp O
upstream O
from O
the O
transcription O
start O
point O
of O
virB B-GENE
was O
identified O
as O
being O
necessary O
for O
full O
activation O
of O
this O
promoter O
by O
VirF B-GENE
. O

METHODS O
: O
Fifty O
- O
one O
healthy O
eyes O
, O
169 O
ocular O
hypertensive O
eyes O
with O
normal O
visual O
fields O
, O
and O
132 O
glaucomatous O
eyes O
with O
early O
visual O
field O
defects O
were O
evaluated O
with O
qualitative O
and O
quantitative O
measures O
of O
structural O
damage O
to O
the O
optic O
nerve O
and O
nerve O
fiber O
layer O
. O

Consistent O
with O
the O
hypothesis O
that O
it O
acts O
as O
transcriptional O
regulator O
, O
wild B-GENE
- I-GENE
type I-GENE
p53 I-GENE
protein I-GENE
binds O
DNA O
and O
activates O
transcription O
of O
several O
promoters O
. O

Instead O
, O
mRNA O
of O
2 O
. O
0 O
and O
2 O
. O
8 O
kb O
are O
detected O
in O
varying O
abundance O
. O

The O
sequence O
of O
the O
HIR1 B-GENE
gene I-GENE
predicts O
an O
88 O
- O
kDa O
protein O
with O
three O
repeats O
of O
a O
motif O
found O
in O
the O
G B-GENE
beta I-GENE
subunit I-GENE
of O
retinal B-GENE
transducin I-GENE
and O
in O
a O
yeast O
transcriptional O
repressor O
, O
Tup1 B-GENE
. O

All O
of O
these O
data O
suggest O
that O
replication O
of O
UV O
- O
damaged O
templates O
occurs O
in O
vitro O
as O
it O
does O
in O
vivo O
and O
that O
this O
replication O
results O
in O
mutation O
fixation O
. O

Biol O
. O

265 O
, O
1102 O
- O
1110 O
) O
. O

The O
use O
of O
this O
model O
for O
investigating O
pathophysiologically O
significant O
issues O
in O
denervating O
diseases O
is O
illustrated O
with O
five O
different O
sets O
of O
parameters O
. O

We O
describe O
a O
novel O
cytoplasmic B-GENE
tyrosine I-GENE
kinase I-GENE
, O
termed O
BPK B-GENE
( O
B B-GENE
cell I-GENE
progenitor I-GENE
kinase I-GENE
) O
, O
which O
is O
expressed O
in O
all O
stages O
of O
the O
B O
lineage O
and O
in O
myeloid O
cells O
. O

However O
, O
L B-GENE
- I-GENE
plastin I-GENE
has O
been O
found O
in O
many O
types O
of O
malignant O
human O
cells O
of O
non O
- O
hemopoietic O
origin O
suggesting O
that O
its O
expression O
is O
induced O
accompanying O
tumorigenesis O
in O
solid O
tissues O
. O

Finally O
, O
we O
present O
evidence O
that O
fimbrin B-GENE
is O
a O
third O
distinct O
plastin B-GENE
isoform I-GENE
which O
is O
specifically O
expressed O
at O
high O
levels O
in O
the O
small O
intestine O
. O

The O
DNase B-GENE
I I-GENE
footprint O
extended O
5 O
' O
in O
the O
silencer O
region O
to O
include O
an O
inverted O
repeat O
of O
a O
six O
- O
nucleotide O
motif O
( O
epsilon O
- O
267 O
to O
- O
278 O
bp O
) O
which O
shares O
5 O
of O
6 O
bases O
with O
the O
GATA B-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
. O

Furthermore O
, O
competitor O
containing O
the O
YY1 B-GENE
consensus I-GENE
sequence I-GENE
competed O
for O
protein B-GENE
B I-GENE
binding O
, O
whereas O
competitor O
containing O
a O
perfect O
yeast B-GENE
ABF I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
did O
not O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Naval O
personnel O
who O
exceed O
standards O
for O
% O
BF O
can O
be O
separated O
from O
active O
duty O
. O

Weak O
promoter O
activity O
was O
observed O
for O
the O
promoter O
of O
the O
C1 B-GENE
and O
C2 B-GENE
ORFs O
( O
C1 B-GENE
- O
C2 B-GENE
gene O
) O
and O
for O
the O
promoter O
of O
the O
V1 B-GENE
ORF I-GENE
. O

The O
activity O
of O
the O
coat B-GENE
protein I-GENE
promoter I-GENE
of O
chloris O
striate O
mosaic O
virus O
is O
enhanced O
by O
its O
own O
and O
C1 B-GENE
- O
C2 B-GENE
gene O
products O
. O

The O
amino O
acid O
sequence O
alignment O
of O
TC B-GENE
II I-GENE
with O
that O
of O
other O
Cbl B-GENE
binding I-GENE
proteins I-GENE
( O
rat B-GENE
intrinsic I-GENE
factor I-GENE
, O
human B-GENE
transcobalamin I-GENE
I I-GENE
and O
porcine B-GENE
haptocorrin I-GENE
) O
revealed O
only O
33 O
% O
overall O
homology O
. O

This O
short O
communication O
compares O
a O
novel O
fluorimetric O
microplate O
enzyme O
immunoassay O
( O
FEIA O
) O
with O
a O
commercial O
time O
- O
resolved O
fluoroimmunoassay O
for O
the O
determination O
of O
thyrotropin B-GENE
in O
dried O
blood O
spots O
. O

The O
evaluation O
was O
performed O
using O
a O
retrospective O
study O
design O
with O
newborn O
blood O
samples O
from O
three O
screening O
centres O
. O

When O
ligated O
to O
the O
proIL B-GENE
- I-GENE
1 I-GENE
beta I-GENE
cap I-GENE
site I-GENE
- I-GENE
proximal I-GENE
region I-GENE
( O
located O
between O
- O
131 O
to O
+ O
12 O
) O
, O
both O
the O
proIL B-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
the O
simian B-GENE
virus I-GENE
40 I-GENE
enhancer I-GENE
elements I-GENE
functioned O
more O
efficiently O
in O
monocytes O
than O
in O
HeLa O
cells O
, O
which O
are O
not O
normally O
competent O
for O
IL B-GENE
- I-GENE
1 I-GENE
beta I-GENE
expression O
. O

Therefore O
, O
PC B-GENE
- I-GENE
PLC I-GENE
is O
a O
component O
of O
a O
signal O
transduction O
pathway O
leading O
to O
transcription O
of O
c B-GENE
- I-GENE
fos I-GENE
and O
junB B-GENE
that O
collaborates O
with O
c B-GENE
- I-GENE
myc I-GENE
and O
is O
independent O
of O
PKC B-GENE
- I-GENE
delta I-GENE
and O
Ras B-GENE
activation O
. O

Southern O
blot O
analysis O
using O
probes O
from O
the O
3 O
' O
portions O
of O
the O
genomic O
and O
B B-GENE
. I-GENE
napus I-GENE
MA I-GENE
and O
MB B-GENE
cDNA I-GENE
clones O
showed O
that O
MA B-GENE
type I-GENE
myrosinases B-GENE
are O
encoded O
by O
approximately O
4 O
genes O
, O
while O
MB B-GENE
type I-GENE
myrosinases B-GENE
are O
encoded O
by O
more O
than O
10 O
genes O
in O
B O
. O
napus O
. O

Type O
II O
could O
be O
divided O
further O
into O
two O
forms O
( O
IIA O
and O
IIB O
) O
that O
may O
represent O
two O
underscribed O
species O
or O
developmental O
stages O
of O
the O
same O
species O
. O

In O
the O
present O
study O
we O
demonstrated O
a O
unique O
mechanism O
of O
action O
of O
8 O
- O
Cl O
- O
cAMP O
in O
the O
regulation O
of O
these O
kinase O
isozymes O
in O
HL O
- O
60 O
human O
promyelocytic O
leukemia O
cells O
. O

There O
are O
, O
however O
, O
several O
differences O
between O
the O
two O
new O
ars O
sequences O
. O

Pokeweed B-GENE
mitogen I-GENE
( O
PWM B-GENE
) O
or O
anti B-GENE
- I-GENE
CD3 I-GENE
significantly O
increases O
c B-GENE
- I-GENE
jun I-GENE
messenger I-GENE
RNA I-GENE
( I-GENE
mRNA I-GENE
) I-GENE
levels O
in O
T O
cells O
. O

Following O
seizure O
induction O
, O
MABP O
increased O
to O
105 O
mm O
Hg O
and O
brain O
pHi O
fell O
to O
6 O
. O
79 O
+ O
/ O
- O
0 O
. O
03 O
within O
15 O
min O
and O
remained O
at O
this O
level O
for O
1 O
h O
( O
P O
< O
0 O
. O
001 O
) O
. O

Sterile O
mutants O
of O
Saccharomyces O
cerevisiae O
were O
isolated O
from O
alpha O
* O
cells O
having O
the O
a B-GENE
/ I-GENE
alpha I-GENE
aar1 I-GENE
- I-GENE
6 I-GENE
genotype O
( O
exhibiting O
alpha O
mating O
ability O
and O
weak O
a O
mating O
ability O
as O
a O
result O
of O
a O
defect O
in O
a1 B-GENE
- I-GENE
alpha I-GENE
2 I-GENE
repression O
) O
. O

OBJECTIVE O
: O
Our O
purpose O
was O
to O
determine O
the O
simultaneous O
concentrations O
of O
serum O
cotinine O
in O
both O
fetal O
and O
maternal O
blood O
. O

5 O
micrograms O
/ O
l O
was O
detected O
in O
urine O
from O
some O
non O
- O
occupationally O
exposed O
persons O
. O

Finger B-GENE
associated I-GENE
box I-GENE
- I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
( O
FAX B-GENE
- I-GENE
ZFPs I-GENE
) O
constitute O
a O
subfamily O
of O
the O
many O
C2H2 B-GENE
type I-GENE
ZFPs I-GENE
in O
Xenopus O
laevis O
. O

Further O
evidence O
for O
a O
clustered O
organization O
of O
FAX B-GENE
- O
ZFP B-GENE
transcription O
units O
is O
provided O
by O
Southern O
blot O
analysis O
of O
large O
genomic O
restriction O
fragments O
separated O
by O
transverse O
field O
gel O
electrophoresis O
, O
and O
by O
in O
situ O
hybridization O
on O
intact O
chromosomes O
. O

Mutational O
analyses O
have O
demonstrated O
the O
importance O
of O
sequences O
within O
the O
327 O
bp O
segment O
that O
contain O
a O
putative O
cyclic B-GENE
AMP I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB B-GENE
) O
binding O
site O
for O
TGF B-GENE
- I-GENE
beta I-GENE
1 I-GENE
and O
PMA O
responsiveness O
and O
putative O
PU B-GENE
- I-GENE
1 I-GENE
and O
Sp1 B-GENE
binding I-GENE
sites I-GENE
for O
basal O
promoter O
activity O
. O

( O
1992 O
) O
J O
. O

We O
obtained O
the O
prevalence O
of O
IgG B-GENE
antibodies I-GENE
against O
Trypanosoma O
cruzi O
among O
1076 O
blood O
donors O
at O
the O
Instituto O
Nacional O
de O
Cardiologia O
" O
Ignacio O
Chavez O
" O
in O
Mexico O
City O
. O

Examination O
of O
the O
immediate O
sequence O
5 O
' O
to O
the O
mRNA O
start O
site O
reveals O
no O
TATA O
box O
and O
multiple O
known O
enhancer O
sequences O
. O

Pseudosubstrate O
( O
19 O
- O
36 O
) O
, O
derived O
from O
the O
C O
- O
terminus O
of O
Ca B-GENE
- I-GENE
dependent I-GENE
PKC I-GENE
isotypes I-GENE
, O
inhibited O
beta B-GENE
- I-GENE
PKC I-GENE
but O
not O
nPKC B-GENE
activity O
using O
either O
Histone B-GENE
IIIS I-GENE
or O
peptide O
( O
19 O
- O
31 O
) O
as O
substrate O
. O

This O
may O
account O
, O
at O
least O
in O
part O
, O
for O
the O
ability O
of O
excess O
wt B-GENE
p53 I-GENE
to O
inhibit O
cell O
proliferation O
and O
to O
interfere O
with O
neoplastic O
processes O
. O

Northern O
blot O
analysis O
of O
total O
cellular O
RNA O
indicated O
that O
xylP B-GENE
encodes O
a O
1 O
. O
3 O
- O
kb O
transcript O
which O
is O
induced O
by O
xylan O
. O

These O
data O
show O
that O
PTH B-GENE
and O
cAMP O
can O
repress O
collagen B-GENE
promoter I-GENE
activity O
in O
calvariae O
from O
transgenic O
mice O
, O
suggesting O
that O
the O
alpha B-GENE
1 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
promoter I-GENE
may O
contain O
cis O
elements O
down O
- O
stream O
of O
- O
2 O
. O
3 O
kilobases O
that O
mediate O
PTH B-GENE
and O
cAMP O
repression O
of O
collagen B-GENE
gene I-GENE
expression O
in O
bone O
. O

The O
yeast O
gene O
that O
encodes O
eIF B-GENE
- I-GENE
5 I-GENE
, O
designated O
TIF5 B-GENE
, O
has O
been O
isolated O
and O
expressed O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
active O
eIF B-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

Xylose O
- O
and O
arabinose O
- O
containing O
polymers O
were O
better O
digested O
than O
was O
cellulose O
for O
both O
breads O
. O

The O
alpha O
- O
subunit O
by O
itself O
binds O
to O
telomeric O
DNA O
. O

We O
conclude O
that O
the O
alpha O
- O
subunit O
of O
the O
telomere B-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
like O
many O
transcription O
factors O
, O
has O
separable O
DNA O
- O
binding O
and O
protein O
- O
protein O
interaction O
domains O
. O

Calcification O
of O
a O
cariogenic O
Streptococcus O
and O
of O
Corynebacterium O
( O
Bacterionema O
) O
matruchotii O
. O

A O
comparison O
of O
the O
promoters O
for O
muMIP B-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
muMIP B-GENE
- I-GENE
1 I-GENE
alpha I-GENE
reveals O
a O
conserved O
CK O
- O
1 O
element O
, O
but O
transient O
expression O
studies O
in O
RAW O
264 O
. O
7 O
macrophages O
with O
proximal O
fragments O
of O
either O
the O
muMIP B-GENE
- I-GENE
1 I-GENE
beta I-GENE
or O
the O
muMIP B-GENE
- I-GENE
1 I-GENE
alpha I-GENE
5 I-GENE
' I-GENE
promoter I-GENE
fused O
to O
a O
human B-GENE
growth I-GENE
hormone I-GENE
reporter I-GENE
gene I-GENE
link O
LPS O
- O
inducibility O
in O
both O
to O
promoter O
segments O
near O
to O
, O
but O
not O
identical O
with O
, O
the O
consensus O
CK O
- O
1 O
sequence O
. O

Sequence O
analysis O
and O
identification O
of O
two O
hyp B-GENE
regulatory I-GENE
mutants I-GENE
. O

The O
gene O
encoding O
the O
receptor O
for O
macrophage B-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
( O
CSF B-GENE
- I-GENE
1 I-GENE
) O
, O
the O
c B-GENE
- I-GENE
fms I-GENE
protooncogene I-GENE
, O
is O
selectively O
expressed O
in O
immature O
and O
mature O
mononuclear O
phagocytes O
and O
trophoblasts O
. O

Since O
the O
regulation O
of O
SWI4 B-GENE
is O
required O
for O
normal O
cell O
cycle O
progression O
, O
we O
have O
characterized O
cis O
- O
and O
trans O
- O
acting O
regulators O
of O
SWI4 B-GENE
transcription O
. O

It O
also O
suggests O
that O
there O
is O
another O
pathway O
which O
can O
activate O
SWI4 B-GENE
transcription O
in O
the O
absence O
of O
SWI6 B-GENE
. O

Multiple O
SWI6 B-GENE
- O
dependent O
cis O
- O
acting O
elements O
control O
SWI4 B-GENE
transcription O
through O
the O
cell O
cycle O
. O

Biol O
. O

Patient O
characteristics O
associated O
with O
deep O
wounds O
as O
well O
as O
patient O
and O
wound O
characteristics O
predictive O
of O
the O
extent O
of O
healing O
and O
time O
required O
for O
healing O
were O
identified O
. O

Yeast O
mutants O
lacking O
a O
functional O
NOP1 B-GENE
gene I-GENE
can O
be O
complemented O
by O
human B-GENE
fibrillarin I-GENE
but O
are O
temperature O
sensitive O
for O
growth O
and O
impaired O
in O
pre O
- O
rRNA O
processing O
. O

The O
patients O
were O
divided O
into O
ischaemia O
and O
non O
- O
ischaemia O
groups O
on O
the O
basis O
of O
the O
change O
in O
lactate O
extraction O
ratio O
during O
balloon O
inflation O
. O

Both O
immunophilins B-GENE
may O
have O
important O
roles O
in O
receptor O
assembly O
and O
may O
represent O
a O
new O
category O
of O
ligand O
- O
and O
calcium O
- O
dependent O
modulators O
of O
protein O
function O
. O

Umweltchem O
. O

Contrary O
to O
expectations O
, O
we O
find O
a O
relatively O
high O
level O
of O
variation O
in O
the O
stripe B-GENE
2 I-GENE
enhancer O
region O
, O
including O
point O
substitutions O
and O
insertion O
/ O
deletions O
in O
binding O
sites O
, O
and O
a O
comparable O
level O
of O
variation O
in O
the O
other O
noncoding O
regions O
. O

I O
report O
here O
that O
induction O
of O
HSP82 B-GENE
is O
regulated O
by O
the O
early O
meiotic O
IME1 B-GENE
- O
IME2 B-GENE
transcriptional O
cascade O
. O

Refugees O
living O
in O
Lund O
and O
repatriated O
to O
Chile O
considered O
their O
health O
as O
bad O
in O
a O
higher O
proportion O
than O
their O
Swedish O
counterparts O
, O
with O
an O
odds O
ratio O
of O
3 O
. O
48 O
( O
2 O
. O
03 O
- O
5 O
. O
66 O
) O
and O
4 O
. O
78 O
( O
2 O
. O
1 O
- O
10 O
. O
25 O
) O
respectively O
. O

This O
study O
underlines O
the O
importance O
of O
terminal O
SC5b B-GENE
- I-GENE
9 I-GENE
complement I-GENE
complex I-GENE
as O
a O
suitable O
marker O
in O
the O
evaluation O
of O
complement O
activation O
during O
cardiopulmonary O
bypass O
. O

Striking O
sequence O
similarities O
( O
57 O
and O
53 O
% O
) O
were O
observed O
with O
yeast O
mitochondrial O
proteins O
, O
SMF1 B-GENE
and O
SMF2 B-GENE
, O
especially O
within O
putative O
functional O
domains O
: O
exon O
6 O
encoding O
the O
second O
transmembrane O
spanning O
domain O
, O
site O
of O
the O
murine B-GENE
susceptibility I-GENE
mutation O
; O
and O
exon O
11 O
encoding O
a O
conserved O
transport O
motif O
. O

Furthermore O
, O
we O
have O
identified O
a O
soluble O
form O
of O
ERp57 B-GENE
/ O
GRP58 B-GENE
by O
Western O
blotting O
and O
biosynthetic O
labeling O
. O

Consistent O
with O
the O
hepatic O
and O
epidermal O
expression O
of O
histidase B-GENE
, O
this O
finding O
suggests O
that O
histidase B-GENE
transcription O
may O
be O
regulated O
by O
these O
factors O
. O

Unlike O
ARF B-GENE
, O
the O
ARP B-GENE
immunoreactivity O
was O
detected O
in O
plasma O
membranes O
but O
not O
in O
cytosol O
of O
fractionated O
3T3 O
- O
L1 O
cells O
. O

An O
infectious O
origin O
should O
always O
be O
excluded O
since O
specific O
etiologic O
therapy O
may O
be O
implemented O
. O

All O
three O
NR B-GENE
isoforms I-GENE
are O
expressed O
in O
cv O
. O

All O
three O
NR B-GENE
isoforms O
are O
expressed O
in O
cv O
. O

The O
Arabidopsis B-GENE
FAD7 I-GENE
gene I-GENE
encodes O
a O
chloroplast B-GENE
omega I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
desaturase I-GENE
that O
catalyzes O
the O
desaturation O
of O
lipid O
- O
linked O
dienoic O
fatty O
acids O
( O
18 O
: O
2 O
and O
16 O
: O
2 O
) O
. O

Certain O
transcript O
patterns O
in O
Epifagus O
plastids O
are O
highly O
complex O
and O
similar O
to O
those O
of O
tobacco O
operons O
. O

The O
XS2 B-GENE
gene I-GENE
down O
- O
regulates O
but O
does O
not O
abolish O
expression O
of O
LU B-GENE
genes I-GENE
and O
does O
not O
affect O
expression O
of O
CD44 B-GENE
. O

Diabetes O
care O
: O
a O
guideline O
to O
the O
facilities O
needed O
to O
support O
internationally O
endorsed O
standards O
. O

The O
gene O
was O
uniquely O
mapped O
with O
odds O
> O
1 O
, O
000 O
: O
1 O
on O
chromosome O
3p O
in O
Centre O
d O
' O
Etude O
du O
Polymorphisme O
Humain O
pedigrees O
. O

Human B-GENE
LAF I-GENE
- I-GENE
4 I-GENE
readily O
hybridized O
with O
genes O
in O
mouse O
and O
chicken O
, O
thus O
showing O
that O
this O
gene O
family O
has O
been O
highly O
conserved O
during O
vertebrate O
evolution O
. O

Cycles O
were O
repeated O
every O
3 O
weeks O
. O

Upstream O
of O
- O
37 O
, O
the O
5 O
' O
untranslated O
sequences O
of O
the O
isolates O
differ O
in O
both O
length O
and O
sequence O
. O

SBF B-GENE
binds O
to O
the O
promoter O
prior O
to O
the O
activation O
of O
transcription O
in O
late O
G1 O
, O
suggesting O
that O
Cln B-GENE
/ O
Cdc28 B-GENE
kinase O
regulates O
the O
ability O
of O
previously O
bound O
SBF B-GENE
to O
activate O
transcription O
. O

However O
, O
it O
remains O
an O
open O
question O
whether O
vertebrate B-GENE
Hox I-GENE
genes I-GENE
expressed O
under O
the O
control O
of O
Drosophila O
regulatory O
sequences O
can O
substitute O
the O
function O
of O
Drosophila B-GENE
Hox I-GENE
genes I-GENE
. O

This O
approach O
places O
gHoxb B-GENE
- I-GENE
1 I-GENE
into O
the O
normal O
embryonic O
spatiotemporal O
context O
in O
which O
lab O
acts O
. O

We O
propose O
that O
CTS1 B-GENE
and I-GENE
CTS2 I-GENE
of I-GENE
Ci I-GENE
are O
members O
of O
two O
distinct O
classes O
of O
fungal B-GENE
chitinases I-GENE
, O
an O
observation O
not O
previously O
reported O
for O
a O
single O
fungus O
. O

The O
purpose O
of O
the O
study O
reported O
here O
was O
to O
investigate O
whether O
differences O
in O
T1 O
and O
T2 O
between O
tumors O
are O
mainly O
a O
consequence O
of O
differences O
in O
the O
fractional O
volume O
of O
the O
extracellular O
compartment O
. O

A O
mutant B-GENE
areA I-GENE
product I-GENE
truncated O
immediately O
after O
the O
last O
residue O
of O
the O
highly O
conserved O
GATA B-GENE
( I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
) I-GENE
domain I-GENE
retains O
partial O
function O
. O

This O
region O
contains O
a O
motif O
with O
partial O
identity O
with O
the O
binding O
site O
for O
the O
ubiquitous O
transcription O
factor O
upstream B-GENE
stimulatory I-GENE
factor I-GENE
( O
USF B-GENE
) O
, O
which O
binds O
to O
the O
human B-GENE
insulin I-GENE
promoter I-GENE
. O

The O
Clb5 B-GENE
kinase I-GENE
, O
which O
promotes O
S O
phase O
, O
remains O
active O
during O
the O
G2 O
- O
phase O
arrest O
of O
cells O
of O
the O
parental O
strain O
, O
but O
its O
activity O
declines O
rapidly O
in O
sim B-GENE
mutants I-GENE
. O

The O
C O
/ O
D O
ratio O
was O
equal O
to O
or O
over O
0 O
. O
6 O
in O
9 O
cases O
( O
16 O
eyes O
) O
, O
and O
the O
values O
were O
inconsistent O
between O
both O
eyes O
in O
55 O
% O
of O
the O
patients O
. O

( O
1989 O
) O
, O
which O
is O
identical O
to O
the O
SSC1 B-GENE
gene I-GENE
( O
Smith O
et O
al O
. O
, O
1988 O
) O
. O

This O
region O
also O
contains O
a O
gene O
specifying O
a O
Leu B-GENE
- I-GENE
tRNA I-GENE
precursor I-GENE
and O
a O
remnant O
of O
a O
tau O
element O
. O

Occupational O
exposure O
to O
hepatitis O
B O
virus O
and O
human O
immunodeficiency O
virus O
: O
a O
comparative O
risk O
analysis O
. O

In O
these O
constructs O
, O
GUS B-GENE
expression O
was O
driven O
by O
promoter O
regions O
derived O
from O
the O
Arabidopsis B-GENE
alcohol I-GENE
dehydrogenase I-GENE
( O
Adh1 B-GENE
) O
, O
maize B-GENE
ubiquitin I-GENE
( O
Ubi1 B-GENE
) O
, O
rice B-GENE
actin I-GENE
( O
Act1 B-GENE
) O
and O
CaMV B-GENE
35S I-GENE
genes I-GENE
. O

Its O
organization O
and O
regulation O
indicate O
that O
the O
S B-GENE
. I-GENE
pombe I-GENE
URA1 I-GENE
gene I-GENE
product I-GENE
appears O
very O
similar O
to O
the O
S B-GENE
. I-GENE
cerevisiae I-GENE
URA2 I-GENE
gene I-GENE
product I-GENE
. O

( O
ii O
) O
opening O
of O
KATP O
attenuates O
, O
inhibition O
of O
the O
channel O
exacerbates O
functional O
consequences O
of O
coronary O
occlusion O
, O
and O
( O
iii O
) O
KATP O
opening O
attenuates O
reperfusion O
- O
induced O
VF O
, O
but O
it O
triggers O
ischemia O
- O
induced O
VF O
. O

Effects O
of O
repeated O
exposures O
of O
hydrogen O
sulphide O
on O
rat O
hippocampal O
EEG O
. O

Pseudomembranous O
conjunctivitis O
following O
bone O
marrow O
transplantation O
: O
immunopathological O
and O
ultrastructural O
study O
of O
one O
case O
. O

In O
view O
of O
the O
presence O
of O
SECIS O
elements O
in O
the O
open O
reading O
frames O
( O
ORFs O
) O
of O
bacterial B-GENE
selenoproteins I-GENE
, O
we O
examine O
the O
effects O
in O
the O
type B-GENE
1 I-GENE
deiodinase I-GENE
of O
extending O
the O
ORF O
into O
the O
SECIS O
element O
, O
and O
find O
that O
this O
dramatically O
inhibits O
SECIS O
function O
. O

This O
spindle O
defect O
of O
pds1 B-GENE
mutants I-GENE
results O
from O
a O
temperature O
- O
sensitive O
step O
that O
occurs O
around O
the O
G1 O
/ O
S O
boundary O
about O
the O
time O
of O
spindle O
assembly O
. O

In O
the O
point O
mutant O
we O
observed O
normal O
repair O
of O
endonuclease B-GENE
III I-GENE
site I-GENE
( O
i O
. O
e O
. O
as O
wild O
type O
) O
, O
but O
no O
removal O
of O
CPDs O
at O
the O
MAT B-GENE
alpha I-GENE
and O
HML B-GENE
alpha I-GENE
loci I-GENE
. O

However O
, O
for O
the O
evaluable O
cases O
, O
the O
performances O
of O
the O
CD3500 O
and O
the O
STKS O
were O
broadly O
similar O
and O
generally O
correlated O
well O
with O
the O
manual O
reference O
procedure O
. O

In O
conclusion O
, O
IgM B-GENE
class O
CIC O
is O
the O
predominant O
CIC O
in O
acute O
hepatitis O
A O
and O
correlated O
with O
disease O
activity O
. O

Left O
atrial O
volumes O
were O
greater O
in O
old O
compared O
with O
young O
subjects O
( O
maximal O
: O
31 O
+ O
/ O
- O
10 O
cm3 O
/ O
m2 O
vs O
24 O
+ O
/ O
- O
8 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
02 O
; O
at O
onset O
of O
atrial O
systole O
: O
23 O
+ O
/ O
- O
8 O
cm3 O
/ O
m2 O
vs O
15 O
+ O
/ O
- O
5 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
0002 O
; O
minimal O
: O
13 O
+ O
/ O
- O
5 O
cm3 O
/ O
m2 O
vs O
9 O
+ O
/ O
- O
4 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
001 O
) O
. O

We O
observed O
abundant O
levels O
of O
Rev B-GENE
- O
erbA B-GENE
alpha I-GENE
mRNA O
in O
dividing O
C2C12 O
myoblasts O
, O
which O
were O
suppressed O
when O
the O
cells O
differentiated O
into O
postmitotic O
multinucleated O
myotubes O
. O

We O
then O
demonstrated O
that O
1 O
) O
GAL4 B-GENE
- O
REV B-GENE
- O
erbA B-GENE
alpha I-GENE
chimeras O
that O
contain O
the O
' O
AB O
' O
region O
and O
lack O
the O
' O
E O
' O
region O
activated O
transcription O
of O
GAL4 B-GENE
response I-GENE
elements I-GENE
in O
the O
presence O
of O
8 O
- O
Br O
- O
cAMP O
and O
2 O
) O
the O
ligand O
- O
binding O
domain O
( O
LBD O
) O
contains O
an O
active O
transcriptional O
silencer O
. O

TNF B-GENE
Treatment O
of O
cell O
activated O
the O
p38 B-GENE
MAP I-GENE
kinase I-GENE
pathway O
, O
as O
revealed O
by O
increased O
phosphorylation O
of O
p38 B-GENE
MAP I-GENE
kinase I-GENE
itself O
, O
activation O
of O
the O
substrate O
protein O
MAPKAP B-GENE
kinase I-GENE
- I-GENE
2 I-GENE
, O
and O
culminating O
in O
the O
phosphorylation O
of O
the O
heat B-GENE
shock I-GENE
protein I-GENE
27 I-GENE
( O
hsp27 B-GENE
) O
. O

However O
, O
while O
the O
sequence O
similarity O
between O
the O
membrane O
exons O
of O
avian B-GENE
mIgY I-GENE
and O
mammalian B-GENE
mIgG I-GENE
and I-GENE
IgE I-GENE
is O
striking O
, O
the O
overall O
similarity O
with O
Xenopus B-GENE
mIgY I-GENE
is O
very O
low O
. O

The O
novel O
hematopoietic B-GENE
growth I-GENE
factor I-GENE
FLT3 I-GENE
ligand I-GENE
( O
FL B-GENE
) O
is O
the O
cognate O
ligand O
for O
the O
FLT3 B-GENE
, O
tyrosine B-GENE
kinase I-GENE
receptor I-GENE
( O
R B-GENE
) O
, O
also O
referred O
to O
as O
FLK B-GENE
- I-GENE
2 I-GENE
and O
STK B-GENE
- I-GENE
1 I-GENE
. O

In O
contrast O
to O
the O
selective O
expression O
of O
the O
receptor O
, O
FL B-GENE
expression O
was O
detected O
in O
90 O
- O
100 O
% O
of O
the O
various O
cell O
types O
of O
leukemia O
cell O
lines O
from O
all O
hematopoietic O
cell O
lineages O
. O

LY290181 O
appears O
to O
inhibit O
uPA B-GENE
promoter I-GENE
activation O
by O
blocking O
phorbol O
ester O
- O
stimulated O
binding O
of O
nuclear O
proteins O
to O
the O
uPA B-GENE
PEA3 B-GENE
/ O
12 O
- O
0 O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
responsive O
element O
( O
TRE O
) O
. O

The O
protein O
folds O
correctly O
with O
two O
disulfide O
bonds O
and O
a O
free O
thiol O
group O
at O
Cys25 O
. O

No O
significant O
differences O
existed O
between O
the O
two O
age O
groups O
in O
baseline O
characteristics O
, O
including O
treatment O
protocol O
, O
performance O
status O
, O
and O
serum B-GENE
lactate I-GENE
dehydrogenase I-GENE
( O
LDH B-GENE
) O
level O
. O

Conversely O
, O
when O
VDR B-GENE
is O
overexpressed O
, O
vitamin O
D3 O
attenuates O
9 O
- O
cis O
RA O
induction O
from O
an O
RXR B-GENE
- O
responsive O
element O
. O

Mutations O
within O
conserved O
region O
2 O
( O
CR2 O
) O
of O
E1A B-GENE
that O
inhibit O
the O
binding O
of O
E1A B-GENE
to O
the O
retinoblastoma B-GENE
gene I-GENE
product I-GENE
( O
pRb B-GENE
) O
further O
enhanced O
the O
stimulation O
of O
transcription O
from O
the O
PEPCK B-GENE
promoter I-GENE
by O
2 O
3 O
- O
fold O
compared O
with O
wild B-GENE
type I-GENE
E1A I-GENE
. O

Using O
autoantibodies O
from O
a O
Sjogren O
' O
s O
syndrome O
patient O
, O
we O
have O
previously O
identified O
a O
230 O
- O
kDa O
peripheral O
membrane O
protein O
associated O
with O
the O
cytosolic O
face O
of O
the O
trans O
- O
Golgi O
( O
Kooy O
, O
J O
. O
, O
Toh O
, O
B O
. O

Apart O
from O
two O
proline O
- O
rich O
regions O
( O
amino O
acids O
1 O
- O
117 O
and O
239 O
- O
270 O
) O
, O
p230 B-GENE
contains O
a O
very O
high O
frequency O
of O
heptad O
repeats O
, O
characteristic O
of O
alpha O
- O
helices O
that O
form O
dimeric O
coiled O
- O
coil O
structures O
. O
p230 B-GENE
also O
includes O
the O
sequence O
ESLALEELEL O
( O
amino O
acids O
538 O
- O
546 O
) O
, O
a O
motif O
found O
in O
the O
granin B-GENE
family I-GENE
of O
acidic O
proteins O
present O
in O
secretory O
granules O
of O
neuroendocrine O
cells O
. O

They O
were O
found O
to O
stimulate O
at O
nanomolar O
concentrations O
the O
turnover O
of O
biosynthetically O
labeled O
ceramide O
, O
glucosylceramide O
, O
and O
lactosylceramide O
. O

These O
findings O
suggest O
that O
the O
increase O
in O
V O
O2 O
may O
have O
been O
a O
consequence O
of O
the O
increase O
in O
Q O
O2 O
rather O
than O
a O
response O
to O
the O
procedure O
itself O
. O

Consistent O
with O
ErbB B-GENE
- I-GENE
2 I-GENE
being O
a O
shared O
receptor O
subunit O
, O
its O
tyrosine O
phosphorylation O
was O
increased O
by O
both O
heterologous O
ligands O
and O
it O
mediated O
a O
trans O
- O
inhibitory O
effect O
of O
NDF B-GENE
on O
EGF B-GENE
binding O
. O

Identification O
of O
a O
consensus O
cyclin B-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
phosphorylation I-GENE
site I-GENE
unique O
to O
the O
nuclear O
form O
of O
human B-GENE
deoxyuridine I-GENE
triphosphate I-GENE
nucleotidohydrolase I-GENE
. O

VDR B-GENE
/ O
RXR B-GENE
bound O
well O
to O
the O
VDREs O
and O
to O
DR4 O
and O
DR5 O
using O
the O
electrophoretic O
mobility O
shift O
assay O
. O

The O
sequence O
and O
isolated O
cDNAs O
will O
provide O
useful O
reagents O
for O
studying O
the O
expression O
of O
Brca1 B-GENE
in O
the O
mouse O
, O
and O
for O
testing O
the O
importance O
of O
the O
evolutionarily O
conserved O
domains O
. O

A O
study O
was O
performed O
to O
compare O
the O
ONLINE O
and O
EMIT O
II O
immunoassays O
with O
gas O
chromatographic O
/ O
mass O
spectrometric O
( O
GC O
/ O
MS O
) O
analysis O
of O
methaqualone O
metabolites O
on O
urine O
using O
samples O
obtained O
from O
a O
clinical O
study O
. O

Isolation O
by O
PCR O
of O
a O
cDNA O
clone O
from O
pea O
petals O
with O
similarity O
to O
petunia O
and O
wheat B-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

Exposure O
of O
peripheral O
blood O
T O
cells O
from O
young O
subjects O
to O
PHA B-GENE
or O
cross O
- O
linked O
anti B-GENE
- I-GENE
CD3 I-GENE
monoclonal I-GENE
antibodies I-GENE
stimulated O
rapid O
increases O
in O
MAPK B-GENE
and O
MEK B-GENE
enzymatic O
activity O
. O

Deletion O
analysis O
of O
rOC B-GENE
promoter I-GENE
- O
chloramphenicol B-GENE
acetyltransferase I-GENE
constructs O
demonstrates O
that O
an O
AML B-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
within O
the O
proximal O
promoter O
( O
- O
138 O
to O
- O
130 O
nt O
) O
contributes O
to O
75 O
% O
of O
the O
level O
of O
osteocalcin B-GENE
gene I-GENE
expression O
. O

Escherichia O
coli O
BL21 O
( O
DE3 O
) O
plysS O
, O
harbouring O
a O
recombinant O
plasmid O
containing O
the O
catalase B-GENE
- O
peroxidase B-GENE
gene O
, O
produced O
a O
large O
amount O
of O
proteins O
that O
co O
- O
migrated O
on O
SDS O
/ O
PAGE O
with O
the O
native O
enzyme O
. O

Cdk2 B-GENE
formed O
a O
complex O
with O
cyclin B-GENE
D1 I-GENE
in O
this O
system O
. O

The O
Cdk2 B-GENE
- O
cyclin B-GENE
- I-GENE
D1 I-GENE
complex O
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 B-GENE
histone I-GENE
, O
pRB B-GENE
, O
SV40 B-GENE
large I-GENE
T I-GENE
antigen I-GENE
, O
p53 B-GENE
, O
E2F B-GENE
- I-GENE
1 I-GENE
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 B-GENE
- O
cyclin B-GENE
- I-GENE
E I-GENE
and O
Cdk2 B-GENE
- O
cyclin B-GENE
- I-GENE
A I-GENE
phosphorylated O
these O
proteins O
. O

Cyclin B-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
( O
Cdk2 B-GENE
) O
forms O
an O
inactive O
complex O
with O
cyclin B-GENE
D1 I-GENE
since O
Cdk2 B-GENE
associated O
with O
cyclin B-GENE
D1 I-GENE
is O
not O
phosphorylated O
by O
Cdk7 B-GENE
- O
cyclin B-GENE
- I-GENE
H I-GENE
. O

A O
human O
cytoplasmic O
signaling O
protein O
has O
been O
cloned O
that O
possesses O
the O
same O
structural O
arrangement O
of O
SH3 B-GENE
- O
SH2 B-GENE
- O
SH3 B-GENE
domains O
as O
Grb2 B-GENE
. O

Cloning O
of O
individual O
ZI O
domains O
upstream O
of O
a O
minimal O
promoter O
demonstrated O
that O
the O
ZIA O
, O
ZIC O
, O
and O
ZID O
domains O
, O
but O
not O
the O
ZIB O
domain O
, O
are O
TPA O
responsive O
. O

Sp1 B-GENE
binds O
two O
sites O
in O
the O
CD11c B-GENE
promoter I-GENE
in O
vivo O
specifically O
in O
myeloid O
cells O
and O
cooperates O
with O
AP1 B-GENE
to O
activate O
transcription O
. O

We O
found O
that O
120 O
bp O
of O
the O
enhancer O
' O
s O
transcriptional O
core O
becomes O
DNase B-GENE
I I-GENE
hypersensitive O
early O
in O
B O
- O
cell O
development O
. O

A O
developmentally O
modulated O
chromatin O
structure O
at O
the O
mouse B-GENE
immunoglobulin I-GENE
kappa I-GENE
3 I-GENE
' I-GENE
enhancer I-GENE
. O

Heme B-GENE
oxygenase I-GENE
1 I-GENE
is O
an O
essential O
enzyme O
in O
heme O
catabolism O
that O
cleaves O
heme O
to O
form O
biliverdin O
, O
iron O
, O
and O
carbon O
monoxide O
. O

An O
inactive O
analog O
of O
wortmannin O
, O
WM12 O
, O
did O
not O
affect O
TCR B-GENE
/ O
CD3 B-GENE
- O
induced O
Erk2 B-GENE
activation O
, O
and O
wortmannin O
had O
no O
effect O
on O
the O
activity O
of O
Erk2 B-GENE
when O
added O
directly O
to O
the O
in O
vitro O
assays O
. O

Defects O
in O
the O
Schizosaccharomyces O
pombe O
( O
Sp O
) O
cell O
cycle O
- O
controlling O
genes O
prevent O
the O
cell O
cycle O
progression O
. O

To O
determine O
the O
signal B-GENE
recognition I-GENE
particle I-GENE
( O
SRP B-GENE
) O
- O
SRP B-GENE
receptor I-GENE
( O
Srb B-GENE
) O
system O
in O
Bacillus O
subtilis O
( O
Bs O
) O
, O
we O
cloned O
the O
Bs B-GENE
srb I-GENE
gene I-GENE
, O
which O
encodes O
a O
homologue O
of O
the O
mammalian B-GENE
SRP I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
[ O
Oguro O
et O
al O
. O
, O
DNA O
Res O
. O

Promoter O
activity O
was O
high O
in O
cell O
lines O
that O
expressed O
high O
levels O
of O
endogenous O
D3 B-GENE
mRNA I-GENE
, O
as O
indicated O
by O
Northern O
blot O
analyses O
, O
and O
was O
significantly O
reduced O
when O
the O
promoter O
was O
truncated O
to O
- O
122 O
bp O
. O

This O
phenomenon O
did O
not O
require O
DNA O
binding O
by O
the O
" O
interfering O
" O
receptor O
but O
required O
it O
to O
be O
hormone O
- O
bound O
, O
indicating O
that O
a O
transcriptionally O
active O
form O
of O
the O
interfering O
receptor O
is O
essential O
for O
the O
interfering O
effect O
. O

A O
cis O
- O
acting O
DNA O
element O
located O
between O
TATA O
box O
and O
transcription O
initiation O
site O
is O
critical O
in O
response O
to O
regulatory O
sequences O
in O
human O
angiotensinogen B-GENE
gene I-GENE
. O

The O
promoter O
of O
the O
rat B-GENE
PGS I-GENE
- I-GENE
2 I-GENE
gene I-GENE
contains O
a O
CAAT B-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
consensus I-GENE
site I-GENE
( I-GENE
CAAT I-GENE
box I-GENE
) I-GENE
which O
can O
confer O
hormone O
inducibility O
to O
a O
PGS B-GENE
- I-GENE
2 I-GENE
. O
CAT B-GENE
reporter O
gene O
, O
as O
well O
as O
a O
putative O
E O
- O
box O
region O
. O

SETTING O
- O
- O
Delhi O
, O
urban O
India O
, O
1985 O
- O
6 O
. O

Selective O
translation O
initiation O
by O
ribosome O
jumping O
in O
adenovirus O
- O
infected O
and O
heat O
- O
shocked O
cells O
. O

Furthermore O
, O
we O
have O
identified O
a O
43 O
- O
bp O
region O
of O
the O
24p3 B-GENE
promoter I-GENE
required O
for O
the O
Dex O
responsiveness O
. O

Our O
data O
demonstrate O
directly O
that O
Rpm1r B-GENE
is O
transcribed O
with O
its O
substrates O
, O
tRNA B-GENE
met I-GENE
f I-GENE
and O
tRNAPro B-GENE
, O
from O
a O
promoter O
located O
upstream O
of O
the O
tRNA B-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
suggest O
that O
a O
portion O
also O
originates O
from O
a O
second O
promoter O
, O
located O
between O
the O
tRNA B-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
RPM1 B-GENE
. O

Furthermore O
, O
strains O
with O
mutant B-GENE
RPM1 I-GENE
genes I-GENE
also O
accumulate O
precursor B-GENE
Rpm1r I-GENE
, O
suggesting O
that O
mutations O
in O
either O
gene O
can O
lead O
to O
similar O
biogenesis O
defects O
. O

Merlie O
, O
Cold O
Spring O
Harbor O
Symp O
. O

Substantial O
evidence O
supports O
a O
critical O
role O
for O
the O
activation O
of O
the O
Raf B-GENE
- I-GENE
1 I-GENE
/ O
MEK B-GENE
/ O
mitogen B-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
in O
oncogenic O
Ras B-GENE
- O
mediated O
transformation O
. O

Stylohyoid O
chain O
ossification O
: O
choice O
of O
the O
surgical O
approach O
. O

63 O
. O
3 O
micromol O
/ O
1 O
, O
p O
< O
0 O
. O
01 O
) O
and O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
extrapolated O
to O
infinity O
AUC O
9 O
( O
0 O
- O
infinity O
) O
( O
518 O
. O
7 O
vs O
. O

Mean O
increase O
of O
milk O
protein O
yield O
was O
46 O
g O
/ O
d O
with O
Met O
plus O
Lys O
, O
and O
mean O
increase O
of O
true O
protein O
content O
was O
1 O
. O
1 O
g O
/ O
kg O
of O
milk O
. O

A O
chimeric O
VP16 B-GENE
- O
Tat B-GENE
construct O
containing O
the O
leucine O
mutations O
showed O
no O
increased O
AP B-GENE
- I-GENE
1 I-GENE
responsiveness O
in O
comparison O
with O
that O
of O
the O
VP16 B-GENE
activation I-GENE
domain I-GENE
alone O
. O

Despite O
significant O
lethality O
and O
cardiovascular O
dysfunction O
, O
in O
the O
septic O
group O
on O
Days O
1 O
and O
2 O
, O
septic O
versus O
control O
animals O
had O
no O
significant O
differences O
in O
mean O
metabolic O
cart O
measured O
( O
Vo2DIR O
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
9 O
versus O
12 O
. O
4 O
, O
p O
= O
0 O
. O
81 O
; O
Day O
2 O
: O
14 O
. O
2 O
versus O
13 O
. O
5 O
, O
p O
= O
0 O
. O
72 O
, O
respectively O
) O
and O
intravascular O
catheter O
calculated O
( O
Vo2INDIR O
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
2 O
versus O
11 O
. O
2 O
, O
p O
= O
0 O
. O
99 O
; O
Day O
2 O
: O
12 O
. O
8 O
versus O
15 O
. O
4 O
, O
p O
= O
0 O
. O
49 O
, O
respectively O
) O
. O

Although O
IL B-GENE
- I-GENE
2 I-GENE
and O
IFN B-GENE
- I-GENE
alpha I-GENE
activated O
STAT1 B-GENE
alpha I-GENE
and O
STAT5 B-GENE
, O
IL B-GENE
- I-GENE
2 I-GENE
predominantly O
activated O
STAT5 B-GENE
, O
while O
IFN B-GENE
- I-GENE
alpha I-GENE
predominantly O
activated O
STAT1 B-GENE
alpha I-GENE
. O

One O
complex O
containing O
a O
70 O
D O
protein O
was O
found O
to O
be O
associated O
specifically O
with O
transcriptionally O
active O
leukemia O
cells O
. O

Our O
results O
confirm O
the O
participation O
of O
intron O
1 O
in O
transcriptional O
regulation O
of O
the O
c B-GENE
- I-GENE
myb I-GENE
gene I-GENE
( O
in O
mouse O
and O
human O
) O
and O
implicate O
multiple O
and O
complex O
regulatory O
mechanisms O
of O
activation O
during O
myelomonocytic O
differentiation O
and O
leukemic O
cell O
growth O
control O
. O

Limited O
role O
for O
PCR O
- O
based O
diagnosis O
of O
Whipple O
' O
s O
disease O
from O
peripheral O
blood O
mononuclear O
cells O
. O

The O
Pro O
- O
258 O
- O
- O
> O
Leu O
( O
P258L O
) O
mutation O
caused O
constitutive O
receptor O
signaling O
that O
was O
equivalent O
to O
about O
45 O
% O
of O
the O
maximum O
level O
observed O
in O
wild O
- O
type O
cells O
stimulated O
with O
alpha B-GENE
- I-GENE
factor I-GENE
. O

CONCLUSIONS O
: O
Our O
findings O
suggest O
that O
pre O
- O
treatment O
with O
coenzyme O
Q10 O
may O
play O
a O
protective O
role O
during O
routine O
vascular O
procedures O
requiring O
abdominal O
aortic O
cross O
clamping O
by O
attenuating O
the O
degree O
of O
peroxidative O
damage O
. O

In O
a O
screen O
for O
genes O
with O
oncogenic O
potential O
expressed O
by O
the O
murine O
B6SUtA1 O
myeloid O
progenitor O
cell O
line O
, O
we O
isolated O
a O
2 O
. O

The O
mechanism O
involves O
Gbetagamma B-GENE
subunit O
- O
mediated O
increases O
in O
tyrosine O
phosphorylation O
of O
the O
Shc B-GENE
adapter I-GENE
protein I-GENE
, O
Shc B-GENE
* O
Grb2 B-GENE
complex O
formation O
, O
and O
recruitment O
of O
Ras B-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
activity O
. O

The O
cis O
- O
acting O
elements O
that O
control O
promoter O
activity O
include O
binding O
sites O
for O
transcription O
factors O
Sp1 B-GENE
and O
alphaCbf B-GENE
, O
a O
60 B-GENE
- I-GENE
kDa I-GENE
CCAAT I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

There O
was O
a O
general O
broadening O
of O
proton O
resonances O
for O
a O
three O
- O
nucleotide O
segment O
centered O
about O
the O
lesion O
site O
which O
resulted O
in O
a O
tentative O
assignment O
for O
the O
sugar O
protons O
of O
the O
C7 O
residue O
in O
the O
spectrum O
of O
the O
adduct O
duplex O
. O

Using O
immunogold O
electron O
microscopy O
, O
we O
found O
that O
p58 B-GENE
/ O
p45 B-GENE
and O
p54 B-GENE
are O
localized O
on O
both O
sides O
of O
the O
nuclear O
pore O
complex O
, O
like O
p62 B-GENE
. O

Transcription O
initiation O
sites O
of O
the O
rat O
II B-GENE
beta I-GENE
- I-GENE
, I-GENE
III I-GENE
beta I-GENE
, I-GENE
and I-GENE
O I-GENE
beta I-GENE
- I-GENE
globin I-GENE
genes O
were O
determined O
to O
be O
52 O
base O
pairs O
( O
bp O
) O
5 O
' O
- O
upstream O
of O
the O
translation O
initiation O
codon O
( O
ATG O
) O
, O
in O
each O
gene O
by O
primer O
extension O
analysis O
. O

Aggravating O
process O
induced O
by O
indomethacin O
on O
chronic O
gastric O
lesion O
in O
rat O
. O

We O
have O
been O
studying O
the O
interaction O
of O
the O
oncogenic O
human O
polyomavirus O
BK O
( O
BKV O
) O
with O
the O
tumor B-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
to O
understand O
the O
biology O
of O
this O
virus O
as O
well O
as O
to O
understand O
the O
basic O
mechanisms O
of O
p53 B-GENE
transactivation O
. O

Site O
S O
- O
II O
also O
spans O
a O
23 O
bp O
sequence O
containing O
two O
tandem O
consensus O
binding O
sites O
with O
three O
base O
pair O
mismatches O
in O
each O
and O
a O
one O
base O
pair O
deletion O
. O

Unaided O
attempts O
to O
quit O
smoking O
are O
generally O
unsuccessful O
. O

The O
experience O
of O
the O
lateral O
rhinotomy O
approach O
in O
transsphenoidal O
surgery O
of O
acromegaly O
has O
been O
favourable O
. O

Possible O
relationship O
between O
hyperinsulinemia O
and O
glomerular O
hypertrophy O
in O
nephrosclerosis O
. O

Blood O
GSH B-GENE
- I-GENE
Px I-GENE
activity O
was O
measured O
with O
a O
spectrophotometer O
, O
using O
a O
modification O
of O
a O
previously O
described O
assay O
. O

The O
concentrations O
of O
vitamin O
A O
precursors O
and O
vitamin O
E O
in O
the O
hay O
were O
below O
currently O
recommended O
dietary O
levels O
for O
llamas O
, O
and O
alfalfa O
hay O
appears O
to O
provide O
an O
unreliable O
source O
of O
vitamins O
A O
and O
E O
in O
this O
species O
. O

Eight O
cats O
infected O
with O
H O
. O
pylori O
were O
used O
in O
the O
study O
. O

However O
, O
as O
determined O
by O
PCR O
with O
primers O
specific O
for O
the O
26 O
- O
kDa O
product O
, O
the O
majority O
of O
cats O
at O
2 O
and O
4 O
weeks O
p O
. O
t O
. O
had O
gastric O
fluid O
samples O
which O
were O
positive O
for O
H O
. O
pylori O
and O
three O
of O
three O
cats O
at O
2 O
weeks O
p O
. O
t O
. O
had O
dental O
plaque O
which O
was O
positive O
for O
H O
. O
pylori O
. O

The O
most O
frequent O
causes O
of O
the O
meningitis O
was O
the O
external O
ventricular O
drainage O
( O
14 O
. O
8 O
% O
) O
, O
post O
- O
neurosurgical O
( O
0 O
. O
8 O
% O
) O
and O
head O
injury O
( O
0 O
. O
0007 O
% O
) O
. O

In O
vitro O
interaction O
studies O
, O
using O
proteins O
fused O
to O
glutathione B-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
, O
showed O
that O
RBP B-GENE
- I-GENE
J I-GENE
kappa I-GENE
and O
Su B-GENE
( I-GENE
H I-GENE
) I-GENE
bind O
directly O
to O
the O
RAM23 B-GENE
regions I-GENE
of O
mouse B-GENE
Notch1 I-GENE
and O
Drosophila B-GENE
Notch I-GENE
, O
respectively O
. O

Twelve O
genomic O
fragments O
containing O
novel O
response O
elements O
are O
described O
, O
and O
the O
transcription O
unit O
associated O
with O
one O
of O
them O
, O
NN B-GENE
- I-GENE
84AG I-GENE
, O
was O
characterized O
in O
detail O
. O

Members O
of O
the O
Ras B-GENE
subfamily I-GENE
of O
small B-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
have O
been O
shown O
to O
be O
promiscuous O
towards O
a O
variety O
of O
putative O
effector O
molecules O
such O
as O
the O
protein B-GENE
kinase I-GENE
c I-GENE
- I-GENE
Raf I-GENE
and O
the O
Ral B-GENE
- I-GENE
specific I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
Ral B-GENE
- I-GENE
GEF I-GENE
) O
. O

The O
cDNA O
encoded O
a O
mature O
protein O
of O
240 O
amino O
acids O
, O
including O
a O
29 O
- O
amino O
acid O
signal O
sequence O
. O

Biol O
. O

The O
effect O
of O
ligustrazine O
hydrochloride O
( O
LTH O
) O
on O
depressing O
pulmonary O
artery O
hypertension O
has O
been O
proved O
in O
recent O
studies O
. O

In O
the O
same O
period O
we O
pointed O
out O
an O
increase O
of O
hematocrit O
( O
from O
29 O
% O
to O
35 O
% O
) O
and O
of O
the O
Hb B-GENE
( O
from O
9 O
. O
3 O
to O
11 O
. O
2 O
g O
/ O
dl O
) O
. O

The O
structure O
of O
these O
genes O
suggests O
a O
common O
ancestor O
for O
all O
viperid B-GENE
PLA2 I-GENE
genes I-GENE
. O

Chloroplast B-GENE
mutator I-GENE
( O
chm B-GENE
) O
of O
Arabidopsis O
is O
a O
recessive O
nuclear O
mutation O
that O
causes O
green O
and O
white O
variegation O
in O
leaves O
and O
is O
inherited O
in O
a O
non O
- O
Mendelian O
fashion O
. O

Also O
like O
the O
thrombin B-GENE
receptor I-GENE
, O
PAR2 B-GENE
can O
be O
activated O
by O
the O
hexapeptide O
corresponding O
to O
its O
tethered O
ligand O
sequence O
independent O
of O
receptor O
cleavage O
. O

Such O
an O
increase O
in O
the O
steady O
- O
state O
testicular B-GENE
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
apparently O
is O
not O
the O
result O
of O
an O
up O
- O
regulation O
by O
germ O
cells O
because O
germ O
cells O
cocultured O
with O
Sertoli O
cells O
failed O
to O
elicit O
an O
increase O
in O
the O
Sertoli O
cell O
steady O
- O
state O
TIMP B-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
. O

In O
the O
SPK O
and O
PTA O
category O
, O
anti O
- O
T O
- O
cell O
therapy O
significantly O
lowered O
the O
risk O
of O
graft O
loss O
. O

Five O
- O
year O
survivals O
amounted O
to O
100 O
% O
, O
86 O
. O
2 O
% O
, O
59 O
. O
4 O
% O
, O
29 O
. O
8 O
% O
, O
and O
20 O
% O
for O
stages O
I O
, O
II O
, O
III O
, O
IVA O
and O
IVB O
respectively O
. O

Targeted O
disruption O
of O
the O
OGG1 B-GENE
gene I-GENE
in O
yeast O
revealed O
a O
second O
OG B-GENE
glycosylase I-GENE
/ I-GENE
lyase I-GENE
protein I-GENE
, O
tentatively O
named O
Ogg2 B-GENE
, O
which O
differs O
from O
Ogg1 B-GENE
in O
that O
it O
preferentially O
acts O
on O
OG O
: O
G O
. O

Sequence O
analysis O
of O
the O
isolated O
genomic O
clone O
revealed O
that O
the O
DNA O
binding O
domain O
of O
this O
orphan O
receptor O
is O
most O
homologous O
to O
the O
human B-GENE
TR2 I-GENE
receptor I-GENE
. O

Genomic O
DNA O
hybridization O
suggests O
that O
SpSHR2 B-GENE
is O
a O
single O
- O
copy O
gene O
in O
the O
S O
. O
purpuratus O
genome O
. O

Its O
hydropathy O
profile O
predicts O
seven O
transmembrane O
spans O
and O
a O
hydrophilic O
amino O
terminus O
of O
approximately O
100 O
residues O
, O
and O
it O
suggests O
the O
presence O
of O
an O
amphiphilic O
alpha O
- O
helix O
( O
L O
- O
61 O
to O
F O
- O
97 O
) O
in O
close O
proximity O
to O
the O
first O
strongly O
hydrophobic O
segment O
of O
ProW B-GENE
. O

There O
are O
four O
polyglutamine O
motifs O
interspersed O
with O
histidine O
- O
rich O
regions O
. O

Quantitative O
analysis O
of O
plasmid O
loss O
rates O
in O
cdc28 B-GENE
- I-GENE
1N I-GENE
strains O
carrying O
plasmids O
with O
multiple O
replication O
origins O
suggests O
that O
a O
defect O
in O
initiating O
DNA O
replication O
probably O
causes O
this O
plasmid O
loss O
phenotype O
. O

Platelet B-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
- O
dependent O
activation O
of O
phosphatidylinositol B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
is O
regulated O
by O
receptor O
binding O
of O
SH2 B-GENE
- I-GENE
domain I-GENE
- I-GENE
containing I-GENE
proteins I-GENE
which O
influence O
Ras B-GENE
activity O
. O

Almost O
complete O
sequence O
identity O
was O
found O
between O
the O
3 O
' O
end O
of O
the O
DXS6673E B-GENE
gene I-GENE
and O
two O
expressed O
sequence O
tags O
( O
ESTs O
) O
and O
between O
the O
5 O
' O
end O
of O
the O
DXS6673E B-GENE
gene I-GENE
and O
a O
third O
EST O
. O

Several O
of O
the O
exon O
boundaries O
correspond O
to O
the O
boundaries O
of O
functional O
domains O
in O
the O
p55 B-GENE
protein I-GENE
. O

Tristetraprolin B-GENE
( O
TTP B-GENE
) O
is O
the O
prototype O
of O
a O
group O
of O
potential O
transcription O
factors O
that O
contain O
two O
or O
more O
unusual O
CCCH O
zinc O
fingers O
. O

The O
ewes O
were O
returned O
to O
normoxia O
, O
and O
monitoring O
was O
continued O
for O
1 O
h O
. O

Feline O
leukemia O
viruses O
( O
FeLVs O
) O
, O
which O
are O
replication O
- O
competent O
oncoretroviruses O
of O
the O
domestic O
cat O
species O
, O
are O
contagiously O
transmitted O
in O
natural O
environments O
. O

Both O
verapamil O
and O
propranolol O
can O
exhibit O
additive O
effects O
with O
adenosine O
in O
prolonging O
AV O
nodal O
conduction O
time O
; O
however O
, O
only O
verapamil O
can O
reduce O
the O
dose O
of O
adenosine O
required O
to O
produce O
AV O
nodal O
block O
. O

RVR B-GENE
' O
loss O
of O
function O
' O
studies O
by O
constitutive O
over O
- O
expression O
of O
a O
dominant O
negative O
RVR B-GENE
delta I-GENE
E I-GENE
resulted O
in O
increased O
levels O
of O
p21Cip1 B-GENE
/ O
Waf1 B-GENE
and O
myogenin B-GENE
mRNAs I-GENE
after O
serum O
withdrawal O
. O

These O
two O
repeat O
motifs O
are O
organized O
in O
an O
extremely O
well O
- O
ordered O
pattern O
in O
each O
domain O
, O
which O
suggests O
that O
SbHRGP3 B-GENE
belongs O
to O
a O
new O
group O
of O
proteins O
having O
the O
repeat O
motifs O
of O
two O
distinct O
groups O
of O
dicot B-GENE
extensins I-GENE
. O

Two O
classes O
of O
inactive O
receptors O
were O
identified O
: O
one O
in O
which O
both O
transcriptional O
activation O
and O
dimerization O
were O
compromised O
and O
a O
second O
in O
which O
only O
transcriptional O
activation O
was O
abolished O
. O

Here O
we O
localize O
a O
transferable O
40 O
- O
amino O
acid O
region O
within O
the O
LBDs B-GENE
of O
RXR B-GENE
, O
RAR B-GENE
, O
TR B-GENE
, O
and O
chicken B-GENE
ovalbumin I-GENE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
that O
is O
critical O
for O
determining O
identity O
in O
the O
heterodimeric O
interaction O
and O
for O
high O
- O
affinity O
DNA O
binding O
. O

OKA O
and O
calyculin O
A O
do O
not O
decrease O
OCFRE B-GENE
DNA O
- O
protein O
interactions O
, O
suggesting O
that O
important O
protein O
- O
protein O
interactions O
are O
phosphatase O
regulated O
. O

IMPLICATIONS O
: O
Given O
the O
small O
size O
of O
this O
study O
and O
the O
inconsistency O
of O
results O
among O
the O
few O
prospective O
studies O
of O
ovarian O
cancer O
conducted O
to O
test O
these O
associations O
, O
replications O
of O
these O
findings O
are O
highly O
desirable O
. O

We O
have O
performed O
toeprinting O
analyses O
on O
repA B-GENE
mRNA I-GENE
of O
plasmid O
R1 O
, O
both O
free O
and O
in O
duplex O
with O
the O
antisense O
RNA O
, O
CopA B-GENE
. O

Previous O
work O
showed O
that O
repA B-GENE
( O
initiator O
protein O
) O
expression O
requires O
tap B-GENE
( O
leader O
peptide O
) O
translation O
. O

Tonsillectomy O
is O
an O
effective O
means O
of O
prophylaxis O
for O
upper O
respiratory O
infection O
in O
habitual O
angina O
patients O
. O

These O
results O
were O
corroborated O
in O
a O
subsequent O
study O
in O
which O
30 O
hypogonadal O
men O
were O
supplemented O
with O
SLT O
5 O
mg O
three O
times O
daily O
for O
6 O
months O
. O

The O
elevations O
achieved O
by O
LDEE O
given O
s O
. O
c O
. O
were O
higher O
than O
those O
achieved O
after O
i O
. O
p O
. O
administration O
and O
lasted O
for O
longer O
periods O
. O

Many O
human O
viruses O
are O
able O
to O
develop O
suitable O
strategies O
for O
modifying O
apoptosis O
in O
virus O
- O
infected O
cells O
and O
in O
virus O
- O
primed O
T O
cells O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
the O
C O
- O
terminal O
24 O
amino O
acids O
are O
sufficient O
for O
NodO B-GENE
secretion O
although O
the O
region O
adjacent O
to O
this O
domain O
appears O
to O
affect O
secretion O
efficiency O
. O

The O
model O
also O
predicts O
that O
blood O
flow O
shunt O
fraction O
( O
Qs O
/ O
QT O
) O
is O
directly O
related O
to O
the O
oxygen O
sine O
- O
wave O
amplitude O
perturbations O
transmitted O
to O
end O
- O
expired O
air O
and O
arterial O
and O
mixed O
- O
venous O
blood O
through O
two O
simple O
equations O
. O

Discrimination O
between O
HIV O
- O
1 O
and O
HIV O
- O
2 O
showed O
evidence O
for O
the O
presence O
of O
HIV O
- O
1 O
only O
. O

However O
, O
an O
intrinsic O
DNA O
- O
binding O
subunit O
for O
HiNF B-GENE
- I-GENE
D I-GENE
was O
not O
identified O
. O

The O
HiNF B-GENE
- I-GENE
D I-GENE
( O
CDP B-GENE
/ O
cut B-GENE
) O
complex O
with O
the O
H4 B-GENE
promoter I-GENE
is O
immunoreactive O
with O
antibodies O
against O
CDP B-GENE
/ O
cut B-GENE
and O
pRB B-GENE
but O
not O
p107 B-GENE
, O
whereas O
the O
CDP B-GENE
/ O
cut B-GENE
complex O
with O
a O
nonhistone O
promoter O
( O
gp91 B-GENE
- O
phox B-GENE
) O
reacts O
only O
with O
CDP B-GENE
and O
p107 B-GENE
antibodies O
. O

Eight O
- O
four O
ACOAs O
were O
tested O
in O
order O
to O
examine O
the O
fit O
of O
the O
model O
to O
the O
data O
by O
path O
analysis O
with O
LISREL O
VII O
. O

Using O
anchored O
PCR O
, O
a O
VL B-GENE
element I-GENE
rearranged O
to O
CL2 B-GENE
was O
isolated O
. O

A O
subset O
of O
these O
DMP1 B-GENE
recognition I-GENE
sequences I-GENE
containing O
a O
GGA O
trinucleotide O
core O
can O
also O
function O
as O
Ets B-GENE
- I-GENE
responsive I-GENE
elements I-GENE
. O

In O
both O
settings O
, O
it O
can O
be O
phosphorylated O
by O
cyclin B-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
suggesting O
that O
its O
transcriptional O
activity O
may O
normally O
be O
regulated O
through O
such O
mechanisms O
. O

Enterococcus O
faecium O
strains O
with O
vanA O
- O
mediated O
glycopeptide O
resistance O
were O
isolated O
by O
enrichment O
culture O
from O
the O
intestines O
and O
feces O
of O
several O
animal O
species O
, O
mainly O
horses O
and O
dogs O
( O
8 O
% O
positive O
) O
, O
chickens O
( O
7 O
% O
positive O
) O
, O
and O
pigs O
( O
6 O
% O
positive O
) O
. O

Oncogenic O
activation O
of O
the O
tyrosine B-GENE
kinase I-GENE
domain I-GENE
of O
the O
human B-GENE
trk I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
by O
fusion O
to O
a O
cell O
adhesion O
molecule O
. O

Physiol O
. O

They O
suggest O
that O
decreased O
steady O
- O
state O
levels O
of O
IME1 B-GENE
and O
IME2 B-GENE
mRNA I-GENE
were O
not O
merely O
the O
result O
of O
non O
- O
specific O
adverse O
affects O
on O
nucleic O
acid O
metabolism O
caused O
by O
the O
yvh1 B-GENE
disruption O
. O

RNase B-GENE
protection O
analysis O
of O
two O
rRNA O
fragments O
whose O
genes O
are O
adjacent O
provided O
evidence O
for O
a O
polycistronic O
transcript O
containing O
sequences O
from O
both O
, O
as O
well O
as O
separate O
small O
RNAs O
. O

These O
two O
contigs O
contain O
a O
total O
of O
163 O
open O
reading O
frames O
( O
ORFs O
) O
in O
26 O
- O
29 O
putative O
operons O
; O
56 O
ORFs O
could O
be O
identified O
with O
reasonable O
certainty O
. O

The O
evidence O
in O
support O
of O
this O
was O
derived O
from O
the O
fact O
that O
the O
affinity O
or O
interaction O
between O
the O
two O
subunits O
was O
impaired O
as O
indicated O
by O
the O
first O
order O
rate O
constant O
of O
hCG B-GENE
alpha I-GENE
1 I-GENE
beta I-GENE
( O
km O
= O
4 O
. O
1 O
x O
10 O
( O
- O
2 O
) O
min O
- O
1 O
) O
at O
pH O
3 O
. O
0 O
at O
23 O
degrees O
C O
which O
is O
one O
order O
of O
magnitude O
greater O
relative O
to O
rehCG B-GENE
( O
kw O
= O
4 O
. O
6 O
x O
10 O
( O
- O
3 O
) O
min O
- O
1 O
) O
. O

Rifabutin O
has O
substantial O
efficacy O
when O
combined O
with O
other O
agents O
. O

Leukemia B-GENE
- I-GENE
inhibitory I-GENE
factor I-GENE
( O
LIF B-GENE
) O
is O
a O
neuropoietin B-GENE
able O
to O
regulate O
the O
differentiation O
and O
the O
survival O
of O
many O
cell O
types O
, O
which O
include O
some O
neuronal O
populations O
. O

Paracrine O
activation O
of O
the O
HIV B-GENE
- I-GENE
1 I-GENE
LTR I-GENE
promoter I-GENE
by O
the O
viral B-GENE
Tat I-GENE
protein I-GENE
is O
mechanistically O
similar O
to O
trans O
- O
activation O
within O
a O
cell O
. O

RUSH B-GENE
- I-GENE
1 I-GENE
beta I-GENE
is O
a O
95 O
- O
kDa O
truncated O
version O
of O
RUSH B-GENE
- I-GENE
1 I-GENE
alpha I-GENE
that O
results O
from O
alternative O
splicing O
of O
a O
57 O
- O
bp O
exon O
as O
confirmed O
by O
genomic O
cloning O
. O

The O
mobility O
shift O
assay O
of O
the O
65 O
bp O
( O
- O
318 O
/ O
- O
254 O
) O
fragment O
with O
nuclear O
extract O
from O
the O
dark O
- O
adapted O
sample O
showed O
an O
additional O
band O
, O
not O
seen O
with O
the O
light O
- O
grown O
sample O
. O

Moreover O
, O
the O
same O
mutations O
alter O
the O
structure O
of O
junB B-GENE
5 O
' O
flanking O
DNA O
within O
chromatin O
. O

RESULTS O
: O
The O
age O
distribution O
was O
28 O
to O
83 O
years O
old O
( O
mean O
was O
54 O
. O
1 O
years O
) O
. O

The O
ERH B-GENE
expression O
profile O
is O
similar O
, O
to O
that O
of O
An3 B-GENE
, O
which O
localizes O
to O
the O
animal O
hemisphere O
of O
oocytes O
and O
is O
abundantly O
expressed O
in O
the O
embryo O
. O

When O
the O
degree O
of O
exercise O
was O
maximal O
, O
mPAP O
was O
maintained O
, O
SVI O
decreased O
, O
HR O
was O
unchanged O
, O
and O
CO O
and O
VO2 O
decreased O
. O

327 O
and O
736 O
protocols O
of O
postmortem O
examinations O
from O
Moscow O
hospitals O
N O
31 O
and O
57 O
, O
respectively O
, O
were O
evaluated O
statistically O
. O

The O
effect O
of O
six O
arginine O
mutations O
of O
oxidative O
phosphorylation O
and O
AAC B-GENE
expression O
. O

The O
RI B-GENE
alpha I-GENE
gene I-GENE
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
introns O
, O
giving O
the O
gene O
a O
total O
length O
of O
at O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
RI B-GENE
alpha I-GENE
pseudogene I-GENE
with O
a O
5 O
' O
- O
noncoding O
region O
different O
from O
the O
previously O
reported O
RI B-GENE
alpha I-GENE
complementary I-GENE
RNA I-GENE
indicated O
that O
the O
RI B-GENE
alpha I-GENE
gene I-GENE
may O
have O
multiple O
leader O
exons O
giving O
rise O
to O
alternately O
spliced O
messenger O
RNAs O
( O
mRNAs O
) O
. O

This O
establishes O
Rad3 B-GENE
/ O
Mec1 B-GENE
as O
the O
only O
conserved O
protein O
which O
is O
required O
for O
all O
the O
DNA O
structure O
checkpoints O
in O
both O
yeast O
model O
systems O
. O

The O
identification O
of O
the O
hepatitis O
C O
virus O
as O
the O
major O
cause O
of O
liver O
disease O
both O
in O
dialysis O
patients O
and O
in O
transplant O
patients O
has O
focused O
attention O
on O
the O
epidemiology O
and O
the O
impact O
of O
continuing O
infection O
in O
these O
patient O
groups O
. O

Stable O
transfection O
of O
the O
BL O
cell O
line O
Raji O
with O
constructs O
containing O
core O
promoter O
mutations O
confirmed O
that O
the O
proximal O
Sp1 B-GENE
site I-GENE
and O
the O
TATA O
box O
are O
essential O
for O
the O
activation O
of O
promoter O
P1 O
by O
the O
Ig B-GENE
kappa I-GENE
enhancers I-GENE
. O

The O
first O
identification O
of O
the O
active O
37LRP B-GENE
/ O
p40 B-GENE
gene O
presented O
in O
this O
study O
is O
a O
critical O
step O
toward O
the O
isolation O
of O
the O
corresponding O
human O
gene O
and O
the O
understanding O
of O
the O
molecular O
mechanisms O
involved O
in O
the O
up O
- O
regulation O
of O
its O
expression O
during O
tumor O
invasion O
and O
metastasis O
. O

The O
promoter O
region O
( O
P1 O
) O
corresponding O
to O
the O
main O
group O
of O
transcription O
initiation O
sites O
is O
devoid O
of O
TATA O
and O
CAAT O
boxes O
but O
has O
putative O
binding O
sites O
for O
the O
transcription B-GENE
factor I-GENE
SP1 I-GENE
and O
is O
embedded O
in O
a O
large O
G O
+ O
C O
- O
rich O
domain O
of O
a O
CpG O
island O
, O
features O
shared O
by O
the O
promoters O
of O
constitutively O
expressed O
housekeeping O
genes O
. O

The O
STAT B-GENE
- I-GENE
1 I-GENE
signaling O
pathway O
provides O
at O
least O
one O
mechanism O
for O
activation O
of O
the O
CAEV B-GENE
LTR I-GENE
by O
IFN B-GENE
- I-GENE
gamma I-GENE
in O
monocytes O
. O

Unlike O
wild B-GENE
- I-GENE
type I-GENE
p53 I-GENE
, O
the O
delta B-GENE
proAE I-GENE
mutant I-GENE
cDNA I-GENE
can O
be O
stably O
expressed O
in O
tumor O
derived O
cell O
lines O
with O
few O
immediate O
detrimental O
effects O
. O

Several O
artifacts O
occurred O
that O
interfered O
with O
visualization O
of O
the O
diaphragm O
. O

During O
skeletal O
muscle O
development O
, O
different O
types O
of O
muscle O
fibers O
are O
generated O
, O
which O
express O
different O
combinations O
of O
muscle O
- O
specific O
gene O
products O
. O

Its O
transcription O
product O
, O
a O
1 O
. O
3 O
kb O
mRNA O
, O
is O
polyadenylated O
at O
a O
site O
containing O
consensus O
eukaryotic O
polyadenylation O
signals O
and O
mapping O
87 O
bp O
downstream O
of O
the O
translation O
termination O
codon O
for O
CG30 B-GENE
. O

BCL B-GENE
- I-GENE
2 I-GENE
, O
an O
inhibitor O
of O
apoptosis O
in O
a O
wide O
variety O
of O
cell O
types O
, O
has O
been O
reported O
to O
prevent O
oxidative O
stress O
- O
induced O
cell O
death O
. O

Full B-GENE
- I-GENE
length I-GENE
AT I-GENE
- I-GENE
PHH1 I-GENE
, O
and O
both O
AT B-GENE
- I-GENE
PHH1 I-GENE
and O
AT B-GENE
- I-GENE
PHH1 I-GENE
delta I-GENE
C I-GENE
- I-GENE
513 I-GENE
( O
truncated O
to O
be O
approximately O
the O
size O
of O
microbial B-GENE
photolyase I-GENE
genes I-GENE
) O
cDNAs O
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast O
and O
Escherichia O
coli O
mutants O
hypersensitive O
to O
ultraviolet O
light O
. O

Serotonin O
concentration O
in O
the O
blood O
of O
patients O
with O
hemorrhagic O
fever O
with O
renal O
syndrome O

Control O
examination O
was O
performed O
at O
the O
end O
of O
each O
period O
. O

The O
total O
number O
of O
specimens O
was O
131 O
with O
78 O
nonsmokers O
and O
53 O
smokers O
. O

In O
Experiment O
1 O
, O
pups O
that O
had O
received O
an O
injection O
of O
the O
noncompetitive O
N B-GENE
- I-GENE
methyl I-GENE
- I-GENE
D I-GENE
- I-GENE
aspartate I-GENE
receptor I-GENE
antagonist O
MK O
- O
801 O
( O
0 O
. O
1 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
either O
30 O
min O
before O
or O
immediately O
after O
conditioning O
spent O
less O
time O
over O
the O
conditioned O
odor O
than O
saline O
- O
treated O
controls O
. O

Serotonin B-GENE
receptors I-GENE
in O
suicide O
victims O
with O
major O
depression O
. O

Experimental O
data O
showed O
that O
these O
abnormal O
proteins O
are O
constitutively O
localized O
in O
the O
nucleus O
, O
have O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
NF B-GENE
- I-GENE
kappa I-GENE
B2p52 I-GENE
and O
may O
be O
capable O
of O
transactivation O
activity O
. O

Because O
L B-GENE
- I-GENE
plastin I-GENE
expression O
in O
tissue O
- O
specifically O
regulated O
in O
both O
humans O
and O
rodents O
, O
it O
is O
likely O
that O
similar O
mechanisms O
regulate O
L B-GENE
- I-GENE
plastin I-GENE
gene I-GENE
expression O
in O
human O
and O
rodent O
cells O
and O
that O
they O
could O
be O
identified O
by O
comparing O
the O
function O
and O
nucleotide O
sequences O
of O
the O
human O
and O
murine O
L B-GENE
- I-GENE
plastin I-GENE
gene O
promoters O
. O

How O
does O
a O
nurse O
go O
about O
maintaining O
her O
level O
of O
competence O
when O
she O
is O
one O
of O
the O
few O
local O
practitioners O
in O
her O
field O
? O
Vancouver O
sex O
therapist O
Bianca O
Rucker O
is O
doing O
it O
by O
cultivating O
a O
network O
of O
colleagues O
and O
mentors O
in O
related O
fields O
both O
at O
home O
and O
across O
the O
continent O
. O

Finally O
, O
antibody O
binding O
to O
site O
IIIa O
on O
the O
hCG B-GENE
- I-GENE
ectodomain I-GENE
complex I-GENE
was O
also O
hindered O
by O
an O
anti O
- O
peptide O
mAb O
directed O
against O
a O
peptide O
encoded O
by O
the O
eighth O
exon O
( O
pE O
x O
8 O
) O
of O
the O
LHR B-GENE
. O

In O
rlf2 B-GENE
mutants I-GENE
, O
telomeric O
chromatin O
is O
perturbed O
: O
Telomeric O
silencing O
is O
reduced O
and O
Rap1p B-GENE
localization O
is O
altered O
. O

This O
0 O
. O
74 O
kb O
cDNA O
contains O
an O
open O
reading O
frame O
( O
ORF O
) O
of O
477 O
bp O
encoding O
a O
polypeptide O
of O
159 O
amino O
acids O
( O
aa O
) O
which O
differs O
at O
only O
one O
position O
( O
position O
65 O
) O
from O
the O
human B-GENE
U1 I-GENE
- I-GENE
C I-GENE
protein I-GENE
. O

However O
, O
the O
action O
of O
each O
cognate O
ligand O
and O
the O
accessory O
cellular O
factors O
that O
can O
differentially O
regulate O
the O
transcriptional O
responses O
of O
a O
heterodimer O
- O
DNA O
complex O
are O
not O
well O
understood O
. O

We O
have O
measured O
the O
MBF O
on O
incisors O
and O
its O
direction O
in O
three O
dimensions O
for O
different O
jaw O
openings O
in O
ten O
subjects O
. O

Clinically O
meaningful O
decreases O
due O
to O
alkalinization O
alone O
within O
30 O
minutes O
are O
unlikely O
. O

In O
co O
- O
transfection O
studies O
, O
an O
AP B-GENE
- I-GENE
2 I-GENE
but O
not O
an O
Egr B-GENE
- I-GENE
1 I-GENE
expression O
vector O
activated O
VPF B-GENE
/ O
VEGF B-GENE
transcription O
, O
thus O
indicating O
that O
AP B-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
functionally O
important O
in O
TGF B-GENE
alpha I-GENE
- O
induced O
VPF B-GENE
/ O
VEGF B-GENE
gene O
expression O
. O

Cytohesin B-GENE
- I-GENE
1 I-GENE
, O
a O
protein O
abundant O
in O
cells O
of O
the O
immune O
system O
, O
has O
been O
proposed O
to O
be O
a O
human O
homolog O
of O
the O
Saccharomyces B-GENE
cerevisiae I-GENE
Sec7 I-GENE
gene I-GENE
product I-GENE
, O
which O
is O
crucial O
in O
protein O
transport O
. O

In O
this O
regard O
, O
it O
differs O
from O
a O
recently O
reported O
BFA O
- O
sensitive O
ARF B-GENE
- O
GEP B-GENE
that O
contains O
a O
Sec7 B-GENE
domain I-GENE
. O

The O
recombinant O
protein O
was O
purified O
to O
homogeneity O
by O
( O
NH4 O
) O
2SO4 O
- O
precipitation O
and O
affinity O
chromatography O
on O
5 O
' O
AMP O
- O
Sepharose O
. O

Derepression O
of O
gene O
expression O
mediated O
by O
the O
5 O
' O
upstream O
region O
of O
the O
isocitrate B-GENE
lyase I-GENE
gene I-GENE
of I-GENE
Candida I-GENE
tropicalis I-GENE
is O
controlled O
by O
two O
distinct O
regulatory O
pathways O
in O
Saccharomyces O
cerevisiae O
. O

99mTc O
- O
HMPAO O
was O
distributed O
in O
the O
territories O
of O
the O
ACA O
and O
MCA O
in O
the O
two O
patients O
who O
were O
treated O
with O
intraarterial O
infusion O
of O
papaverine O
from O
the O
C4 O
segment O
, O
but O
was O
distributed O
only O
to O
the O
territory O
of O
the O
ACA O
in O
four O
patients O
who O
were O
treated O
with O
intraarterial O
infusion O
of O
papaverine O
from O
the O
C1 O
segment O
at O
1 O
ml O
/ O
min O
. O

This O
brief O
review O
analyses O
these O
interactions O
and O
defines O
clinical O
settings O
where O
antibiotic O
- O
induced O
endotoxin O
release O
may O
prove O
to O
be O
clinically O
relevant O
. O

These O
changes O
in O
virus O
entry O
features O
may O
result O
in O
coronaviruses O
with O
novel O
pathogenic O
properties O
. O

Effect O
of O
Azadirachta O
indica O
hydroalcoholic O
leaf O
extract O
on O
the O
cardiovascular O
system O
. O

In O
cellular O
supernatant O
fraction O
, O
SHRSP O
showed O
a O
decrease O
of O
magnesium O
in O
many O
tissues O
and O
an O
elevation O
of O
the O
calcium O
to O
magnesium O
ratio O
when O
compared O
to O
age O
- O
matched O
WKY O
and O
SHRSR O
. O

The O
reduced O
NO O
production O
in O
these O
cells O
was O
associated O
with O
low O
levels O
of O
mRNA O
of O
inducible B-GENE
NO I-GENE
synthetase I-GENE
. O

Apart O
from O
iron O
regulation O
, O
sodA B-GENE
expression O
was O
affected O
by O
changes O
in O
DNA O
topology O
induced O
by O
coumermycin O
A O
but O
not O
by O
the O
global O
virulence O
regulatory O
Bvg B-GENE
system I-GENE
. O

In O
the O
present O
study O
, O
we O
have O
isolated O
and O
sequenced O
several O
p15E B-GENE
cDNA I-GENE
gene I-GENE
fragments I-GENE
amplified O
by O
means O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
from O
parental O
( O
P815 O
) O
and O
xenogenized O
( O
P815 O
/ O
DTIC O
) O
tumour O
cells O
. O

Transcriptional O
activity O
was O
measured O
by O
slot O
- O
blot O
hybridization O
with O
steady O
- O
state O
RNA O
isolated O
from O
lacZ B-GENE
+ I-GENE
M I-GENE
. I-GENE
smegmatis I-GENE
clones O
. O

Movement O
time O
and O
kinematic O
characteristics O
were O
analyzed O
together O
with O
the O
magnitude O
of O
cerebral O
blood O
flow O
to O
identify O
areas O
of O
brain O
activity O
proportionate O
to O
task O
and O
movement O
variables O
. O

Areas O
with O
significantly O
greater O
rCBF O
for O
targeting O
were O
the O
left O
motor O
cortex O
, O
left O
intraparietal O
sulcus O
, O
and O
left O
caudate O
. O

Recent O
studies O
have O
demonstrated O
that O
the O
U1 B-GENE
snRNP I-GENE
is O
recruited O
to O
the O
5 O
' O
splice O
site O
by O
protein O
/ O
protein O
interactions O
involving O
the O
SR B-GENE
domains O
of O
the O
U1 B-GENE
- I-GENE
70K I-GENE
protein I-GENE
and O
SF2 B-GENE
/ O
ASF B-GENE
. O

Thus O
, O
the O
tri O
- O
snRNP O
- O
specific O
27K O
protein O
could O
potentially O
be O
involved O
in O
SR B-GENE
protein O
- O
mediated O
protein O
/ O
protein O
interactions O
and O
, O
additionally O
, O
its O
phosphorylation O
state O
could O
modulate O
pre O
- O
mRNA O
splicing O
. O

Although O
methods O
to O
align O
the O
control O
and O
activation O
fMR O
images O
may O
correct O
for O
some O
of O
this O
motional O
error O
, O
they O
will O
be O
incomplete O
in O
correcting O
for O
those O
that O
depend O
on O
spatial O
orientation O
. O

Three O
women O
have O
had O
abnormal O
endocervical O
follow O
up O
cytology O
suggestive O
of O
residual O
disease O
. O

This O
site O
is O
upstream O
from O
the O
TATA O
box O
used O
in O
somatic O
cells O
. O

An O
aromatic O
stacking O
interaction O
between O
subunits O
helps O
mediate O
DNA O
sequence O
specificity O
: O
operator O
site O
discrimination O
by O
phage B-GENE
lambda I-GENE
cI I-GENE
repressor I-GENE
. O

We O
have O
characterized O
a O
panel O
of O
6 O
monoclonal O
antibodies O
raised O
against O
human B-GENE
platelet I-GENE
talin I-GENE
by O
Western O
blotting O
, O
immune O
precipitation O
, O
and O
immunofluorescence O
, O
and O
shown O
that O
antibodies B-GENE
TA205 I-GENE
and O
TD77 B-GENE
disrupt O
actin B-GENE
stress O
fibers O
and O
focal O
adhesions O
, O
and O
inhibit O
cell O
motility O
when O
microinjected O
into O
human O
fibroblasts O
. O

Here O
we O
report O
the O
purification O
of O
this O
larger O
form O
as O
an O
approximately O
320 O
- O
kDa O
particle O
that O
contains O
mRNP3 B-GENE
+ I-GENE
4 I-GENE
and O
nine O
additional O
polypeptides O
, O
including O
mRNA O
- O
binding O
polypeptides O
of O
34 O
and O
36 O
kDa O
and O
a O
doublet O
of O
110 O
/ O
105 O
kDa O
that O
proved O
to O
be O
nucleolin B-GENE
. O

This O
study O
indicates O
that O
the O
phenotype O
of O
myofibrillar O
disarray O
seen O
in O
HCM O
patients O
which O
harbor O
either O
of O
these O
two O
mutations O
may O
not O
be O
directly O
due O
to O
the O
failure O
of O
the O
mutant B-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
protein I-GENE
to O
assemble O
and O
form O
normal O
sarcomeres O
, O
but O
may O
rather O
be O
a O
secondary O
effect O
possibly O
resulting O
from O
the O
chronic O
stress O
of O
decreased O
beta B-GENE
MHC I-GENE
function O
. O

A O
method O
for O
the O
simultaneous O
determination O
of O
de O
( O
N O
- O
methyl O
) O
- O
N O
- O
ethyl O
- O
8 O
, O
9 O
- O
anhydroerythromycin O
A O
6 O
, O
9 O
- O
hemiacetal O
( O
EM523 O
, O
I O
) O
and O
its O
three O
metabolites O
in O
human O
plasma O
and O
urine O
has O
been O
developed O
using O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
chemiluminescence O
( O
CL O
) O
detection O
. O

Cotransfection O
of O
Ets B-GENE
- I-GENE
2 I-GENE
and O
p44 B-GENE
mitogen B-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
expression O
vectors O
strongly O
potentiated O
HB B-GENE
- O
EGF B-GENE
promoter O
activation O
in O
response O
to O
deltaRaf B-GENE
- I-GENE
1 I-GENE
: O
ER B-GENE
. O

The O
Rlm1 B-GENE
protein I-GENE
, O
a O
member O
of O
the O
MADS B-GENE
box I-GENE
family I-GENE
of O
transcription O
factors O
, O
functions O
downstream O
of O
Mpk1 B-GENE
in O
the O
pathway O
. O

The O
likelihood O
that O
a O
common O
region O
of O
deletions O
would O
contain O
a O
tumor O
suppressor O
is O
strongly O
enhanced O
by O
coincidence O
of O
that O
region O
with O
a O
chromosome O
fragment O
suppressing O
tumorigenicity O
upon O
introduction O
in O
tumor O
cells O
. O

The O
carboxyl O
- O
terminal O
CCCC O
module O
is O
structurally O
related O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
erythroid B-GENE
transcription I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
. O

The O
different O
holoenzyme B-GENE
RNA I-GENE
polymerases I-GENE
generated O
upon O
reconstituting O
these O
mutants O
independently O
with O
core B-GENE
RNA I-GENE
polymerase I-GENE
( O
alpha2beta B-GENE
beta I-GENE
' I-GENE
) O
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild B-GENE
- I-GENE
type I-GENE
sigma I-GENE
factor I-GENE
. O

These O
data O
are O
consistent O
with O
a O
model O
in O
which O
GATA B-GENE
- I-GENE
5 I-GENE
performs O
a O
unique O
temporally O
and O
spatially O
restricted O
function O
in O
the O
embryonic O
heart O
and O
lung O
. O

The O
similar O
phenotypes O
of O
bur6 B-GENE
and O
bur3 B-GENE
( O
mot1 B-GENE
) O
mutations O
suggest O
that O
Bur6p B-GENE
and O
Mot1p B-GENE
have O
related O
, O
but O
not O
identical O
, O
functions O
in O
modulating O
the O
activity O
of O
the O
general O
transcription O
machinery O
in O
vivo O
. O

A O
genetic O
screen O
applied O
to O
mutants O
in O
the O
branch O
site O
region O
shows O
that O
all O
positions O
in O
the O
conserved O
TACTAAC O
sequence O
are O
important O
for O
intron O
recognition O
. O

Implication O
of O
PAF B-GENE
and O
acetylhydrolase B-GENE
( O
PAF B-GENE
- I-GENE
AH I-GENE
) O
activity O
in O
periodontal O
disease O
. O

A O
polypeptide O
encoded O
by O
the O
NTS O
16 O
open O
reading O
frame O
has O
sequence O
similarity O
to O
the O
catalytic O
domain O
of O
several O
receptor B-GENE
protein I-GENE
kinases I-GENE
from I-GENE
plants I-GENE
including O
the O
S B-GENE
- I-GENE
receptor I-GENE
kinases I-GENE
implicated O
in O
the O
rejection O
of O
self O
- O
pollen O
in O
Brassica O
species O
and O
the O
Pto B-GENE
gene I-GENE
product I-GENE
of I-GENE
tomato I-GENE
which O
confers O
resistance O
to O
a O
bacterial O
pathogen O
. O

The O
atp B-GENE
1 I-GENE
and O
atp B-GENE
2 I-GENE
types O
of O
cDNA O
sequences O
were O
the O
most O
redundant O
among O
the O
28 O
different O
isoperoxidases B-GENE
identified O
among O
about O
200 O
peroxidase B-GENE
encoding I-GENE
ESTs I-GENE
. O

Glycemic O
response O
to O
malted O
, O
popped O
and O
roller O
dried O
wheat O
- O
legume O
based O
foods O
in O
normal O
subjects O
. O

4 O
. O
26 O
+ O
/ O
- O
1 O
. O
54 O
mmol O
/ O
l O
, O
P O
< O
0 O
. O
01 O
) O
, O
and O
systolic O
BP O
responses O
to O
intravenous O
norepinephrine O
and O
angiotensin B-GENE
II I-GENE
were O
significantly O
higher O
on O
glibenclamide O
than O
on O
metformin O
( O
P O
< O
0 O
. O
02 O
and O
P O
< O
0 O
. O
05 O
, O
respectively O
) O
. O

Is O
leishmaniasis O
endemic O
on O
the O
island O
of O
Minorca O
( O
Spain O
) O
? O
A O
human O
visceral O
case O
after O
living O
13 O
years O
in O
Minorca O
. O

RESULTS O
: O
Surprisingly O
, O
PAF B-GENE
blockade O
increased O
mortality O
after O
trauma O
( O
5 O
of O
11 O
WEB O
- O
2086 O
animals O
versus O
1 O
of O
9 O
vehicle O
animals O
; O
p O
= O
0 O
. O
15 O
) O
and O
depressed O
cardiac O
index O
and O
O2 O
delivery O
at O
72 O
hours O
( O
p O
< O
0 O
. O
05 O
) O
. O

This O
finding O
is O
the O
first O
example O
of O
utilization O
of O
noncomplementary O
dinucleotide O
primer O
by O
an O
RNA B-GENE
polymerase I-GENE
. O

Pure O
T1 O
and O
dual O
- O
T1 O
images O
were O
visually O
evaluated O
for O
image O
quality O
( O
IQ O
) O
on O
a O
five O
- O
point O
scale O
( O
0 O
= O
unacceptable O
to O
4 O
= O
excellent O
) O
. O

This O
conformer O
features O
a O
Type O
I O
beta O
- O
turn O
and O
has O
extensive O
hydrophobic O
contacts O
with O
the O
FKBP12 B-GENE
binding O
surface O
. O

Children O
' O
s O
temperament O
and O
maternal O
socialization O
at O
Time O
1 O
( O
n O
= O
103 O
, O
aged O
2 O
- O
3 O
years O
) O
were O
considered O
predictors O
of O
future O
conscience O
, O
assessed O
using O
new O
observational O
and O
narrative O
measures O
. O

One O
P1 O
genomic O
clone O
and O
six O
subsequent O
plasmid O
subclones O
were O
isolated O
and O
analyzed O
for O
the O
exon O
- O
intron O
organization O
of O
the O
Ctpct B-GENE
gene I-GENE
. O

Congruent O
with O
empirical O
predictions O
, O
the O
most O
homesick O
children O
perceived O
low O
control O
over O
homesickness O
and O
separation O
, O
and O
coped O
by O
relinquishing O
control O
. O

We O
also O
review O
the O
role O
of O
grains O
in O
the O
formation O
of O
complex O
molecules O
in O
interstellar O
molecular O
clouds O
. O

The O
C O
- O
LIP O
also O
was O
compared O
with O
transcather O
arterial O
embolization O
( O
TAE O
; O
C O
- O
LIP O
followed O
by O
gelatin O
sponge O
) O
and O
percutaneous O
ethanol O
injection O
therapy O
( O
PEIT O
) O
. O

We O
also O
demonstrate O
that O
preformed O
triplexes O
are O
quite O
stable O
when O
precipitated O
with O
ethanol O
and O
resuspended O
in O
water O
. O

Transfection O
experiments O
using O
preformed O
triplexes O
with O
a O
reporter O
plasmid O
containing O
the O
collagen B-GENE
promoter I-GENE
sequence I-GENE
showed O
significant O
inhibition O
of O
transcription O
when O
compared O
with O
a O
control O
phosphorothioate O
ODN O
. O

Thus O
, O
an O
increase O
in O
plasma B-GENE
TBG I-GENE
and O
a O
shift O
from O
adrenal O
androgen O
and O
mineralocorticoid O
steroid O
secretion O
towards O
cortisol O
secretion O
may O
be O
endocrine O
markers O
for O
progression O
of O
the O
disease O
in O
patients O
with O
HIV O
- O
infection O
. O

Latanoprost O
produces O
an O
additional O
reduction O
of O
intraocular O
pressure O
( O
IOP O
) O
when O
used O
in O
combination O
with O
timolol O
, O
pilocarpine O
, O
acetazolamide O
and O
dipivefrin O
. O

Transient O
overexpression O
of O
c B-GENE
- I-GENE
Jun I-GENE
induced O
tenascin B-GENE
- I-GENE
C I-GENE
expression O
in O
primary O
REF O
and O
in O
FR3T3 O
, O
an O
established O
fibroblast O
cell O
line O
. O

Selected O
parameters O
: O
heart O
rate O
( O
HR O
) O
, O
arterial O
blood O
pressure O
( O
ABP O
) O
and O
arterial O
O2 O
saturation O
( O
SaO2 O
) O
monitored O
by O
pulsoximetry O
were O
measured O
during O
the O
procedure O
. O

We O
have O
tested O
this O
proposal O
by O
carrying O
out O
circular O
dichroism O
( O
CD O
) O
and O
NMR O
experiments O
on O
the O
Skn B-GENE
domain I-GENE
and O
five O
truncated O
proteins O
. O

Genes O
for O
ocs B-GENE
element I-GENE
binding I-GENE
factors I-GENE
( O
OBFs B-GENE
) O
, O
belonging O
to O
a O
specific O
class O
of O
basic B-GENE
- I-GENE
region I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bZIP I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
, O
have O
been O
isolated O
in O
a O
number O
of O
plants O
. O

SRE O
activity O
is O
dependent O
upon O
the O
activation O
by O
phosphorylation O
of O
a O
ternary O
complex O
factor O
; O
included O
among O
the O
ternary O
complex O
factors O
is O
Elk B-GENE
- I-GENE
1 I-GENE
. O

A O
xylE B-GENE
transcriptional I-GENE
fusion I-GENE
to O
the O
putative O
mxbD B-GENE
promoter I-GENE
showed O
low O
- O
level O
expression O
in O
wild O
- O
type O
cells O
grown O
on O
one O
- O
carbon O
( O
C1 O
) O
compounds O
and O
no O
detectable O
expression O
in O
cells O
grown O
on O
succinate O
. O

Pax B-GENE
- I-GENE
3 I-GENE
is O
a O
paired B-GENE
- I-GENE
type I-GENE
homeobox I-GENE
gene I-GENE
that O
is O
specifically O
expressed O
in O
the O
dorsal O
and O
posterior O
neural O
tube O
. O

Instead O
, O
they O
contained O
dendritic O
cells O
that O
express O
melanogenic O
marker O
proteins O
such O
as O
tyrosinase B-GENE
and O
tyrosinase B-GENE
- I-GENE
related I-GENE
protein I-GENE
1 I-GENE
. O

These O
mutations O
create O
stop O
codons O
in O
exon O
7 O
and O
8 O
, O
respectively O
, O
and O
probably O
result O
in O
truncated O
proteins O
lacking O
HLH O
- O
Zip O
or O
Zip O
structure O
. O

These O
six O
amino O
acids O
are O
part O
of O
an O
amphipathic O
helix O
that O
is O
highly O
conserved O
among O
nuclear B-GENE
hormone I-GENE
receptors I-GENE
and O
contains O
the O
core O
domain O
of O
the O
ligand O
- O
dependent O
transactivation O
function O
, O
AF O
- O
2 O
. O

Surprisingly O
, O
the O
RXR B-GENE
- O
specific O
ligand O
9 O
- O
cis O
- O
retinoic O
acid O
induced O
binding O
of O
SRC B-GENE
- I-GENE
1 I-GENE
to O
the O
RXR B-GENE
component I-GENE
of O
the O
TRE O
- O
bound O
heterodimer O
. O

Using O
PRL B-GENE
- I-GENE
R I-GENE
tagged O
both O
in O
the O
N O
- O
terminal O
or O
C O
- O
terminal O
regions O
of O
the O
mature O
receptor O
excludes O
the O
possibility O
of O
a O
cleaved O
fragment O
which O
could O
have O
been O
subsequently O
imported O
into O
the O
nucleus O
. O

Transcription O
of O
these O
genes O
was O
also O
elevated O
in O
gut O
and O
lung O
during O
freezing O
, O
but O
mRNA O
levels O
in O
these O
tissues O
were O
lower O
than O
in O
liver O
. O

The O
most O
important O
one O
among O
them O
is O
Cyclosporin O
A O
, O
which O
is O
a O
selective O
immunosuppressive O
drug O
. O

Using O
a O
conditional O
- O
lethal O
mutant O
allele O
of O
SUP45 B-GENE
( O
sup45 B-GENE
- I-GENE
2 I-GENE
) O
and O
a O
combination O
of O
in O
vivo O
and O
in O
vitro O
approaches O
, O
we O
demonstrate O
that O
the O
product O
of O
the O
SUP45 B-GENE
gene I-GENE
( O
Sup45p B-GENE
or O
eRF1 B-GENE
) O
is O
a O
factor O
required O
for O
translation O
termination O
in O
yeast O
. O

She O
was O
able O
to O
stand O
unaided O
by O
3 O
years O
of O
age O
with O
then O
progressive O
worsening O
of O
motor O
abilities O
. O

Merosin B-GENE
positive O
congenital O
muscular O
dystrophy O
with O
mental O
deficiency O
, O
epilepsy O
and O
MRI O
changes O
in O
the O
cerebral O
white O
matter O
. O

Also O
, O
transient O
overexpression O
of O
this O
protein O
in O
C2C12 O
cells O
reduced O
the O
transcription O
of O
a O
CAT B-GENE
- O
reporter O
regulated O
by O
an O
E12 B-GENE
/ O
MyoD B-GENE
driven O
enhancer O
. O

Type O
I O
position O
- O
vestibular O
- O
pause O
( O
PVP O
I O
) O
and O
vestibular O
- O
only O
( O
V O
I O
) O
neurons O
, O
as O
well O
as O
a O
smaller O
number O
of O
other O
type O
I O
and O
type O
II O
eye O
- O
plus O
- O
vestibular O
neurons O
were O
studied O
. O

Using O
mouse O
- O
human O
somatic O
hybrids O
and O
FISH O
analysis O
, O
the O
PE B-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
localized O
to O
human O
chromosome O
19q13 O
. O
2 O
, O
a O
region O
involved O
in O
translocations O
and O
deletions O
in O
leukemias O
and O
several O
solid O
tumors O
, O
suggesting O
that O
this O
novel O
ETS B-GENE
factor I-GENE
may O
play O
a O
role O
in O
carcinogenesis O
. O

Sequence O
divergence O
is O
observed O
in O
untranslated O
regions O
which O
allows O
the O
definition O
of O
gene O
- O
specific O
probes O
. O

In O
adherent O
macrophages O
, O
absence O
of O
CD45 B-GENE
led O
to O
the O
hyperphosphorylation O
and O
hyperactivation O
of O
p56 B-GENE
/ I-GENE
59 I-GENE
( O
hck B-GENE
) O
and O
p53 B-GENE
/ I-GENE
56 I-GENE
( O
lyn B-GENE
) O
, O
but O
not O
of O
p58 B-GENE
( O
c B-GENE
- I-GENE
fgr I-GENE
) O
. O

Secretion O
in O
milk O
and O
transplacental O
transfer O
of O
two O
iodized O
oils O
, O
Lipiodol O
UF O
and O
Oriodol O
, O
in O
rabbits O
. O

The O
RNA O
- O
binding O
and O
RNA B-GENE
- I-GENE
DNA I-GENE
helicase I-GENE
activities O
of O
the O
Escherichia B-GENE
coli I-GENE
transcription I-GENE
termination I-GENE
factor I-GENE
rho I-GENE
have O
been O
investigated O
using O
natural O
RNA O
molecules O
that O
are O
255 O
and O
391 O
nucleotide O
residues O
in O
length O
and O
that O
contain O
the O
trp B-GENE
t I-GENE
' I-GENE
rho I-GENE
- I-GENE
dependent I-GENE
termination I-GENE
sequence I-GENE
of O
E O
. O
coli O
. O

The O
serum O
levels O
of O
beta B-GENE
- I-GENE
human I-GENE
chorionic I-GENE
gonadotropin I-GENE
( O
HCG B-GENE
) O
and O
placental B-GENE
alkaline I-GENE
phosphatase I-GENE
( O
PLAP B-GENE
) O
were O
not O
elevated O
. O

Thus O
E14 O
. O
1TG3B1 O
is O
a O
useful O
ES O
cell O
line O
for O
modifying O
the O
mouse O
genome O
using O
the O
HPRT B-GENE
gene I-GENE
as O
a O
selection O
marker O
and O
for O
transmission O
at O
a O
high O
frequency O
into O
the O
mouse O
germ O
line O
. O

OBJECTIVE O
: O
This O
study O
was O
designed O
to O
analyze O
the O
common O
cause O
of O
asthenopia O
, O
mixed O
astigmatism O
. O

One O
RNA O
construct O
which O
consisted O
of O
112 O
nucleotides O
( O
nt O
) O
from O
nt O
639 O
to O
nt O
750 O
formed O
a O
heterodimeric O
complex O
with O
the O
RNA O
which O
consisted O
of O
200 O
nucleotides O
from O
nt O
551 O
to O
nt O
750 O
. O

However O
, O
we O
could O
not O
find O
the O
homologous O
regions O
with O
guanine B-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
or O
GTPase B-GENE
- I-GENE
activating I-GENE
proteins I-GENE
in O
the O
c B-GENE
- I-GENE
cbl I-GENE
gene I-GENE
. O

Aryl B-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
translocator I-GENE
( O
ARNT B-GENE
) O
is O
a O
component O
of O
the O
transcription O
factors O
, O
aryl B-GENE
hydrocarbon I-GENE
receptor I-GENE
( O
AhR B-GENE
) O
and O
hypoxia B-GENE
- I-GENE
inducible I-GENE
factor I-GENE
1 I-GENE
, O
which O
transactivate O
their O
target O
genes O
, O
such O
as O
CYP1A1 B-GENE
and O
erythropoietin B-GENE
, O
in O
response O
to O
xenobiotic O
aromatic O
hydrocarbons O
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

We O
also O
provide O
evidence O
that O
gar2 B-GENE
is O
phosphorylated O
in O
vitro O
by O
a O
p13 B-GENE
( O
suc1 B-GENE
) O
- O
Sepharose O
- O
bound O
kinase O
from O
Schizosaccharomyces O
pombe O
extracts O
that O
displays O
cell O
cycle O
- O
regulated O
activity O
similar O
to O
that O
of O
the O
p34 B-GENE
( O
cdc2 B-GENE
( O
kinase O
. O

However O
, O
by O
immobilized O
metal O
affinity O
chromatography O
assay O
, O
self O
- O
association O
of O
PR B-GENE
- I-GENE
A I-GENE
was O
3 O
. O
5 O
- O
fold O
more O
efficient O
than O
that O
of O
either O
the O
DhLBD O
or O
hLBD O
constructs O
. O

The O
overall O
results O
of O
this O
paper O
are O
consistent O
with O
the O
conclusion O
that O
the O
carboxyl O
- O
terminal O
LBD O
is O
not O
sufficient O
for O
mediating O
PR B-GENE
dimerization O
and O
that O
multiple O
regions O
, O
including O
the O
hinge O
and O
amino O
- O
terminal O
sequences O
, O
contribute O
either O
directly O
or O
indirectly O
to O
homodimerization O
of O
PR B-GENE
. O

Colorectal O
carcinoma O
: O
therapeutic O
approach O
in O
patients O
already O
treated O
with O
metastasis O
resection O

Alternative O
splicing O
of O
ClC B-GENE
- I-GENE
6 I-GENE
( O
a O
member O
of O
the O
CIC B-GENE
chloride I-GENE
- I-GENE
channel I-GENE
family I-GENE
) O
transcripts O
generates O
three O
truncated O
isoforms O
one O
of O
which O
, O
ClC B-GENE
- I-GENE
6c I-GENE
, O
is O
kidney O
- O
specific O
. O

The O
frequency O
of O
positive O
anti B-GENE
- I-GENE
GM1 I-GENE
antibody I-GENE
titers O
in O
the O
Guillain O
- O
Barre O
syndrome O
patients O
with O
PEN O
19 O
isolates O
was O
higher O
than O
that O
in O
the O
Guillain O
- O
Barre O
syndrome O
and O
Fisher O
' O
s O
syndrome O
patients O
without O
PEN O
19 O
isolates O
. O

NF B-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ O
Rel B-GENE
transcription O
factors O
participate O
in O
the O
activation O
of O
numerous O
genes O
involved O
in O
immune O
regulation O
/ O
inflammation O
including O
cytokines O
, O
cell O
surface O
receptors O
, O
adhesion O
molecules O
, O
and O
acute O
phase O
proteins O
. O

However O
, O
mean O
food O
intake O
in O
the O
40 O
% O
group O
was O
half O
that O
of O
the O
ACT O
group O
( O
p O
< O
0 O
. O
001 O
) O
and O
significantly O
less O
( O
p O
< O
0 O
. O
01 O
) O
than O
the O
SEP O
group O
, O
which O
consumed O
amounts O
equivalent O
to O
65 O
% O
of O
daily O
requirement O
. O

We O
have O
separated O
a O
dermatan O
sulfate O
proteoglycan O
, O
epiphycan O
, O
from O
decorin B-GENE
and O
biglycan O
by O
using O
dissociative O
extraction O
of O
bovine O
fetal O
epiphyseal O
cartilage O
, O
followed O
by O
sequential O
ion O
- O
exchange O
, O
gel O
permeation O
, O
hydrophobic O
, O
and O
Zn2 O
+ O
chelate O
chromatographic O
steps O
. O

The O
mean O
times O
to O
detection O
of O
all O
mycobacteria O
with O
BACTEC O
9000 O
MB O
and O
BACTEC O
460 O
TB O
were O
similar O
( O
10 O
. O
3 O
and O
10 O
. O
0 O
days O
, O
respectively O
) O
. O

Though O
the O
BACTEC O
9000 O
MB O
system O
is O
recommended O
for O
respiratory O
specimens O
, O
we O
demonstrated O
that O
it O
can O
be O
successfully O
used O
also O
for O
recovery O
of O
mycobacteria O
from O
clinical O
specimens O
from O
various O
extrapulmonary O
sites O
. O

A O
pre O
- O
boutonniere O
deformity O
was O
simulated O
by O
dividing O
the O
central O
slip O
. O

This O
regulation O
requires O
two O
HMG B-GENE
- I-GENE
box I-GENE
proteins I-GENE
: O
the O
ubiquitous O
Ste11 B-GENE
transcription I-GENE
factor I-GENE
and O
the O
M O
cell O
- O
controlling O
protein O
Mat1 B-GENE
- I-GENE
Mc I-GENE
. O

Neither O
of O
these O
proteins O
, O
individually O
or O
as O
a O
pair O
, O
can O
bind O
the O
alpha B-GENE
- I-GENE
globin I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
unless O
they O
are O
complexed O
with O
the O
remaining O
non O
- O
poly O
( O
C O
) O
binding O
proteins O
of O
the O
alpha B-GENE
- I-GENE
complex I-GENE
. O

( O
1996a O
) O
Biochemistry O
35 O
, O
1589 O
- O
1598 O
] O
. O

A O
prospective O
observational O
study O
was O
conducted O
to O
identify O
early O
indicators O
of O
acute O
dengue O
virus O
infection O
. O

It O
is O
present O
in O
the O
nucleus O
of O
the O
cells O
in O
which O
it O
is O
expressed O
and O
can O
phosphorylate O
and O
activate O
the O
cyclic B-GENE
AMP I-GENE
response I-GENE
element I-GENE
binding I-GENE
proteins I-GENE
CREB B-GENE
and O
CREM B-GENE
tau I-GENE
in O
a O
manner O
analogous O
to O
protein B-GENE
kinase I-GENE
A I-GENE
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB B-GENE
and O
produce O
significantly O
less O
of O
the O
cytokine O
Interleukin B-GENE
- I-GENE
2 I-GENE
( O
IL B-GENE
- I-GENE
2 I-GENE
) O
in O
response O
to O
agents O
that O
either O
increase O
intracellular O
Ca2 O
+ O
and O
/ O
or O
activate O
protein B-GENE
kinase I-GENE
C I-GENE
. O

Both O
of O
these O
dogs O
had O
low O
serum O
IgG B-GENE
( O
3 O
. O
5 O
to O
7 O
. O
2 O
mg O
/ O
ml O
) O
and O
the O
second O
littermate O
also O
had O
reduced O
serum O
IgA B-GENE
( O
< O
0 O
. O
1 O
to O
0 O
. O
15 O
mg O
/ O
ml O
) O
. O

CONCLUSIONS O
: O
Valproate O
appears O
to O
inhibit O
the O
glucuronidation O
of O
carbamazepine O
- O
10 O
, O
11 O
- O
trans O
- O
diol O
, O
and O
probably O
also O
inhibits O
the O
conversion O
of O
carbamazepine O
- O
10 O
, O
11 O
- O
epoxide O
to O
this O
trans O
- O
diol O
derivative O
, O
rather O
than O
simply O
inhibiting O
the O
latter O
reaction O
only O
. O

Proteinuria O
in O
a O
young O
man O
. O

Neural O
blockade O
in O
chronic O
and O
cancer O
pain O
. O

Five O
cell O
strains O
of O
human O
dermal O
fibroblasts O
were O
each O
treated O
with O
three O
samples O
of O
burn O
blister O
fluid O
and O
the O
effect O
compared O
with O
the O
rate O
of O
contraction O
of O
free O
floating O
fibroblast O
populated O
collagen B-GENE
lattices O
( O
FPCL O
) O
. O

It O
is O
thus O
one O
of O
the O
key O
enzymes O
involved O
in O
the O
triiodothyronine O
- O
mediated O
control O
of O
growth O
, O
differentiation O
and O
basal O
metabolism O
in O
vertebrates O
. O

We O
had O
previously O
analyzed O
repair O
rates O
of O
cyclobutane O
pyrimidine O
dimers O
at O
nucleotide O
resolution O
along O
the O
human B-GENE
JUN I-GENE
gene I-GENE
in O
normal O
fibroblasts O
and O
found O
very O
efficient O
repair O
of O
sequences O
near O
the O
transcription O
initiation O
site O
but O
slow O
repair O
along O
the O
promoter O
. O

The O
used O
expression O
system O
could O
allow O
to O
produce O
mutated O
forms O
of O
SsEF B-GENE
- I-GENE
2 I-GENE
obtained O
by O
mutagenesis O
of O
the O
corresponding O
gene O
. O

Crosstalk O
among O
the O
pathways O
may O
explain O
how O
some O
forms O
of O
stress O
can O
contribute O
to O
the O
development O
of O
a O
malignancy O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
Lung O
elastance O
( O
EL O
) O
and O
resistance O
( O
RL O
) O
were O
calculated O
from O
measurements O
of O
airway O
pressure O
, O
esophageal O
pressure O
, O
and O
airway O
flow O
in O
five O
anesthetized O
, O
paralyzed O
dogs O
during O
sinusoidal O
forcing O
at O
a O
constant O
mean O
airway O
pressure O
of O
10 O
cmH2O O
in O
a O
wide O
range O
of O
breathing O
frequencies O
( O
0 O
. O
2 O
to O
1 O
. O
0 O
Hz O
in O
intervals O
of O
0 O
. O
2 O
) O
and O
tidal O
volumes O
( O
50 O
, O
100 O
, O
200 O
, O
and O
to O
300 O
mL O
) O
. O

Because O
the O
biosynthetic O
pathway O
to O
the O
vacuole O
intersects O
with O
the O
endocytic O
pathway O
, O
internalization O
of O
a O
bulk O
membrane O
endocytic O
marker O
FM O
4 O
- O
64 O
was O
assayed O
in O
the O
sop B-GENE
mutants I-GENE
. O

Naltrexone O
has O
been O
recently O
approved O
by O
the O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
alcohol O
dependence O
. O

Consistent O
with O
this O
model O
, O
a O
synthetic O
construct O
containing O
three O
tandem O
copies O
of O
the O
native O
LDL B-GENE
receptor I-GENE
SREBP B-GENE
site O
linked O
to O
a O
single O
Sp1 B-GENE
site I-GENE
was O
also O
significantly O
activated O
in O
a O
buttonhead B-GENE
- O
independent O
fashion O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

The O
m7GpppN O
cap O
structure O
of O
eukaryotic O
mRNA O
is O
formed O
cotranscriptionally O
by O
the O
sequential O
action O
of O
three O
enzymes O
: O
RNA B-GENE
triphosphatase I-GENE
, O
RNA B-GENE
guanylyltransferase I-GENE
, O
and O
RNA B-GENE
( I-GENE
guanine I-GENE
- I-GENE
7 I-GENE
) I-GENE
- I-GENE
methyltransferase I-GENE
. O

CONCLUSION O
: O
Patients O
wit O
clinically O
palpable O
neck O
disease O
( O
N1 O
- O
3 O
) O
, O
histological O
evidence O
of O
metastatic O
nodal O
disease O
, O
extracapsular O
spread O
, O
and O
three O
or O
more O
positive O
lymph O
nodes O
are O
at O
greater O
risk O
of O
developing O
failure O
at O
distant O
sites O
. O

4 O
. O

Area O
under O
the O
drug O
concentration O
- O
time O
curves O
( O
AUC0 O
- O
24 O
hr O
) O
for O
MTX O
were O
2379 O
and O
3534 O
ng O
* O
hr O
/ O
ml O
from O
PG O
- O
2 O
. O
5 O
% O
Azone O
and O
PG O
- O
7 O
. O
5 O
% O
Azone O
systems O
respectively O
. O

There O
were O
differences O
between O
males O
( O
p O
< O
0 O
. O
05 O
) O
for O
most O
of O
the O
characteristics O
studied O
. O

Although O
previous O
data O
have O
suggested O
that O
Rev B-GENE
uses O
the O
same O
export O
pathway O
as O
uracil O
- O
rich O
small O
nuclear O
RNAs O
and O
5S B-GENE
ribosomal I-GENE
RNA I-GENE
, O
the O
CTE O
seems O
to O
interact O
with O
evolutionarily O
conserved O
factors O
that O
are O
essential O
for O
cellular O
mRNA O
export O
. O

S2F B-GENE
, O
a O
leaf O
- O
specific O
trans O
- O
acting O
factor O
, O
binds O
to O
a O
novel O
cis O
- O
acting O
element O
and O
differentially O
activates O
the O
RPL21 B-GENE
gene I-GENE
. O

Polarised O
expression O
of O
human O
intestinal O
N B-GENE
- I-GENE
benzoyl I-GENE
- I-GENE
L I-GENE
- I-GENE
tyrosyl I-GENE
- I-GENE
p I-GENE
- I-GENE
aminobenzoic I-GENE
acid I-GENE
hydrolase I-GENE
( O
human B-GENE
meprin I-GENE
) O
alpha O
and O
beta O
subunits O
in O
Madin O
- O
Darby O
canine O
kidney O
cells O
. O

Neither O
mutant O
exhibited O
derepression O
of O
the O
silent B-GENE
mating I-GENE
type I-GENE
loci I-GENE
. O

In O
contrast O
to O
the O
wild O
- O
type O
protein O
, O
expression O
of O
p45 B-GENE
NF B-GENE
- I-GENE
E2 I-GENE
lacking O
this O
activation O
domain O
in O
an O
NF B-GENE
- I-GENE
E2 I-GENE
null O
cell O
line O
fails O
to O
support O
enhancer O
- O
dependent O
transcription O
in O
transient O
assays O
. O

These O
findings O
suggest O
one O
potential O
mechanism O
for O
direct O
recruitment O
of O
distal O
regulatory O
regions O
of O
the O
globin B-GENE
loci I-GENE
to O
the O
individual O
promoters O
. O

The O
promoter O
region O
showed O
no O
consensus O
TATA O
box O
but O
it O
contains O
CCAAT O
and O
CreA B-GENE
boxes O
known O
to O
be O
involved O
in O
both O
stress O
and O
carbon O
- O
catabolite O
regulation O
of O
fungal O
promoters O
. O

In O
support O
of O
this O
interpretation O
we O
demonstrate O
that O
MQ9b B-GENE
binds O
strongly O
5 O
of O
17 O
motif O
- O
positive O
, O
pathogen O
- O
derived O
synthetic O
peptides O
. O

These O
discoloration O
' O
s O
can O
be O
treated O
in O
several O
ways O
but O
up O
to O
lately O
tooth O
structure O
had O
to O
be O
removed O
in O
an O
irreversible O
manner O
in O
order O
to O
provide O
sufficient O
bulk O
for O
the O
new O
restorative O
material O
. O

Overexpression O
of O
BAG B-GENE
- I-GENE
1 I-GENE
also O
protected O
certain O
cell O
lines O
from O
heat O
shock O
- O
induced O
cell O
death O
. O

The O
5 O
' O
flanking O
region O
contains O
potential O
binding O
sites O
for O
TATA B-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
Sp1 B-GENE
, O
nuclear B-GENE
factor I-GENE
1 I-GENE
( O
NF1 B-GENE
) O
, O
CAAT B-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
C B-GENE
/ I-GENE
EBP I-GENE
) O
, O
hepatocyte B-GENE
nuclear I-GENE
factors I-GENE
1 I-GENE
and I-GENE
5 I-GENE
( O
HNF1 B-GENE
, O
HNF5 B-GENE
) O
and O
activator B-GENE
proteins I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
AP1 B-GENE
, O
AP2 B-GENE
) O
. O

The O
recognition O
specificity O
of O
the O
p55 B-GENE
PDZ B-GENE
domain I-GENE
appears O
to O
be O
unique O
, O
since O
the O
three O
PDZ B-GENE
domains I-GENE
of O
hDlg B-GENE
( O
human O
lymphocyte O
homologue O
of O
the O
Drosophila B-GENE
discs I-GENE
large I-GENE
tumor I-GENE
suppressor I-GENE
) O
do O
not O
bind O
the O
cytoplasmic O
domain O
of O
glycophorin B-GENE
C I-GENE
. O

In O
the O
United O
States O
high O
- O
MW O
HES O
480 O
which O
is O
difficult O
to O
degrade O
is O
most O
frequently O
used O
and O
results O
in O
a O
larger O
in O
vivo O
MW O
and O
subsequent O
decrease O
in O
factor B-GENE
VIII I-GENE
/ O
von B-GENE
Willebrand I-GENE
factor I-GENE
levels O
. O

In O
our O
previous O
studies O
, O
transcriptional O
activation O
was O
shown O
to O
correlate O
with O
IEP86 B-GENE
binding O
to O
both O
the O
TATA B-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
TBP B-GENE
) O
and O
the O
transcription O
factor O
bound O
upstream O
. O

Previously O
, O
we O
reported O
that O
scanthrough O
translation O
, O
where O
the O
initiating O
AUG O
of O
a O
primary O
open O
reading O
frame O
is O
bypassed O
, O
is O
most O
likely O
to O
account O
for O
the O
presentation O
of O
cryptic O
epitopes O
from O
alternative O
reading O
frames O
within O
the O
influenza B-GENE
A I-GENE
PR I-GENE
/ I-GENE
8 I-GENE
/ I-GENE
34 I-GENE
nucleoprotein I-GENE
gene I-GENE
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
gene O
has O
significant O
homology O
to O
the O
interferon B-GENE
regulatory I-GENE
factors I-GENE
( O
IRFs B-GENE
) O
. O

The O
pheromone O
response O
pathway O
activates O
transcription O
of O
Ty5 B-GENE
retrotransposons I-GENE
located O
within O
silent O
chromatin O
of O
Saccharomyces O
cerevisiae O
. O

The O
malate B-GENE
synthase I-GENE
gene I-GENE
, O
MLS1 B-GENE
, O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
is O
transcriptionally O
regulated O
by O
the O
carbon O
source O
in O
the O
growth O
medium O
. O

By O
deletion O
analysis O
of O
the O
MLS1 B-GENE
control O
region O
, O
we O
identified O
two O
sites O
, O
UAS1 O
and O
UAS2 O
, O
as O
important O
for O
efficient O
derepression O
of O
the O
gene O
. O

Prior O
to O
meals O
2 O
to O
3 O
times O
daily O
, O
1 O
- O
2 O
tablespoons O
of O
Alzoon O
are O
recommended O
. O

These O
results O
suggest O
that O
UBP41 B-GENE
may O
play O
an O
important O
role O
in O
the O
recycling O
of O
ubiquitin B-GENE
by O
hydrolysis O
of O
branched B-GENE
poly I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
generated O
by O
the O
action O
of O
26 B-GENE
S I-GENE
proteasome I-GENE
on O
poly O
- O
ubiquitinated O
protein O
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin B-GENE
from O
linear B-GENE
poly I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin B-GENE
fusion I-GENE
proteins I-GENE
. O

The O
regurgitation O
of O
large O
vitreous O
injections O
. O

Attenuation O
from O
the O
vit B-GENE
A2 I-GENE
consensus O
ERE O
is O
not O
necessarily O
dependent O
on O
DNA O
binding O
as O
the O
TR B-GENE
alpha I-GENE
DNA O
binding O
mutant O
was O
still O
able O
to O
inhibit O
E O
- O
dependent O
transactivation O
. O

Null O
mutations O
in O
daf B-GENE
- I-GENE
3 I-GENE
suppress O
mutations O
in O
genes O
encoding O
this O
TGF B-GENE
- I-GENE
beta I-GENE
signal O
, O
its O
receptors O
, O
and O
associated O
Smad B-GENE
signal I-GENE
transduction I-GENE
proteins I-GENE
. O
daf B-GENE
- I-GENE
3 I-GENE
encodes O
a O
Smad B-GENE
protein I-GENE
that O
is O
most O
closely O
related O
to O
mammalian B-GENE
DPC4 I-GENE
, O
and O
is O
expressed O
throughout O
development O
in O
many O
of O
the O
tissues O
that O
are O
remodeled O
during O
dauer O
development O
. O

We O
have O
overexpressed O
, O
purified O
, O
characterized O
, O
and O
crystallized O
the O
BTB B-GENE
/ O
POZ O
domain O
from O
PLZF B-GENE
( O
PLZF B-GENE
- O
BTB B-GENE
/ O
POZ O
) O
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B-GENE
- I-GENE
1 I-GENE
promoter I-GENE
performed O
with O
chloramphenicol B-GENE
acetyltransferase I-GENE
constructs I-GENE
revealed O
that O
Tax B-GENE
was O
trans O
activating O
the O
VCAM B-GENE
- I-GENE
1 I-GENE
promoter I-GENE
via O
two O
NF B-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B-GENE
- I-GENE
1 I-GENE
gene I-GENE
promoter I-GENE
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B-GENE
- O
induced O
expression O
of O
this O
adhesion O
molecule O
. O

The O
AGM B-GENE
and I-GENE
NIH I-GENE
/ I-GENE
Swiss I-GENE
mouse I-GENE
CCR5 I-GENE
proteins I-GENE
are O
97 O
. O
7 O
to O
98 O
. O
3 O
% O
and O
79 O
. O
8 O
% O
identical O
to O
the O
human O
protein O
, O
respectively O
. O

Recently O
, O
roles O
also O
have O
been O
suggested O
for O
the O
nuclear O
trans O
- O
factor O
GATA B-GENE
- I-GENE
1 I-GENE
in O
regulating O
progenitor O
cell O
proliferation O
. O

( O
ii O
) O
An O
AF O
G B-GENE
- I-GENE
CSF I-GENE
level O
> O
2000 O
pg O
/ O
ml O
is O
a O
strong O
positive O
predictor O
of O
CAM O
. O

[ O
Pulmonary O
vascular O
resistance O
( O
PVR O
) O
during O
10 O
% O
O2 O
- O
PVR O
during O
21 O
% O
O2 O
/ O
PVR O
during O
21 O
% O
O2 O
] O
x O
100 O
was O
termed O
as O
hypoxic O
pulmonary O
vasoconstriction O
( O
HPV O
) O
. O

An O
unusual O
cysteine O
triplet O
conserved O
in O
the O
sequences O
of O
TB B-GENE
domains I-GENE
is O
localized O
to O
the O
hydrophobic O
core O
, O
at O
the O
C O
- O
terminus O
of O
an O
alpha O
- O
helix O
. O

Protein O
phosphatases O
play O
a O
critical O
role O
in O
the O
regulation O
of O
the O
eukaryotic O
cell O
cycle O
and O
signal O
transduction O
. O

Re O
: O
" O
Assessing O
the O
direction O
of O
causality O
in O
cross O
- O
sectional O
studies O
" O
. O

Restriction O
enzyme O
mapping O
, O
subcloning O
, O
and O
DNA O
sequencing O
analysis O
of O
recombinant O
phage O
lambda O
and O
P1 O
clones O
revealed O
that O
exons O
encoding O
the O
1 O
. O
9 O
- O
kb O
mouse B-GENE
TS I-GENE
mRNA I-GENE
are O
dispersed O
over O
> O
150 O
kb O
genomic O
DNA O
. O

Transfection O
analyses O
indicated O
that O
the O
expression O
of O
Tbxas1 B-GENE
is O
controlled O
by O
a O
short O
( O
70 O
- O
bp O
) O
positive O
regulatory O
sequence O
and O
several O
upstream O
repressive O
elements O
. O

Electromobility O
shift O
and O
cotransfection O
assays O
demonstrated O
that O
HNF1alpha B-GENE
, O
but O
not O
HNF4 B-GENE
, O
bound O
to O
its O
cognate O
site O
and O
transactivated O
G6Pase B-GENE
gene I-GENE
expression O
. O

Differential O
regulation O
of O
the O
pre B-GENE
- I-GENE
C I-GENE
and O
pregenomic O
promoters O
of O
human O
hepatitis O
B O
virus O
by O
members O
of O
the O
nuclear B-GENE
receptor I-GENE
superfamily I-GENE
. O

These O
results O
implicate O
a O
precursor O
- O
specific O
base O
- O
paired O
structure O
involving O
sequences O
on O
both O
sides O
of O
the O
mature O
cleavage O
site O
in O
the O
3 O
' O
processing O
of O
human B-GENE
U2 I-GENE
RNA I-GENE
. O

The O
mouse B-GENE
M I-GENE
- I-GENE
lysozyme I-GENE
downstream I-GENE
enhancer I-GENE
has O
been O
previously O
characterized O
on O
several O
levels O
of O
gene O
regulation O
. O

Bitter O
cassava O
contains O
cyanogenic O
glycosides O
; O
processing O
breaks O
them O
down O
to O
acetone O
cyanohydrin O
and O
hydrogen O
cyanide O
. O

First O
, O
two O
MCTs O
using O
a O
long O
electrode O
, O
3 O
cm O
in O
size O
, O
were O
performed O
in O
the O
central O
area O
of O
the O
tumor O
, O
and O
eight O
MCTs O
by O
a O
short O
electrode O
, O
2 O
cm O
in O
size O
, O
were O
done O
in O
the O
peripheral O
and O
surrounding O
area O
of O
the O
tumor O
. O

We O
also O
show O
by O
immunogold O
electron O
microscopy O
immunocytochemistry O
that O
amphiphysin B-GENE
I I-GENE
is O
localized O
in O
the O
nerve O
terminal O
cytomatrix O
and O
is O
partially O
associated O
with O
endocytic O
intermediates O
. O

The O
prescription O
for O
apoplexy O
includes O
C1 O
- O
7 O
, O
T1 O
- O
9 O
and O
L2 O
- O
4 O
. O

Thus O
, O
dpp B-GENE
and O
omb B-GENE
promote O
both O
dorsal O
leg O
cell O
fate O
as O
well O
as O
transdetermination O
- O
competent O
leg O
disc O
cells O
. O

These O
observations O
provide O
strong O
support O
for O
the O
idea O
that O
expression O
of O
mutant O
tRNA O
can O
confer O
a O
mutator O
phenotype O
, O
including O
the O
UVM O
- O
constitutive O
phenotype O
observed O
in O
mutA B-GENE
and O
mutC B-GENE
cells O
. O

We O
now O
demonstrate O
that O
CCAAT B-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
delta I-GENE
is O
a O
major O
component O
of O
a O
PGE2 O
- O
stimulated O
DNA O
- O
protein O
complex O
involving O
HS3D B-GENE
and O
find O
that O
C B-GENE
/ I-GENE
EBPdelta I-GENE
transactivates O
IGF B-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
through O
this O
site O
. O

Interleukin B-GENE
- I-GENE
1 I-GENE
levels O
remained O
low O
throughout O
the O
course O
. O

Southern O
blot O
analysis O
of O
endonuclease O
- O
digested O
genomic O
DNA O
from O
primary O
chick O
embryo O
fibroblasts O
( O
CEF O
) O
suggested O
that O
MEK2 B-GENE
is O
a O
single O
- O
copy O
gene O
in O
this O
vertebrate O
species O
. O

SCID O
V B-GENE
( O
D B-GENE
) O
J B-GENE
recombination O
can O
be O
partly O
rescued O
in O
T O
- O
lymphocytes O
by O
either O
DNA O
- O
damaging O
agents O
( O
gamma O
- O
irradiation O
and O
bieomycin O
) O
or O
a O
null O
mutation O
of O
the O
p53 B-GENE
gene I-GENE
, O
possibly O
because O
of O
transiently O
elevated O
DNA O
repair O
activity O
in O
response O
to O
DNA O
damage O
or O
to O
delayed O
apoptosis O
in O
the O
absence O
of O
p53 B-GENE
. O

The O
existence O
of O
these O
two O
categories O
of O
strains O
offers O
a O
new O
genetic O
system O
in O
which O
the O
properties O
of O
a O
potential O
invertebrate O
retrovirus O
can O
be O
tested O
. O

TSA O
treatment O
, O
however O
, O
did O
not O
detectably O
alter O
enhancer O
factor O
binding O
or O
the O
positioning O
of O
nuc B-GENE
- I-GENE
1 I-GENE
on O
the O
majority O
of O
the O
chromatin O
templates O
indicating O
that O
protein O
acetylation O
and O
chromatin O
remodeling O
may O
be O
limiting O
steps O
that O
occur O
only O
on O
transcriptionally O
competent O
templates O
, O
or O
that O
remodeling O
of O
nuc B-GENE
- I-GENE
1 I-GENE
requires O
additional O
factors O
. O

Y15170 B-GENE
( O
Surf B-GENE
- I-GENE
2 I-GENE
, O
Surf B-GENE
- I-GENE
4 I-GENE
) O
, O
Y15171 B-GENE
( O
Surf B-GENE
- I-GENE
3 I-GENE
, O
Surf B-GENE
- I-GENE
1 I-GENE
, O
Surf B-GENE
- I-GENE
6 I-GENE
) O
, O
and O
Y15172 B-GENE
( O
Surf B-GENE
- I-GENE
5 I-GENE
. O
) O
] O

The O
mean O
values O
of O
the O
first O
three O
components O
were O
not O
significantly O
different O
in O
ARVD O
patients O
and O
control O
subjects O
. O

However O
, O
the O
signaling O
cascade O
utilized O
by O
the O
urokinase B-GENE
receptor I-GENE
is O
only O
incompletely O
understood O
. O

The O
interaction O
between O
DDB B-GENE
and O
E2F1 B-GENE
can O
also O
be O
detected O
by O
coimmunoprecipitation O
experiments O
. O

Lysine B-GENE
- I-GENE
ketoglutarate I-GENE
reductase I-GENE
and O
saccharopine B-GENE
dehydrogenase I-GENE
from O
Arabidopsis O
thaliana O
: O
nucleotide O
sequence O
and O
characterization O
. O

The O
pel B-GENE
gene I-GENE
from O
an O
Amycolata O
sp O
. O
encoding O
a O
pectate B-GENE
lyase I-GENE
( O
EC B-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
) O
was O
isolated O
by O
activity O
screening O
a O
genomic O
DNA O
library O
in O
Streptomyces O
lividans O
TK24 O
. O

In O
the O
clinical O
study O
, O
the O
defect O
size O
shown O
by O
BMIPP O
imaging O
was O
greater O
in O
anterior O
than O
in O
inferior O
infarcts O
( O
p O
< O
0 O
. O
001 O
) O
and O
correlated O
well O
with O
the O
risk O
area O
revealed O
by O
contrast O
ventriculography O
( O
r O
= O
0 O
. O
80 O
, O
p O
< O
0 O
. O
0001 O
) O
CONCLUSION O
: O
The O
above O
preliminary O
data O
, O
admittedly O
from O
a O
small O
group O
of O
patients O
, O
suggest O
that O
tomographic O
BMIPP O
imaging O
provides O
an O
accurate O
quantification O
of O
defect O
size O
by O
means O
of O
a O
simple O
threshold O
technique O
and O
, O
in O
the O
subacute O
phase O
, O
permits O
determination O
of O
the O
amount O
of O
myocardium O
at O
risk O
after O
acute O
myocardial O
infarction O
. O

The O
promoter O
for O
HMG B-GENE
- I-GENE
CoA I-GENE
synthase I-GENE
contains O
two O
binding O
sites O
for O
the O
sterol B-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
SREBPs B-GENE
) O
. O

Although O
RAD17 B-GENE
, O
RAD24 B-GENE
and O
MEC3 B-GENE
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S O
phase O
is O
inhibited O
by O
hydroxyurea O
( O
HU O
) O
, O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
HU O
, O
possibly O
because O
they O
are O
required O
for O
the O
repair O
of O
HU O
- O
induced O
DNA O
damage O
. O

Protein B-GENE
C I-GENE
deficiency O
or O
protein B-GENE
S I-GENE
deficiency O
was O
the O
only O
identified O
risk O
factor O
for O
5 O
. O
4 O
% O
( O
2 O
patients O
) O
and O
13 O
. O
5 O
% O
( O
5 O
patients O
) O
, O
respectively O
, O
of O
these O
37 O
children O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP B-GENE
- I-GENE
1 I-GENE
and O
SHP B-GENE
- I-GENE
2 I-GENE
revealed O
specific O
association O
of O
SHP B-GENE
- I-GENE
2 I-GENE
( O
but O
not O
SHP B-GENE
- I-GENE
1 I-GENE
) O
with O
a O
glutathione B-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
incorporating O
GHR B-GENE
cytoplasmic I-GENE
domain I-GENE
residues I-GENE
485 I-GENE
- I-GENE
620 I-GENE
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered O
tyrosine O
- O
phosphorylated O
. O

We O
have O
used O
mutation O
- O
directed O
chemical O
cross O
- O
linking O
with O
bis O
( O
sulfosuccinimidyl O
) O
suberate O
( O
BS3 O
) O
to O
investigate O
the O
architecture O
of O
the O
gp41 B-GENE
oligomer I-GENE
. O

Consistent O
with O
previous O
reports O
, O
addition O
of O
a O
myristoylation O
signal O
to O
mSos1 B-GENE
( O
MyrSos1 B-GENE
) O
rendered O
it O
transforming O
for O
NIH O
3T3 O
cells O
and O
deletion O
of O
the O
mSos B-GENE
C I-GENE
terminus I-GENE
( O
MyrSos1 B-GENE
- I-GENE
deltaC I-GENE
) O
did O
not O
interfere O
with O
this O
activity O
. O

Demonstration O
of O
tissue O
lesions O
after O
intramuscular O
injection O
by O
determination O
of O
creatine B-GENE
kinase I-GENE
in O
blood O

Levels O
of O
the O
MEK B-GENE
inhibitor O
PD98059 O
that O
block O
EGF B-GENE
- O
induced O
mitogenesis O
and O
MAP B-GENE
kinase I-GENE
phosphorylation O
also O
abrogate O
EGF B-GENE
- O
induced O
focal O
adhesion O
disassembly O
and O
cell O
motility O
. O

Surprisingly O
, O
the O
COOH O
- O
terminal O
domain O
of O
RanGAP1 B-GENE
was O
also O
found O
to O
harbor O
a O
nuclear O
localization O
signal O
. O

Here O
, O
we O
present O
evidence O
that O
exposure O
of O
DT40 O
lymphoma O
B O
cells O
to O
low O
energy O
electromagnetic O
field O
( O
EMF O
) O
results O
in O
a O
tyrosine B-GENE
kinase I-GENE
- O
dependent O
activation O
of O
phospholipase B-GENE
Cgamma2 I-GENE
( O
PLC B-GENE
- I-GENE
gamma2 I-GENE
) O
leading O
to O
increased O
inositol O
phospholipid O
turnover O
. O

PATIENTS O
AND O
METHOD O
: O
Since O
1986 O
, O
62 O
patients O
were O
irradiated O
stereotactically O
. O

Training O
for O
audit O
. O

Cytoskeletal O
polarization O
of O
T O
cells O
is O
regulated O
by O
an O
immunoreceptor O
tyrosine O
- O
based O
activation O
motif O
- O
dependent O
mechanism O
. O

Here O
we O
have O
examined O
the O
ability O
of O
the O
cellular O
protein O
YB B-GENE
- I-GENE
1 I-GENE
to O
modulate O
transcription O
of O
the O
HIV B-GENE
- I-GENE
1 I-GENE
promoter I-GENE
in O
a O
human O
astrocytic O
cell O
line O
( O
U O
- O
87MG O
) O
, O
a O
neuronal O
cell O
line O
( O
SK O
- O
N O
- O
MC O
) O
and O
lymphoid O
cells O
( O
Jurkat O
) O
by O
transfection O
assay O
. O

Substrates O
for O
p210 B-GENE
( O
bcr B-GENE
- O
abl B-GENE
) O
are O
likely O
to O
be O
involved O
in O
the O
pathogenesis O
of O
CML O
. O

The O
COOH O
- O
terminal O
region O
of O
the O
transcripts O
contained O
fifteen O
triplet O
repeats O
( O
GCT O
; O
alanine O
) O
at O
nucleotide O
465 O
to O
509 O
, O
which O
is O
significantly O
expanded O
compared O
to O
the O
rat B-GENE
RL14 I-GENE
. O

Control O
of O
fatty O
liver O
syndrome O
in O
a O
Jersey O
herd O
by O
a O
change O
of O
diet O
and O
the O
use O
of O
recombinant O
bovine O
somatotrophin B-GENE
. O

During O
organogenesis O
, O
HFH B-GENE
- I-GENE
8 I-GENE
expression O
is O
found O
in O
the O
splanchnic O
mesoderm O
in O
close O
apposition O
of O
the O
gut O
endoderm O
, O
suggesting O
a O
role O
in O
mesenchymal O
- O
epithelial O
induction O
of O
lung O
and O
gut O
morphogenesis O
. O

However O
, O
laparoscopy O
failed O
to O
establish O
inoperability O
in O
any O
cases O
of O
carcinoma O
spread O
to O
areas O
not O
accessible O
to O
laparoscopic O
visualization O
. O

No O
difference O
in O
telomere O
length O
was O
seen O
in O
mutants O
affected O
in O
the O
regulation O
of O
Cdc2 B-GENE
, O
whereas O
some O
of O
the O
DNA O
repair O
mutants O
examined O
had O
slightly O
longer O
telomeres O
than O
did O
the O
wild O
type O
. O

Sp1 B-GENE
can O
activate O
transcription O
through O
immunoglobulin B-GENE
kappa I-GENE
- I-GENE
chain I-GENE
enhancer I-GENE
or O
P B-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
NF B-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
. O
p50 B-GENE
homodimers I-GENE
replace O
Sp1 B-GENE
from O
the O
P B-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
by O
binding O
site O
competition O
and O
thereby O
either O
inhibit O
basal O
Sp1 B-GENE
- O
driven O
expression O
or O
, O
in O
concert O
with O
Bcl B-GENE
- I-GENE
3 I-GENE
, O
stimulate O
expression O
. O

For O
the O
5HT5A B-GENE
receptor I-GENE
the O
addition O
of O
yohimbine O
resulted O
in O
a O
similar O
but O
smaller O
effect O
. O

CONCLUSIONS O
: O
XCoe2 B-GENE
may O
play O
a O
pivotal O
role O
in O
the O
transcriptional O
cascade O
that O
specifies O
primary O
neurons O
in O
Xenopus O
embryos O
: O
by O
maintaining O
Delta B-GENE
- O
Notch B-GENE
signalling O
, O
XCoe2 B-GENE
stabilises O
the O
higher O
neural O
potential O
of O
selected O
progenitor O
cells O
that O
express O
X B-GENE
- I-GENE
ngnr I-GENE
- I-GENE
1 I-GENE
, O
ensuring O
the O
transition O
between O
neural O
competence O
and O
irreversible O
commitment O
to O
a O
neural O
fate O
; O
and O
it O
promotes O
neuronal O
differentiation O
by O
activating O
XNeuroD B-GENE
expression O
, O
directly O
or O
indirectly O
. O

RESULTS O
: O
Patients O
in O
Group O
A O
had O
a O
higher O
incidence O
of O
posterolateral O
wall O
motion O
abnormalities O
( O
p O
< O
0 O
. O
001 O
) O
on O
radionuclide O
ventriculography O
, O
a O
larger O
infarct O
area O
( O
as O
evidenced O
by O
higher O
peak O
creatine B-GENE
kinase I-GENE
levels O
) O
( O
p O
< O
0 O
. O
02 O
) O
and O
a O
lower O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
at O
hospital O
discharge O
( O
p O
< O
0 O
. O
008 O
) O
than O
those O
in O
Group O
B O
. O

In O
all O
cells O
, O
the O
accumulation O
of O
high O
Dsg B-GENE
protein I-GENE
levels O
required O
calcium O
and O
was O
not O
observed O
in O
low O
calcium O
( O
0 O
. O
05 O
- O
0 O
. O
07 O
mM O
) O
media O
. O

RESULTS O
: O
Using O
information O
in O
the O
dbEST O
database O
of O
expressed O
sequence O
tags O
, O
we O
isolated O
an O
Arabidopsis O
thaliana O
gene O
( O
GCR1 B-GENE
) O
that O
encodes O
a O
protein O
with O
seven O
predicted O
membrane O
- O
spanning O
domains O
and O
other O
features O
characteristic O
of O
7TM B-GENE
receptors I-GENE
. O

E1A B-GENE
represses O
apolipoprotein B-GENE
AI I-GENE
enhancer I-GENE
activity O
in O
liver O
cells O
through O
a O
pRb B-GENE
- O
and O
CBP B-GENE
- O
independent O
pathway O
. O

M B-GENE
- I-GENE
66 I-GENE
identified O
the O
14 O
- O
kDa O
protein O
in O
another O
MMTV O
bearing O
T O
- O
cell O
lymphoma O
, O
EL O
- O
4 O
. O

RT O
- O
PCR O
indicated O
that O
p21 B-GENE
mRNA I-GENE
was O
induced O
1 O
. O
4 O
- O
, O
2 O
. O
0 O
- O
, O
and O
3 O
. O
1 O
- O
fold O
in O
the O
2 O
- O
day O
neonatal O
, O
7 O
- O
day O
neonatal O
, O
and O
adult O
stages O
, O
respectively O
, O
compared O
to O
the O
17 O
- O
day O
fetal O
stage O
. O

Ganciclovir O
and O
foscarnet O
efficacy O
in O
AIDS O
- O
related O
CMV O
polyradiculopathy O
. O

BACKGROUND O
AND O
OBJECTIVES O
: O
The O
sexually O
transmitted O
diseases O
( O
STD O
) O
control O
program O
for O
female O
sex O
workers O
( O
FSW O
) O
in O
Lima O
, O
Peru O
, O
provided O
periodic O
serological O
tests O
for O
syphilis O
and O
cervical O
smears O
for O
gonococci O
, O
but O
not O
medication O
for O
STD O
or O
condoms O
. O

In O
order O
to O
examine O
the O
potential O
role O
of O
transcriptional O
silencing O
during O
productive O
HSV O
- O
1 O
infection O
, O
recombinant O
viruses O
were O
generated O
in O
which O
wild B-GENE
- I-GENE
type I-GENE
or I-GENE
mutant I-GENE
ICP34 I-GENE
. I-GENE
5 I-GENE
promoters I-GENE
controlling O
the O
expression O
of O
a O
chloramphenicol B-GENE
acetyltransferase I-GENE
reporter I-GENE
gene I-GENE
were O
inserted O
into O
the O
thymidine B-GENE
kinase I-GENE
gene I-GENE
of O
the O
viral O
genome O
. O

Members O
of O
the O
meis1 B-GENE
and O
pbx B-GENE
homeodomain I-GENE
protein I-GENE
families I-GENE
cooperatively O
bind O
a O
cAMP O
- O
responsive O
sequence O
( O
CRS1 O
) O
from O
bovine B-GENE
CYP17 I-GENE
. O

The O
RAS B-GENE
- O
cyclic B-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
cAPK B-GENE
pathway O
prevents O
the O
UAS O
activity O
of O
IREu B-GENE
in O
the O
presence O
of O
glucose O
as O
the O
sole O
carbon O
source O
, O
while O
the O
transcriptional O
activators O
Msn2p B-GENE
and O
Msn4p B-GENE
promote O
the O
UAS O
activity O
of O
this O
repeat O
in O
the O
presence O
of O
acetate O
. O

Alternative O
splicing O
of O
fibroblast B-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
( O
FGF B-GENE
- I-GENE
R2 I-GENE
) O
is O
an O
example O
of O
highly O
regulated O
alternative O
splicing O
in O
which O
exons O
IIIb O
and O
IIIc O
are O
utilized O
in O
a O
mutually O
exclusive O
manner O
in O
different O
cell O
types O
. O

SNAC O
or O
PBS O
was O
infused O
for O
6 O
. O
5 O
h O
, O
beginning O
30 O
min O
before O
ischemia O
and O
continuing O
throughout O
the O
duration O
of O
reperfusion O
. O

Moreover O
, O
it O
is O
the O
assumptions O
behind O
steady O
- O
state O
O2 O
uptake O
that O
do O
not O
permit O
proper O
interpretation O
of O
energy O
expenditure O
during O
EPOC O
; O
1 O
l O
O2 O
not O
= O
20 O
. O
9 O
kJ O
. O

The O
predicted O
amino O
acid O
sequence O
of O
m B-GENE
- I-GENE
Staf I-GENE
is O
highly O
homologous O
to O
that O
of O
Staf B-GENE
, O
another O
selenocysteine B-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
of O
Xenopus O
laevis O
. O

Recent O
studies O
have O
revealed O
unconventional O
myosin B-GENE
V I-GENE
to O
be O
an O
important O
actin B-GENE
- O
based O
molecular O
motor O
involved O
in O
vesicular O
movement O
. O

Furthermore O
, O
a O
minor O
start O
site O
was O
localized O
179 O
bp O
upstream O
of O
the O
major O
site O
using O
reverse B-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
with O
various O
P1 O
primers O
( O
primer O
walking O
) O
, O
primer O
extension O
, O
and O
cDNA O
cloning O
. O

Analysis O
of O
promoter O
and O
androgen O
regulatory O
sequences O
required O
for O
optimal O
transcription O
of O
the O
rat O
androgen B-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene O
. O

In O
a O
gntR B-GENE
deletion I-GENE
mutant I-GENE
, O
the O
expression O
of O
a O
chromosomal O
gntT B-GENE
: O
: O
lacZ B-GENE
fusion O
is O
both O
high O
and O
constitutive O
, O
confirming O
that O
GntR B-GENE
is O
the O
negative O
regulator O
of O
gntT B-GENE
. O

Therefore O
, O
we O
conclude O
that O
DnaA B-GENE
may O
contact O
the O
beta O
subunit O
of O
RNA B-GENE
polymerase I-GENE
during O
activation O
of O
the O
pR B-GENE
promoter I-GENE
. O

Expression O
of O
Bcl B-GENE
- I-GENE
XL I-GENE
inhibited O
the O
association O
of O
Apaf B-GENE
- I-GENE
1 I-GENE
with O
caspase B-GENE
- I-GENE
9 I-GENE
in O
mammalian O
cells O
. O

Whole O
- O
mount O
in O
situ O
hybridization O
to O
early O
mouse O
embryos O
of O
9 O
. O
5 O
- O
10 O
. O
5 O
days O
indicated O
a O
complex O
pattern O
of O
Arp1 B-GENE
expression O
spatially O
overlapping O
with O
the O
expression O
of O
All1 B-GENE
. O

Creatine B-GENE
kinase I-GENE
release O
after O
hepatic O
artery O
embolization O
in O
patients O
with O
carcinoid O
tumors O
. O

Our O
observations O
suggest O
that O
members O
of O
the O
HMG B-GENE
- I-GENE
I I-GENE
family I-GENE
play O
an O
important O
role O
in O
SRF B-GENE
- O
dependent O
transcription O
and O
that O
their O
effect O
is O
mediated O
primarily O
by O
a O
protein O
- O
protein O
interaction O
. O

We O
recently O
characterized O
a O
single O
yeast B-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
HMT1 B-GENE
) O
. O

We O
recently O
characterized O
a O
single O
yeast B-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
HMT1 B-GENE
) O
. O

Recombinant B-GENE
HRMT1L2 I-GENE
protein I-GENE
encoded O
by O
the O
most O
common O
5 O
' O
- O
variant O
exhibited O
methyltransferase O
activity O
in O
vitro O
. O

The O
possible O
roles O
of O
HRMT1L1 B-GENE
and O
HRMT1L2 B-GENE
in O
human O
disease O
are O
currently O
unknown O
. O

Identification O
and O
characterization O
of O
two O
putative O
human B-GENE
arginine I-GENE
methyltransferases I-GENE
( O
HRMT1L1 B-GENE
and O
HRMT1L2 B-GENE
) O
. O

To O
identify O
nuclear O
regulatory O
factors O
, O
we O
have O
located O
and O
functionally O
characterized O
the O
CCR5 B-GENE
gene I-GENE
promoter I-GENE
. O

The O
interaction O
between O
piroxicam O
and O
poloxamer O
was O
studied O
by O
x O
- O
ray O
diffractometry O
( O
XRD O
) O
, O
infrared O
( O
IR O
) O
spectroscopy O
and O
differential O
thermal O
analysis O
( O
DTA O
) O
with O
a O
solid O
dispersion O
, O
coprecipitate O
, O
or O
physical O
mixture O
. O

The O
results O
confirm O
that O
a O
single O
base O
change O
in O
the O
branchpoint O
consensus O
sequence O
of O
an O
intron O
can O
cause O
human O
disease O
although O
this O
sequence O
is O
poorly O
conserved O
in O
mammals O
. O

It O
bound O
to O
vitamin B-GENE
D I-GENE
receptor I-GENE
( O
VDR B-GENE
) O
but O
not O
retinoic B-GENE
acid I-GENE
Xalpha I-GENE
receptor I-GENE
( O
RXRalpha B-GENE
) O
in O
the O
human O
T O
cell O
line O
MT2 O
cells O
. O

Based O
on O
the O
current O
literature O
, O
the O
mechanisms O
involved O
in O
the O
toxicity O
of O
OA B-GENE
indicate O
three O
major O
effects O
: O
( O
1 O
) O
inhibition O
of O
mitochondrial O
respiration O
correlated O
with O
a O
depletion O
of O
ATP O
; O
( O
2 O
) O
inhibition O
of O
tRNA B-GENE
- I-GENE
synthetase I-GENE
accompanied O
by O
a O
reduced O
protein O
synthesis O
; O
and O
( O
3 O
) O
enhanced O
lipid O
peroxidation O
. O

Another O
stem O
- O
loop O
called O
structure O
III O
near O
the O
3 O
' O
- O
end O
of O
repY B-GENE
sequesters O
both O
the O
5 O
' O
- O
rCGCC O
- O
3 O
' O
sequence O
and O
the O
repZ B-GENE
ribosome I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
general O
transcription B-GENE
factor I-GENE
IIA I-GENE
( O
TFIIA B-GENE
) O
interacts O
with O
the O
TATA B-GENE
binding I-GENE
protein I-GENE
( O
TBP B-GENE
) O
and O
promoter O
DNA O
to O
mediate O
transcription O
activation O
in O
vitro O
. O

Localization O
of O
67 O
exons O
on O
a O
YAC O
contig O
spanning O
1 O
. O
5 O
Mb O
around O
the O
multidrug B-GENE
resistance I-GENE
gene I-GENE
region I-GENE
of O
human O
chromosome O
7q21 O
. O
1 O
. O

Using O
Southern O
blot O
analysis O
and O
restriction O
mapping O
of O
genomic O
YAC O
( O
yeast O
artificial O
chromosome O
) O
and O
cosmid O
clones O
, O
we O
located O
the O
human B-GENE
RIL I-GENE
gene I-GENE
240 O
- O
260 O
kb O
telomeric O
to O
the O
IRF1 B-GENE
gene I-GENE
and O
characterized O
its O
genomic O
structure O
. O

U73 B-GENE
contains O
C O
, O
D O
and O
D O
' O
boxes O
and O
a O
12 O
- O
nucleotide O
antisense O
complementarity O
to O
the O
28S B-GENE
ribosomal I-GENE
RNA I-GENE
. O

However O
, O
mandibular O
position O
( O
S O
- O
N O
- O
B O
and O
S O
- O
N O
- O
Pog O
) O
was O
found O
to O
be O
significantly O
more O
retrusive O
in O
Class O
II O
when O
compared O
with O
Class O
I O
subjects O
. O

Echinostomiasis O
is O
aggravated O
by O
socioeconomic O
factors O
such O
as O
poverty O
, O
malnutrition O
, O
an O
explosively O
growing O
free O
- O
food O
market O
, O
a O
lack O
of O
supervised O
food O
inspection O
, O
poor O
or O
insufficient O
sanitation O
, O
other O
helminthiases O
, O
and O
declining O
economic O
conditions O
. O

The O
localization O
of O
ZAP B-GENE
- I-GENE
70 I-GENE
to O
the O
cell O
cortex O
is O
, O
therefore O
, O
regulated O
by O
the O
activity O
of O
SRC B-GENE
- I-GENE
family I-GENE
kinases I-GENE
, O
independently O
of O
their O
ability O
to O
phosphorylate O
immunoreceptor O
tyrosine O
- O
based O
activation O
motifs O
of O
the O
TCR B-GENE
. O

The O
effect O
of O
nitric B-GENE
oxide I-GENE
synthase I-GENE
inhibitor O
on O
reperfusion O
injury O
of O
the O
brain O
under O
hypothermic O
circulatory O
arrest O
. O

UDP B-GENE
- I-GENE
GlcNAc I-GENE
: O
alpha B-GENE
- I-GENE
6 I-GENE
- I-GENE
D I-GENE
- I-GENE
mannoside I-GENE
beta I-GENE
- I-GENE
1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
N I-GENE
- I-GENE
acetylglucosaminyltransferase I-GENE
II I-GENE
( O
GnT B-GENE
II I-GENE
; O
EC B-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
1 I-GENE
. I-GENE
143 I-GENE
) O
is O
essential O
for O
the O
normal O
assembly O
of O
complex O
Asn O
- O
linked O
glycans O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
silymarin O
may O
exert O
a O
strong O
anticarcinogenic O
effect O
against O
PCA O
and O
that O
this O
effect O
is O
likely O
to O
involve O
impairment O
of O
erbB1 B-GENE
- O
SHC B-GENE
- O
mediated O
signaling O
pathway O
, O
induction O
of O
CDKIs B-GENE
, O
and O
a O
resultant O
G1 O
arrest O
. O

In O
connective O
tissue O
, O
cell O
structure O
contributes O
to O
type B-GENE
I I-GENE
collagen I-GENE
expression O
. O

A O
point O
mutation O
in O
Galphao B-GENE
and O
Galphai1 B-GENE
blocks O
interaction O
with O
regulator O
of O
G B-GENE
protein I-GENE
signaling O
proteins O
. O

Indeed O
, O
it O
is O
shown O
that O
it O
mediates O
the O
formation O
of O
disulfide O
- O
linked O
homodimers O
and O
that O
the O
formation O
of O
homo O
- O
and O
heterodimers O
are O
mutually O
excluded O
. O

N O
. O
, O
and O
Fanning O
, O
E O
. O

In O
patients O
with O
type O
IA O
maple O
syrup O
urine O
disease O
, O
the O
E1alpha B-GENE
subunit I-GENE
is O
affected O
, O
resulting O
in O
the O
loss O
of O
E1 B-GENE
and O
branched B-GENE
- I-GENE
chain I-GENE
ketoacid I-GENE
dehydrogenase I-GENE
catalytic O
activities O
. O

All O
patients O
diagnosed O
of O
H O
. O
influenza O
type O
b O
meningitis O
were O
less O
than O
3 O
years O
old O
. O

Immunohistochemically O
, O
anticytokeratin B-GENE
19 I-GENE
antibody I-GENE
revealed O
strong O
staining O
in O
both O
epithelial O
and O
sarcomatous O
MPM O
tissues O
. O

Combined O
expression O
of O
c B-GENE
- I-GENE
Jun I-GENE
and O
p65 B-GENE
induced O
vigorous O
transcription O
of O
IL B-GENE
- I-GENE
2 I-GENE
promoter O
- O
and O
CD28RE B-GENE
- I-GENE
driven I-GENE
reporter I-GENE
constructs I-GENE
in O
both O
LFA B-GENE
- I-GENE
3 I-GENE
- O
and O
B7 B-GENE
- I-GENE
1 I-GENE
- O
costimulated O
Jurkat O
cells O
. O

Liquid O
chromatographic O
method O
for O
analysis O
of O
all O
- O
rac O
- O
alpha O
- O
tocopheryl O
acetate O
and O
retinyl O
palmitate O
in O
milk O
- O
based O
infant O
formula O
using O
matrix O
solid O
- O
phase O
dispersion O
. O

The O
ability O
to O
maintain O
expression O
of O
FAS1 B-GENE
in O
nmt1 B-GENE
- O
451Dino2 B-GENE
Delta O
cells O
suggests O
the O
existence O
of O
another O
transcription O
factor O
, O
or O
factors O
, O
whose O
expression O
/ O
activity O
is O
inversely O
related O
to O
overall O
levels O
of O
cellular O
protein O
N O
- O
myristoy O
- O
lation O
. O

The O
identified O
isolates O
of O
CSF O
( O
20 O
of O
29 O
) O
were O
: O
ECHO O
30 O
( O
9 O
) O
, O
ECHO O
11 O
( O
7 O
) O
, O
ECHO O
9 O
( O
3 O
) O
and O
ECHO O
7 O
( O
1 O
) O
. O

There O
was O
no O
evidence O
of O
any O
persistent O
oscillation O
within O
the O
ULF O
band O
. O

A O
large O
deletion O
in O
the O
CTD B-GENE
- I-GENE
binding I-GENE
motif I-GENE
blocks O
down O
- O
regulation O
but O
does O
not O
affect O
the O
essential O
function O
of O
Nrd1 B-GENE
. O

Thus O
, O
included O
in O
the O
KG1a O
EST O
dataset O
are O
candidates O
for O
new O
human O
genes O
that O
may O
play O
roles O
in O
hematopoietic O
differentiative O
progression O
and O
lineage O
commitment O
. O

Sp1 B-GENE
and O
two O
Sp3 B-GENE
isoforms I-GENE
were O
detected O
as O
the O
primary O
cellular O
constituents O
of O
DNA O
- O
protein O
complexes O
formed O
with O
the O
NF B-GENE
- I-GENE
kappaB I-GENE
- I-GENE
proximal I-GENE
site I-GENE
. O

The O
second O
patient O
had O
received O
pituitary B-GENE
- I-GENE
derived I-GENE
growth I-GENE
hormone I-GENE
for O
treatment O
of O
growth B-GENE
hormone I-GENE
deficiency O
, O
secondary O
to O
a O
third O
ventricle O
teratoma O
, O
exised O
13 O
yr O
earlier O
. O

Binding O
affinities O
of O
different O
nucleotide O
mono O
- O
, O
di O
- O
and O
triphosphates O
and O
non O
- O
hydrolyzable O
analogs O
indicate O
that O
the O
beta O
- O
phosphate O
moiety O
is O
required O
for O
substrate O
binding O
. O

[ O
Treatment O
of O
early O
T1 O
small O
T2N O
breast O
cancers O
. O

Malaria O
had O
diminished O
significantly O
by O
the O
early O
1940s O
, O
and O
this O
paper O
queries O
whether O
that O
reduction O
was O
due O
to O
the O
control O
projects O
of O
the O
thirties O
, O
and O
, O
if O
so O
, O
whether O
such O
projects O
should O
be O
a O
model O
for O
the O
current O
developing O
world O
, O
where O
malaria O
is O
a O
growing O
problem O
today O
. O

Fowlpox O
virus O
encodes O
nonessential O
homologs O
of O
cellular B-GENE
alpha I-GENE
- I-GENE
SNAP I-GENE
, O
PC B-GENE
- I-GENE
1 I-GENE
, O
and O
an O
orphan O
human O
homolog O
of O
a O
secreted O
nematode O
protein O
. O

Further O
, O
Ser O
/ O
Thr O
phosphorylation O
of O
downstream O
molecules O
Akt B-GENE
and O
p70 B-GENE
S6 I-GENE
kinase I-GENE
was O
inhibited O
. O

Quantitative O
evaluation O
of O
the O
steady O
state O
kinetics O
of O
MEK B-GENE
inhibition O
by O
these O
compounds O
reveals O
that O
U0126 O
has O
approximately O
100 O
- O
fold O
higher O
affinity O
for O
deltaN3 B-GENE
- I-GENE
S218E I-GENE
/ I-GENE
S222D I-GENE
MEK I-GENE
than O
does O
PD098059 O
. O

However O
, O
little O
is O
known O
regarding O
the O
genomic O
organization O
and O
developmental O
expression O
of O
the O
caveolin B-GENE
gene I-GENE
family I-GENE
. O

Tensile O
bond O
strengths O
between O
resin O
composite O
and O
bovine O
dentin O
using O
dentin O
adhesive O
systems O
( O
Clearfil O
Liner O
Bond O
II O
: O
LB O
II O
; O
Scotchbond O
Multi O
- O
Purpose O
: O
MP O
) O
bonding O
systems O
showed O
a O
large O
scatter O
among O
students O
and O
dentists O
. O

To O
better O
understand O
the O
role O
of O
Ets B-GENE
proteins I-GENE
in O
Ras B-GENE
transformation O
, O
we O
have O
now O
analyzed O
the O
effects O
of O
stably O
expressing O
a O
variety O
of O
Ets2 B-GENE
constructs I-GENE
in O
Ras B-GENE
- O
transformed O
NIH3T3 O
( O
DT O
) O
cells O
. O

Manipulation O
of O
the O
checkpoint O
regulators O
involved O
in O
cell O
cycle O
arrest O
and O
apoptosis O
may O
thus O
provide O
a O
novel O
strategy O
to O
cancer O
therapy O
. O

The O
diagnostic O
accuracy O
of O
serum O
PE B-GENE
- I-GENE
1 I-GENE
was O
0 O
. O
80 O
, O
and O
that O
of O
amylase B-GENE
0 O
. O
97 O
. O

We O
demonstrate O
that O
Ddc1p B-GENE
interacts O
physically O
in O
vivo O
with O
Mec3p B-GENE
, O
and O
this O
interaction O
requires O
Rad17p B-GENE
. O

Deleting O
SNF1 B-GENE
repressed O
meiosis O
at O
the O
same O
three O
steps O
that O
were O
inhibited O
by O
glucose O
, O
suggesting O
that O
glucose O
blocks O
meiosis O
by O
inhibiting O
Snf1 B-GENE
. O

Ligand O
- O
independent O
activation O
of O
platelet B-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
is O
a O
necessary O
intermediate O
in O
lysophosphatidic O
, O
acid O
- O
stimulated O
mitogenic O
activity O
in O
L O
cells O
. O

In O
canrenoate O
- O
treated O
rats O
, O
ANP B-GENE
infusion O
caused O
greater O
increases O
in O
sodium O
excretion O
( O
FENA O
from O
3 O
. O
05 O
+ O
/ O
- O
0 O
. O
71 O
to O
7 O
. O
21 O
+ O
/ O
- O
0 O
. O
45 O
% O
; O
P O
< O
0 O
. O
05 O
; O
n O
= O
8 O
) O
than O
saline O
infusion O
( O
FENA O
from O
4 O
. O
16 O
+ O
/ O
- O
1 O
. O
11 O
to O
5 O
. O
47 O
+ O
/ O
- O
0 O
. O
66 O
% O
; O
n O
= O
6 O
) O
, O
despite O
the O
hypocapnia O
. O

Identical O
c B-GENE
- I-GENE
erbB3 I-GENE
transcripts I-GENE
are O
expressed O
in O
normal O
human O
placental O
tissues O
. O

Downregulation O
of O
FUS B-GENE
expression O
in O
BCR B-GENE
/ O
ABL B-GENE
- O
expressing O
32Dcl3 O
cells O
was O
associated O
with O
suppression O
of O
growth O
factor O
- O
independent O
colony O
formation O
, O
restoration O
of O
G B-GENE
- I-GENE
CSF I-GENE
- O
induced O
granulocytic O
differentiation O
and O
reduced O
tumorigenic O
potential O
in O
vivo O
. O

We O
propose O
a O
model O
in O
which O
Sro7 B-GENE
function O
is O
involved O
in O
the O
targeting O
of O
the O
myosin B-GENE
proteins I-GENE
to O
their O
intrinsic O
pathways O
. O

In O
experiments O
with O
the O
D1 O
antagonist O
SCH O
23390 O
, O
buprenorphine O
- O
induced O
depression O
was O
consistently O
blocked O
, O
but O
facilitation O
was O
unaffected O
. O

Acute O
idiopathic O
thrombocytopenic O
purpura O
presenting O
a O
high O
serum O
level O
of O
immunoglobulin B-GENE
E I-GENE
and O
eosinophilia O
in O
an O
elderly O
patient O
. O

The O
purpose O
of O
this O
article O
is O
to O
discuss O
the O
factors O
involved O
in O
the O
selection O
of O
antibodies O
, O
radionuclides O
and O
labeling O
methods O
in O
the O
development O
of O
radioimmunotherapy O
( O
RIT O
) O
for O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
NHL O
) O
from O
a O
single O
clinical O
study O
site O
through O
multicenter O
trials O
and O
commercialization O
. O

Transcriptional O
regulation O
of O
the O
GluR2 B-GENE
gene I-GENE
: O
neural O
- O
specific O
expression O
, O
multiple O
promoters O
, O
and O
regulatory O
elements O
. O

The O
binding O
of O
NF B-GENE
- I-GENE
ATp I-GENE
, O
although O
not O
NF B-GENE
- I-GENE
AT4 I-GENE
, O
to O
this O
enhancer O
also O
occurs O
along O
with O
HTLV O
- O
I O
- O
mediated O
infection O
of O
human O
peripheral O
blood O
T O
- O
cells O
. O

Thus O
, O
TRAF2 B-GENE
initiates O
SAPK B-GENE
and O
p38 B-GENE
activation O
by O
binding O
two O
proximal O
protein O
kinases O
: O
GCK B-GENE
and O
RIP B-GENE
. O

Tumor B-GENE
necrosis I-GENE
factor I-GENE
signaling O
to O
stress B-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK B-GENE
) O
/ O
Jun B-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK B-GENE
) O
and O
p38 B-GENE
. O

The O
activity O
of O
the O
minimal O
promoter O
was O
found O
to O
be O
controlled O
by O
a O
combination O
of O
the O
activities O
of O
the O
transcription O
factors O
Sp1 B-GENE
, O
Sp3 B-GENE
, O
and O
NF B-GENE
- I-GENE
Y I-GENE
. O

Pressure O
ulcers O
. O

TBP B-GENE
can O
be O
phosphorylated O
in O
vitro O
by O
extracts O
of O
U937 O
cells O
or O
by O
bacterially O
expressed O
activated O
ERK2 B-GENE
; O
the O
phosphorylation O
sites O
were O
mapped O
to O
ERK B-GENE
kinase I-GENE
consensus I-GENE
sites I-GENE
in O
the O
TBP B-GENE
amino I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
. O

During O
the O
CR O
/ O
PP O
diet O
only O
the O
HS O
subjects O
did O
not O
show O
the O
stress O
- O
induced O
rise O
in O
depression O
, O
decline O
in O
vigour O
and O
cortisol O
elevation O
that O
they O
showed O
after O
the O
PR O
/ O
CP O
diet O
. O

Evidence O
for O
a O
novel O
MAPKKK B-GENE
- O
independent O
pathway O
controlling O
the O
stress O
activated O
Sty1 B-GENE
/ O
Spc1 B-GENE
MAP O
kinase O
in O
fission O
yeast O
. O

Furthermore O
, O
we O
demonstrated O
that O
Galpha11 B-GENE
Q209L I-GENE
stimulated O
Src B-GENE
family I-GENE
kinase O
activity O
and O
induced O
tyrosine O
phosphorylation O
of O
several O
proteins O
in O
HEK O
- O
293 O
cells O
. O

The O
micturition O
pressure O
was O
significantly O
decreased O
only O
after O
injection O
with O
BUP O
- O
4 O
in O
both O
normal O
and O
obstructed O
rats O
. O

Peroxisome B-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPAR B-GENE
) O
modulate O
transcription O
by O
binding O
to O
specific O
peroxisome O
proliferator O
- O
response O
elements O
( O
PPRE O
) O
through O
heterodimerization O
with O
the O
9 B-GENE
- I-GENE
cis I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RXR B-GENE
) O
. O

Molecular O
cloning O
and O
functional O
characterization O
of O
murine B-GENE
sphingosine I-GENE
kinase I-GENE
. O

Our O
results O
show O
that O
, O
from O
a O
thermodynamical O
standpoint O
, O
melatonin O
may O
directly O
scavenge O
hydroxyl O
radicals O
both O
in O
vacuum O
and O
in O
aqueous O
solution O
. O

This O
sequence O
, O
Thr O
- O
Gly O
- O
X O
- O
X O
- O
Gly O
- O
Asp O
- O
Gly O
- O
Lys O
- O
Ile O
- O
Phe O
, O
forms O
part O
of O
the O
B O
- O
loop O
and O
is O
conserved O
in O
a O
wide O
variety O
of O
organisms O
that O
include O
bacteria O
, O
algae O
and O
archeabacteria O
. O

The O
only O
abundant O
viral O
transcript O
expressed O
during O
latency O
is O
the O
latency B-GENE
- I-GENE
related I-GENE
( O
LR B-GENE
) O
RNA O
. O

Expression O
of O
constitutively O
active O
MEK1 B-GENE
, O
the O
kinase O
that O
activates O
ERKs B-GENE
, O
or O
overexpression O
of O
ERK2 B-GENE
, O
but O
not O
JNK1 B-GENE
, O
inhibited O
Stat3 B-GENE
activation O
. O

MEKs B-GENE
and O
ERKs B-GENE
inhibited O
IL B-GENE
- I-GENE
6 I-GENE
activation O
of O
Stat3 B-GENE
harboring O
a O
mutation O
at O
serine O
- O
727 O
, O
the O
major O
site O
for O
serine O
phosphorylation O
, O
similar O
to O
inhibition O
of O
wild B-GENE
- I-GENE
type I-GENE
Stat3 I-GENE
, O
and O
inhibited O
Janus B-GENE
kinases I-GENE
Jak1 B-GENE
and O
Jak2 B-GENE
upstream O
of O
Stat3 B-GENE
in O
the O
Jak B-GENE
- O
STAT B-GENE
- O
signaling O
pathway O
. O

Genome O
plasticity O
in O
the O
distal O
tail O
fiber O
locus O
of O
the O
T O
- O
even O
bacteriophage O
: O
recombination O
between O
conserved O
motifs O
swaps O
adhesin B-GENE
specificity O
. O

Whereas O
, O
in O
the O
single O
- O
chambered O
body O
box O
, O
PenH O
units O
( O
Enhanced O
Pause O
) O
reflect O
" O
effort O
of O
breathing O
. O
" O
This O
is O
measured O
as O
the O
pause O
between O
inspiration O
and O
expiration O
. O

This O
suggests O
that O
while O
underpredictions O
of O
pain O
do O
not O
hurt O
more O
, O
disruption O
on O
primary O
tasks O
and O
physiological O
impact O
are O
higher O
. O

Badcock O
and O
Westheimer O
( O
Spatial O
Vision O
1 O
( O
1 O
) O
, O
3 O
- O
11 O
, O
1985 O
) O
showed O
that O
a O
thin O
vertical O
line O
induces O
nearby O
zones O
of O
attraction O
and O
repulsion O
; O
this O
study O
extends O
those O
results O
by O
more O
closely O
examining O
the O
horizontal O
and O
vertical O
extents O
of O
the O
repulsion O
zone O
and O
by O
using O
an O
illusory O
contour O
to O
induce O
repulsion O
. O

desmethyltrimebutine O
was O
inactive O
. O

A O
5 O
. O
0 O
- O
kb O
transcript O
detected O
by O
the O
differential O
display O
amplicon O
3G1 O
was O
found O
to O
correlate O
strongly O
with O
RAG1 B-GENE
mRNA I-GENE
expression O
in O
various O
human O
cell O
lines O
. O

The O
hBRAG B-GENE
gene I-GENE
was O
localized O
to O
the O
long O
arm O
of O
chromosome O
10 O
( O
10q26 O
) O
. O

Genomic O
locus O
of O
chCTCF B-GENE
contains O
a O
GC O
- O
rich O
untranslated O
exon O
separated O
from O
seven O
coding O
exons O
by O
a O
long O
intron O
. O

Small B-GENE
GTPases I-GENE
of O
the O
Ypt B-GENE
/ O
Rab B-GENE
family O
are O
involved O
in O
the O
regulation O
of O
vesicular O
transport O
. O

The O
GEF B-GENE
and O
GAP B-GENE
activities O
for O
Ypt1p B-GENE
localize O
to O
particulate O
cellular O
fractions O
. O

Dopamine B-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
( O
DBH B-GENE
) O
catalyzes O
the O
conversion O
of O
dopamine O
to O
noradrenaline O
and O
is O
selectively O
expressed O
in O
noradrenergic O
and O
adrenergic O
neurons O
and O
neuroendocrine O
cells O
. O

Collectively O
, O
this O
study O
emphasizes O
a O
critical O
role O
of O
Phox2a B-GENE
as O
well O
as O
its O
functional O
synergism O
with O
other O
transcription O
factors O
( O
e O
. O
g O
. O
, O
CREB B-GENE
, O
AP2 B-GENE
, O
and O
Sp1 B-GENE
) O
in O
transcriptional O
activation O
of O
the O
DBH B-GENE
gene I-GENE
. O

Sequence O
comparisons O
strongly O
suggest O
that O
the O
S27a B-GENE
and O
the O
ubiquitin B-GENE
coding O
sequences O
found O
in O
the O
genome O
of O
CP O
Rit O
were O
both O
derived O
from O
a O
bovine O
mRNA O
encoding O
a O
hybrid O
protein O
with O
the O
structure O
NH2 O
- O
ubiquitin B-GENE
- O
S27a B-GENE
- O
COOH O
. O

J O
. O

There O
was O
a O
trend O
in O
all O
studies O
favouring O
PVI O
. O

This O
domain O
, O
although O
adjacent O
to O
the O
5 O
' O
edge O
of O
the O
SD O
sequence O
, O
does O
not O
inhibit O
ribosome O
binding O
as O
long O
as O
the O
single O
- O
stranded O
region O
of O
domain O
3 O
is O
present O
. O

Previous O
genetic O
studies O
led O
to O
the O
conclusion O
that O
nitrate O
and O
nitrite O
induction O
of O
nasF B-GENE
operon I-GENE
expression O
is O
determined O
by O
a O
transcriptional O
antitermination O
mechanism O
. O

EGFR B-GENE
levels O
were O
found O
to O
be O
elevated O
5 O
- O
, O
3 O
. O

Furthermore O
, O
LB1 B-GENE
gene I-GENE
mapped O
to O
chromosome O
13q14 O
, O
a O
region O
that O
has O
been O
involved O
as O
a O
chromosomal O
breakpoint O
in O
DLBL O
. O

Wild B-GENE
- I-GENE
type I-GENE
AT1A I-GENE
receptors I-GENE
, O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
, O
rapidly O
internalized O
after O
Ang B-GENE
II I-GENE
stimulation O
[ O
t1 O
/ O
2 O
2 O
. O
3 O
min O
; O
maximal O
level O
of O
internalization O
( O
Ymax O
) O
78 O
. O
2 O
% O
] O
, O
as O
did O
mutant O
receptors O
carrying O
single O
acidic O
substitutions O
( O
T332E O
, O
t1 O
/ O
2 O
2 O
. O
7 O
min O
, O
Ymax O
76 O
. O
3 O
% O
; O
S335D O
, O
t1 O
/ O
2 O
2 O
. O
4 O
min O
, O
Ymax O
76 O
. O
7 O
% O
; O
T336E O
, O
t1 O
/ O
2 O
2 O
. O
5 O
min O
, O
Ymax O
78 O
. O
2 O
% O
; O
S338D O
, O
t1 O
/ O
2 O
2 O
. O
6 O
min O
, O
Ymax O
78 O
. O
4 O
% O
) O
. O

The O
activated O
glucocorticoid B-GENE
receptor I-GENE
forms O
a O
complex O
with O
Stat5 B-GENE
and O
enhances O
Stat5 B-GENE
- O
mediated O
transcriptional O
induction O
. O

T O
. O
, O
Mahasneh O
, O
A O
. O
, O
and O
Cote O
, O
G O
. O

RESULTS O
: O
The O
binding O
of O
99mTc O
d O
, O
1 O
- O
HMPAO O
to O
human O
placenta O
ranged O
from O
2 O
. O
95 O
% O
+ O
/ O
- O
1 O
. O
5 O
% O
to O
5 O
. O
82 O
% O
+ O
/ O
- O
0 O
. O
3 O
% O
per O
1 O
ml O
standard O
solution O
. O

CM O
reduced O
the O
nuclear O
binding O
activity O
of O
transcription B-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
. O

NF B-GENE
- I-GENE
kappaB I-GENE
, O
which O
is O
probably O
important O
for O
basal O
activity O
of O
the O
human B-GENE
NOS I-GENE
II I-GENE
promoter I-GENE
, O
is O
unlikely O
to O
function O
as O
a O
major O
effector O
of O
CM O
in O
DLD O
- O
1 O
cells O
. O

RESULTS O
: O
The O
cardiac O
index O
significantly O
changed O
with O
varying O
PaCO2 O
levels O
( O
hypocapnia O
, O
- O
9 O
% O
; O
hypercapnia O
, O
13 O
% O
) O
. O

Sequencing O
of O
a O
40 O
- O
kb O
DNA O
segment O
of O
the O
FK506 O
gene O
cluster O
from O
Streptomyces O
sp O
. O

The O
predicted O
domain O
structures O
of O
FkbB B-GENE
and O
FkbC B-GENE
are O
analogous O
to O
that O
of O
FkbA B-GENE
and O
comprise O
30 O
fatty B-GENE
- I-GENE
acid I-GENE
- I-GENE
synthase I-GENE
( O
FAS B-GENE
) O
- O
like O
domains O
arranged O
in O
6 O
modules O
. O

The O
cwg2 B-GENE
- I-GENE
1 I-GENE
mutation I-GENE
was O
identified O
as O
a O
guanine O
to O
adenine O
substitution O
at O
nucleotide O
604 O
of O
the O
coding O
region O
, O
originating O
the O
change O
A202T O
in O
the O
cwg2p B-GENE
. O

Handling O
on O
PND O
9 O
did O
not O
result O
in O
elevated O
CORT O
levels O
in O
any O
of O
the O
groups O
. O

633 O
+ O
/ O
- O
258 O
aggregates O
/ O
ml O
at O
0 O
rpm O
; O
P O
< O
0 O
. O
001 O
) O
. O

These O
results O
indicate O
that O
the O
total O
number O
of O
subunit O
c O
in O
F0 B-GENE
should O
be O
a O
multiple O
of O
2 O
and O
3 O
. O

BACKGROUND O
: O
The O
c B-GENE
- I-GENE
myc I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
has O
been O
suggested O
to O
play O
key O
roles O
in O
cell O
proliferation O
, O
differentiation O
, O
transformation O
and O
apoptosis O
. O

AMY B-GENE
- I-GENE
1 I-GENE
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c B-GENE
- I-GENE
myc I-GENE
at O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c B-GENE
- I-GENE
myc I-GENE
expression O
in O
transiently O
transfected O
cells O
. O

Antidepressant O
- O
like O
properties O
of O
some O
serotonin B-GENE
receptor I-GENE
ligands O
and O
calcium O
channel O
antagonists O
measured O
with O
the O
forced O
swimming O
test O
in O
mice O
. O

The O
various O
available O
data O
strongly O
suggesting O
an O
environmental O
toxic O
origin O
for O
the O
" O
sperm O
fall O
" O
will O
be O
presented O
as O
well O
as O
the O
most O
frequently O
suspected O
class O
of O
substances O
, O
the O
xenoestrogens O
. O

Examination O
of O
DNA O
: O
protein O
binding O
complexes O
by O
gel O
- O
shift O
analysis O
indicated O
that O
nuclear O
factors O
from O
both O
proliferative O
and O
growth O
- O
arrested O
cells O
bound O
to O
the O
DNA O
fragment O
spanning O
- O
949 O
- O
- O
722 O
bp O
. O

RESULTS O
: O
An O
herpetic O
seroconversion O
is O
observed O
with O
presence O
of O
type O
I O
herpes O
simplex O
virus O
( O
HSV O
I O
) O
nucleic O
acids O
in O
the O
recipient O
' O
s O
aqueous O
humor O
. O

GH B-GENE
failed O
to O
stimulate O
phosphorylation O
or O
activation O
of O
Jun B-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
under O
the O
conditions O
used O
. O

CD4 B-GENE
lymphocyte O
and O
viral O
load O
levels O
suggested O
an O
optimal O
response O
to O
ARV O
therapy O
at O
the O
time O
LD O
developed O
. O

By O
DNase B-GENE
I I-GENE
footprint O
analysis O
of O
the O
PNR O
element O
, O
a O
palindrome O
of O
two O
high O
- O
affinity O
Ets B-GENE
- I-GENE
binding I-GENE
sites I-GENE
( O
CTTCCCTGGAAG O
) O
was O
identified O
. O

No O
mutations O
were O
found O
in O
follicular O
adenomas O
. O

Expression O
of O
lacZ B-GENE
from O
the O
promoter O
of O
the O
Escherichia B-GENE
coli I-GENE
spc I-GENE
operon I-GENE
cloned O
into O
vectors O
carrying O
the O
W205 O
trp B-GENE
- O
lac B-GENE
fusion O
. O

RT O
- O
PCR O
analysis O
showed O
that O
PLP B-GENE
- I-GENE
H I-GENE
as O
well O
as O
PLP B-GENE
- I-GENE
C I-GENE
and O
PLP B-GENE
- I-GENE
D I-GENE
are O
expressed O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
PLP B-GENE
diversity O
is O
not O
due O
to O
strain O
differences O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
new O
member O
of O
the O
rat B-GENE
placental I-GENE
prolactin I-GENE
( O
PRL B-GENE
) O
family O
, O
PRL B-GENE
- O
like O
protein B-GENE
H I-GENE
. O

Thus O
, O
we O
have O
identified O
an O
activation O
target O
of O
a O
human O
activator O
, O
Oct B-GENE
- I-GENE
1 I-GENE
, O
within O
its O
cognate O
basal O
transcription O
complex O
. O

The O
results O
raise O
the O
possibility O
that O
pH O
induced O
post O
- O
translational O
modifications O
of O
DdRPA B-GENE
are O
involved O
in O
events O
that O
halt O
cell O
proliferation O
and O
induce O
differentiation O
in O
Dictyostelium O
. O

P B-GENE
- I-GENE
CIP1 I-GENE
, O
a O
novel O
protein O
that O
interacts O
with O
the O
cytosolic O
domain O
of O
peptidylglycine B-GENE
alpha I-GENE
- I-GENE
amidating I-GENE
monooxygenase I-GENE
, O
is O
associated O
with O
endosomes O
. O

In O
this O
study O
we O
provide O
evidence O
that O
B B-GENE
- I-GENE
Myb I-GENE
is O
a O
direct O
physiological O
target O
for O
cyclin B-GENE
A I-GENE
/ O
Cdk2 B-GENE
. O

The O
highly O
amyloidogenic O
42 O
- O
residue O
form O
of O
Abeta B-GENE
( O
Abeta42 B-GENE
) O
is O
the O
first O
species O
to O
be O
deposited O
in O
both O
sporadic O
and O
familial O
AD O
. O

This O
model O
is O
supported O
by O
experiments O
showing O
that O
Cdr2 B-GENE
associates O
with O
the O
N B-GENE
- I-GENE
terminal I-GENE
regulatory I-GENE
domain I-GENE
of I-GENE
Wee1 I-GENE
in O
cell O
lysates O
and O
phosphorylates O
Wee1 B-GENE
in O
vitro O
. O

RESULTS O
: O
Significant O
changes O
from O
pretreatment O
to O
posttreatment O
were O
observed O
( O
p O
< O
0 O
. O
001 O
) O
. O

The O
tip O
of O
the O
button O
caused O
a O
perforation O
of O
the O
posterior O
stomach O
wall O
, O
leading O
to O
death O
. O

Also O
, O
the O
amplitude O
of O
the O
oscillatory O
potentials O
( O
O1 O
+ O
O2 O
+ O
O3 O
+ O
O4 O
) O
was O
significantly O
reduced O
in O
the O
early O
postoperative O
period O
. O

Both O
NUP98 B-GENE
- O
HOXA9 B-GENE
chimeras O
transformed O
NIH O
3T3 O
fibroblasts O
, O
and O
this O
transformation O
required O
the O
HOXA9 B-GENE
domains I-GENE
for O
DNA O
binding O
and O
PBX B-GENE
interaction O
. O

Ethylene O
is O
involved O
in O
endosperm O
rupture O
and O
high O
- O
level O
betaGLU B-GENE
I I-GENE
expression O
; O
but O
, O
it O
does O
not O
affect O
the O
spatial O
and O
temporal O
pattern O
of O
betaGLU B-GENE
I I-GENE
expression O
. O

The O
divergence O
in O
primary O
structure O
between O
the O
sheep O
CRF1 B-GENE
and O
the O
other O
mammalian B-GENE
CRF1s I-GENE
is O
primarily O
localized O
to O
the O
extracellular O
amino O
terminal O
domain O
of O
the O
receptor O
( O
18 O
of O
22 O
divergent O
residues O
, O
ovine O
vs O
human B-GENE
CRF1 I-GENE
) O
. O

Agonist O
- O
induced O
receptor O
internalization O
, O
determined O
as O
the O
percent O
of O
total O
[ O
125I O
] O
Tyr0 B-GENE
- I-GENE
oCRF I-GENE
bound O
located O
in O
the O
acid O
- O
resistant O
fraction O
of O
transfected O
Cos O
7 O
cells O
, O
increased O
with O
time O
( O
0 O
- O
60 O
min O
at O
37 O
degrees O
C O
) O
for O
both O
wild O
- O
type O
and O
variant O
oCRF1 B-GENE
. O

This O
c B-GENE
- I-GENE
Jun I-GENE
activity O
is O
inhibited O
by O
c B-GENE
- I-GENE
Fos I-GENE
, O
another O
protooncoprotein O
that O
can O
dimerize O
with O
c B-GENE
- I-GENE
Jun I-GENE
to O
form O
the O
transcription O
factor O
AP B-GENE
- I-GENE
1 I-GENE
. O

CONCLUSION O
: O
Our O
study O
shows O
that O
( O
1 O
) O
total O
body O
BMD O
and O
femoral O
neck O
BMD O
were O
significantly O
higher O
in O
the O
study O
group O
that O
performed O
weight O
- O
bearing O
exercises O
than O
in O
control O
subjects O
, O
( O
2 O
) O
swimming O
exercise O
had O
no O
effect O
on O
BMD O
, O
and O
( O
3 O
) O
although O
swimming O
is O
not O
a O
bone O
- O
building O
exercise O
, O
it O
can O
significantly O
improve O
shoulder O
, O
back O
, O
and O
grip O
muscle O
strength O
. O

Comparisons O
with O
other O
known O
germins B-GENE
and O
germin B-GENE
- I-GENE
like I-GENE
proteins I-GENE
indicate O
that O
these O
Arabidopsis O
GLP B-GENE
subfamilies O
are O
unique O
from O
wheat O
germin B-GENE
. O

However O
, O
there O
has O
not O
been O
any O
evidence O
of O
A O
. O
salmonicida O
infections O
, O
specifically O
furunculosis O
, O
associated O
with O
the O
fish O
in O
this O
loch O
. O

Improving O
the O
evidence O
base O
for O
anaesthesia O
. O

Plasma O
CCK B-GENE
levels O
were O
determined O
at O
regular O
intervals O
. O

Consistent O
with O
these O
findings O
, O
relatively O
weak O
transcriptional O
silencing O
by O
the O
native O
VDR B-GENE
was O
observed O
using O
the O
osteopontin B-GENE
VDRE O
. O

A O
motif O
( O
TGATGTCA O
) O
which O
matches O
a O
CREB B-GENE
site I-GENE
and O
is O
similar O
to O
an O
AP B-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
embedded O
within O
ER2 B-GENE
. O

Conventionally O
, O
four O
nominal O
allotypic O
variants O
, O
b4 O
, O
b5 O
, O
b6 O
and O
b9 O
have O
been O
shown O
to O
be O
co O
- O
dominantly O
expressed O
at O
the O
Ckappa1 B-GENE
gene I-GENE
locus I-GENE
. O

Therefore O
, O
in O
order O
to O
search O
for O
the O
latent O
genes O
, O
we O
used O
allotype O
- O
specific O
oligonucleotides O
for O
b5 O
, O
b6 O
and O
b9 O
to O
probe O
DNAs O
from O
both O
normal O
and O
T O
. O
brucei O
- O
infected O
rabbits O
by O
Southern O
blotting O
. O

TRAF2 B-GENE
is O
known O
to O
associate O
with O
TRADD B-GENE
, O
and O
expression O
of O
a O
dominant O
- O
negative O
N O
- O
terminal O
deletion O
TRAF2 B-GENE
mutant I-GENE
was O
found O
to O
partially O
inhibit O
LMP1 B-GENE
- O
induced O
JNK B-GENE
activation O
in O
293 O
cells O
. O

These O
data O
further O
define O
a O
role O
for O
TRADD B-GENE
and O
TRAF2 B-GENE
in O
JNK B-GENE
activation O
and O
confirm O
that O
LMP1 B-GENE
utilizes O
signalling O
mechanisms O
used O
by O
the O
TNF B-GENE
receptor I-GENE
/ O
CD40 B-GENE
family O
to O
elicit O
its O
pleiotropic O
activities O
. O

Epstein B-GENE
- I-GENE
Barr I-GENE
virus I-GENE
- I-GENE
encoded I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
activates O
the O
JNK B-GENE
pathway O
through O
its O
extreme O
C O
terminus O
via O
a O
mechanism O
involving O
TRADD B-GENE
and O
TRAF2 B-GENE
. O

In O
contrast O
, O
transiently O
transfected O
cells O
expressing O
EBNA B-GENE
- I-GENE
3 I-GENE
revealed O
a O
sixfold O
increase O
in O
EBNA B-GENE
- I-GENE
3 I-GENE
protein I-GENE
expression O
from O
the O
genomic O
EBNA B-GENE
- I-GENE
3 I-GENE
gene I-GENE
compared O
to O
EBNA B-GENE
- I-GENE
3 I-GENE
cDNA I-GENE
. O

However O
, O
serial O
passages O
of O
fetal O
lamb O
kidney O
( O
FLK O
) O
cells O
, O
which O
are O
sensitive O
to O
infection O
with O
BLV O
, O
after O
transient O
transfection O
revealed O
that O
mutation O
of O
a O
second O
tyrosine O
residue O
in O
the O
N O
- O
terminal O
motif O
completely O
prevented O
the O
propagation O
of O
the O
virus O
. O

To O
search O
for O
transcriptional O
regulators O
, O
we O
used O
a O
fragment O
of O
the O
SpHE B-GENE
promoter I-GENE
containing O
several O
individual O
elements O
instead O
of O
the O
conventional O
bait O
that O
contains O
a O
multimerized O
cis O
element O
. O

As O
expected O
for O
a O
positive O
SpHE B-GENE
transcriptional I-GENE
regulator I-GENE
, O
the O
timing O
of O
SpEts4 B-GENE
gene I-GENE
expression O
precedes O
the O
transient O
expression O
of O
SpHE B-GENE
in O
the O
very O
early O
sea O
urchin O
blastula O
. O

Induction O
of O
anaesthesia O
was O
standardised O
: O
fentanyl O
( O
3 O
micrograms O
/ O
kg O
) O
, O
thiopentone O
( O
5 O
mg O
/ O
kg O
) O
, O
atracurium O
( O
0 O
. O
4 O
mg O
/ O
kg O
) O
. O

Conserved O
and O
distinct O
roles O
of O
kreisler B-GENE
in O
regulation O
of O
the O
paralogous O
Hoxa3 B-GENE
and O
Hoxb3 B-GENE
genes I-GENE
. O

Moreover O
, O
this O
enhancement O
of O
transcriptional O
activation O
by O
COUP B-GENE
- I-GENE
TFI I-GENE
requires O
specifically O
the O
AF O
- O
1 O
transactivation O
function O
of O
ER B-GENE
and O
can O
be O
observed O
in O
the O
presence O
of O
E2 O
or O
4 O
- O
hydroxytamoxifen O
but O
not O
ICI O
164384 O
. O

Recombinant B-GENE
Ffh I-GENE
has O
a O
melting O
point O
of O
tm O
= O
89 O
degreesC O
. O

This O
region O
of O
hsp90 B-GENE
mediates O
ATP O
- O
independent O
chaperone O
activity O
, O
overlaps O
the O
hsp90 B-GENE
dimerization I-GENE
domain I-GENE
, O
and O
includes O
structural O
elements O
important O
for O
steroid B-GENE
receptor I-GENE
interaction O
. O

The O
RNA B-GENE
polymerase I-GENE
III I-GENE
- I-GENE
recruiting I-GENE
factor I-GENE
TFIIIB I-GENE
induces O
a O
DNA O
bend O
between O
the O
TATA O
box O
and O
the O
transcriptional O
start O
site O
. O

Analysis O
of O
hematopoietic B-GENE
growth I-GENE
factor I-GENE
prescriptions O
in O
19 O
french O
cancer O
centers O

Chem O
. O

These O
results O
suggest O
that O
the O
c B-GENE
- I-GENE
met I-GENE
gene I-GENE
is O
also O
a O
target O
of O
p53 B-GENE
gene I-GENE
regulation O
. O

Pokeweed B-GENE
antiviral I-GENE
protein I-GENE
( O
PAP B-GENE
) O
from O
Phytolacca O
americana O
is O
a O
highly O
specific O
N B-GENE
- I-GENE
glycosidase I-GENE
removing O
adenine O
residues O
( O
A4324 O
in O
28S B-GENE
rRNA I-GENE
and O
A2660 O
in O
23S B-GENE
rRNA I-GENE
) O
from O
intact O
ribosomes O
of O
both O
eukaryotes O
and O
prokaryotes O
. O

Among O
these O
360 O
ZFPs B-GENE
, O
a O
novel O
ZFP B-GENE
cDNA I-GENE
named O
HFHZ B-GENE
( O
human B-GENE
fetal I-GENE
heart I-GENE
ZFP I-GENE
) O
with O
sequence O
homology O
to O
a O
Kruppel B-GENE
- I-GENE
associated I-GENE
box I-GENE
( O
KRAB B-GENE
) O
was O
identified O
. O

The O
3 O
. O
3 O
- O
fold O
higher O
expression O
in O
the O
fetal O
heart O
than O
in O
the O
adult O
heart O
suggests O
that O
HFHZ B-GENE
mRNA I-GENE
is O
downregulated O
in O
the O
process O
of O
development O
. O

CONTEXT O
: O
ThinPrep O
, O
AutoPap O
, O
and O
Papnet O
are O
3 O
new O
technologies O
that O
increase O
the O
sensitivity O
and O
cost O
of O
cervical O
cancer O
screening O
. O

Experiments O
on O
narcotized O
cats O
demonstrated O
that O
the O
derivatives O
of O
2 O
- O
mercaptobenzimidazole O
possessing O
the O
properties O
of O
specific O
bradycardic O
agents O
and O
coded O
as O
CM O
- O
251 O
, O
CM O
- O
266 O
, O
and O
CM O
- O
345 O
, O
reduce O
the O
mean O
rise O
of O
segment O
ST O
on O
numerous O
leads O
of O
the O
epicardial O
electrogram O
during O
5 O
- O
min O
occlusion O
of O
the O
anterior O
descending O
branch O
of O
the O
left O
coronary O
artery O
. O

Expression O
of O
the O
second O
gene O
( O
XT3 B-GENE
) O
was O
found O
to O
be O
conserved O
in O
human O
kidney O
, O
and O
partial O
sequence O
was O
obtained O
from O
a O
human O
cDNA O
library O
. O

Internal O
modes O
of O
a O
soliton O
. O

( O
2 O
) O
Erythroid O
32D O
Epo1 B-GENE
cells O
showed O
a O
lower O
level O
of O
bulk O
PKC B-GENE
catalytic O
activity O
, O
lacked O
the O
expression O
of O
epsilon B-GENE
and I-GENE
eta I-GENE
PKC I-GENE
isoforms I-GENE
, O
and O
showed O
a O
weak O
or O
absent O
upregulation O
of O
the O
remaining O
isoforms O
, O
except O
betaI B-GENE
, O
upon O
readdition O
of O
Epo B-GENE
to O
growth O
factor O
- O
starved O
cells O
. O

We O
used O
expression O
cloning O
to O
identify O
interleukin B-GENE
- I-GENE
6 I-GENE
( O
IL B-GENE
- I-GENE
6 I-GENE
) O
as O
one O
factor O
that O
suppressed O
growth O
of O
a O
pre O
- O
B O
- O
cell O
variant O
line O
, O
1A9 O
- O
M O
. O

Airflow O
through O
the O
dust O
trap O
was O
controlled O
with O
a O
vacuum O
pump O
. O

Several O
mutations O
disrupted O
the O
endonuclease O
and O
helicase B-GENE
activities O
; O
however O
, O
only O
one O
amino B-GENE
- I-GENE
terminal I-GENE
- I-GENE
charge I-GENE
cluster I-GENE
mutant I-GENE
protein I-GENE
( O
D40A O
- O
D42A O
- O
D44A O
) O
completely O
lost O
AAV O
hairpin O
DNA O
binding O
activity O
. O

Here O
we O
describe O
the O
identification O
and O
characterization O
of O
several O
Sp100 B-GENE
splice I-GENE
variant I-GENE
proteins I-GENE
and O
support O
their O
existence O
by O
elucidation O
of O
the O
3 O
' O
- O
end O
of O
the O
Sp100 B-GENE
gene I-GENE
. O

It O
was O
demonstrated O
that O
the O
processing O
signals O
in O
the O
transcript O
, O
i O
. O
e O
. O
both O
donor O
splice O
sites O
and O
the O
polyadenylation O
site O
located O
in O
the O
muscle O
- O
specific O
intron O
, O
have O
to O
be O
weak O
. O

Chirality O
- O
glass O
and O
spin O
- O
glass O
correlations O
in O
the O
two O
- O
dimensional O
random O
- O
bond O
XY O
model O
. O

Echo O
modulation O
in O
Pr3 O
+ O
: O
YAlO3 O
. O

Mechanisms O
of O
visible O
- O
light O
emission O
from O
electro O
- O
oxidized O
porous O
silicon O
. O

Optically O
detected O
librons O
and O
phonons O
in O
crystalline O
C60 O
. O

Factors O
influencing O
direct O
- O
immersion O
( O
DI O
) O
- O
SPME O
process O
were O
also O
checked O
and O
chosen O
experimentally O
. O

In O
contrast O
, O
an O
amino O
- O
terminal O
fragment O
containing O
the O
C O
/ O
H1 O
domain O
was O
sufficient O
for O
coactivation O
of O
Zta B-GENE
transcription O
and O
viral O
reactivation O
function O
. O

In O
addition O
, O
a O
potent O
splicing O
enhancer O
sequence O
isolated O
in O
the O
selection O
specifically O
binds O
a O
20 B-GENE
- I-GENE
kDa I-GENE
SR I-GENE
protein I-GENE
. O

These O
data O
suggest O
that O
other O
Ras B-GENE
effectors I-GENE
can O
collaborate O
with O
PI B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
with O
each O
other O
to O
activate O
Pak B-GENE
. O

Electrophoretic O
mobility O
- O
shift O
assays O
performed O
with O
the O
HNF B-GENE
- I-GENE
3 I-GENE
X O
and O
Y O
sites O
demonstrated O
that O
both O
sites O
are O
capable O
of O
binding O
HNF B-GENE
- I-GENE
3alpha I-GENE
and O
HNF B-GENE
- I-GENE
3beta I-GENE
. O

Proteins O
known O
to O
bind O
the O
PEPCK B-GENE
CRE O
include O
the O
CRE B-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CREB B-GENE
) O
and O
members O
of O
the O
CCAAT B-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C B-GENE
/ I-GENE
EBP I-GENE
) O
family O
. O

This O
construct O
, O
termed O
pDeltaCREC B-GENE
/ O
EBP B-GENE
, O
binds O
C B-GENE
/ I-GENE
EBPalpha I-GENE
and I-GENE
beta I-GENE
but O
not O
CREB B-GENE
, O
yet O
it O
confers O
a O
nearly O
complete O
glucocorticoid O
response O
when O
transiently O
transfected O
into O
H4IIE O
rat O
hepatoma O
cells O
. O

Systematic O
functional O
analysis O
of O
V1a B-GENE
/ I-GENE
V2 I-GENE
hybrid I-GENE
receptors I-GENE
showed O
that O
the O
second O
intracellular O
loop O
of O
the O
V1a B-GENE
receptor I-GENE
is O
required O
and O
sufficient O
for O
efficient O
coupling O
to O
Gq B-GENE
/ I-GENE
11 I-GENE
, O
whereas O
the O
third O
intracellular O
loop O
of O
the O
V2 B-GENE
receptor I-GENE
is O
required O
and O
sufficient O
for O
coupling O
to O
Gs B-GENE
. O

The O
fatigue O
exercise O
showed O
relatively O
high O
blood O
lactate O
concentration O
[ O
12 O
. O
5 O
( O
SD O
2 O
. O
6 O
) O
mmol O
x O
l O
( O
- O
1 O
) O
] O
and O
an O
increase O
of O
serum B-GENE
creatine I-GENE
kinase I-GENE
( O
CK B-GENE
) O
activity O
delayed O
by O
2 O
days O
[ O
540 O
( O
SD O
407 O
) O
U O
x O
l O
( O
- O
1 O
) O
] O
. O

New O
Langevin O
equations O
for O
a O
translating O
and O
simultaneously O
rotating O
asymmetric O
top O
. O

In O
the O
brain O
, O
muscarinic B-GENE
receptors I-GENE
mediate O
motor O
and O
memory O
function O
by O
interaction O
with O
their O
ligand O
acetylcholine O
. O

In O
this O
study O
, O
we O
investigated O
the O
signal O
transduction O
pathways O
that O
are O
involved O
in O
OM B-GENE
- O
induced O
LDLR B-GENE
transcription O
. O

The O
Lp B-GENE
mouse I-GENE
mutant I-GENE
provides O
a O
model O
for O
the O
severe O
human O
neural O
tube O
defect O
( O
NTD O
) O
, O
cranio O
- O
rachischisis O
. O

Therefore O
, O
high O
set O
- O
up O
accuracy O
and O
reproducibility O
are O
mandatory O
. O

CPDs O
at O
these O
three O
sites O
may O
partially O
displace O
TFIIIA B-GENE
, O
thereby O
enabling O
rapid O
repair O
. O

There O
was O
no O
difference O
in O
the O
hormone O
receptor O
status O
between O
the O
cases O
without O
lymph O
node O
metastases O
and O
with O
lymph O
node O
metastases O
, O
' O
clandestine O
' O
or O
macrometastases O
. O

Gel O
filtration O
, O
sedimentation O
velocity O
, O
and O
immunoprecipitation O
experiments O
revealed O
that O
beta4 O
is O
a O
component O
of O
a O
multisubunit O
complex O
( O
AP B-GENE
- I-GENE
4 I-GENE
) O
that O
also O
contains O
the O
sigma4 O
polypeptide O
and O
two O
additional O
adaptor O
subunit O
homologs O
named O
mu4 O
( O
mu O
- O
ARP2 O
) O
and O
epsilon O
. O

We O
show O
that O
the O
mouse O
genome O
contains O
four O
copies O
of O
the O
ubc B-GENE
- I-GENE
9 I-GENE
gene I-GENE
. O

Independent O
splicing O
events O
involve O
three O
previously O
described O
cassette O
exons O
, O
which O
are O
predicted O
to O
encode O
most O
of O
the O
second O
transmembrane O
domain O
. O

Each O
of O
these O
genes O
contains O
a O
putative O
upstream O
ORF O
, O
while O
STA2 B-GENE
has O
two O
additional O
in O
- O
frame O
AUG O
codons O
5 O
' O
to O
the O
major O
cistron O
. O

Primary O
and O
secondary O
structural O
elements O
required O
for O
synthesis O
of O
barley O
yellow O
dwarf O
virus O
subgenomic O
RNA1 O
. O

The O
H O
- O
reflex O
recovery O
curve O
was O
obtained O
after O
stimulation O
of O
the O
median O
nerve O
at O
the O
elbow O
and O
recording O
from O
the O
flexor O
carpi O
radialis O
. O

To O
identify O
additional O
non O
- O
Sir B-GENE
factors I-GENE
that O
affect O
rDNA O
silencing O
, O
we O
performed O
a O
genetic O
screen O
designed O
to O
isolate O
mutations O
which O
alter O
the O
expression O
of O
reporter O
genes O
integrated O
within O
the O
rDNA O
. O

In O
this O
study O
, O
we O
elucidate O
signaling O
pathways O
induced O
by O
photodynamic O
therapy O
( O
PDT O
) O
with O
hypericin O
. O

These O
results O
indicate O
that O
ATF B-GENE
- I-GENE
2 I-GENE
plays O
a O
central O
role O
in O
TGF B-GENE
- I-GENE
beta I-GENE
signaling O
by O
acting O
as O
a O
common O
nuclear O
target O
of O
both O
Smad B-GENE
and O
TAK1 B-GENE
pathways O
. O

FASEB O
Federal O
Funding O
Consensus O
Conference O
FY O
2000 O
. O

Analysis O
of O
the O
protein O
sequences O
of O
these O
two O
replicases B-GENE
, O
together O
with O
previously O
characterized O
H B-GENE
. I-GENE
pylori I-GENE
plasmid I-GENE
replication I-GENE
proteins I-GENE
, O
supports O
the O
formation O
of O
a O
distinct O
class O
of O
H B-GENE
. I-GENE
pylori I-GENE
plasmid I-GENE
proteins I-GENE
. O

The O
algorithm O
also O
limited O
TG O
to O
20 O
and O
64 O
% O
, O
apoB B-GENE
to O
6 O
and O
20 O
% O
, O
and O
Lp B-GENE
( I-GENE
a I-GENE
) I-GENE
to O
15 O
and O
56 O
% O
, O
of O
low O
- O
and O
high O
- O
risk O
groups O
, O
respectively O
. O

Conformational O
studies O
combining O
secondary O
structure O
predictions O
, O
CD O
and O
NMR O
spectroscopy O
together O
with O
ELISA O
assays O
, O
showed O
that O
the O
greater O
is O
the O
propensity O
of O
the O
epitope O
for O
helix O
formation O
the O
higher O
is O
the O
recognition O
by O
anti B-GENE
- I-GENE
K159 I-GENE
. O

Schwab O
and O
England O
ADL O
scores O
in O
the O
" O
off O
" O
state O
were O
improved O
by O
18 O
% O
and O
in O
the O
" O
on O
" O
state O
the O
scores O
declined O
by O
2 O
% O
. O

Sequence O
analysis O
revealed O
that O
the O
MEMA B-GENE
protein I-GENE
is O
identical O
with O
a O
160 B-GENE
kDa I-GENE
nuclear I-GENE
' I-GENE
domain I-GENE
rich I-GENE
in I-GENE
serines I-GENE
' I-GENE
( I-GENE
DRS I-GENE
) I-GENE
protein I-GENE
occurring O
free O
in O
the O
nucleoplasm O
and O
in O
U2 B-GENE
- I-GENE
ribonucleoprotein I-GENE
structures I-GENE
. O

Dopaminergic O
modulation O
of O
transcallosal O
activity O
of O
cat O
motor O
cortical O
neurons O
. O

The O
induced O
respiratory O
burst O
was O
investigated O
by O
the O
intracellular O
oxidative O
transformation O
of O
dihydrorhodamine O
123 O
to O
the O
fluorescent O
dye O
rhodamine O
123 O
via O
flow O
cytometry O
. O

JCAHO O
asks O
for O
hospitals O
' O
patience O
. O

25 O
- O
OH O
- O
D3 O
did O
not O
adversely O
affect O
animal O
health O
at O
the O
proposed O
use O
level O
of O
99 O
micrograms O
/ O
kg O
feed O
when O
replacing O
vitamin O
D3 O
in O
turkey O
rations O
. O

As O
such O
the O
findings O
support O
existing O
studies O
that O
have O
identified O
given O
social O
characteristics O
of O
drink O
drivers O
. O

Analysis O
of O
lacZ B-GENE
transcriptional I-GENE
fusions I-GENE
shows O
that O
the O
KdgR B-GENE
- I-GENE
binding I-GENE
sites I-GENE
negatively O
affect O
the O
expression O
of O
rsmB B-GENE
. O

In O
the O
cell O
- O
free O
import O
assay O
, O
beta B-GENE
- I-GENE
catenin I-GENE
rapidly O
migrates O
into O
the O
nucleus O
without O
the O
exogenous O
addition O
of O
cytosol O
, O
Ran B-GENE
, O
or O
ATP O
/ O
GTP O
. O

In O
ischemic O
and O
hypoxic O
hypoxia O
, O
a O
strong O
correlation O
was O
found O
between O
cyt O
a O
, O
a3 O
oxidation O
level O
and O
VO2 O
in O
both O
ischemic O
and O
hypoxic O
hypoxia O
( O
r2 O
= O
. O
90 O
and O
. O
87 O
, O
respectively O
) O
. O

Each O
recombinant O
product O
was O
a O
fusion O
protein O
with O
a O
B O
domain O
of O
Staphylococcal B-GENE
protein I-GENE
A I-GENE
( O
SPA B-GENE
) O
. O

Polypyrimidine O
and O
ssDNA O
binding O
by O
the O
isolated O
VH B-GENE
domain I-GENE
of O
immunization O
- O
induced O
anti O
- O
Z O
- O
DNA O
Ab O
resembles O
the O
activity O
of O
natural O
autoantibodies O
and O
suggests O
that O
VH B-GENE
- O
dependent O
binding O
to O
a O
ligand O
mimicked O
by O
polypyrimidines O
may O
play O
a O
role O
in O
B O
cell O
selection O
before O
immunization O
with O
Z O
- O
DNA O
. O

INTERVENTIONS O
: O
Study O
patients O
were O
randomly O
divided O
into O
four O
parallel O
groups O
to O
receive O
either O
terbinafine O
250 O
mg O
a O
day O
for O
12 O
or O
16 O
weeks O
( O
groups O
T12 O
and O
T16 O
) O
or O
itraconazole O
400 O
mg O
a O
day O
for O
1 O
week O
in O
every O
4 O
weeks O
for O
12 O
or O
16 O
weeks O
( O
groups O
I3 O
and O
I4 O
) O
. O

Bacteria O
can O
also O
cause O
a O
labyrinthitis O
acting O
directly O
on O
the O
inner O
ear O
: O
among O
these O
, O
Treponemas O
Pallidum O
, O
a O
spirochaete O
which O
causes O
syphilis O
and O
Borrelia O
Burgdorferi O
, O
a O
spirochaete O
that O
causes O
Lyme O
Disease O
, O
must O
be O
mentioned O
. O

Initial O
control O
of O
bleeding O
is O
similar O
, O
but O
eradication O
is O
achieved O
in O
fewer O
sessions O
with O
EVL O
. O

Canalith O
repositioning O
is O
the O
mainstay O
of O
treatment O
. O

Solution O
structure O
and O
mechanism O
of O
the O
MutT B-GENE
pyrophosphohydrolase I-GENE
. O

The O
binding O
of O
PH B-GENE
domains I-GENE
to O
Gbetagamma B-GENE
was O
inhibited O
by O
preincubation O
of O
Gbetagamma B-GENE
with O
the O
GDP O
- O
bound O
but O
not O
the O
GTP O
- O
bound O
form O
of O
Gialpha B-GENE
. O

Two O
- O
dimensional O
gel O
electrophoresis O
of O
anti B-GENE
- I-GENE
p59fyn I-GENE
immunoprecipitates O
obtained O
from O
non O
- O
transformed O
resting O
human O
T O
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
oligomeric O
protein O
complex O
which O
is O
constitutively O
formed O
between O
Fyn B-GENE
and O
several O
additional O
phosphoproteins O
( O
pp43 B-GENE
, O
pp72 B-GENE
, O
pp85 B-GENE
, O
the O
protein B-GENE
tyrosine I-GENE
kinase I-GENE
Pyk2 B-GENE
, O
as O
well O
as O
the O
two O
recently O
cloned O
adaptor O
proteins O
, O
SKAP55 B-GENE
and O
SLAP B-GENE
- I-GENE
130 I-GENE
) O
. O

The O
gene O
structure O
of O
Elk1 B-GENE
spans O
15 O
. O
2 O
kb O
and O
consists O
of O
seven O
exons O
and O
six O
introns O
. O

Sequence O
analysis O
suggests O
that O
TtrA B-GENE
contains O
a O
molybdopterin O
guanine O
dinucleotide O
cofactor O
and O
a O
[ O
4Fe O
- O
4S O
] O
cluster O
, O
that O
TtrB B-GENE
binds O
four O
[ O
4Fe O
- O
4S O
] O
clusters O
, O
and O
that O
TtrC B-GENE
is O
an O
integral O
membrane O
protein O
containing O
a O
quinol O
oxidation O
site O
. O

Previous O
work O
has O
shown O
that O
spleen B-GENE
necrosis I-GENE
virus I-GENE
( I-GENE
SNV I-GENE
) I-GENE
long I-GENE
terminal I-GENE
repeats I-GENE
( O
LTRs O
) O
are O
associated O
with O
Rex B-GENE
/ O
Rex B-GENE
- O
responsive O
element O
- O
independent O
expression O
of O
bovine O
leukemia O
virus O
RNA O
and O
supports O
the O
hypothesis O
that O
SNV O
RNA O
contains O
a O
cis O
- O
acting O
element O
that O
interacts O
with O
cellular B-GENE
Rex I-GENE
- I-GENE
like I-GENE
proteins I-GENE
. O

Online O
LATCH O
demonstrates O
a O
shift O
in O
identification O
of O
the O
library O
as O
an O
isolated O
unit O
to O
an O
interactive O
resource O
center O
. O

We O
calculated O
differences O
in O
late O
occlusion O
rates O
by O
the O
chi2 O
( O
chi O
- O
square O
) O
test O
, O
and O
found O
these O
differences O
were O
significant O
( O
P O
= O
. O
04 O
) O
. O

We O
describe O
a O
genetic O
system O
for O
further O
characterizing O
the O
role O
of O
the O
extreme O
C O
- O
terminus O
of O
the O
beta O
subunit O
of O
E B-GENE
. I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

The O
enhanced O
binding O
of O
c B-GENE
- I-GENE
Abl I-GENE
to O
DNA O
containing O
5 O
- O
methylcytosine O
residues O
may O
result O
from O
an O
increased O
propensity O
of O
the O
double O
helix O
to O
denature O
locally O
coupled O
with O
a O
protein O
- O
induced O
reduction O
in O
the O
base O
stacking O
interaction O
. O

We O
further O
demonstrate O
that O
the O
Stress B-GENE
- I-GENE
Activated I-GENE
- I-GENE
Protein I-GENE
- I-GENE
Kinase I-GENE
( O
SAPK B-GENE
) O
target O
sites O
of O
ATF2 B-GENE
, O
Thr69 O
and O
Thr71 O
are O
not O
required O
for O
the O
formation O
of O
the O
p300 B-GENE
/ O
CBP B-GENE
- O
ATF2 B-GENE
multiprotein O
complex O
. O

O B-GENE
. I-GENE
novo I-GENE
- I-GENE
ulmi I-GENE
RNA I-GENE
- I-GENE
7 I-GENE
, O
previously O
believed O
to O
be O
a O
satellite O
- O
like O
RNA O
, O
is O
shown O
to O
be O
a O
defective O
RNA O
, O
derived O
from O
OnuMV4 B-GENE
- I-GENE
Ld I-GENE
RNA I-GENE
by O
multiple O
internal O
deletions O
. O

The O
paramyxovirus B-GENE
fusion I-GENE
( I-GENE
F I-GENE
) I-GENE
protein I-GENE
mediates O
membrane O
fusion O
. O

In O
the O
present O
study O
, O
we O
show O
that O
SRm160 B-GENE
/ I-GENE
300 I-GENE
is O
required O
for O
a O
purine O
- O
rich O
ESE B-GENE
to O
promote O
the O
splicing O
of O
a O
pre O
- O
mRNA O
derived O
from O
the O
Drosophila B-GENE
doublesex I-GENE
gene I-GENE
. O

The O
coefficient O
of O
determination O
, O
r2 O
, O
of O
the O
other O
scores O
ranged O
from O
0 O
. O
56 O
to O
0 O
. O
61 O
. O

While O
determination O
of O
the O
protein O
content O
of O
the O
formulae O
gave O
no O
valid O
information O
, O
RAST O
/ O
EAST O
inhibition O
was O
highest O
for O
cow O
' O
s O
milk O
, O
followed O
by O
the O
partially O
hydrolysed O
whey O
formula O
, O
partially O
hydrolysed O
whey O
/ O
casein B-GENE
formula O
, O
soy B-GENE
/ I-GENE
pork I-GENE
collagen I-GENE
formula O
, O
and O
the O
amino O
acid O
formula O
. O

In O
light O
of O
the O
importance O
of O
GnRHR B-GENE
, O
the O
molecular O
mechanisms O
underlying O
the O
transcriptional O
regulation O
of O
the O
human B-GENE
GnRHR I-GENE
( O
hGnRHR B-GENE
) O
gene O
become O
a O
key O
issue O
in O
understanding O
human O
reproduction O
. O

Competitive O
mobility O
shift O
assays O
using O
either O
alphaT3 O
- O
1 O
nuclear O
extract O
or O
recombinant B-GENE
SF I-GENE
- I-GENE
1 I-GENE
protein I-GENE
clearly O
indicated O
that O
SF B-GENE
- I-GENE
1 I-GENE
is O
able O
to O
interact O
specifically O
with O
this O
GSE B-GENE
element I-GENE
positioned O
at O
- O
134 O
. O

Grade O
3 O
mucositis O
was O
reported O
in O
1 O
patient O
. O

In O
a O
heterologous O
transcriptional O
system O
in O
which O
the O
upstream O
regions O
of O
oIFNtau B-GENE
were O
inserted O
in O
front O
of O
simian B-GENE
virus I-GENE
40 I-GENE
( I-GENE
SV40 I-GENE
) I-GENE
promoter I-GENE
, O
the O
regions O
between O
bases O
- O
654 O
and O
- O
555 O
were O
determined O
as O
being O
the O
enhancer O
region O
required O
for O
oIFNtau B-GENE
- O
SV40 O
- O
CAT B-GENE
transactivation O
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c B-GENE
- I-GENE
Jun I-GENE
plus O
c B-GENE
- I-GENE
Fos I-GENE
enhanced O
the O
transactivation O
of O
oIFNtau B-GENE
- O
CAT B-GENE
but O
the O
expression O
of O
GATA B-GENE
- I-GENE
1 I-GENE
, O
GATA B-GENE
- I-GENE
2 I-GENE
or O
GATA B-GENE
- I-GENE
3 I-GENE
did O
not O
. O

The O
relatively O
mild O
defects O
observed O
in O
Rpd3 B-GENE
mutants I-GENE
suggest O
that O
the O
recently O
identified O
Groucho B-GENE
and O
dCtBP B-GENE
corepressor I-GENE
proteins I-GENE
do O
not O
function O
solely O
through O
the O
recruitment O
of O
histone B-GENE
deacetylases I-GENE
. O

Both O
carbachol O
( O
100 O
microM O
) O
and O
EGF B-GENE
( O
10 O
nM O
) O
induced O
Ras B-GENE
activation O
. O

Dominant O
negative O
Sos B-GENE
did O
not O
affect O
carbachol O
stimulation O
of O
HA B-GENE
- O
ERK2 B-GENE
but O
inhibited O
the O
stimulatory O
effect O
of O
EGF B-GENE
by O
60 O
% O
. O

Hrs B-GENE
has O
a O
FYVE O
double O
zinc O
finger O
domain O
, O
which O
specifically O
binds O
phosphatidylinositol O
( O
3 O
) O
- O
phosphate O
and O
is O
conserved O
in O
several O
proteins O
involved O
in O
vesicular O
traffic O
. O

Three O
subgenomes O
also O
comprised O
15 O
to O
75 O
nucleotides O
derived O
from O
the O
5 O
' O
part O
of O
the O
NS2 B-GENE
gene I-GENE
. O

The O
hybrid O
viruses O
were O
found O
to O
accumulate O
to O
high O
levels O
in O
infected O
plants O
, O
to O
form O
stable O
virions O
, O
and O
to O
be O
mechanically O
transmissible O
. O

Nevertheless O
cryopreservation O
of O
spermatozoa O
in O
a O
medium O
containing O
neither O
SP O
nor O
biological O
substances O
could O
offer O
an O
acceptable O
cryoprotection O
of O
spermatozoa O
to O
be O
used O
in O
assisted O
fertilization O
procedures O
, O
especially O
for O
intracytoplasmic O
sperm O
injection O
. O

EMSA O
with O
crude O
nuclear O
extracts O
demonstrated O
that O
stimulation O
with O
CD40L B-GENE
results O
in O
the O
induction O
of O
NF B-GENE
- I-GENE
kappaB I-GENE
complexes I-GENE
that O
bind O
to O
each O
of O
the O
three O
NF B-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
and O
are O
composed O
mainly O
of O
p50 B-GENE
and O
RelB B-GENE
, O
but O
also O
include O
c B-GENE
- I-GENE
Rel I-GENE
and O
p65 B-GENE
. O

The O
major O
transcription O
factors O
controlling O
arginine O
metabolism O
in O
Escherichia O
coli O
and O
Bacillus O
subtilis O
, O
ArgR B-GENE
and O
AhrC B-GENE
, O
respectively O
, O
are O
homologous O
multimeric O
proteins O
that O
form O
l O
- O
arginine O
- O
dependent O
DNA O
- O
binding O
complexes O
capable O
of O
repressing O
transcription O
of O
the O
biosynthetic O
genes O
( O
both O
) O
, O
activating O
transcription O
of O
catabolic O
genes O
( O
AhrC B-GENE
only O
) O
or O
facilitating O
plasmid O
dimer O
resolution O
( O
both O
) O
. O

The O
studied O
protein O
fragments O
consist O
of O
residues O
Arg183 O
- O
His267 O
of O
the O
human B-GENE
ER I-GENE
and O
residues O
Lys438 O
- O
Gln520 O
of O
the O
rat O
GR B-GENE
. O

CONCLUSIONS O
: O
Turbutest O
is O
a O
valuable O
tool O
in O
asthmatic O
patients O
' O
training O
, O
allowing O
identification O
and O
improvement O
of O
an O
inadequate O
inhalation O
technique O
with O
Turbuhaler O
. O

The O
potency O
of O
the O
effect O
of O
Nim O
( O
0 O
. O
5 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
. O
) O
was O
similar O
to O
that O
of O
NBP O
( O
10 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
. O
) O
. O

CONCLUSION O
: O
NBP O
pre O
- O
treatment O
or O
post O
- O
treatment O
markedly O
enhanced O
the O
rCBF O
to O
striatum O
in O
RMCAO O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
spontaneous O
reports O
of O
suspected O
adverse O
drug O
reactions O
, O
observed O
in O
elderly O
patients O
( O
over O
65 O
years O
of O
age O
) O
in O
Sicily O
( O
Italy O
) O
during O
the O
period O
from O
1 O
January O
1995 O
to O
31 O
December O
1997 O
. O

The O
high B-GENE
density I-GENE
lipoprotein I-GENE
( I-GENE
HDL I-GENE
) I-GENE
receptor I-GENE
mediates O
the O
uptake O
of O
cholesterol O
and O
cholesteryl O
esters O
, O
substrates O
for O
steroidogenesis O
, O
from O
an O
HDL B-GENE
particle O
in O
the O
adrenal O
gland O
and O
gonads O
. O

Ozagrel O
, O
ifenprodil O
, O
cinnarizine O
and O
dilazep O
were O
more O
effective O
than O
pentoxifylline O
in O
increasing O
rCBF O
at O
the O
HPC O
. O

Using O
sequence O
information O
from O
human B-GENE
BMAL1 I-GENE
( O
hBMAL1 B-GENE
) O
cDNAs O
previously O
reported O
by O
our O
laboratory O
, O
we O
have O
isolated O
and O
characterized O
cDNAs O
encoding O
three O
splice O
variants O
of O
the O
mouse B-GENE
BMAL1 I-GENE
( O
mBMAL1 B-GENE
) O
gene O
. O

Comparison O
with O
the O
bHLH B-GENE
/ O
PAS B-GENE
family O
genes O
revealed O
that O
the O
intron O
/ O
exon O
splice O
pattern O
of O
mBMAL1 B-GENE
most O
closely O
matches O
that O
of O
the O
mAhr B-GENE
, O
which O
suggests O
that O
BMAL1 B-GENE
and O
Ahr B-GENE
belong O
to O
the O
same O
subclass O
and O
may O
be O
derived O
from O
a O
common O
primordial O
gene O
. O

We O
were O
able O
to O
detect O
significant O
differences O
in O
functional O
residual O
capacity O
adjusted O
for O
weight O
or O
height O
, O
and O
compliance O
of O
the O
respiratory O
system O
adjusted O
for O
weight O
or O
lung O
volume O
in O
the O
ILD O
infants O
compared O
to O
the O
healthy O
controls O
or O
infants O
who O
had O
PPHN O
, O
indicating O
that O
these O
PFTs O
were O
sensitive O
enough O
to O
determine O
abnormal O
lung O
function O
in O
this O
age O
group O
. O

Classical O
ligand O
- O
activated O
nuclear O
receptors O
( O
e O
. O
g O
. O
thyroid B-GENE
hormone I-GENE
receptor I-GENE
, O
retinoic B-GENE
acid I-GENE
receptor I-GENE
) O
, O
orphan B-GENE
nuclear I-GENE
receptors I-GENE
( O
e O
. O
g O
. O

We O
have O
shown O
previously O
that O
in O
contrast O
to O
other O
extracellular O
matrix O
molecules O
pepsin B-GENE
- O
solubilized O
collagen B-GENE
VI I-GENE
( O
CVI B-GENE
) O
can O
stimulate O
DNA O
synthesis O
of O
various O
mesenchymal O
cell O
types O
, O
apparently O
independent O
of O
integrin B-GENE
- O
mediated O
signal O
transduction O
. O

The O
enzyme O
displays O
optimal O
activity O
at O
about O
0 O
. O
5 O
mM O
pantoate O
( O
k O
( O
cat O
) O
0 O
. O
63 O
s O
( O
- O
1 O
) O
) O
and O
at O
pH O
7 O
. O
8 O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
the O
RP B-GENE
, O
like O
the O
20S B-GENE
proteasome I-GENE
, O
is O
functionally O
and O
structurally O
conserved O
among O
eukaryotes O
and O
indicate O
that O
the O
plant B-GENE
RPT I-GENE
subunits I-GENE
, O
like O
their O
yeast O
counterparts O
, O
have O
non O
- O
redundant O
functions O
. O

Structure O
and O
expression O
of O
the O
mouse B-GENE
growth I-GENE
hormone I-GENE
receptor I-GENE
/ O
growth B-GENE
hormone I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
. O

Repair O
of O
double O
- O
strand O
breaks O
( O
DSBs O
) O
in O
chromosomal O
DNA O
by O
nonhomologous O
end O
- O
joining O
( O
NHEJ O
) O
is O
not O
well O
characterized O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Thus O
, O
elongin B-GENE
C I-GENE
is O
found O
to O
oligomerize O
in O
solution O
and O
to O
undergo O
significant O
structural O
rearrangements O
upon O
binding O
of O
two O
different O
partner O
proteins O
. O

Gel O
filtration O
and O
co O
- O
immunoprecipitation O
analyses O
reveal O
that O
Mad2p B-GENE
tightly O
associates O
with O
another O
spindle O
checkpoint O
component O
, O
Mad1p B-GENE
. O

John O
leonard O
dawson O

Microcirculatory O
oxygenation O
and O
shunting O
in O
sepsis O
and O
shock O
. O

The O
present O
investigation O
conducted O
in O
a O
population O
of O
258 O
dentally O
aware O
individuals O
in O
the O
age O
range O
20 O
- O
69 O
years O
, O
was O
initiated O
to O
elucidate O
the O
relationship O
between O
tobacco O
smoking O
and O
supragingival O
calculus O
, O
taking O
into O
account O
possible O
confounding O
factors O
such O
as O
age O
, O
gender O
, O
oral O
hygiene O
and O
gingival O
inflammation O
. O

Interaction O
of O
HRI B-GENE
with O
Hsc70 B-GENE
was O
required O
for O
the O
transformation O
of O
HRI B-GENE
, O
as O
the O
Hsc70 B-GENE
antagonist O
clofibric O
acid O
inhibited O
the O
folding O
of O
HRI B-GENE
into O
a O
mature O
- O
competent O
conformation O
. O

In O
the O
budding O
yeast O
, O
Saccharomyces O
cerevisiae O
, O
replicators O
can O
function O
outside O
the O
chromosome O
as O
autonomously O
replicating O
sequence O
( O
ARS O
) O
elements O
; O
however O
, O
within O
chromosome O
III O
, O
certain O
ARSs O
near O
the O
transcriptionally O
silent O
HML B-GENE
locus I-GENE
show O
no O
replication O
origin O
activity O
. O

These O
results O
suggest O
that O
, O
for O
the O
HML B-GENE
ARS O
cluster O
( O
ARS303 B-GENE
, O
ARS320 B-GENE
, O
and O
ARS302 B-GENE
) O
, O
inactivity O
of O
origins O
is O
independent O
of O
local O
transcriptional O
silencing O
, O
even O
though O
origins O
and O
silencers O
share O
key O
cis O
- O
and O
trans O
- O
acting O
components O
. O

We O
report O
the O
construction O
of O
an O
approximately O
1 O
. O
7 O
- O
Mb O
sequence O
- O
ready O
YAC O
/ O
BAC O
clone O
contig O
of O
8p22 O
- O
p23 O
. O

The O
recruitment O
of O
constitutively O
phosphorylated O
p185 B-GENE
( O
neu B-GENE
) O
and O
the O
activated O
mitogenic O
pathway O
proteins O
to O
this O
membrane O
- O
microfilament O
interaction O
site O
provides O
a O
physical O
model O
for O
integrating O
the O
assembly O
of O
the O
mitogenic O
pathway O
with O
the O
transmission O
of O
growth O
factor O
signal O
to O
the O
cytoskeleton O
. O

ECG O
- O
gated O
myocardial O
Technetium O
- O
99m O
sestamibi O
SPECT O
is O
a O
useful O
technique O
to O
measure O
myocardial O
perfusion O
and O
function O
simultaneously O
. O

The O
controversy O
of O
significance O
testing O
: O
misconceptions O
and O
alternatives O
. O

The O
arrangement O
of O
these O
cutoff O
- O
levels O
leads O
to O
a O
sensitivity O
of O
85 O
% O
at O
a O
specificity O
of O
55 O
% O
for O
Protein B-GENE
S100 I-GENE
when O
measured O
by O
RIA O
, O
and O
to O
a O
sensitivity O
of O
77 O
% O
at O
a O
specificity O
of O
61 O
% O
when O
measured O
by O
LIA O
. O

Null O
alleles O
of O
SAS4 B-GENE
and O
SAS5 B-GENE
bypassed O
the O
role O
of O
the O
Abf1p B-GENE
binding I-GENE
site I-GENE
of O
the O
HMR B-GENE
- I-GENE
E I-GENE
silencer I-GENE
but O
not O
the O
role O
of O
the O
ACS B-GENE
or O
Rap1p B-GENE
binding I-GENE
site I-GENE
. O

RESULTS O
: O
256 O
Periods O
of O
TTP O
or O
PUNP O
were O
reported O
by O
men O
and O
174 O
by O
women O
. O

Cytokine O
- O
induced O
NF B-GENE
- I-GENE
kappa I-GENE
B I-GENE
DNA O
binding O
activity O
, O
RelA B-GENE
nuclear O
translocation O
, O
I B-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
degradation O
, O
I B-GENE
kappa I-GENE
B I-GENE
serine O
32 O
phosphorylation O
, O
and O
I B-GENE
kappa I-GENE
B I-GENE
kinase I-GENE
( O
IKK B-GENE
) O
activity O
were O
blocked O
by O
curcumin O
treatment O
. O

To O
estimate O
the O
locations O
of O
sources O
with O
the O
TF O
- O
MUSIC O
algorithm O
, O
we O
first O
set O
the O
target O
region O
on O
the O
spectrogram O
of O
the O
somatosensory O
responses O
. O

Immunohistochemical O
staining O
with O
MIB B-GENE
- I-GENE
1 I-GENE
and O
p53 B-GENE
antibodies I-GENE
showed O
low O
( O
< O
1 O
% O
) O
and O
negative O
reaction O
. O

Two O
patients O
with O
recurrent O
tumors O
had O
high O
S O
- O
phase O
fractions O
both O
on O
the O
first O
resected O
specimens O
and O
at O
the O
time O
of O
the O
second O
operation O
. O

Treatment O
of O
unstable O
angina O
: O
role O
of O
antithrombotic O
therapy O
. O

Mutations O
of O
the O
RET B-GENE
gene I-GENE
, O
encoding O
a O
receptor B-GENE
tyrosine I-GENE
kinase I-GENE
, O
have O
been O
associated O
with O
the O
inherited O
cancer O
syndromes O
MEN O
2A O
and O
MEN O
2B O
. O

Protein B-GENE
kinase I-GENE
A I-GENE
- I-GENE
Ialpha I-GENE
subunit O
- O
directed O
antisense O
inhibition O
of O
ovarian O
cancer O
cell O
growth O
: O
crosstalk O
with O
tyrosine B-GENE
kinase I-GENE
signaling O
pathway O
. O

During O
both O
encephalopathy O
episodes O
, O
CSF O
protein O
and O
immunoglobulin B-GENE
G I-GENE
( O
IgG B-GENE
) O
levels O
were O
elevated O
without O
an O
increased O
IgG B-GENE
index O
or O
IgG B-GENE
synthesis O
rate O
. O

SCOB O
testing O
of O
food O
- O
restricted O
animals O
, O
using O
a O
multiple O
fixed O
ratio O
( O
FR O
) O
/ O
fixed O
interval O
( O
FI O
) O
schedule O
( O
FR20 O
: O
FI120 O
) O
, O
was O
conducted O
prior O
to O
each O
exposure O
to O
maintain O
the O
operant O
behavior O
; O
the O
data O
from O
Weeks O
- O
1 O
, O
4 O
, O
8 O
, O
and O
13 O
were O
evaluated O
for O
evidence O
of O
neurotoxicity O
. O

Differential O
expression O
was O
confirmed O
by O
Northern O
blot O
analysis O
employing O
multiple O
normal O
and O
tumor O
cell O
lines O
. O

Several O
genes O
or O
transcriptional O
units O
were O
identified O
, O
including O
the O
3 O
' O
end O
of O
ribosomal B-GENE
s6 I-GENE
kinase I-GENE
( O
Rsk3 B-GENE
) O
; O
two O
apparently O
intronless O
and O
ORF O
- O
less O
genes O
; O
and O
Gpr31 B-GENE
, O
an O
intronless O
, O
putative O
G B-GENE
- I-GENE
protein I-GENE
coupled I-GENE
receptor I-GENE
. O

The O
results O
suggest O
that O
GATA B-GENE
- I-GENE
5 I-GENE
may O
have O
specific O
downstream O
targets O
and O
that O
GATA B-GENE
- I-GENE
4 I-GENE
, I-GENE
- I-GENE
5 I-GENE
, I-GENE
and I-GENE
- I-GENE
6 I-GENE
can O
only O
partially O
substitute O
for O
each O
other O
in O
cardiogenesis O
. O

This O
study O
was O
designed O
to O
compare O
the O
efficacy O
of O
efegatran O
plus O
streptokinase B-GENE
versus O
heparin O
plus O
accelerated O
tissue B-GENE
plasminogen I-GENE
activator I-GENE
( O
TPA B-GENE
) O
in O
coronary O
reperfusion O
in O
acute O
MI O
. O

From O
February O
1991 O
to O
August O
1997 O
, O
124 O
patients O
with O
endometrial O
carcinoma O
were O
treated O
postoperatively O
with O
high O
- O
dose O
- O
rate O
vaginal O
vault O
brachytherapy O
as O
the O
only O
adjuvant O
treatment O
. O

Twelve O
patients O
had O
stage O
IBG3 O
, O
14 O
had O
ICG1 O
, O
9 O
had O
ICG2 O
, O
and O
3 O
had O
ICG3 O
disease O
. O

For O
EPV O
3 O
, O
10 O
, O
or O
40 O
, O
the O
bias O
exceeded O
25 O
% O
for O
7 O
, O
3 O
, O
and O
1 O
in O
the O
8 O
- O
predictor O
model O
respectively O
, O
when O
a O
conventional O
selection O
criterion O
was O
used O
( O
alpha O
= O
0 O
. O
05 O
) O
. O

Me O
( O
2 O
) O
SO O
- O
induced O
neuronal O
differentiation O
of O
N1E O
- O
115 O
neuroblastoma O
cells O
increased O
both O
the O
expression O
of O
the O
endogenous B-GENE
Ntr I-GENE
- I-GENE
1 I-GENE
gene I-GENE
and O
reporter O
genes O
driven O
by O
NTR B-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sequences I-GENE
by O
3 O
- O
4 O
- O
fold O
. O

Although O
the O
Src B-GENE
tyrosine I-GENE
kinase I-GENE
induces O
constitutive O
Stat3 B-GENE
phosphorylation O
on O
tyrosine O
, O
activation O
of O
Stat3 B-GENE
- O
mediated O
gene O
regulation O
requires O
both O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 B-GENE
. O

RESULTS O
: O
Factors O
associated O
with O
significantly O
( O
P O
< O
. O
05 O
) O
increased O
risk O
of O
treatment O
failure O
in O
a O
Cox O
multivariate O
analysis O
included O
age O
older O
than O
45 O
years O
( O
relative O
hazard O
, O
1 O
. O
17 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1 O
. O
02 O
- O
1 O
. O
33 O
) O
, O
Karnofsky O
performance O
score O
less O
than O
90 O
% O
( O
1 O
. O
27 O
; O
95 O
% O
CI O
, O
1 O
. O
07 O
- O
1 O
. O
51 O
) O
, O
absence O
of O
hormone O
receptors O
( O
1 O
. O
31 O
; O
95 O
% O
CI O
, O
1 O
. O
15 O
- O
1 O
. O
51 O
) O
, O
prior O
use O
of O
adjuvant O
chemotherapy O
( O
1 O
. O
31 O
; O
95 O
% O
CI O
, O
1 O
. O
10 O
- O
1 O
. O
56 O
) O
, O
initial O
disease O
- O
free O
survival O
interval O
after O
adjuvant O
treatment O
of O
no O
more O
than O
18 O
months O
( O
1 O
. O
99 O
; O
95 O
% O
CI O
, O
1 O
. O
62 O
- O
2 O
. O
43 O
) O
, O
metastases O
in O
the O
liver O
( O
1 O
. O
47 O
; O
95 O
% O
CI O
, O
1 O
. O
20 O
- O
1 O
. O
80 O
) O
or O
central O
nervous O
system O
( O
1 O
. O
56 O
; O
95 O
% O
CI O
, O
0 O
. O
99 O
- O
2 O
. O
46 O
[ O
approaches O
significance O
] O
) O
vs O
soft O
tissue O
, O
bone O
, O
or O
lung O
, O
3 O
or O
more O
sites O
of O
metastatic O
disease O
( O
1 O
. O
32 O
; O
95 O
% O
CI O
, O
1 O
. O
13 O
- O
1 O
. O
54 O
) O
, O
and O
incomplete O
response O
vs O
complete O
response O
to O
standard O
- O
dose O
chemotherapy O
( O
1 O
. O
65 O
; O
95 O
% O
CI O
, O
1 O
. O
36 O
- O
1 O
. O
99 O
) O
. O

The O
proteasome O
is O
a O
large O
complex O
consisting O
of O
two O
multisubunit O
structures O
, O
the O
20S B-GENE
and O
19S B-GENE
( O
PA700 B-GENE
) O
or O
P28 B-GENE
complexes I-GENE
, O
that O
combine O
to O
form O
the O
26S B-GENE
particles I-GENE
. O

We O
have O
cloned O
cDNA O
and O
genomic O
DNA O
for O
a O
mouse O
gene O
encoding O
a O
protein O
with O
significant O
sequence O
similarity O
to O
conserved O
domains O
found O
in O
proteins O
of O
the O
Spo11p B-GENE
family I-GENE
. O

RT O
- O
PCR O
and O
in O
situ O
hybridization O
analyses O
of O
a O
time O
course O
of O
juvenile O
testis O
development O
indicate O
that O
Spo11 B-GENE
expression O
begins O
in O
early O
meiotic O
Prophase O
I O
, O
prior O
to O
the O
pachytene O
stage O
, O
with O
increasing O
accumulation O
of O
mRNA O
through O
the O
pachytene O
stage O
. O

Animals O
were O
put O
to O
death O
8 O
weeks O
later O
and O
the O
grafts O
were O
sterilely O
explanted O
and O
analyzed O
via O
microbiologic O
culture O
and O
standard O
histologic O
procedures O
for O
evidence O
of O
infection O
. O

Oseltamivir O
( O
GS4104 O
) O
, O
which O
can O
be O
administered O
orally O
, O
is O
the O
prodrug O
of O
GS4071 O
, O
a O
potent O
and O
selective O
inhibitor O
of O
influenzavirus B-GENE
neuraminidases I-GENE
. O

We O
also O
show O
that O
activation O
of O
protein B-GENE
kinase I-GENE
A I-GENE
( O
PKA B-GENE
) O
signaling O
is O
sufficient O
to O
down O
- O
regulate O
caveolin B-GENE
- I-GENE
1 I-GENE
protein I-GENE
expression O
and O
promoter O
activity O
. O

Phosphatidylinositol B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
requirement O
in O
activation O
of O
the O
ras B-GENE
/ O
C B-GENE
- I-GENE
raf I-GENE
- I-GENE
1 I-GENE
/ O
MEK B-GENE
/ O
ERK B-GENE
and O
p70 B-GENE
( O
s6k B-GENE
) O
signaling O
cascade O
by O
the O
insulinomimetic O
agent O
vanadyl O
sulfate O
. O

For O
example O
, O
introduction O
of O
immunogenic O
and O
purification O
tag O
sequences O
into O
the O
C O
- O
terminal O
coding O
region O
significantly O
decreased O
bop B-GENE
gene I-GENE
mRNA I-GENE
and O
protein O
accumulation O
. O

We O
recommend O
that O
paracervical O
block O
with O
lignocaine O
should O
be O
used O
in O
conjunction O
with O
i O
. O
v O
. O
sedation O
/ O
analgesia O
during O
egg O
collection O
performed O
through O
the O
transvaginal O
route O
under O
ultrasound O
guidance O
( O
TUGOR O
) O
to O
reduce O
the O
pain O
of O
the O
procedure O
. O

This O
report O
describes O
a O
patient O
with O
a O
previous O
inferior O
acute O
myocardial O
infarction O
who O
developed O
right O
ventricular O
infarction O
with O
significant O
anterior O
lead O
ST O
segment O
elevation O
( O
V1 O
- O
V4 O
) O
caused O
by O
the O
loss O
of O
two O
large O
right O
ventricular O
branches O
during O
a O
coronary O
angioplasty O
of O
the O
right O
coronary O
artery O
. O

PURPOSE O
: O
Previous O
WR O
- O
2721 O
human O
pharmacokinetic O
studies O
were O
limited O
to O
plasma O
levels O
in O
patients O
receiving O
platinum O
- O
based O
compounds O
, O
and O
none O
includes O
the O
effects O
of O
WR O
- O
2721 O
on O
endogenous O
thiols O
. O

CONCLUSIONS O
: O
In O
addition O
to O
the O
superiority O
of O
octafluoropropane O
- O
filled O
microspheres O
to O
air O
- O
filled O
microspheres O
for O
LV O
opacification O
, O
the O
efficacy O
of O
OCTA O
is O
relatively O
unaffected O
by O
impaired O
LV O
function O
and O
is O
less O
susceptible O
to O
the O
effects O
of O
poor O
echogenicity O
than O
AIR O
. O

These O
kinases O
belong O
to O
a O
new O
subfamily O
related O
to O
the O
Trk B-GENE
subfamily I-GENE
. O

The O
data O
indicate O
that O
etr B-GENE
- I-GENE
1 I-GENE
is O
essential O
for O
muscle O
development O
in O
C O
. O
elegans O
, O
perhaps O
by O
playing O
a O
role O
in O
post O
- O
transcriptional O
processing O
of O
some O
muscle O
component O
, O
and O
thus O
suggesting O
a O
possible O
conservation O
of O
gene O
function O
with O
human B-GENE
CUG I-GENE
- I-GENE
bp I-GENE
. O

Detection O
of O
poisoning O
by O
Impila O
( O
Callilepis O
laureola O
) O
in O
a O
mother O
and O
child O
. O

In O
HCMV O
( O
Towne O
) O
- O
infected O
HF O
cells O
at O
24 O
to O
48 O
h O
, O
IE2 B-GENE
also O
accumulated O
in O
newly O
formed O
viral O
DNA O
replication O
compartments O
containing O
the O
polymerase B-GENE
processivity I-GENE
factor I-GENE
( O
UL44 B-GENE
) O
, O
the O
single B-GENE
- I-GENE
stranded I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
( O
SSB B-GENE
; O
UL57 B-GENE
) O
, O
the O
UL112 B-GENE
- I-GENE
113 I-GENE
accessory I-GENE
protein I-GENE
, O
and O
newly O
incorporated O
bromodeoxyuridine O
( O
BrdU O
) O
. O

Macroscopic O
researches O
on O
heart O
vascularization O
have O
indicated O
that O
the O
angioarchitecture O
of O
the O
conducting O
system O
differs O
from O
that O
of O
the O
normal O
myocardium O
. O

However O
, O
reoperation O
for O
bulky O
cervical O
disease O
( O
group O
3 O
) O
rarely O
results O
in O
normal O
calcitonin B-GENE
levels O
and O
is O
associated O
with O
a O
high O
incidence O
of O
permanent O
hypoparathyroidism O
. O

We O
present O
a O
case O
of O
carcinoma O
of O
the O
breast O
presenting O
concurrently O
with O
SSc O
that O
subsequently O
progressed O
to O
dialysis O
- O
dependent O
renal O
failure O
in O
just O
1 O
month O
. O

The O
GPI O
anchor O
moiety O
is O
either O
absent O
or O
present O
at O
a O
very O
low O
level O
in O
the O
polypeptide O
expressed O
from O
the O
cDNA O
that O
contained O
both O
the O
signal O
peptide O
and O
GPI O
signal O
sequences O
. O

They O
self O
- O
completed O
the O
SF O
- O
36 O
questionnaire O
and O
their O
QoL O
was O
described O
and O
retrospectively O
compared O
to O
that O
of O
historical O
controls O
. O

There O
was O
a O
trend O
toward O
an O
association O
between O
IENF O
and O
sural O
nerve O
unmyelinated O
fiber O
densities O
( O
r O
= O
0 O
. O
32 O
, O
p O
= O
0 O
. O
054 O
) O
. O

FISH O
using O
a O
whole O
chromosome O
4 O
paint O
demonstrated O
multiple O
rearrangements O
involving O
chromosome O
4 O
in O
MCF O
- O
7 O
AdVp3000 O
and O
MCF O
- O
7 O
MX O
, O
while O
S1 O
- O
M1 O
- O
80 O
contained O
only O
a O
simple O
reciprocal O
translocation O
. O

The O
MXR B-GENE
gene I-GENE
encodes O
a O
half O
- O
transporter O
and O
the O
absence O
of O
cytogenetic O
evidence O
of O
coamplification O
of O
other O
regions O
suggests O
that O
a O
partner O
may O
not O
be O
overexpressed O
, O
and O
instead O
the O
MXR B-GENE
half I-GENE
- I-GENE
transporter I-GENE
homodimerizes O
to O
mediate O
drug O
transport O
. O

Serum B-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF B-GENE
- I-GENE
I I-GENE
) O
SD O
score O
increased O
from O
- O
2 O
. O
2 O
and O
- O
4 O
. O
2 O
in O
men O
and O
women O
, O
respectively O
, O
to O
1 O
. O
8 O
and O
- O
0 O
. O
9 O
at O
6 O
months O
and O
0 O
. O
8 O
and O
- O
0 O
. O
7 O
at O
12 O
months O
. O

The O
level O
of O
serum B-GENE
creatine I-GENE
kinase I-GENE
was O
significantly O
high O
2 O
days O
after O
ESWIB O
, O
but O
it O
recovered O
in O
a O
week O
. O

Several O
7SL B-GENE
RNA I-GENE
- I-GENE
encoding I-GENE
sequences I-GENE
and O
various O
intergenic O
spacers O
were O
amplified O
from O
the O
individual O
HindIII B-GENE
fragments I-GENE
of O
about O
1 O
. O
3 O
and O
2 O
. O
8 O
kb O
. O

Analysis O
of O
its O
genomic O
region O
revealed O
that O
the O
13 O
- O
kb O
Cdc6 B-GENE
gene I-GENE
is O
divided O
into O
12 O
exons O
by O
11 O
introns O
. O

Phosphorylation O
of O
myosin B-GENE
- I-GENE
binding I-GENE
subunit I-GENE
( O
MBS B-GENE
) O
of O
myosin B-GENE
phosphatase I-GENE
by O
Rho B-GENE
- I-GENE
kinase I-GENE
in O
vivo O
. O

Because O
the O
Pit B-GENE
- I-GENE
1 I-GENE
sites I-GENE
in O
the O
hGH B-GENE
- I-GENE
N I-GENE
gene I-GENE
promoter I-GENE
are O
insufficient O
for O
such O
gene O
activation O
in O
vivo O
, O
these O
data O
suggested O
a O
unique O
chromatin O
- O
mediated O
developmental O
role O
for O
Pit B-GENE
- I-GENE
1 I-GENE
in O
the O
hGH B-GENE
LCR I-GENE
. O

Recombinant B-GENE
prenylcysteine I-GENE
lyase I-GENE
was O
produced O
in O
a O
baculovirus O
- O
Sf9 O
expression O
system O
. O

Mycoplasma O
hominis O
infections O
are O
easily O
missed O
because O
conventional O
methods O
for O
bacterial O
detection O
may O
fail O
. O

For O
this O
purpose O
, O
we O
used O
a O
series O
of O
plasmid O
constructs O
encoding O
different O
forms O
of O
the O
envelope B-GENE
glycoprotein I-GENE
E I-GENE
of I-GENE
the I-GENE
flavivirus I-GENE
tick I-GENE
- I-GENE
borne I-GENE
encephalitis I-GENE
virus I-GENE
. O

By O
an O
induced O
- O
fit O
mechanism O
, O
contacts O
with O
the O
anticodon O
can O
activate O
formation O
of O
a O
robust O
transition O
state O
at O
a O
site O
over O
70 O
A O
away O
. O

This O
revealed O
a O
minimum O
of O
six O
novel O
OSBP B-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
designated O
ORP B-GENE
- I-GENE
1 I-GENE
to O
ORP B-GENE
- I-GENE
6 I-GENE
. O

In O
conclusion O
: O
( O
i O
) O
TECRA O
kit O
is O
suggested O
to O
be O
used O
for O
screening O
SE O
producing O
strains O
; O
( O
ii O
) O
SET O
- O
RPLA O
and O
RIDASCREEN O
kits O
are O
suitable O
for O
epidemiological O
investigation O
of O
SE O
types O
, O
but O
the O
lack O
of O
ability O
for O
detecting O
SEE O
, O
long O
time O
required O
for O
testing O
with O
SET O
- O
RPLA O
kit O
and O
high O
background O
when O
using O
RIDASCREEN O
kit O
must O
be O
overcome O
; O
and O
( O
iii O
) O
because O
of O
the O
complicated O
test O
procedures O
and O
the O
lack O
of O
ability O
for O
detecting O
SEE O
, O
the O
practicality O
of O
SET O
- O
EIA O
kit O
in O
screening O
and O
epidemiological O
research O
purposes O
is O
low O
. O

Comparison O
of O
immunoassay O
kits O
for O
detection O
of O
staphylococcal B-GENE
enterotoxins I-GENE
produced O
by O
Staphylococcus O
aureus O

Sequence O
analysis O
of O
the O
promoter O
region O
showed O
no O
TATA O
box O
but O
identified O
consensus O
binding O
motifs O
for O
Sp1 B-GENE
, O
CREB B-GENE
, O
and O
half O
sites O
of O
the O
estrogen B-GENE
receptor I-GENE
binding I-GENE
site I-GENE
. O

Sak B-GENE
kinase I-GENE
gene O
structure O
and O
transcriptional O
regulation O
. O

Based O
on O
a O
type O
I O
error O
of O
0 O
. O
05 O
, O
our O
study O
had O
a O
power O
greater O
than O
or O
equal O
to O
75 O
% O
to O
detect O
group O
differences O
in O
treatment O
effect O
of O
greater O
than O
or O
equal O
to O
15 O
% O
to O
20 O
% O
. O

However O
, O
no O
genetic O
alteration O
was O
detected O
in O
any O
of O
the O
cancers O
examined O
. O

Statins B-GENE
: O
lower O
lipids O
and O
better O
bones O
? O
Although O
statins O
are O
widely O
used O
as O
cholesterol O
- O
lowering O
drugs O
, O
a O
recent O
study O
suggests O
that O
these O
compounds O
have O
anabolic O
effects O
on O
bone O
and O
could O
be O
developed O
into O
new O
treatments O
for O
common O
metabolic O
bone O
diseases O
such O
as O
osteoporosis O

Leukocyte O
cultures O
, O
prepared O
from O
blood O
drawn O
from O
these O
18 O
children O
at O
6 O
months O
of O
age O
, O
produced O
lower O
yields O
of O
IFN B-GENE
than O
those O
of O
the O
remaining O
53 O
children O
, O
when O
stimulated O
with O
adenovirus O
( O
P O
< O
0 O
. O
001 O
) O
, O
coronavirus O
( O
P O
< O
0 O
. O
001 O
) O
or O
rhinovirus O
( O
P O
= O
0 O
. O
002 O
) O
. O

In O
the O
BF O
ECT O
group O
the O
- O
age O
based O
dose O
would O
have O
been O
similarly O
dependent O
on O
the O
initial O
seizure O
threshold O
level O
. O

Haycocknema O
perplexum O
n O
. O
g O
. O
, O
n O
. O
sp O
. O

Hypothermia O
After O
Cardiac O
Arrest O
( O
HACA O
) O
Study O
Group O
. O

Two O
US O
commercial O
cultivars O
( O
Tehama O
and O
Vina O
) O
, O
three O
European O
commercial O
cultivars O
( O
Esterhazy O
, O
139 O
, O
G120 O
) O
and O
five O
New O
Zealand O
selections O
( O
Rex O
, O
Dublin O
' O
s O
Glory O
, O
Meyric O
, O
McKinster O
, O
Stanley O
) O
were O
evaluated O
. O

Previously O
, O
we O
showed O
that O
the O
APRE O
is O
a O
cytokine O
[ O
tumor B-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNFalpha B-GENE
) O
] O
- O
inducible O
enhancer O
by O
binding O
the O
heterodimeric B-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
( O
NF B-GENE
- I-GENE
kappaB I-GENE
) O
complex O
Rel B-GENE
A I-GENE
x O
NF B-GENE
- I-GENE
kappaB1 I-GENE
. O

Angiotensin B-GENE
II I-GENE
induces O
nuclear B-GENE
factor I-GENE
( I-GENE
NF I-GENE
) I-GENE
- I-GENE
kappaB1 I-GENE
isoforms I-GENE
to O
bind O
the O
angiotensinogen B-GENE
gene I-GENE
acute O
- O
phase O
response O
element O
: O
a O
stimulus O
- O
specific O
pathway O
for O
NF B-GENE
- I-GENE
kappaB I-GENE
activation O
. O

Arhythmacanthus O
Yamaguti O
, O
1935 O
is O
maintained O
as O
a O
synonym O
of O
Heterosentis O
because O
the O
distinction O
between O
two O
and O
three O
hook O
types O
is O
made O
equivocal O
when O
the O
transition O
between O
the O
apical O
and O
subapical O
hooks O
is O
gradual O
. O

We O
describe O
a O
case O
of O
acetaminophen O
overdose O
that O
was O
treated O
with O
both O
hemodialysis O
( O
HD O
) O
and O
NAC O
due O
to O
severe O
intoxication O
and O
slow O
drug O
clearance O
. O

Following O
conditioning O
, O
a O
single O
coat O
of O
adhesive O
was O
applied O
and O
light O
- O
cured O
. O

Upon O
tyrosine O
phosphorylation O
at O
the O
ITIMs O
, O
these O
molecules O
recruit O
SH2 B-GENE
domain O
- O
containing O
phosphatases O
such O
as O
SH2 B-GENE
- O
containing O
tyrosine B-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
and O
negatively O
regulate O
cell O
activity O
. O

These O
results O
suggest O
that O
VP1 B-GENE
was O
efficiently O
transported O
to O
the O
nucleus O
and O
localized O
in O
the O
discrete O
subnuclear O
regions O
, O
possibly O
with O
VP2 B-GENE
and O
VP3 B-GENE
. O

The O
case O
for O
completing O
the O
lymphadenectomy O
when O
positive O
lymph O
nodes O
are O
found O
during O
radical O
hysterectomy O
for O
cervical O
carcinoma O
. O

Isolation O
of O
cDNAs B-GENE
encoding I-GENE
gibbon I-GENE
and I-GENE
monkey I-GENE
platelet I-GENE
and I-GENE
T I-GENE
cell I-GENE
activation I-GENE
antigen I-GENE
1 I-GENE
( O
PTA1 B-GENE
) O
. O

All O
clones O
and O
strains O
produced O
have O
been O
deposited O
in O
the O
EUROFAN O
genetic O
stock O
centre O
( O
EUROSCARF O
, O
Frankfurt O
) O
. O

High O
resolution O
computed O
tomography O
of O
the O
lungs O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Actins B-GENE
show O
two O
different O
forms O
of O
N O
- O
terminal O
processing O
dependent O
on O
their O
N O
- O
terminal O
sequence O
. O

All O
four O
domains O
were O
linked O
via O
proline O
- O
threonine O
- O
rich O
peptides O
. O

METHODS O
: O
The O
former O
group O
included O
patients O
who O
had O
been O
treated O
with O
at O
least O
four O
PGE1 O
alpha O
- O
ciclodestrina O
, O
short O
- O
term O
treatment O
cycles O
per O
year O
while O
the O
latter O
was O
a O
historical O
reference O
group O
managed O
without O
prostaglandins O
. O

Zebrafish O
cyclops B-GENE
( O
cyc B-GENE
) O
encodes O
a O
Transforming B-GENE
Growth I-GENE
Factor I-GENE
beta I-GENE
( O
TGFbeta B-GENE
) O
signaling O
factor O
closely O
related O
to O
mouse O
Nodal B-GENE
. O

The O
genome O
organization O
of O
the O
mite O
- O
transmitted O
wheat O
streak O
mosaic O
virus O
( O
WSMV O
) O
appears O
to O
parallel O
that O
of O
members O
of O
the O
Potyviridae O
with O
monopartite O
genomes O
, O
but O
there O
are O
substantial O
amino O
acid O
dissimilarities O
with O
other O
potyviral O
polyproteins O
. O

The O
two O
- O
hybrid O
assay O
was O
then O
performed O
using O
full O
- O
length O
genes O
of O
CI B-GENE
, O
HC B-GENE
- I-GENE
Pro I-GENE
, O
P1 B-GENE
, O
P3 B-GENE
, O
and O
CP B-GENE
, O
but O
no O
heterologous O
interactions O
were O
detected O
. O

Diverse O
endogenous O
light O
chains O
contribute O
to O
basement O
membrane O
reactivity O
in O
nonautoimmune O
mice O
transgenic O
for O
an O
anti B-GENE
- I-GENE
laminin I-GENE
Ig B-GENE
heavy I-GENE
chain I-GENE
. O

Mechanisms O
of O
tachyphylaxis O
in O
regional O
anesthesia O
of O
long O
duration O

Dermatology O
is O
no O
exception O
. O

Molecular O
cloning O
of O
a O
novel O
human B-GENE
I I-GENE
- I-GENE
mfa I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
that O
differently O
regulates O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
and O
HIV O
- O
1 O
expression O
. O

The O
central O
( O
R O
) O
domain O
is O
responsible O
for O
receptor O
- O
binding O
activity O
whereas O
the O
N O
- O
terminal O
( O
T O
) O
domain O
mediates O
translocation O
, O
the O
process O
by O
which O
the O
C O
- O
terminal O
cytotoxic O
domain O
is O
transported O
from O
the O
receptor O
to O
the O
site O
of O
its O
cytotoxicity O
. O

We O
have O
previously O
demonstrated O
that O
expression O
of O
the O
gene O
for O
the O
reproductive O
neuropeptide O
, O
GnRH B-GENE
, O
is O
repressed O
by O
the O
glutamate O
/ O
NO O
/ O
cyclic O
GMP O
( O
cGMP O
) O
signal O
transduction O
pathway O
through O
cGMP B-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
in O
the O
hypothalamic O
GnRH B-GENE
- O
secreting O
neuronal O
cell O
line O
GT1 O
- O
7 O
. O

MSSPs B-GENE
are O
believed O
to O
regulate O
DNA O
replication O
, O
transcription O
, O
apopotosis O
and O
cell O
cycle O
progression O
by O
interacting O
with O
the O
C B-GENE
- I-GENE
MYC I-GENE
protein I-GENE
. O

As O
no O
complete O
PPARgamma B-GENE
antagonists O
have O
been O
described O
hitherto O
, O
we O
have O
constructed O
a O
dominant O
- O
negative O
mutant O
receptor O
to O
inhibit O
wild O
- O
type O
PPARgamma B-GENE
action O
. O

Forty O
4 O
- O
month O
old O
SD O
female O
rats O
were O
randomly O
divided O
into O
four O
groups O
, O
namely O
sham O
operation O
, O
bilateral O
ovariectomy O
, O
ovariectomy O
plus O
supplementary O
ethinyl O
estradiol O
( O
0 O
. O
2 O
microgram O
/ O
100 O
g O
B O
. O

The O
requirement O
of O
3 O
' O
complementarity O
for O
a O
ligation O
reaction O
is O
reaffirmed O
by O
results O
from O
1 O
nt O
insertions O
on O
either O
the O
3 O
' O
- O
or O
5 O
' O
- O
side O
of O
the O
nick O
. O

Expression O
in O
early O
postnatal O
pituitary O
and O
in O
pre O
- O
somatotrophic O
cells O
suggests O
that O
Zn B-GENE
- I-GENE
16 I-GENE
could O
play O
a O
role O
in O
pituitary O
development O
prior O
to O
somatotroph O
differentiation O
. O

Mouse B-GENE
growth I-GENE
hormone I-GENE
transcription I-GENE
factor I-GENE
Zn I-GENE
- I-GENE
16 I-GENE
: O
unique O
bipartite O
structure O
containing O
tandemly O
repeated O
zinc O
finger O
domains O
not O
reported O
in O
rat B-GENE
Zn I-GENE
- I-GENE
15 I-GENE
. O

The O
CCAAT O
core O
sequence O
mutants O
in O
which O
both O
CIII O
and O
CI O
/ O
CII O
were O
abolished O
, O
also O
increased O
the O
promoter O
activity O
. O

Finally O
, O
the O
mechanism O
of O
ASK1 B-GENE
activation O
involves O
, O
in O
part O
, O
homo O
- O
oligomerization O
. O

Two O
other O
patients O
underwent O
PRFR O
. O

The O
variations O
were O
caused O
by O
opposite O
shifts O
in O
TSH B-GENE
frequency O
distribution O
in O
mothers O
and O
neonates O
. O

However O
, O
such O
a O
mechanism O
was O
not O
detected O
in O
preliminary O
observations O
on O
M O
. O
synoviae O
. O

The O
expression O
of O
the O
yam8 B-GENE
( I-GENE
+ I-GENE
) I-GENE
cDNA I-GENE
in O
the O
mid1 B-GENE
mutant I-GENE
cells O
partially O
remediated O
the O
mid O
phenotype O
and O
resulted O
in O
a O
slight O
increase O
in O
Ca O
( O
2 O
+ O
) O
uptake O
activity O
. O

TIP30 B-GENE
has O
an O
intrinsic O
kinase O
activity O
required O
for O
up O
- O
regulation O
of O
a O
subset O
of O
apoptotic O
genes O
. O

Alternatively O
, O
PC12 O
- O
E2 O
cells O
were O
submitted O
to O
treatment O
with O
antibodies O
to O
the O
fibroblast B-GENE
growth I-GENE
factor I-GENE
( I-GENE
FGF I-GENE
) I-GENE
receptor I-GENE
, O
inhibitors O
of O
the O
nonreceptor B-GENE
tyrosine I-GENE
kinase I-GENE
p59 B-GENE
( O
fyn B-GENE
) O
, O
PLC B-GENE
, O
PKC B-GENE
and O
MEK B-GENE
and O
an O
activator O
of O
PKC B-GENE
, O
phorbol O
- O
12 O
- O
myristate O
- O
13 O
- O
acetate O
( O
PMA O
) O
. O

Approximately O
20 O
% O
of O
ALCLs O
that O
express O
ALK B-GENE
do O
not O
contain O
the O
t O
( O
2 O
; O
5 O
) O
, O
suggesting O
that O
other O
genetic O
abnormalities O
can O
result O
in O
aberrant O
ALK B-GENE
expression O
. O

In O
addition O
, O
expected O
decreases O
in O
ATIC B-GENE
enzymatic O
function O
in O
ATIC B-GENE
- O
ALK B-GENE
- O
containing O
lymphomas O
may O
render O
these O
tumors O
more O
sensitive O
to O
antifolate O
drugs O
such O
as O
methotrexate O
. O

Manganese O
ions O
were O
found O
to O
be O
essential O
for O
autophosphorylation O
of O
BGLF4 B-GENE
, O
and O
magnesium O
can O
stimulate O
the O
activity O
. O

An O
amino O
- O
acid O
sequence O
comparison O
revealed O
that O
Bacillus B-GENE
YM55 I-GENE
- I-GENE
1 I-GENE
aspartase I-GENE
shared O
71 O
% O
homology O
with O
Bacillus B-GENE
subtilis I-GENE
aspartase I-GENE
and O
49 O
% O
with O
Escherichia O
coli O
and O
Pseudomonas B-GENE
fluorescens I-GENE
aspartases I-GENE
. O

Unique O
to O
this O
system O
, O
the O
activity O
of O
TraR B-GENE
is O
negatively O
modulated O
by O
an O
antiactivator O
called O
TraM B-GENE
. O

As O
assessed O
by O
a O
genetic O
assay O
that O
measures O
AAI O
- O
dependent O
DNA O
binding O
, O
TraM B-GENE
inhibited O
TraR B-GENE
function O
before O
and O
after O
the O
transcription O
factor O
had O
bound O
to O
its O
DNA O
recognition O
site O
. O

Collectively O
, O
the O
results O
suggest O
that O
ARF B-GENE
binding O
to O
Mdm2 B-GENE
induces O
a O
conformational O
change O
that O
facilitates O
nucleolar O
import O
of O
the O
ARF B-GENE
- O
Mdm2 B-GENE
complex O
and O
p53 B-GENE
- O
dependent O
cell O
cycle O
arrest O
. O

The O
AtERF B-GENE
genes I-GENE
were O
differentially O
regulated O
by O
ethylene O
and O
by O
abiotic O
stress O
conditions O
, O
such O
as O
wounding O
, O
cold O
, O
high O
salinity O
, O
or O
drought O
, O
via O
ETHYLENE B-GENE
- I-GENE
INSENSITIVE2 I-GENE
( O
EIN2 B-GENE
) O
- O
dependent O
or O
- O
independent O
pathways O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
that O
Sp1 B-GENE
binds O
to O
two O
different O
regions O
in O
the O
proximal O
promoter O
, O
a O
typical O
Sp1 B-GENE
site I-GENE
located O
at O
( O
- O
38 O
; O
- O
33 O
) O
and O
a O
G O
/ O
C O
- O
rich O
region O
between O
( O
- O
67 O
; O
- O
62 O
) O
. O

Eight O
patients O
received O
1 O
. O
5 O
mg O
of O
adefovir O
dipivoxil O
per O
kg O
of O
body O
weight O
, O
and O
six O
patients O
received O
3 O
. O
0 O
mg O
of O
adefovir O
dipivoxil O
per O
kg O
. O

Most O
likely O
they O
might O
represent O
regulatory O
RNAs O
or O
transcribed O
transposable O
elements O
. O

Here O
we O
describe O
the O
cloning O
, O
tissue O
- O
specific O
expression O
pattern O
, O
and O
functional O
characterization O
of O
two O
novel O
TEF B-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
, O
TEF B-GENE
- I-GENE
1beta I-GENE
and O
TEF B-GENE
- I-GENE
1gamma I-GENE
. O

The O
comparison O
of O
the O
expression O
patterns O
of O
the O
known O
Kv4 B-GENE
family I-GENE
members I-GENE
shows O
subtype O
specificity O
with O
significant O
overlaps O
. O

Preliminary O
use O
of O
the O
Nottingham O
Eczema O
Severity O
Score O
would O
support O
further O
development O
as O
a O
research O
tool O
for O
a O
simple O
assessment O
of O
disease O
severity O
that O
could O
be O
used O
in O
epidemiological O
studies O
. O

Advanced O
adenoma O
was O
defined O
as O
an O
adenoma O
larger O
than O
10 O
mm O
or O
an O
adenoma O
of O
any O
size O
with O
villous O
component O
, O
high O
- O
grade O
dysplasia O
or O
invasive O
carcinoma O
. O

To O
understand O
whether O
Shc B-GENE
localization O
in O
membrane O
rafts O
is O
sufficient O
to O
regulate O
Shc B-GENE
function O
, O
we O
constructed O
a O
Shc B-GENE
chimera I-GENE
containing O
the O
Ras B-GENE
membrane I-GENE
localization I-GENE
motif I-GENE
at O
the O
C O
- O
terminus O
. O

RegA B-GENE
is O
a O
positive O
yet O
nonessential O
regulator O
of O
tol B-GENE
- O
oprL B-GENE
expression O
. O

Schlegel O
, O
J O
. O

The O
early O
dg O
. O
of O
rejection O
and O
especially O
acute O
rejection O
, O
it O
' O
s O
adequate O
management O
, O
decreased O
risk O
for O
the O
future O
chronic O
rejection O
nephropathy O
. O

Extracellular B-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK B-GENE
) O
activation O
and O
molecular O
coupling O
of O
the O
adaptor O
proteins O
p130 B-GENE
Crk B-GENE
- I-GENE
associated I-GENE
substrate I-GENE
( O
CAS B-GENE
) O
and O
c B-GENE
- I-GENE
CrkII I-GENE
( O
Crk B-GENE
) O
represent O
two O
distinct O
pathways O
that O
induce O
cell O
invasion O
and O
protect O
cells O
from O
apoptosis O
in O
a O
three O
- O
dimensional O
collagen B-GENE
matrix O
. O

The O
evolution O
of O
the O
CCR5 B-GENE
cis I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
versus O
the O
open O
reading O
frame O
as O
well O
as O
among O
different O
domains O
of O
the O
open O
reading O
frame O
differed O
from O
one O
another O
. O

Scanning O
mutations O
throughout O
the O
AC O
element O
interfered O
with O
induction O
but O
allowed O
us O
to O
define O
five O
overlapping O
sites O
for O
regulatory O
factors O
in O
AC O
and O
to O
design O
probes O
binding O
just O
one O
or O
two O
factors O
. O

Bites O
by O
two O
species O
of O
adders O
( O
Vipera O
aspis O
and O
Vipera O
berus O
) O
can O
lead O
to O
extensive O
swelling O
with O
multiorgan O
failure O
. O

CONCLUSION O
: O
Treatment O
of O
sepsis O
with O
the O
platelet B-GENE
- I-GENE
activating I-GENE
factor I-GENE
antagonist O
BB O
- O
882 O
offers O
no O
advantage O
over O
placebo O
on O
survival O
, O
hemodynamic O
status O
, O
respiratory O
function O
, O
or O
organ O
failure O
scores O
. O

In O
vivo O
dimethyl O
sulfate O
footprinting O
of O
the O
cyclin B-GENE
E I-GENE
promoter I-GENE
revealed O
several O
regions O
of O
protection O
and O
hypersensitivity O
that O
were O
unique O
to O
infected O
cells O
. O

A O
total O
of O
194 O
STSs O
map O
to O
this O
interval O
of O
3 O
Mb O
, O
giving O
an O
average O
marker O
resolution O
of O
approximately O
one O
per O
15 O
kb O
. O

Recently O
, O
a O
mutation O
in O
the O
amino O
- O
terminus O
of O
IB1 B-GENE
was O
associated O
with O
diabetes O
. O

Biol O
. O

These O
data O
show O
that O
the O
alpha O
- O
helix O
domain O
of O
p57 B-GENE
( O
Kip2 B-GENE
) O
, O
which O
is O
conserved O
in O
the O
Cip B-GENE
/ O
Kip B-GENE
proteins O
, O
is O
implicated O
in O
protein O
- O
protein O
interaction O
and O
confers O
a O
specific O
regulatory O
mechanism O
, O
outside O
of O
their O
Cdk B-GENE
- O
inhibitory O
activity O
, O
by O
which O
the O
p57 B-GENE
( O
Kip2 B-GENE
) O
family O
members O
positively O
act O
on O
myogenic O
differentiation O
. O

The O
somatoform O
conundrum O
: O
a O
question O
of O
nosological O
valves O
. O

Intra O
- O
operative O
ultrasound O
( O
IOUS O
) O
has O
been O
widely O
used O
in O
an O
attempt O
to O
overcome O
these O
difficulties O
, O
but O
is O
limited O
by O
its O
two O
- O
dimensional O
nature O
, O
inter O
- O
user O
variability O
, O
and O
image O
obliteration O
with O
ablative O
or O
resectional O
techniques O
. O

CONCLUSIONS O
: O
This O
randomized O
study O
shows O
that O
Vivostat O
fibrin B-GENE
sealant O
is O
effective O
in O
preventing O
air O
leakage O
after O
small O
lung O
resections O
in O
pigs O
, O
even O
at O
high O
inspiratory O
pressures O
. O

Hailey O
- O
Hailey O
disease O
is O
caused O
by O
mutations O
in O
ATP2C1 B-GENE
encoding O
a O
novel O
Ca O
( O
2 O
+ O
) O
pump O
. O

A O
cause O
of O
increase O
of O
alkaline B-GENE
phosphatase I-GENE
in O
children O

Significantly O
, O
two O
proximal O
GATA B-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( O
- O
118 O
/ O
- O
113 O
and O
- O
98 O
/ O
- O
93 O
) O
and O
a O
region O
located O
within O
- O
518 O
to O
- O
315bp O
of O
the O
mouse B-GENE
ALAS2 I-GENE
promoter I-GENE
were O
essential O
for O
transcriptional O
activation O
during O
chemically O
induced O
differentiation O
of O
MEL O
cells O
, O
implying O
their O
importance O
in O
conferring O
erythroid O
specificity O
to O
the O
ALAS2 B-GENE
transcriptional O
activation O
. O

The O
HMG B-GENE
domain I-GENE
of O
both O
HMG20 B-GENE
proteins I-GENE
is O
most O
similar O
to O
that O
of O
yeast B-GENE
NHP6A I-GENE
( O
38 O
% O
to O
42 O
% O
) O
. O

IgM B-GENE
and O
IgG B-GENE
anti I-GENE
A I-GENE
and O
anti B-GENE
B I-GENE
antibody I-GENE
status O
of O
100 O
antenatal O
O O
group O
mothers O
( O
who O
had O
non O
O O
group O
husbands O
) O
were O
studied O
. O

In O
an O
attempt O
to O
understand O
Wee1 B-GENE
regulation O
during O
cell O
cycle O
, O
yeast O
two O
- O
hybrid O
screening O
was O
used O
to O
identify O
Wee1 B-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
s I-GENE
) I-GENE
. O

Retroviral O
transduction O
of O
T B-GENE
/ I-GENE
T I-GENE
( I-GENE
L I-GENE
) I-GENE
causes O
a O
rapidly O
fatal O
myeloproliferative O
disease O
in O
a O
murine O
bone O
marrow O
transplant O
( O
BMT O
) O
model O
, O
whereas O
T B-GENE
/ I-GENE
T I-GENE
( I-GENE
F I-GENE
) I-GENE
causes O
a O
long O
- O
latency O
, O
pre O
- O
B O
- O
cell O
lymphoblastic O
lymphoma O
. O

The O
codon O
usage O
is O
particularly O
marked O
for O
the O
gag B-GENE
, O
pol B-GENE
, O
and O
env B-GENE
genes I-GENE
. O

Slap B-GENE
negatively O
regulates O
Src B-GENE
mitogenic O
function O
but O
does O
not O
revert O
Src B-GENE
- O
induced O
cell O
morphology O
changes O
. O

We O
examine O
current O
models O
of O
the O
effects O
of O
aging O
on O
mean O
response O
time O
and O
show O
how O
they O
might O
be O
reinterpreted O
. O

The O
effects O
of O
these O
mutations O
on O
protein O
function O
require O
further O
examination O
. O

Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
viral B-GENE
interferon I-GENE
regulatory I-GENE
factor I-GENE
confers O
resistance O
to O
the O
antiproliferative O
effect O
of O
interferon B-GENE
- I-GENE
alpha I-GENE
. O

AMDA O
white O
paper O
identifies O
ways O
to O
improve O
pharmaceutical O
care O
in O
SNFs O
. O

Because O
the O
mutant O
defective O
in O
DNA O
binding O
also O
fails O
to O
stimulate O
Abf1 B-GENE
ARS1 O
DNA O
- O
binding O
activity O
, O
our O
results O
suggest O
that O
Cdc6 B-GENE
DNA O
- O
binding O
activity O
may O
play O
a O
pivotal O
role O
in O
the O
initiation O
of O
DNA O
replication O
. O

The O
structural O
study O
of O
peptides O
belonging O
to O
the O
terminal O
domains O
of O
histone B-GENE
H1 I-GENE
can O
be O
considered O
as O
a O
step O
toward O
the O
understanding O
of O
the O
function O
of O
H1 B-GENE
in O
chromatin O
. O

The O
recovery O
rates O
for O
the O
MB O
/ O
BacT O
, O
MGIT O
960 O
, O
and O
solid O
media O
were O
91 O
. O
6 O
, O
87 O
. O
4 O
, O
and O
54 O
. O
7 O
% O
, O
respectively O
, O
for O
all O
mycobacteria O
; O
the O
recovery O
rates O
were O
93 O
. O
6 O
, O
88 O
. O
9 O
, O
and O
63 O
. O
4 O
% O
, O
respectively O
, O
for O
M O
. O
tuberculosis O
complex O
alone O
, O
and O
87 O
. O
5 O
, O
84 O
. O
4 O
, O
and O
37 O
. O
5 O
% O
, O
respectively O
, O
for O
all O
nontuberculous O
mycobacteria O
. O

SELECTION O
CRITERIA O
: O
Randomised O
and O
possibly O
randomised O
trials O
using O
acupuncture O
to O
treat O
asthma O
and O
asthma O
- O
like O
symptoms O
. O

SELECTION O
CRITERIA O
: O
Randomised O
trials O
comparing O
children O
undergoing O
systematic O
therapy O
focusing O
on O
the O
family O
in O
conjunction O
with O
asthma O
medication O
, O
with O
children O
taking O
asthma O
medication O
only O
. O

The O
models O
were O
tested O
by O
studying O
their O
response O
to O
disturbances O
of O
the O
afferent O
signal O
from O
the O
bladder O
. O

We O
also O
show O
that O
p65 B-GENE
binds O
to O
these O
targets O
with O
almost O
equal O
affinity O
and O
that O
different O
residues O
have O
variable O
roles O
in O
binding O
different O
kappaB B-GENE
targets I-GENE
. O

To O
illustrate O
its O
performance O
, O
measurements O
of O
photoluminescence O
in O
GaAs O
/ O
AlGaAs O
heterostructures O
are O
presented O
. O

D5 B-GENE
/ I-GENE
D1 I-GENE
( I-GENE
CT I-GENE
) I-GENE
or O
D5 B-GENE
/ I-GENE
D1D I-GENE
( I-GENE
CT I-GENE
) I-GENE
tail O
substitution O
mutants O
displayed O
a O
rank O
order O
of O
potency O
and O
agonist O
affinities O
virtually O
mimicking O
wild B-GENE
- I-GENE
type I-GENE
( I-GENE
wt I-GENE
) I-GENE
D1 I-GENE
receptors I-GENE
, O
as O
indexed O
by O
both O
ligand O
binding O
and O
dopamine O
- O
stimulated O
cAMP O
accumulation O
assays O
, O
and O
, O
similar O
to O
wt O
D1 B-GENE
receptors I-GENE
, O
did O
not O
exhibit O
receptor O
constitutive O
activity O
or O
responsiveness O
to O
inverse O
agonists O
. O

Modeling O
also O
revealed O
a O
very O
hydrophobic O
surface O
due O
to O
the O
absence O
of O
H12 O
, O
exposing O
residues O
from O
H3 O
, O
loop O
3 O
- O
4 O
, O
H4 O
, O
and O
H11 O
. O

The O
immune O
system O
is O
closely O
integrated O
with O
the O
neuroendocrine O
system O
, O
and O
infection O
- O
induced O
increases O
in O
cytokines O
such O
as O
IL B-GENE
- I-GENE
1 I-GENE
, O
IL B-GENE
- I-GENE
6 I-GENE
and O
TNF B-GENE
have O
numerous O
effects O
on O
the O
central O
nervous O
system O
. O

Flavonoids O
from O
Brosimum O
acutifolium O
. O

Although O
the O
OC B-GENE
promoter I-GENE
is O
activated O
in O
a O
C O
terminus O
dependent O
manner O
, O
the O
MDR B-GENE
, O
LTR O
and O
BSP B-GENE
promoters I-GENE
are O
repressed O
by O
three O
distinct O
mechanisms O
, O
either O
independent O
of O
or O
involving O
the O
AML B-GENE
C I-GENE
terminus I-GENE
, O
or O
requiring O
only O
the O
conserved O
C O
- O
terminal O
pentapeptide O
VWRPY O
. O

Therefore O
, O
analogs O
of O
vitamin O
D3 O
have O
been O
investigated O
in O
a O
number O
of O
trials O
showing O
improvement O
of O
psoriasis O
. O

The O
network O
evolution O
was O
interpreted O
by O
an O
approach O
based O
on O
the O
Flory O
model O
. O

Biologically O
significant O
amounts O
of O
platelet B-GENE
activating I-GENE
factor I-GENE
were O
eluted O
from O
the O
sorbent O
during O
the O
entire O
treatment O
time O
. O

Mucin B-GENE
gene I-GENE
expression O
has O
been O
shown O
to O
be O
altered O
in O
many O
intestinal O
diseases O
and O
especially O
cancers O
of O
the O
gastrointestinal O
tract O
. O

E2F B-GENE
- I-GENE
1 I-GENE
is O
a O
transcription O
factor O
that O
regulates O
cell O
cycle O
progression O
into O
S O
- O
phase O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
MAP B-GENE
kinase I-GENE
stimulates O
the O
hPL B-GENE
- I-GENE
B I-GENE
enhancer I-GENE
by O
an O
NF B-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
- O
dependent O
pathway O
. O

Using O
adenoviral O
transfer O
of O
IkappaBalpha B-GENE
( O
IkappaBalpha B-GENE
overexpression O
) O
, O
the O
production O
of O
TNF B-GENE
- I-GENE
alpha I-GENE
induced O
by O
whole O
GBS O
was O
inhibited O
by O
only O
20 O
% O
. O

The O
delta B-GENE
srb10 I-GENE
mutation I-GENE
also O
influenced O
on O
the O
transcript O
levels O
of O
meiosis O
- O
inducing O
genes O
called O
IME1 B-GENE
and O
IME2 B-GENE
: O
the O
mutation O
elevated O
the O
transcript O
level O
of O
IME1 B-GENE
but O
reduced O
that O
of O
IME2 B-GENE
, O
resulting O
in O
partial O
defects O
in O
premeiotic O
DNA O
synthesis O
and O
meiosis O
. O

We O
also O
found O
that O
environmental O
conditions O
for O
meiosis O
finely O
regulate O
the O
transcript O
levels O
of O
KIN28 B-GENE
and O
CCL1 B-GENE
, O
such O
that O
nitrogen O
starvation O
first O
elevates O
them O
but O
subsequent O
alkalization O
of O
medium O
decreases O
them O
. O

The O
effect O
of O
acute O
, O
mid O
- O
cervical O
spinal O
cord O
lesions O
on O
neuronal O
and O
reflex O
activity O
evoked O
by O
the O
noxious O
visceral O
stimulus O
, O
colorectal O
distension O
( O
CRD O
; O
80 O
mmHg O
, O
20 O
s O
) O
, O
was O
determined O
in O
halothane O
- O
anesthetized O
rats O
. O

The O
results O
suggest O
that O
the O
role O
of O
S O
. O
argyrostoma O
in O
the O
dissemination O
of O
Trichinella O
larvae O
in O
nature O
is O
limited O
in O
comparison O
to O
the O
role O
played O
by O
mammals O
with O
scavenger O
and O
cannibalistic O
behavior O
. O

The O
equilibrium O
dissociation O
binding O
constant O
for O
the O
interaction O
of O
TnrA B-GENE
with O
the O
nrgAB B-GENE
promoter I-GENE
fragment I-GENE
was O
7 O
. O
7 O
nM O
under O
the O
conditions O
used O
here O
. O

Phd B-GENE
antibody O
- O
immunoreactive O
peptides O
are O
seen O
in O
light O
- O
adapted O
mouse O
retinal O
cytosolic O
and O
nuclear O
extracts O
. O

In O
contrast O
to O
the O
morphological O
criteria O
, O
the O
few O
data O
available O
from O
recent O
studies O
at O
the O
genetic O
level O
have O
suggested O
that O
EPVs O
infecting O
different O
insect O
orders O
are O
phylogenetically O
distant O
. O

Prevention O
, O
differential O
diagnosis O
and O
therapy O
of O
travel O
diarrhea O

Mutation O
analysis O
demonstrates O
that O
the O
motif O
TCCCCT O
is O
critical O
for O
PyRo1 B-GENE
interaction O
. O

Our O
results O
suggest O
that O
proteasome O
inhibition O
leads O
to O
upregulation O
of O
specific O
members O
of O
transcription O
factor O
families O
controlling O
cellular O
stress O
response O
and O
proliferation O
. O

In O
hemodialyzed O
patients O
( O
Epo B-GENE
and O
Non O
- O
Epo B-GENE
group O
) O
leptin B-GENE
levels O
were O
significantly O
higher O
when O
compared O
to O
CAPD O
patients O
( O
Epo B-GENE
and O
Non O
- O
Epo B-GENE
group O
, O
respectively O
) O
. O

ID O
- O
PaGIA O
diphtheria B-GENE
toxin I-GENE
polymer O
particle O
diagnostic O
agent O
manufactured O
by O
DiaMed O
AG O
, O
Switzerland O
, O
was O
tried O
at O
bacteriological O
laboratory O
of O
Institute O
of O
Childhood O
Infections O
in O
St O
. O

Topics O
reviewed O
here O
include O
: O
data O
supporting O
the O
association O
of O
myositis O
with O
cancer O
and O
the O
appropriate O
evaluations O
for O
malignancy O
in O
a O
myositis O
patient O
; O
an O
approach O
to O
the O
assessment O
of O
patients O
with O
dermatomyositis O
sine O
myositis O
; O
the O
usefulness O
of O
the O
clinicopathological O
and O
serological O
classifications O
; O
a O
discussion O
of O
whether O
childhood O
and O
adult O
myositis O
are O
the O
same O
or O
different O
entities O
; O
a O
review O
of O
those O
prognostic O
factors O
to O
consider O
in O
the O
clinical O
management O
of O
myositis O
patients O
; O
current O
approaches O
and O
their O
limitations O
for O
assessing O
disease O
activity O
and O
damage O
. O

The O
outer O
diameter O
and O
the O
thickness O
of O
the O
rotor O
are O
60 O
mm O
and O
8 O
mm O
, O
respectively O
. O

CONCLUSIONS O
: O
There O
is O
a O
relation O
in O
the O
topography O
of O
some O
visual O
field O
areas O
assessed O
by O
SWAP O
and O
the O
inferotemporal O
neuroretinal O
rim O
area O
, O
which O
may O
play O
a O
role O
in O
the O
diagnosis O
and O
follow O
- O
up O
of O
suspected O
glaucoma O
. O

ACE B-GENE
- I-GENE
2 I-GENE
has O
a O
hydrophobic O
C O
terminus O
of O
H O
type O
. O

We O
concluded O
that O
activation O
of O
c B-GENE
- I-GENE
fosER I-GENE
mediated O
transcriptional O
inhibition O
of O
p21 B-GENE
( O
Cip1 B-GENE
/ O
WAF1 B-GENE
) O
through O
a O
previously O
uncharacterized O
AP B-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
revealing O
an O
important O
role O
for O
c B-GENE
- I-GENE
fos I-GENE
in O
negative O
control O
of O
cell O
cycle O
regulatory O
genes O
. O

The O
first O
symptoms O
of O
enzootic O
calcinosis O
were O
noted O
in O
March O
1998 O
, O
when O
some O
of O
the O
cows O
developed O
locomotor O
abnormalities O
. O

Screening O
, O
counseling O
, O
and O
treatment O
for O
alcohol O
and O
illicit O
drug O
use O
should O
be O
essential O
components O
in O
comprehensive O
HBP O
care O
. O

Transcriptional O
regulation O
of O
the O
mouse B-GENE
cytosolic I-GENE
chaperonin I-GENE
subunit I-GENE
gene I-GENE
Ccta B-GENE
/ I-GENE
t I-GENE
- I-GENE
complex I-GENE
polypeptide I-GENE
1 I-GENE
by O
selenocysteine B-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
family I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

We O
have O
shown O
that O
the O
epidural O
( O
EPI O
) O
delivery O
of O
morphine O
encapsulated O
in O
multivesicular O
liposomes O
( O
DepoFoam O
drug O
delivery O
system O
) O
produces O
a O
sustained O
clearance O
of O
morphine O
and O
a O
prolonged O
analgesia O
. O

Following O
EPI O
- O
C0401 O
, O
but O
not O
saline O
or O
DepoFoam O
vehicle O
, O
there O
were O
transient O
( O
< O
72 O
hr O
) O
decreases O
in O
food O
consumption O
, O
arousal O
, O
hindlimb O
muscle O
tone O
, O
and O
body O
temperature O
. O

Resistance O
ratios O
for O
the O
other O
field O
strains O
obtained O
by O
comparison O
with O
the O
R5 O
strain O
ranged O
from O
24 O
. O
5 O
to O
239 O
for O
topical O
application O
and O
from O
1 O
. O
2 O
to O
9 O
. O
8 O
for O
the O
glass O
jar O
method O
. O

Reliability O
of O
cervical O
range O
of O
motion O
using O
the O
OSI O
CA O
6000 O
spine O
motion O
analyser O
on O
asymptomatic O
and O
symptomatic O
subjects O
. O

Activation O
of O
PKA B-GENE
by O
8 O
- O
bromo O
- O
cyclic O
AMP O
or O
forskolin O
, O
and O
inhibition O
of O
PKC B-GENE
by O
calphostin O
C O
, O
resulted O
in O
a O
significant O
decrease O
in O
3TP B-GENE
activity O
as O
well O
as O
in O
vitro O
ERK B-GENE
kinase I-GENE
activity O
in O
CRAC O
. O

Mus81p B-GENE
also O
shares O
homology O
with O
motifs O
found O
in O
the O
XPF B-GENE
endonuclease I-GENE
superfamily I-GENE
. O

Double O
mutant O
analysis O
suggests O
that O
Rad54p B-GENE
and O
Mus81p B-GENE
act O
in O
one O
pathway O
for O
the O
repair O
of O
, O
or O
tolerance O
to O
, O
UV O
- O
induced O
DNA O
damage O
. O

SELECTION O
CRITERIA O
: O
All O
controlled O
trials O
where O
adults O
with O
schizophrenia O
or O
similar O
illnesses O
were O
randomised O
to O
quetiapine O
, O
placebo O
or O
other O
neuroleptic O
drugs O
and O
where O
clinically O
relevant O
outcomes O
were O
reported O
. O

Six O
distinct O
Ets B-GENE
mRNAs I-GENE
were O
identified O
: O
Ets2 B-GENE
, O
Fli1 B-GENE
, O
GABPalpha B-GENE
, O
SAP1 B-GENE
, O
Elk1 B-GENE
, O
and O
PE1 B-GENE
. O

A O
2 O
kb O
transcript O
was O
isolated O
from O
brain O
that O
encodes O
a O
approximately O
57 O
kDa O
protein O
; O
the O
predicted O
protein O
contains O
the O
known O
N B-GENE
- I-GENE
terminal I-GENE
Ets I-GENE
domain I-GENE
of O
PE1 B-GENE
and O
a O
novel O
C O
- O
terminal O
domain O
with O
signficant O
homology O
to O
murine B-GENE
ERF I-GENE
. O

Twenty O
eligible O
patients O
with O
cirrhosis O
were O
randomized O
into O
two O
groups O
: O
10 O
patients O
treated O
with O
6 O
million O
units O
of O
natural O
IFN B-GENE
- I-GENE
beta I-GENE
twice O
a O
week O
for O
36 O
months O
and O
10 O
patients O
without O
IFN B-GENE
therapy O
. O

It O
is O
now O
well O
accepted O
that O
the O
p53 B-GENE
C I-GENE
- I-GENE
terminus I-GENE
plays O
a O
central O
role O
in O
controlling O
the O
activity O
of O
the O
wild O
- O
type O
molecule O
. O

The O
transcription O
factor O
Jun B-GENE
( O
c B-GENE
- I-GENE
Jun I-GENE
) O
functions O
as O
a O
recipient O
of O
extracellular O
growth O
signals O
and O
converts O
them O
into O
patterns O
of O
gene O
expression O
. O

This O
compound O
is O
the O
main O
bioactive O
metabolite O
of O
trimebutine O
II O
( O
Debridat O
, O
CAS O
39133 O
- O
31 O
- O
8 O
) O
, O
an O
antispasmodic O
widely O
used O
for O
intestinal O
diseases O
since O
1969 O
. O

This O
enabled O
the O
formation O
of O
stem O
- O
loop O
templates O
with O
the O
fusion O
point O
of O
the O
chimeric O
transcript O
in O
the O
loop O
and O
the O
use O
of O
MLL B-GENE
primers O
in O
two O
- O
sided O
PCR O
. O

It O
contains O
25 O
exons O
coding O
for O
a O
4 O
. O
7kb O
transcript O
including O
large O
5 O
' O
- O
and O
3 O
' O
- O
( O
1218bp O
and O
701bp O
, O
respectively O
) O
untranslated O
regions O
( O
UTRs O
) O
. O

The O
limit O
between O
the O
cecum O
and O
the O
ascending O
colon O
was O
externally O
marked O
by O
the O
sulcus O
cecocolicus O
dorsalis O
and O
ventralis O
. O

These O
results O
further O
support O
an O
important O
role O
for O
CBF2 B-GENE
in O
mediating O
EBNA2 B-GENE
transactivation O
; O
they O
identify O
the O
hnRNP B-GENE
protein I-GENE
AUF1 I-GENE
as O
a O
major O
component O
of O
CBF2 B-GENE
and O
are O
also O
the O
first O
evidence O
of O
a O
cis O
- O
acting O
sequence O
other O
than O
a O
CBF1 B-GENE
binding I-GENE
element I-GENE
that O
is O
able O
to O
confer O
responsiveness O
to O
EBNA2 B-GENE
. O

Viruses O
were O
isolated O
from O
9 O
lungs O
: O
7 O
with O
PI O
- O
3V O
, O
1 O
with O
NCP O
BVDV O
type O
1 O
, O
and O
1 O
with O
both O
BVHV O
- O
1 O
and O
BVDV O
. O

Splicing O
of O
the O
K B-GENE
- I-GENE
SAM I-GENE
alternative O
exon O
of O
the O
fibroblast B-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
gene I-GENE
is O
heavily O
dependent O
on O
the O
U O
- O
rich O
sequence O
IAS1 B-GENE
lying O
immediately O
downstream O
from O
its O
5 O
' O
splice O
site O
. O

During O
treatment O
, O
the O
phosphorylation O
state O
of O
Rb B-GENE
shifted O
to O
a O
hypophosphorylated O
form O
. O
mRNA O
for O
the O
HPV O
E6 B-GENE
/ O
E7 B-GENE
genes O
decreased O
; O
however O
, O
significant O
changes O
in O
the O
E7 B-GENE
protein I-GENE
were O
not O
observed O
, O
while O
increased O
levels O
of O
Rb B-GENE
immunoprecipitated O
with O
anti B-GENE
- I-GENE
E7 I-GENE
antibodies I-GENE
were O
observed O
. O

Five O
of O
the O
Aeromonas O
strains O
and O
one O
of O
V O
cholerae O
non O
- O
O1 O
were O
positive O
for O
enterotoxin O
activity O
. O

The O
2 O
cDNAs O
differed O
in O
the O
length O
of O
their O
respective O
3 O
' O
untranslated O
regions O
, O
of O
577 O
bp O
in O
Cp B-GENE
. I-GENE
F6 I-GENE
and O
72 O
bp O
in O
Cp B-GENE
. I-GENE
F10 I-GENE
, O
in O
both O
of O
which O
a O
putative O
polyadenylation O
signal O
was O
identified O
. O

Platelet O
counts O
and O
function O
as O
well O
as O
fibrinogen B-GENE
and O
von B-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF B-GENE
) O
levels O
were O
determined O
in O
each O
sample O
. O

The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
level O
of O
oxidative O
stress O
in O
healthy O
controls O
( O
CTL O
) O
compared O
with O
CRF O
and O
HD O
patients O
before O
( O
pre O
- O
HD O
) O
and O
after O
( O
post O
- O
HD O
) O
the O
dialysis O
session O
, O
carried O
out O
on O
a O
high O
biocompatible O
polyacrylonitrile O
membrane O
AN69 O
. O

Indirect O
plasma O
parameters O
such O
as O
vitamin O
E O
, O
thiol O
and O
uric O
acid O
levels O
were O
also O
quantified O
. O

The O
results O
indicate O
that O
the O
relationship O
between O
comprehension O
and O
production O
is O
different O
at O
different O
stages O
in O
development O
. O

On O
long O
- O
term O
follow O
- O
up O
, O
there O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
hospitalizations O
( O
1 O
per O
2 O
. O
1 O
vs O
. O

The O
tumor B-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
is O
involved O
in O
maintaining O
genomic O
stability O
. O

Abrogation O
of O
p53 B-GENE
function O
by O
E6 B-GENE
resulted O
in O
an O
increase O
in O
the O
spontaneous O
mutation O
frequencies O
at O
the O
heterozygous O
thymidine B-GENE
kinase I-GENE
( O
TK B-GENE
) O
locus O
but O
not O
at O
the O
hemizygous O
hypoxanthine B-GENE
phosphoribosyl I-GENE
transferase I-GENE
( O
HPRT B-GENE
) O
locus O
. O

Cytogenetic O
analysis O
of O
LOH O
mutants O
by O
chromosome O
painting O
indicated O
a O
mosaic O
of O
chromosomal O
aberrations O
involving O
chromosome O
17 O
, O
in O
which O
partial O
chromosome O
deletions O
, O
amplifications O
, O
and O
multiple O
translocations O
appeared O
heterogeneously O
in O
a O
single O
mutant O
. O

These O
results O
support O
a O
model O
in O
which O
p53 B-GENE
protein I-GENE
contributes O
to O
the O
maintenance O
of O
genomic O
integrity O
through O
recombinational O
repair O
. O

In O
patients O
with O
type O
II O
tumors O
, O
the O
pattern O
of O
lymphatic O
spread O
was O
primarily O
directed O
toward O
the O
paracardial O
, O
lesser O
curvature O
, O
and O
left O
gastric O
artery O
nodes O
; O
esophagectomy O
offered O
no O
survival O
benefit O
over O
extended O
gastrectomy O
in O
these O
patients O
. O

The O
muskox O
is O
a O
new O
host O
record O
for O
T O
. O
gondii O
. O

Mucosal O
application O
of O
NCX O
- O
4016 O
, O
however O
, O
did O
not O
cause O
PD O
reduction O
and O
luminal O
H O
+ O
loss O
, O
but O
produced O
a O
marked O
hyperemia O
, O
resulting O
in O
no O
damage O
in O
the O
stomach O
of O
both O
normal O
and O
STZ O
- O
diabetic O
rats O
. O

The O
amino O
acid O
sequence O
of O
matrilysin B-GENE
- I-GENE
2 I-GENE
also O
contains O
a O
threonine O
residue O
adjacent O
to O
the O
Zn O
- O
binding O
site O
that O
has O
been O
defined O
as O
a O
specific O
feature O
of O
matrilysin B-GENE
. O

Regarding O
" O
the O
relation O
between O
sexual O
orientation O
and O
penile O
size O
, O
" O
by O
A O
. O

Analysis O
of O
Standard O
Reference O
Material O
1846 O
, O
Infant O
Formula O
, O
gave O
a O
mean O
value O
of O
0 O
. O
95 O
+ O
/ O
- O
0 O
. O
088 O
mg O
vitamin O
K O
/ O
kg O
( O
K O
or O
K1 O
? O
) O
( O
n O
= O
31 O
) O
with O
a O
coefficient O
of O
variation O
of O
9 O
. O
26 O
. O

The O
Spo0F B-GENE
residues I-GENE
making O
up O
the O
hydrophobic O
patch O
are O
very O
similar O
in O
all O
response O
regulators O
suggesting O
that O
the O
binding O
is O
initiated O
through O
the O
same O
residues O
in O
all O
interacting O
response O
regulator O
- O
kinase O
pairs O
. O

While O
mutations O
in O
K B-GENE
- I-GENE
Rev I-GENE
that O
inactivate O
any O
one O
of O
these O
properties O
also O
blocked O
K B-GENE
- I-GENE
Rev I-GENE
- O
dependent O
nuclear O
RNA O
export O
, O
several O
K B-GENE
- I-GENE
Rev I-GENE
mutants I-GENE
were O
comparable O
to O
wild O
type O
when O
assayed O
for O
any O
of O
these O
individual O
activities O
yet O
nevertheless O
defective O
for O
RNA O
export O
. O

These O
results O
suggest O
that O
Cdc42p B-GENE
is O
in O
fact O
required O
for O
pheromone O
response O
and O
that O
interaction O
with O
the O
PAK B-GENE
Ste20p B-GENE
is O
critical O
for O
that O
role O
. O

Symptoms O
, O
however O
, O
appear O
to O
correlate O
poorly O
with O
oesophagitis O
; O
hence O
, O
severe O
symptoms O
do O
not O
indicate O
there O
is O
greater O
oesophageal O
damage O
. O

The O
variable O
phenotype O
of O
the O
allotetraploids O
could O
not O
be O
explained O
by O
cytological O
abnormalities O
. O

It O
is O
now O
estimated O
that O
inactivation O
mutants O
of O
PTEN B-GENE
exist O
in O
60 O
% O
of O
all O
forms O
of O
solid O
tumors O
. O

We O
have O
demonstrated O
that O
the O
activity O
of O
ILK B-GENE
is O
constitutively O
elevated O
in O
PTEN B-GENE
mutant I-GENE
cells O
. O

The O
detector O
has O
the O
advantage O
of O
finding O
both O
ST O
segment O
deviations O
and O
entire O
ST O
- O
T O
complex O
changes O
thereby O
providing O
a O
wider O
characterization O
of O
the O
potential O
ischemic O
events O
. O

Primary O
adrenal O
hypersensitivity O
to O
ACTH B-GENE
drive O
in O
obesity O
has O
also O
been O
suggested O
. O

In O
addition O
, O
a O
noncanonical O
C B-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
within O
the O
Gadd45gamma B-GENE
promoter I-GENE
where O
C B-GENE
/ I-GENE
EBPbeta I-GENE
and O
C B-GENE
/ I-GENE
EBPdelta I-GENE
could O
bind O
, O
was O
identified O
by O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
and O
reporter O
gene O
analysis O
. O

From O
two O
inhibitor O
scaffolds O
, O
we O
have O
identified O
potent O
and O
selective O
inhibitors O
for O
sensitized O
kinases O
from O
five O
distinct O
subfamilies O
. O

By O
progressive O
5 O
' O
- O
deletion O
studies O
, O
we O
have O
identified O
a O
248 O
- O
bp O
DNA O
fragment O
( O
- O
1018 O
to O
- O
771 O
, O
relative O
to O
the O
translation O
start O
site O
) O
at O
the O
5 O
' O
- O
flanking O
region O
of O
the O
human B-GENE
GnRHR I-GENE
gene I-GENE
that O
is O
responsible O
for O
the O
GnRHa O
- O
mediated O
down O
- O
regulation O
of O
human B-GENE
GnRHR I-GENE
promoter I-GENE
activity O
. O

Intracellular O
localization O
studies O
using O
the O
mDAP B-GENE
- I-GENE
3 I-GENE
/ O
EGFP B-GENE
fusion O
protein O
, O
cell O
fractionation O
and O
protease O
protection O
experiments O
localized O
mDAP B-GENE
- I-GENE
3 I-GENE
to O
the O
mitochondrial O
matrix O
. O

Reporter O
gene O
expression O
analyses O
indicate O
that O
both O
WASP B-GENE
promoters I-GENE
show O
high O
levels O
of O
expression O
in O
different O
hematopoietic O
cell O
lines O
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
KG1a O
cells O
, O
TNFalpha B-GENE
can O
stimulate O
in O
parallel O
PC B-GENE
- I-GENE
PLC I-GENE
and O
PLD B-GENE
, O
whose O
lipid O
products O
activate O
in O
turn O
mitogen B-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAP B-GENE
kinase I-GENE
) O
and O
NF B-GENE
- I-GENE
kappaB I-GENE
signalling O
respectively O
. O

Polysome O
and O
40S B-GENE
ribosome I-GENE
fractions O
were O
severely O
decreased O
in O
the O
krr1 B-GENE
mutant I-GENE
and O
Kri1p B-GENE
- O
depleted O
cells O
. O

They O
also O
negatively O
modulate O
the O
PI B-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic O
activity O
but O
to O
different O
extents O
, O
dependent O
on O
the O
unique O
N O
- O
terminal O
structure O
of O
each O
isoform O
. O

The O
Drosophila B-GENE
melanogaster I-GENE
suppressor I-GENE
of I-GENE
sable I-GENE
gene I-GENE
, O
su B-GENE
( I-GENE
s I-GENE
) I-GENE
, O
encodes O
a O
novel O
, O
150 O
- O
kDa O
nuclear O
RNA O
binding O
protein O
, O
SU B-GENE
( I-GENE
S I-GENE
) I-GENE
, O
that O
negatively O
regulates O
RNA O
accumulation O
from O
mutant O
alleles O
of O
other O
genes O
that O
have O
transposon O
insertions O
in O
the O
5 O
' O
transcribed O
region O
. O

As O
a O
result O
, O
we O
have O
defined O
two O
arginine O
- O
rich O
motifs O
( O
ARM1 O
and O
ARM2 O
) O
that O
mediate O
the O
RNA O
binding O
activity O
of O
SU B-GENE
( I-GENE
S I-GENE
) I-GENE
. O

Vasoactive B-GENE
intestinal I-GENE
peptide I-GENE
and O
pituitary B-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
inhibit O
nuclear B-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
activation O
at O
multiple O
levels O
in O
the O
human O
monocytic O
cell O
line O
THP O
- O
1 O
. O

Overexpression O
of O
Trdpm1 B-GENE
in O
a O
dpm1 B-GENE
( I-GENE
+ I-GENE
) I-GENE
: O
: O
his7 B-GENE
/ I-GENE
dpm1 I-GENE
( I-GENE
+ I-GENE
) I-GENE
S O
. O
pombe O
diploid O
resulted O
in O
a O
4 O
- O
fold O
increase O
in O
specific O
DPM B-GENE
synthase I-GENE
activity O
. O

The O
N O
- O
terminal O
small O
segment O
of O
yeast B-GENE
TAF145 I-GENE
( O
yTAF145 B-GENE
) O
binds O
to O
TBP B-GENE
and O
thereby O
inhibits O
TBP B-GENE
function O
. O

These O
probable O
border O
sequences O
are O
closely O
related O
to O
those O
of O
other O
known O
T O
- O
regions O
and O
define O
a O
second O
T O
- O
region O
of O
pTiChry5 O
, O
called O
T O
- O
right O
( O
TR O
) O
, O
that O
confers O
production O
of O
the O
Amadoriopines O
. O

Another O
cis O
- O
acting O
element O
, O
exonic O
splicing O
suppressor O
1 O
( O
ESS1 O
) O
, O
represses O
use O
of O
the O
nt O
3225 O
3 O
' O
splice O
site O
. O

5 O
' O
- O
RACE O
analysis O
suggested O
a O
single O
transcription O
initiation O
site O
187 O
bp O
upstream O
from O
the O
translational O
start O
site O
. O

Thromboelastography O
is O
a O
test O
that O
could O
potentially O
correlate O
with O
the O
degree O
of O
anticoagulation O
produced O
by O
low O
molecular O
weight O
heparin O
. O

Expression O
of O
a O
hybrid O
protein O
containing O
the O
cytoplasmic O
C O
- O
terminal O
half O
of O
UhpB B-GENE
fused O
to O
glutathione B-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST B-GENE
) O
also O
interfered O
with O
Uhp B-GENE
signaling O
. O

RESULTS O
: O
Glaucoma O
suspects O
were O
divided O
into O
two O
groups O
according O
to O
their O
SWAP O
results O
: O
high O
risk O
( O
with O
SWAP O
abnormalities O
) O
and O
low O
risk O
( O
with O
normal O
SWAP O
result O
) O
. O

To O
begin O
to O
understand O
this O
role O
, O
we O
overexpressed O
ATF B-GENE
- I-GENE
2 I-GENE
in O
a O
human O
cancer O
cell O
line O
. O

Botulinum B-GENE
toxin I-GENE
A I-GENE
in O
the O
treatment O
of O
hemiplegic O
spastic O
foot O
drop O
- O
- O
clinical O
and O
functional O
outcomes O
. O

The O
U17 B-GENE
/ O
U16 B-GENE
and O
the O
U16 B-GENE
+ I-GENE
gene I-GENE
products I-GENE
transactivated O
the O
HIV B-GENE
LTR I-GENE
. O

The O
Cili B-GENE
- I-GENE
2 I-GENE
sequences I-GENE
possess O
similarity O
to O
the O
RNaseH B-GENE
domain I-GENE
of O
Lian B-GENE
- O
Aa1 B-GENE
, O
a O
mosquito B-GENE
non I-GENE
- I-GENE
LTR I-GENE
retrotransposon I-GENE
. O

This O
dynamic O
response O
strongly O
suggests O
that O
the O
p53 B-GENE
and O
Rb B-GENE
tumor O
suppressor O
pathways O
are O
intact O
in O
HeLa O
cells O
and O
that O
repression O
of O
HPV B-GENE
E6 I-GENE
and O
E7 B-GENE
mobilizes O
these O
pathways O
in O
an O
orderly O
fashion O
to O
deliver O
growth O
inhibitory O
signals O
to O
the O
cells O
. O

Effects O
of O
spatial O
and O
temporal O
smoothing O
on O
stimulated O
brillouin O
scattering O
in O
the O
independent O
- O
hot O
- O
spot O
model O
limit O
The O
influence O
of O
laser O
beam O
smoothing O
on O
stimulated O
Brillouin O
backscattering O
( O
SBBS O
) O
is O
studied O
analytically O
in O
the O
limit O
of O
the O
independent O
hot O
spot O
model O
. O

Association O
of O
stress O
during O
delivery O
with O
increased O
numbers O
of O
nucleated O
cells O
and O
hematopoietic O
progenitor O
cells O
in O
umbilical O
cord O
blood O
. O

Transformation O
of O
the O
sconC3 B-GENE
mutant I-GENE
with O
sconB B-GENE
+ I-GENE
restores O
the O
wild O
- O
type O
phenotype O
. O

RESULTS O
: O
The O
main O
effect O
of O
muscle O
pain O
, O
compared O
to O
non O
- O
painful O
stimulation O
, O
was O
a O
significant O
and O
long O
- O
lasting O
increase O
of O
delta O
( O
1 O
- O
3 O
Hz O
) O
power O
and O
an O
alpha O
- O
1 O
( O
9 O
- O
11 O
Hz O
) O
power O
increase O
over O
the O
contralateral O
parietal O
locus O
. O

Based O
on O
16S B-GENE
rRNA I-GENE
gene I-GENE
sequence I-GENE
analysis O
, O
the O
11 O
species O
having O
two O
tuf B-GENE
genes I-GENE
all O
have O
a O
common O
ancestor O
, O
while O
the O
six O
species O
having O
only O
one O
copy O
diverged O
from O
the O
enterococcal O
lineage O
before O
that O
common O
ancestor O
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
forkhead B-GENE
transcription I-GENE
factor I-GENE
FKHR B-GENE
- I-GENE
L1 I-GENE
, O
and O
IL B-GENE
- I-GENE
3 I-GENE
inhibited O
FKHR B-GENE
- I-GENE
L1 I-GENE
activity O
in O
a O
PI3K B-GENE
- O
dependent O
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
inhibition O
of O
p27 B-GENE
( O
KIP1 B-GENE
) O
transcription O
through O
PI3K B-GENE
- O
induced O
FKHR B-GENE
- I-GENE
L1 I-GENE
phosphorylation O
provides O
a O
novel O
mechanism O
of O
regulating O
cytokine O
- O
mediated O
survival O
and O
proliferation O
. O

DNase B-GENE
I I-GENE
genomic O
footprinting O
revealed O
that O
the O
c B-GENE
- I-GENE
Myb I-GENE
site I-GENE
is O
occupied O
in O
a O
tissue O
- O
specific O
fashion O
in O
vivo O
. O

We O
conclude O
that O
c B-GENE
- I-GENE
Myb I-GENE
regulates O
the O
RAG B-GENE
- I-GENE
2 I-GENE
promoter I-GENE
in O
T O
cells O
by O
binding O
to O
this O
consensus B-GENE
c I-GENE
- I-GENE
Myb I-GENE
binding I-GENE
site I-GENE
. O

RESULTS O
: O
Average O
age O
at O
symptom O
onset O
was O
41 O
. O
2 O
years O
. O

Unlike O
the O
mammalian O
proteins O
, O
XFGF3 B-GENE
is O
efficiently O
secreted O
as O
a O
Mr O
31 O
, O
000 O
glycoprotein O
, O
gp31 B-GENE
, O
which O
undergoes O
proteolytic O
cleavage O
to O
produce O
an O
NH2 O
- O
terminally O
truncated O
product O
, O
gp27 B-GENE
. O

NH2 O
- O
terminal O
trimming O
of O
Xenopus O
and O
mammalian B-GENE
FGF3s I-GENE
may O
therefore O
be O
a O
prerequisite O
of O
optimal O
biological O
activity O
. O

Here O
, O
we O
identified O
three O
cis O
- O
elements O
required O
for O
replication O
within O
the O
200 O
bp O
promoter O
, O
using O
autonomously O
replicating O
plasmids O
carrying O
various O
mutations O
and O
deletions O
. O

The O
objectives O
of O
the O
present O
study O
were O
to O
evaluate O
the O
effects O
of O
adding O
Equex O
to O
a O
TRIS O
- O
extender O
, O
diluting O
the O
semen O
in O
1 O
or O
2 O
steps O
, O
freezing O
according O
to O
2 O
methods O
, O
thawing O
at O
2 O
rates O
, O
and O
the O
interactions O
between O
these O
treatments O
, O
on O
the O
post O
- O
thaw O
survival O
of O
dog O
spermatozoa O
at O
38 O
degrees O
C O
. O

Molecular O
cloning O
and O
expression O
of O
human B-GENE
UDP I-GENE
- I-GENE
d I-GENE
- I-GENE
Xylose I-GENE
: I-GENE
proteoglycan I-GENE
core I-GENE
protein I-GENE
beta B-GENE
- I-GENE
d I-GENE
- I-GENE
xylosyltransferase I-GENE
and O
its O
first O
isoform B-GENE
XT I-GENE
- I-GENE
II I-GENE
. O

Oncogenic O
signalling O
by O
E2F1 B-GENE
has O
recently O
been O
linked O
to O
stabilization O
and O
activation O
of O
the O
tumour O
suppressor O
p53 B-GENE
( O
refs O
1 O
, O
3 O
, O
4 O
) O
. O

We O
describe O
the O
identification O
and O
initial O
characterization O
of O
neurobeachin B-GENE
, O
a O
neuron O
- O
specific O
multidomain O
protein O
of O
327 O
kDa O
with O
a O
high O
- O
affinity O
binding O
site O
( O
K O
( O
d O
) O
, O
10 O
nm O
) O
for O
the O
type B-GENE
II I-GENE
regulatory I-GENE
subunit I-GENE
of I-GENE
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA B-GENE
RII I-GENE
) O
. O

Antimicrobial O
Susceptibility O
of O
Klebsiella O
pneumoniae O
Producing O
Extended B-GENE
- I-GENE
Spectrum I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
( O
ESBL B-GENE
) O
Isolated O
in O
Hospitals O
in O
Brazil O
. O

CONCLUSION O
: O
Our O
results O
suggest O
that O
AIF O
peak O
saturation O
leads O
to O
a O
significant O
systematic O
error O
in O
the O
determination O
of O
CBV O
and O
CBF O
values O
and O
has O
necessarily O
to O
be O
taken O
into O
account O
for O
dynamic O
contrast O
- O
enhanced O
MR O
perfusion O
studies O
. O

Toward O
this O
end O
, O
we O
prepared O
synthetic O
proteins O
with O
either O
the O
catalytic O
domain O
of O
FAP B-GENE
- I-GENE
1 I-GENE
( I-GENE
C I-GENE
- I-GENE
terminal I-GENE
399 I-GENE
amino I-GENE
acids I-GENE
) I-GENE
or O
its O
inactive O
form O
( O
Cys2408 O
- O
- O
> O
Ser O
) O
fused O
to O
glutathione B-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST B-GENE
) O
. O

Furthermore O
, O
transfection O
of O
cells O
with O
the O
spacer O
- O
RING O
domain O
alone O
suppressed O
the O
antiapoptotic O
function O
of O
the O
N O
- O
terminal O
BIR B-GENE
domain O
of O
c B-GENE
- I-GENE
IAP1 I-GENE
and O
induced O
apoptosis O
. O

MS O
characteristics O
of O
coumarins O
, O
psoralens O
and O
polymethoxylated O
flavones O
with O
different O
substitution O
patterns O
were O
determined O
on O
the O
basis O
of O
the O
response O
obtained O
with O
the O
APcI O
interface O
. O

Copyright O
2000 O
Academic O
Press O
. O

Plectin B-GENE
and O
desmoplakin B-GENE
have O
GSR O
- O
containing O
domains O
at O
their O
C O
- O
termini O
and O
we O
further O
demonstrate O
that O
the O
GSR O
- O
containing O
domain O
of O
plectin B-GENE
, O
but O
not O
desmoplakin B-GENE
, O
can O
bind O
to O
MTs O
in O
vivo O
. O

Characterization O
of O
the O
microtubule O
binding O
domain O
of O
microtubule B-GENE
actin I-GENE
crosslinking I-GENE
factor I-GENE
( O
MACF B-GENE
) O
: O
identification O
of O
a O
novel O
group O
of O
microtubule B-GENE
associated I-GENE
proteins I-GENE
. O

Fecal O
samples O
were O
collected O
at O
the O
beginning O
and O
end O
of O
each O
trial O
period O
and O
were O
analyzed O
for O
gastrointestinal O
nematode O
eggs O
and O
Giardia O
cyst O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
risk O
factors O
for O
background O
diabetic O
retinopathy O
( O
BDR O
) O
and O
PDR O
by O
following O
394 O
Japanese O
patients O
with O
early O
- O
onset O
type O
2 O
diabetes O
diagnosed O
before O
30 O
years O
of O
age O
( O
mean O
age O
27 O
, O
mean O
blood O
pressure O
at O
entry O
116 O
/ O
73 O
mm O
Hg O
) O
. O

These O
cells O
produced O
P2Y B-GENE
( I-GENE
11 I-GENE
) I-GENE
mRNA I-GENE
during O
culture O
. O

Differential O
association O
of O
products O
of O
alternative O
transcripts O
of O
the O
candidate O
tumor B-GENE
suppressor I-GENE
ING1 I-GENE
with O
the O
mSin3 B-GENE
/ O
HDAC1 B-GENE
transcriptional O
corepressor O
complex O
. O

As O
hypothesized O
, O
believers O
showed O
relatively O
higher O
right O
hemispheric O
activation O
and O
reduced O
hemispheric O
asymmetry O
of O
functional O
complexity O
. O

Nucleotide O
sequence O
, O
genome O
organization O
and O
phylogenetic O
analysis O
of O
pineapple O
mealybug O
wilt O
- O
associated O
virus O
- O
2 O
. O

Adjuvant O
therapy O
for O
colon O
cancer O
] O
Surgery O
alone O
may O
fail O
to O
cure O
a O
considerable O
number O
of O
locally O
advanced O
colon O
cancers O
. O

Effects O
of O
Trypanosoma O
vivax O
on O
pregnancy O
of O
Yankasa O
sheep O
and O
the O
results O
of O
homidum O
chloride O
chemotherapy O
. O

NF B-GENE
kappa I-GENE
B I-GENE
was O
activated O
to O
a O
much O
greater O
extent O
by O
roscovitine O
in O
the O
WT O
cells O
than O
in O
Y8 O
cells O
. O

Additionally O
, O
MIP B-GENE
- I-GENE
2A I-GENE
antagonizes O
cell O
growth O
regulatory O
role O
of O
MBP B-GENE
- I-GENE
1 I-GENE
. O

3 O
. O
04 O
+ O
/ O
- O
1 O
. O
2 O
, O
P O
< O
0 O
. O
0001 O
) O
, O
large O
accelerations O
/ O
30 O
min O
( O
1 O
. O
46 O
+ O
/ O
- O
1 O
. O
96 O
vs O
. O

In O
addition O
, O
we O
identified O
two O
mutations O
, O
Delta O
M1281 O
and O
IVS51 O
+ O
5G O
- O
- O
> O
A O
, O
in O
a O
German O
USH1 B-GENE
patient O
. O

Nuclease O
probing O
and O
structure O
- O
directed O
mutagenesis O
revealed O
that O
the O
105 O
- O
nt O
TE O
( O
TE105 O
) O
forms O
a O
cruciform O
secondary O
structure O
containing O
four O
helices O
connected O
by O
single O
- O
stranded O
regions O
. O

Tele O
- O
Talk O
has O
the O
extra O
capability O
of O
operating O
in O
live O
conference O
situations O
using O
microphone O
input O
. O

Perfusion O
technique O
for O
perfusion O
- O
assisted O
direct O
coronary O
artery O
bypass O
( O
PADCAB O
) O
. O

As O
well O
, O
mixtures O
of O
( O
LA O
) O
( O
12 O
) O
with O
the O
longer O
chain O
PEs O
exhibit O
unusual O
biomodal O
enthalpy O
variations O
, O
suggesting O
peptide O
immiscibility O
in O
thicker O
gel O
state O
bilayers O
. O

Energy O
expenditure O
was O
obtained O
using O
a O
primed O
, O
3 O
- O
hour O
infusion O
of O
NaH O
( O
13 O
) O
CO O
( O
3 O
' O
) O
, O
breath O
( O
13 O
) O
CO O
( O
2 O
) O
enrichment O
determination O
by O
isotope O
ratio O
mass O
spectroscopy O
, O
and O
the O
application O
of O
a O
standard O
regression O
equation O
. O

Workload O
, O
UAPs O
, O
and O
you O
. O

Naltrexone O
hydrochloride O
is O
a O
synthetic O
opioid B-GENE
receptor I-GENE
antagonist O
recently O
used O
in O
efforts O
to O
provide O
rapid O
opioid O
detoxification O
. O

Derivation O
and O
initial O
characterization O
of O
a O
mouse O
mammary O
tumor O
cell O
line O
carrying O
the O
polyomavirus B-GENE
middle I-GENE
T I-GENE
antigen I-GENE
: O
utility O
in O
the O
development O
of O
novel O
cancer O
therapeutics O
. O

Hypomorphic O
dSLBP B-GENE
alleles I-GENE
support O
zygotic O
development O
but O
cause O
female O
sterility O
. O

We O
mapped O
the O
DGCR6 B-GENE
gene I-GENE
to O
chromosome O
22q11 O
within O
a O
low O
copy O
repeat O
, O
termed O
sc11 O
. O
1a O
, O
and O
identified O
a O
second O
copy O
of O
the O
gene O
, O
DGCR6L B-GENE
, O
within O
the O
duplicate O
locus O
, O
termed O
sc11 O
. O
1b O
. O

Recruitment O
of O
an O
RNA B-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
is O
mediated O
by O
the O
constitutive O
activation O
domain O
in O
CREB B-GENE
, O
independently O
of O
CREB B-GENE
phosphorylation O
. O

The O
observed O
phenotypes O
may O
be O
explained O
by O
( O
i O
) O
a O
selective O
disruption O
of O
very B-GENE
- I-GENE
low I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
secretion O
due O
to O
decreased O
expression O
of O
genes O
encoding O
apolipoprotein B-GENE
B I-GENE
and O
microsomal B-GENE
triglyceride I-GENE
transfer I-GENE
protein I-GENE
, O
( O
ii O
) O
an O
increase O
in O
hepatic O
cholesterol O
uptake O
due O
to O
increased O
expression O
of O
the O
major O
high B-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
, O
scavenger B-GENE
receptor I-GENE
BI I-GENE
, O
and O
( O
iii O
) O
a O
decrease O
in O
bile O
acid O
uptake O
to O
the O
liver O
due O
to O
down O
- O
regulation O
of O
the O
major O
basolateral B-GENE
bile I-GENE
acid I-GENE
transporters I-GENE
sodium I-GENE
taurocholate I-GENE
cotransporter I-GENE
protein I-GENE
and O
organic B-GENE
anion I-GENE
transporter I-GENE
protein I-GENE
1 I-GENE
. O

Inactivity O
of O
the O
human B-GENE
cytomegalovirus I-GENE
( I-GENE
HCMV I-GENE
) I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
regulatory I-GENE
region I-GENE
( O
MIERR B-GENE
) O
, O
which O
is O
composed O
of O
promoter O
, O
enhancer O
, O
unique O
region O
, O
and O
modulator O
, O
is O
linked O
to O
lack O
of O
HCMV O
replication O
in O
latently O
infected O
cells O
and O
in O
other O
nonpermissive O
cell O
types O
, O
including O
human O
embryonal O
NTera2 O
carcinoma O
( O
NT2 O
) O
cells O
. O

Both O
Z B-GENE
and O
R B-GENE
expression O
resulted O
in O
PML O
dispersion O
in O
EBV O
- O
positive O
cells O
. O

Immunofluorescence O
studies O
in O
C2C12 O
myotubes O
show O
that O
Smad2 B-GENE
and O
MEF2A B-GENE
co O
- O
localise O
in O
the O
nucleus O
of O
multinuclear O
myotubes O
during O
differentiation O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
somatic O
cell O
hybrids O
showed O
that O
endothelial B-GENE
- I-GENE
TACC I-GENE
- I-GENE
related I-GENE
cDNA I-GENE
maps O
to O
chromosome O
10 O
. O

The O
presence O
of O
truncated O
receptor O
isoforms O
in O
diverse O
species O
suggests O
that O
these O
proteins O
may O
have O
important O
functional O
roles O
in O
regulating O
EGFR B-GENE
activity O
. O

The O
continuing O
development O
of O
ligands O
that O
function O
as O
selective O
estrogens O
or O
antiestrogens O
for O
ERalpha B-GENE
or O
ERbeta B-GENE
should O
allow O
optimized O
tissue O
selectivity O
of O
these O
agents O
for O
menopausal O
hormone O
replacement O
therapy O
and O
the O
treatment O
and O
prevention O
of O
breast O
cancer O
. O

Behavioural O
tests O
with O
192 O
specimen O
of O
the O
roman O
garden O
snail O
Helix O
pomatia O
L O
. O
were O
performed O
in O
order O
to O
clarify O
whether O
the O
thermopreferendum O
of O
this O
pulmonate O
is O
influenced O
not O
only O
by O
the O
temperature O
of O
the O
substratum O
but O
also O
by O
air O
temperature O
. O

Increased O
erythropoietin B-GENE
synthesis O
in O
patients O
with O
COLD O
or O
left O
heart O
failure O
is O
related O
to O
alterations O
in O
renal O
haemodynamics O
. O

Using O
immunochemical O
co O
- O
precipitation O
methods O
, O
we O
also O
found O
that O
the O
two O
proteins O
are O
bound O
in O
vivo O
. O

An O
additional O
9 O
patients O
achieved O
normal O
levels O
with O
adjunctive O
drug O
therapy O
. O

For O
immunological O
methods O
, O
identification O
of O
such O
antigens O
with O
intermolecular O
variability O
, O
e O
. O
g O
. O
, O
the O
structural O
aescin O
analogs O
, O
is O
of O
unknown O
validity O
. O

Blood O
from O
dams O
was O
collected O
prior O
to O
inoculation O
and O
at O
time O
of O
necropsy O
for O
measurement O
of O
IgM B-GENE
and O
IgG B-GENE
antibodies I-GENE
to O
M O
. O
pulmonis O
. O

Single O
amino O
acid O
substitutions O
at O
the O
acyl O
- O
CoA O
- O
binding O
domain O
interrupt O
14 O
[ O
C O
] O
palmitoyl O
- O
CoA O
binding O
of O
ACBP2 B-GENE
, O
an O
Arabidopsis O
acyl B-GENE
- I-GENE
CoA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with O
ankyrin B-GENE
repeats O
. O

The O
bovine B-GENE
PGHS I-GENE
- I-GENE
2 I-GENE
cDNA I-GENE
was O
cloned O
by O
a O
combination O
of O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
cDNA O
library O
screening O
. O

The O
regulation O
of O
PGHS B-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
and O
protein O
was O
studied O
in O
primary O
cultures O
of O
bovine O
uterine O
stromal O
cells O
stimulated O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
; O
100 O
nM O
) O
. O

Anti B-GENE
- I-GENE
nucleolin I-GENE
mAb I-GENE
was O
used O
to O
confirm O
the O
antigenic O
properties O
of O
this O
p95 B-GENE
component I-GENE
. O

Furthermore O
, O
stable O
expression O
of O
a O
constitutively O
active O
form O
of O
chicken O
Notch1 B-GENE
or O
Notch2 B-GENE
in O
a O
B O
cell O
line O
results O
in O
a O
down O
- O
regulation O
of O
surface O
IgM B-GENE
expression O
, O
which O
is O
accompanied O
by O
the O
reduction O
of O
IgH B-GENE
gene I-GENE
transcripts I-GENE
. O

The O
effects O
of O
the O
transfected O
receptors O
were O
associated O
with O
antagonism O
of O
activator B-GENE
protein I-GENE
1 I-GENE
( O
AP B-GENE
- I-GENE
1 I-GENE
) O
activity O
. O

Recent O
studies O
using O
isolated O
rat O
adipocytes O
and O
chemically O
synthesized O
PIG O
compounds O
point O
to O
IRS1 B-GENE
/ I-GENE
3 I-GENE
tyrosine O
phosphorylation O
by O
p59Lyn B-GENE
kinase I-GENE
as O
the O
site O
of O
cross O
- O
talk O
, O
the O
negative O
regulation O
of O
which O
by O
interaction O
with O
caveolin B-GENE
is O
apparently O
abrogated O
by O
PIG O
. O

As O
an O
oral O
, O
nontoxic O
compound O
with O
a O
mechanism O
of O
action O
distinct O
from O
that O
of O
ABL B-GENE
tyrosine I-GENE
kinase I-GENE
inhibition O
, O
FTI O
SCH66336 O
shows O
promise O
for O
the O
treatment O
of O
BCR B-GENE
/ O
ABL B-GENE
- O
induced O
leukemia O
. O

We O
conclude O
that O
RPMS B-GENE
acts O
as O
a O
negative O
regulator O
of O
EBNA2 B-GENE
and O
Notch B-GENE
activity O
through O
its O
interactions O
with O
the O
CBF1 B-GENE
- I-GENE
associated I-GENE
corepressor I-GENE
complex I-GENE
. O

Transactivation O
of O
oIFNtau B-GENE
enhancer O
- O
reporter O
constructs O
was O
primarily O
regulated O
by O
three O
regions O
containing O
AP B-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
GATA B-GENE
like I-GENE
sequence I-GENE
and O
site O
( O
s O
) O
unidentified O
. O

Copyright O
2000 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

Fluorimetric O
determination O
of O
methylmercury O
as O
an O
ion O
- O
association O
complex O
with O
rhodamine O
B O
in O
the O
presence O
of O
iodide O
. O

Cells O
containing O
alpha O
subunits O
that O
lacked O
a O
distal O
domain O
( O
term O
- O
3 O
) O
or O
had O
the O
alternatively O
spliced O
alpha O
- O
2 O
distal O
domain O
showed O
markedly O
decreased O
ability O
to O
support O
tyrosine O
phosphorylation O
of O
Jak B-GENE
- I-GENE
2 I-GENE
and O
its O
substrates O
or O
to O
up O
- O
regulate O
CD86 B-GENE
. O

In O
Saccharomyces O
cerevisiae O
, O
eIF6 B-GENE
is O
encoded O
by O
a O
single O
- O
copy O
essential O
gene O
. O

TaqMan O
analysis O
of O
gene O
expression O
following O
chronic O
FA O
treatment O
showed O
neither O
a O
decrease O
in O
the O
amount O
of O
leptin B-GENE
receptor I-GENE
( O
Ob B-GENE
- I-GENE
R I-GENE
) O
mRNA O
, O
nor O
an O
increase O
in O
the O
negative O
regulators O
of O
STAT B-GENE
signalling O
, O
SOCS3 B-GENE
( O
suppressors B-GENE
of I-GENE
cytokine I-GENE
signalling I-GENE
) O
or O
cytokine B-GENE
inducible I-GENE
sequence I-GENE
( O
CIS B-GENE
) O
. O

The O
blood O
levels O
of O
lactate O
, O
pyruvate O
and O
amino O
acids O
were O
not O
elevated O
. O

The O
expression O
of O
alpha B-GENE
- I-GENE
amylase I-GENE
can O
be O
transactivated O
by O
the O
transcription O
factor O
GAMyb B-GENE
, O
which O
is O
itself O
induced O
by O
GA O
. O

Only O
nine O
patients O
were O
offered O
surgery O
( O
six O
were O
resected O
and O
three O
were O
found O
inoperable O
) O
. O

Adjuvant O
and O
neoadjuvant O
treatment O
of O
breast O
cancer O
. O

Sequence O
analysis O
revealed O
significant O
differences O
between O
the O
5 O
' O
region O
of O
the O
beta O
subunit O
gene O
and O
the O
corresponding O
regions O
of O
the O
homologous B-GENE
GlyR I-GENE
alpha I-GENE
subunit I-GENE
genes I-GENE
; O
it O
also O
identified O
a O
novel O
exon O
( O
exon O
0 O
) O
that O
encodes O
most O
of O
the O
5 O
' O
- O
untranslated O
portion O
of O
the O
GlyR B-GENE
beta I-GENE
mRNA I-GENE
. O

Anecdotal O
observations O
scattered O
throughout O
the O
literature O
have O
often O
provided O
clues O
to O
underlying O
variations O
in O
humans O
' O
ability O
to O
handle O
dietary O
chemicals O
. O

The O
human B-GENE
cytomegalovirus I-GENE
( I-GENE
HCMV I-GENE
) I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 I-GENE
is O
a O
nuclear O
phosphoprotein O
that O
is O
believed O
to O
be O
a O
key O
regulator O
in O
both O
lytic O
and O
latent O
infections O
. O

OBJECTIVE O
: O
To O
determine O
whether O
RSTD O
predicts O
coronary O
anatomy O
during O
acute O
coronary O
occlusion O
. O

We O
have O
now O
tested O
all O
known O
mammalian B-GENE
Groucho I-GENE
family I-GENE
members I-GENE
for O
their O
ability O
to O
interact O
specifically O
with O
individual O
Tcf B-GENE
/ O
Lef B-GENE
family O
members O
. O

We O
show O
here O
that O
the O
in O
vitro O
transcription O
extract O
contains O
a O
binding O
activity O
that O
is O
specific O
for O
the O
initiator O
element O
and O
thus O
may O
participate O
in O
recruiting O
RNA B-GENE
polymerase I-GENE
II I-GENE
to O
the O
SL O
RNA O
gene O
promoter O
. O

The O
438 B-GENE
bp I-GENE
EcoRI I-GENE
fragment I-GENE
, O
which O
was O
detected O
by O
Southern O
hybridization O
, O
reveals O
an O
open O
reading O
frame O
which O
encodes O
a O
protein O
of O
103 O
amino O
acids O
. O

Furthermore O
, O
this O
kinase O
- O
deficient O
mutant O
inhibited O
2 O
- O
MeSADP O
- O
induced O
caspase B-GENE
- I-GENE
3 I-GENE
stimulation O
and O
the O
associated O
decrease O
in O
cell O
number O
. O

A O
20 O
- O
base O
pair O
oligonucleotide O
containing O
this O
nonamer O
confers O
up O
- O
regulation O
by O
hypoxia O
and O
inhibition O
by O
unsaturated O
fatty O
acids O
when O
placed O
upstream O
of O
a O
heterologous O
promoter O
in O
a O
lacZ B-GENE
reporter I-GENE
construct I-GENE
. O

Deletion O
analyses O
implicate O
the O
N O
- O
terminal O
110 O
amino O
acids O
of O
Grb14 B-GENE
and O
ankyrin B-GENE
repeats O
10 O
- O
19 O
of O
tankyrase B-GENE
2 I-GENE
in O
mediating O
this O
interaction O
. O

Finally O
a O
10 O
- O
nucleotide O
region O
flanking O
the O
exon O
4 O
protein O
- O
binding O
site O
is O
homologous O
to O
instability O
elements O
within O
five O
other O
transcripts O
, O
suggesting O
that O
a O
common O
coding O
region O
determinant O
may O
exist O
. O

Analysis O
of O
regulatory O
regions O
in O
the O
promoter O
of O
the O
ctr4 B-GENE
( I-GENE
+ I-GENE
) I-GENE
copper I-GENE
transporter I-GENE
gene I-GENE
in O
fission O
yeast O
Schizosaccharomyces O
pombe O
reveals O
the O
identity O
of O
a O
conserved O
copper O
- O
signaling O
element O
( O
CuSE O
) O
, O
which O
is O
recognized O
by O
the O
transcription B-GENE
factor I-GENE
Cuf1 I-GENE
. O

WRN B-GENE
helicase I-GENE
resolves O
alternate O
DNA O
structures O
including O
tetraplex O
and O
triplex O
DNA O
, O
and O
Holliday O
junctions O
. O

These O
data O
suggest O
that O
ADAM B-GENE
- I-GENE
TS12 I-GENE
may O
play O
roles O
in O
pulmonary O
cells O
during O
fetal O
development O
or O
in O
tumor O
processes O
through O
its O
proteolytic O
activity O
or O
as O
a O
molecule O
potentially O
involved O
in O
regulation O
of O
cell O
adhesion O
. O

Biol O
. O

CONCLUSIONS O
: O
Using O
icodextrin O
- O
based O
instead O
of O
glucose O
- O
based O
PD O
fluids O
can O
largely O
reduce O
the O
formation O
of O
Amadori O
albumin B-GENE
and O
AGEs O
. O

In O
contrast O
, O
exogenous B-GENE
PTHrP1 I-GENE
- I-GENE
34 I-GENE
and I-GENE
1 I-GENE
- I-GENE
86 I-GENE
peptides I-GENE
did O
not O
significantly O
affect O
IL B-GENE
- I-GENE
8 I-GENE
production O
; O
moreover O
, O
PTHrP B-GENE
- I-GENE
neutralizing I-GENE
antibodies I-GENE
did O
not O
inhibit O
the O
production O
of O
IL B-GENE
- I-GENE
8 I-GENE
by O
transfected O
PTHrP B-GENE
. O

Our O
results O
suggest O
that O
WASP B-GENE
activates O
transcription O
following O
TCR B-GENE
stimulation O
in O
a O
manner O
that O
is O
independent O
of O
its O
role O
in O
Arp2 B-GENE
/ I-GENE
3 I-GENE
- O
directed O
actin B-GENE
polymerization O
. O

These O
data O
define O
a O
conserved O
pathway O
wherein O
sequential O
histone B-GENE
modifications O
establish O
a O
" O
histone B-GENE
code O
" O
essential O
for O
the O
epigenetic O
inheritance O
of O
heterochromatin O
assembly O
. O

The O
Delta6CCI O
virus O
was O
extremely O
attenuated O
in O
replication O
capacity O
yet O
retained O
infectiousness O
for O
CEMx174 O
and O
MT4 O
cells O
. O

PABP B-GENE
is O
a O
modular O
protein O
, O
with O
four O
N O
- O
terminal O
RNA O
- O
binding O
domains O
and O
an O
extensive O
C O
terminus O
. O

In O
addition O
, O
another O
derivative O
of O
pCMVJS21 O
( O
pCMVJS21DeltaGP O
) O
in O
which O
the O
gag B-GENE
, O
pol B-GENE
( O
and O
orf B-GENE
- I-GENE
x I-GENE
) O
coding O
sequences O
were O
deleted O
also O
gave O
transformed O
foci O
. O

In O
contrast O
, O
neither O
I O
. O
argentina O
nor O
I O
. O
theezans O
exerted O
any O
effect O
on O
BF O
or O
intestinal O
propulsion O
. O

These O
data O
reveal O
a O
complex O
network O
of O
interactions O
between O
GTPases B-GENE
in O
the O
ARF B-GENE
family I-GENE
and O
their O
effectors O
and O
reveal O
a O
potential O
for O
cross O
- O
talk O
not O
demonstrated O
previously O
. O

A O
mutation O
in O
the O
C O
domain O
of O
Rb B-GENE
, O
L901Q O
, O
has O
been O
identified O
that O
completely O
abolishes O
cdk4 B-GENE
/ O
D1 B-GENE
phosphorylation O
of O
the O
isolated O
C O
domain O
. O

We O
previously O
showed O
that O
this O
proteolysis O
1 O
) O
can O
be O
acutely O
promoted O
by O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
, O
2 O
) O
requires O
a O
metalloprotease B-GENE
activity O
, O
3 O
) O
generates O
both O
shed O
GHBP B-GENE
and O
a O
membrane B-GENE
- I-GENE
associated I-GENE
GHR I-GENE
transmembrane I-GENE
/ I-GENE
cytoplasmic I-GENE
domain I-GENE
remnant O
, O
and O
4 O
) O
results O
in O
down O
- O
regulation O
of O
GHR B-GENE
abundance O
and O
GH B-GENE
signaling O
. O

These O
disorders O
include O
low O
- O
back O
pain O
, O
saddle O
anesthesia O
, O
bilateral O
sciatica O
, O
then O
motor O
weakness O
of O
the O
lower O
extremities O
or O
chronic O
paraplegia O
and O
, O
bladder O
dysfunction O
. O

Sural O
nerve O
biopsy O
showed O
mild O
thickening O
of O
the O
perineurium O
, O
vascular O
alterations O
with O
inflammatory O
cell O
infiltration O
in O
the O
perineurium O
, O
and O
remarkable O
loss O
of O
large O
and O
small O
myelinated O
fibers O
. O

When O
this O
CCAAT O
box O
was O
inserted O
into O
a O
heterologous O
promoter O
construct O
, O
OA O
induction O
was O
dependent O
on O
an O
intact O
CCAAT O
box O
. O

The O
JHRLSS O
has O
been O
used O
in O
prior O
studies O
to O
assess O
RLS O
severity O
, O
but O
has O
not O
previously O
been O
validated O
in O
relation O
to O
direct O
measures O
of O
the O
morbidity O
associated O
with O
RLS O
. O

Our O
results O
suggest O
that O
the O
C O
- O
terminal O
region O
of O
Crk B-GENE
contains O
negative O
regulatory O
elements O
important O
for O
both O
Abl B-GENE
and O
FAK B-GENE
dependent O
signal O
pathways O
, O
and O
offers O
a O
paradigm O
for O
an O
autoinhibitory O
region O
in O
the O
SH3 B-GENE
linker O
/ O
C O
- O
terminal O
SH3 B-GENE
domain O
. O

This O
unique O
location O
of O
cavernous O
malformation O
is O
associated O
with O
a O
risk O
of O
permanent O
loss O
of O
the O
vision O
. O

The O
MSL B-GENE
complex I-GENE
is O
specifically O
localized O
on O
the O
male O
X O
chromosome O
to O
increase O
its O
expression O
approximately O
2 O
- O
fold O
. O

Consistent O
effects O
on O
pVHL B-GENE
function O
were O
observed O
for O
all O
mutations O
within O
each O
subclass O
. O

Here O
, O
we O
identify O
Rsc3 B-GENE
and O
Rsc30 B-GENE
as O
novel O
components O
of O
the O
essential O
yeast B-GENE
remodeler I-GENE
RSC I-GENE
complex I-GENE
. O

Early O
indicators O
of O
the O
effect O
of O
a O
breast O
cancer O
screening O
program O
for O
low O
- O
income O
women O
. O

Linear O
eight O
- O
or O
nine O
- O
residue O
D O
- O
peptides O
derived O
from O
the O
pocket O
- O
binding O
domain O
of O
the O
cyclic O
molecules O
also O
bind O
specifically O
. O

Here O
we O
present O
evidence O
that O
the O
distal O
half O
( O
Stem O
2 O
) O
of O
the O
conserved O
base O
- O
paired O
stem O
structure O
found O
in O
all O
hY B-GENE
RNAs I-GENE
also O
plays O
a O
critical O
role O
in O
the O
export O
process O
. O

Here O
we O
provide O
the O
first O
evidence O
for O
the O
involvement O
of O
GCN1 B-GENE
- O
GCN2 B-GENE
interaction O
in O
activation O
of O
GCN2 B-GENE
per O
se O
. O

Expression O
of O
human B-GENE
RACK1 I-GENE
efficiently O
relieves O
E1A B-GENE
- O
mediated O
growth O
inhibition O
in O
HF7c O
and O
protects O
human O
tumor O
cells O
from O
E1A B-GENE
- O
induced O
apoptosis O
. O

Molecular O
analysis O
of O
the O
pRA2 O
partitioning O
region O
: O
ParB B-GENE
autoregulates O
parAB B-GENE
transcription O
and O
forms O
a O
nucleoprotein O
complex O
with O
the O
plasmid O
partition O
site O
, O
parS B-GENE
. O

SERS O
spectra O
were O
obtained O
by O
vacuum O
evaporation O
and O
casting O
of O
p O
- O
NTP O
onto O
silver O
island O
films O
, O
and O
also O
from O
colloidal O
silver O
solutions O
. O

Copyright O
2001 O
Academic O
Press O
. O

These O
corrections O
do O
not O
involve O
sequences O
predicted O
to O
function O
as O
transcription O
factor O
binding O
sites O
. O

A O
patient O
is O
described O
with O
skin O
lesions O
resembling O
Kaposi O
' O
s O
sarcoma O
( O
KS O
) O
. O

The O
images O
showed O
rapid O
, O
predominantly O
urinary O
excretion O
of O
99mTc O
ciprofloxacin O
, O
with O
low O
to O
absent O
brain O
, O
lung O
and O
bone O
marrow O
uptake O
and O
low O
liver O
uptake O
and O
excretion O
. O

To O
this O
end O
, O
an O
expression O
cassette O
consisting O
of O
the O
gene O
for O
a O
green B-GENE
fluorescent I-GENE
protein I-GENE
( O
GFP B-GENE
) O
flanked O
at O
its O
3 O
' O
end O
by O
EAV O
- O
specific O
transcription O
- O
regulating O
sequences O
was O
constructed O
. O

In O
addition O
, O
severe O
vision O
loss O
can O
be O
seen O
with O
interferon B-GENE
alfa I-GENE
- I-GENE
2b I-GENE
- O
associated O
retinopathy O
. O

The O
mechanism O
of O
the O
induction O
of O
3beta B-GENE
- I-GENE
HSD I-GENE
type I-GENE
1 I-GENE
gene I-GENE
expression O
was O
further O
characterized O
in O
ZR O
- O
75 O
- O
1 O
human O
breast O
cancer O
cells O
. O

The O
application O
of O
the O
biotechnology O
at O
the O
plants O
for O
treatment O
of O
the O
surface O
storm O
waters O
from O
the O
industrial O
zone O
Telychka O
of O
the O
city O
of O
Kyiv O
has O
allowed O
the O
content O
of O
petroleum O
in O
water O
dropped O
to O
the O
Dnieper O
to O
be O
constantly O
reduced O
50 O
- O
100 O
times O
. O

Fans O
in O
tunnels O
and O
open O
windows O
at O
aboveground O
locations O
appeared O
to O
greatly O
reduce O
the O
likelihood O
of O
high O
PH3 O
concentrations O
in O
enclosed O
areas O
. O

The O
first O
case O
of O
HCV O
seroconversion O
in O
Portugal O
after O
the O
introduction O
of O
HCV O
NAT O
screening O
. O

The O
observed O
triplexes O
depend O
on O
the O
length O
of O
the O
repeat O
. O

We O
used O
stored O
plasma O
samples O
from O
409 O
patients O
in O
the O
National O
Institute O
of O
Neurological O
Diseases O
and O
Stroke O
( O
NINDS O
) O
tissue B-GENE
plasminogen I-GENE
activator I-GENE
( O
t B-GENE
- I-GENE
PA I-GENE
) O
Stroke O
Trial O
to O
examine O
the O
relationship O
between O
an O
apolipoprotein B-GENE
( I-GENE
Apo I-GENE
) I-GENE
E2 I-GENE
or O
an O
Apo B-GENE
E4 I-GENE
phenotype O
and O
a O
favorable O
outcome O
3 O
months O
after O
stroke O
, O
the O
risk O
of O
intracerebral O
hemorrhage O
, O
and O
the O
response O
to O
intravenous O
t B-GENE
- I-GENE
PA I-GENE
therapy O
. O

Colorectal O
cancer O
was O
shown O
to O
disproportionately O
overburden O
Ashkenazi O
Jews O
, O
who O
may O
also O
be O
at O
increased O
risk O
for O
ovarian O
, O
pancreatic O
and O
stomach O
cancer O
, O
and O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

RANTES B-GENE
( O
regulated B-GENE
upon I-GENE
activation I-GENE
, I-GENE
normally I-GENE
T I-GENE
- I-GENE
cell I-GENE
expressed I-GENE
and I-GENE
presumably I-GENE
secreted I-GENE
) O
is O
a O
CC O
chemokine O
which O
recruits O
and O
activates O
monocytes O
, O
lymphocytes O
, O
and O
eosinophils O
, O
all O
cell O
types O
present O
in O
the O
lung O
inflammatory O
infiltrate O
induced O
by O
RSV O
infection O
. O

Five O
modalities O
of O
nonpharmacologic O
approaches O
are O
recommended O
at O
present O
for O
lifestyle O
modification O
and O
control O
of O
arterial O
blood O
pressure O
elevation O
: O
1 O
) O
weight O
reduction O
to O
ideal O
body O
weight O
, O
since O
it O
reduces O
risk O
of O
hypertension O
as O
well O
as O
overall O
cardiovascular O
morbidity O
and O
mortality O
; O
2 O
) O
dietary O
sodium O
restriction O
to O
less O
than O
2 O
g O
a O
day O
, O
without O
assurance O
that O
it O
will O
normalize O
arterial O
pressure O
although O
it O
may O
help O
reduce O
dosage O
and O
numbers O
of O
prescribed O
antihypertensive O
drugs O
; O
3 O
) O
moderation O
of O
alcohol O
consumption O
to O
less O
than O
1 O
ounce O
a O
day O
; O
4 O
) O
a O
regular O
isotonic O
exercise O
program O
; O
and O
5 O
) O
cessation O
of O
tobacco O
consumption O
. O

Ga O
- O
67 O
and O
Tl O
- O
201 O
scintigraphy O
in O
extramedullary O
plasmacytoma O
: O
a O
case O
report O
. O

Arterial O
blood O
gas O
tensions O
were O
similar O
across O
all O
ventilation O
modes O
. O

As O
expected O
, O
homologous B-GENE
loxP I-GENE
sequences I-GENE
efficiently O
underwent O
Cre B-GENE
- O
mediated O
recombination O
. O

The O
Van O
der O
Hoeve O
' O
s O
syndrome O
lesions O
as O
poorly O
mineralized O
, O
with O
low O
calcium O
salt O
and O
apparent O
increase O
of O
phosphates O
. O

A O
5 O
- O
month O
- O
old O
infant O
with O
persistent O
congenital O
stridor O
and O
acute O
respiratory O
distress O
is O
presented O
. O

PURPOSE O
: O
The O
objective O
of O
this O
study O
was O
to O
assess O
first O
embryo O
cleavage O
( O
FEC O
) O
25 O
- O
27 O
h O
after O
intracytoplasmic O
sperm O
injection O
( O
ICSI O
) O
as O
a O
parameter O
for O
the O
embryo O
selection O
process O
. O

In O
35 O
of O
those O
patients O
DD O
was O
measured O
also O
with O
microlatex O
tests O
- O
- O
Tinaquant O
and O
BC O
d O
- O
dimer O
. O

Cytosolic B-GENE
acetyl I-GENE
- I-GENE
CoA I-GENE
synthetase I-GENE
( O
AceCS1 B-GENE
) O
activates O
acetate O
to O
supply O
the O
cells O
with O
acetyl O
- O
CoA O
for O
lipid O
synthesis O
. O

Tolerance O
in O
renal O
transplantation O
after O
allogeneic O
bone O
marrow O
transplantation O
- O
6 O
- O
year O
follow O
- O
up O
. O

Foreigners O
return O
. O

The O
present O
chemotherapy O
of O
AE O
is O
based O
on O
the O
administration O
of O
benzimidazole O
carbamate O
derivatives O
, O
such O
as O
mebendazole O
and O
albendazole O
. O

Topological O
and O
mutational O
analysis O
of O
Saccharomyces B-GENE
cerevisiae I-GENE
Ste14p I-GENE
, O
founding O
member O
of O
the O
isoprenylcysteine B-GENE
carboxyl I-GENE
methyltransferase I-GENE
family I-GENE
. O

Hormonal O
regulation O
of O
multiple O
promoters O
of O
the O
rat B-GENE
mitochondrial I-GENE
glycerol I-GENE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
gene I-GENE
: O
identification O
of O
a O
complex O
hormone O
- O
response O
element O
in O
the O
ubiquitous O
promoter O
B O
. O

The O
telomerase B-GENE
RNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
responsible O
for O
maintenance O
of O
telomeric O
DNA O
at O
chromosome O
ends O
, O
is O
usually O
inactive O
in O
most O
primary O
somatic O
human O
cells O
, O
but O
is O
specifically O
activated O
with O
in O
vitro O
immortalization O
and O
during O
tumorigenesis O
. O

Our O
results O
show O
that O
CVN B-GENE
specifically O
recognizes O
with O
nanomolar O
affinity O
Man O
( O
9 O
) O
GlcNAc O
( O
2 O
) O
and O
the O
D1D3 O
isomer O
of O
Man O
( O
8 O
) O
GlcNAc O
( O
2 O
) O
. O

Zhu O
, O
V O
. O

The O
novel O
approach O
to O
insulin B-GENE
administration O
known O
as O
chronic O
intermittent O
intravenous O
insulin B-GENE
therapy O
( O
CIIIT O
) O
delivers O
insulin B-GENE
in O
a O
pulsatile O
fashion O
and O
achieves O
physiological O
insulin B-GENE
concentration O
in O
the O
portal O
vein O
. O

The O
activity O
of O
Rac1 B-GENE
leads O
to O
STAT3 B-GENE
translocation O
to O
the O
nucleus O
coincident O
with O
STAT3 B-GENE
- O
dependent O
gene O
expression O
. O

Mss4 B-GENE
also O
acts O
as O
a O
relatively O
inefficient O
guanine B-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
GEF B-GENE
) O
. O

She O
has O
since O
developed O
a O
positive O
anti B-GENE
- I-GENE
cardiolipin I-GENE
antibody I-GENE
but O
does O
not O
meet O
diagnostic O
criteria O
for O
systemic O
lupus O
erythematosis O
. O
CONCLUSION O
: O
The O
presence O
of O
known O
autoimmune O
disease O
in O
a O
woman O
with O
POF O
should O
not O
dissuade O
the O
clinician O
from O
evaluating O
for O
a O
potential O
genetic O
cause O
. O

Effects O
of O
aerosol O
- O
vapor O
JP O
- O
8 O
jet O
fuel O
on O
the O
functional O
observational O
battery O
, O
and O
learning O
and O
memory O
in O
the O
rat O
. O

CONCLUSION O
: O
There O
are O
no O
differences O
in O
the O
measurement O
data O
derived O
from O
this O
method O
and O
actual O
measurement O
data O
from O
an O
object O
created O
by O
the O
computer O
- O
aided O
dental O
design O
program O
. O

Many O
factors O
do O
influence O
the O
educational O
outcome O
in O
students O
and O
large O
statistical O
power O
( O
such O
as O
meta O
analysis O
) O
should O
be O
helpful O
to O
eliminate O
many O
sources O
of O
error O
. O

Our O
results O
demonstrated O
that O
50 O
% O
of O
the O
hepatic O
artery O
- O
alone O
ALT O
graft O
showed O
almost O
normal O
structure O
histologically O
at O
1 O
month O
after O
grafting O
, O
with O
bile O
secretion O
preserved O
. O

The O
human B-GENE
ABCG1 I-GENE
gene I-GENE
encodes O
a O
member O
of O
the O
ATP B-GENE
- I-GENE
binding I-GENE
cassette I-GENE
( O
ABC B-GENE
) O
superfamily O
of O
transporter B-GENE
proteins I-GENE
and O
is O
highly O
induced O
when O
macrophages O
are O
incubated O
with O
oxysterols O
. O

C B-GENE
/ I-GENE
EBPbeta I-GENE
LIP I-GENE
overexpressing O
HC11 O
cells O
did O
not O
express O
beta B-GENE
- I-GENE
casein I-GENE
mRNA I-GENE
( O
mammary O
epithelial O
cell O
differentiation O
marker O
) O
in O
response O
to O
lactogenic O
hormones O
. O

EXAFS O
measurements O
around O
the O
Ge O
- O
K O
edge O
have O
been O
carried O
out O
for O
liquid O
Ge O
- O
Si O
alloys O
for O
the O
first O
time O
to O
investigate O
the O
local O
structure O
around O
a O
Ge O
atom O
. O

Although O
metabolized O
by O
the O
cytochrome B-GENE
P I-GENE
- I-GENE
450 I-GENE
( O
CYP B-GENE
) O
system O
, O
venlafaxine O
inhibits O
CYP B-GENE
2D6 I-GENE
and I-GENE
3A4 I-GENE
to O
a O
far O
lesser O
extent O
than O
do O
the O
SSRIs O
. O

Analysis O
of O
the O
promoter O
sequence O
revealed O
the O
presence O
of O
a O
major O
transcriptional O
start O
site O
, O
a O
canonical O
TATA O
box O
and O
putative O
cis O
regulatory O
elements O
for O
pituitary O
specific O
expression O
as O
well O
as O
an O
E O
- O
responsive O
element O
. O

Novel O
intronic O
promoter O
in O
the O
rat B-GENE
ER I-GENE
alpha I-GENE
gene I-GENE
responsible O
for O
the O
transient O
transcription O
of O
a O
variant O
receptor O
. O

Pitx2 B-GENE
rescues O
the O
GABAergic O
differentiation O
defect O
and O
partially O
rescues O
the O
axon O
guidance O
and O
behavioral O
phenotypes O
of O
unc B-GENE
- I-GENE
30 I-GENE
mutants I-GENE
, O
indicating O
a O
high O
degree O
of O
functional O
conservation O
between O
these O
evolutionarily O
related O
genes O
. O

We O
have O
previously O
shown O
that O
the O
adenoviral B-GENE
12S I-GENE
E1A I-GENE
protein I-GENE
modulates O
the O
phosphorylation O
status O
of O
p130 B-GENE
and O
p107 B-GENE
without O
apparent O
changes O
in O
the O
cell O
cycle O
dependent O
phosphorylation O
of O
the O
retinoblastoma B-GENE
protein I-GENE
. O

The O
prevalence O
of O
tobacco O
dependence O
diagnosed O
according O
to O
the O
ICD O
- O
10 O
criteria O
was O
higher O
in O
alcohol O
- O
dependent O
individuals O
( O
58 O
. O
1 O
% O
) O
than O
in O
nondrinkers O
or O
social O
drinkers O
( O
12 O
. O
8 O
% O
) O
. O

Diffuse O
myalgias O
were O
more O
frequent O
in O
patients O
with O
than O
without O
an O
MMF O
lesion O
at O
deltoid O
muscle O
biopsy O
( O
P O
< O
0 O
. O
0001 O
) O
. O

Additionally O
, O
a O
CaCO3 O
- O
CO2 O
/ O
N2 O
buffered O
solution O
was O
necessary O
to O
maintain O
a O
pH O
of O
8 O
. O

Copyright O
2001 O
S O
. O

NF B-GENE
- I-GENE
kappaB I-GENE
is O
involved O
in O
the O
regulation O
of O
CD154 B-GENE
( O
CD40 B-GENE
ligand I-GENE
) O
expression O
in O
primary O
human O
T O
cells O
. O

Mutation O
of O
the O
octamer O
element O
also O
significantly O
reduced O
the O
ability O
of O
HDAC1 B-GENE
to O
confer O
repression O
of O
inducible O
HLA B-GENE
- I-GENE
DRA I-GENE
promoter I-GENE
activation O
. O

In O
such O
conditions O
, O
the O
following O
kinetic O
reactions O
have O
been O
studied O
: O
N2 O
( O
A O
) O
+ O
N2 O
( O
A O
) O
- O
- O
> O
N2 O
( O
C O
, O
B O
, O
V O
' O
) O
+ O
N2 O
( O
X O
) O
, O
N2 O
( O
A O
) O
+ O
N2 O
( O
X O
, O
V O
> O
5 O
) O
- O
- O
> O
N2 O
( O
X O
) O
+ O
N2 O
( O
B O
, O
V O
' O
) O
in O
pure O
N2 O
post O
- O
discharges O
and O
N2 O
( O
A O
) O
+ O
CH4 O
- O
- O
> O
products O
, O
C O
+ O
N O
+ O
M2 O
- O
- O
> O
CN O
( O
B O
, O
V O
' O
) O
+ O
M2 O
, O
N2 O
( O
X O
, O
V O
> O
4 O
) O
+ O
CN O
- O
- O
> O
N2 O
( O
X O
) O
+ O
CN O
( O
B O
, O
A O
, O
V O
' O
) O
, O
in O
N2 O
- O
1 O
% O
CH4 O
post O
- O
discharges O
. O

Six O
of O
the O
gstC B-GENE
' I-GENE
mutants I-GENE
, O
primarily O
in O
the O
C O
- O
terminal O
half O
of O
C B-GENE
' I-GENE
, O
exhibited O
a O
defect O
in O
the O
ability O
to O
bind O
L B-GENE
protein I-GENE
. O

A O
proposal O
of O
50 O
performance O
indicators O
divided O
into O
five O
different O
groups O
is O
presented O
here O
, O
namely O
structural O
indicators O
, O
operational O
indicators O
, O
water O
and O
service O
quality O
indicators O
, O
personnel O
indicators O
and O
economic O
indicators O
. O

CONCLUSIONS O
: O
ChromaFlo O
- O
enhanced O
IVUS O
demonstrates O
colorized O
blood O
flow O
inside O
the O
vessel O
lumen O
, O
which O
is O
helpful O
in O
distinguishing O
echolucent O
disease O
from O
luminal O
blood O
flow O
and O
can O
also O
be O
used O
to O
perform O
peripheral O
interventions O
in O
patients O
with O
renal O
failure O
or O
allergy O
, O
avoiding O
the O
use O
of O
contrast O
media O
. O

The O
hatcher O
incubators O
of O
both O
companies O
were O
also O
persistently O
contaminated O
with O
Salmonella O
livingstone O
and O
Salmonella O
thomasville O
in O
company O
A O
and O
with O
Salmonella O
senftenberg O
in O
company O
B O
. O

At O
both O
companies O
sites O
Salmonella O
enteritidis O
and O
Salmonella O
typhimurium O
Tr104 O
were O
also O
isolated O
occasionally O
from O
various O
locations O
. O

E2F1 B-GENE
- O
mediated O
transcriptional O
inhibition O
of O
the O
plasminogen B-GENE
activator I-GENE
inhibitor I-GENE
type I-GENE
1 I-GENE
gene I-GENE
. O

The O
small O
copepod O
Pseudonychocamptus O
proximus O
progressively O
replaced O
the O
large O
Tisbe O
furcata O
in O
sand O
filters O
during O
the O
fall O
of O
1995 O
and O
was O
responsible O
for O
the O
large O
increase O
in O
meiofaunal O
biomass O
observed O
after O
spring O
1996 O
. O

The O
probability O
of O
treatment O
with O
lamotrigine O
being O
maintained O
for O
six O
months O
was O
86 O
% O
, O
for O
twelve O
months O
61 O
% O
and O
for O
three O
years O
31 O
% O
. O

Data O
from O
in O
vitro O
splicing O
assays O
, O
UV O
crosslinking O
and O
RNA O
- O
binding O
competition O
experiments O
indicates O
a O
strong O
correlation O
between O
the O
binding O
affinities O
of O
PSI B-GENE
for O
the O
SELEX O
sequences O
and O
their O
ability O
to O
modulate O
splicing O
of O
P B-GENE
element I-GENE
IVS3 B-GENE
in O
vitro O
. O

This O
paper O
describes O
the O
results O
of O
an O
initial O
study O
on O
the O
application O
of O
linear O
solvation O
energy O
relationships O
( O
LSERs O
) O
to O
the O
prediction O
of O
internal O
standard O
compounds O
in O
reversed O
- O
phase O
liquid O
chromatographic O
( O
RPLC O
) O
method O
development O
. O

ICAM B-GENE
- I-GENE
1 I-GENE
has O
been O
suggested O
a O
predictor O
of O
the O
onset O
of O
GO O
. O

Northern O
blot O
analysis O
with O
one O
of O
the O
PARNAs B-GENE
revealed O
a O
highly O
abundant O
signal O
of O
approximately O
2 O
. O
0 O
kilobases O
( O
kb O
) O
present O
in O
all O
cell O
lines O
tested O
. O

The O
corresponding O
orifice O
voltages O
for O
the O
three O
instruments O
were O
20 O
/ O
50 O
/ O
80 O
V O
( O
API O
365 O
) O
, O
30 O
/ O
90 O
/ O
130 O
V O
( O
API O
2000 O
) O
and O
40 O
/ O
80 O
/ O
120 O
V O
( O
API O
3000 O
) O
. O

The O
LA O
50s O
derived O
from O
this O
combined O
data O
when O
compared O
with O
our O
earlier O
series O
from O
1965 O
to O
1970 O
also O
did O
not O
show O
a O
significant O
change O
in O
mortality O
. O

Treatment O
of O
ischemic O
heart O
disease O
in O
the O
elderly O

A O
peculiar O
people O
: O
" O
the O
physiological O
aspects O
of O
Mormonism O
1850 O
- O
1975 O
. O
" O

She O
drank O
alcohol O
once O
or O
twice O
a O
week O
and O
regularly O
took O
an O
analgesic O
preparation O
, O
containing O
aspirin O
and O
acetaminophen O
, O
for O
alleviation O
of O
headaches O
. O

The O
most O
important O
risk O
factors O
are O
: O
1 O
) O
genetic O
; O
2 O
) O
Epstein O
- O
Barr O
virus O
( O
infectious O
mononucleosis O
) O
; O
3 O
) O
congenital O
and O
acquired O
immunodeficiency O
; O
4 O
) O
occupational O
exposure O
( O
the O
wood O
industry O
) O
. O

OBJECTIVES O
: O
The O
objective O
of O
this O
review O
was O
to O
assess O
the O
effects O
of O
prophylactic O
prostaglandin O
use O
in O
the O
third O
stage O
of O
labour O
. O

Under O
our O
conditions O
, O
the O
combination O
O3 O
/ O
UV O
did O
not O
improve O
the O
degradation O
rate O
obtained O
by O
ozonation O
. O

On O
the O
other O
hand O
, O
hepatic O
arterial O
infusion O
therapy O
prolongs O
the O
survival O
of O
H3 O
patients O
only O
. O

Finally O
, O
there O
are O
a O
growing O
number O
of O
arguments O
favouring O
the O
use O
of O
ACE B-GENE
inhibitors O
very O
early O
in O
patients O
with O
diabetes O
mellitus O
. O

Is O
clopidogrel O
superior O
to O
aspirin O
in O
secondary O
prevention O
of O
vascular O
disease O
? O
The O
cornerstone O
in O
clinical O
evidence O
of O
the O
relative O
efficacy O
of O
thienopyridines O
( O
clopidogrel O
, O
ticlopidine O
) O
versus O
aspirin O
in O
the O
secondary O
prevention O
of O
vascular O
disease O
is O
the O
Clopidogrel O
versus O
Aspirin O
in O
Patients O
at O
Risk O
of O
Ischaemic O
Events O
trial O
. O

We O
hypothesize O
that O
proprioception O
may O
be O
used O
to O
calibrate O
the O
efference O
copy O
during O
development O
and O
in O
response O
to O
perturbations O
by O
signaling O
potential O
mismatches O
between O
eye O
movement O
information O
derived O
from O
the O
efferent O
command O
and O
the O
actual O
motion O
of O
the O
eye O
transduced O
by O
the O
proprioceptive O
organs O
. O

The O
severity O
of O
clinical O
course O
was O
expressed O
by O
means O
of O
SOFA O
score O
( O
group O
A O
0 O
. O
3 O
- O
1 O
- O
1 O
. O
3 O
point O
, O
group O
B O
2 O
. O
2 O
- O
2 O
. O
9 O
- O
2 O
. O
6 O
point O
, O
group O
C O
7 O
. O
4 O
- O
8 O
. O
3 O
- O
7 O
. O
7 O
point O
) O
and O
APACHE O
II O
score O
( O
group O
A O
3 O
. O
7 O
- O
7 O
. O
6 O
- O
8 O
. O
1 O
point O
, O
group O
B O
8 O
. O
6 O
- O
11 O
. O
1 O
- O
10 O
. O
5 O
point O
, O
group O
C O
16 O
. O
3 O
- O
15 O
. O
2 O
- O
14 O
. O
3 O
point O
) O
. O

These O
results O
were O
compared O
with O
the O
estimates O
of O
penetration O
from O
steady O
- O
state O
calculations O
, O
square O
root O
of O
time O
calculations O
, O
and O
a O
biologically O
based O
mathematical O
model O
. O

Treadmill O
training O
at O
least O
for O
2 O
weeks O
can O
reduce O
the O
infarction O
size O
and O
edema O
caused O
by O
MCA O
occlusion O
( O
P O
< O
0 O
. O
01 O
) O
. O

Modality O
- O
specific O
areas O
( O
e O
. O
g O
. O
, O
right O
Wernicke O
, O
left O
fusiform O
gyrus O
, O
Broca O
BA44 O
, O
supramarginal O
gyrus O
) O
, O
appear O
to O
cope O
with O
the O
computations O
relevant O
to O
making O
contact O
with O
these O
more O
abstract O
dimensions O
. O

We O
found O
no O
correlation O
between O
plasma O
COP O
and O
body O
weight O
at O
the O
same O
age O
( O
r2 O
= O
0 O
. O
05 O
, O
P O
= O
0 O
. O
155 O
) O
. O

Both O
toxins O
in O
a O
dose O
10 O
- O
fold O
surpassing O
the O
maximum O
permissible O
concentration O
increased O
activity O
of O
glutathione B-GENE
peroxidase I-GENE
in O
brain O
tissue O
; O
moreover O
, O
toluene O
increased O
chemiluminescence O
intensity O
, O
which O
attested O
to O
activation O
of O
free O
radical O
processes O
. O

The O
performance O
of O
pH O
- O
sensitive O
particles O
is O
attributed O
to O
their O
ability O
to O
release O
the O
drug O
selectively O
in O
the O
upper O
part O
of O
the O
intestine O
in O
a O
molecular O
or O
amorphous O
form O
. O

Comparison O
of O
remnant O
- O
like O
lipoprotein O
particles O
in O
postmenopausal O
women O
with O
and O
without O
coronary O
artery O
disease O
and O
in O
men O
with O
coronary O
artery O
disease O
. O

Because O
results O
of O
recent O
randomized O
trials O
indicate O
minimal O
efficacy O
of O
continuing O
MAC O
prophylaxis O
in O
patients O
who O
respond O
to O
potent O
combination O
antiretroviral O
therapy O
, O
the O
observed O
high O
incidence O
of O
macrolide O
- O
resistant O
bacterial O
colonization O
of O
the O
respiratory O
tract O
in O
this O
trial O
supports O
the O
discontinuation O
of O
macrolide O
prophylaxis O
in O
all O
AIDS O
patients O
whose O
CD4 B-GENE
counts O
have O
risen O
above O
100 O
cells O
/ O
microL O
. O

METHODS O
: O
302 O
consecutive O
patients O
with O
BS O
and O
438 O
patients O
with O
other O
rheumatological O
conditions O
were O
surveyed O
for O
the O
presence O
or O
absence O
of O
the O
features O
of O
BS O
by O
means O
of O
a O
standard O
form O
which O
had O
been O
prepared O
according O
to O
ISG O
criteria O
. O

A O
computer O
program O
, O
ACCESS O
- O
IAQ O
, O
is O
developed O
to O
simulate O
the O
airflow O
pattern O
, O
the O
time O
history O
of O
the O
contaminant O
concentrations O
in O
the O
occupied O
zone O
, O
and O
the O
inhalation O
exposures O
. O

Classification O
according O
to O
the O
ILAR O
criteria O
was O
possible O
in O
321 O
patients O
; O
290 O
patients O
had O
a O
disease O
duration O
> O
or O
= O
3 O
months O
and O
were O
classified O
according O
to O
the O
EULAR O
criteria O
. O

We O
conducted O
a O
clinical O
and O
pathologic O
review O
of O
nine O
patients O
with O
immature O
ovarian O
teratoma O
. O

The O
results O
are O
discussed O
in O
relation O
to O
acoustical O
models O
of O
sound O
propagation O
and O
physiology O
, O
and O
it O
is O
suggested O
that O
height O
- O
dependent O
degradation O
within O
a O
forest O
is O
an O
important O
selection O
pressure O
for O
transmissibility O
in O
avian O
communication O
. O

In O
sterilized O
milk O
there O
was O
a O
slight O
decrease O
of O
linoleic O
acid O
( O
C18 O
: O
2n6 O
; O
- O
0 O
. O
7 O
% O
vs O
. O
fresh O
; O
P O
= O
0 O
. O
006 O
) O
and O
arachidonic O
acid O
( O
C20 O
: O
4n6 O
; O
- O
2 O
. O
5 O
% O
; O
P O
= O
0 O
. O
045 O
) O
. O

The O
electrodes O
themselves O
do O
not O
need O
to O
be O
polished O
prior O
to O
their O
use O
but O
are O
observed O
to O
be O
slightly O
recessed O
from O
the O
surrounding O
insulating O
surface O
. O

Because O
the O
DPPD B-GENE
gene I-GENE
is O
not O
present O
in O
non O
- O
tuberculous O
bacilli O
, O
these O
results O
suggest O
that O
this O
molecule O
can O
be O
an O
additional O
tool O
for O
a O
more O
specific O
diagnosis O
of O
tuberculosis O
. O

Patients O
with O
a O
secondary O
cardiac O
event O
had O
more O
common O
Type O
A O
behavior O
patterns O
and O
higher O
Bortner O
scores O
than O
patients O
without O
a O
secondary O
cardiac O
event O
. O

Interestingly O
, O
continuation O
of O
the O
interferon B-GENE
therapy O
in O
the O
presence O
of O
a O
mild O
- O
to O
- O
moderate O
exacerbation O
of O
sarcoidosis O
may O
be O
safe O
in O
a O
minority O
of O
patients O
with O
noncritical O
organ O
involvement O
. O

There O
was O
no O
difference O
in O
apnea O
duration O
between O
the O
supine O
and O
prone O
positions O
. O

TNFalpha B-GENE
and O
IL B-GENE
- I-GENE
6 I-GENE
levels O
were O
determined O
in O
the O
culture O
supernatants O
. O

Therefore O
, O
this O
study O
has O
demonstrated O
that O
prenatal O
disturbance O
can O
induce O
a O
lasting O
change O
in O
cytokine O
biology O
, O
which O
persists O
well O
beyond O
the O
fetal O
and O
infant O
stage O
. O

Based O
on O
analytic O
precisions O
, O
a O
+ O
/ O
- O
2 O
% O
urine O
- O
plasma O
difference O
was O
set O
as O
the O
cut O
- O
off O
value O
. O

Schistosoma O
mansoni O
schistosomiasis O
] O
Schistosomosis O
are O
parasitic O
diseases O
caused O
by O
blood O
flukes O
of O
the O
Schistosoma O
genus O
. O

Emphysematous O
cholecystitis O
: O
sonographic O
findings O
. O

Age O
was O
categorized O
into O
four O
groups O
: O
20 O
- O
44 O
, O
45 O
- O
64 O
, O
65 O
- O
74 O
, O
and O
75 O
+ O
. O
RESULTS O
: O
At O
the O
initiation O
of O
dialysis O
PD O
patients O
were O
approximately O
6 O
years O
younger O
( O
P O
< O
0 O
. O
0001 O
) O
than O
HD O
patients O
. O

The O
utility O
of O
such O
analyses O
in O
the O
design O
of O
ceramic O
/ O
substrate O
bilayer O
systems O
for O
optimal O
resistance O
to O
lifetime O
- O
threatening O
damage O
is O
discussed O
. O

Adjacent O
to O
those O
lesions O
, O
and O
in O
homologous O
contralateral O
structures O
, O
FMZ O
binding O
was O
analysed O
in O
four O
pairs O
of O
cortical O
9 O
x O
9 O
- O
mm O
regions O
of O
interest O
( O
ROIs O
) O
placed O
on O
transaxial O
and O
coronal O
slices O
, O
respectively O
, O
as O
well O
as O
in O
the O
lesion O
volume O
and O
its O
mirror O
region O
. O

Because O
a O
close O
correlation O
between O
regional O
decreases O
in O
FMZ O
binding O
and O
spiking O
activity O
was O
recently O
demonstrated O
in O
neocortical O
epilepsies O
, O
abnormal O
peri O
- O
lesional O
FMZ O
binding O
may O
bear O
some O
relation O
to O
the O
mechanisms O
of O
epileptogenesis O
in O
symptomatic O
epilepsies O
. O

We O
found O
three O
out O
of O
four O
original O
( O
Volkan O
' O
s O
) O
groups O
of O
linking O
objects O
, O
but O
also O
an O
additional O
one O
, O
hitherto O
undescribed O
, O
comprising O
objects O
used O
for O
designing O
a O
memorial O
shrine O
to O
the O
deceased O
. O

One O
CKD O
patient O
' O
s O
journey O
. O

In O
patients O
who O
respond O
to O
quetiapine O
, O
therapy O
should O
be O
continued O
at O
the O
optimal O
dose O
that O
maintains O
remission O
, O
within O
the O
range O
of O
150 O
to O
750 O
mg O
/ O
d O
. O

With O
such O
analysis O
, O
one O
can O
test O
hypotheses O
about O
the O
structure O
of O
latent O
variability O
within O
a O
given O
data O
set O
. O

In O
this O
study O
we O
wanted O
to O
assess O
the O
DR O
using O
the O
' O
combined O
test O
' O
in O
an O
unselected O
population O
of O
self O
- O
referred O
pregnant O
women O
at O
a O
false O
- O
positive O
rate O
( O
FPR O
) O
of O
about O
5 O
% O
. O

SETTING O
: O
University O
hospital-based O
, O
tertiary O
care O
infertility O
center O
. O

Large B-GENE
T I-GENE
antigen I-GENE
was O
coimmunoprecipitated O
by O
antibodies O
to O
epitope-tagged O
TBP B-GENE
, O
endogenous O
TBP B-GENE
, O
hTAF B-GENE
( I-GENE
II I-GENE
) I-GENE
100 I-GENE
, O
hTAF B-GENE
( I-GENE
II I-GENE
) I-GENE
130 I-GENE
, O
and O
hTAF B-GENE
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
, O
under O
conditions O
where O
holo-TFIID B-GENE
would O
be O
precipitated O
. O

CONCLUSIONS O
: O
This O
randomized O
study O
shows O
that O
Vivostat O
fibrin B-GENE
sealant O
is O
effective O
in O
preventing O
air O
leakage O
after O
small O
lung O
resections O
in O
pigs O
, O
even O
at O
high O
inspiratory O
pressures O
. O

We O
propose O
a O
model O
in O
which O
Sro7 B-GENE
function O
is O
involved O
in O
the O
targeting O
of O
the O
myosin B-GENE
proteins I-GENE
to O
their O
intrinsic O
pathways O
. O

The O
response O
properties O
of O
cat O
horizontal O
canal O
afferents O
( O
N O
= O
81 O
) O
were O
characterized O
by O
three O
parameters O
: O
their O
long O
time O
constants O
( O
tau O
) O
, O
low O
frequency O
gain O
constants O
( O
G1 O
) O
, O
and O
middle O
frequency O
gain O
constants O
( O
Gm O
) O
. O

Glycogen O
synthesis O
and O
catabolism O
, O
gluconeogenesis O
, O
glycolysis O
, O
motility O
, O
cell O
surface O
properties O
and O
adherence O
are O
modulated O
by O
csrA B-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
, O
while O
the O
production O
of O
several O
secreted O
virulence O
factors O
, O
the O
plant O
hypersensitive O
response O
elicitor O
HrpN O
( O
Ecc O
) O
and O
, O
potentially O
, O
other O
secondary O
metabolites O
are O
regulated O
by O
rsmA B-GENE
in I-GENE
Erwinia I-GENE
carotovora I-GENE
. O

We O
have O
applied O
the O
mRNA O
differential O
display O
method O
to O
compare O
and O
analyze O
mRNAs O
prepared O
from O
five O
normal O
nasopharyngeal O
epithelial O
cell O
cultures O
and O
five O
nasopharyngeal O
carcinoma O
cell O
lines O
. O

Lung O
and O
multi-system O
damage O
were O
early O
indicators O
of O
poor O
outcome O
in O
severe O
non-fatal O
disease O
. O

Histological O
slides O
of O
one O
biopsy O
of O
each O
patient O
( O
formalin-fixed O
and O
paraffin-embedded O
) O
were O
stained O
with O
a O
Modified O
Giemsa O
( O
MG O
) O
, O
the O
Warthin-Starry O
( O
WS O
) O
, O
and O
an O
immunohistochemical O
method O
( O
IMM O
) O
using O
purified O
polyclonal O
H O
. O
pylori O
antiserum O
( O
DAKO O
B471 O
) O
. O

BACKGROUND O
: O
Chemicals O
vary O
considerably O
in O
their O
intrinsic O
ability O
to O
cause O
allergic O
contact O
dermatitis O
. O

Demispan O
is O
a O
reliable O
and O
reproducible O
measure O
of O
stature O
in O
the O
elderly O
. O

In O
one O
acromegalic O
patient O
visual O
improvement O
was O
obtained O
while O
the O
abnormal O
GH B-GENE
secretion O
remained O
unaltered O
. O

When O
the O
blood O
pressure O
increase O
in O
response O
to O
smoking O
was O
blunted O
by O
nitroprusside O
infusion O
, O
there O
was O
a O
striking O
increase O
in O
muscle O
SNA O
. O

Multiple O
single-stranded O
cis O
elements O
are O
associated O
with O
activated O
chromatin O
of O
the O
human B-GENE
c-myc I-GENE
gene I-GENE
in O
vivo O
. O

Removal O
of O
thick O
, O
permanently O
altered O
mucoas O
is O
recommended O
even O
in O
the O
absence O
of O
squamous O
epithelium O
. O

The O
position O
, O
transcription O
orientation O
, O
and O
imprinted O
status O
of O
the O
genes O
immediately O
flanking O
Igf2r B-GENE
have O
been O
assessed O
. O

High-pressure O
effects O
on O
ultrafast-relaxation O
kinetics O
of O
excitons O
in O
polydiacetylene O
4BCMU O
. O

Interestingly O
, O
we O
find O
that O
the O
interaction O
between O
Tat B-GENE
and O
hCycT1 B-GENE
requires O
zinc O
as O
well O
as O
essential O
cysteine O
residues O
in O
both O
proteins O
. O

Treatment O
of O
2 O
patients O
with O
pseudohypoparathyroidism O
type O
I O
with O
vitamin-D-3 O
and O
1 O
alpha-Hydroxycholecalciferol O
consecutively O
resulted O
in O
a O
nonuniform O
response O
with O
regard O
to O
the O
normalisation O
of O
serum-calcium O
. O

Tumour B-GENE
necrosis I-GENE
factor I-GENE
and O
adult O
respiratory O
distress O
syndrome O
. O

Immunologic O
mechanisms O
in O
chronic O
brucellosis O
in O
humans O
. O

Biological O
evaluation O
of O
mibolerone O
in O
the O
female O
Beagle O
. O

These O
results O
suggest O
that O
Rho1p B-GENE
regulates O
cytoskeletal O
reorganization O
at O
least O
through O
Bni1p B-GENE
and O
Pkc1p B-GENE
. O

This O
protein-protein O
interaction O
does O
not O
require O
the O
simultaneous O
binding O
of O
Oct B-GENE
proteins I-GENE
to O
DNA O
, O
and O
high O
resolution O
footprinting O
of O
the O
Oct-DNA B-GENE
interaction O
reveals O
that O
binding O
of O
BOB B-GENE
. I-GENE
1 I-GENE
OBF I-GENE
. I-GENE
1 I-GENE
to I-GENE
Oct1 O
or B-GENE
Oct2 O
does B-GENE
not O
alter O
the O
interaction O
with O
DNA O
. O

The O
lytic O
cycle O
of O
KSHV O
, O
probably O
under O
the O
initial O
control O
of O
the O
KSHV B-GENE
Rta I-GENE
gene I-GENE
, I-GENE
may O
directly O
contribute O
to O
tumor O
pathogenesis O
. O

In O
about O
770 O
bp O
upstream O
region O
of O
Spam1 B-GENE
that O
has O
been O
cloned O
and O
sequenced O
, O
multiple O
transcription O
factor O
binding O
sites O
including O
a O
CRE B-GENE
( O
cAMP-responsive B-GENE
element I-GENE
) O
were O
found O
. O

Perfusion O
washout O
: O
increasing O
a O
microvascular O
free O
flap O
tolerance O
to O
ischemia O
. O

A O
case O
of O
M O
hemoglobinosis O
. O

The O
location O
and O
approximate O
length O
of O
the O
intron O
are O
conserved O
in O
both O
the O
tomato O
and O
Arabidopsis O
genes O
, O
with O
the O
intron O
separating O
the O
'nose' O
region O
( O
encoded O
by O
exon O
1 O
) O
from O
the O
central O
globular O
domain O
( O
exon O
2 O
) O
. O

Thus O
, O
the O
bovine B-GENE
PEDF I-GENE
cDNA I-GENE
isolated O
here O
codes O
for O
a O
functional O
soluble O
secreted B-GENE
PEDF I-GENE
glycoprotein I-GENE
. O

Using O
16 O
strains O
of O
C O
. O
trachomatis O
in O
triplicate O
assays O
, O
we O
found O
the O
RT-PCR O
method O
consistently O
more O
sensitive O
than O
the O
conventional O
technique O
for O
all O
eight O
antimicrobials O
tested O
, O
with O
resultant O
MICs O
determined O
by O
RT-PCR O
ranging O
from O
1 O
. O
6-fold O
higher O
( O
erythromycin O
) O
to O
> O
= O
195-fold O
higher O
( O
amoxicillin O
) O
. O

However O
, O
the O
element O
proximal O
to O
the O
transcription O
start O
site O
is O
dependent O
on O
the O
SRE-1 B-GENE
. O

Klebsiella O
oxytoca O
can O
assimilate O
nitrate O
and O
nitrite O
by O
using O
enzymes O
encoded O
by O
the O
nasFEDCBA B-GENE
operon I-GENE
. O

Use O
of O
the O
immunofluorescence O
method O
for O
identification O
of O
enteroviruses O
in O
cell O
cultures O
. O

Atcys1 B-GENE
, O
Athyp1 B-GENE
, O
AKin10 B-GENE
and O
the O
ORF O
are O
very O
close O
to O
each O
other O
and O
organized O
in O
the O
same O
polarity O
; O
hence O
, O
the O
intergenic O
regions O
probably O
contain O
, O
within O
less O
than O
0 O
. O
5 O
kb O
, O
all O
the O
regulatory O
elements O
necessary O
to O
govern O
initiation O
and O
termination O
of O
transcription O
. O

The O
increase O
in O
amplitudes O
of O
the O
b-wave O
during O
the O
adaptation O
period O
was O
more O
prominent O
in O
lead-exposed O
subjects O
than O
in O
controls O
. O

( O
ii O
) O
An O
AF O
G-CSF B-GENE
level O
> O
2000 O
pg O
ml O
is O
a O
strong O
positive O
predictor O
of O
CAM O
. O

I O
report O
here O
that O
induction O
of O
HSP82 B-GENE
is O
regulated O
by O
the O
early O
meiotic O
IME1-IME2 B-GENE
transcriptional O
cascade O
. O

We O
now O
report O
the O
isolation O
and O
expression O
of O
cDNAs O
encoding O
PTF B-GENE
gamma I-GENE
and O
PTF B-GENE
delta I-GENE
, O
as O
well O
as O
functional O
studies O
with O
cognate O
antibodies O
that O
recognize O
the O
native O
PTF B-GENE
complex I-GENE
in O
HeLa O
extracts O
. O

Primers O
for O
subsequent O
rounds O
of O
RACE O
were O
designed O
from O
the O
5'-ends O
of O
amplified O
RACE B-GENE
products I-GENE
. O

Current O
status O
of O
zinc O
deficiency O
in O
the O
pathogenesis O
of O
neurological O
, O
dermatological O
and O
musculoskeletal O
disorders O
. O

Several O
free O
2nd-generation O
schizonts O
, O
which O
varied O
in O
diameter O
from O
11 O
to O
21 O
. O
6 O
micrometer O
, O
were O
found O
on O
the O
epithelial O
surface O
of O
the O
cecum O
. O

Active O
lambda B-GENE
and I-GENE
kappa I-GENE
antibody I-GENE
gene I-GENE
rearrangement O
in O
Abelson O
murine O
leukemia O
virus-transformed O
pre-B O
cell O
lines O
. O

Brainstem O
auditory O
evoked O
responses O
( O
BAERs O
) O
and O
quantitative O
saccadic O
eye O
movement O
studies O
provide O
information O
on O
the O
integrity O
of O
pathways O
traversing O
the O
brainstem O
. O

Spinal O
cord O
representation O
of O
the O
micturition O
reflex O
. O

The O
patients O
were O
divided O
into O
ischaemia O
and O
non-ischaemia O
groups O
on O
the O
basis O
of O
the O
change O
in O
lactate O
extraction O
ratio O
during O
balloon O
inflation O
. O

Glycemic O
response O
to O
malted O
, O
popped O
and O
roller O
dried O
wheat-legume O
based O
foods O
in O
normal O
subjects O
. O

Sterol-mediated O
suppression O
of O
cleavage O
of O
SREBP-1 B-GENE
was O
found O
to O
be O
dependent O
on O
the O
extreme O
COOH-terminal O
region O
( O
residue O
1034 O
to O
the O
COOH O
terminus O
) O
, O
which O
exists O
in O
two O
forms O
as O
a O
result O
of O
alternative O
splicing O
. O

The O
difference O
between O
the O
patients O
and O
the O
controls O
was O
statistically O
significant O
( O
p O
= O
0 O
. O
03 O
) O
. O

The O
coefficient O
of O
determination O
, O
r2 O
, O
of O
the O
other O
scores O
ranged O
from O
0 O
. O
56 O
to O
0 O
. O
61 O
. O

The O
androgen B-GENE
receptor I-GENE
( O
AR B-GENE
) O
amino-terminus O
imposes O
androgen-specific O
regulation O
of O
AR B-GENE
gene I-GENE
expression O
via O
an O
exonic O
enhancer O
. O

A O
yeast O
DNA O
fragment O
carrying O
the O
gene B-GENE
CP I-GENE
A1 I-GENE
encoding O
the O
small O
subunit O
of O
the O
arginine O
pathway O
carbamoyl-phosphate B-GENE
synthetase I-GENE
has O
been O
sequenced O
. O

In O
an O
effort O
to O
identify O
the O
USH1C B-GENE
disease I-GENE
gene I-GENE
we O
have O
isolated O
the O
region O
between O
these O
markers O
in O
yeast O
artificial O
chromosomes O
( O
YACs O
) O
using O
a O
combination O
of O
STS O
content O
mapping O
and O
Alu-PCR O
hybridization O
. O

Critical O
residues O
required O
for O
repression O
are O
located O
within O
the O
C-terminal O
27 O
amino O
acids O
of O
c-Fos B-GENE
, O
since O
v-Fos B-GENE
and O
C-terminal O
truncations O
of O
c-Fos B-GENE
did O
not O
down O
regulate O
. O

Altogether O
these O
results O
indicate O
that O
the O
Syn B-GENE
5 I-GENE
locus I-GENE
segregates O
from O
the O
gene O
specifying O
gH B-GENE
, O
to O
a O
region O
encompassing O
portions O
of O
the O
TK B-GENE
and O
UL B-GENE
24 I-GENE
genes I-GENE
, O
and O
that O
the O
syn B-GENE
mutation I-GENE
does O
not O
affect O
the O
expression O
or O
activity O
of O
TK O
. O

To O
identify O
factors O
that O
may O
modify O
the O
heterosexual O
transmission O
of O
human O
T O
cell O
leukemia O
lymphoma O
virus O
type O
I O
( O
HTLV-I O
) O
, O
534 O
married O
couples O
enrolled O
in O
the O
Miyazaki O
Cohort O
Study O
between O
November O
1984 O
and O
April O
1989 O
were O
studied O
: O
95 O
husband O
HTLV-I-seropositive O
( O
H+ O
) O
wife O
seropositive O
( O
W+ O
) O
, O
33 O
H+ O
W- O
, O
64 O
H- O
W+ O
, O
and O
342 O
H- O
W- O
. O

2 O
. O

Upon O
analysis O
of O
various O
deletion O
and O
point-mutated O
variants O
of O
the O
human B-GENE
IL-6 I-GENE
gene I-GENE
promoter I-GENE
coupled O
to O
a O
reporter O
gene O
, O
we O
screened O
for O
possible O
cooperating O
transcription O
factors O
. O

Characterization O
of O
the O
5' O
end O
of O
the O
growth-regulated O
Syrian B-GENE
hamster I-GENE
CAD I-GENE
gene I-GENE
. O

Horvath O
, O
I O
. O

Switching O
FDC-P1 O
MAC O
cells O
from O
growth O
in O
M-CSF O
to B-GENE
GM-CSF O
caused B-GENE
the O
selective O
degradation O
of O
c-fms O
mRNA B-GENE
within I-GENE
6 O
h O
after O
factor O
switching O
. O

Analysis O
of O
the O
gag B-GENE
and O
rev B-GENE
proteins I-GENE
in O
the O
transfected O
cells O
demonstrated O
that O
these O
proteins O
were O
not O
detectable O
in O
cells O
transfected O
with O
the O
tat B-GENE
mutants I-GENE
but O
could O
be O
readily O
detected O
when O
the O
mutations O
were O
complemented O
in O
trans O
with O
a O
tat B-GENE
expression O
vector O
. O

However O
, O
the O
BCH O
group O
showed O
inferior O
gross O
motor O
performance O
on O
the O
Bruininks-Oseretsky O
Test O
of O
Motor O
Proficiency O
( O
Bruininks O
1978 O
) O
. O

Repression O
is O
alleviated O
when O
the O
two O
( O
for O
E2 B-GENE
) O
or O
three O
( O
for O
E2-C B-GENE
) O
promoter-proximal O
copies O
of O
E2-RS B-GENE
are O
mutated O
. O

Our O
findings O
suggest O
that O
striatal O
FDG O
and O
particularly O
RACLO O
are O
sensitive O
and O
effective O
measures O
of O
striatal O
function O
and O
may O
help O
characterizing O
patients O
with O
multiple O
system O
atrophy O
. O

A O
prospective O
trail O
comparing O
hysterectomy O
, O
hysterectomy O
plus O
vaginal O
radium O
, O
and O
uterine O
radium O
plus O
hysterectomy O
in O
stage O
I O
endometrial O
carcinoma O
. O

Serum B-GENE
Fibrin I-GENE
Degradation O
Products O
( O
FDP O
) O
were O
determined O
in O
50 O
oral O
cancer O
patients O
and O
50 O
normal O
individuals O
prior O
to O
any O
kind O
of O
treatment O
. O

Among O
these O
360 O
ZFPs B-GENE
, O
a O
novel O
ZFP B-GENE
cDNA I-GENE
named O
HFHZ B-GENE
( O
human B-GENE
fetal I-GENE
heart I-GENE
ZFP I-GENE
) O
with O
sequence O
homology O
to O
a O
Kruppel-associated B-GENE
box I-GENE
( O
KRAB B-GENE
) O
was O
identified O
. O

Such O
a O
mechanism O
may O
allow O
acceleration O
of O
degenerative O
joint O
conditions O
, O
and O
may O
account O
for O
the O
increased O
prevalence O
of O
such O
conditions O
seen O
with O
HMS O
subjects O
. O

Furthermore O
, O
stable O
expression O
of O
a O
constitutively O
active O
form O
of O
chicken O
Notch1 B-GENE
or O
Notch2 B-GENE
in O
a O
B O
cell O
line O
results O
in O
a O
down-regulation O
of O
surface O
IgM B-GENE
expression O
, O
which O
is O
accompanied O
by O
the O
reduction O
of O
IgH B-GENE
gene I-GENE
transcripts I-GENE
. O

Cochlear O
microphonic O
potentials O
in O
patients O
with O
vestibular O
schwannomas O
. O

A O
case O
of O
chronic O
hepatitis O
C O
with O
primary O
hypothyroidism O
manifested O
during O
interferon B-GENE
treatment O
. O

For O
this O
purpose O
, O
a O
segment O
of O
dxr B-GENE
was O
amplified O
from O
Synechococcus O
leopoliensis O
SAUG O
1402-1 O
DNA O
via O
PCR O
using O
oligonucleotides O
for O
conserved O
regions O
. O

This O
result O
indicates O
that O
separate O
complexes O
exist O
containing O
ankyrin B-GENE
and O
fodrin B-GENE
with O
either O
uvomorulin B-GENE
or O
Na+ B-GENE
, I-GENE
K+-ATPase I-GENE
. O

Nerve B-GENE
growth I-GENE
factor I-GENE
( O
NGF B-GENE
) O
and O
retinoic O
acid O
( O
RA O
) O
exert O
important O
actions O
on O
PC12 O
cells O
. O

Sustained O
ventricular O
tachycardia O
and O
its O
successful O
prophylaxis O
during O
high-dose O
bolus O
interleukin-2 B-GENE
therapy O
for O
metastatic O
renal O
cell O
carcinoma O
. O

Because O
of O
its O
wide O
spectrum O
of O
activity O
particularly O
against O
ampicillin O
resistant O
strains O
of O
H O
. O
influenzae O
and O
because O
of O
its O
good O
tolerance O
Cefaclor O
is O
very O
useful O
in O
treatment O
of O
respiratory O
tract O
infections O
in O
children O
. O

Using O
purified O
recombinant B-GENE
HMG I-GENE
I I-GENE
, O
we O
have O
identified O
several O
high-affinity O
binding O
sites O
which O
overlap O
important O
transcription O
factor O
binding O
sites O
. O

BCL6 B-GENE
encodes O
a O
POZ B-GENE
Zn I-GENE
finger I-GENE
protein I-GENE
, I-GENE
a O
structure O
similar O
to O
that O
of O
many O
Drosophila O
developmental O
regulators O
and O
to O
another O
protein O
involved O
in O
a O
human O
hematopoietic O
malignancy O
, O
PLZF O
. B-GENE

The O
level O
of O
contamination O
in O
the O
wound O
can O
be O
determined O
with O
the O
rapid O
biopsy O
fixation O
technique O
. O

A O
sequence O
homology O
analysis O
between O
human B-GENE
nm23-H1 I-GENE
and O
the O
homolog O
gene O
of O
the O
rat O
( O
NDP-K B-GENE
beta I-GENE
) O
shows O
that O
exon-intron O
boundaries O
are O
well O
conserved O
between O
these O
two O
species O
. O

The O
presence O
of O
PDZ B-GENE
and O
SAM B-GENE
domains I-GENE
in O
the O
KS5 B-GENE
protein I-GENE
suggests O
that O
it O
may O
act O
as O
a O
molecular O
adaptor O
, O
promoting O
and O
relaying O
information O
in O
a O
signal O
transduction O
pathway O
. O

An O
IgG B-GENE
monoclonal O
gammopathy O
was O
present O
in O
the O
serum O
of O
4 O
patients O
and O
Bence-Joanes O
proteinuria O
was O
found O
in O
1 O
patient O
. O

The O
eluting O
solvent O
was O
methanol-chloroform O
( O
10+90 O
) O
at O
a O
flow O
rate O
of O
2 O
. O
0 O
ml O
min O
. O

HLA-A B-GENE
and I-GENE
B I-GENE
phenotypes O
of O
105 O
patients O
suffering O
from O
malignant O
melanomas O
were O
determined O
, O
with O
special O
regard O
for O
metastatic O
form O
or O
relapse O
. O

PATIENTS O
OR O
OTHER O
PARTICIPANTS O
: O
Twenty O
children O
met O
the O
criteria O
for O
being O
learning O
disabled O
. O

Further O
investigation O
on O
the O
chemotactic O
influence O
of O
thymic B-GENE
hormone I-GENE
on O
lymphocytes O
. O

Tumor B-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
, O
the O
cytokine O
that O
participates O
in O
the O
autocrine O
growth O
control O
of O
hairy O
cell O
leukemia O
has O
strong O
bone O
resorptive O
properties O
. O

This O
rapid O
and O
extensive O
penetration O
of O
intrathecally O
administered O
chemotherapy O
may O
offer O
insight O
into O
the O
myelopathy O
observed O
with O
these O
treatments O
. O

The O
'field O
of O
stress' O
of O
the O
supervisory O
nurse O
. O

Using O
transgenic O
Xenopus O
embryos O
, O
we O
demonstrate O
that O
the O
integrity O
of O
these O
two O
sequences O
is O
necessary O
for O
correct O
spatial O
expression O
of O
a O
Xbra2 B-GENE
promoter-driven I-GENE
reporter I-GENE
gene I-GENE
. O

Its O
role O
in O
these O
processes O
suggests O
that O
the O
function O
of O
c-Myb B-GENE
may O
be O
important O
early O
in O
the O
establishment O
of O
the O
hematopoietic O
lineage O
. O

The O
development O
and O
distribution O
of O
Trypanosoma O
congolense O
, O
T O
vivax O
and O
T O
brucei O
in O
the O
skin O
of O
goats O
was O
examined O
after O
the O
animals O
were O
bitten O
by O
infected O
Glossina O
morsitans O
centralis O
. O

The O
purpose O
of O
this O
study O
is O
twofold O
: O
( O
1 O
) O
to O
present O
a O
parallel O
form O
of O
the O
Gudjonsson O
Suggestibility O
Scale O
( O
GSS O
, O
Form O
1 O
) O
; O
( O
2 O
) O
to O
study O
test-retest O
reliabilities O
of O
interrogative O
suggestibility O
. O

Antimicrobial O
Susceptibility O
of O
Klebsiella O
pneumoniae O
Producing O
Extended-Spectrum B-GENE
beta-lactamase I-GENE
( O
ESBL B-GENE
) O
Isolated O
in O
Hospitals O
in O
Brazil O
. O

Coronary O
T1 O
and O
T2 O
weighted O
images O
were O
obtained O
. O

CONCLUSION O
: O
These O
findings O
imply O
that O
eotaxin O
either O
is O
mechanistically O
involved O
in O
acute O
asthma O
or O
serves O
as O
a O
biomarker O
for O
activity O
of O
the O
CCR3 B-GENE
receptor I-GENE
ligand I-GENE
system O
, O
which O
is O
functionally O
linked O
to O
asthma O
. O

GH B-GENE
failed O
to O
stimulate O
phosphorylation O
or O
activation O
of O
Jun B-GENE
N-terminal I-GENE
kinase I-GENE
under O
the O
conditions O
used O
. O

Surgical O
treatment O
of O
pulmonary O
metastases O
. O

We O
found O
that O
the O
expression O
of O
the O
protein O
was O
maximum O
in O
mitosis O
and O
minimum O
in O
G1 O
, O
which O
correlated O
with O
the O
expression O
of O
its O
messenger O
RNA O
. O

Three O
separate O
activation O
subdomains O
, O
and O
one O
negative-acting O
region O
, O
which O
function O
in O
yeast O
were O
located O
in O
the O
carboxyl-terminal O
region O
of O
NIT4 B-GENE
. O

The O
existence O
of O
threshold O
concentrations O
, O
above O
which O
certain O
phenomena O
may O
occur O
, O
strengthens O
the O
role O
of O
sentinels O
. O

Our O
results O
indicate O
that O
Gab1 B-GENE
is O
involved O
in O
the O
control O
of O
egr-1 B-GENE
expression O
regulated O
by O
insulin B-GENE
. O

Object O
relations O
, O
affect O
management O
, O
and O
psychic O
structure O
formation O
. O

The O
molecular O
weight O
of O
in O
vivo-labeled O
proteins O
was O
increased O
relative O
to O
that O
of O
in O
vitro-translated O
proteins O
, O
indicating O
that O
a O
posttranslational O
modification O
had O
occurred O
. O

Cross-linking O
the O
B B-GENE
cell I-GENE
Ag I-GENE
receptor I-GENE
( O
BCR B-GENE
) O
to O
surface B-GENE
Fc I-GENE
receptors I-GENE
for O
IgG B-GENE
( O
Fc B-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1-to-S O
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

We O
report O
here O
the O
identification O
of O
HSF B-GENE
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
. O

Role O
of O
secondary O
structure O
in O
discrimination O
between O
constitutive O
and O
inducible O
activators O
. O

A O
study O
of O
the O
E O
. O
O O
. O
R O
. O
T O
. O
C O
. O

METHODS O
: O
The O
most O
distal O
muscle O
fibres O
from O
the O
deep O
and O
superficial O
finger O
flexors O
were O
measured O
relative O
to O
the O
pisiform O
bone O
in O
18 O
cadaveric O
specimens O
. O

The O
microcirculatory O
dynamics O
of O
prostaglandin B-GENE
E1 I-GENE
and O
or O
nicardipine O
and O
their O
different O
reactions O
in O
the O
hyper- O
and O
hypodynamic O
state O
of O
septic O
shock O
in O
a O
rat O
model O
. O

A O
new O
, O
flexible O
fiberoptic O
ventriculoscope O
for O
observation O
of O
the O
ventricles O
and O
major O
cisterns O
is O
reported O
. O

The O
highly O
conserved O
ninth O
heptad O
, O
which O
is O
involved O
in O
heterodimerization O
, O
appears O
to O
participate O
in O
the O
receptor-inhibitor O
interaction O
, O
suggesting O
that O
the O
inhibitor O
is O
a O
related O
member O
of O
the O
receptor O
gene O
family O
. O

The O
human B-GENE
eps15 I-GENE
gene I-GENE
, O
encoding O
a O
tyrosine B-GENE
kinase I-GENE
substrate O
, O
is O
conserved O
in O
evolution O
and O
maps O
to O
1p31-p32 O
. O

The O
rate O
of O
decrement O
in O
DPOAE O
amplitude O
over O
a O
prescribed O
time O
period O
was O
utilized O
as O
a O
measure O
of O
susceptibility O
to O
the O
acoustic O
trauma O
. O

Its O
C-terminal O
catalytic O
domain O
was O
found O
to O
be O
highly O
conserved O
in O
the O
homologues B-GENE
p140 I-GENE
( I-GENE
ras-GRF I-GENE
) I-GENE
and O
Sos B-GENE
. O

Expression O
of O
six O
genes O
, O
ipaB B-GENE
, O
ipaC B-GENE
, O
invE B-GENE
, O
invG B-GENE
, O
invJ B-GENE
, O
and O
invK B-GENE
, O
was O
apparently O
regulated O
by O
the O
positive O
regulator O
virF B-GENE
. O

These O
combined O
observations O
define O
a O
promoter O
and O
an O
enhancer O
for O
the O
chicken B-GENE
L-CAM I-GENE
gene I-GENE
. O

METHODS O
: O
Fifty-one O
healthy O
eyes O
, O
169 O
ocular O
hypertensive O
eyes O
with O
normal O
visual O
fields O
, O
and O
132 O
glaucomatous O
eyes O
with O
early O
visual O
field O
defects O
were O
evaluated O
with O
qualitative O
and O
quantitative O
measures O
of O
structural O
damage O
to O
the O
optic O
nerve O
and O
nerve O
fiber O
layer O
. O

From O
these O
results O
, O
CBF-A B-GENE
is O
a O
novel O
CArG O
box- O
, O
ssDNA- B-GENE
and I-GENE
RNA-binding I-GENE
protein I-GENE
, O
as O
well O
as O
a O
repressive O
transcriptional O
factor O
. O

We O
have O
tested O
the O
function O
of O
two O
potential O
NF-kappaB-like B-GENE
sites I-GENE
present O
in O
the O
PAI-2 B-GENE
proximal I-GENE
promoter I-GENE
for O
responsiveness O
to O
TNFalpha B-GENE
using O
chloramphenicol B-GENE
acetyl I-GENE
transferase I-GENE
reporter I-GENE
gene I-GENE
deletion O
and O
mutation O
analyses O
. O

Overexpression O
of O
wild-type B-GENE
p53 I-GENE
also O
induces O
apoptosis O
in O
an O
LCL O
. O

RESULTS O
: O
The O
medians O
of O
average O
daily O
CD34+ B-GENE
cell O
yields O
for O
patients O
who O
received O
paclitaxel O
plus O
CY O
, O
CE O
, O
and O
CEP O
with O
G-CSF B-GENE
were O
12 O
. O
9 O
, O
11 O
. O
03 O
, O
and O
5 O
. O
37 O
x O
10 O
( O
6 O
) O
kg O
, O
respectively O
, O
compared O
with O
2 O
. O
02 O
x O
10 O
( O
6 O
) O
kg O
in O
the O
reference O
group O
that O
received O
CY O
with O
G-CSF O
( O
P B-GENE
= O
< O
. O
0001 O
, O
. O
002 O
, O
and O
. O
09 O
, O
respectively O
) O
. O

The O
calculated O
pD2 O
values O
were O
8 O
. O
8 O
for O
E O
, O
8 O
. O
6 O
for O
DHE O
and O
6 O
. O
6 O
for O
M O
. O

Significant O
intergroup O
differences O
are O
highlighted O
for O
both O
selected O
dentoskeletal O
and O
soft O
tissue O
profile O
variables O
. O

Mutations O
in O
the O
VPS45 B-GENE
gene I-GENE
, O
a O
SEC1 B-GENE
homologue O
, O
result O
in O
vacuolar O
protein O
sorting O
defects O
and O
accumulation O
of O
membrane O
vesicles O
. O

B O
cell-specific O
mb-1 B-GENE
and O
B29 B-GENE
genes I-GENE
encode O
the O
alpha O
beta O
components O
of O
the O
BCR-associated O
complex B-GENE
in I-GENE
mature O
sIgM+ O
B B-GENE
cells O
. O

Comparative O
DNA O
sequence O
analysis O
showed O
the O
Genethon O
microsatellite B-GENE
D19S596 I-GENE
lies O
2 O
. O
2 O
kb O
downstream O
of O
the O
coding O
region O
of O
FUT1 B-GENE
, O
indicating O
that O
the O
cluster O
comprising O
the O
closely O
linked O
FUT1 B-GENE
and O
FUT2 B-GENE
genes I-GENE
is O
located O
4 O
cM O
distal O
to O
D19S412 B-GENE
( O
lod O
score O
13 O
. O
7 O
) O
and O
9 O
cM O
proximal O
to O
D19S571 B-GENE
( O
lod O
score O
11 O
. O
7 O
) O
. O

Only O
17% O
of O
all O
patients O
admitted O
it O
at O
all O
times O
. O

The O
c-myc B-GENE
gene I-GENE
is O
overexpressed O
in O
a O
variety O
of O
tumor O
types O
and O
appears O
to O
play O
an O
important O
role O
in O
the O
abnormal O
growth O
of O
a O
number O
of O
cell O
types O
. O

Inhibition O
of O
the O
apolipoprotein B-GENE
B I-GENE
mRNA I-GENE
editing O
enzyme-complex O
by O
hnRNP B-GENE
C1 I-GENE
protein I-GENE
and O
40S B-GENE
hnRNP I-GENE
complexes I-GENE
. O

Twenty-six O
( O
55% O
) O
( O
95% O
CI O
, O
41-69% O
) O
patients O
experienced O
> O
or O
= O
grade O
3 O
acute O
toxicity O
( O
RTOG O
) O
. O

To O
estimate O
the O
locations O
of O
sources O
with O
the O
TF-MUSIC O
algorithm O
, O
we O
first O
set O
the O
target O
region O
on O
the O
spectrogram O
of O
the O
somatosensory O
responses O
. O

A O
microsporidian O
, O
Nosema O
algerae O
Vavra O
and O
undeen O
, O
was O
found O
parasitizing O
larvae O
and O
adults O
of O
a O
laboratory O
colony O
of O
Culex O
pipiens O
L O
. O
originated O
from O
Gharbia O
Governorate O
. O

Serological O
studies O
of O
antibodies O
to O
Epstein-Barr O
virus O
in O
infectious O
mononucleosis O
. O

The O
mean O
transfer O
ratios O
of O
the O
drug O
into O
the O
genital O
tissues O
to O
the O
concentration O
in O
the O
uterine O
arterial O
blood O
were O
such O
that O
the O
transfer O
ratio O
into O
the O
portio O
vaginalis O
was O
the O
highest O
, O
followed O
by O
the O
uterine O
cervix O
and O
the O
myometrium O
, O
and O
that O
into O
the O
oviduct O
was O
the O
lowest O
with O
about O
1 O
2 O
that O
into O
the O
portio O
vaginalis O
. O

We O
have O
also O
isolated O
and O
analyzed O
the O
5' O
flanking O
region O
of O
the O
pea O
33RNP B-GENE
gene I-GENE
. O

We O
conclude O
that O
for O
mono-intronic O
precursors O
in O
which O
there O
is O
only O
one O
choice O
of O
splice O
sites O
, O
most O
of O
the O
exon O
sequences O
are O
not O
mechanistically O
involved O
in O
the O
splicing O
process O
. O

Identification O
and O
characterization O
of O
two O
putative O
human B-GENE
arginine I-GENE
methyltransferases I-GENE
( O
HRMT1L1 B-GENE
and O
HRMT1L2 B-GENE
) O
. O

The O
contraceptive O
pattern O
of O
157 O
women O
was O
analysed O
and O
13 O
. O
8 O
percent O
were O
using O
inefficient O
methods O
. O

In O
fus3 B-GENE
mutants I-GENE
, O
the O
levels O
of O
Ty1 B-GENE
RNA I-GENE
, O
protein O
synthesis O
, O
and O
proteolytic O
processing O
were O
not O
altered O
relative O
to O
those O
in O
FUS3 B-GENE
strains O
but O
steady-state O
levels O
of O
TyA B-GENE
, O
integrase B-GENE
, O
and O
reverse B-GENE
transcriptase I-GENE
proteins O
and O
Ty1 B-GENE
cDNA I-GENE
were O
all O
increased O
. O

Patients O
at O
risk O
of O
hypothyroidism O
. O

Thus O
, O
included O
in O
the O
KG1a O
EST O
dataset O
are O
candidates O
for O
new O
human O
genes O
that O
may O
play O
roles O
in O
hematopoietic O
differentiative O
progression O
and O
lineage O
commitment O
. O

Restoration O
of O
opponens O
function O
with O
transplantation O
of O
free O
composites O
dorsal O
pedal O
skin O
flap O
containing O
m O
. O
extensor O
hallucis O
brevis O
. O

They O
also O
interact O
with O
GTPase B-GENE
activating I-GENE
proteins I-GENE
encoded O
by O
IRA1 B-GENE
and O
IRA2 B-GENE
. O

Activation O
of O
T O
cells O
via O
the O
TCR B-GENE
and O
other O
costimulatory O
receptors O
triggers O
a O
number O
of O
signaling O
cascades O
. O

GLRaV-2 O
is O
the O
only O
closterovirus O
, O
so O
far O
, O
that O
matches O
the O
genome O
organization O
of O
the O
type O
member O
of O
the O
group O
, O
BYV O
, O
and O
thus O
can O
be O
unambiguously O
classified O
as O
a O
definitive O
member O
of O
the O
genus O
Closterovirus O
. O

Our O
results O
demonstrate O
that O
the O
promoter O
and O
enhancer O
regions O
identified O
here O
are O
essential O
for O
maintaining O
the O
efficient O
promoter O
activity O
of O
the O
human B-GENE
activin I-GENE
betaA I-GENE
subunit I-GENE
gene I-GENE
. O

CONCLUSIONS O
: O
Significant O
elevations O
of O
IL-1alpha B-GENE
and O
IL-1beta B-GENE
occur O
in O
patients O
with O
bacterial O
cystitis O
and O
microscopic O
hematuria O
. O

Recent O
work O
in O
this O
laboratory O
has O
shown O
that O
the O
gene O
coding O
for O
acetate B-GENE
kinase I-GENE
( O
ackA B-GENE
) O
in O
Sinorhizobium O
meliloti O
is O
up-regulated O
in O
response O
to O
phosphate O
limitation O
. O

Five O
additional O
copies O
of O
Lian B-GENE
elements I-GENE
were O
isolated O
, O
mapped O
by O
restriction O
digestion O
, O
and O
partially O
sequenced O
. O

Autoimmune O
neutropenia O
( O
AIN O
) O
is O
a O
frequent O
cause O
of O
chronic O
neutropenia O
especially O
in O
youngest O
children O
. O

Comparison O
of O
the O
amino O
acid O
sequences O
of O
the O
RPO1 B-GENE
polypeptides I-GENE
of I-GENE
IIV6 I-GENE
, I-GENE
LCDV I-GENE
, I-GENE
and I-GENE
MCV-1 I-GENE
with O
the O
corresponding O
prokaryotic O
, O
eukaryotic O
, O
and O
viral O
proteins O
revealed O
differences O
in O
amino O
acid O
similarity O
and O
phylogenetic O
relationships O
. O

Intravenous O
antibiotic O
therapy O
in O
cystic O
fibrosis O
: O
in O
hospital O
or O
at O
home O
? O

Concordantly O
, O
it O
was O
shown O
that O
the O
dnHLH B-GENE
protein I-GENE
Id1 B-GENE
inhibits O
differentiation O
of O
muscle O
and O
myeloid O
cells O
in O
vitro O
. O

Data O
from O
119 O
men O
and O
40 O
women O
undergoing O
coronary O
angiography O
provide O
an O
opportunity O
to O
compare O
these O
associations O
in O
relation O
to O
a O
direct O
and O
continuous O
measure O
of O
atherosclerosis O
while O
controlling O
for O
age O
, O
sex O
, O
income O
, O
hypertension O
, O
serum O
cholesterol O
, O
smoking O
, O
angina O
, O
diabetes O
, O
family O
history O
of O
heart O
disease O
, O
Type O
A O
behavior O
pattern O
, O
and O
hostility O
. O

The O
Drosophila B-GENE
melanogaster I-GENE
suppressor I-GENE
of I-GENE
sable I-GENE
gene I-GENE
, O
su B-GENE
( I-GENE
s I-GENE
) I-GENE
, O
encodes O
a O
novel O
, O
150-kDa O
nuclear O
RNA O
binding O
protein O
, O
SU B-GENE
( I-GENE
S I-GENE
) I-GENE
, O
that O
negatively O
regulates O
RNA O
accumulation O
from O
mutant O
alleles O
of O
other O
genes O
that O
have O
transposon O
insertions O
in O
the O
5' O
transcribed O
region O
. O

0 O
. O
61 O
+ O
- O
0 O
. O
04 O
) O
. O

In O
addition O
, O
both O
the O
exon O
1- O
and O
exon O
2-initiated O
forms O
of O
the O
c-Myc B-GENE
protein I-GENE
stimulated O
transcription O
of O
a O
Myc B-GENE
Max-responsive I-GENE
reporter I-GENE
construct I-GENE
to I-GENE
a O
similar O
level O
. O

Productive O
growth O
of O
phage O
P22 O
in O
wild-type O
Salmonella O
typhimurium O
correlates O
with O
the O
presence O
of O
Abc2 B-GENE
, O
but O
is O
independent O
of O
the O
absolute O
level O
of O
ATP-dependent B-GENE
nuclease I-GENE
activity O
, O
suggesting O
a O
qualitative O
change O
in O
the O
nature O
of O
Abc2-modified O
RecBCD B-GENE
nuclease I-GENE
activity O
relative O
to O
the O
native O
enzyme O
. O

These O
data O
may O
also O
aid O
in O
the O
localization O
of O
other O
disease O
loci O
mapped O
to O
this O
region O
, O
including O
the O
gene O
for O
tricho-dento-osseous O
syndrome O
and O
a O
murine O
locus O
for O
susceptibility O
to O
ozone-induced O
acute O
lung O
injury O
. O

Thus O
, O
endemic O
cumlations O
of O
hepatitis O
A O
diseases O
are O
possible O
. O

Systematic O
review O
of O
diagnostic O
tests O
for O
vaginal O
trichomoniasis O
. O

Modification O
by O
this O
latter O
compound O
was O
so O
extensive O
that O
the O
amount O
of O
membrane-associated O
N-myristoylated O
protein O
was O
decreased O
. O

Rearrangements O
of O
the O
NFKB2 B-GENE
gene I-GENE
are O
associated O
with O
lymphoid O
malignancies O
, O
but O
the O
functional O
significance O
of O
these O
alterations O
is O
not O
known O
. O

Using O
fluorescence O
in O
situ O
hybridization O
, O
we O
mapped O
the O
chromosome-17 O
breakpoint O
in O
a O
patient O
with O
acampomelic O
CMPD O
and O
sex O
reversal O
, O
who O
carries O
a O
de O
novo O
constitutional O
t O
( O
12 O
; O
17 O
) O
translocation O
, O
between O
two O
known O
cosmid O
markers O
in O
the O
17q24-q25 O
region O
. O

Thus O
, O
in O
the O
presence O
of O
active B-GENE
S-CDKs I-GENE
and O
Dbf4 B-GENE
Cdc7 I-GENE
, I-GENE
Mcms O
may B-GENE
open O
origins O
and O
thereby O
facilitate O
the O
loading O
of O
RPA O
. B-GENE

In O
canrenoate-treated O
rats O
, O
ANP B-GENE
infusion O
caused O
greater O
increases O
in O
sodium O
excretion O
( O
FENA O
from O
3 O
. O
05 O
+ O
- O
0 O
. O
71 O
to O
7 O
. O
21 O
+ O
- O
0 O
. O
45% O
; O
P O
< O
0 O
. O
05 O
; O
n O
= O
8 O
) O
than O
saline O
infusion O
( O
FENA O
from O
4 O
. O
16 O
+ O
- O
1 O
. O
11 O
to O
5 O
. O
47 O
+ O
- O
0 O
. O
66% O
; O
n O
= O
6 O
) O
, O
despite O
the O
hypocapnia O
. O

RT-PCR O
analysis O
showed O
that O
PLP-H B-GENE
as O
well O
as O
PLP-C B-GENE
and O
PLP-D B-GENE
are O
expressed O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
PLP B-GENE
diversity O
is O
not O
due O
to O
strain O
differences O
. O

In O
rats O
bearing O
Walker-256-carcinosarcoma O
4-EPI O
was O
effective O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Resultant O
activation O
of O
c-Jun B-GENE
N-terminal I-GENE
kinase I-GENE
stress-activated I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
JNK O
SAPK B-GENE
) I-GENE
. I-GENE

This O
makes O
these O
compounds O
attractive O
as O
vehicles O
for O
these O
and O
other O
gases O
in-vivo O
and O
in-vitro O
. O

Chem O
. O

We O
now O
show O
that O
the O
BAT1 B-GENE
translation I-GENE
product I-GENE
is O
the O
homolog O
of O
the O
rat B-GENE
p47 I-GENE
nuclear I-GENE
protein I-GENE
, O
the O
WM6 B-GENE
Drosophila I-GENE
gene I-GENE
product I-GENE
, O
and O
probably O
also O
Ce08102 B-GENE
of O
Caenorhabditis O
elegans O
, O
all O
members O
of O
the O
DEAD B-GENE
protein I-GENE
family I-GENE
of O
ATP-dependent B-GENE
RNA I-GENE
helicases I-GENE
. O

In O
synchronized O
HeLa O
cells O
, O
expression O
of O
luciferase B-GENE
activity O
was O
induced O
at O
the O
beginning O
of O
DNA O
synthesis O
and O
was O
dependent O
on O
the O
presence O
of O
an O
E2F-binding B-GENE
site I-GENE
in O
the O
H2A B-GENE
. I-GENE
1 I-GENE
promoter I-GENE
. O

The O
DNA O
binding O
domain O
of O
NirA B-GENE
was O
expressed O
as O
a O
fusion O
protein O
with O
the O
glutathione B-GENE
S-transferase I-GENE
of O
Schistosoma O
japonicum O
. O

Seventy-one O
supplementary O
doses O
of O
vecuronium O
were O
used O
for O
muscle O
relaxation O
during O
a O
22-h-long O
NLA O
II O
anaesthesia O
. O

Strikingly O
, O
these O
cells O
contain O
a O
missense O
mutation O
of O
the O
p53 B-GENE
gene I-GENE
at O
codon O
242 O
( O
p53 O
( O
242 O
) O
) O
, O
which O
substitutes O
alanine O
for O
glycine O
. O

The O
mapping O
was O
completed O
with O
Southern O
blotting O
and O
restriction O
analysis O
. O

Together O
, O
the O
data O
suggest O
that O
cAMP-dependent O
control O
of O
the O
amounts O
of O
the O
activator O
SF-1 B-GENE
vs O
. O
the O
repressor O
COUP-TF B-GENE
could O
influence O
CRS2-dependent O
transcription O
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
KG1a O
cells O
, O
TNFalpha B-GENE
can O
stimulate O
in O
parallel O
PC-PLC B-GENE
and O
PLD B-GENE
, O
whose O
lipid O
products O
activate O
in O
turn O
mitogen-activated B-GENE
protein I-GENE
kinase I-GENE
( O
MAP B-GENE
kinase I-GENE
) O
and O
NF-kappaB B-GENE
signalling O
respectively O
. O

The O
findings O
are O
discussed O
in O
the O
context O
of O
known O
properties O
of O
cortical-bar O
detectors O
. O

Human B-GENE
alpha-galactosidase I-GENE
A I-GENE
: O
nucleotide O
sequence O
of O
a O
cDNA O
clone O
encoding O
the O
mature O
enzyme O
. O

In O
the O
absence O
of O
MHC B-GENE
class I-GENE
II I-GENE
, O
purified B-GENE
soluble I-GENE
D10 I-GENE
TCR I-GENE
bound O
to O
Staphylococcus B-GENE
aureus I-GENE
enterotoxin I-GENE
C2 I-GENE
with O
an O
association O
rate O
of O
1 O
. O
69+ O
-0 O
. O
12 O
x O
10 O
( O
4 O
) O
M O
( O
-1 O
) O
sec O
( O
-1 O
) O
and O
a O
dissociation O
rate O
of O
1 O
. O
9+ O
-0 O
. O
47 O
x O
10 O
( O
-2 O
) O
sec O
( O
-1 O
) O
, O
giving O
a O
dissociation O
constant O
of O
1 O
. O
1 O
microM O
. O

The O
case O
for O
completing O
the O
lymphadenectomy O
when O
positive O
lymph O
nodes O
are O
found O
during O
radical O
hysterectomy O
for O
cervical O
carcinoma O
. O

To O
further O
characterize O
the O
structure O
and O
evolutionary O
synthesis O
of O
the O
CMT1A-REP B-GENE
repeat I-GENE
, O
fluorescent O
in O
situ O
hybridization O
( O
FISH O
) O
analysis O
and O
heterologous O
PCR-based O
assays O
were O
carried O
out O
for O
a O
series O
of O
primates O
. O

When O
expressed O
per O
kilogram O
body O
weight O
, O
mean O
GIT O
increased O
in O
the O
dF O
group O
from O
0 O
. O
14% O
to O
0 O
. O
16% O
above O
RMR O
, O
with O
a O
significant O
decrease O
from O
0 O
. O
15% O
to O
0 O
. O
13% O
in O
the O
P O
group O
. O

The O
mature O
chromosome O
4 O
FRG1 B-GENE
transcript I-GENE
is O
1042 O
bp O
in O
length O
and O
contains O
nine O
exons O
which O
encode O
a O
putative O
protein O
of O
258 O
amino O
acid O
residues O
. O

Various O
transcripts O
are O
generated O
from O
the O
VCSA1 B-GENE
gene I-GENE
by O
alternative O
splicing O
and O
poly O
( O
A O
) O
processing O
in O
the O
rat O
submandibular O
gland O
. O

A O
stochastic O
version O
of O
Kernell's O
( O
1968 O
, O
1972 O
) O
model O
with O
cumulative O
afterhyperpolarization O
( O
AHP O
) O
was O
simulated O
. O

The O
data O
indicate O
that O
etr-1 B-GENE
is O
essential O
for O
muscle O
development O
in O
C O
. O
elegans O
, O
perhaps O
by O
playing O
a O
role O
in O
post-transcriptional O
processing O
of O
some O
muscle O
component O
, O
and O
thus O
suggesting O
a O
possible O
conservation O
of O
gene O
function O
with O
human B-GENE
CUG-bp I-GENE
. O

This O
hypothesis O
was O
tested O
by O
introducing O
mutations O
at O
each O
of O
the O
three O
histidine O
pairs O
, O
the O
H382-X2-H385 B-GENE
pair I-GENE
, O
the O
H411-X2-H414 B-GENE
pair I-GENE
and O
the O
H430-X5-H436 B-GENE
pair I-GENE
, O
which O
constitute O
the O
histidine-rich O
region O
near O
the O
C O
terminus O
of O
gp17 B-GENE
. O

The O
isolated O
plasmin O
fragments O
of O
VEGF B-GENE
were O
compared O
with O
respect O
to O
heparin O
binding O
, O
interaction O
with O
soluble O
VEGF B-GENE
receptors I-GENE
, O
and O
ability O
to O
promote O
endothelial O
cell O
mitogenesis O
. O

Hepatitis O
A O
infected O
food O
handler O
at O
an O
Edmonton O
, O
Alberta O
retail O
food O
facility O
: O
public O
health O
protection O
strategies O
. O

METHODS O
: O
126 O
patients O
with O
histologically O
confirmed O
MFH O
were O
analyzed O
. O

A O
recently O
reported O
new O
member O
of O
the O
Vav B-GENE
family I-GENE
proteins I-GENE
, O
Vav3 B-GENE
has O
been O
identified O
as O
a O
Ros B-GENE
receptor B-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
( O
RPTK B-GENE
) O
interacting O
protein O
by O
yeast O
two-hybrid O
screening O
. O

Our O
purpose O
was O
to O
determine O
if O
intact O
perianal O
( O
S4-5 O
) O
pin O
sensation O
( O
PPS O
) O
and O
bulbocavernosus O
( O
S2-4 O
) O
reflex O
( O
BCR O
) O
shortly O
after O
spinal O
cord O
injury O
( O
SCI O
) O
are O
predictive O
of O
bladder O
function O
recovery O
. O

Further O
studies O
demonstrated O
that O
the O
PPARalpha B-GENE
ligand O
8 O
( O
S O
) O
-hydroxyeicosatetraenoic O
acid O
strongly O
promotes O
the O
interaction O
of O
PPARalpha B-GENE
with O
the O
co-activator O
RIP-140 B-GENE
but O
decreases O
the O
interaction O
of O
PPARalpha B-GENE
with O
the O
co-repressor O
SMRT B-GENE
. O

When O
O2 O
therapy O
was O
controlled O
for O
, O
the O
association O
between O
RBT O
and O
RLF O
did O
not O
achieve O
statistical O
significance O
( O
P O
= O
. O
07 O
) O
. O

In O
the O
brain O
, O
muscarinic B-GENE
receptors I-GENE
mediate O
motor O
and O
memory O
function O
by O
interaction O
with O
their O
ligand O
acetylcholine O
. O

Batch O
cultures O
of O
S O
. O
mutans O
serotype O
a O
demonstrated O
no O
growth O
on O
MSB O
agar O
. O

Management O
often O
involves O
beta- O
and O
calcium O
channel O
blocking O
drugs O
or O
type O
IC O
antiarrhythmic O
drugs O
. O

Sensitivity O
and O
specificity O
was O
established O
for O
the O
Pharmacia O
CAP O
System O
and O
the O
DPC O
AlaSTAT O
System O
by O
comparison O
with O
results O
of O
the O
skin O
prick O
test O
. O

The O
interferon-inducible O
protein B-GENE
kinase I-GENE
PKR I-GENE
modulates O
the O
transcriptional O
activation O
of O
immunoglobulin B-GENE
kappa I-GENE
gene I-GENE
. O

We O
report O
a O
case O
of O
vasculitis O
( O
cutaneous O
and O
neurologic O
) O
which O
led O
to O
the O
discovery O
of O
a O
selective O
immunodeficit O
towards O
EBV O
, O
similar O
to O
Purtilo's O
syndrome O
. O

A O
stretch O
of O
16 O
nucleotides O
just O
upstream O
of O
the O
IL-4RE B-GENE
contributed O
to O
IL-4 B-GENE
inducibility O
and O
formed O
nucleoprotein O
complexes O
with O
constitutive O
factors O
. O

Inhibition O
appears O
to O
result O
from O
titration O
of O
general O
transcription O
factors O
because O
MDM2 B-GENE
overexpression O
inhibits O
c-fos B-GENE
as O
well O
as O
other O
promoters O
in O
vivo O
and O
basal O
transcription O
in O
vitro O
. O

A O
13-bp O
cis-regulatory O
element O
in O
the O
LTR O
promoter O
of O
the O
tobacco B-GENE
retrotransposon I-GENE
Tto1 I-GENE
is O
involved O
in O
responsiveness O
to O
tissue O
culture O
, O
wounding O
, O
methyl O
jasmonate O
and O
fungal O
elicitors O
. O

Serum O
leptin B-GENE
concentrations O
in O
women O
during O
gonadotropin B-GENE
stimulation O
cycles O
. O

In O
this O
study O
, O
we O
purified O
and O
characterized O
the O
recombinant B-GENE
furin I-GENE
from O
the O
conditioned O
medium O
of O
these O
cells O
. O

The O
presence O
of O
regulatory O
sequences O
for O
the O
binding O
of O
transcription O
factors O
such O
as O
NF-kappa B-GENE
B I-GENE
and O
AP-2 B-GENE
, O
whose O
activation O
is O
associated O
with O
the O
immediate O
response O
of O
the O
cell O
to O
an O
injury O
, O
may O
be O
an O
indication O
of O
the O
important O
role O
which O
HO-1 B-GENE
may O
play O
in O
defense O
mechanisms O
against O
tissue O
injury O
. O

Moreover O
, O
the O
effect O
exerted O
by O
TIS1 B-GENE
appeared O
to O
be O
selective O
for O
the O
MCK B-GENE
promoter I-GENE
. O

CD7+ B-GENE
CD3- I-GENE
T-cell I-GENE
precursors O
exhibit O
V O
delta B-GENE
2D I-GENE
delta I-GENE
3 I-GENE
rearrangements I-GENE
. I-GENE

GCR1 B-GENE
gene I-GENE
function O
is O
required O
for O
high-level O
glycolytic O
gene O
expression O
in O
Saccharomyces O
cerevisiae O
. O

Crohn's O
disease O
in O
prolonged O
remission O
: O
should O
one O
augment O
protein-calorie O
intake O
as O
compared O
to O
healthy O
subjects O
? O
The O
aim O
of O
our O
two O
year O
prospective O
study O
was O
to O
evaluate O
whether O
adult O
Crohn's O
disease O
patients O
in O
prolonged O
remission O
( O
CDAI O
< O
150 O
) O
, O
in O
order O
to O
maintain O
their O
body O
weight O
as O
close O
as O
possible O
to O
the O
ideal O
one O
, O
need O
a O
protein-calorie O
intake O
higher O
than O
the O
predicted O
one O
and O
that O
of O
healthy O
controls O
. O

We O
are O
reporting O
an O
autopsy O
case O
of O
so-called O
"acute O
multiple O
sclerosis" O
that O
was O
difficult O
to O
differentiate O
from O
a O
brain O
tumor O
on O
MRI O
findings O
. O

Thus O
, O
this O
study O
provides O
evidence O
that O
a O
novel O
, O
ubiquitous O
factor O
( O
HF-1a B-GENE
) O
and O
a O
muscle O
factor O
( O
HF-1b B-GENE
MEF-2 I-GENE
) I-GENE
can O
form O
a O
novel O
, O
E-box-independent O
pathway O
for O
muscle-specific O
expression O
in O
ventricular O
cardiac O
muscle O
cells O
. O

Thyroid O
function O
tests O
were O
performed O
on O
300 O
admissions O
, O
leaving O
707 O
untested O
. O

Molecular O
cloning O
and O
expression O
of O
RPE65 B-GENE
, O
a O
novel O
retinal O
pigment O
epithelium-specific O
microsomal O
protein O
that O
is O
post-transcriptionally O
regulated O
in O
vitro O
. O

The O
concentrations O
of O
apo B-GENE
A-I I-GENE
and O
apo B-GENE
A-II I-GENE
of O
abstainers O
decreased O
significantly O
compared O
with O
the O
corresponding O
changes O
in O
controls O
. O

Inclusion O
of O
the O
extended O
N O
terminus O
into O
the O
originally O
reported O
protein O
resulted O
in O
a O
striking O
similarity O
to O
the O
lymphoid B-GENE
factor I-GENE
Lef-1 I-GENE
. O

These O
results O
provide O
the O
first O
demonstration O
that O
an O
SR B-GENE
protein I-GENE
can O
influence O
splicing O
of O
specific O
pre-mRNAs O
in O
vivo O
. O

Yeast O
mutants O
assigned O
to O
the O
pet O
complementation O
group O
G104 O
were O
found O
to O
lack O
alpha-ketoglutarate B-GENE
dehydrogenase I-GENE
activity O
as O
a O
result O
of O
mutations O
in O
the O
dihydrolipoyl B-GENE
transsuccinylase I-GENE
( O
KE2 B-GENE
) O
component O
of O
the O
complex O
. O

We O
show O
, O
by O
injection O
of O
synthetic O
mRNAs O
, O
that O
the O
cis-acting O
sequences O
responsible O
for O
repression O
of O
cyclin B-GENE
B1 I-GENE
mRNA I-GENE
reside O
within O
its O
3'UTR O
. O

The O
present O
study O
was O
designed O
to O
evaluate O
the O
sensitivity O
and O
specificity O
of O
AMP O
CT O
( O
Gen-Probe O
Incorporated O
, O
San O
Diego O
, O
CA O
, O
USA O
) O
on O
urogenital O
specimens O
taken O
from O
symptomatic O
patients O
and O
on O
first O
void O
urine O
( O
FVU O
) O
specimens O
from O
asymptomatic O
patients O
. O

The O
range O
of O
eosinophils O
was O
22-56% O
of O
the O
number O
of O
peripheral O
white O
blood O
cells O
( O
mean O
nadir O
33% O
) O
. O

There O
were O
35 O
boys O
and O
15 O
girls O
, O
with O
a O
mean O
age O
of O
five O
and O
a O
half O
years O
. O

Analysis O
of O
mig B-GENE
CAT I-GENE
chimeric I-GENE
constructs O
transiently O
transfected O
into O
the O
RAW O
264 O
. O
7 O
mouse O
monocytic O
cell O
line O
revealed O
a O
unique O
IFN-gamma-responsive O
element B-GENE
( I-GENE
gamma O
RE-1 B-GENE
) I-GENE
. O

In O
most O
cases O
, O
DR4-homozygous O
, O
DRB1-heterozygous O
individuals O
could O
be O
genotyped O
with O
the O
panel O
of O
probes O
. O

In O
study O
2 O
, O
the O
correlation O
coefficients O
between O
the O
ISO2 O
measurements O
obtained O
at O
the O
ulcer O
margin O
and O
at O
the O
adjacent O
normal O
mucosa O
, O
and O
delta O
ISO2 O
obtained O
by O
the O
experienced O
observer O
and O
one O
of O
the O
three O
learners O
were O
0 O
. O
94 O
, O
0 O
. O
97 O
, O
and O
0 O
. O
94 O
, O
respectively O
. O

More O
specific O
adverse O
events O
, O
also O
frequently O
considered O
as O
dose-limiting O
toxicities O
, O
include O
hypotension O
with O
IL-1 B-GENE
, O
severe O
headache O
or O
skin O
rash O
with O
IL-3 B-GENE
, O
and O
nasal O
congestion O
and O
gastroduodenal O
lesions O
with O
IL-4 B-GENE
. O

Much O
evidence O
indicates O
that O
p38 B-GENE
is O
an O
activator O
of O
MyoD B-GENE
: O
( O
i O
) O
p38 B-GENE
kinase I-GENE
activity O
is O
required O
for O
the O
expression O
of O
MyoD-responsive B-GENE
genes I-GENE
, O
( O
ii O
) O
enforced O
induction O
of O
p38 B-GENE
stimulates O
the O
transcriptional O
activity O
of O
a O
Gal4-MyoD B-GENE
fusion I-GENE
protein I-GENE
and O
allows O
efficient O
activation O
of O
chromatin-integrated O
reporters O
by O
MyoD B-GENE
, O
and O
( O
iii O
) O
MyoD-dependent O
myogenic O
conversion O
is O
reduced O
in O
mouse O
embryonic O
fibroblasts O
derived O
from O
p38alpha B-GENE
( I-GENE
- I-GENE
- I-GENE
) I-GENE
embryos I-GENE
. O

Magnetic O
storm O
indicators O
could O
be O
used O
in O
medicine O
, O
in O
geophysics O
and O
for O
special O
purposes O
. O

However O
, O
a O
strongly O
increased O
frequency O
of O
CpG O
dinucleotides O
was O
found O
. O

Thus O
, O
as O
expected O
, O
trans-splicing O
depends O
on O
the O
integrity O
of O
U2 B-GENE
, O
U4 B-GENE
, O
and O
U6 B-GENE
snRNAs I-GENE
. O

An O
exaggerated O
tissue O
response O
adjacent O
to O
the O
cyanoacrylate O
site O
suggested O
a O
potential O
toxic O
chemical O
or O
thermal O
reaction O
, O
or O
both O
, O
to O
the O
tissue O
adhesive O
, O
but O
there O
was O
no O
evidence O
of O
any O
distant O
ocular O
effects O
. O

The O
protein O
folds O
correctly O
with O
two O
disulfide O
bonds O
and O
a O
free O
thiol O
group O
at O
Cys25 O
. O

In O
this O
study O
, O
we O
used O
footprinting O
and O
gel O
mobility O
retardation O
assays O
to O
reveal O
that O
bacterially O
synthesized O
Zta B-GENE
fusion I-GENE
proteins I-GENE
bound O
directly O
to O
six O
TGTGCAA-like B-GENE
motifs I-GENE
within O
DSL B-GENE
. O

Dsh B-GENE
is O
required O
for O
two O
different O
pathways O
, O
the O
Wnt B-GENE
pathway O
and O
planar O
polarity O
pathway O
in O
Drosophila O
. O

The O
C2C-Prx B-GENE
is O
encoded O
as O
a O
preprotein O
of O
273 O
amino O
acids O
containing O
a O
putative O
chloroplast-targeting O
signal O
of O
65 O
amino O
acids O
at O
its O
N-terminus O
. O

In O
throttling O
valves O
, O
the O
aim O
is O
to O
correlate O
the O
effect O
of O
shear O
to O
a O
parameter O
related O
to O
the O
inner O
geometry O
of O
the O
valve O
and O
to O
operating O
conditions O
. O

Here O
we O
show O
in O
mouse O
fibroblasts O
stably O
transformed O
by O
v-Src B-GENE
that O
mRNA O
and O
protein O
levels O
of O
p21 B-GENE
( O
WAF1 B-GENE
CIP1 I-GENE
) I-GENE
, O
cyclin O
D1 B-GENE
, I-GENE
and O
cyclin O
E B-GENE
are I-GENE
elevated O
. O

These O
experiments O
confirm O
that O
the O
6-S O
liganded O
form O
of O
the O
receptor O
identified O
in O
nuclear O
extracts O
of O
cells O
treated O
with O
2 O
, O
3 O
, O
7 O
, O
8-tetrachlorodibenzo-p-dioxin O
( O
TCDD O
) O
contains O
the O
Ah B-GENE
receptor I-GENE
protein I-GENE
and O
ARNT B-GENE
but O
not O
the O
90-kDa B-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

These O
children O
were O
grouped O
into O
four O
diagnostic O
categories O
: O
1 O
) O
idiopathic O
GH B-GENE
deficiency O
( O
n O
= O
10 O
) O
; O
2 O
) O
organic O
hypopituitarism O
( O
n O
= O
7 O
) O
; O
3 O
) O
intrauterine O
growth O
retardation O
( O
n O
= O
5 O
) O
; O
and O
4 O
) O
constitutional O
delay O
of O
growth O
and O
or O
familial O
short O
stature O
( O
n O
= O
18 O
) O
, O
by O
standard O
clinical O
criteria O
and O
physiological O
and O
pharmacological O
tests O
of O
GH O
reserve B-GENE
. O

A O
total O
of O
125 O
acute O
leukemia O
adult O
patients O
were O
autografted O
with O
bone O
marrow O
( O
BM O
) O
purged O
by O
mafosfamide O
( O
ASTA O
Z O
) O
during O
the O
period O
of O
January O
1983 O
to O
January O
1993 O
. O

Members O
of O
the O
meis1 B-GENE
and O
pbx B-GENE
homeodomain I-GENE
protein I-GENE
families I-GENE
cooperatively O
bind O
a O
cAMP-responsive B-GENE
sequence I-GENE
( O
CRS1 B-GENE
) O
from O
bovine B-GENE
CYP17 I-GENE
. O

We O
have O
investigated O
the O
contribution O
of O
specific O
TATA-binding B-GENE
protein I-GENE
( O
TBP B-GENE
) O
-TATA O
interactions O
to O
the O
promoter O
activity O
of O
a O
constitutively O
expressed O
silkworm B-GENE
tRNA I-GENE
( I-GENE
C I-GENE
) I-GENE
( I-GENE
Ala I-GENE
) I-GENE
gene I-GENE
and O
have O
also O
asked O
whether O
the O
lack O
of O
similar O
interactions O
accounts O
for O
the O
low O
promoter O
activity O
of O
a O
silk B-GENE
gland-specific I-GENE
tRNA I-GENE
( I-GENE
SG I-GENE
) I-GENE
( I-GENE
Ala I-GENE
) I-GENE
gene I-GENE
. O

Differences O
in O
the O
clinical O
presentation O
and O
the O
gross O
appearance O
of O
the O
two O
cases O
are O
described O
, O
and O
similarities O
in O
the O
microscopic O
features O
are O
discussed O
. O

Superoxide B-GENE
dismutase I-GENE
( O
SOD B-GENE
) O
activity O
decreased O
significantly O
in O
sperm O
subjected O
to O
direct O
electric O
current O
in O
comparison O
to O
the O
control O
or O
the O
sample O
incubated O
with O
electrolyzed O
medium O
. O

Thus O
, O
in O
normal O
intestinal O
epithelial O
goblet O
cells O
, O
TbetaRI B-GENE
and O
TbetaRII B-GENE
can O
respond O
to O
autocrine O
but O
not O
exogenous O
TGF-beta B-GENE
without O
the O
participation O
of O
TbetaRIII B-GENE
. O

Reverse O
transcription-PCR O
was O
then O
used O
to O
clone O
from O
human O
poly O
( O
A O
) O
+ O
RNA O
the O
cDNA O
corresponding O
to O
the O
expressed O
homolog O
of O
psi B-GENE
ARF I-GENE
4 I-GENE
, O
referred O
to O
as O
human B-GENE
ARF I-GENE
4 I-GENE
. O

A O
full-length B-GENE
PRL I-GENE
receptor I-GENE
( O
PRLR B-GENE
) O
complementary O
DNA O
from O
pigeons O
was O
obtained O
by O
screening O
pigeon O
crop O
sac O
libraries O
and O
by O
reverse O
transcription O
coupled O
with O
polymerase B-GENE
chain O
reaction O
. O

Individual O
mutations O
in O
motifs B-GENE
III I-GENE
, I-GENE
IV I-GENE
, I-GENE
and I-GENE
V I-GENE
had O
distinctive O
effects O
on O
the O
affinity O
of O
enzyme O
for O
GTP O
, O
the O
rate O
of O
covalent O
catalysis O
( O
EpG O
formation O
) O
, O
or O
the O
transfer O
of O
GMP O
from O
enzyme O
to O
RNA O
. O

Mutagenesis O
of O
each O
NRF-1 B-GENE
motif I-GENE
in O
the O
ALAS B-GENE
promoter I-GENE
gave O
substantially O
lowered O
levels O
of O
chloramphenicol B-GENE
acetyltransferase I-GENE
expression O
, O
whereas O
mutagenesis O
of O
both O
NRF-1 B-GENE
motifs I-GENE
resulted O
in O
the O
almost O
complete O
loss O
of O
expression O
. O

The O
C-terminal O
mutants O
were O
strongly O
dominant O
over O
TraR B-GENE
, O
suggesting O
that O
they O
can O
form O
heteromultimers O
with O
the O
wild-type O
activator O
. O

The O
major O
RNase B-GENE
E I-GENE
cleavage O
product O
( O
denoted O
pSok-6 B-GENE
) O
is O
rapidly O
degraded O
by O
polynucleotide B-GENE
phosphorylase I-GENE
( O
PNPase B-GENE
) O
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic O
E6 B-GENE
motif I-GENE
detected O
a O
B-cell-specific O
complex O
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

Mutations O
in O
either O
gene O
block O
some O
crucial O
late O
step O
in O
assembly O
of O
F1 B-GENE
, O
causing O
the O
alpha O
and O
beta O
subunits O
to O
accumulate O
in O
mitochondria O
as O
inactive O
aggregates O
( O
Ackerman O
, O
S O
. O

Sp1 B-GENE
and O
two O
Sp3 B-GENE
isoforms I-GENE
were O
detected O
as O
the O
primary O
cellular O
constituents O
of O
DNA-protein O
complexes O
formed O
with O
the O
NF-kappaB-proximal B-GENE
site I-GENE
. O

Strains O
bearing O
the O
drs2 B-GENE
mutation I-GENE
process O
the O
20S B-GENE
precursor I-GENE
of O
the O
mature B-GENE
18S I-GENE
rRNA I-GENE
slowly O
and O
are O
deficient O
in O
40S B-GENE
ribosomal I-GENE
subunits I-GENE
. O

We O
observed O
abundant O
levels O
of O
Rev-erbA B-GENE
alpha I-GENE
mRNA I-GENE
in O
dividing O
C2C12 O
myoblasts O
, O
which O
were O
suppressed O
when O
the O
cells O
differentiated O
into O
postmitotic O
multinucleated O
myotubes O
. O

The O
recovery O
of O
labelled O
methoxydextrane O
is O
98 O
+ O
- O
7% O
. O

RESULTS O
: O
The O
overall O
FNF O
for O
1992 O
was O
12 O
. O
3% O
and O
was O
19 O
. O
1% O
, O
22 O
. O
2% O
, O
3 O
. O
8% O
and O
6 O
. O
1% O
per O
successive O
quarters O
in O
1992 O
. O

In O
cerebrospinal O
fluid O
, O
an O
ADA B-GENE
catalytic O
concentration O
above O
0 O
. O
15 O
mu O
kat O
L O
strongly O
suggests O
tuberculous O
meningitis O
in O
patients O
older O
than O
7 O
years O
( O
sensitivity O
1 O
. O
00 O
, O
specificity O
0 O
. O
99 O
and O
efficiency O
0 O
. O
99 O
) O
. O

Along O
with O
previously O
mapped O
genes O
including O
Ly-1 B-GENE
and O
CD20 B-GENE
, O
OSBP B-GENE
defines O
a O
new O
conserved O
syntenic O
group O
on O
the O
long O
arm O
of O
chromosome O
11 O
in O
the O
human O
and O
the O
proximal O
end O
of O
chromosome O
19 O
in O
the O
mouse O
. O

The O
proteins O
are O
more O
than O
90% O
identical O
to O
each O
other O
within O
the O
protein B-GENE
kinase I-GENE
domain I-GENE
but O
only O
51-59% O
identical O
to O
other O
casein B-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
within O
this O
region O
. O

The O
conserved O
ninth O
C-terminal O
heptad O
in O
thyroid O
hormone O
and O
retinoic B-GENE
acid I-GENE
receptors I-GENE
mediates O
diverse O
responses O
by O
affecting O
heterodimer O
but O
not O
homodimer O
formation O
. O

Secondly O
, O
an O
ethanol B-GENE
repression I-GENE
autoregulation I-GENE
( I-GENE
ERA I-GENE
) I-GENE
twelve-fold I-GENE
TA I-GENE
repeat I-GENE
( I-GENE
TAB I-GENE
) I-GENE
repressor I-GENE
element I-GENE
was I-GENE
identified O
within O
the O
promoter O
region O
of O
the O
GLK1 O
gene B-GENE
. I-GENE

With O
a O
sample O
of O
mothers O
of O
healthy O
infants O
, O
all O
three O
subscales O
of O
the O
revised O
instrument O
, O
WPL-R O
, O
had O
acceptable O
levels O
of O
internal O
consistency O
at O
7 O
, O
30 O
, O
and O
90 O
days O
postpartum O
, O
and O
stability O
across O
administrations O
. O

These O
results O
implicate O
a O
precursor-specific O
base-paired O
structure O
involving O
sequences O
on O
both O
sides O
of O
the O
mature O
cleavage O
site O
in O
the O
3' O
processing O
of O
human B-GENE
U2 I-GENE
RNA I-GENE
. O

To O
further O
understand O
the O
role O
of O
cis-acting O
elements O
in O
these O
regulatory O
mechanisms O
, O
we O
have O
characterized O
a O
transcriptional O
promoter O
that O
drives O
germline O
expression O
of O
TCR B-GENE
beta I-GENE
gene I-GENE
segments I-GENE
in O
vivo O
. O

It O
corresponds O
to O
the O
complete O
mitochondrial O
presequence O
and O
the O
lipoyl-bearing O
domain O
that O
are O
encoded O
by O
exons O
I O
through O
IV O
of O
the O
functional O
E2 B-GENE
gene I-GENE
. O

Viscosity O
experiments O
on O
the O
catalytic O
fragment O
kinase B-GENE
reaction O
demonstrated O
that O
the O
chemical O
( O
phosphoryl O
transfer O
) O
step O
had O
a O
reduced O
rate O
. O

To O
define O
the O
mechanism O
responsible O
for O
the O
loss O
of O
transcription O
elongation O
blockage O
and O
resulting O
c-myc B-GENE
deregulation O
in O
Burkitt's O
lymphoma O
, O
we O
analyzed O
transcription O
patterns O
after O
transfer O
of O
normal O
and O
Burkitt's O
lymphoma O
c-myc B-GENE
alleles O
into O
murine O
cells O
and O
Xenopus O
oocyte O
germinal O
vesicles O
. O

Mutation O
analyses O
identified O
the O
cobalt-responsive O
sequences O
as O
the O
stress-response B-GENE
elements I-GENE
( O
StREs B-GENE
) O
. O

Space O
limitations O
prevent O
an O
exhaustive O
review O
of O
all O
biologic O
pharmaceuticals O
, O
such O
as O
tissue B-GENE
plasminogen I-GENE
activating I-GENE
substance I-GENE
, O
hormones O
( O
e O
. O
g O
. O
, O
thyroid O
, O
insulin B-GENE
, O
growth B-GENE
hormone I-GENE
, O
erythropoietin B-GENE
) O
, O
clotting O
factors O
, O
and O
blood O
products O
. O

Molecular O
characterization O
of O
type-specific B-GENE
capsular I-GENE
polysaccharide I-GENE
biosynthesis I-GENE
genes I-GENE
of I-GENE
Streptococcus I-GENE
agalactiae I-GENE
type I-GENE
Ia O
. O

The O
model O
also O
predicts O
that O
blood O
flow O
shunt O
fraction O
( O
Qs O
QT O
) O
is O
directly O
related O
to O
the O
oxygen O
sine-wave O
amplitude O
perturbations O
transmitted O
to O
end-expired O
air O
and O
arterial O
and O
mixed-venous O
blood O
through O
two O
simple O
equations O
. O

Filter O
and O
cytocentrifuge O
preparations O
of O
the O
urine O
were O
studied O
and O
all O
cases O
displayed O
numerous O
scattered O
aggregates O
or O
single O
tumor O
cells O
in O
an O
inflammatory O
background O
. O

Mean O
longitudinal O
extension O
of O
the O
epidural O
lesion O
was O
2 O
. O
6 O
vertebral O
segments O
. O

The O
effects O
of O
these O
mutations O
on O
RNA B-GENE
polymerase I-GENE
II I-GENE
activity O
were O
assayed O
by O
measuring O
the O
ability O
of O
mutant O
genes O
to O
confer O
alpha-amanitin B-GENE
resistance O
after O
transfection O
of O
susceptible O
rodent O
cells O
. O

Cis-acting O
CCAAT B-GENE
elements I-GENE
are O
frequently O
found O
in O
eukaryotic O
promoter O
regions O
. O

Expression O
of O
Bcl-XL B-GENE
inhibited O
the O
association O
of O
Apaf-1 B-GENE
with O
caspase-9 B-GENE
in O
mammalian O
cells O
. O

SF-1 B-GENE
does O
not O
have O
an O
N-terminal B-GENE
AF1 I-GENE
domain I-GENE
. O

Basing O
on O
experimental O
toxicity O
research O
it O
was O
established O
that O
, O
out O
of O
50 O
atmosphere O
metal O
corrosion O
inhibitors O
, O
some O
14 O
per O
cent O
were O
found O
extremely O
hazardous O
, O
42 O
per O
cent--of O
high O
level O
hazardous O
, O
33 O
percent--of O
moderate O
and O
11 O
per O
cent--of O
low O
hazardous O
. O

Paralemmin B-GENE
is O
also O
phosphorylated O
, O
and O
its O
mRNA O
is O
differentially O
spliced O
in O
a O
tissue-specific O
and O
developmentally O
regulated O
manner O
. O

Azygos O
vein O
abutting O
the O
posterior O
wall O
of O
the O
right O
main O
and O
upper O
lobe O
bronchi O
: O
a O
normal O
CT O
variant O
. O

We O
also O
report O
that O
AHR B-GENE
interacts O
with O
COUP-TF B-GENE
in O
transfected O
CV-1 O
cells O
. O

Acute O
pancreatitis O
as O
a O
complication O
of O
polyarteritis O
nodosa O
. O

Cluster O
formation O
of O
E-cadherin B-GENE
on O
the O
cell O
surface O
is O
believed O
to O
be O
of O
major O
importance O
for O
cell-cell O
adhesion O
. O

DPA O
attenuated O
the O
increase O
of O
the O
intensity O
of O
the O
ischemic O
and O
pressure O
pain O
components O
with O
increasing O
ischemia O
duration O
, O
but O
only O
the O
effect O
on O
the O
pressure O
pain O
component O
was O
significant O
. O

Following O
seven O
days' O
incubation O
both O
at O
20 O
degrees O
C O
and O
28 O
degrees O
C O
, O
Ae O
. O
vexans O
nip O
. O
was O
capable O
of O
transmitting O
the O
virus O
. O

Interplane O
coupling O
in O
the O
superconductor O
Y2Ba4Cu7O15 O
as O
revealed O
by O
NQR O
spin-echo O
double O
resonance O
. O

The O
evidence O
in O
support O
of O
this O
was O
derived O
from O
the O
fact O
that O
the O
affinity O
or O
interaction O
between O
the O
two O
subunits O
was O
impaired O
as O
indicated O
by O
the O
first O
order O
rate O
constant O
of O
hCG B-GENE
alpha I-GENE
1 I-GENE
beta I-GENE
( O
km O
= O
4 O
. O
1 O
x O
10 O
( O
-2 O
) O
min-1 O
) O
at O
pH O
3 O
. O
0 O
at O
23 O
degrees O
C O
which O
is O
one O
order O
of O
magnitude O
greater O
relative O
to O
rehCG B-GENE
( O
kw O
= O
4 O
. O
6 O
x O
10 O
( O
-3 O
) O
min-1 O
) O
. O

Correlation O
coefficients O
between O
the O
reference O
methods O
and O
NIT O
were O
> O
or O
= O
0 O
. O
95 O
for O
water O
, O
fat O
, O
crude O
protein O
and O
connective-tissue-protein O
frei O
meat O
protein O
, O
and O
> O
or O
= O
0 O
. O
86 O
for O
connective-tissue-protein O
. O

Further O
analysis O
of O
AP-1 B-GENE
DNA O
binding O
activities O
in O
7- O
to O
14-day O
culture O
activated O
HSCs O
led O
to O
the O
discovery O
of O
high B-GENE
mobility I-GENE
AP-1 I-GENE
complexes I-GENE
( O
HMAP-1 B-GENE
) O
. O

Sci O
. O

A O
miracle O
cure O
and O
its O
solution O
. O

The O
human B-GENE
SHBG I-GENE
proximal I-GENE
promoter I-GENE
was O
analyzed O
by O
DNase B-GENE
I I-GENE
footprinting O
, O
and O
the O
functional O
significance O
of O
6 O
footprinted O
regions O
( O
FP1-FP6 O
) O
within O
the O
proximal O
promoter O
was O
studied O
in O
human O
HepG2 O
hepatoblastoma O
cells O
. O

Two O
activities O
of O
the O
D B-GENE
protein I-GENE
of O
the O
miniF O
plasmid O
have O
been O
found O
. O

No O
patient O
in O
group O
2 O
developed O
HAT O
( O
P O
= O
0 O
. O
006 O
versus O
group O
1 O
) O
. O

After O
nitric O
oxide O
inhalation O
, O
the O
results O
showed O
moderate O
increases O
in O
PaO2 O
and O
SaO2 O
( O
P O
> O
0 O
. O
05 O
) O
and O
a O
significant O
decrease O
in O
Qs O
Q O
tau O
ratio O
( O
P O
< O
0 O
. O
01 O
) O
. O

The O
mass O
of O
UO2 O
in O
the O
extrapulmonary O
bronchi O
and O
first O
bifurcation O
decreased O
more O
slowly O
over O
0--8 O
d O
after O
inhalation O
than O
the O
corresponding O
mass O
on O
the O
trachea O
. O

This O
region O
is O
required O
for O
activation O
of O
DNA O
binding O
of O
MyoD B-GENE
and O
E12 B-GENE
homodimers I-GENE
and O
E12 B-GENE
MyoD I-GENE
heterodimers I-GENE
. I-GENE

In O
this O
paper O
, O
we O
report O
a O
detailed O
study O
of O
the O
structure O
and O
the O
functional O
role O
of O
the O
MalT B-GENE
binding I-GENE
sites I-GENE
located O
in O
the O
adjacent O
and O
divergent O
pulAp B-GENE
and O
pulCp B-GENE
promoters I-GENE
. O

Thus O
, O
the O
presence O
of O
the O
Cln2 B-GENE
PEST I-GENE
domain I-GENE
was O
sufficient O
to O
destabilize O
a O
heterologous O
protein O
. O

Interestingly O
, O
EGF B-GENE
, O
but O
not O
insulin B-GENE
, O
stimulated O
tyrosine O
phosphorylation O
of O
c-cbl B-GENE
and O
its O
association O
with O
Crk-II B-GENE
. O

Interferon-alpha B-GENE
may O
exacerbate O
cryoblobulinemia-related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti-angiogenic O
activity O
. O

Two O
such O
genes O
, O
designated O
hsiggll150 B-GENE
and O
hsiggll295 B-GENE
, O
were O
cloned O
and O
sequenced O
from O
genomic O
DNA O
. O

Cyclin B-GENE
D1 I-GENE
could O
not O
be O
displaced O
from O
cdk4 B-GENE
in O
the O
resistant O
184A1L5R O
cell O
lysates O
. O

These O
characteristics O
indicated O
the O
pronounced O
activity O
of O
collagenous O
fiber O
synthesis O
and O
the O
matrix O
of O
the O
osteoid O
tissue O
. O

RESULTS O
: O
Patients O
in O
Group O
A O
had O
a O
higher O
incidence O
of O
posterolateral O
wall O
motion O
abnormalities O
( O
p O
< O
0 O
. O
001 O
) O
on O
radionuclide O
ventriculography O
, O
a O
larger O
infarct O
area O
( O
as O
evidenced O
by O
higher O
peak O
creatine B-GENE
kinase I-GENE
levels O
) O
( O
p O
< O
0 O
. O
02 O
) O
and O
a O
lower O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
at O
hospital O
discharge O
( O
p O
< O
0 O
. O
008 O
) O
than O
those O
in O
Group O
B O
. O

The O
incompatibility O
group O
W O
plasmid O
pSa O
suppresses O
Agrobacterium O
tumefaciens O
oncogenicity O
( O
J O
. O

In O
this O
report O
, O
we O
identify O
and O
characterize O
two O
overlapping O
ELL B-GENE
functional I-GENE
domains I-GENE
that O
govern O
its O
interaction O
with O
RNA B-GENE
polymerase I-GENE
II I-GENE
and O
the O
ternary O
elongation O
complex O
. O

The O
Spo0F B-GENE
residues I-GENE
making O
up O
the O
hydrophobic O
patch O
are O
very O
similar O
in O
all O
response O
regulators O
suggesting O
that O
the O
binding O
is O
initiated O
through O
the O
same O
residues O
in O
all O
interacting O
response O
regulator-kinase O
pairs O
. O

We O
performed O
dipole O
estimation O
of O
spikes O
and O
SEP O
components O
in O
identical O
patients O
. O

The O
so-called O
"SH3" B-GENE
segment I-GENE
of O
the O
linker O
domain O
, O
in O
contrast O
, O
shows O
species-specific O
sequence O
identity O
in O
all O
but O
one O
amino O
acid O
residues O
in O
both O
factors O
, O
in O
cattle O
, O
human O
, O
and O
mouse O
. O

Early O
indicators O
of O
the O
effect O
of O
a O
breast O
cancer O
screening O
program O
for O
low-income O
women O
. O

There O
was O
no O
significant O
difference O
in O
developmental O
scores O
at O
9 O
or O
18 O
months O
, O
although O
PDF O
infants O
had O
a O
2 O
. O
8 O
( O
-1 O
. O
3-6 O
. O
8 O
) O
point O
advantage O
in O
Bayley O
motor O
score O
scales O
. O

Analysis O
of O
its O
genomic O
region O
revealed O
that O
the O
13-kb O
Cdc6 B-GENE
gene I-GENE
is O
divided O
into O
12 O
exons O
by O
11 O
introns O
. O

These O
incisors O
were O
studied O
by O
scanning O
electron O
microscopy-energy O
dispersive O
spectroscopy O
analysis O
( O
SEM-EDS O
) O
and O
light O
microscopy O
to O
examine O
the O
calciotraumatic O
lines O
of O
strontium O
in O
the O
rat B-GENE
incisor I-GENE
labial I-GENE
dentin I-GENE
. O

Private O
hospital O
accreditation O
. O

One O
of O
these O
is O
located O
in O
the O
5'-untranslated O
region O
, O
and O
may O
encode O
regulatory O
sequences O
. O

Glomerular O
mesangial O
cells O
expressed O
an O
abundant O
1 O
. O
1 O
kb O
mRNA O
transcript O
for O
Id1 B-GENE
, O
but O
in O
contrast O
to O
other O
cell O
types O
Id1 B-GENE
mRNA I-GENE
was O
expressed O
in O
both O
randomly O
cycling O
cells O
and O
in O
serum-deprived O
, O
quiescent O
cultures O
. O

CNS O
effects O
of O
local O
anesthetics O
only O
partially O
dependent O
on O
biogenic O
amine O
mechanisms O
. O

By O
Felix O
Lagrange O
, O
1918 O
. O

Transcriptional O
activity O
was O
measured O
by O
slot-blot O
hybridization O
with O
steady-state O
RNA O
isolated O
from O
lacZ+ B-GENE
M I-GENE
. I-GENE
smegmatis I-GENE
clones O
. O

CONCLUSION O
: O
The O
MTD O
for O
CPT-11 O
administered O
in O
a O
3 O
consecutive-days-every-3 O
weeks O
schedule O
in O
this O
patient O
population O
is O
115 O
mg O
m2 O
day O
. O

4 O
. O

ICP4 B-GENE
has O
been O
shown O
to O
form O
tripartite O
complexes O
cooperatively O
with O
the O
TATA B-GENE
box-binding I-GENE
protein I-GENE
and O
TFIIB B-GENE
on O
DNA O
containing O
an O
ICP4 B-GENE
binding I-GENE
site I-GENE
and O
a O
TATA O
box O
( O
C O
. O

However O
, O
a O
specific O
ICE B-GENE
caspase-1 I-GENE
inhibitor I-GENE
called O
N1445 O
completely O
abolished O
the O
CK-induced O
apoptosis O
by O
reactivating O
PKB O
, B-GENE
but O
without O
affecting O
the O
CK-induced O
suppression O
of O
Ras O
transformation B-GENE
. O

OBJECTIVE O
: O
Our O
purpose O
was O
to O
determine O
the O
simultaneous O
concentrations O
of O
serum O
cotinine O
in O
both O
fetal O
and O
maternal O
blood O
. O

Records O
of O
31 O
children O
with O
AIDS O
or O
AIDS-related O
complex O
admitted O
to O
the O
pediatric O
intensive O
care O
unit O
for O
acute O
respiratory O
failure O
throughout O
a O
46-month O
period O
were O
reviewed O
. O

The O
artery O
cuff O
was O
slightly O
superior O
to O
the O
fat O
wrap O
, O
particularly O
in O
having O
fewer O
adhesions O
and O
a O
better O
histological O
picture O
. O

Liquid O
chromatographic O
separation O
was O
achieved O
on O
a O
Zorbax O
RX O
C8 O
analytical O
column O
using O
gradient O
elution O
. O

Estrogen O
treatment O
in O
high O
doses O
is O
effective O
in O
reducing O
adult O
stature O
in O
constitutionally O
tall O
girls O
. O

A O
cDNA O
clone O
corresponding O
to O
the O
putative O
GA B-GENE
20-oxidase I-GENE
genomic I-GENE
sequence I-GENE
was O
constructed O
with O
the O
reverse O
transcription-PCR O
method O
, O
and O
the O
identity O
of O
the O
cDNA O
clone O
was O
confirmed O
by O
analyzing O
the O
capability O
of O
the O
fusion O
protein O
expressed O
in O
Escherichia O
coli O
to O
convert O
GA53 B-GENE
to O
GA44 B-GENE
and O
GA19 B-GENE
to O
GA20 B-GENE
. O

The O
incidence O
of O
DNCB O
reactions O
was O
78 O
per O
cent O
for O
Stage O
I O
and O
II O
cancers O
( O
37 O
patinets O
) O
, O
73 O
per O
cent O
for O
resectable O
Stage O
III O
cancer O
( O
22 O
patients O
) O
, O
and O
66 O
per O
cent O
in O
patients O
with O
unresectable O
or O
inoperable O
Stage O
III O
cancer O
. O

An O
analysis O
of O
the O
dynamics O
is O
performed O
of O
exactly O
solvable O
models O
for O
fragile O
and O
strong O
glasses O
, O
exploiting O
the O
partitioning O
of O
the O
free-energy O
landscape O
in O
inherent O
structures O
. O

Moreover O
, O
elderly O
men O
with O
bioavailable O
estradiol O
levels O
below O
the O
median O
[ O
40 O
pmol O
liter O
( O
11 O
pg O
ml O
) O
] O
had O
significantly O
higher O
rates O
of O
bone O
loss O
and O
levels O
of O
bone O
resorption O
markers O
than O
men O
with O
bioavailable O
estradiol O
levels O
above O
40 O
pmol O
liter O
. O

We O
also O
report O
here O
the O
complete O
structural O
organization O
of O
the O
goat B-GENE
alpha I-GENE
s1-casein I-GENE
transcription I-GENE
unit I-GENE
, O
deduced O
from O
polymerase O
chain O
reaction O
experiments O
. O

Replacing O
residues O
405-419 O
on O
delta419 O
with O
the O
conserved O
AF-2 B-GENE
domain I-GENE
from O
the O
vitamin B-GENE
D3 I-GENE
receptor I-GENE
or O
the O
estrogen B-GENE
receptor I-GENE
results O
in O
a O
receptor O
with O
wild-type O
or O
low O
transcriptional O
activity O
, O
respectively O
. O

Psychological O
disturbance O
was O
greater O
in O
the O
high O
life O
stress O
group O
as O
indicated O
by O
significant O
elevations O
on O
the O
global O
severity O
index O
of O
the O
Symptom O
Checklist-90 O
and O
elevations O
on O
somatization O
, O
obsessive O
compulsive O
, O
interpersonal O
sensitivity O
, O
depression O
, O
anxiety O
and O
psychoticism O
subscales O
. O

Since O
electrical O
stimulation O
of O
neurones O
may O
activate O
not O
only O
cell O
bodies O
but O
also O
neuronal O
fibres O
, O
this O
study O
aimed O
to O
test O
a O
selectively O
cholinergic O
neurochemical O
stimulation O
of O
the O
rat O
substantia O
innominata O
( O
SI O
) O
by O
the O
local O
microinjection O
of O
carbachol O
; O
the O
effects O
of O
this O
acetylcholine O
agonist O
were O
compared O
with O
glutamate O
. O

Eucaryotic O
transcription O
factors O
that O
stimulate O
RNA B-GENE
polymerase I-GENE
II I-GENE
by O
increasing O
the O
efficiency O
of O
elongation O
of O
specifically O
or O
randomly O
initiated O
RNA O
chains O
have O
been O
isolated O
and O
characterized O
. O

The O
mRNAs O
of O
these O
genes O
contain O
respectively O
one O
( O
YAP1 B-GENE
uORF I-GENE
) O
and O
two O
( O
YAP2 B-GENE
uORF1 I-GENE
and O
uORF2 B-GENE
) O
upstream O
open O
reading O
frames O
. O
uORF-mediated O
modulation O
of O
post-termination O
events O
on O
the O
5'-untranslated O
region O
( O
5'-UTR O
) O
directs O
differential O
control O
not O
only O
of O
translation O
but O
also O
of O
mRNA O
decay O
. O

We O
used O
a O
rev- O
and O
RRE-defective O
HIV O
type O
1 O
( O
HIV-1 O
) O
molecular O
clone O
in O
complementation O
experiments O
to O
establish O
a O
method O
for O
the O
rapid O
isolation O
of O
posttranscriptional O
regulatory O
elements O
from O
the O
mammalian O
genome O
by O
selecting O
for O
rescue O
of O
virus O
replication O
. O

Evolutionary O
conservation O
of O
homeodomain-binding B-GENE
sites I-GENE
and O
other O
sequences O
upstream O
and O
within O
the O
major O
transcription O
unit O
of O
the O
Drosophila B-GENE
segmentation I-GENE
gene I-GENE
engrailed I-GENE
. O

Furthermore O
, O
the O
NH2-terminal O
portion O
of O
the O
homologue O
was O
not O
translocated O
into O
the O
outer O
membrane O
without O
its O
COOH-terminal O
part O
. O

The O
5' O
flanking O
regions O
of O
both O
pelA B-GENE
and O
pelB B-GENE
were O
translationally O
fused O
to O
the O
beta-glucuronidase B-GENE
gene I-GENE
and O
introduced O
into O
F O
. O
solani O
f O
. O
sp O
. O
pisi O
, O
and O
beta-glucuronidase B-GENE
activities O
of O
the O
transformants O
were O
measured O
. O

The O
results O
suggest O
that O
GATA-5 B-GENE
may O
have O
specific O
downstream O
targets O
and O
that O
GATA-4 B-GENE
, I-GENE
-5 I-GENE
, I-GENE
and I-GENE
-6 I-GENE
can O
only O
partially O
substitute O
for O
each O
other O
in O
cardiogenesis O
. O

A O
human O
recombinant O
cDNA O
clone O
that O
encoded O
253 O
amino O
acids O
residues O
of O
a O
zinc-finger B-GENE
protein I-GENE
( O
THZif-1 B-GENE
) O
was O
cloned O
by O
screening O
a O
cDNA O
library O
prepared O
from O
human O
promyelocytic O
leukemia O
HL60 O
cells O
with O
synthetic O
oligodeoxynucleotide O
probes O
that O
corresponded O
to O
the O
amino O
acid O
sequences O
of O
tryptic O
peptides O
derived O
from O
the O
DNA-binding O
protein O
specific O
for O
the O
nuclease-hypersensitive B-GENE
element I-GENE
( O
NHE B-GENE
) O
of O
the O
human B-GENE
c-myc I-GENE
gene I-GENE
. O

Human B-GENE
papillomavirus I-GENE
type I-GENE
31b I-GENE
late I-GENE
gene I-GENE
expression O
is O
regulated O
through O
protein B-GENE
kinase I-GENE
C-mediated O
changes O
in O
RNA O
processing O
. O

Amino O
acid O
residues O
of O
beta O
1' O
, O
alpha O
A' O
, O
alpha O
B' O
, O
and O
the O
loop O
containing O
His539 O
of O
the O
RNase B-GENE
H I-GENE
domain I-GENE
interact O
with O
the O
primer O
strand O
of O
the O
dsDNA O
. O

Regulated O
activity O
of O
the O
distal O
promoter-like O
element O
of O
the O
human B-GENE
corticotropin-releasing I-GENE
hormone I-GENE
gene I-GENE
and O
secondary O
structural O
features O
of O
its O
corresponding O
transcripts O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
regulation O
of O
the O
synthesis O
of O
the O
c-mos B-GENE
oncogene I-GENE
product I-GENE
, O
which O
is O
necessary O
for O
the O
activation O
of O
Cdc2 B-GENE
. O

The O
60A B-GENE
transcripts I-GENE
and O
protein O
are O
first O
detected O
at O
the O
onset O
of O
gastrulation O
, O
primarily O
in O
the O
mesoderm O
of O
the O
extending O
germ O
band O
. O

An O
11-month-old O
girl O
suffering O
from O
Dandy-Walker O
malformation O
( O
DWM O
) O
associated O
with O
tetralogy O
of O
Fallot O
( O
TOF O
) O
is O
presented O
. O

Determination O
of O
transaminases B-GENE
with O
an O
autoanalyzer O
. O

The O
proteins O
encoded O
downstream O
of O
rpoN B-GENE
are O
known O
to O
negatively O
regulate O
sigma B-GENE
54 I-GENE
activity O
. O

Sings O
which O
are O
indicative O
of O
metaplastic O
erythropoiesis O
are O
absent O
. O

The O
genomic O
and O
transcriptional O
complexity O
of O
the O
Crry B-GENE
and O
Crry-ps B-GENE
genes I-GENE
. O

The O
apparatus O
consists O
of O
an O
Am-241 O
exciting O
source O
( O
300 O
mCi O
) O
and O
pure O
Ge O
detector O
( O
50 O
mm2 O
X O
5 O
mm O
) O
for O
measuring O
K O
alpha O
fluorescent O
x-rays O
( O
28 O
. O
3 O
and O
28 O
. O
6 O
KeV O
) O
emitted O
from O
exited O
iodine O
. O

The O
potentially O
SLE-inducing O
drugs O
are O
reviewed O
. O

In O
this O
study O
, O
we O
sought O
to O
identify O
mechanisms O
that O
could O
account O
for O
the O
antimitogenic O
effects O
of O
IL-4 B-GENE
. O

12 O
: O
2684-2697 O
, O
1998 O
) O
: O
a O
key O
step O
of O
this O
model O
is O
the O
activation O
of O
the O
MAPK B-GENE
Fus3p I-GENE
through O
the O
G O
( O
betagamma O
) O
-dependent O
relocalization O
of O
the O
Ste5p-MAPK B-GENE
cascade I-GENE
to O
the O
plasma O
membrane O
. O

Subsequent O
cloning O
and O
nucleotide O
sequence O
analysis O
of O
the O
S B-GENE
. I-GENE
pombe I-GENE
adenylate I-GENE
kinase I-GENE
gene I-GENE
, O
adk1 B-GENE
, O
revealed O
a O
coding O
region O
of O
660 O
nucleotides O
. O

Three O
subgenomes O
also O
comprised O
15 O
to O
75 O
nucleotides O
derived O
from O
the O
5' O
part O
of O
the O
NS2 B-GENE
gene I-GENE
. O

The O
present O
investigation O
sought O
to O
identify O
the O
principal O
dimensions O
of O
the O
Framingham O
Type O
A O
scale O
( O
FTAS O
) O
and O
then O
to O
examine O
their O
physiological O
and O
psychological O
correlates O
. O

SCL O
prolonged O
promptly O
after O
verapamil O
, O
and O
sinus O
arrest O
developed O
in O
two O
of O
10 O
group O
2 O
and O
two O
of O
five O
group O
3 O
animals O
. O

The O
CRE B-GENE
, O
5'-TGACGTCA-3' B-GENE
, O
has O
been O
described O
as O
the O
consensus O
sequence O
for O
the O
cis-element O
that O
directs O
cAMP-regulated O
gene O
expression O
. O

Enhanced O
hepatic O
portal O
blood O
flow O
induced O
by O
prostaglandin O
E1 O
following O
liver O
transplantation O
in O
pigs O
. O

The O
promoter O
of O
the O
rat B-GENE
PGS-2 I-GENE
gene I-GENE
contains O
a O
CAAT B-GENE
enhancer-binding I-GENE
protein I-GENE
consensus I-GENE
site I-GENE
( I-GENE
CAAT I-GENE
box I-GENE
) I-GENE
which O
can O
confer O
hormone O
inducibility O
to O
a O
PGS-2 B-GENE
. I-GENE
CAT I-GENE
reporter I-GENE
gene I-GENE
, O
as O
well O
as O
a O
putative O
E-box O
region O
. O

A O
3-week O
regimen O
of O
erythropoietin B-GENE
may O
help O
prevent O
the O
donor's O
need O
to O
receive O
allogeneic O
blood O
transfusion O
, O
when O
the O
initial O
Hb B-GENE
levels O
were O
below O
130 O
milligrams O
. O

Nutritional O
cataracts O
in O
timber O
wolves O
. O

Nine O
strains O
were O
subtyped O
as O
Camp O
. O
jejuni O
subsp O
. O
jejuni O
biotype O
II O
and O
the O
remaining O
ones O
as O
biotype O
I O
. O

Molecular O
and O
functional O
characterization O
of O
the O
promoter O
of O
ETS2 B-GENE
, O
the O
human O
c-ets-2 B-GENE
gene O
. O

Calcification O
of O
a O
cariogenic O
Streptococcus O
and O
of O
Corynebacterium O
( O
Bacterionema O
) O
matruchotii O
. O

E O
. O
, O
Scott O
, O
J O
. O

These O
results O
suggest O
that O
HAC1 B-GENE
may O
also O
be O
one O
of O
the O
meiotic O
genes O
. O

Examination O
of O
the O
MMP-2 B-GENE
RE1 I-GENE
sequence I-GENE
revealed O
an O
incomplete O
Y-box B-GENE
sequence I-GENE
( O
CTGCTGGGCAAG B-GENE
) O
, O
which O
specifically O
interacted O
with O
recombinant B-GENE
YB-1 I-GENE
on O
DMS O
protection O
footprinting O
analysis O
. O

In O
some O
of O
the O
cases O
of O
solitary O
lesion O
, O
serum B-GENE
TSH I-GENE
levels O
, O
serum B-GENE
thyroglobulin I-GENE
values O
, O
and O
131I O
protein O
bounded O
iodine O
( O
131I-PBI O
) O
were O
measured O
, O
but O
there O
were O
no O
significant O
differences O
between O
successful O
and O
unsuccessful O
therapy O
. O

RESULTS O
: O
Each O
year O
, O
on O
average O
39% O
of O
cases O
seen O
in O
Sardinia O
are O
notified O
; O
646 O
( O
40% O
) O
of O
the O
1591 O
patients O
notified O
during O
the O
study O
period O
were O
never O
seen O
by O
regional O
medical O
centres O
. O

Northern O
blot O
and O
in O
situ O
hybridization O
analyses O
revealed O
GPR34 B-GENE
mRNA I-GENE
transcripts I-GENE
in O
several O
human O
and O
rat O
brain O
regions O
. O

A O
high O
reactor O
pH O
( O
+ O
-8 O
) O
, O
a O
short O
solid O
retention O
time O
( O
< O
150 O
days O
) O
, O
and O
the O
presence O
of O
a O
substantial O
SRB O
population O
in O
the O
inoculum O
may O
considerably O
reduce O
the O
time O
required O
for O
acetate-utilising O
SRB O
to O
outcompete O
MB O
. O

The O
study O
included O
139 O
eyes O
with O
presumed O
ocular O
histoplasmosis O
syndrome O
( O
POHS O
) O
and O
age-related O
macular O
degeneration O
( O
AMD O
) O
. O

Five O
of O
the O
patients O
with O
increased O
L-L O
size O
had O
a O
normal O
A-P O
diameter O
. O

Antibodies O
directed O
against O
the O
SNM1 B-GENE
protein I-GENE
immunoprecipitated O
RNase B-GENE
MRP I-GENE
RNA I-GENE
from O
whole-cell O
extracts O
without O
precipitating O
the O
structurally O
and O
functionally O
related O
RNase B-GENE
P I-GENE
RNA I-GENE
. O

METHOD O
: O
50 O
consecutive O
children O
aged O
from O
6 O
months O
to O
17 O
years O
were O
included O
into O
the O
study O
which O
comprised O
questionnaires O
of O
patient O
and O
family O
histories O
, O
serological O
screening O
tests O
for O
common O
inhalational O
allergens O
( O
CAP O
SX1 O
) O
, O
and O
determination O
of O
total O
serum B-GENE
immunoglobulin I-GENE
E I-GENE
( O
IgE B-GENE
) O
and O
of O
latex-specific O
serum B-GENE
IgE I-GENE
by O
solid-phase O
immunoassays O
. O

We O
have O
cloned O
and O
sequenced O
COX12 B-GENE
, O
the O
nuclear O
gene O
for O
subunit B-GENE
VIb I-GENE
of O
Saccharomyces B-GENE
cerevisiae I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
. O

Steroidogenic B-GENE
factor I-GENE
1 I-GENE
, O
an O
orphan B-GENE
nuclear I-GENE
receptor I-GENE
, O
regulates O
the O
expression O
of O
the O
rat B-GENE
aromatase I-GENE
gene I-GENE
in O
gonadal O
tissues O
. O

The O
efficacy O
of O
these O
immunosuppressive O
drugs O
is O
clinical O
proven O
. O

Neonatal O
lupus O
erythematosus O
is O
most O
often O
associated O
with O
autoantibodies O
against O
Ro B-GENE
and O
La B-GENE
antigens O
. O

The O
etiology O
, O
pathology O
, O
brain O
CT O
scan O
features O
, O
clinical O
manifestations O
and O
treatment O
of O
these O
accidents O
were O
discussed O
. O

Among O
booked O
patients O
the O
maternal O
mortality O
rate O
was O
0 O
. O
32 O
and O
among O
unbooked O
patients O
11 O
. O
13 O
per O
1000 O
deliveries O
. O

The O
peroxisome O
biogenesis O
disorders O
( O
PBDs O
) O
are O
a O
set O
of O
lethal O
genetic O
diseases O
characterized O
by O
peroxisomal O
metabolic O
deficiencies O
, O
multisystem O
abnormalities O
, O
mental O
retardation O
, O
and O
premature O
death O
. O

Effect O
of O
nitrous O
oxide O
( O
N2O O
) O
on O
the O
somatosympathetic O
A- O
and O
C-reflexes O
was O
investigated O
using O
artificially O
ventilated O
rats O
anesthetized O
with O
alpha-chloralose O
and O
urethane O
. O

The O
sensitivity O
of O
the O
vas O
deferens O
to O
adrenaline O
was O
also O
reduced O
in O
scorbutic O
guinea O
pigs O
, O
thus O
decreasing O
their O
fertility O
rate O
. O

An O
amino-acid O
sequence O
comparison O
revealed O
that O
Bacillus B-GENE
YM55-1 I-GENE
aspartase I-GENE
shared O
71% O
homology O
with O
Bacillus B-GENE
subtilis I-GENE
aspartase I-GENE
and O
49% O
with O
Escherichia O
coli O
and O
Pseudomonas B-GENE
fluorescens I-GENE
aspartases I-GENE
. O

In O
contrast O
, O
the O
full O
mu-opioid O
agonists O
fentanyl O
, O
morphine O
, O
I-methadone O
and O
levorphanol O
produced O
50% O
fentanyl-appropriate O
responding O
at O
doses O
only O
1 O
. O
3 O
to O
10 O
. O
9 O
times O
smaller O
than O
those O
required O
to O
decrease O
response O
rates O
by O
50% O
. O

This O
activity O
is O
stimulated O
by O
complex O
formation O
with O
the O
other O
eIF2B B-GENE
subunits I-GENE
. O

A O
portion O
of O
p193 B-GENE
is O
nuclear O
and O
localizes O
to O
the O
mitotic O
spindle O
. O

Evolutive O
morphology O
of O
the O
olfactory O
bulb O
in O
man O
and O
certain O
non-human O
mammals O
. O

The O
core O
promoter O
of O
human B-GENE
thioredoxin I-GENE
reductase I-GENE
1 I-GENE
. I-GENE
cloning O
, O
transcriptional O
activity O
, O
and O
oct-1 B-GENE
, O
sp1 B-GENE
, O
and O
sp3 B-GENE
binding O
reveal O
a O
housekeeping-type O
promoter O
for O
the O
au-rich O
element-regulated O
gene O
. O

The O
five-drug O
combination O
of O
fluorouracil O
imidazole O
carboxamide O
dimethyl O
triazeno O
, O
vincristine O
, O
bis-chloroethyl O
nitrosourea O
, O
and O
prednisone O
( O
FIVB O
+ O
P O
) O
was O
given O
to O
120 O
women O
with O
metastatic O
breast O
cancer O
. O

Recombinant B-GENE
prenylcysteine I-GENE
lyase I-GENE
was O
produced O
in O
a O
baculovirus-Sf9 O
expression O
system O
. O

Here O
, O
we O
correlate O
Dox O
effects O
on O
cell O
cycle O
with O
changes O
of O
E2F B-GENE
DP I-GENE
complexes I-GENE
and I-GENE
activity O
in O
differentiating O
C2C12 O
myocytes B-GENE
. O

We O
have O
determined O
the O
structure O
of O
the O
WNT-2B B-GENE
gene I-GENE
. O

Positive O
genetic O
selections O
for O
inhibition O
of O
cyclin B-GENE
CDK I-GENE
function I-GENE
were O
characterized O
using O
the O
E O
. B-GENE
coli I-GENE
neo I-GENE
and I-GENE
yeast O
LEU2 B-GENE
genes I-GENE
. I-GENE

Finger B-GENE
associated I-GENE
box-zinc I-GENE
finger I-GENE
proteins I-GENE
( O
FAX-ZFPs B-GENE
) O
constitute O
a O
subfamily O
of O
the O
many O
C2H2 B-GENE
type I-GENE
ZFPs I-GENE
in O
Xenopus O
laevis O
. O

Neither O
class O
II O
nor O
IV O
infections O
precluded O
transplantation O
. O

This O
report O
has O
reviewed O
some O
of O
the O
reasons O
for O
treatment O
failures O
and O
has O
presented O
a O
philosophy O
for O
their O
management O
. O

Ceftazidime O
shows O
promise O
as O
single-agent O
therapy O
for O
serious O
gram-negative O
bacillary O
infections O
. O

Anti-anxiety O
action O
of O
diazepam O
after O
intra-amygdaloid O
application O
in O
the O
rat O
. O

The O
Ogg1 B-GENE
protein I-GENE
efficiently O
cleaves O
a O
DNA O
duplex O
where O
a O
preformed O
AP B-GENE
site I-GENE
is O
placed O
opposite O
a O
cytosine O
( O
AP O
C O
) O
. O

We O
report O
here O
that O
a O
25-bp O
promoter O
element O
previously O
shown O
to O
be O
important O
for O
the O
G1-S O
activation O
of O
the O
human B-GENE
thymidine I-GENE
kinase I-GENE
( O
htk B-GENE
) O
promoter O
in O
growth-stimulated O
cells O
is O
a O
cellular O
target O
of O
cyclin B-GENE
A I-GENE
and O
the O
p33cdk2 B-GENE
complexes I-GENE
. O

Molecular O
structure O
and O
evolutionary O
origin O
of O
human B-GENE
cardiac I-GENE
muscle I-GENE
actin I-GENE
gene I-GENE
. O

Serine O
phosphorylation O
of O
STAT3 B-GENE
was O
only O
apparent O
after O
somatostatin B-GENE
treatment O
and O
was O
abolished O
by O
pertussis B-GENE
toxin I-GENE
or O
PD O
98059 O
, O
together O
with O
the O
associated O
increases O
in O
proliferation O
. O

The O
genome O
of O
avian O
erythroblastosis O
virus O
contains O
two O
independently O
expressed O
genetic O
loci O
( O
v-erbA B-GENE
and O
v-erbB B-GENE
) O
whose O
activities O
are O
probably O
responsible O
for O
oncogenesis O
by O
the O
virus O
. O

This O
phenomenon O
did O
not O
require O
DNA O
binding O
by O
the O
"interfering" O
receptor O
but O
required O
it O
to O
be O
hormone-bound O
, O
indicating O
that O
a O
transcriptionally O
active O
form O
of O
the O
interfering O
receptor O
is O
essential O
for O
the O
interfering O
effect O
. O

Here O
we O
report O
that O
in O
cultured O
cells O
from O
Drosophila O
melanogaster O
human B-GENE
Sp1 I-GENE
efficiently O
activates O
transcription O
from O
synthetic O
promoters O
containing O
TATA O
boxes O
, O
but O
not O
from O
promoters O
that O
contain O
an O
initiator O
instead O
of O
a O
TATA O
box O
. O

We O
recommend O
that O
paracervical O
block O
with O
lignocaine O
should O
be O
used O
in O
conjunction O
with O
i O
. O
v O
. O
sedation O
analgesia O
during O
egg O
collection O
performed O
through O
the O
transvaginal O
route O
under O
ultrasound O
guidance O
( O
TUGOR O
) O
to O
reduce O
the O
pain O
of O
the O
procedure O
. O

Thyroid O
disease O
and O
pregnancy O
. O

To O
study O
retinoid O
signalling O
in O
zebrafish O
embryos O
, O
we O
developed O
a O
novel O
method O
to O
detect O
endogenous O
retinoids O
in O
situ O
in O
embryos O
, O
using O
a O
fusion O
protein O
of O
the O
ligand O
inducible O
transactivation O
domain O
of O
a O
retinoic B-GENE
acid I-GENE
receptor I-GENE
and O
a O
heterologous O
DNA O
binding O
domain O
. O

Northern O
blot O
analysis O
revealed O
that O
mlt B-GENE
1 I-GENE
is O
normally O
expressed O
in O
brain O
, O
spleen O
, O
stom O
ach O
, O
and O
liver O
. O

The O
results O
indicated O
that O
two O
genes O
( O
citA B-GENE
and O
citB B-GENE
) O
have O
separate O
promoters O
, O
and O
the O
location O
of O
the O
promoter O
for O
the O
citB B-GENE
gene I-GENE
in O
the O
Tn3411 B-GENE
nucleotide O
sequence O
was O
different O
from O
that O
in O
pMS185 O
. O

This O
distinction O
was O
based O
upon O
whether O
the O
diagnosis O
provided O
a O
straightforward O
range O
of O
prognoses O
or O
an O
ambiguous O
clinical O
implication O
. O

However O
, O
vancomycin O
and O
fosfomycin O
, O
which O
revealed O
suboptimal O
in O
vitro O
bactericidal O
activity O
, O
proved O
as O
efficacious O
as O
penicillin O
G O
and O
imipenem O
in O
an O
experimental O
mode O
of O
murine O
gas O
gangrene O
. O

For O
HeLa O
, O
293 O
, O
U937 O
, O
and O
A549 O
cells O
, O
participation O
of O
E2F-1 B-GENE
, O
DP-1 B-GENE
, O
cyclin B-GENE
A I-GENE
, O
and O
RB B-GENE
was O
involved O
in O
formation O
of O
some O
complexes O
only O
, O
assuming O
participation O
of O
factors O
different O
from O
E2F-1 B-GENE
or O
DP-1 B-GENE
in O
others O
. O

The O
severity O
of O
clinical O
course O
was O
expressed O
by O
means O
of O
SOFA O
score O
( O
group O
A O
0 O
. O
3-1-1 O
. O
3 O
point O
, O
group O
B O
2 O
. O
2-2 O
. O
9-2 O
. O
6 O
point O
, O
group O
C O
7 O
. O
4-8 O
. O
3-7 O
. O
7 O
point O
) O
and O
APACHE O
II O
score O
( O
group O
A O
3 O
. O
7-7 O
. O
6-8 O
. O
1 O
point O
, O
group O
B O
8 O
. O
6-11 O
. O
1-10 O
. O
5 O
point O
, O
group O
C O
16 O
. O
3-15 O
. O
2-14 O
. O
3 O
point O
) O
. O

5 O
microU O
l O
thyrotropin O
: O
75% O
( O
1974 O
) O
, O
45% O
( O
1977 O
) O
and O
20% O
( O
1980 O
) O
. O

Partial O
N-terminal O
amino O
acid O
sequence O
analysis O
showed O
that O
the O
43K B-GENE
and I-GENE
42K I-GENE
T I-GENE
antigens I-GENE
contain O
methionine O
at O
residues O
1 O
and O
5 O
, O
as O
predicted O
from O
the O
DNA O
sequence O
, O
whereas O
no O
methionine O
was O
released O
from O
the O
39K B-GENE
T I-GENE
antigen I-GENE
during O
the O
first O
six O
cycles O
of O
Edman O
degradation O
. O

A O
new O
Onchocerca O
species O
, O
a O
parasite O
of O
domestic O
cattle O
, O
in O
Senegal O
. O

Ga-67 O
and O
Tl-201 O
scintigraphy O
in O
extramedullary O
plasmacytoma O
: O
a O
case O
report O
. O

The O
addition O
of O
diatrizoate O
to O
the O
IPRK O
led O
to O
a O
dose-dependent O
biphasic O
change O
in O
RPF O
and O
GFR O
characterized O
by O
an O
initial O
transient O
increase O
followed O
by O
a O
marked O
and O
sustained O
decrease O
. O

Role O
of O
estrogen B-GENE
receptor I-GENE
ligand O
and O
estrogen B-GENE
response I-GENE
element I-GENE
sequence O
on O
interaction O
with O
chicken B-GENE
ovalbumin I-GENE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
( O
COUP-TF B-GENE
) O
. O

Chemical O
stability O
tests O
and O
site-specific O
mutagenesis O
identified O
amino O
acids O
H219 O
and O
D63 O
of O
RegS B-GENE
and O
RegR B-GENE
, O
respectively O
, O
as O
the O
phosphorylated O
residues O
. O

Prostacyclin O
formation O
, O
reflected O
by O
the O
excretion O
rate O
of O
its O
stable O
metabolite O
6-keto-prostaglandin O
F1 O
alpha O
, O
was O
measured O
by O
means O
of O
radioimmunoassay O
in O
4-hour O
urine O
specimens O
obtained O
during O
a O
smoking-free O
period O
and O
after O
participants O
had O
inhaled O
smoke O
from O
four O
high-nicotine O
cigarettes O
. O

There O
were O
gene O
clusters O
encoding O
photosynthesis O
components O
such O
as O
the O
psbB-psbH-petB-petD B-GENE
and O
the O
psbE-psbF B-GENE
clusters I-GENE
. O

Together O
, O
these O
results O
suggest O
that O
EGF B-GENE
Ras I-GENE
Raf I-GENE
induces I-GENE
transcription I-GENE
via O
combined O
activation O
of O
ATF3 O
c-Jun O
and B-GENE
a I-GENE
52-kDa I-GENE
nuclear O
factor O
, O
whereas O
JunD O
acts O
as O
a B-GENE
repressor O
of O
this O
response O
. O

Both O
Rep78 B-GENE
and O
Rep68 B-GENE
cut O
the O
terminal O
AAV O
sequence O
at O
the O
same O
site O
( O
nucleotide O
124 O
) O
. O

The O
SR B-GENE
protein I-GENE
family I-GENE
is O
involved O
in O
constitutive O
and O
regulated O
pre-mRNA O
splicing O
and O
has O
been O
found O
to O
be O
evolutionarily O
conserved O
in O
metazoan O
organisms O
. O

Here O
we O
describe O
and O
map O
two O
more O
new O
genes O
identified O
as O
allele-specific O
suppressors O
that O
compensate O
for O
carboxy-terminal O
truncation O
of O
PET122 B-GENE
. O

2 O
. O

Analysis O
of O
Msy2 B-GENE
mRNA I-GENE
expression O
in O
prepubertal O
and O
adult O
mouse O
testes O
, O
and O
in O
isolated O
populations O
of O
germ O
cells O
, O
reveals O
maximal O
expression O
in O
postmeiotic O
round O
spermatids O
, O
a O
cell O
type O
with O
abundant O
amounts O
of O
stored O
messenger O
ribonucleoproteins O
. O

Northern O
( O
RNA O
) O
analysis O
demonstrated O
expression O
of O
human O
PI B-GENE
3-kinase I-GENE
in O
all O
tissues O
and O
cell O
lines O
tested O
. O

In O
vitro O
metabolism O
of O
progesterone O
by O
the O
human O
undescended O
testis O
. O

Asthmatic O
patients O
showed O
greater O
responses O
of O
both O
parameters O
to O
adrenaline O
than O
controls O
indicating O
that O
long-term O
corticosteroid O
treatment O
enhances O
the O
acute O
responses O
of O
plasminogen B-GENE
activator I-GENE
and O
clotting B-GENE
factor I-GENE
VIII I-GENE
to O
adrenaline O
infusion O
. O

The O
heart O
rate O
, O
respiratory O
rate O
, O
arterial O
O2 O
and O
systemic O
vascular O
resistance O
were O
not O
significantly O
altered O
. O

National O
abortion O
laws O
usually O
do O
not O
allow O
abortion O
when O
a O
foetus O
is O
independently O
viable O
, O
i O
. O
e O
. O
from O
a O
gestational O
age O
of O
about O
24 O
weeks O
. O

Chernoff O
, O
submitted O
for O
publication O
) O
. O

Although O
E2FBP1 B-GENE
lacks O
the O
transactivation O
domain O
, O
it O
stimulates O
E2F B-GENE
site-dependent O
transcription O
in O
cooperation O
with O
E2F-1 B-GENE
. O

Although O
olfactory O
associative O
conditioning O
in O
newborn O
rats O
produces O
marked O
structural O
and O
functional O
changes O
in O
the O
olfactory O
bulb O
, O
recent O
evidence O
suggests O
that O
extrabulbar O
circuits O
must O
be O
involved O
in O
storing O
these O
early O
memories O
. O

The O
3' O
region O
, O
GA2 B-GENE
, O
is O
necessary O
for O
maximal O
expression O
. O

There O
was O
no O
clear O
correlation O
between O
the O
MFA O
and O
the O
severity O
of O
the O
UTS O
phenotype O
. O

A O
high O
degree O
of O
correlation O
in O
the O
sense O
of O
the O
classic O
conception O
of O
brain O
localization O
of O
neuropsychological O
syndromes O
was O
found O
. O

Encouraged O
by O
a O
Dutch O
study O
using O
etidronate O
fluoride O
in O
corticoid-induced O
osteoporosis O
, O
we O
performed O
a O
pilot O
study O
in O
33 O
men O
with O
severe O
established O
primary O
osteoporosis O
giving O
cyclically O
etidronate O
for O
14 O
days O
followed O
by O
fluoride O
plus O
calcium O
vitamin O
D O
for O
76 O
days O
. O

The O
prevalence O
of O
malnutrition O
was O
30% O
in O
the O
47 O
patients O
without O
CVD O
and O
was O
significantly O
higher O
( O
70% O
, O
P O
< O
0 O
. O
001 O
) O
in O
the O
70 O
patients O
with O
CVD O
, O
who O
also O
had O
lower O
tHcy O
, O
SAlb O
, O
plasma B-GENE
IGF-1 I-GENE
, O
serum O
creatinine O
( O
SCr O
) O
, O
and O
blood B-GENE
hemoglobin I-GENE
. O

The O
assay O
exhibits O
a O
dynamic O
range O
of O
0 O
. O
1-100 O
micrograms O
l-1 O
using O
a O
monoclonal O
antibody O
or O
alternatively O
10 O
micrograms O
l-1 O
to O
10 O
mg O
l-1 O
using O
commercially O
available O
antiserum O
. O

Mapping O
results O
suggested O
that O
the O
complementation O
group O
identified O
by O
these O
mutants O
is O
allelic O
to O
the O
ag B-GENE
alpha I-GENE
1 I-GENE
mutation O
identified O
previously O
. O

Some O
of O
the O
mutations O
obtained O
do O
not O
contain O
a O
copy O
of O
the O
Ulysses B-GENE
element I-GENE
at O
the O
mutant O
locus O
, O
suggesting O
that O
a O
different O
transposable O
element O
may O
be O
responsible O
for O
the O
mutation O
. O

3 O
. O
04+ O
-1 O
. O
2 O
, O
P O
< O
0 O
. O
0001 O
) O
, O
large O
accelerations O
30 O
min O
( O
1 O
. O
46+ O
-1 O
. O
96 O
vs O
. O

We O
describe O
a O
total O
of O
39 O
DEAH B-GENE
helicases I-GENE
in O
these O
four O
species O
. O

Quantitation O
of O
exocrine B-GENE
IgA I-GENE
in O
human O
serum O
in O
health O
and O
disease O
. O

For O
228 O
of O
425 O
deaths O
( O
54% O
) O
occurring O
among O
26 O
100 O
people O
of O
known O
age O
in O
the O
Malumfashi O
area O
of O
northern O
Nigeria O
, O
data O
were O
collected O
on O
symptoms O
present O
prior O
to O
death O
. O

The O
transcription O
of O
most O
RP B-GENE
genes I-GENE
is O
activated O
by O
two O
Rap1p B-GENE
binding I-GENE
sites I-GENE
, O
250 O
to O
400 O
bp O
upstream O
from O
the O
initiation O
of O
transcription O
. O

As O
regards O
lipid O
metabolism O
, O
the O
mean O
values O
for O
total O
triglycerides O
, O
cholesterol O
, O
LDL-cholesterol O
and O
HDL-cholesterol O
seen O
at O
the O
end O
of O
five O
years O
of O
Norplant-2 O
rod O
use O
and O
six O
months O
postremoval O
were O
similar O
to O
the O
preinsertion O
mean O
. O

We O
have O
recently O
shown O
that O
the O
tissue-specific O
expression O
of O
the O
RAR B-GENE
beta I-GENE
2 I-GENE
gene I-GENE
in I-GENE
mouse I-GENE
embryos I-GENE
is O
regulated O
at O
the O
translational O
level O
by O
short O
upstream O
open O
reading O
frames O
( O
uORFs O
) O
In O
the O
5'-untranslated O
region O
( O
Zimmer O
, O
A O
. O
, O
A O
. O
M O
. O

Frequent O
loss O
of O
heterozygosity O
( O
LOH O
) O
of O
> O
30% O
of O
the O
informative O
cases O
was O
observed O
on O
chromosomes O
3p O
( O
41 O
. O
1% O
) O
, O
5q O
( O
52 O
. O
6% O
) O
, O
6p O
( O
30 O
. O
4% O
) O
, O
8p O
( O
33 O
. O
3% O
) O
, O
9p O
( O
35 O
. O
7% O
) O
, O
9q O
( O
30 O
. O
8% O
) O
, O
11p O
( O
32 O
. O
4% O
) O
, O
13q O
( O
52 O
. O
7% O
) O
, O
17p O
( O
55 O
. O
2% O
) O
, O
17q O
( O
33 O
. O
3% O
) O
, O
18q O
( O
45 O
. O
7% O
) O
, O
and O
19q O
( O
30 O
. O
4% O
) O
. O

PowerBLAST O
analysis O
identified O
six O
clusters O
of O
expressed O
sequence O
tags O
( O
ESTs O
) O
, O
two O
known O
genes O
( O
BIR B-GENE
, O
SUR1 B-GENE
) O
mapped O
previously O
to O
this O
region O
, O
and O
a O
previously O
characterized O
but O
unmapped O
gene B-GENE
NEFA I-GENE
( O
DNA B-GENE
binding I-GENE
EF I-GENE
hand I-GENE
acidic I-GENE
amino-acid-rich I-GENE
) I-GENE
. I-GENE

A O
cDNA O
clone O
pCZ1 O
, O
with O
a O
1 O
. O
1 O
kb O
insert O
, O
was O
isolated O
from O
a O
NaCl-adapted O
tobacco O
cell O
cDNA O
library O
that O
encodes O
an O
apparently O
full-length O
29 O
kDa O
protein O
( O
251 O
amino O
acids O
) O
with O
a O
calculated O
pI O
of O
5 O
. O
7 O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
The O
two O
groups O
were O
similar O
on O
entry O
into O
the O
study O
, O
including O
mean O
FEV1 O
measurements O
( O
0 O
. O
70 O
L O
atropine O
0 O
. O
60 O
L O
metaproterenol O
, O
P O
greater O
than O
. O
05 O
) O
. O

Decreased O
levels O
of O
alpha2-antiplasmin B-GENE
were O
also O
observed O
in O
the O
mediastinum O
( O
0 O
. O
50 O
versus O
0 O
. O
61 O
U O
mL O
; O
p O
< O
0 O
. O
05 O
) O
. O

Postnatal O
volumetric O
development O
of O
the O
prefrontal O
cortex O
in O
the O
rat O
. O

There O
was O
no O
significant O
correlation O
between O
baseline O
PC40 O
methacholine O
and O
the O
maximal O
fall O
in O
Vp30 O
after O
either O
the O
first O
( O
12 O
micrograms O
) O
or O
the O
second O
dose O
( O
24 O
micrograms O
) O
of O
platelet B-GENE
activating I-GENE
factor I-GENE
. O

S1 B-GENE
nuclease I-GENE
analysis O
of O
RNA O
prepared O
after O
transfection O
of O
these O
HIV O
constructs O
into O
HeLa O
cells O
infected O
with O
wild-type O
adenovirus O
indicated O
that O
the O
enhancer O
, O
SP1 B-GENE
, O
TATA O
, O
and O
a O
portion O
of O
the O
transactivation-responsive B-GENE
element I-GENE
were O
each O
required O
for O
complete O
E1A O
E1B-mediated O
activation O
of O
the O
HIV O
LTR B-GENE
. I-GENE

Long-range O
mapping O
of O
the O
11q23 O
region O
involved O
in O
chromosome O
aberrations O
in O
human O
tumors O
by O
pulsed-field O
gel O
electrophoresis O
with O
a O
yeast O
artificial O
chromosome O
. O

An O
implant O
may O
release O
a O
drug O
either O
by O
diffusion O
concurrent O
with O
dissolution O
of O
the O
polymeric O
implant O
material O
without O
depolymerization O
( O
Type O
A O
) O
or O
by O
bioerosion O
involving O
depolymerization O
( O
Type O
B O
) O
. O

Plasma B-GENE
secretin I-GENE
, O
pancreozymin B-GENE
, O
and O
somatostatin-like B-GENE
hormone I-GENE
in O
chronic O
renal O
failure O
patients O
. O

Insertion O
of O
4 O
bp O
reduced O
SV40 O
early O
promoter-dependent O
chloramphenicol B-GENE
acetyltransferase I-GENE
( O
CAT B-GENE
) O
expression O
by O
six- O
to O
eightfold O
. O

CONCLUSIONS O
: O
AMVT O
is O
rare O
but O
a O
potentially O
lethal O
emergency O
disease O
. O

Lewis O
, O
N O
. O

The O
preferences O
were O
for O
intact O
vis-a-vis O
castrated O
males O
, O
though O
injections O
of O
TP O
restored O
the O
castrates' O
attractiveness O
to O
the O
females O
. O

This O
animal O
model O
of O
dystonia O
appears O
to O
be O
a O
model O
of O
NAD O
in O
man O
from O
the O
viewpoint O
of O
treatment-response O
. O

These O
changes O
correlate O
directly O
with O
an O
increase O
in O
the O
acetylation O
levels O
of O
all O
four O
core B-GENE
histones I-GENE
in O
vivo O
. O

In O
group O
B O
37 O
MBq O
in O
150 O
microL O
of O
99mTc-HSA O
nanocolloid O
was O
additionally O
injected O
intradermally O
18 O
h O
before O
surgery O
( O
3-6 O
aliquots O
injected O
perilesionally O
) O
. O

Coronary O
flow O
was O
reduced O
by O
10% O
in O
the O
phosphocreatine O
and O
by O
18% O
in O
the O
control O
group O
. O

In O
vivo O
, O
MyoD B-GENE
requires O
this O
tryptophan O
motif O
to O
evoke O
chromatin O
remodeling O
in O
the O
Myogenin B-GENE
promoter I-GENE
and O
to O
activate O
Myogenin B-GENE
transcription O
. O

Using O
autoantibodies O
from O
a O
Sjogren's O
syndrome O
patient O
, O
we O
have O
previously O
identified O
a O
230-kDa O
peripheral O
membrane O
protein O
associated O
with O
the O
cytosolic O
face O
of O
the O
trans-Golgi O
( O
Kooy O
, O
J O
. O
, O
Toh O
, O
B O
. O

The O
single O
strandedness O
is O
manifested O
as O
a O
terminal O
extension O
of O
the O
G-rich O
strand O
( O
G O
tails O
) O
that O
can O
occur O
independently O
of O
telomerase B-GENE
, O
suggesting O
that O
cdc17 B-GENE
pol1 I-GENE
mutants I-GENE
exhibit I-GENE
defects O
in O
telomeric O
lagging-strand O
synthesis O
. O

The O
plasmatic B-GENE
albumin I-GENE
concentration O
( O
3 O
. O
5-4 O
. O
5 O
g O
dl O
) O
represents O
about O
60% O
of O
the O
total O
plasma O
protein O
. O

Group O
6 O
was O
given O
physostigmine O
, O
0 O
. O
1 O
mg O
kg O
i O
. O
v O
. O
, O
known O
to O
inhibit O
cholinesterase O
degradation B-GENE
, O
5 O
min O
before O
bupivacaine O
administration O
, O
and O
Group O
7 O
received O
a O
combination O
of O
physostigmine O
pretreatment O
and O
electrical O
vagal O
stimulation O
. O

We O
conclude O
that O
, O
with O
autonomic O
nervous O
system O
activity O
intact O
, O
carotid O
chemoreceptor O
reflex O
activation O
can O
elicit O
an O
absolute O
reflexly O
mediated O
reduction O
in O
coronary O
blood O
flow O
in O
the O
normal O
, O
conscious O
dog O
, O
despite O
an O
increase O
in O
arterial O
pressure O
. O

Furthermore O
, O
in O
the O
ischemia O
angiotension O
II-induced O
AHF O
model O
, O
NIC O
decreased O
left O
ventricular O
end-diastolic O
pressure O
( O
LVEDP O
) O
. O

These O
results O
suggest O
that O
decreased O
class B-GENE
I I-GENE
enhancer I-GENE
activity O
in O
Ad12-transformed O
cells O
may O
, O
at O
least O
in O
part O
, O
be O
due O
to O
the O
higher O
levels O
of O
an O
enhancer-specific O
factor O
, O
possibly O
acting O
as O
a O
repressor O
. O

Evaluation O
of O
thyroid O
function O
. O

Combined O
expression O
of O
c-Jun B-GENE
and O
p65 B-GENE
induced O
vigorous O
transcription O
of O
IL-2 B-GENE
promoter- O
and O
CD28RE-driven B-GENE
reporter I-GENE
constructs I-GENE
in O
both O
LFA-3- O
and O
B7-1-costimulated O
Jurkat O
cells O
. O

Treadmill O
training O
at O
least O
for O
2 O
weeks O
can O
reduce O
the O
infarction O
size O
and O
edema O
caused O
by O
MCA O
occlusion O
( O
P O
< O
0 O
. O
01 O
) O
. O

However O
, O
unlike O
the O
SIN3 B-GENE
gene I-GENE
of O
Saccharomyces O
cerevisiae O
, O
pst1 B-GENE
( I-GENE
+ I-GENE
) I-GENE
is O
essential O
for O
cell O
viability O
. O

Calmodulin-binding B-GENE
peptide I-GENE
( O
CBP B-GENE
) O
, O
a O
peptide O
of O
26 O
amino O
acids O
derived O
from O
muscle B-GENE
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
( O
MLCK B-GENE
) O
, O
binds O
to O
calmodulin B-GENE
with O
nanomolar O
affinity O
. O

After O
the O
meal O
containing O
potato O
, O
plasma O
glucose O
levels O
rose O
sharply O
, O
peaked O
at O
30-45 O
min O
and O
fell O
below O
initial O
levels O
2 O
to O
3 O
h O
later O
. O

ATP O
gamma O
S O
inhibition O
can O
be O
overcome O
by O
high O
concentrations O
of O
ATP O
, O
dATP O
, O
araATP O
, O
or O
ddATP O
. O

The O
gene O
encodes O
an O
ATP-binding B-GENE
cassette I-GENE
, I-GENE
ABC I-GENE
transporter I-GENE
. O

Muscle B-GENE
GSH-Px I-GENE
activity O
after O
prolonged O
exercise O
, O
training O
, O
and O
selenium O
supplementation O
. O

RESULTS O
: O
The O
bovine O
cDNA O
insert O
sequence O
was O
273 O
nucleotides O
in O
length O
for O
the O
entire O
mRNA O
coding O
region O
, O
212 O
nucleotides O
in O
the O
5' O
untranslated O
region O
, O
83 O
nucleotides O
in O
the O
3' O
untranslated O
region O
and O
a O
poly O
( O
A O
) O
tail O
. O

Therapeutic O
use O
of O
cannabis O
. O

Toxicity O
was O
mild O
, O
mainly O
consisting O
of O
emesis O
( O
81% O
of O
the O
patients O
; O
66% O
of O
the O
courses O
) O
, O
leukopenia O
of O
World O
Health O
Organization O
( O
WHO O
) O
grade O
1 O
to O
2 O
( O
47% O
of O
the O
patients O
; O
18% O
of O
the O
courses O
) O
, O
and O
thrombocytopenia O
( O
12% O
of O
the O
patients O
; O
3% O
of O
the O
courses O
) O
. O

Refractory O
periods O
of O
the O
AV O
junction O
were O
altered O
in O
a O
comparable O
fashion O
to O
conduction O
through O
the O
AV O
node O
. O

Development O
of O
a O
yeast O
system O
to O
assay O
mutational O
specificity O
. O

Although O
some O
residues O
are O
found O
reactive O
toward O
dimethylsulphate O
and O
kethoxal O
in O
regions O
predicted O
to O
be O
unpaired O
by O
the O
phylogenetic O
secondary O
structure O
model O
of O
4 B-GENE
. I-GENE
5S I-GENE
RNA I-GENE
, O
generally O
the O
reactivity O
is O
low O
, O
and O
some O
residues O
in O
internal O
loops O
are O
not O
reactive O
at O
all O
. O

Interpersonal O
style O
differences O
among O
drug O
abusers O
were O
explored O
using O
Ryan's O
( O
1977 O
) O
typological O
system O
of O
FIRO-B O
interpretation O
. O

Fasting O
plasma O
and O
lipoprotein O
lipid O
concentrations O
, O
adipose B-GENE
tissue I-GENE
lipoprotein I-GENE
lipase I-GENE
activity O
, O
anthropometric O
data O
, O
alcohol O
consumption O
, O
smoking O
habits O
, O
weekly O
mileage O
run O
and O
performance O
on O
a O
bicycle O
ergometer O
were O
recorded O
before O
and O
after O
the O
training O
period O
. O

The O
presence O
of O
circulating O
platelet O
aggregates O
and O
elevated O
levels O
of O
fibrinopeptide B-GENE
A I-GENE
( O
a O
cleavage O
product O
of O
fibrin B-GENE
) O
suggests O
that O
platelet O
activation O
and O
fibrin B-GENE
deposition O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
disorder O
. O

Additionally O
in O
seven O
subjects O
adrenaline O
( O
A O
) O
and O
noradrenaline O
( O
NA O
) O
concentrations O
were O
determined O
. O

Direct O
current O
polarography O
and O
differential O
pulse O
polarographic O
methods O
have O
been O
developed O
for O
the O
qualitative O
as O
well O
as O
quantitative O
analysis O
of O
vitamin O
B1 O
, O
B2 O
and O
B6 O
. O

Body O
fat O
distribution O
was O
determined O
by O
abdominal O
computed O
tomography O
. O

Induction O
of O
Jurkat O
leukemic O
T O
cells O
with O
phorbol O
12-myristate O
13-acetate O
and O
ionomycin O
did O
not O
affect O
the O
level O
of O
FKBP B-GENE
mRNA I-GENE
. O

Because O
the O
DPPD B-GENE
gene I-GENE
is O
not O
present O
in O
non-tuberculous O
bacilli O
, O
these O
results O
suggest O
that O
this O
molecule O
can O
be O
an O
additional O
tool O
for O
a O
more O
specific O
diagnosis O
of O
tuberculosis O
. O

Mo O
+ O
SV O
M-MuLV-inoculated O
animals O
became O
moribund O
at O
3 O
to O
13 O
months O
postinoculation O
, O
whereas O
delta O
Mo O
+ O
SV O
M-MuLV-inoculated O
animals O
became O
moribund O
at O
6 O
to O
24 O
months O
postinoculation O
. O

Cowpox O
virus O
contains O
two O
copies O
of O
an O
early O
gene O
encoding O
a O
soluble O
secreted O
form O
of O
the O
type B-GENE
II I-GENE
TNF I-GENE
receptor I-GENE
. O

Fetal O
growth O
retardation O
as O
a O
cause O
of O
impaired O
ovarian O
development O
. O

Gas6 B-GENE
contains O
an O
NH2-terminal O
Gla O
domain O
followed O
by O
four O
epidermal B-GENE
growth I-GENE
factor-like I-GENE
repeats I-GENE
and O
tandem O
globular O
( O
G O
) O
domains O
. O

As O
control O
, O
the O
cells O
were O
transfected O
with O
DNA O
mixtures O
containing O
vector O
mU6-C1 O
or O
mU6-C2 O
. O

This O
result O
suggests O
that O
phosphorylation O
of O
Thr O
14 O
and O
or O
Tyr O
15 O
inhibits O
p34cdc2 O
kinase B-GENE
activity I-GENE
, O
in O
line O
with O
the O
location O
of O
these O
residues O
within O
the O
putative O
ATP O
binding O
site O
of O
the O
kinase O
. B-GENE

We O
have O
previously O
identified O
a O
liver-enriched O
transcription O
factor O
, O
HNF-6 B-GENE
, O
which O
is O
required O
for O
HNF-3 B-GENE
beta I-GENE
promoter I-GENE
activity O
and O
also O
recognizes O
the O
regulatory O
region O
of O
numerous O
hepatocyte-specific O
genes O
. O

Two O
evolutionarily O
conserved O
kinases B-GENE
, O
the O
cyclin B-GENE
B I-GENE
( I-GENE
Clb I-GENE
) I-GENE
cyclin-dependent I-GENE
kinase I-GENE
( I-GENE
Cdk O
Cdc28p B-GENE
) I-GENE
and I-GENE
Cdc7p O
along O
with B-GENE
its O
interacting O
factor O
Dbf4p O
, O
are B-GENE
required O
late O
in O
G1 O
to O
initiate O
DNA O
replication O
. O

An O
ion O
chromatographic O
method O
was O
used O
to O
determine O
Br O
ion O
in O
the O
urine O
of O
Greyhounds O
. O

On O
the O
other O
hand O
, O
knowledge O
of O
the O
epidemiology O
of O
Parkinson's O
disease O
is O
necessary O
in O
creating O
etiological O
hypotheses O
, O
since O
only O
hypotheses O
consistent O
with O
the O
epidemiological O
profile O
deserve O
careful O
testing O
. O

To O
define O
transcriptional O
control O
elements O
responsible O
for O
muscle-specific O
expression O
of O
the O
human B-GENE
myoglobin I-GENE
gene I-GENE
, O
we O
performed O
mutational O
analysis O
of O
upstream O
sequences O
( O
nucleotide O
positions O
-373 O
to O
+7 O
relative O
to O
the O
transcriptional O
start O
site O
) O
linked O
to O
a O
firefly B-GENE
luciferase I-GENE
gene I-GENE
. O

A O
DNA O
fragment O
carrying O
1 O
, O
100 O
nucleotides O
derived O
from O
the O
5'-flanking O
region O
of O
the O
UGT1A1 B-GENE
gene I-GENE
was O
enough O
for O
MC O
induction O
. O

The O
present O
chemotherapy O
of O
AE O
is O
based O
on O
the O
administration O
of O
benzimidazole O
carbamate O
derivatives O
, O
such O
as O
mebendazole O
and O
albendazole O
. O

Limits O
of O
energy O
turnover O
in O
relation O
to O
physical O
performance O
were O
addressed O
in O
terms O
of O
upper O
and O
lower O
limit O
, O
changes O
during O
a O
training O
programme O
and O
how O
to O
regulate O
energy O
balance O
at O
a O
changing O
energy O
turnover O
. O

Non-poliomyelitis O
AFP O
rate O
had O
increased O
from O
0 O
. O
9 O
in O
1997 O
to O
2 O
. O
8 O
in O
1998 O
. O

Most O
yeast B-GENE
peroxisomal I-GENE
matrix I-GENE
proteins I-GENE
contain O
a O
type B-GENE
1C-terminal I-GENE
peroxisomal I-GENE
targeting I-GENE
signal I-GENE
( O
PTS1 B-GENE
) O
consisting O
of O
the O
tripeptide B-GENE
SKL I-GENE
or O
a O
conservative O
variant O
thereof O
. O

On O
the O
basis O
of O
these O
relations O
, O
a O
risk O
factor-selection O
scale O
( O
RFSS O
) O
( O
range O
, O
0 O
to O
10 O
) O
was O
developed O
by O
computing O
appropriate O
weights O
for O
each O
risk O
factor O
. O

Mis3 B-GENE
is O
needed O
for O
the O
formation O
of O
18S B-GENE
ribosome I-GENE
RNA I-GENE
, O
and O
may O
hence O
direct O
the O
level O
of O
proteins O
required O
for O
the O
coupling O
. O

GRFI B-GENE
bound O
to O
sequences O
at O
the O
negative O
regulatory O
elements O
( O
silencers O
) O
of O
the O
silent B-GENE
mating I-GENE
type I-GENE
loci I-GENE
HML B-GENE
E I-GENE
and O
HMR B-GENE
E I-GENE
and O
to O
the O
upstream B-GENE
activating I-GENE
sequence I-GENE
( O
UAS B-GENE
) O
required O
for O
transcription O
of O
the O
MAT B-GENE
alpha I-GENE
genes I-GENE
. O

Large-scale O
sequencing O
of O
two O
regions O
in O
human O
chromosome O
7q22 O
: O
analysis O
of O
650 O
kb O
of O
genomic O
sequence O
around O
the O
EPO B-GENE
and O
CUTL1 B-GENE
loci I-GENE
reveals O
17 O
genes O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
the O
FCR1 B-GENE
gene I-GENE
behaves O
as O
a O
negative O
regulator O
of O
drug O
resistance O
in O
C O
. O
albicans O
and O
constitute O
the O
first O
evidence O
that O
FCZ O
resistance O
can O
result O
from O
the O
inactivation O
of O
a O
regulatory O
factor O
such O
as O
Fcr1p B-GENE
. O

This O
emancipation O
of O
the O
ability O
to O
copulate O
from O
hormonal O
influence O
makes O
female O
sexual O
motivation O
the O
primary O
regulator O
of O
mating O
in O
primates O
. O

These O
data O
demonstrate O
that O
the O
STR B-GENE
family I-GENE
of O
genes O
is O
represented O
in O
a O
nematode O
whose O
ancestor O
appeared O
well O
before O
the O
branching O
that O
gave O
rise O
to O
the O
Arthropoda O
and O
Chordata O
. O

The O
Saccharomyces B-GENE
cerevisiae I-GENE
APS1 I-GENE
gene I-GENE
encodes O
a O
homolog O
of O
the O
small O
subunit O
of O
the O
mammalian B-GENE
clathrin I-GENE
AP-1 B-GENE
complex I-GENE
: O
evidence O
for O
functional O
interaction O
with O
clathrin B-GENE
at O
the O
Golgi O
complex O
. O

In O
girls O
prolactin B-GENE
levels O
rise O
at O
stage O
2 O
, O
and O
are O
higher O
after O
menarche O
; O
in O
boys O
there O
is O
no O
change O
in O
prolactin B-GENE
levels O
. O

Spasmus O
nutans O
: O
a O
syndrome O
of O
auto-arousal O
. O

The O
effects O
of O
diltiazem O
were O
stereoselective O
, O
thus O
the O
potentiation O
induced O
by O
d-cis O
diltiazem O
was O
significantly O
greater O
in O
all O
cases O
than O
that O
induced O
by O
l-cis O
diltiazem O
, O
which O
suggests O
that O
calcium O
channel O
blockade O
plays O
a O
role O
in O
these O
interactions O
. O

These O
results O
suggest O
that O
the O
c-met B-GENE
gene I-GENE
is O
also O
a O
target O
of O
p53 B-GENE
gene I-GENE
regulation O
. O

Dorsal O
foot O
TcpO2 O
was O
measured O
by O
using O
oxygen-sensing O
electrodes O
with O
surface O
temperatures O
of O
42 O
degrees O
C O
and O
45 O
degrees O
C O
; O
in O
theory O
, O
changes O
in O
sympathetic O
activity O
should O
affect O
vasomotor O
tone O
and O
TcpO2 O
in O
skin O
beneath O
an O
electrode O
at O
42 O
degrees O
C O
( O
submaximal O
vasodilation O
) O
, O
but O
not O
at O
45 O
degrees O
C O
( O
maximal O
vasodilation O
) O
. O

The O
84 B-GENE
. I-GENE
1C I-GENE
mAb I-GENE
recognizes O
a O
site O
on O
IgE B-GENE
which O
is O
identical O
or O
very O
close O
to O
the O
Fc B-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
, O
and O
95 O
. O
3 O
recognizes O
a O
site O
on O
IgE B-GENE
which O
is O
related O
, O
but O
not O
identical O
to O
the O
Fc B-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
. O

Previous O
studies O
have O
shown O
that O
the O
pro-inflammatory O
cytokines O
tumor B-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
and O
interferon B-GENE
gamma I-GENE
reduce O
the O
expression O
of O
the O
cystic B-GENE
fibrosis I-GENE
transmembrane I-GENE
conductance I-GENE
regulator I-GENE
( O
CFTR B-GENE
) O
gene O
( O
CFTR B-GENE
) O
in O
HT-29 O
and O
T84 O
cells O
by O
acting O
post-transcriptionally O
. O

Therefore O
, O
we O
propose O
that O
p27 B-GENE
represents O
a O
crucial O
molecule O
in O
HMBA O
signaling O
that O
cannot O
be O
replaced O
by O
p21 B-GENE
. O

No O
case O
of O
SMF O
demonstrated O
expansive O
tumorous O
growth O
. O

The O
injection O
of O
XDRP1 B-GENE
protein I-GENE
into O
fertilized O
Xenopus O
eggs O
blocked O
embryonic O
cell O
division O
. O

Lck B-GENE
has O
been O
postulated O
to O
dimerize O
through O
the O
SH2 B-GENE
and O
SH3 B-GENE
domains I-GENE
. O

The O
kinase O
activity O
of O
PfPK6 B-GENE
is O
sensitive O
to O
CDK B-GENE
inhibitors O
such O
as O
olomoucine O
and O
roscovitine O
. O

Both O
HERV-K O
type O
1 O
and O
2 O
clones O
were O
isolated O
. O

These O
results O
were O
compared O
with O
the O
estimates O
of O
penetration O
from O
steady-state O
calculations O
, O
square O
root O
of O
time O
calculations O
, O
and O
a O
biologically O
based O
mathematical O
model O
. O

Human B-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
Vpr I-GENE
is O
a O
virion-associated O
, O
regulatory O
protein O
that O
is O
required O
for O
efficient O
viral O
replication O
in O
monocytes O
macrophages O
. O

Treatment O
of O
Paget's O
disease O
. O

Furthermore O
, O
bone O
marrow-derived O
macrophages O
from O
LAT-deficient O
mice O
displayed O
reduced O
phagocytic O
efficiency O
in O
comparison O
to O
the O
macrophages O
from O
wild-type O
mice O
. O

SETTING O
: O
University O
of O
Paris O
VII O
hospital O
. O
Patient O
( O
s O
) O
: O
Nine O
women O
had O
embolization O
for O
symptomatic O
myoma O
, O
with O
12 O
pregnancies O
observed O
. O

Analysis O
of O
functional O
domains O
of O
Arix B-GENE
reveals O
an O
N-terminal O
activation O
domain O
and O
a O
C-terminal O
repression O
domain O
. O

Nuclear B-GENE
receptors I-GENE
( O
NRs B-GENE
) O
can O
function O
as O
ligandinducible O
transregulators O
in O
both O
mammalian O
and O
yeast O
cells O
, O
indicating O
that O
important O
features O
of O
transcriptional O
control O
have O
been O
conserved O
throughout O
evolution O
. O

Mn2+ O
increased O
both O
the O
junction O
binding O
and O
cleaving O
activities O
of O
the O
mutant O
proteins O
. O

The O
Drosophila B-GENE
suppressor I-GENE
of I-GENE
sable I-GENE
gene I-GENE
encodes O
a O
polypeptide O
with O
regions O
similar O
to O
those O
of O
RNA-binding O
proteins O
. O

High O
resolution O
computed O
tomography O
of O
the O
lungs O
in O
patients O
with O
rheumatoid O
arthritis O
. O

RESULTS O
: O
During O
the O
7-year O
period O
, O
10 O
, O
331 O
symptomatic O
duodenal O
ulcer O
diseases O
were O
diagnosed O
. O

In O
our O
opinion O
, O
the O
SM-CMA O
system O
is O
, O
despite O
some O
shortcomings O
in O
its O
user-interface O
, O
a O
useful O
and O
versatile O
instrument O
for O
examination O
of O
human O
semen O
samples O
, O
with O
desirable O
features O
. O

These O
results O
support O
the O
diagnostic O
validity O
of O
NFPD O
in O
CP O
NCA O
patients O
, O
because O
such O
patients O
had O
a O
family O
history O
of O
panic O
disorder O
similar O
to O
patients O
with O
a O
more O
classical O
panic O
disorder O
presentation O
. O

On O
the O
basis O
of O
histopathological O
findings O
, O
the O
origin O
of O
amyloid O
appeared O
to O
be O
closely O
related O
to O
the O
fibroblasts O
. O

We O
have O
isolated O
a O
Drosophila O
melanogaster O
( O
Dm O
) O
cDNA O
encoding O
a O
polypeptide O
that O
has O
extensive O
sequence O
similarity O
to O
the O
mammalian B-GENE
MAPKAPK-2 I-GENE
. O

Here O
, O
we O
present O
evidence O
that O
exposure O
of O
DT40 O
lymphoma O
B O
cells O
to O
low O
energy O
electromagnetic O
field O
( O
EMF O
) O
results O
in O
a O
tyrosine O
kinase-dependent O
activation O
of O
phospholipase B-GENE
Cgamma2 I-GENE
( O
PLC-gamma2 B-GENE
) O
leading O
to O
increased O
inositol O
phospholipid O
turnover O
. O

Inhibition O
of O
RNA2 B-GENE
translation O
was O
selective O
, O
with O
no O
effect O
on O
general O
cellular O
translation O
or O
translation O
of O
BMV O
RNA1-encoded B-GENE
replication I-GENE
factor I-GENE
1a I-GENE
, O
and O
was O
independent O
of O
p20 B-GENE
, O
a O
cellular O
antagonist O
of O
DED1 B-GENE
function O
in O
translation O
. O

Clinical O
and O
anatomical O
considerations O
. O

Salazopyrine O
desensitization O
. O

Despite O
the O
favourable O
natural O
history O
of O
acute O
BI O
, O
mild O
, O
moderate O
, O
and O
severe O
posttraumatic O
changes O
were O
shown O
to O
appear O
as O
cicatricial-adhesive O
and O
atrophic O
processes O
, O
intracerebral O
cysts O
, O
porencephaly O
, O
which O
result O
in O
posttraumatic O
epilepsy O
, O
hydrocephalus O
, O
etc O
. O

Third- O
and O
later-parity O
cows O
were O
randomly O
assigned O
after O
each O
parturition O
to O
Charolais O
and O
Red O
Poll O
bulls O
in O
multiple-sire O
pastures O
. O

Under O
our O
conditions O
, O
the O
combination O
O3 O
UV O
did O
not O
improve O
the O
degradation O
rate O
obtained O
by O
ozonation O
. O

For O
sputum B-GENE
interleukin-8 I-GENE
there O
was O
an O
estimated O
true O
treatment O
median O
difference O
of O
142 O
pg O
ml O
( O
95% O
confidence O
interval O
( O
CI O
) O
8 O
to O
2866 O
pg O
ml O
) O
in O
favour O
of O
placebo O
; O
while O
for O
maximal O
expiratory O
flow O
at O
25% O
( O
MEF25% O
) O
remaining O
forced O
vital O
capacity O
predicted O
for O
sex O
and O
height O
there O
was O
a O
15 O
percentage O
points O
( O
pp O
) O
( O
95% O
CI O
4 O
to O
26 O
pp O
) O
mean O
treatment O
difference O
in O
favour O
of O
placebo O
. O

Genetic O
alterations O
in O
elements O
of O
normal O
signal O
transduction O
mechanisms O
are O
known O
to O
be O
oncogenic O
events O
often O
resulting O
in O
aberrant O
activation O
of O
programs O
of O
gene O
transcription O
. O

In O
the O
diabetics O
, O
Ca2+ O
infusions O
induced O
a O
rise O
of O
plasma O
Ca2+ O
up O
to O
3 O
. O
2 O
+ O
- O
0 O
. O
1 O
mmol O
1 O
and O
a O
fall O
of O
circulating O
glucagon O
( O
-26 B-GENE
. O
4 O
+ O
- O
5 O
. O
7% O
; O
p O
less O
than O
0 O
. O
001 O
) O
and O
glucose O
( O
-23 O
. O
3 O
+ O
- O
3 O
. O
6% O
; O
p O
less O
than O
0 O
. O
05 O
) O
. O

This O
gene O
spans O
23 O
kb O
and O
is O
composed O
of O
five O
exons O
and O
four O
introns O
. O

They O
observed O
depressed O
protein B-GENE
C I-GENE
activity O
that O
significantly O
( O
p O
< O
0 O
. O
005 O
) O
increased O
and O
became O
normal O
immediately O
after O
hemodialysis O
while O
factor B-GENE
X I-GENE
and O
factor B-GENE
VII I-GENE
increased O
( O
p O
< O
0 O
. O
01 O
; O
p O
< O
0 O
. O
05 O
) O
despite O
heparinization O
together O
with O
amount O
of O
serum B-GENE
lipoprotein I-GENE
( I-GENE
a I-GENE
) I-GENE
. O

The O
data O
presented O
in O
this O
work O
indicate O
that O
thi1 B-GENE
may O
also O
be O
involved O
in O
DNA O
damage O
tolerance O
in O
plant O
cells O
. O

For O
the O
5HT5A B-GENE
receptor I-GENE
the O
addition O
of O
yohimbine O
resulted O
in O
a O
similar O
but O
smaller O
effect O
. O

Sequence O
comparisons O
have O
shown O
that O
Aps1p B-GENE
is O
more O
similar O
to O
the O
sigma O
subunit O
of O
the O
Golgi-localized O
mammalian O
AP-1 B-GENE
complex I-GENE
than O
Aps2p B-GENE
, O
which O
is O
more O
related O
to O
the O
plasma O
membrane O
AP-2 B-GENE
sigma I-GENE
subunit O
. O

The O
levels O
of O
fibrinogen B-GENE
as O
well O
as O
antithrombin B-GENE
III I-GENE
( O
ATIII B-GENE
) O
and O
heparin B-GENE
cofactor I-GENE
II I-GENE
( O
HCII B-GENE
) O
activities O
were O
steadily O
increased O
in O
loop-bearing O
animals O
. O

Another O
group O
of O
HIPP- O
and O
HCX-lesioned O
animals O
trained O
on O
the O
tasks O
after O
the O
lesion O
showed O
reduced O
impairments O
of O
the O
type O
described O
above O
, O
suggesting O
that O
extrahippocampal O
structures O
trained O
after O
the O
lesion O
can O
assume O
the O
role O
of O
the O
hippocampus O
to O
some O
degree O
. O

Two O
domains O
of O
EBNA2 B-GENE
defined O
by O
deletion O
of O
amino O
acids O
247-337 O
and O
437-476 O
were O
found O
to O
be O
important O
for O
the O
activation O
of O
both O
promoters O
, O
while O
two O
different O
domains O
corresponding O
to O
residues O
4-18 O
and O
118-198 O
were O
required O
solely O
for O
the O
LMP1 B-GENE
promoter I-GENE
. O

These O
results O
indicate O
that O
the O
total O
number O
of O
subunit O
c O
in O
F0 B-GENE
should O
be O
a O
multiple O
of O
2 O
and O
3 O
. O

At O
termination O
( O
gd O
20 O
) O
, O
confirmed-pregnant O
females O
( O
21 O
to O
25 O
per O
group O
) O
were O
evaluated O
for O
clinical O
status O
and O
gestational O
outcome O
; O
live O
fetuses O
were O
examined O
for O
external O
, O
visceral O
, O
and O
skeletal O
malformations O
. O

Is O
more O
better O
? O
About O
dose O
levels O
of O
ACE B-GENE
inhibitors O
in O
chronic O
heart O
failure O
. O

To O
determine O
which O
region O
of O
SulA B-GENE
is O
essential O
for O
the O
inhibition O
of O
cell O
division O
, O
we O
constructed O
a O
series O
of O
N-terminal O
and O
C-terminal O
deletions O
of O
SulA B-GENE
and O
a O
series O
of O
alanine O
substitution O
mutants O
. O

Shape O
factor O
correlated O
well O
with O
hemodynamic O
data O
for O
RV O
LV O
systolic O
pressure O
ratios O
( O
r O
= O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
001 O
) O
for O
normalized O
interventricular O
pressure O
differences O
( O
r O
= O
-0 O
. O
95 O
, O
p O
less O
than O
0 O
. O
001 O
) O
. O

The O
mutation O
experiments O
showed O
that O
the O
most O
critical O
sequence O
for O
the O
repression O
of O
PTH B-GENE
was O
5'-GGGGGAGGGGAG-3' B-GENE
( I-GENE
+1 I-GENE
to I-GENE
+12 I-GENE
) I-GENE
of O
PTHSR B-GENE
. O

In O
general O
, O
the O
filtration O
rate O
in O
relevant O
areas O
appears O
to O
be O
an O
integrative O
and O
easily O
determined O
parameter O
, O
reflecting O
hormonal O
and O
neurogenic O
vascular O
as O
well O
as O
local O
interstitial O
control O
of O
the O
Starling O
forces O
. O

Two O
putative O
12-O-tetradecanoyl-phorbol-13-acetate B-GENE
( I-GENE
TPA I-GENE
) I-GENE
response I-GENE
elements I-GENE
, O
that O
might O
serve O
as O
binding O
sites O
for O
the O
transcription B-GENE
factor I-GENE
AP-1 I-GENE
and O
a O
consensus O
sequence O
of O
a O
transforming B-GENE
growth I-GENE
factor I-GENE
beta I-GENE
1 I-GENE
( O
TGF-beta B-GENE
1 I-GENE
) O
inhibitory O
element O
were O
found O
in O
the O
promoter O
region O
. O

Crosstalk O
among O
the O
pathways O
may O
explain O
how O
some O
forms O
of O
stress O
can O
contribute O
to O
the O
development O
of O
a O
malignancy O
. O

Analysis O
of O
electrically O
evoked O
response O
( O
EER O
) O
in O
relation O
to O
the O
central O
visual O
pathway O
of O
the O
cat O
( O
1 O
) O
. O

The O
effectiveness O
of O
alpha-mercapto-beta- O
( O
2-furyl O
) O
acrylic O
acid O
( O
MFA O
) O
and O
N-benzyl-N-dithiocarboxy-D-glucamine O
( O
NaB O
) O
, O
used O
in O
combination O
, O
in O
the O
mobilization O
and O
excretion O
of O
lead O
was O
investigated O
in O
rats O
. O

The O
319 O
base O
pair O
region O
immediately O
upstream O
of O
the O
CAP O
site O
is O
characterized O
by O
the O
lack O
of O
a O
proximal O
TATA O
box O
and O
the O
presence O
of O
sequences O
similar O
to O
GC O
boxes O
, O
CACCC O
boxes O
, O
CCAAT O
boxes O
, O
activator B-GENE
protein I-GENE
2 I-GENE
( O
Ap-2 B-GENE
) O
sites O
, O
partial O
glucocorticoid B-GENE
response I-GENE
elements I-GENE
( O
GREs B-GENE
) O
, O
and O
partial O
cyclic B-GENE
AMP I-GENE
response I-GENE
elements I-GENE
( O
CREs B-GENE
) O
. O

This O
two-helix O
motif O
is O
thought O
to O
be O
involved O
in O
specific O
DNA O
sequence O
recognition O
by O
CAP B-GENE
. O

Vitamin O
D3 O
and O
calcium O
absorption O
in O
the O
chick O
. O

Far O
from O
this O
being O
the O
case O
, O
however O
, O
the O
measurement O
of O
apo B-GENE
B I-GENE
has O
met O
every O
reasonable O
standard O
of O
laboratory O
precision O
and O
reliability O
to O
allow O
its O
widespread O
introduction O
in O
clinical O
laboratories O
. O

Under O
halothane O
anesthesia O
, O
the O
flow O
pneumocardiogram O
( O
PnCG O
) O
and O
its O
time O
derivative O
( O
acceleration O
pneumocardiogram O
or O
dPn O
dt O
) O
were O
transduced O
during O
apnea O
by O
a O
small O
high-gain O
pneumotachograph O
. O

Phosphorylation O
of O
myosin-binding B-GENE
subunit I-GENE
( O
MBS B-GENE
) O
of O
myosin B-GENE
phosphatase I-GENE
by O
Rho-kinase B-GENE
in O
vivo O
. O

GTRE B-GENE
, O
TRE B-GENE
, O
and O
CRE B-GENE
oligonucleotides O
all O
compete O
more O
efficiently O
for O
protein O
binding O
to O
their O
labeled O
congeners O
than O
for O
protein O
binding O
to O
either O
of O
the O
other O
labeled O
oligonucleotides O
, O
suggesting O
that O
the O
GTRE B-GENE
, O
TRE B-GENE
, O
and O
CRE B-GENE
oligonucleotides O
, O
suggesting O
that O
the O
GTRE B-GENE
, O
TRE B-GENE
, O
and O
CRE B-GENE
oligonucleotides O
each O
bind O
unique O
as O
well O
as O
common O
proteins O
, O
likely O
to O
be O
members O
of O
the O
Jun B-GENE
Fos I-GENE
and I-GENE
cAMP-responsive O
element-binding B-GENE
protein I-GENE
activating I-GENE
transcription I-GENE
factors I-GENE
( I-GENE
CREB I-GENE
ATF O
) B-GENE
families I-GENE
of I-GENE
transcription O
factors O
, O
in O
chromaffin O
cells O
. O

We O
have O
generated O
various O
base O
substitutions O
and O
internal O
deletions O
in O
and O
around O
DRE B-GENE
( O
nucleotide O
positions O
-93 O
to O
-100 O
with O
respect O
to O
the O
transcription O
initiation O
site O
) O
of O
the O
PCNA B-GENE
gene I-GENE
in O
vitro O
and O
subsequently O
examined O
their O
effects O
on O
the O
binding O
to O
DREF B-GENE
( O
DRE-binding B-GENE
factor I-GENE
) O
and O
PCNA B-GENE
gene I-GENE
promote O
activity O
in O
cultured O
Drosophila O
Kc O
cells O
as O
well O
as O
in O
living O
flies O
. O

Transient O
transfections O
showed O
that O
a O
single O
mutation O
( O
556M O
) O
decreased O
TBLV B-GENE
enhancer I-GENE
activity O
at O
least O
20-fold O
in O
two O
different O
T-cell O
lines O
. O

Fas B-GENE
has O
been O
shown O
to O
require O
ICE B-GENE
( O
interleukin-1 B-GENE
beta-converting I-GENE
enzyme I-GENE
) O
family O
proteases O
to O
induce O
apoptosis O
from O
studies O
utilizing O
the O
cowpox O
ICE B-GENE
inhibitor I-GENE
protein I-GENE
CrmA B-GENE
, O
the O
synthetic O
tetrapeptide O
ICE B-GENE
inhibitor O
YVAD-CMK B-GENE
, O
and O
the O
tripeptide O
pan-ICE O
inhibitor O
Z-VAD-FMK B-GENE
. O

However O
, O
the O
lens O
dose O
( O
3 O
. O
6 O
Gy O
25 O
fractions O
) O
was O
higher O
compared O
to O
the O
other O
techniques O
. O

An O
inverted O
Alu B-GENE
repeat I-GENE
element I-GENE
, O
flanked O
by O
nonamer O
direct O
repeats O
, O
was O
identified O
within O
the O
region O
-913 O
-620 O
, O
relative O
to O
the O
cap O
site O
. O

Studies O
using O
a O
reporter O
plasmid O
with O
a O
functionally O
disrupted O
sterol-responsive B-GENE
element I-GENE
( O
SRE B-GENE
) O
-1 O
revealed O
a O
reduced O
stimulatory O
response O
to O
IL-6 B-GENE
. O

The O
proposed O
algorithm O
consists O
of O
several O
steps O
. O

Ganciclovir O
and O
foscarnet O
efficacy O
in O
AIDS-related O
CMV O
polyradiculopathy O
. O

A O
. O

Although O
both O
transfected O
cell O
lines O
contain O
FGF-1 B-GENE
cell I-GENE
surface I-GENE
receptors I-GENE
as O
judged O
by O
crosslinking O
studies O
, O
the O
wild-type O
transfectants O
are O
refractory O
to O
exogenous O
FGF-1 B-GENE
, O
whereas O
the O
mutant O
transfectants O
respond O
normally O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

This O
report O
presents O
the O
isolation O
and O
characterization O
of O
the O
5'-flanking O
region O
( O
1 O
. O
2 O
kb O
) O
and O
exon O
1 O
of O
the O
human B-GENE
RII I-GENE
alpha I-GENE
gene I-GENE
. O

It O
is O
also O
homologous O
to O
other O
sugar O
carriers O
from O
human O
, O
mouse O
and O
Escherichia O
coli O
. O

Our O
results O
confirm O
the O
participation O
of O
intron O
1 O
in O
transcriptional O
regulation O
of O
the O
c-myb B-GENE
gene I-GENE
( O
in O
mouse O
and O
human O
) O
and O
implicate O
multiple O
and O
complex O
regulatory O
mechanisms O
of O
activation O
during O
myelomonocytic O
differentiation O
and O
leukemic O
cell O
growth O
control O
. O

There O
was O
a O
general O
broadening O
of O
proton O
resonances O
for O
a O
three-nucleotide O
segment O
centered O
about O
the O
lesion O
site O
which O
resulted O
in O
a O
tentative O
assignment O
for O
the O
sugar O
protons O
of O
the O
C7 O
residue O
in O
the O
spectrum O
of O
the O
adduct O
duplex O
. O

We O
report O
here O
the O
cloning O
of O
the O
human B-GENE
goosecoid I-GENE
gene I-GENE
( O
GSC B-GENE
) O
from O
a O
genomic O
library O
and O
the O
sequence O
of O
its O
encoded O
protein O
. O

The O
accumulated O
products O
of O
ancient O
duplication O
events O
can O
be O
readily O
observed O
among O
the O
genes O
encoding O
voltage-dependent O
Ca O
( O
2+ O
) O
ion O
channels O
. O

On O
the O
other O
hand O
, O
lack O
of O
conservation O
of O
the O
membrane B-GENE
attachment I-GENE
sequence I-GENE
arginine-glycine-aspartic I-GENE
acid I-GENE
argues O
against O
its O
functional O
importance O
in O
CgA B-GENE
. O

The O
hcKrox B-GENE
gene O
family O
regulates O
multiple O
extracellular O
matrix O
genes O
. O

A O
noncatalytic O
domain O
conserved O
among O
cytoplasmic B-GENE
protein-tyrosine I-GENE
kinases I-GENE
modifies O
the O
kinase O
function O
and O
transforming O
activity O
of O
Fujinami B-GENE
sarcoma I-GENE
virus I-GENE
P130gag-fps I-GENE
. O

Northern O
blot O
analysis O
indicates O
that O
AHA2 B-GENE
mRNA I-GENE
relative O
to O
total O
cellular O
RNA O
is O
expressed O
at O
significantly O
higher O
levels O
in O
root O
tissue O
as O
compared O
with O
shoot O
tissue O
. O

A O
unified O
approach O
to O
the O
standardization O
of O
allergens O
. O

Sevelamer O
hydrochloride O
( O
Renagel O
) O
is O
a O
nonabsorbed O
phosphate-binding O
polymer O
marketed O
for O
the O
treatment O
of O
hyperphosphatemia O
in O
adult O
patients O
receiving O
hemodialysis O
. O

Here O
we O
show O
that O
messenger O
RNAs O
encoding O
trans-sialidases B-GENE
containing O
the O
repeats O
are O
not O
present O
in O
epimastigotes O
but O
are O
abundant O
in O
trypomastigotes O
. O

Doctor O
Berglund O
warns O
members O
of O
union O
pitfalls O
. O

Enzyme-linked O
immunosorbent O
assay O
for O
screening O
aflatoxin B-GENE
B1 I-GENE
in O
cottonseed O
products O
and O
mixed O
feed O
: O
collaborative O
study O
. O

Molecular O
characterization O
and O
expression O
of O
the O
Erwinia B-GENE
carotovora I-GENE
hrpNEcc I-GENE
gene I-GENE
, O
which O
encodes O
an O
elicitor O
of O
the O
hypersensitive O
reaction O
. O

CONCLUSIONS O
: O
Although O
the O
levels O
of O
oxLDL B-GENE
antibodies I-GENE
might O
be O
modified O
in O
early O
hypertension O
, O
once O
advanced O
coronary O
artery O
disease O
has O
developed O
the O
presence O
of O
hypertension O
does O
not O
affect O
anti-oxLDL B-GENE
levels O
. O

The O
strategy O
has O
been O
used O
to O
determine O
2 O
. O
6 O
kilobases O
of O
nucleotide O
sequence O
in O
the O
Saccharomyces B-GENE
cerevisiae I-GENE
ADE I-GENE
1 I-GENE
locus I-GENE
. O

A O
subset O
of O
mutations O
in O
the O
Psi B-GENE
synthase I-GENE
domain I-GENE
impairs O
association O
of O
the O
altered O
Cbf5p B-GENE
proteins I-GENE
with O
selected O
box O
H B-GENE
ACA I-GENE
snoRNAs I-GENE
, I-GENE
suggesting O
that O
the O
functional O
catalytic O
domain O
is O
essential O
for O
that O
interaction O
. O

Female O
Wistar O
rats O
were O
fed O
a O
liquid O
diet O
, O
Sustacal O
, O
which O
contained O
ethanol O
( O
40% O
of O
calories O
) O
or O
isocaloric O
sucrose O
. O

They O
share O
many O
downstream O
targets O
, O
including O
remodeling O
of O
the O
actin B-GENE
cytoskeleton O
, O
activation O
of O
p70 B-GENE
( I-GENE
S6 I-GENE
) I-GENE
kinase I-GENE
and O
c-jun B-GENE
N-terminal I-GENE
kinase I-GENE
( O
JNK B-GENE
) O
, O
and O
regulation O
of O
transcription O
and O
cell O
proliferation O
. O

272 O
, O
19107-19110 O
) O
. O

In O
the O
further O
development O
of O
bladder O
neck O
suspension O
according O
to O
Stamey-Pereyra O
, O
the O
use O
of O
miniature O
bone O
anchors O
received O
considerable O
support O
. O

GHB O
, O
2 O
CB O
, O
HMB O
, O
are O
some O
of O
these O
recent O
substances O
. O

Previous O
transactivation O
experiments O
indicated O
that O
three O
amino O
acids O
residing O
in O
this O
region O
, O
Gly O
, O
Ser O
and O
Val O
, O
appear O
to O
be O
critical O
for O
target-site O
discrimination O
. O

Control O
of O
fatty O
liver O
syndrome O
in O
a O
Jersey O
herd O
by O
a O
change O
of O
diet O
and O
the O
use O
of O
recombinant O
bovine O
somatotrophin B-GENE
. O

A O
comparison O
of O
physical O
and O
cytogenetic O
estimates O
of O
radiation O
dose O
in O
patients O
treated O
with O
iodine-131 O
for O
thyroid O
carcinoma O
. O

Initial O
experience O
with O
the O
new O
technology O
indicates O
that O
SieScape O
is O
an O
alternative O
to O
other O
methods O
such O
as O
CT O
and O
MRI O
. O

To O
map O
this O
regulatory O
serine O
phosphorylation O
site O
we O
developed O
a O
baculovirus-mediated O
expression O
system O
for O
wild-type B-GENE
annexin I-GENE
II I-GENE
and O
for O
a O
series O
of O
annexin B-GENE
II I-GENE
mutants I-GENE
which O
contained O
substitutions O
in O
one O
or O
more O
serine O
residues O
present O
in O
the O
N-terminal O
domain O
. O

No O
difference O
in O
elastin B-GENE
peptide I-GENE
concentration O
was O
observed O
between O
emphysematous O
patients O
and O
control O
subjects O
( O
mean O
+ O
- O
SD O
= O
2 O
. O
39 O
+ O
- O
1 O
. O
18 O
micrograms O
ml O
in O
patients O
versus O
2 O
. O
55 O
+ O
- O
1 O
. O
34 O
micrograms O
ml O
in O
policemen O
and O
2 O
. O
59 O
+ O
- O
1 O
. O
20 O
micrograms O
ml O
in O
coal O
miners O
) O
. O

CONCLUSIONS O
: O
In O
healthy O
individuals O
, O
whole O
body O
insulin B-GENE
sensitivity O
is O
related O
, O
or O
"coupled O
, O
" O
to O
the O
anaerobic O
threshold O
. O

The O
survival O
rate O
at O
forty O
months O
in O
15 O
patients O
with O
N2 O
disease O
who O
underwent O
R2b O
operation O
was O
51% O
. O

Furthermore O
, O
we O
have O
identified O
a O
43-bp O
region O
of O
the O
24p3 B-GENE
promoter I-GENE
required O
for O
the O
Dex O
responsiveness O
. O

Histamine O
reactivity O
was O
significantly O
reduced O
after O
the O
nifedipine O
aerosol O
, O
the O
geometric O
mean O
provocative O
concentration O
causing O
a O
35% O
fall O
in O
specific O
airway O
conductance O
, O
rising O
from O
5 O
. O
0 O
to O
10 O
. O
9 O
mg O
ml O
of O
histamine O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

Handgrip O
dynamometry O
was O
also O
carried O
out O
in O
249 O
of O
the O
patients O
. O

By O
applying O
the O
potentiometric O
method O
, O
in O
aqueous O
medium O
of O
ionic O
strength O
mu O
= O
0 O
. O
2 O
, O
the O
stability O
constants O
, O
log O
beta O
1 O
= O
4 O
. O
42 O
and O
log O
beta O
2 O
= O
8 O
. O
57 O
were O
obtained O
. O

Induction O
of O
B O
cell O
apoptosis O
by O
co-cross-linking O
CD23 B-GENE
and O
sIg B-GENE
involves O
aberrant O
regulation O
of O
c-myc B-GENE
and O
is O
inhibited O
by O
bcl-2 B-GENE
. O

SAECG O
, O
echocardiography O
and O
thallium-201 O
imaging O
were O
performed O
before O
and O
1 O
month O
after O
attempted O
angioplasty O
. O

Our O
results O
suggest O
that O
protein O
binding O
to O
the O
E2F-like B-GENE
sequences I-GENE
may O
act O
to O
reduce O
expression O
. O

The O
patient O
was O
homozygous O
for O
the O
underlying O
mutation O
, O
which O
was O
found O
to O
be O
a O
G-- O
> O
T O
transversion O
within O
the O
acceptor O
splice O
site O
between O
intron O
e O
and O
exon O
6 O
, O
abolishing O
normal O
RNA O
splicing O
. O

The O
genomic O
structure O
of O
four O
members O
of O
the O
SRC-family B-GENE
revealed O
nearly O
identical O
exon O
intron O
boundaries O
within O
the O
catalytic O
domain O
of O
this O
family O
. O

The O
students O
who O
had O
abnormal O
urine O
screening O
results O
at O
the O
first O
time O
received O
a O
second O
urine O
analysis O
10 O
to O
15 O
days O
later O
to O
confirm O
the O
abnormal O
urine O
analysis O
. O

However O
, O
addition O
of O
core B-GENE
DNA I-GENE
polymerase I-GENE
III I-GENE
to O
preinitiation O
complex O
, O
fully O
reconstituting O
holoenzyme O
resulted O
in O
replacement O
of O
gamma O
by O
alpha O
at O
the O
primer O
terminus O
. O

Characterisation O
of O
the O
chicken B-GENE
apolipoprotein I-GENE
A-I I-GENE
gene I-GENE
5'-flanking O
region O
. O

Plasma O
, O
LDL B-GENE
and O
liver O
cholesterol O
concentrations O
were O
higher O
in O
the O
hyperlipidemic O
control O
than O
the O
nonhyperlipidemic O
control O
and O
lower O
in O
the O
groups O
fed O
diets O
containing O
pectin B-GENE
or O
prune O
fiber O
than O
in O
the O
hyperlipidemic O
control O
group O
. O

All O
of O
these O
data O
suggest O
that O
replication O
of O
UV-damaged O
templates O
occurs O
in O
vitro O
as O
it O
does O
in O
vivo O
and O
that O
this O
replication O
results O
in O
mutation O
fixation O
. O

In O
group O
I O
adults O
both O
of O
these O
variables O
increased O
. O

The O
plasma B-GENE
growth I-GENE
hormone I-GENE
concentration O
of O
the O
foetal O
lamb O
. O

Despite O
resolution O
of O
the O
solid O
portion O
of O
the O
tumor O
, O
serial O
MRI O
showed O
enlargement O
of O
a O
bilobar O
tumor O
cyst O
3 O
years O
after O
the O
original O
diagnosis O
. O

This O
approximately O
125-nt O
RNA O
proved O
to O
arise O
via O
RNase B-GENE
E I-GENE
cleavage O
from O
the O
3'-terminal O
region O
of O
the O
mRNAs O
bearing O
the O
terminator O
. O

Electrophoretic O
mobility O
shift O
assays O
using O
crude O
extracts O
from O
FREJ4 O
cells O
revealed O
the O
binding O
of O
a O
member O
( O
s O
) O
of O
the O
Ets B-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
to O
the O
P4 B-GENE
EBS I-GENE
, O
as O
well O
as O
the O
interaction O
of O
two O
members O
of O
the O
Sp1 B-GENE
family I-GENE
, O
Sp1 B-GENE
and O
Sp3 B-GENE
, O
with O
the O
adjacent O
GC O
box O
. O

The O
binary O
and O
tertiary O
combinations O
of O
plant-derived O
molluscicides O
Azadirachta O
indica O
and O
Cedrus O
deodara O
oil O
with O
synergists O
MGK-264 O
, O
piperonyl O
butoxide O
( O
PB O
) O
and O
fruit O
powder O
of O
Embelia O
ribes O
were O
used O
against O
the O
Lymnaea O
acuminata O
. O

The O
known O
B1 O
- O
deficiency O
reaches O
excessive O
high O
values O
with O
light O
exercise O
. O

The O
rate O
of O
enzymic O
stimulation O
induced O
by O
a O
given O
nitrate O
correlates O
closely O
with O
the O
rate O
of O
measured O
NO O
production O
from O
the O
nitrate O
molecule O
. O

Physiology O
and O
Physiopathology O
. O

Experiments O
were O
performed O
in O
which O
brain-stem O
auditory-evoked O
responses O
( O
BAERs O
) O
were O
elicited O
by O
two O
types O
of O
pseudorandom O
pulse O
trains O
: O
maximum O
length O
sequences O
( O
MLS O
) O
and O
Legendre O
sequences O
( O
LGS O
) O
. O

Six O
patients O
with O
the O
diagnosis O
of O
acute O
mania O
were O
treated O
with O
high O
doses O
of O
the O
beta-adrenergic O
blocking O
agent O
propranolol O
. O

PKA B-GENE
phosphorylated O
WT1 B-GENE
at O
Ser-365 O
and O
Ser-393 O
in O
vitro O
, O
as O
well O
as O
at O
additional O
sites O
, O
and O
this O
phosphorylation O
abolished O
the O
DNA-binding O
activity O
of O
WT1 B-GENE
in O
vitro O
. O

The O
color-word O
interference O
effect O
previously O
reported O
with O
normal O
populations O
when O
given O
the O
Stroop O
test O
was O
demonstrated O
for O
this O
retarded O
sample O
using O
a O
special O
format O
. O

Estral O
cycle O
in O
white O
rats O
in O
the O
low O
and O
high O
mountains O
of O
Kirghizia O
. O

Use O
of O
Selenastrum O
capricornutum O
and O
Microfeast O
as O
food O
for O
Daphnia O
pulex O
. O

The O
other O
is O
located O
at O
-1335 O
, O
outside O
this O
highly O
conserved O
region O
. O

No O
consistent O
correlation O
between O
blood O
pressure O
change O
and O
SCR-change O
was O
seen O
. O

Although O
YopH B-GENE
is O
a O
highly O
active O
PTP B-GENE
, O
it O
preferentially O
targets O
a O
subset O
of O
tyrosine-phosphorylated O
proteins O
in O
host O
cells O
, O
including O
p130Cas B-GENE
. O

These O
results O
indicate O
that O
baculovirus-expressed O
TR B-GENE
mediates O
transcriptional O
activation O
and O
repression O
in O
a O
promoter-specific O
manner O
in O
vitro O
. O

The O
carboxyl-terminal O
proline-rich O
domain O
of O
SOS1 B-GENE
is O
involved O
in O
the O
interaction O
with O
the O
PLC-gamma1 B-GENE
SH3 B-GENE
domain I-GENE
. O

The O
pilE B-GENE
gene I-GENE
product I-GENE
of I-GENE
Pseudomonas I-GENE
aeruginosa I-GENE
, O
required O
for O
pilus O
biogenesis O
, O
shares O
amino O
acid O
sequence O
identity O
with O
the O
N-termini O
of O
type B-GENE
4 I-GENE
prepilin I-GENE
proteins I-GENE
. O

In O
contrast O
to O
the O
signaling O
triggered O
by O
surface O
Ig O
engagement O
in O
B O
lymphocytes O
, O
CD38 B-GENE
ligation O
did O
not O
appear O
to O
induce O
tyrosine O
phosphorylation O
of O
the O
src-like B-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
lyn B-GENE
, O
fyn B-GENE
, O
and O
btk B-GENE
, O
or O
of O
vav- O
and O
ras-GTPase-activating B-GENE
protein I-GENE
, O
nor O
did O
it O
induce O
detectable O
changes O
in O
cytosolic O
CA2+ O
concentrations O
. O

A O
total O
of O
57 O
patients O
with O
Hodgkin's O
disease O
limited O
to O
above O
the O
diaphragm O
( O
Stages O
I O
and O
II O
, O
A O
and O
B O
) O
were O
treated O
with O
radiation O
therapy O
alone O
at O
the O
University O
of O
Florida O
between O
1964 O
and O
1974 O
. O

The O
RET B-GENE
PTC3 I-GENE
rearrangement I-GENE
is I-GENE
formed O
by O
fusion O
of O
the O
ELE1 O
and B-GENE
RET O
genes B-GENE
, I-GENE
and O
is O
highly O
prevalent O
in O
radiation-induced O
post-Chernobyl O
papillary O
thyroid O
carcinomas O
. O

The O
ns2 B-GENE
gene I-GENE
comprises O
an O
open O
reading O
frame O
( O
ORF O
) O
encoding O
a O
putative O
nonstructural O
( O
ns O
) O
protein O
of O
279 O
amino O
acids O
with O
a O
predicted O
molecular O
mass O
of O
32-kDa O
. O

These O
cognitive O
deficits O
were O
prevented O
in O
animals O
treated O
with O
MK-801 O
during O
SE O
. O

We O
previously O
showed O
that O
v-Rel B-GENE
, O
the O
oncoprotein O
of O
the O
avian O
retrovirus O
Rev-T O
, O
can O
increase O
expression O
from O
promoters O
containing O
binding O
sites O
for O
the O
cellular O
transcription O
factor O
Sp1 B-GENE
in O
chicken O
embryo O
fibroblasts O
( O
S O
. O

Allergic O
reaction O
to O
Patent O
Blue O
Violet O
during O
lymphography O
. O

The O
data O
indicate O
that O
Bmp2 B-GENE
is O
directly O
regulated O
by O
retinoic B-GENE
acid-bound I-GENE
receptors I-GENE
and O
Sp1 B-GENE
. O

NuA4 B-GENE
has O
an O
apparent O
molecular O
mass O
of O
1 O
. O
3 O
MDa O
. O

We O
also O
raised O
a O
polyclonal O
antibody O
against O
the O
glutathione B-GENE
S-transferase I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
NH2-terminal O
86 O
amino O
acids O
of O
human B-GENE
NRAMP2 I-GENE
. O

The O
protein O
coding O
region O
, O
1 O
, O
696 O
bps O
long O
, O
is O
divided O
by O
an O
intron O
into O
two O
exons O
. O

Transcription O
of O
the O
gene O
for O
ivanolysin B-GENE
O I-GENE
and O
expression O
of O
other O
genes O
of O
the O
virulence B-GENE
gene I-GENE
cluster I-GENE
in I-GENE
L I-GENE
. I-GENE
ivanovii I-GENE
were O
dependent O
on O
PrfA B-GENE
. O

MBP-Rep68 B-GENE
delta-mediated I-GENE
DNA-RNA I-GENE
helicase I-GENE
activity O
required O
ATP O
hydrolysis O
and O
the O
presence O
of O
Mg2+ O
ions O
and O
was O
inhibited O
by O
high O
ionic O
strength O
. O

The O
nm23-H1 B-GENE
nm23-H2 I-GENE
gene I-GENE
transcriptional I-GENE
activity O
ratio O
varied O
depending O
on O
the O
cell O
line O
. O

Experimentally O
in O
green O
monkeys O
, O
Syrian O
hamsters O
and O
white O
mice O
the O
authors O
studied O
the O
pathogenic O
properties O
of O
a O
new O
virus O
Issyk-Kul O
. O

METHODS O
: O
Millipore O
ultrafiltration O
membranes O
of O
three O
different O
pore O
sizes O
were O
used O
as O
model O
lenticule O
materials O
. O
The O
nominal O
membrane O
pore O
sizes O
were O
0 O
. O
1 O
microm O
, O
0 O
. O
45 O
microm O
, O
and O
3 O
microm O
; O
the O
surface O
roughness O
increased O
in O
the O
same O
order O
The O
membranes O
were O
coated O
with O
a O
thin O
layer O
of O
collagen B-GENE
I I-GENE
and O
implanted O
in O
a O
circular O
pocket O
of O
the O
anterior O
cornea O
of O
adult O
cats O
, O
and O
were O
clinically O
evaluated O
for O
the O
extent O
of O
epithelialization O
and O
the O
persistence O
of O
epithelial O
attachment O
. O

Comparative O
study O
on O
acute O
oral O
overload O
using O
tolbutamide O
and O
tolazamide O
in O
normal O
and O
diabetic O
subjects O
. O

3 O
. O

According O
to O
the O
changes O
of O
perfusion O
defects O
between O
Ex O
, O
RD O
and O
ReI O
images O
, O
they O
were O
classified O
into O
3 O
types O
: O
Type O
I O
; O
perfusion O
defect O
on O
the O
RD O
image O
was O
identical O
to O
ReI O
image O
( O
75% O
) O
Type O
I O
was O
divided O
into O
2 O
subgroups O
whether O
perfusion O
defect O
at O
Ex O
was O
unchanged O
( O
Ia O
, O
42% O
) O
or O
improved O
( O
Ib O
, O
33% O
) O
on O
the O
RD O
image O
. O

The O
associations O
between O
sex-hormone-binding B-GENE
globulin I-GENE
capacity O
( O
SHBG B-GENE
) O
, O
age O
, O
body O
mass O
index O
( O
BMI O
) O
, O
and O
physical O
fitness O
have O
been O
studied O
in O
34 O
men O
and O
36 O
women O
. O

In O
Malmo O
, O
Sweden O
, O
17 O
, O
181 O
school O
children O
born O
in O
the O
years O
1961-1965 O
were O
screened O
for O
scoliosis O
once O
a O
year O
between O
the O
ages O
of O
7 O
and O
16 O
years O
, O
during O
1971-1980 O
. O

A O
platelet-derived B-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
PDGF-R B-GENE
) O
phosphopeptide O
containing O
Tyr-857 O
does O
not O
bind O
appreciably O
to O
the O
Src B-GENE
SH2 I-GENE
domain I-GENE
, O
suggesting O
it O
is O
not O
the O
PDGF-R B-GENE
binding O
site O
for O
Src B-GENE
as O
previously O
reported O
. O

Amplification O
and O
overexpression O
of O
the O
c-erbB-2 B-GENE
gene I-GENE
in O
21MT-2 O
and O
21MT-1 O
human O
breast O
carcinoma O
cells O
results O
in O
progressively O
elevated O
levels O
of O
constitutively O
tyrosine-phosphorylated B-GENE
p185erbB-2 I-GENE
and O
is O
associated O
with O
progressive O
insulin-like B-GENE
growth I-GENE
factor I-GENE
( O
IGF B-GENE
) O
and O
combined O
IGF B-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
( I-GENE
EGF O
) B-GENE
independence O
in O
culture O
. O

Here O
we O
have O
tested O
the O
hypothesis O
that O
the O
short O
transcripts O
, O
or O
proteins O
translated O
from O
the O
short O
transcripts O
, O
are O
also O
required O
for O
respiration O
. O

Also O
, O
the O
human B-GENE
glycoprotein I-GENE
alpha-subunit I-GENE
promoter I-GENE
was O
induced O
10-fold O
by O
FSK B-GENE
in O
GH4 O
rat O
pituitary O
cells O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Three O
chromosomal B-GENE
crsA I-GENE
mutations I-GENE
, O
crsA1 B-GENE
, O
crsA4 B-GENE
, O
and O
crsA47 B-GENE
, O
were O
transferred O
by O
the O
"gene O
conversion" O
process O
to O
B O
. O
subtilis O
plasmid O
pRPD11 O
, O
which O
consists O
of O
the O
entire O
wild-type B-GENE
rpoD I-GENE
coding I-GENE
sequence I-GENE
, O
encoding O
the O
major B-GENE
sigma I-GENE
43 I-GENE
factor I-GENE
of I-GENE
B I-GENE
. I-GENE
subtilis I-GENE
RNA I-GENE
polymerase I-GENE
, O
and O
pUB110 O
. O

Lymphocytes O
from O
all O
3 O
species O
yielded O
maximum O
responses O
with O
a O
48-hour O
prelabel O
and O
12- O
to- O
16 O
hour O
postlabel O
incubation O
period O
at O
41 O
C O
and O
1 O
: O
20 O
blood O
dilution O
. O

The O
persistence O
of O
members O
of O
the O
prostigmatid O
families O
Tydeidae O
, O
Nanorchestidae O
and O
Tarsonemidae O
in O
the O
moisture-deficient O
90%-concentration O
treatments O
supports O
previous O
evidence O
of O
adaptations O
to O
low-water-content O
habitats O
. O

Unlike O
class B-GENE
II- I-GENE
and I-GENE
III-specific I-GENE
TBP-TAF I-GENE
complexes I-GENE
, O
the O
corresponding O
murine O
and O
human B-GENE
class I-GENE
I-specific I-GENE
transcription I-GENE
initiation I-GENE
factor I-GENE
TIF-IB I-GENE
SL1 I-GENE
exhibits I-GENE
a O
pronounced O
selectivity O
for O
its O
homologous O
promoter O
. O

The O
suppression O
was O
also O
demonstrated O
in O
a O
transient O
expression O
assay O
in O
vivo O
using O
isolated O
barley O
endosperms O
. O

CREST O
syndrome O
; O
a O
changing O
clinical O
significance O
. O

Hormonal O
regulation O
of O
multiple O
promoters O
of O
the O
rat B-GENE
mitochondrial I-GENE
glycerol-3-phosphate I-GENE
dehydrogenase I-GENE
gene I-GENE
: O
identification O
of O
a O
complex O
hormone-response B-GENE
element I-GENE
in O
the O
ubiquitous O
promoter O
B O
. O

Mutants O
with O
mild O
lace B-GENE
alleles I-GENE
grow O
to O
become O
adults O
with O
multiple O
aberrant O
morphologies O
in O
the O
appendages O
, O
compound O
eye O
, O
and O
bristles O
. O

Isolation O
and O
characterization O
of O
a O
vinculin B-GENE
cDNA I-GENE
from I-GENE
chick-embryo I-GENE
fibroblasts I-GENE
. O

Long-term O
effects O
of O
clofibrate O
( O
Atromid-S O
) O
on O
serum O
lipids O
in O
man O
. O

Drosophila O
230-kD O
TFIID B-GENE
subunit O
, O
a O
functional O
homolog O
of O
the O
human O
cell O
cycle O
gene O
product O
, O
negatively O
regulates O
DNA O
binding O
of O
the O
TATA B-GENE
box-binding I-GENE
subunit I-GENE
of I-GENE
TFIID I-GENE
. O

Recent O
investigations O
have O
shown O
that O
Grenz O
rays O
can O
suppress O
the O
allergic O
contact O
dermatitis O
reaction O
completely O
and O
that O
Langerhans O
cells O
, O
identified O
by O
OKT6 B-GENE
antibodies I-GENE
and O
electron O
microscopy O
, O
disappear O
from O
the O
epidermis O
at O
the O
same O
time O
. O

SBF B-GENE
binds O
to O
the O
promoter O
prior O
to O
the O
activation O
of O
transcription O
in O
late O
G1 O
, O
suggesting O
that O
Cln B-GENE
Cdc28 I-GENE
kinase I-GENE
regulates I-GENE
the O
ability O
of O
previously O
bound O
SBF O
to B-GENE
activate O
transcription O
. O

Recombinant B-GENE
Leishmania I-GENE
surface I-GENE
glycoprotein I-GENE
GP63 I-GENE
is O
secreted O
in O
the O
baculovirus O
expression O
system O
as O
a O
latent O
metalloproteinase B-GENE
. O

The O
mean O
jitter O
and O
the O
fiber O
density O
did O
not O
change O
significantly O
from O
day O
0 O
( O
30 O
. O
1 O
+ O
- O
3 O
. O
6 O
microseconds O
; O
1 O
. O
4 O
+ O
- O
0 O
. O
07 O
) O
to O
day O
30 O
( O
34 O
. O
5 O
+ O
- O
2 O
. O
7 O
microseconds O
; O
1 O
. O
6 O
+ O
- O
0 O
. O
13 O
) O
. O

9 O
, O
11-Seco O
steroids O
derived O
from O
estradiol O
3-methyl O
ether O
. O

Several O
demographic O
indices O
of O
isolated O
populations O
in O
Uzbekistan O
. O

Interferon-alpha B-GENE
may O
exacerbate O
cryoblobulinemia-related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti-angiogenic O
activity O
. O

Our O
findings O
confirm O
the O
high O
frequency O
of O
proximal O
nerve O
lesions O
in O
early O
GBS O
and O
CIDP O
, O
not O
all O
of O
which O
are O
associated O
with O
distal O
motor O
conduction O
abnormalities O
, O
and O
suggest O
that O
assessment O
of O
multiple O
F O
wave O
parameters O
, O
in O
particular O
chronodispersion O
, O
mean O
latency O
and O
mean O
amplitude O
( O
in O
addition O
to O
absence O
and O
minimum O
latency O
) O
, O
increases O
the O
yield O
of O
F O
wave O
studies O
. O

Each O
causative O
organism O
has O
a O
species-specific O
preference O
and O
requirement O
for O
temperature O
, O
salinity O
, O
pH O
, O
the O
basic O
nutrients O
, O
and O
growth B-GENE
factors I-GENE
, O
and O
the O
toxin O
formation O
is O
affected O
by O
these O
environmental O
factors O
. O

Structural O
analysis O
and O
characterization O
of O
tissue O
and O
hormonal O
responsive O
expression O
of O
the O
avian B-GENE
bone I-GENE
sialoprotein I-GENE
( O
BSP B-GENE
) O
gene O
. O

I O
. O

This O
emphasizes O
the O
conclusion O
that O
CDF-1 B-GENE
is O
not O
an O
E2F B-GENE
family I-GENE
member I-GENE
and O
points O
to O
profound O
differences O
in O
the O
cell O
cycle O
regulation O
of O
CDF-1 B-GENE
and O
E2F B-GENE
. O

Identical O
results O
were O
obtained O
when O
transfections O
and O
mobility O
shift O
assays O
were O
performed O
in O
primary O
rat O
hepatocytes O
in O
which O
the O
endogenous O
ALS B-GENE
gene I-GENE
is O
expressed O
. O

Elimination O
of O
gamma-irradiation O
induced O
oxidation O
in O
aqueous O
drug O
preparations O
. O

The O
timing O
of O
fla B-GENE
gene I-GENE
expression O
in O
the O
cell O
cycle O
is O
determined O
by O
specialized O
forms O
of O
RNA B-GENE
polymerase I-GENE
and O
the O
appearance O
and O
or O
activation O
of O
regulatory O
proteins O
. O

Growth O
, O
4-PA O
and O
14C O
turnover O
data O
indicated O
that O
WB O
contributed O
to O
B-6 O
intake O
of O
these O
rats O
. O

Catheter O
transit O
slows O
the O
response O
to O
a O
step O
increase O
in O
concentration O
by O
about O
0 O
. O
13 O
s O
( O
from O
10 O
per O
cent-90 O
per O
cent O
) O
and O
prolongs O
the O
transit O
time O
through O
the O
catheter O
for O
a O
volatile O
anesthetic O
by O
about O
0 O
. O
04 O
s O
more O
than O
N2 O
. O

Advances O
in O
the O
management O
of O
gynecologic O
cancer--radiation O
therapy O
. O

To O
test O
the O
role O
of O
ML O
in O
human O
reproductive O
axis O
, O
128 O
healthy O
children O
, O
68 O
boys O
and O
60 O
girls O
, O
were O
studied O
. O

It O
has O
been O
suggested O
that O
members O
of O
this O
protein O
family O
exhibit O
both O
prolyl B-GENE
isomerase I-GENE
and O
chaperone O
activity O
. O

Recently O
, O
identical O
RBE B-GENE
sequences I-GENE
have O
been O
identified O
at O
other O
locations O
in O
the O
human O
genome O
. O

The O
appropriate O
use O
and O
benefits O
of O
bile O
acid O
sequestrants O
, O
nicotinic O
acid O
, O
fibric O
acids O
, O
3-hydroxy-3-methylglutaryl B-GENE
coenzyme I-GENE
A I-GENE
( I-GENE
HMG-CoA I-GENE
) I-GENE
reductase I-GENE
inhibitors O
, O
and O
probucol O
are O
individually O
discussed O
, O
whereas O
nonpharmacologic O
approaches O
used O
in O
conjunction O
with O
the O
drugs O
are O
recommended O
emphatically O
. O

Increased O
granulocyte-colony B-GENE
stimulating I-GENE
factor I-GENE
( O
G-CSF B-GENE
) O
levels O
in O
neonates O
with O
perinatal O
complications O
. O

In O
some O
instances O
, O
this O
is O
partly O
mediated O
by O
the O
expression O
of O
virally O
encoded O
proteases B-GENE
which O
lead O
to O
the O
cleavage O
of O
initiation B-GENE
factor I-GENE
eIF4G I-GENE
. O

In O
contrast O
, O
tobacco B-GENE
GS-2 I-GENE
is O
composed O
of O
subunits O
of O
identical O
size O
in O
all O
organs O
examined O
. O

Women's O
opportunities O
for O
paid O
work O
outside O
the O
home O
are O
constrained O
by O
their O
role O
as O
primary O
carer O
within O
the O
family O
, O
writes O
Trudy O
Wynne O
. O

Multi O
drug O
regimens O
like O
C-MOPP O
, O
CHOP O
and O
BACOP O
led O
to O
high O
remission O
rates O
and O
in O
some O
cases O
probably O
also O
to O
a O
cure O
of O
the O
disease O
. O

The O
mean O
percentage O
of O
linoleic O
acid O
in O
the O
triglycerides O
of O
the O
subcutaneous O
adipose O
tissue O
( O
PLASAT O
) O
of O
these O
subjects O
was O
substantially O
higher O
than O
that O
in O
a O
similar O
group O
examined O
in O
1975-1976 O
. O

However O
, O
the O
ratio O
M O
Pc O
provides O
a O
useful O
index O
that O
seems O
to O
be O
independent O
of O
the O
metabolic O
demand O
. O

Cys-757 O
within O
the O
( B-GENE
Fe4S4 I-GENE
) I-GENE
-siroheme-binding I-GENE
domain I-GENE
was O
essential O
for O
native O
enzyme O
activity O
. O

The O
amplitude O
of O
detrusor O
contractions O
at O
6 O
, O
12 O
, O
and O
24 O
hours O
showed O
no O
significant O
difference O
from O
that O
in O
the O
controls O
. O

A O
third O
is O
a O
partial O
element O
terminating O
at O
a O
probable O
internal O
restriction O
site O
used O
for O
cloning O
. O

Zebrafish O
cyclops B-GENE
( O
cyc B-GENE
) O
encodes O
a O
Transforming B-GENE
Growth I-GENE
Factor I-GENE
beta I-GENE
( O
TGFbeta B-GENE
) O
signaling O
factor O
closely O
related O
to O
mouse O
Nodal B-GENE
. O

Breitbart O
, O
L O
. O

A O
newly O
synthesized O
anti-inflammatory O
agent O
, O
Y-8004 O
demonstrated O
a O
greater O
inhibition O
than O
did O
indomethacin O
( O
IM O
) O
. O
on O
inflammatory O
response O
such O
as O
ultraviolet O
erythema O
in O
guinea O
pigs O
, O
carrageenin O
edema O
, O
evans O
blue O
and O
carrageenin-induced O
pleuritis O
and O
acetic O
acid-induced O
peritonitis O
in O
rats O
. O

Polyvinyl O
alcohol O
as O
a O
solution O
mediator O
. O

Herein O
PPARgamma B-GENE
, O
liganded O
by O
either O
natural O
( O
15d-PGJ O
( O
2 O
) O
and O
PGD O
( O
2 O
) O
) O
or O
synthetic O
ligands O
( O
BRL49653 O
and O
troglitazone O
) O
, O
selectively O
inhibited O
expression O
of O
the O
cyclin B-GENE
D1 I-GENE
gene I-GENE
. O

Ovaries O
of O
10 O
animals O
per O
group O
from O
16 O
studies O
in O
CD-1 O
mice O
and O
1 O
study O
each O
in O
C3H O
and O
C57BL O
6 O
mice O
were O
sectioned O
serially O
at O
6 O
&mgr O
; O
m O
. O

5'-RACE O
analysis O
suggested O
a O
single O
transcription O
initiation O
site O
187 O
bp O
upstream O
from O
the O
translational O
start O
site O
. O

Treatment O
also O
led O
to O
a O
significant O
dose O
dependent O
reduction O
in O
the O
sum O
of O
ST O
segment O
depression O
at O
both O
trough O
and O
peak O
concentrations O
. O

Our O
data O
demonstrate O
directly O
that O
Rpm1r B-GENE
is O
transcribed O
with O
its O
substrates O
, O
tRNA B-GENE
met I-GENE
f I-GENE
and O
tRNAPro B-GENE
, O
from O
a O
promoter O
located O
upstream O
of O
the O
tRNA B-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
suggest O
that O
a O
portion O
also O
originates O
from O
a O
second O
promoter O
, O
located O
between O
the O
tRNA B-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
RPM1 B-GENE
. O

Furthermore O
, O
expression O
of O
the O
promoter O
in O
embryonic O
Drosophila O
melanogaster O
cells O
that O
lack O
MyoD1 B-GENE
and O
Sp1 B-GENE
is O
strictly O
dependent O
on O
all O
three O
sites O
remaining O
intact O
and O
on O
the O
presence O
of O
exogenously O
supplied O
Sp1 B-GENE
and O
MyoD1 B-GENE
. O

Retinoid-dependent O
activation O
of O
the O
tissue B-GENE
transglutaminase I-GENE
promoter I-GENE
depends O
on O
both O
a O
proximal O
regulatory O
region O
containing O
sequences O
highly O
conserved O
between O
the O
human O
and O
the O
mouse B-GENE
tissue I-GENE
transglutaminase I-GENE
promoters I-GENE
and O
a O
distal O
region O
that O
includes O
a O
30-base B-GENE
pair I-GENE
retinoid I-GENE
response I-GENE
element I-GENE
( I-GENE
mTGRRE1 I-GENE
) I-GENE
. O
mTGRRE1 B-GENE
contains O
three O
hexanucleotide O
half-sites O
( O
two O
canonical O
and O
one O
non-canonical O
) O
in O
a O
DR7 B-GENE
DR5 I-GENE
motif I-GENE
that I-GENE
bind O
both O
RAR*RXR O
heterodimers B-GENE
and I-GENE
RXR O
homodimers B-GENE
. I-GENE

However O
, O
the O
published O
reports O
consist O
of O
a O
small O
number O
of O
patients O
and O
limited O
data O
. O

Relationship O
between O
mitochondrial B-GENE
NADH-ubiquinone I-GENE
reductase I-GENE
and O
a O
bacterial B-GENE
NAD-reducing I-GENE
hydrogenase I-GENE
. O

The O
combination O
of O
hydralazine O
hydrochloride O
and O
isosorbide O
dinitrate O
also O
improves O
survival O
, O
but O
direct O
comparison O
of O
both O
regimens O
provided O
evidence O
for O
a O
less O
favourable O
effect O
than O
that O
of O
the O
ACE B-GENE
inhibitors O
. O

Quinone-binding O
domain O
and O
amino O
acid O
residues O
involved O
in O
quinone O
binding O
. O

In O
fact O
, O
families O
of O
polypeptides O
were O
produced O
by O
initiation O
of O
translation O
at O
AUG O
codons O
within O
sequences O
coding O
for O
VP1 B-GENE
and O
T B-GENE
, O
presumably O
as O
a O
result O
of O
transcription O
initiation O
events O
that O
generated O
5' O
ends O
immediately O
upstream O
from O
these O
AUGs O
. O

Although O
the O
expression O
of O
the O
4E-BP1 B-GENE
gene I-GENE
alone O
has O
not O
yet O
been O
accomplished O
, O
the O
gene O
was O
expressed O
in O
Escherichia O
coli O
[ O
BL21 O
( O
DE3 O
) O
] O
as O
a O
fusion O
gene O
with O
the O
glutathione-S-transferase B-GENE
( O
GST B-GENE
) O
gene O
using O
a O
prokaryotic O
gene O
fusion O
vector O
( O
pGEX-4T-2 O
) O
, O
which O
contains O
a O
gene O
sequence O
coding O
the O
cleavage O
site O
for O
a O
specific O
protease B-GENE
, O
alpha-thrombin B-GENE
. O

Reporter O
gene O
expression O
analyses O
indicate O
that O
both O
WASP B-GENE
promoters I-GENE
show O
high O
levels O
of O
expression O
in O
different O
hematopoietic O
cell O
lines O
. O

The O
geometric O
mean O
hemagglutination-inhibition O
antibody O
titers O
( O
GMT O
) O
of O
non-immunized O
, O
once-immunized O
, O
and O
twice-immunized O
chickens O
were O
compared O
at O
2-week O
intervals O
following O
primary O
immunization O
, O
secondary O
immunization O
, O
and O
challenge O
. O

These O
results O
suggest O
that O
FK O
506 O
is O
a O
useful O
immunosuppressive O
agent O
in O
kidney O
transplantation O
. O

The O
micturition O
pressure O
was O
significantly O
decreased O
only O
after O
injection O
with O
BUP-4 O
in O
both O
normal O
and O
obstructed O
rats O
. O

We O
have O
previously O
isolated O
a O
cDNA O
for O
a O
transcription O
factor O
referred O
to O
as O
Zfhep B-GENE
( O
zinc B-GENE
finger I-GENE
homeodomain I-GENE
enhancer-binding I-GENE
protein I-GENE
) O
containing O
two O
separate O
zinc O
finger O
domains O
, O
ZD1 B-GENE
and O
ZD2 B-GENE
, O
each O
of O
which O
binds O
DNA O
, O
and O
a O
homeodomain O
. O

Inactivation O
of O
p53 B-GENE
but O
not O
p73 B-GENE
by O
adenovirus B-GENE
type I-GENE
5 I-GENE
E1B I-GENE
55-kilodalton I-GENE
and I-GENE
E4 I-GENE
34-kilodalton I-GENE
oncoproteins I-GENE
. O

Following O
EPI-C0401 O
, O
but O
not O
saline O
or O
DepoFoam O
vehicle O
, O
there O
were O
transient O
( O
< O
72 O
hr O
) O
decreases O
in O
food O
consumption O
, O
arousal O
, O
hindlimb O
muscle O
tone O
, O
and O
body O
temperature O
. O

Upstream B-GENE
activating I-GENE
sequences I-GENE
( O
UASs B-GENE
) O
derived O
from O
known O
Ste12p-dependent O
genes O
have O
previously O
been O
characterized O
to O
require O
either O
multiple O
PREs B-GENE
or O
a O
single O
PRE B-GENE
coupled O
to O
a O
binding O
site O
for O
a O
second O
protein O
. O

Deletion O
studies O
identified O
a O
distal O
response O
element O
that O
is O
responsible O
for O
the O
cytokine O
response O
and O
has O
properties O
of O
an O
inducible O
transcriptional O
enhancer O
. O

195mPt-labeled O
cisplatin O
was O
administered O
iv O
and O
ip O
to O
control O
mice O
and O
to O
mice O
bearing O
Sarcoma O
180 O
. O

Both O
groups O
rejected O
pops O
with O
added O
SOA O
, O
decreasing O
mouthing O
times O
as O
SOA O
concentration O
increased O
. O

One O
millimolar O
ouabain O
completely O
inhibited O
net O
HCO3- O
secretion O
. O

These O
results O
are O
consistent O
with O
the O
well O
established O
polarity O
of O
RXR B-GENE
heterodimer O
binding O
to O
bipartite B-GENE
hormone I-GENE
response I-GENE
elements I-GENE
, O
with O
the O
VDR B-GENE
recognizing O
the O
3'-half-element O
. O

The O
uncomplicated O
cases O
of O
typhoid O
fever O
were O
found O
to O
have O
an O
intact O
CMIR O
as O
compared O
to O
the O
complicated O
cases O
. O

Copyright O
1998 O
Academic O
Press O
. O

Zatebradine O
weakly O
depressed O
the O
ectopic O
ventricular O
rate O
but O
not O
the O
arrhythmic O
ratio O
of O
the O
ventricular O
arrhythmias O
induced O
by O
two-stage O
coronary O
ligation O
24 O
h O
after O
the O
ligation O
in O
conscious O
dogs O
. O

The O
sense O
of O
self O
. O

On O
catabolism O
of O
aminoketones O
in O
climacteric O
age O
. O

The O
existence O
of O
these O
two O
categories O
of O
strains O
offers O
a O
new O
genetic O
system O
in O
which O
the O
properties O
of O
a O
potential O
invertebrate O
retrovirus O
can O
be O
tested O
. O

( O
ii O
) O
ICP27 B-GENE
binds O
preferentially O
to O
less O
modified O
forms O
of O
ICP4 B-GENE
, O
a O
protein O
that O
is O
extensively O
modified O
posttranslationally O
. O

To O
prepare O
for O
analyses O
with O
the O
family O
variables O
, O
we O
next O
present O
descriptive O
data O
based O
on O
separate O
principal O
components O
analysis O
( O
PCA O
) O
and O
multidimensional O
scaling O
analysis O
( O
MDS O
) O
of O
14 O
self-reported O
health O
scores O
for O
husbands O
and O
for O
wives O
. O

Based O
on O
16S B-GENE
rRNA I-GENE
gene I-GENE
sequence I-GENE
analysis O
, O
the O
11 O
species O
having O
two O
tuf B-GENE
genes I-GENE
all O
have O
a O
common O
ancestor O
, O
while O
the O
six O
species O
having O
only O
one O
copy O
diverged O
from O
the O
enterococcal O
lineage O
before O
that O
common O
ancestor O
. O

In O
addition O
, O
the O
acetyltransferase B-GENE
activity O
of O
p300 B-GENE
was O
observed O
to O
be O
distinct O
from O
the O
broadly O
essential O
activation O
function O
of O
the O
CH3 B-GENE
domain I-GENE
E1A-binding I-GENE
region I-GENE
. I-GENE

The O
locus O
encoding O
the O
XD B-GENE
gene I-GENE
( O
designated O
Xd B-GENE
) O
was O
mapped O
to O
the O
distal O
part O
of O
mouse O
chromosome O
17 O
by O
haplotype O
analysis O
of O
114 O
interspecific O
backcross O
mice O
. O

Merosin B-GENE
positive O
congenital O
muscular O
dystrophy O
with O
mental O
deficiency O
, O
epilepsy O
and O
MRI O
changes O
in O
the O
cerebral O
white O
matter O
. O

Lacrimal O
secretion O
in O
hyperthyroidism O
. O

Once O
ICP O
reaches O
critical O
values O
( O
> O
30 O
mm O
Hg O
) O
herniation O
occurs O
, O
usually O
within O
2 O
to O
5 O
days O
. O

The O
proofreading O
domain O
of O
Escherichia B-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
other O
DNA B-GENE
and I-GENE
or I-GENE
RNA I-GENE
exonuclease I-GENE
domains I-GENE
. I-GENE

Changes O
following O
periodontal O
surgery O
. O

Pro-inflammatory O
cytokine O
, O
tumor B-GENE
necrosis I-GENE
factor-alpha I-GENE
( O
TNF-alpha B-GENE
) O
, O
produced O
from O
adipose O
tissues O
in O
obese O
subjects O
, O
is O
known O
to O
play O
a O
predominant O
role O
in O
inducing O
insulin B-GENE
resistance O
. O

Below O
50% O
decrease O
of O
PaO2 O
, O
NADH O
was O
reduced O
largely O
. O

In O
all O
cases O
, O
high-level O
expression O
of O
the O
truncated B-GENE
avian I-GENE
integrins I-GENE
was O
obtained O
. O

Her O
serum O
FT3 O
concentration O
was O
, O
however O
, O
much O
higher O
than O
the O
ranges O
in O
normal O
pregnancy O
or O
in O
GTD O
patients O
without O
clinical O
hyperthyroidism O
. O

A O
system O
is O
described O
in O
which O
the O
volume O
flow O
rate O
of O
blood O
in O
a O
vessel O
is O
determined O
using O
transverse O
colour O
Doppler O
ultrasound O
imaging O
. O

Studies O
of O
lipogenesis O
by O
labelled O
precursors O
in O
the O
pregnant O
rat O
. O

A O
prospective O
trial O
was O
carried O
out O
in O
156 O
unselected O
patients O
( O
41 O
men O
, O
mean O
age O
67 O
. O
5 O
years O
, O
115 O
women O
, O
mean O
age O
71 O
. O
4 O
years O
) O
who O
had O
undergone O
total O
hip O
joint O
replacement O
because O
of O
degenerative O
or O
inflammatory O
arthritis O
or O
fracture O
of O
the O
neck O
of O
the O
femur O
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
DNA B-GENE
polymerase I-GENE
gene I-GENE
of I-GENE
Bombyx I-GENE
mori I-GENE
nuclear I-GENE
polyhedrosis I-GENE
virus I-GENE
. O

In O
view O
of O
these O
results O
, O
simultaneous O
pancreas-kidney O
transplantation O
appears O
to O
be O
the O
treatment O
of O
choice O
for O
Type O
I O
diabetic O
patients O
. O

Sequence O
analysis O
of O
a O
6 O
. O
3-kbp O
genomic O
EcoRI-fragment O
of O
Alcaligenes O
eutrophus O
, O
which O
was O
recently O
identified O
by O
using O
a O
dihydrolipoamide O
dehydrogenase-specific O
DNA O
probe O
( O
A O
. O

Polysome O
analysis O
further O
indicated O
that O
these O
germ B-GENE
cell-specific I-GENE
Sp1 I-GENE
mRNAs I-GENE
are O
translated O
, O
albeit O
with O
a O
lower O
efficiency O
than O
the O
somatic O
transcript O
. O

Transgenic O
tobacco O
plants O
( O
ppa-1 O
) O
constitutively O
expressing O
Escherichia B-GENE
coli I-GENE
pyrophosphatase I-GENE
behind O
the O
35S B-GENE
CaMV I-GENE
promoter I-GENE
accumulate O
high O
levels O
of O
soluble O
sugars O
in O
their O
leaves O
[ O
27 O
] O
. O

Deletions O
were O
examined O
in O
the O
LYS2 B-GENE
gene I-GENE
, O
using O
a O
set O
of O
31- O
to O
156-bp O
inserts O
that O
included O
inserts O
with O
no O
apparent O
potential O
for O
secondary O
structure O
as O
well O
as O
two O
quasipalindromes O
. O

Since O
1948 O
, O
the O
use O
of O
saline-washed O
red O
cells O
( O
WRBCs O
) O
has O
been O
advocated O
to O
minimize O
hemolysis O
after O
transfusion O
to O
patients O
with O
PNH O
. O

Diagnosis O
and O
differential O
diagnosis O
. O

In O
addition O
, O
the O
utility O
of O
beta B-GENE
2 I-GENE
transferrin I-GENE
assay O
in O
the O
diagnosis O
of O
cerebrospinal O
fluid O
otorrhea O
is O
presented O
. O

We O
show O
here O
that O
, O
despite O
their O
structural O
and O
functional O
similarities O
, O
the O
pop1 B-GENE
and O
pop2 B-GENE
genes I-GENE
fail O
to O
complement O
each O
other's O
deletion O
phenotypes O
, O
indicating O
that O
they O
perform O
non-redundant O
, O
but O
potentially O
interdependent O
, O
functions O
in O
proteolysis O
. O

To O
identify O
the O
precise O
location O
of O
the O
phosphorylation O
site O
on O
the O
64-kDa O
protein O
, O
a O
step-by-step O
mutagenesis O
procedures O
was O
followed O
. O

A O
major O
task O
for O
sports O
scientists O
may O
be O
to O
verify O
empirically O
the O
nature O
of O
an O
integrated O
model O
of O
the O
sport O
performer O
. O

To O
better O
understand O
the O
role O
of O
Ets B-GENE
proteins I-GENE
in O
Ras B-GENE
transformation O
, O
we O
have O
now O
analyzed O
the O
effects O
of O
stably O
expressing O
a O
variety O
of O
Ets2 B-GENE
constructs I-GENE
in O
Ras-transformed O
NIH3T3 O
( O
DT O
) O
cells O
. O

They O
were O
randomly O
allocated O
to O
receive O
either O
625 O
mg O
of O
calcium O
carbonate O
( O
250 O
mg O
of O
elemental O
calcium O
) O
at O
the O
end O
of O
a O
meal O
three O
times O
a O
day O
( O
group O
A O
, O
n O
= O
26 O
) O
or O
calcium O
carbonate O
in O
the O
same O
manner O
plus O
0 O
. O
625 O
mg O
day O
of O
conjugated O
equine O
estrogen O
and O
5 O
mg O
medrogestone O
acetate O
from O
day O
1-12 O
each O
month O
( O
group O
B O
, O
n O
= O
30 O
) O
. O

In O
addition O
to O
the O
signals O
obtained O
by O
ligation O
of O
the O
TCR B-GENE
, O
T O
cells O
need O
additional O
, O
co-stimulatory O
signals O
to O
be O
activated O
. O

However O
, O
most O
produced O
significant O
alteration O
of O
small O
intestinal O
permeability O
. O

Cyclin B-GENE
D1 I-GENE
promoter I-GENE
activity O
was O
stimulated O
by O
overexpression O
of O
mitogen-activated B-GENE
protein I-GENE
kinase I-GENE
( O
p41MAPK B-GENE
) O
or O
c-Ets-2 B-GENE
through O
the O
proximal O
22 O
base O
pairs O
. O

Synthetic O
enantiomers O
of O
drugs O
. O

Furthermore O
, O
in O
vitro O
decay O
reaction O
mixtures O
supplemented O
with O
the O
20-nt O
sense O
RNA O
transcript O
resulted O
in O
stabilization O
of O
R2 B-GENE
message I-GENE
. O

The O
5' O
and O
3' O
untranslated O
sequences O
contain O
characteristic O
sequences O
that O
are O
involved O
in O
the O
initiation O
and O
termination O
of O
transcription O
, O
including O
two O
possible O
promoters O
, O
one O
of O
which O
may O
contain O
two O
overlapping O
-10 O
sequences O
. O

In O
this O
study O
, O
we O
investigated O
the O
molecular O
mechanisms O
underlying O
the O
inducible O
expression O
of O
the O
flt-1 B-GENE
gene I-GENE
during O
the O
activation O
of O
THP-1 O
cells O
. O

Estimated O
daily O
intakes O
( O
EDIs O
) O
per O
person O
were O
0 O
. O
56 O
microgram O
for O
total O
HCH O
, O
0 O
. O
20 O
microgram O
for O
gamma-HCH O
, O
0 O
. O
09 O
microgram O
for O
dieldrin O
, O
1 O
. O
42 O
micrograms O
for O
total O
DDT O
, O
and O
0 O
. O
15 O
microgram O
for O
HCB O
. O

A O
protocol O
is O
elaborated O
for O
the O
preparation O
and O
characterization O
of O
a O
quality O
control O
material O
( O
QCM O
) O
containing O
intrinsic O
concentration O
of O
cadmium O
( O
Cd O
) O
( O
0 O
. O
8 O
microgram O
L O
) O
and O
lead O
( O
Pb O
) O
( O
13 O
. O
4 O
micrograms O
dL O
) O
from O
bovine O
blood O
and O
an O
elevated O
QCM O
containing O
Cd O
( O
5 O
. O
0 O
micrograms O
L O
) O
, O
mercury O
( O
Hg O
) O
( O
11 O
. O
2 O
micrograms O
L O
) O
, O
and O
Pb O
( O
34 O
. O
5 O
micrograms O
dL O
) O
from O
bovine O
blood O
spiked O
with O
aqueous O
spiking-solutions O
prepared O
with O
salts O
of O
Cd O
, O
Hg O
, O
and O
Pb O
. O

Gab2 B-GENE
, O
a O
new O
pleckstrin B-GENE
homology O
domain-containing O
adapter O
protein O
, O
acts O
to O
uncouple O
signaling O
from O
ERK B-GENE
kinase I-GENE
to O
Elk-1 B-GENE
. O

In O
HeLa O
cells O
, O
it O
activated O
transcription O
from O
the O
herpes B-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
linked O
to O
the O
chloramphenicol B-GENE
acetyltransferase I-GENE
gene I-GENE
when O
located O
in O
inverted O
orientation O
upstream O
of O
the O
thymidine B-GENE
kinase I-GENE
promoter I-GENE
or O
downstream O
of O
the O
chloramphenicol B-GENE
acetyltransferase I-GENE
gene I-GENE
coding I-GENE
sequence I-GENE
. O

Guiding O
patients O
in O
the O
decision O
should O
involve O
a O
multidisciplinary O
team O
composed O
of O
a O
surgical O
oncologist O
, O
geneticist O
, O
pathologist O
, O
psychotherapist O
and O
plastic O
surgeon O
. O

Neither O
model O
, O
as O
applied O
, O
provided O
a O
satisfactory O
account O
of O
the O
effects O
of O
the O
main O
variables O
of O
number O
of O
tones O
and O
amount O
of O
perturbation O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Treatment O
of O
ovarian O
neoplasms O
. O

The O
variable O
HMG B-GENE
dosage O
regimen O
was O
found O
to O
offer O
no O
advantages O
when O
compared O
with O
our O
standard O
daily O
dosage O
regimen O
. O

The O
improved O
CSF O
outflow O
conductance O
may O
increase O
the O
intracranial O
compliance O
and O
thereby O
dampen O
a O
pathological O
ICP O
waveform O
. O

The O
sequence O
of O
this O
region O
shows O
high O
G+C O
content O
( O
62% O
) O
, O
which O
is O
particularly O
emphasized O
in O
the O
200 O
bp O
upstream O
from O
the O
mRNA O
start O
( O
80% O
G+C O
) O
. O

This O
difference O
may O
result O
from O
the O
lower O
match O
to O
the O
ARG B-GENE
box I-GENE
consensus I-GENE
of O
the O
O B-GENE
( I-GENE
rocD I-GENE
) I-GENE
site I-GENE
. O

Expression O
, O
nucleotide O
sequence O
and O
mutational O
analysis O
of O
two O
open O
reading O
frames O
in O
the O
nif B-GENE
gene I-GENE
region I-GENE
of I-GENE
Anabaena I-GENE
sp I-GENE
. I-GENE
strain I-GENE
PCC7120 I-GENE
. O

We O
postulate O
that O
CaM B-GENE
binding O
by O
HIV B-GENE
envelope I-GENE
proteins I-GENE
is O
likely O
to O
exert O
diverse O
modulatory O
effects O
, O
and O
the O
mechanism O
for O
HIV-induced O
cytotoxicity O
may O
involve O
, O
in O
part O
, O
inhibition O
of O
CaM-regulated O
cellular O
functions O
. O

Both O
of O
these O
domains O
have O
striking O
sequence O
homology O
with O
human O
SIM B-GENE
and O
Drosophila O
SIM B-GENE
proteins O
. O

Truncations O
composed O
of O
78 O
and O
64 O
amino O
acids O
were O
translocated O
across O
the O
endoplasmic O
reticulum O
membrane O
, O
and O
translocation O
was O
found O
to O
be O
strictly O
co-translational O
and O
SRP-dependent O
. O

Toxicity O
was O
very O
mild O
with O
both O
regimens O
, O
although O
sedation O
was O
significantly O
higher O
in O
arm O
B O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

6 O
. O

The O
uterine O
response O
to O
prostaglandin O
E2 O
( O
PGE2 O
) O
and O
prostaglandin O
F2alpha O
( O
administered O
by O
intravenous O
and O
intrauterine O
routes O
) O
was O
evaluated O
during O
different O
phases O
of O
the O
menstrual O
cycle O
in O
five O
functionally O
infertile O
women O
. O

Shift-down O
experiments O
indicated O
that O
the O
10 O
( O
4 O
) O
- O
to O
10 O
( O
5 O
) O
-fold O
reduction O
in O
virus O
yield O
at O
the O
nonpermissive O
temperature O
was O
due O
to O
the O
disfunction O
of O
alpha B-GENE
TIF I-GENE
late O
in O
infection O
, O
presumably O
in O
virion O
maturation O
. O

Specifically O
, O
the O
deduced O
FR-19 B-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
has O
approximately89 O
, O
77 O
, O
and O
68% O
overall O
identity O
to O
chicken B-GENE
TEF-1A I-GENE
, O
mouse B-GENE
TEF-1 I-GENE
, O
and O
mouse B-GENE
embryonic I-GENE
TEA I-GENE
domain-containing I-GENE
factor I-GENE
, O
respectively O
. O

We O
examined O
the O
effects O
of O
long-term O
perfusion O
with O
pyridoxalated O
hemoglobin B-GENE
polyoxyethylene O
conjugate O
( O
PHP O
) O
solution O
on O
cardiac O
function O
of O
isolated O
rat O
hearts O
. O

Two O
classes O
of O
mutations O
were O
obtained O
: O
( O
i O
) O
those O
that O
altered O
the O
coding O
region O
of O
HOL1 B-GENE
, O
conferring O
the O
ability O
to O
take O
up O
histidinol O
; O
and O
( O
ii O
) O
cis-acting O
mutations O
( O
selected O
in O
a O
mutant O
HOL1-1 B-GENE
background O
) O
that O
increased O
expression O
of O
the O
Hol1 B-GENE
protein I-GENE
. O

INTERVENTION O
( O
S O
) O
: O
Twenty-six O
hemostasis O
parameters O
evaluated O
repeatedly O
in O
patients O
undergoing O
IVF-ET O
. O

NF B-GENE
kappa I-GENE
B I-GENE
was O
activated O
to O
a O
much O
greater O
extent O
by O
roscovitine O
in O
the O
WT O
cells O
than O
in O
Y8 O
cells O
. O

Although O
pathological O
thyroid O
function O
is O
related O
to O
changes O
in O
energy O
expenditure O
and O
body O
composition O
, O
its O
possible O
influence O
on O
leptin B-GENE
levels O
remains O
to O
be O
determined O
. O

Identification O
and O
characterization O
of O
the O
promoter O
for O
the O
cytotactin B-GENE
gene I-GENE
. O

A O
coiled-coil O
domain O
, O
conserved O
within O
each O
encoded O
protein O
, O
serves O
as O
a O
potential O
interaction O
motif O
for O
FLI B-GENE
LRR I-GENE
. O

We O
have O
identified O
two O
Marek's O
Disease O
Virus O
( O
MDV O
) O
genes O
within O
the O
EcoRI-B B-GENE
fragment I-GENE
of O
MDV-GA O
genomic O
DNA O
. O

Twenty-eight O
were O
excluded O
as O
gallstones O
were O
not O
proved O
: O
of O
the O
remainder O
, O
21 O
patients O
received O
glucagon B-GENE
and O
22 O
placebo O
. O

Fibrinogen B-GENE
determination O
using O
the O
KZM-1 O
meter O
. O

Unexpectedly O
, O
ALK7 B-GENE
signaling O
produced O
a O
remarkable O
change O
in O
cell O
morphology O
characterized O
by O
cell O
flattening O
and O
elaboration O
of O
blunt O
, O
short O
cell O
processes O
. O

The O
effect O
of O
echothiophate O
on O
the O
biphasic O
response O
of O
rabbit O
ocular O
pressure O
to O
dipivefrin O
. O

At O
the O
time O
of O
the O
blind O
therapeutic O
doses O
, O
Tg-off O
values O
ranged O
from O
8 O
to O
608 O
microg O
l O
. O

We O
report O
here O
the O
cloning O
of O
the O
murine B-GENE
p44 I-GENE
MAP I-GENE
kinase I-GENE
( O
extracellular B-GENE
signal-regulated I-GENE
kinase I-GENE
1 I-GENE
) O
gene O
, O
the O
determination O
of O
its O
intron O
exon O
boundaries O
, O
and O
the O
characterization O
of O
its O
promoter O
. O

Besides O
, O
we O
found O
in O
3 O
patients O
increased O
serum O
immunoglobulins O
, O
chiefly O
IgG B-GENE
, O
as O
first O
Russe O
, O
Busey O
and O
Barbeau O
demonstrated O
in O
a O
large O
French-Canadian O
family O
. O

Uptake O
of O
ofloxacin O
by O
Escherichia O
coli O
. O

A O
rapid O
staining O
technique O
for O
Leishmania O
parasites O
in O
splenic O
aspirate O
smears O
. O

Role O
of O
superoxide B-GENE
dismutase I-GENE
in O
cellular O
oxidative O
processes O
and O
method O
of O
its O
determination O
in O
biological O
materials O
. O

This O
study O
analyzed O
whether O
the O
localization O
of O
an O
accessory O
pathway O
could O
be O
predicted O
by O
using O
the O
polarity O
of O
the O
QRS O
complex O
during O
sinus O
rhythm O
on O
the O
surface O
ECG O
, O
instead O
of O
the O
delta O
wave O
polarity O
as O
used O
in O
many O
reports O
. O

Here O
we O
show O
that O
phosphorylation-induced O
loss O
of O
the O
protein B-GENE
kinase I-GENE
activity O
of O
DNA-PK B-GENE
is O
restored O
by O
the O
addition O
of O
the O
purified O
catalytic O
subunit O
of O
either O
protein B-GENE
phosphatase I-GENE
1 I-GENE
or O
protein B-GENE
phosphatase I-GENE
2A I-GENE
( O
PP2A B-GENE
) O
and O
that O
this O
reactivation O
is O
blocked O
by O
the O
potent O
protein B-GENE
phosphatase I-GENE
inhibitor O
, O
microcystin O
. O

Transcripts O
for O
both O
ODV-E18 B-GENE
and O
ODV-EC27 B-GENE
initiate O
from O
conserved O
TAAG O
motifs O
, O
and O
transcripts O
are O
detected O
from O
16 O
through O
72 O
hr O
p O
. O
i O
. O

Control O
of O
transcription O
of O
the O
erbB-2 B-GENE
gene I-GENE
is O
an O
important O
determinant O
of O
receptor O
expression O
. O

The O
incidence O
of O
second O
malignant O
neoplasms O
was O
lower O
( O
1 O
. O
3% O
) O
in O
the O
group O
treated O
with O
5-fluorouracil O
, O
doxorubicin O
, O
and O
cyclophosphamide O
than O
in O
the O
historical O
control O
group O
( O
4 O
. O
8% O
) O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
antimicrobial O
susceptibility O
to O
10 O
currently O
used O
antimicrobial O
agents O
of O
50 O
strains O
of O
P O
. O
acnes O
isolated O
from O
acne O
lesions O
and O
identified O
using O
a O
Rap O
ID O
ANA O
II O
panel O
. O

Polyhomeotic B-GENE
and I-GENE
Posterior I-GENE
Sex I-GENE
Combs I-GENE
may O
participate O
in O
a O
more O
general O
transcriptional O
mechanism O
that O
causes O
modulated O
gene O
repression O
, O
whereas O
the O
inclusion O
of O
Polycomb B-GENE
protein I-GENE
in O
the O
complex O
at O
PREs B-GENE
leads O
to O
stable O
silencing O
. O

The O
tumorigenic O
E1A B-GENE
+ O
cHa-ras B-GENE
cells O
are O
characterized O
by O
high O
and O
constitutive O
DNA O
binding O
activities O
of O
AP-1 B-GENE
, O
in O
contrast O
to O
nontransformed O
cells O
and O
the O
E1A B-GENE
cells O
. O

Unitary-group O
approach O
to O
spin-dependent O
operators O
. O

The O
transcription O
factor O
E2F B-GENE
plays O
an O
important O
role O
in O
G O
( O
1 O
) O
to O
S O
phase O
transition O
in O
the O
higher O
eukaryotic O
cell O
cycle O
. O

The O
RMR O
was O
measured O
twice O
in O
each O
phase O
and O
found O
to O
be O
similar O
( O
F O
( O
1 O
, O
18 O
) O
= O
0 O
. O
863 O
) O
across O
the O
follicular O
( O
5018 O
kJ O
24 O
h O
) O
and O
the O
luteal O
( O
5098 O
kJ O
24 O
h O
) O
phases O
. O

Inductively O
coupled O
plasma O
atomic O
emission O
spectroscopy O
was O
employed O
to O
obtain O
the O
tissue O
silicon O
measurements O
. O

The O
expression O
of O
alpha-amylase B-GENE
can O
be O
transactivated O
by O
the O
transcription O
factor O
GAMyb B-GENE
, O
which O
is O
itself O
induced O
by O
GA O
. O

Zn B-GENE
( I-GENE
II I-GENE
) I-GENE
coordination I-GENE
domain I-GENE
mutants O
of O
T4 O
gene B-GENE
32 I-GENE
protein O
. O

Deletion O
of O
the O
NF-IL6 B-GENE
beta I-GENE
leucine I-GENE
zipper I-GENE
domain I-GENE
also O
greatly O
diminished O
the O
interaction O
between O
these O
two O
proteins O
. O

These O
findings O
suggest O
that O
the O
increase O
in O
V O
O2 O
may O
have O
been O
a O
consequence O
of O
the O
increase O
in O
Q O
O2 O
rather O
than O
a O
response O
to O
the O
procedure O
itself O
. O

Significant O
alterations O
in O
CBC O
results O
and O
serum B-GENE
CRP I-GENE
concentration O
, O
compared O
with O
baseline O
values O
, O
were O
lacking O
in O
dogs O
of O
the O
control O
group O
. O

For O
Al O
, O
the O
exposure O
to O
1 O
. O
36 O
mg O
m3 O
during O
the O
shift O
corresponded O
to O
a O
urinary O
concentration O
at O
the O
end O
of O
the O
shift O
of O
200 O
microgram O
g O
creatinine O
. O

The O
tetraphasic O
action O
of O
lidocaine O
on O
CNS O
electrical O
activity O
and O
behavior O
in O
cats O
. O

An O
analytic O
method O
for O
comparative O
parameter O
weighting O
in O
magnetic O
resonance O
( O
MR O
) O
imaging O
has O
been O
developed O
using O
the O
concept O
of O
"fractional O
sensitivity O
. O
" O
This O
new O
approach O
results O
in O
easily O
calculated O
indexes O
for O
T1 O
, O
T2 O
, O
and O
hydrogen O
weighting O
. O

Here O
we O
report O
the O
purification O
of O
this O
larger O
form O
as O
an O
approximately O
320-kDa O
particle O
that O
contains O
mRNP3+4 B-GENE
and O
nine O
additional O
polypeptides O
, O
including O
mRNA-binding B-GENE
polypeptides I-GENE
of I-GENE
34 I-GENE
and I-GENE
36 I-GENE
kDa I-GENE
and O
a O
doublet O
of O
110 O
105 O
kDa O
that O
proved O
to O
be O
nucleolin O
. B-GENE

SIP1 B-GENE
( O
Smad B-GENE
interacting I-GENE
protein I-GENE
1 I-GENE
) O
and O
deltaEF1 B-GENE
( O
delta-crystallin B-GENE
enhancer I-GENE
binding I-GENE
factor I-GENE
) O
are O
structurally O
similar O
transcriptional O
repressors O
. O

A O
new O
non-LTR O
retrotransposon O
provides O
evidence O
for O
multiple O
distinct O
site-specific O
elements O
in O
Crithidia O
fasciculata O
miniexon O
arrays O
. O

Overproduction O
of O
HrcA B-GENE
protein I-GENE
from O
a O
second O
copy O
of O
hrcA B-GENE
derived O
from O
a O
plasmid O
( O
phrcA+ O
) O
in O
B O
. O
subtilis O
wild-type O
and O
delta O
hrcA B-GENE
strains O
prevented O
heat O
shock O
induction O
of O
the O
dnaK B-GENE
and O
groE B-GENE
operons I-GENE
at O
the O
level O
of O
transcription O
almost O
completely O
and O
strongly O
reduced O
the O
amounts O
of O
mRNA O
at O
a O
low O
temperature O
as O
well O
. O

The O
construct O
was O
introduced O
into O
BW2001 O
( O
xth-11 O
, O
nfo-2 O
) O
strain O
cells O
of O
Escherichia O
coli O
. O

These O
data O
suggest O
that O
: O
( O
a O
) O
proSRIF B-GENE
cleavage O
is O
initiated O
in O
the O
TGN O
, O
and O
( O
b O
) O
this O
reaction O
requires O
an O
acidic O
pH O
which O
is O
facilitated O
by O
a O
Golgi-associated B-GENE
vacuolar-type I-GENE
ATPase I-GENE
. O

High-resolution O
structure O
of O
the O
diphtheria B-GENE
toxin I-GENE
repressor I-GENE
complexed O
with O
cobalt O
and O
manganese O
reveals O
an O
SH3-like B-GENE
third O
domain O
and O
suggests O
a O
possible O
role O
of O
phosphate O
as O
co-corepressor O
. O

Second O
, O
nitrate O
induction O
of O
aeg-46 B-GENE
. I-GENE
5 I-GENE
operon I-GENE
expression O
is O
substantially O
enhanced O
in O
narL B-GENE
null O
strains O
( O
M O
. O
H O
. O

In O
spite O
of O
this O
and O
other O
complications O
of O
corticosteroids O
, O
she O
made O
a O
full O
recovery O
from O
the O
fungal O
infection O
following O
treatment O
with O
amphotericin O
B O
and O
surgical O
excision O
of O
the O
lung O
abscess O
. O

The O
GALT-primed O
calves O
had O
increased O
serum O
IgG B-GENE
, O
lavage O
IgG B-GENE
and O
IgA B-GENE
and O
increased O
LNA B-GENE
titers O
in O
both O
lavage O
fluids O
and O
serum O
following O
the O
SC O
dose O
of O
killed O
bacteria O
. O

We O
describe O
a O
case O
of O
a O
perinephric O
abscess O
treated O
with O
amphotericin O
B O
and O
nephrectomy O
. O

Our O
results O
indicate O
that O
the O
binding O
of O
CBF B-GENE
NF-Y I-GENE
to I-GENE
the O
inverted O
CCAAT O
box O
is O
responsible O
for O
transcriptional O
activation O
of O
the O
nTPH O
gene B-GENE
. I-GENE

Mutation O
of O
the O
C B-GENE
EBP I-GENE
binding I-GENE
sites I-GENE
in I-GENE
the O
Rous O
sarcoma O
virus O
long O
terminal O
repeat O
and O
gag O
enhancers B-GENE
. I-GENE

There O
were O
27 O
men O
and O
156 O
women O
. O

A O
new O
set O
of O
cDNA O
clones O
spanning O
approximately O
3 O
. O
2 O
kb O
was O
isolated O
from O
a O
lambda-ZAP O
goose O
liver O
cDNA O
library O
using O
the O
5'-most O
exon-containing O
fragment O
of O
the O
5'-most O
genomic O
DNA O
clone O
. O

The O
sequence O
contains O
an O
open O
reading O
frame O
of O
1744 O
nt O
in O
the O
virus-sense O
strand O
, O
a O
3' O
untranslated O
region O
of O
1360 O
nt O
and O
a O
3' O
poly O
( O
A O
) O
tail O
. O

We O
found O
that O
total O
PSA B-GENE
can O
be O
detected O
in O
all O
cyst O
fluids O
and O
in O
about O
75% O
of O
female O
sera O
. O

Depending O
on O
the O
location O
and O
size O
of O
the O
mass O
, O
a O
wide O
range O
of O
clinical O
presentations O
is O
associated O
with O
the O
lesion O
. O

Human O
adenovirus O
type O
41 O
contains O
two O
fibers O
. O

The O
likelihood O
that O
a O
common O
region O
of O
deletions O
would O
contain O
a O
tumor O
suppressor O
is O
strongly O
enhanced O
by O
coincidence O
of O
that O
region O
with O
a O
chromosome O
fragment O
suppressing O
tumorigenicity O
upon O
introduction O
in O
tumor O
cells O
. O

Denaturation O
of O
the O
simian O
virus O
40 O
origin O
of O
replication O
mediated O
by O
human B-GENE
replication I-GENE
protein I-GENE
A O
. O

In O
both O
these O
respects O
, O
however O
, O
the O
DBP B-GENE
mRNA I-GENE
resembles O
the O
late O
messengers O
of O
SV40 O
and O
polyoma O
viruses O
. O

Genomic O
clones O
encompassing O
the O
human B-GENE
ETS1 I-GENE
gene I-GENE
were O
isolated O
and O
utilized O
to O
define O
its O
molecular O
organization O
. O

Type O
2 O
genomes O
containing O
this O
sequence O
presumably O
more O
closely O
reflect O
the O
structure O
of O
the O
infectious O
, O
replication-competent O
retrovirus O
ancestors O
of O
the O
HERV-K O
family O
than O
do O
type O
1 O
genomes O
that O
lack O
the O
sequence O
. O

Multidrug O
resistance O
in O
Saccharomyces O
cerevisiae O
mainly O
results O
from O
the O
overexpression O
of O
genes O
coding O
for O
the O
membrane O
efflux O
pumps O
, O
the O
major O
facilitators O
and O
the O
ABC B-GENE
binding I-GENE
cassette I-GENE
transporters I-GENE
, O
under O
the O
control O
of O
key O
transcription O
regulators O
encoded O
by O
the O
PDR1 B-GENE
and O
PDR3 B-GENE
genes I-GENE
. O

In O
the O
Oct-1 B-GENE
crystal O
, O
the O
POU-specific B-GENE
domain I-GENE
recognizes O
a O
GCAT B-GENE
half-site I-GENE
, O
while O
the O
corresponding O
sequence O
recognized O
by O
the O
Pit-1 B-GENE
POU-specific I-GENE
domain I-GENE
, O
GTAT B-GENE
, O
is O
on O
the O
opposing O
strand O
. O

Blood O
samples O
were O
obtained O
daily O
during O
this O
supplementation O
period O
and O
5 O
d O
thereafter O
( O
d O
11 O
to O
15 O
) O
. O

We O
were O
able O
to O
detect O
significant O
differences O
in O
functional O
residual O
capacity O
adjusted O
for O
weight O
or O
height O
, O
and O
compliance O
of O
the O
respiratory O
system O
adjusted O
for O
weight O
or O
lung O
volume O
in O
the O
ILD O
infants O
compared O
to O
the O
healthy O
controls O
or O
infants O
who O
had O
PPHN O
, O
indicating O
that O
these O
PFTs O
were O
sensitive O
enough O
to O
determine O
abnormal O
lung O
function O
in O
this O
age O
group O
. O

The O
in O
vitro O
antibacterial O
potency O
is O
greatest O
when O
the O
1-substituent O
is O
2 O
, O
4-difluorophenyl O
and O
the O
7-substituent O
is O
a O
3-amino-1-pyrrolidinyl O
group O
. O

Previous O
analysis O
of O
the O
98-bp O
sequence O
has O
delineated O
several O
protein-binding O
domains O
that O
are O
recognized O
by O
nuclear O
factors O
present O
in O
human O
brain O
cells O
. O

There O
is O
no O
correlation O
between O
C2-C3 O
disk O
morphology O
and O
the O
diskographically O
provoked O
response O
. O

In O
experiment O
2 O
the O
rats O
had O
free O
access O
to O
two O
bottles O
, O
one O
of O
which O
contained O
tap O
water O
, O
and O
the O
other O
contained O
either O
an O
ethanol O
( O
6% O
) O
or O
a O
sucrose O
( O
5% O
) O
solution O
. O

The O
phenotypes O
of O
the O
ICP0 B-GENE
nonsense O
mutants O
were O
intermediate O
between O
those O
of O
the O
wild-type O
virus O
and O
7134 O
in O
that O
the O
more O
ICP0-coding B-GENE
sequence I-GENE
expressed O
by O
a O
given O
nonsense O
mutant O
, O
the O
more O
wild O
type-like O
was O
its O
phenotype O
. O

Here O
we O
describe O
a O
mutant O
alpha O
subunit O
designed O
to O
inhibit O
receptor-mediated O
hormonal O
activation O
of O
Gs B-GENE
, O
the O
stimulatory O
regulator O
of O
adenylyl B-GENE
cyclase I-GENE
. O

An O
inactive O
analog O
of O
wortmannin O
, O
WM12 O
, O
did O
not O
affect O
TCR O
CD3-induced O
Erk2 O
activation B-GENE
, O
and O
wortmannin O
had O
no O
effect O
on O
the O
activity O
of O
Erk2 O
when B-GENE
added O
directly O
to O
the O
in O
vitro O
assays O
. O

Concordance O
of O
IBDQ O
scores O
was O
tested O
in O
280 O
stable O
subjects O
. O

The O
UCR B-GENE
core I-GENE
sequence I-GENE
, O
CGCCATTTT B-GENE
, O
binds O
a O
ubiquitous O
nuclear O
factor O
and O
mediates O
negative O
regulation O
of O
MuLV O
promoter O
activity O
. O

The O
systolic O
peak O
of O
pulmonary O
vein O
was O
higher O
than O
the O
diastolic O
peak O
in O
45 O
out O
of O
56 O
cases O
. O

The O
effects O
of O
Codonopsis O
pilosula O
oral O
liquor O
( O
CPOL O
) O
on O
tissue-type B-GENE
plasminogen I-GENE
activator I-GENE
( O
t-PA B-GENE
) O
and O
plasminogen B-GENE
activator I-GENE
inhibitor I-GENE
( O
PAI B-GENE
) O
in O
the O
plasma O
of O
25 O
patients O
of O
coronary O
heart O
disease O
with O
blood O
stasis O
were O
studied O
. O

Here O
, O
the O
PEX5-TPR B-GENE
domains I-GENE
from O
human O
, O
tobacco O
, O
and O
nematode O
were O
inserted O
into O
a O
TPR-less O
yeast O
Pex5p B-GENE
construct O
to O
generate O
Pex5p B-GENE
chimaeras O
. O

Despite O
total O
tumor O
resection O
, O
multiple O
intraperitoneal O
tumor O
nodules O
of O
varying O
sizes O
were O
found O
and O
resected O
six O
months O
and O
one O
year O
later O
. O

Primary O
adrenal O
hypersensitivity O
to O
ACTH B-GENE
drive O
in O
obesity O
has O
also O
been O
suggested O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
determine O
the O
feasibility O
of O
retrovirus O
mediated O
expression O
of O
rp47phox B-GENE
in O
the O
HL60 O
and O
U937 O
human O
hematopoietic O
cell O
lines O
, O
and O
in O
an O
Epstein-Barr O
virus O
transformed O
B-lymphocyte O
cell O
line O
( O
EBV-BCL O
) O
derived O
from O
a O
p47phox-deficient O
CGD O
patient O
. O

To O
determine O
which O
sequences O
in O
the O
rat B-GENE
P450c17 I-GENE
promoter I-GENE
may O
be O
responsible O
for O
basal O
and O
cAMP-stimulated O
gene O
transcription O
, O
deletion O
constructs O
containing O
between O
-1 O
, O
560 O
and O
-53 O
base O
pairs O
of O
5'-flanking O
DNA O
from O
the O
rat B-GENE
P450c17 I-GENE
gene I-GENE
were O
ligated O
to O
plasmids O
expressing O
the O
reporter O
gene O
luciferase B-GENE
and O
transfected O
into O
two O
mouse O
cell O
lines O
, O
adrenal O
Y-1 O
cells O
, O
and O
testicular O
Leydig O
MA-10 O
cells O
. O

Eliminating O
any O
subset O
of O
ASCUS O
reduces O
the O
ASCUS O
SIL O
ratio O
but O
also O
significantly O
diminishes O
the O
sensitivity O
of O
the O
Papanicolaou O
test O
. O

However O
, O
besides O
the O
kinase O
catalytic O
domain O
and O
double O
leucine O
isoleucine O
zippers O
, O
there O
was O
no O
significant O
homology O
with O
known O
proteins O
. O

We O
characterized O
the O
structure O
of O
this O
leader O
mRNA O
by O
using O
the O
program O
Mfold O
and O
a O
combination O
of O
nested O
and O
internal O
deletions O
transcriptionally O
fused O
to O
a O
promoterless O
lac B-GENE
operon I-GENE
. O

Despite O
continuous O
compliance O
, O
unexplained O
resurgence O
of O
serum O
ferritin B-GENE
levels O
occurred O
in O
4 O
7 O
patients O
of O
the O
'veteran' O
group O
after O
4-5 O
years O
on O
L1 O
. O

Signal O
transduction O
via O
modulation O
of O
phosphorylation O
after O
selective O
inhibition O
of O
protein B-GENE
phosphatase I-GENE
( I-GENE
PP I-GENE
) I-GENE
1 I-GENE
and O
or O
PP2A O
appears B-GENE
to O
play O
a O
role O
in O
okadaic O
acid O
( O
OA O
) O
-mediated O
effects O
. O

The O
dual O
specificity O
kinases O
mitogen-activated B-GENE
protein I-GENE
kinase I-GENE
( I-GENE
MAPK I-GENE
) I-GENE
kinase I-GENE
( O
MKK B-GENE
) O
7 O
and O
MKK4 B-GENE
are O
the O
only O
molecules O
known O
to O
directly O
activate O
the O
stress B-GENE
kinases I-GENE
stress-activated B-GENE
protein I-GENE
kinases I-GENE
( O
SAPKs B-GENE
) O
c-Jun B-GENE
N-terminal I-GENE
kinases I-GENE
( I-GENE
JNKs O
) B-GENE
in O
response O
to O
environmental O
or O
mitogenic O
stimuli O
. O

After O
2 O
min O
of O
dobutamine O
injection O
, O
or O
after O
20 O
min O
of O
pimobendan O
injection O
, O
the O
myocardium O
was O
removed O
, O
and O
used O
for O
determination O
of O
the O
tissue O
levels O
of O
metabolites O
of O
energy O
and O
carbohydrate O
metabolism O
. O

Quantitative O
evaluation O
of O
the O
steady O
state O
kinetics O
of O
MEK B-GENE
inhibition O
by O
these O
compounds O
reveals O
that O
U0126 O
has O
approximately O
100-fold O
higher O
affinity O
for O
deltaN3-S218E B-GENE
S222D I-GENE
MEK I-GENE
than I-GENE
does O
PD098059 O
. O

Technetium-99m O
methylene O
diphosphonate O
scintimammography O
for O
evaluation O
of O
palpable O
breast O
masses O
. O

Although O
there O
was O
a O
high O
correlation O
between O
sap O
flux O
densities O
registered O
by O
the O
old O
and O
new O
sensors O
, O
significant O
differences O
in O
sap O
flux O
densities O
between O
the O
duplicated O
sensors O
were O
detected O
. O

Modern O
cancer O
therapy O
has O
included O
surgery O
, O
radiotherapy O
, O
chemotherapy O
, O
and O
most O
recently O
, O
immunotherapy O
and O
hyperthermia O
. O

One O
skull O
does O
not O
a O
species O
make O
. O

Clones O
33F O
and O
34B O
encoded O
identical O
aromatase B-GENE
proteins I-GENE
of O
503 O
amino O
acids O
, O
but O
differed O
in O
size O
due O
to O
alternative O
polyadenylation O
signal O
usage O
for O
the O
corresponding O
mRNAs O
. O

Constitutive O
phosphorylation O
and O
nuclear O
localization O
of O
Smad3 B-GENE
are O
correlated O
with O
increased O
collagen B-GENE
gene I-GENE
transcription O
in O
activated O
hepatic O
stellate O
cells O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
risk O
factors O
for O
background O
diabetic O
retinopathy O
( O
BDR O
) O
and O
PDR O
by O
following O
394 O
Japanese O
patients O
with O
early-onset O
type O
2 O
diabetes O
diagnosed O
before O
30 O
years O
of O
age O
( O
mean O
age O
27 O
, O
mean O
blood O
pressure O
at O
entry O
116 O
73 O
mm O
Hg O
) O
. O

The O
possible O
benefits O
of O
LMW O
heparin O
( O
reduced O
frequency O
of O
bleeding O
, O
alleviation O
of O
hypertriglyceridemia O
) O
were O
not O
, O
however O
, O
apparent O
, O
possibly O
because O
of O
the O
short O
observation O
period O
and O
the O
low O
incidence O
of O
hemorrhagic O
complications O
in O
routine O
dialyses O
. O

Percentages O
of O
recovery O
for O
overload O
and O
dilution O
tests O
were O
between O
87 O
and O
120% O
. O

Different O
cortical O
malformations O
were O
produced O
in O
rats O
by O
a O
single O
dose O
of O
X-rays O
( O
200 O
cGy O
) O
given O
on O
different O
days O
during O
gestation O
. O

Thus O
, O
growth B-GENE
factor I-GENE
activation O
of O
ER B-GENE
can O
mediate O
transactivation O
vs O
ER B-GENE
Sp1 I-GENE
binding I-GENE
to O
GC-rich O
sites O
and O
represents O
a O
novel O
pathway O
for O
ligand-independent O
ER O
action B-GENE
. O

The O
yeast O
gene O
that O
encodes O
eIF-5 B-GENE
, O
designated O
TIF5 B-GENE
, O
has O
been O
isolated O
and O
expressed O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
active O
eIF-5 B-GENE
protein I-GENE
. O

After O
nerve O
injury O
, O
the O
nociceptive O
responses O
through O
type O
I O
neurons O
, O
which O
are O
polymodal O
C-fibers O
and O
drive O
NK1-receptor B-GENE
mechanisms O
in O
spinal O
pain O
transmission O
, O
were O
completely O
lost O
, O
but O
without O
changes O
in O
type O
II O
ones O
, O
which O
are O
polymodal O
C-fibers O
and O
drive O
NMDA O
receptor-mechanisms O
, O
while O
type O
III O
ones O
, O
which O
are O
capsaicin-insensitive O
( O
possibly O
A-fibers O
) O
and O
drive O
NMDA-receptor B-GENE
mechanisms O
, O
were O
markedly O
enhanced O
. O

Respondents O
who O
lived O
with O
a O
spouse O
partner O
only O
were O
less O
likely O
to O
have O
an O
unfavorable O
BMI O
status O
than O
people O
in O
the O
other O
two O
groups O
. O

Catalytic O
activation O
of O
mitogen-activated B-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
phosphatase-1 I-GENE
by O
binding O
to O
p38 B-GENE
MAP I-GENE
kinase I-GENE
: O
critical O
role O
of O
the O
p38 B-GENE
C-terminal I-GENE
domain I-GENE
in O
its O
negative O
regulation O
. O

Mastocytosis O
. O

Whereas O
a O
PR55 B-GENE
beta I-GENE
transcript I-GENE
of O
about O
2 O
. O
3 O
kb O
was O
detected O
at O
high O
levels O
in O
the O
neuroblastoma O
derived O
cell O
line O
LA-N-1 O
, O
the O
level O
of O
the O
mRNA O
was O
very O
low O
in O
the O
other O
human O
cell O
lines O
analyzed O
. O

These O
observations O
indicate O
that O
there O
are O
multiple O
mechanisms O
by O
which O
an O
individual O
transcript O
can O
be O
degraded O
following O
deadenylation O
. O

Total O
PGE O
levels O
in O
synovial O
fluid O
remained O
significantly O
depressed O
in O
the O
patient O
group O
for O
24 O
hours O
after O
the O
400-mg O
test O
dose O
of O
tolmetin O
on O
day O
8 O
. O

Mutually O
exclusive O
interaction O
of O
the O
adenovirus B-GENE
E4-6 I-GENE
7 I-GENE
protein I-GENE
and I-GENE
the O
retinoblastoma O
gene B-GENE
product I-GENE
with I-GENE
internal O
domains O
of O
E2F-1 O
and B-GENE
DP-1 O
. B-GENE

BACKGROUND O
PURPOSE O
: O
Anomalous O
arrangement O
of O
the O
pancreaticobiliary O
duct O
( O
AAPBD O
) O
is O
closely O
related O
to O
congenital O
biliary O
dilatation O
and O
frequently O
associated O
with O
biliary O
tract O
malignancy O
. O

These O
results O
indicate O
that O
mutL B-GENE
, O
miaA B-GENE
, O
and O
hfq B-GENE
expression O
could O
be O
regulated O
by O
multiple O
mechanisms O
, O
including O
degree O
of O
cotranscription O
from O
upstream O
genes O
, O
modulation O
of O
internal O
promoter O
strength O
, O
and O
by O
RNase B-GENE
E I-GENE
activity O
. O

Transfection O
and O
in O
vitro O
binding O
studies O
identified O
within O
HEFT1 B-GENE
a I-GENE
promoter I-GENE
whose O
basal O
activity O
required O
a O
GC O
box O
activated O
by O
Sp1 B-GENE
or O
Sp3 B-GENE
. O

The O
RAS-cyclic B-GENE
AMP-dependent I-GENE
protein I-GENE
kinase I-GENE
cAPK I-GENE
pathway O
prevents O
the O
UAS B-GENE
activity O
of O
IREu B-GENE
in O
the O
presence O
of O
glucose O
as O
the O
sole O
carbon O
source O
, O
while O
the O
transcriptional O
activators O
Msn2p B-GENE
and O
Msn4p B-GENE
promote O
the O
UAS B-GENE
activity O
of O
this O
repeat O
in O
the O
presence O
of O
acetate O
. O

CONCLUSIONS O
: O
In O
essential O
hypertension O
an O
acute O
protein O
load O
induces O
a O
decrease O
in O
GFR O
that O
may O
normalize O
under O
antihypertensive O
treatment O
. O

In O
contrast O
, O
peak O
filling O
rate O
( O
PFR O
) O
, O
normalized O
to O
end O
diastolic O
volume O
( O
EDV O
) O
, O
or O
stroke O
volume O
( O
SV O
) O
, O
or O
expressed O
as O
the O
ratio O
of O
PFR-to-PER O
was O
reduced O
( O
p O
< O
0 O
. O
01 O
) O
, O
time O
to O
PFR O
( O
TPFR O
) O
was O
prolonged O
( O
p O
< O
0 O
. O
01 O
) O
, O
and O
echocardiographic O
left O
ventricular O
mass O
index O
was O
higher O
( O
p O
< O
0 O
. O
001 O
) O
in O
patients O
with O
acromegaly O
compared O
to O
normals O
. O

Beta O
blocking O
agents O
. O

There O
was O
no O
further O
increase O
in O
oxygen O
consumption O
when O
these O
subjects O
breathed O
with O
inspiratory O
pressures O
above O
SIP O
. O

This O
dimer O
interface O
is O
likely O
important O
for O
increasing O
the O
DNA-binding O
specificity O
and O
affinity O
of O
the O
trimeric O
form O
of O
HSF B-GENE
, O
as O
well O
as O
for O
increasing O
cooperativity O
between O
adjacent O
trimers O
. O

Three O
missense O
mutants O
in O
subunit O
a O
of O
the O
Escherichia B-GENE
coli I-GENE
F1F0-ATPase I-GENE
were O
isolated O
and O
characterized O
after O
hydroxylamine O
mutagenesis O
of O
a O
plasmid O
carrying O
the O
uncB B-GENE
( I-GENE
subunit I-GENE
a I-GENE
) I-GENE
gene I-GENE
. O

CONCLUSIONS O
: O
The O
surgical O
or O
multimodality O
treatment O
of O
MSGT O
has O
provided O
a O
good O
locoregional O
control O
( O
78% O
) O
and O
68% O
10-year O
survival O
in O
a O
series O
of O
patients O
treated O
at O
the O
oncology O
department O
of O
a O
general O
hospital O
in O
Quito O
, O
Ecuador O
. O

The O
predicted O
DNA-binding O
, O
zinc O
finger O
domain O
protein O
sequence O
was O
strictly O
conserved O
. O

In O
transient O
cotransfection O
assays O
using O
Chang O
liver O
cells O
( O
CCL O
13 O
) O
, O
pM1 O
DNA O
exerts O
a O
6- O
to O
10-fold O
trans-activating O
effect O
on O
the O
expression O
of O
the O
pSV2CAT O
reporter O
plasmid O
. O

During O
treatment O
, O
the O
phosphorylation O
state O
of O
Rb B-GENE
shifted O
to O
a O
hypophosphorylated O
form O
. O
mRNA O
for O
the O
HPV B-GENE
E6 I-GENE
E7 I-GENE
genes I-GENE
decreased I-GENE
; O
however O
, O
significant O
changes O
in O
the O
E7 O
protein B-GENE
were I-GENE
not O
observed O
, O
while O
increased O
levels O
of O
Rb O
immunoprecipitated B-GENE
with O
anti-E7 O
antibodies B-GENE
were I-GENE
observed O
. O

51 O
. O
9% O
( O
P O
= O
0 O
. O
0006 O
) O
in O
the O
MMF O
versus O
the O
AZA O
groups O
, O
respectively O
. O

The O
General O
Practice O
Research O
Database O
( O
GPRD O
) O
is O
the O
world's O
largest O
computerized O
database O
of O
anonymized O
longitudinal O
patient O
records O
from O
general O
practice O
and O
is O
a O
unique O
public O
health O
research O
tool O
. O

Velocity O
sedimentation O
, O
cross-linking O
, O
and O
immunoprecipitation O
analyses O
of O
detergent-solubilized O
rat O
brain O
revealed O
that O
the O
32 O
and O
34 O
kDa O
polypeptides O
reside O
within O
heterotetramers O
. O

Characterization O
of O
the O
3' O
ends O
of O
the O
plus-strand O
DNA O
fragments O
reveals O
( O
1 O
) O
that O
the O
upstream O
fragment O
is O
elongated O
beyond O
PPT2 B-GENE
creating O
a O
plus-strand O
overlap O
and O
( O
2 O
) O
that O
the O
majority O
of O
plus-strand O
strong-stop O
DNA O
fragments O
bear O
a O
copy O
of O
the O
minus-strand O
primer O
binding O
site O
in O
agreement O
with O
the O
accepted O
model O
of O
retroviral O
genomic O
RNA O
reverse O
transcription O
. O

Further O
, O
they O
are O
consistent O
with O
the O
suggestion O
that O
sites O
homologous O
to O
the O
CAR1 B-GENE
URS I-GENE
may O
be O
situated O
in O
the O
5'-flanking O
regions O
of O
multiple O
unrelated O
yeast O
genes O
. O

A23187 O
did O
not O
induce O
any O
modifications O
of O
the O
endolymphatic O
potential O
, O
the O
ampullar O
direct O
current O
or O
the O
frequency O
of O
the O
evoked O
afferent O
spikes O
. O

Electrophoretic O
characteriaztion O
of O
virus-induced O
interferon B-GENE
of O
the O
blood O
and O
urine O
in O
rabbits O
. O

GnRH B-GENE
treatment O
was O
found O
to O
increase O
the O
phosphorylation O
of O
tyrosine O
residues O
of O
MAPK B-GENE
and O
to O
increase O
MAPK B-GENE
activity O
, O
as O
determined O
by O
an O
immune O
complex O
kinase B-GENE
assay O
. O

Hemodynamics O
changes O
in O
man O
during O
flight O
. O

Nasal O
absorption O
was O
rapid O
, O
nasal O
bioavailability O
was O
43% O
, O
and O
the O
iv O
and O
nasal O
elimination O
profiles O
were O
similar O
. O

In O
experiment O
2 O
, O
no O
difference O
in O
gastric O
emptying O
of O
40% O
peptone O
or O
25% O
glucose O
was O
found O
between O
rats O
receiving O
TPN O
and O
those O
receiving O
intragastric O
nutrition O
for O
10 O
to O
12 O
days O
. O

To O
derive O
quantitative O
concentration O
changes O
from O
measurements O
of O
light O
attenuation O
, O
the O
optical O
path O
length O
must O
be O
known O
. O

Analysis O
of O
chromosomal O
DNA O
sequence O
immediately O
downstream O
of O
the O
transposon O
insertion O
identified O
two O
open O
reading O
frames O
, O
designated O
csrR B-GENE
and O
csrS B-GENE
, O
which O
exhibited O
sequence O
similarity O
to O
bacterial O
two-component O
regulatory O
systems O
. O

Rev-erbAalpha B-GENE
beta I-GENE
) I-GENE
, I-GENE
Mxi-1 O
and B-GENE
Mad O
bHLH-zip B-GENE
proteins I-GENE
and I-GENE
the O
oncoproteins O
PLZF O
and B-GENE
LAZ3 O
BCL6 B-GENE
is I-GENE
mediated I-GENE
by O
the O
corepressors O
N-CoR O
and O
SMRT B-GENE
. O

Reporting O
of O
adverse O
events O
occurring O
during O
clinical O
trials O
of O
investigational O
drugs O
is O
a O
complex O
and O
controversial O
issue O
. O

The O
effects O
of O
two O
levels O
of O
caffeine O
ingestion O
on O
excess O
postexercise O
oxygen O
consumption O
in O
untrained O
women O
. O

Of O
the O
117 O
patients O
( O
out O
of O
the O
136 O
) O
with O
serologic O
evidence O
of O
chronic O
thyroiditis O
who O
could O
be O
studied O
, O
eight O
( O
7% O
) O
had O
hyperthyroidism O
and O
45 O
( O
38% O
) O
were O
hypothyroid O
. O

Unfortunately O
, O
these O
preservatives O
may O
also O
interfere O
with O
microbiological O
assays O
used O
to O
determine O
product O
sterility O
or O
bioburden O
levels O
. O

Where O
UMDNJ O
is O
headed O
. O

Serum B-GENE
relaxin I-GENE
levels O
in O
prostaglandin O
E2 O
induced O
abortions O
. O

Human B-GENE
GATA-3 I-GENE
: O
a O
lineage-restricted O
transcription O
factor O
that O
regulates O
the O
expression O
of O
the O
T B-GENE
cell I-GENE
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

Induction O
of O
Fas B-GENE
ligand I-GENE
expression O
by O
HIV O
involves O
the O
interaction O
of O
Nef B-GENE
with O
the O
T B-GENE
cell I-GENE
receptor I-GENE
zeta I-GENE
chain I-GENE
. O

Telomeres O
prevent O
end-to-end O
fusions O
and O
exonucleolytic O
degradation O
, O
enable O
the O
end O
of O
the O
linear O
DNA O
molecule O
to O
replicate O
, O
and O
function O
in O
cell O
division O
. O

Specifically O
, O
by O
the O
type O
of O
adjuvant O
therapy O
, O
the O
median O
disease-free O
interval O
and O
survival O
from O
stage O
IVA O
for O
23 O
patients O
receiving O
Corynebacterium O
parvum O
were O
6 O
. O
9 O
and O
19 O
months O
; O
for O
39 O
patients O
receiving O
BCG O
, O
eight O
months O
and O
26 O
months O
; O
for O
24 O
patients O
receiving O
BCG O
+ O
DTIC O
, O
eight O
and O
17 O
. O
4 O
months O
; O
and O
for O
all O
51 O
DTIC O
treated O
patients O
6 O
. O
3 O
and O
17 O
. O
8 O
months O
, O
respectively O
. O

Merr O
. O
) O
embryo O
library O
. O

Altogether O
, O
we O
confirm O
that O
all O
genes O
of O
the O
Rad52 B-GENE
recombinational I-GENE
repair I-GENE
pathway I-GENE
are O
required O
for O
the O
survival O
of O
rad27 B-GENE
Delta I-GENE
strains O
at O
both O
permissive O
( O
23 O
degrees O
C O
) O
and O
semipermissive O
( O
30 O
degrees O
C O
) O
temperatures O
for O
growth O
. O

A O
single O
amino O
acid O
substitution O
in O
the O
cyclin B-GENE
D I-GENE
binding I-GENE
domain I-GENE
of O
the O
infected B-GENE
cell I-GENE
protein I-GENE
no O
. O

Improving O
the O
evidence O
base O
for O
anaesthesia O
. O

Seven O
of O
these O
had O
counterparts O
in O
the O
US O
of O
herpes O
simplex O
type O
1 O
( O
HSV-1 O
) O
, O
pseudorabies O
virus O
( O
PRV O
) O
, O
and O
equine O
herpesvirus O
type O
1 O
( O
EHV-1 O
) O
. O

Since O
high O
levels O
of O
immunoglobulin B-GENE
G I-GENE
were O
demonstrated O
against O
the O
surface O
of O
the O
NVS O
after O
immunization O
, O
passive O
transfer O
experiments O
were O
initiated O
. O

Our O
results O
show O
that O
CVN B-GENE
specifically O
recognizes O
with O
nanomolar O
affinity O
Man B-GENE
( I-GENE
9 I-GENE
) I-GENE
GlcNAc I-GENE
( I-GENE
2 I-GENE
) I-GENE
and O
the O
D1D3 B-GENE
isomer I-GENE
of O
Man B-GENE
( I-GENE
8 I-GENE
) I-GENE
GlcNAc I-GENE
( I-GENE
2 I-GENE
) I-GENE
. O

No O
definite O
conclusions O
are O
possible O
because O
of O
the O
small O
number O
of O
patients O
involved O
in O
this O
phase O
II O
trial O
. O

Out O
of O
these O
families O
74 O
, O
3% O
planned O
next O
pregnancy O
( O
table O
IX O
) O
, O
57 O
, O
6% O
wanted O
to O
have O
prenatal O
diagnosis O
( O
table O
VI O
) O
. O

CONCLUSIONS O
: O
The O
special O
clinical O
presentation O
of O
our O
case O
of O
possible O
Gardner's O
syndrome O
is O
discussed O
. O

Interestingly O
, O
addition O
of O
purified O
CBP B-GENE
to O
the O
nuclear O
extracts O
of O
T47D O
cells O
markedly O
stimulated O
progesterone- O
and O
PR-dependent O
transcription O
from O
a O
nucleosome-free O
, O
progesterone B-GENE
response I-GENE
element I-GENE
( O
PRE B-GENE
) O
-linked O
reporter O
DNA O
template O
. O

Therefore O
, O
it O
was O
concluded O
that O
thrombotic O
tendency O
certainly O
existed O
in O
patients O
with O
MS O
compared O
to O
those O
with O
non O
RHD O
and O
that O
it O
was O
one O
of O
the O
causes O
of O
the O
significantly O
high O
incidence O
of O
thromboembolism O
in O
comparison O
with O
non O
RHD O
. O

Before O
PO3 O
administration O
, O
more O
than O
half O
( O
57 O
. O
4% O
) O
of O
the O
patients O
received O
only O
1 O
or O
2 O
antituberculous O
drugs O
( O
ethambutole O
and O
ethionamide O
or O
ethambutole O
and O
oprofloxacin O
) O
. O

Routine O
psychometric O
screening O
of O
IHD O
patients O
may O
provide O
a O
cost-effective O
means O
of O
alerting O
cardiologists O
and O
internists O
to O
the O
relatively O
high O
levels O
of O
distress O
among O
their O
patients O
. O

In O
addition O
, O
computer O
analysis O
suggests O
that O
sequences O
similar O
to O
the O
A O
stem O
element O
are O
present O
within O
the O
three O
AAV B-GENE
promoter I-GENE
regions O
. O

Another O
cis-acting O
element O
, O
exonic B-GENE
splicing I-GENE
suppressor I-GENE
1 I-GENE
( O
ESS1 B-GENE
) O
, O
represses O
use O
of O
the O
nt O
3225 O
3' O
splice O
site O
. O

After O
hemodynamic O
stabilization O
, O
the O
goal O
of O
therapy O
is O
to O
diminish O
the O
chance O
that O
an O
ulcer O
will O
continue O
to O
bleed O
or O
will O
rebleed O
. O

Two O
splice O
variants O
of O
ALF1 B-GENE
cDNA I-GENE
have O
been O
found O
, O
differing O
by O
a O
72-bp O
insertion O
, O
coding O
for O
putative O
proteins O
of O
682 O
and O
706 O
amino O
acids O
. O

Our O
results O
suggest O
that O
while O
many O
muscle O
gene O
E-boxes O
are O
capable O
of O
binding O
the O
previously O
characterized O
spectrum O
of O
MDF B-GENE
bH-L-H I-GENE
heterodimers I-GENE
in I-GENE
vitro O
, O
MCK-L O
type B-GENE
E-boxes O
probably O
bind O
qualitatively O
different O
factors O
in O
vivo O
. O

The O
amino O
acid O
sequence O
of O
matrilysin-2 B-GENE
also O
contains O
a O
threonine O
residue O
adjacent O
to O
the O
Zn-binding O
site O
that O
has O
been O
defined O
as O
a O
specific O
feature O
of O
matrilysin B-GENE
. O

Value O
of O
determination O
of O
alkaline B-GENE
phosphatase I-GENE
isoenzymes I-GENE
for O
differential O
diagnosis O
of O
obstructive O
jaundice O
and O
biliary O
liver O
cirrhosis O
. O

Aedes O
aegypti O
( O
L O
. O
) O
and O
Aedes O
albopictus O
( O
Skuse O
) O
in O
Singapore O
City O
. O

Ras- B-GENE
and I-GENE
ultra-violet-responsive I-GENE
protein I-GENE
kinases I-GENE
that O
phosphorylate O
c-Jun B-GENE
on O
serine O
residues O
at O
positions O
63 O
and O
73 O
and O
stimulate O
its O
transcriptional O
activity O
have O
been O
identified O
. O

CONCLUSIONS O
: O
Lymphoscintigraphy O
of O
the O
cynomolgus O
monkey O
eyelids O
reveals O
discrete O
lymphatic O
drainage O
pathways O
for O
the O
upper O
and O
lower O
eyelids O
and O
a O
dual O
pathway O
for O
the O
central O
upper O
eyelid O
. O

Regional O
blood O
blow O
was O
measured O
by O
means O
of O
microspheres O
in O
predefined O
regions O
of O
the O
C6 O
, O
T11 O
, O
and O
L6 O
vertebrae O
. O

CMV O
hyperimmunoglobulin B-GENE
treatment O
( O
Cytotect O
, O
Biotest O
) O
was O
started O
( O
2 O
ml O
kg O
bw O
on O
day O
1 O
and O
3 O
, O
and O
1 O
ml O
kg O
on O
days O
5 O
, O
7 O
and O
9 O
) O
, O
which O
led O
to O
the O
eradication O
of O
the O
residual O
infiltrate O
and O
CMV-DNA O
in O
the O
myocardium O
. O

The O
ewes O
were O
returned O
to O
normoxia O
, O
and O
monitoring O
was O
continued O
for O
1 O
h O
. O

The O
major O
promoter O
responds O
strongly O
to O
virus-encoded O
trans O
activators O
EIA B-GENE
and O
EIV B-GENE
and O
contains O
four O
elements O
: O
a O
TAGA O
motif O
analogous O
to O
the O
TATA O
box O
, O
two O
EIIF B-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
, O
and O
an O
ATF B-GENE
CREB I-GENE
site I-GENE
. I-GENE

Interestingly O
, O
in O
the O
adult O
, O
transgene O
expression O
patterns O
within O
the O
cerebellum O
in O
two O
lines O
appeared O
to O
mark O
distinct O
anterior-posterior O
compartments O
. O

Heterogeneous B-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
binds O
to O
the O
transcription-regulatory O
region O
of O
mouse O
hepatitis O
virus O
RNA O
. O

In O
17 O
patients O
with O
deletions O
, O
the O
parental O
origin O
of O
deletion O
was O
determined O
. O

Clinical O
accuracy O
of O
updated O
version O
of O
the O
Phadebas O
RAST O
test O
. O

On O
the O
basis O
of O
the O
mechanism O
of O
action O
, O
two O
groups O
of O
inodilators O
are O
distinguished O
, O
the O
phosphodiesterase B-GENE
inhibitors O
and O
the O
dopaminergic O
agents O
. O

The O
detection O
ratio O
peaked O
at O
ages O
30 O
to O
34 O
and O
decreased O
heavily O
during O
the O
next O
15 O
years O
of O
age O
. O

Phase O
II O
trial O
of O
the O
anti-G B-GENE
( I-GENE
D2 I-GENE
) I-GENE
monoclonal I-GENE
antibody I-GENE
3F8 I-GENE
and O
granulocyte-macrophage B-GENE
colony-stimulating I-GENE
factor I-GENE
for O
neuroblastoma O
. O

Another O
ORF O
, O
dda B-GENE
. I-GENE
2 I-GENE
located O
between O
modA B-GENE
and O
dda B-GENE
, O
shares O
sequence O
similarity O
with O
sigma70 B-GENE
, O
and O
we O
call O
it O
srd B-GENE
. O

The O
authors O
present O
the O
only O
two O
studies O
that O
have O
proved O
successful O
in O
treating O
animal O
models O
of O
osteoarthritis O
using O
gene O
therapy O
, O
and O
propose O
an O
overview O
of O
several O
strategies O
for O
the O
development O
of O
gene O
therapy O
in O
osteoarthritis O
treatment O
in O
the O
future O
. O

There O
was O
significant O
correlation O
of O
LVM O
M2 O
and O
PWVn O
for O
pre-AVR O
and O
post O
AVR O
studies O
. O

A O
gene O
in O
Drosophila O
melanogaster O
that O
maps O
cytologically O
to O
2C1-3 O
on O
the O
distal O
portion O
of O
the O
X-chromosome O
encodes O
a O
member O
of O
the O
steroid B-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. I-GENE

We O
investigated O
the O
diagnostic O
value O
of O
a O
new O
in O
vitro O
test O
, O
Pharmacia O
CAP O
System O
( O
Pharmacia O
Diagnostics O
AB O
, O
Uppsala O
, O
Sweden O
) O
, O
for O
the O
quantitative O
measurement O
of O
allergen-specific B-GENE
IgE I-GENE
antibodies I-GENE
by O
comparison O
with O
RAST O
in O
2 O
groups O
of O
patients O
, O
71 O
atopic O
and O
48 O
non-atopic O
. O

One O
complex O
containing O
a O
70 O
D O
protein O
was O
found O
to O
be O
associated O
specifically O
with O
transcriptionally O
active O
leukemia O
cells O
. O

This O
finding O
suggested O
that O
the O
PI3K-Akt B-GENE
activation I-GENE
pathway I-GENE
plays O
some O
role O
in O
the O
antiapoptotic O
effect O
of O
EPO B-GENE
. O

G O
. O

Strikingly O
, O
this O
subdomain O
is O
also O
present O
in O
the O
otherwise O
unrelated O
N-terminal O
activating O
region O
of O
p58c-ets-2 B-GENE
and O
was O
thus O
named O
BEC B-GENE
for O
Ets-1-beta B-GENE
Ets-2-Conserved I-GENE
sequence I-GENE
. I-GENE

Consistent O
with O
the O
hepatic O
and O
epidermal O
expression O
of O
histidase B-GENE
, O
this O
finding O
suggests O
that O
histidase B-GENE
transcription O
may O
be O
regulated O
by O
these O
factors O
. O

The O
respiratory O
rate O
was O
13 O
+ O
- O
1 O
breaths O
min O
with O
52 O
+ O
- O
4% O
of O
the O
respiratory O
cycle O
spent O
in O
inspiration O
; O
end-tidal O
CO2 O
pressure O
increased O
by O
3 O
. O
3 O
+ O
- O
1 O
. O
0 O
Torr O
during O
runs O
at O
SIP O
. O

Previous O
studies O
have O
indicated O
that O
a O
hamster O
cell O
line O
( O
ts13 O
) O
with O
a O
point O
mutation O
in O
the O
TAF B-GENE
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
CCG1 I-GENE
( I-GENE
TAF O
( B-GENE
II I-GENE
) I-GENE
250 I-GENE
) I-GENE
gene O
shows O
temperature-sensitive O
expression O
of O
a O
subset O
of O
genes O
and O
arrests O
in O
late O
G1 O
at O
39 O
. O
5 O
degrees O
C O
. O

Model O
of O
spatiotemporal O
dynamics O
of O
stick-slip O
motion O
. O

A O
hydrodynamic O
description O
of O
the O
osmotic O
reflection O
coefficient O
with O
application O
to O
the O
pore O
theory O
of O
transcapillary O
exchange O
. O

Sequential O
MR O
examinations O
of O
the O
nasal O
cavity O
and O
paranasal O
sinuses O
were O
performed O
within O
a O
6-8 O
h O
period O
in O
five O
normal O
volunteers O
. O

Comparison O
of O
patients O
receiving O
phenytoin O
and O
those O
who O
were O
not O
showed O
significantly O
lower O
serum O
folate O
in O
the O
sub-group O
receiving O
phenytoin O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
sub-groups O
with O
respect O
to O
vitamin O
B12 O
or O
behaviour O
problem O
rating O
. O

Jerseys O
had O
higher O
hepatic O
Cu O
concentrations O
than O
did O
Holsteins O
on O
d O
60 O
( O
346 O
vs O
. O

A O
region O
approximately O
100 O
bp O
upstream O
from O
the O
transcription O
start O
point O
of O
virB B-GENE
was O
identified O
as O
being O
necessary O
for O
full O
activation O
of O
this O
promoter O
by O
VirF B-GENE
. O

We O
also O
found O
that O
the O
same O
males O
, O
breeding O
in O
different O
years O
on O
the O
same O
territories O
, O
had O
significantly O
larger O
harems O
in O
the O
years O
they O
had O
familiar O
neighbors O
. O

Galoyan O
has O
summarized O
the O
results O
of O
his O
discovery O
of O
cardioactive O
neurohormones O
. O

The O
authors O
proposed O
that O
the O
highly O
convergent O
inputs O
to O
the O
entorhinal O
cortex O
indicate O
this O
region O
may O
be O
particularly O
important O
for O
selecting O
or O
compressing O
information O
. O

Serum B-GENE
TNF I-GENE
concentrations O
were O
elevated O
at O
diagnosis O
and O
gradually O
decreased O
toward O
the O
reference O
limits O
by O
week O
16 O
. O

In O
group O
III O
, O
patients O
also O
received O
their O
own O
mediastinal O
drainage O
blood O
, O
shed O
for O
6 O
hours O
after O
operation O
, O
after O
concentration O
and O
washing O
in O
a O
MBRS O
. O

The O
importance O
of O
selective O
renal O
vein O
phlebography O
in O
the O
evaluation O
of O
unexplained O
hematuria O
and O
filing O
defects O
in O
the O
excretory O
urogram O
is O
illustrated O
. O

Gluzman O
, O
EMBO O
J O
. O

Comparison O
was O
made O
with O
other O
neuroradiological O
imaging O
modalities O
including O
CT O
, O
myelography O
, O
CT O
ventriculography O
, O
and O
CT O
myelocisternography O
. O

The O
best O
regression O
model O
for O
predicting O
changes O
in O
the O
WCXR O
included O
time O
to O
first O
positive O
culture O
and O
antibody O
titer O
for O
Pa B-GENE
elastase I-GENE
. O

Two O
patients O
had O
immediate O
adverse O
effects O
from O
NMF O
; O
one O
had O
a O
grand O
mal O
seizure O
and O
the O
other O
developed O
severe O
abdominal O
pain O
. O

A O
possible O
role O
for O
the O
mixed O
function O
oxidase B-GENE
enzyme I-GENE
system I-GENE
in O
the O
requirement O
for O
selenium O
in O
the O
rat O
. O

Monospecific O
antibodies O
raised O
against O
rat B-GENE
cytochrome I-GENE
P-450 I-GENE
1A1 I-GENE
recognized O
a O
protein O
in O
the O
hepatic O
microsomes O
of O
the O
double-crested O
cormorant O
, O
and O
also O
in O
those O
of O
the O
great O
blue O
heron O
( O
Ardea O
herodias O
) O
, O
using O
immunoblotting O
. O

Blood O
sampling O
procedures O
were O
videotaped O
. O

Calcimimetic O
agents O
directly O
inhibit O
PTH B-GENE
secretion O
by O
activating O
the O
calcium-sensing O
receptor O
in O
the O
parathyroid O
glands O
, O
but O
clinical O
experience O
with O
them O
is O
limited O
. O

The O
drug-resistant O
cell O
lines O
P388 O
ADR O
3 O
and O
P388 O
ADR O
7 O
express O
a O
shortened O
topo O
II O
alpha O
mRNA O
transcript B-GENE
in I-GENE
addition I-GENE
to I-GENE
the I-GENE
native O
transcript O
present O
in O
the O
drug-sensitive O
P388 O
4 O
cell O
line O
. O

Taken O
together O
, O
differences O
in O
signaling O
and O
tissue O
expression O
suggest O
that O
the O
human B-GENE
intermediate I-GENE
PRLr I-GENE
differs O
from O
the O
long B-GENE
PRLr I-GENE
in O
physiological O
function O
. O

Conservative O
treatment O
of O
bladder O
carcinoma O
by O
partial O
cystectomy O
and O
interstitial O
iridium O
192 O
. O

This O
fragment O
can O
bind O
several O
trans-acting O
factors O
in O
vitro O
, O
including O
GATA-1 B-GENE
and O
members O
of O
the O
Ets B-GENE
family I-GENE
. O

This O
study O
determined O
the O
arthritogenic O
potential O
of O
silicone O
gel O
by O
either O
mixing O
it O
with O
bovine B-GENE
collagen I-GENE
II I-GENE
( O
BII B-GENE
) O
or O
by O
injecting O
silicone O
gel O
alone O
in O
DA O
rats O
. O

Administration O
of O
the O
dopamine O
agonist O
bromocriptine O
( O
2 O
. O
5 O
mg O
three O
times O
a O
day O
for O
4 O
days O
) O
suppressed O
( O
P O
less O
than O
0 O
. O
01 O
) O
mean O
24-h O
plasma O
18-OHB O
levels O
from O
21 O
. O
9 O
+ O
- O
2 O
. O
0 O
to O
14 O
. O
8 O
+ O
- O
1 O
. O
4 O
ng O
dl O
. O

Group O
I O
comprised O
5 O
adult O
Collies O
that O
received O
at O
least O
400 O
microg O
kg O
ivermectin O
p O
. O
o O
. O
and O
were O
presented O
to O
the O
VMTH O
3 O
hours O
after O
intoxication O
. O

At O
cuticular O
positions O
exhibiting O
the O
Brd B-GENE
bristle I-GENE
loss I-GENE
phenotype I-GENE
, O
we O
have O
found O
that O
the O
progeny O
of O
the O
multiplied O
SOPs O
develop O
aberrantly O
, O
in O
that O
neurons O
and O
thecogen O
( O
sheath O
) O
cells O
appear O
but O
not O
trichogen O
( O
shaft O
) O
and O
tormogen O
( O
socket O
) O
cells O
. O

Optimal O
activation O
of O
T O
cells O
requires O
at O
least O
two O
signals O
. O

Use O
of O
free-access O
minerals O
. O

63 O
. O
3 O
micromol O
1 O
, O
p O
< O
0 O
. O
01 O
) O
and O
area O
under O
the O
plasma O
concentration-time O
curve O
extrapolated O
to O
infinity O
AUC O
9 O
( O
0-infinity O
) O
( O
518 O
. O
7 O
vs O
. O

Purified B-GENE
Pra I-GENE
was O
also O
shown O
to O
physically O
interact O
with O
pyruvate B-GENE
kinase I-GENE
( O
Pk B-GENE
) O
; O
Pk B-GENE
and O
Pra B-GENE
can O
form O
a O
complex O
, O
but O
when O
the O
12-kDa B-GENE
Ndk I-GENE
, O
Pk B-GENE
, O
and O
Pra B-GENE
are O
all O
present O
, O
Pk B-GENE
has O
a O
higher O
affinity O
than O
Pra B-GENE
for O
forming O
a O
complex O
with O
the O
12-kDa B-GENE
Ndk I-GENE
. O

The O
data O
suggest O
that O
plasminogen B-GENE
, O
alpha B-GENE
2AP I-GENE
, O
and O
C1-INH B-GENE
, O
should O
be O
considered O
equine B-GENE
acute-phase I-GENE
proteins I-GENE
. O

We O
here O
demonstrate O
that O
a O
temperature-sensitive O
fission O
yeast O
mutant O
which O
has O
a O
mutation O
in O
a O
homologous O
gene O
, O
and O
two O
of O
three O
additional O
( O
mtr1 B-GENE
prp20 I-GENE
srm1 I-GENE
) I-GENE
mutants I-GENE
accumulate O
nuclear O
poly O
( O
A O
) O
+ O
RNA O
at O
37 O
degrees O
C O
. O

Grossly O
, O
the O
experimental O
vulvitis O
was O
identical O
to O
the O
field O
condition O
, O
and O
bacteria O
indistinguishable O
from O
the O
inoculated O
strains O
were O
reisolated O
. O

Inhibition O
of O
the O
Mek B-GENE
Erk I-GENE
pathway I-GENE
in I-GENE
Rat1 O
ras O
cells O
, O
using O
the O
Mek O
inhibitor O
, B-GENE
PD98059 O
, O
resulted O
in O
complete O
cytoskeletal O
recovery O
, O
indistinguishable O
from O
that O
induced O
by O
HR12 O
. O

In O
Saccharomyces O
cerevisiae O
, O
PHO85 B-GENE
encodes O
a O
cyclin-dependent B-GENE
protein I-GENE
kinase I-GENE
( O
Cdk B-GENE
) O
catalytic O
subunit O
with O
multiple O
regulatory O
roles O
thought O
to O
be O
specified O
by O
association O
with O
different O
cyclin B-GENE
partners O
( O
Pcls B-GENE
) O
. O

Tonometry O
of O
blood O
samples O
from O
patients O
may O
also O
be O
used O
in O
the O
determination O
of O
acid-base O
quantities O
and O
hemoglobin-oxygen O
affinity O
e O
. O
g O
. O
p50 O
. O

The O
natural O
history O
of O
these O
lesions O
, O
locoregional O
efficiency O
of O
the O
different O
treatments O
used O
, O
the O
part O
played O
by O
chemotherapy O
, O
survival O
, O
causes O
of O
death O
and O
therapeutic O
modalities O
used O
as O
a O
last O
measure O
, O
have O
been O
analysed O
. O

The O
homologies O
between O
RAD16 B-GENE
, O
RAD54 B-GENE
and O
SNF2 B-GENE
are O
also O
shared O
by O
several O
additional O
, O
recently O
isolated O
yeast O
and O
Drosophila O
genes O
. O

Plasma B-GENE
secretin I-GENE
levels O
also O
augmented O
after O
the O
administration O
of O
ethanol O
solutions O
, O
with O
a O
delay O
of O
about O
one O
hour O
after O
the O
onset O
of O
acid O
secretion O
. O

Background O
Aims O
: O
Hepatitis O
C O
and O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFL O
) O
are O
the O
two O
most O
common O
forms O
of O
liver O
disease O
in O
the O
United O
States O
. O

The O
progression O
of O
acute O
bronchitis O
is O
associated O
with O
elevated O
blood O
concentrations O
of O
acute-phase B-GENE
proteins I-GENE
, O
KKS B-GENE
activation O
in O
the O
blood O
and O
high O
serotonin O
and O
lactic O
acid O
content O
in O
the O
humor O
condensated O
from O
the O
exhaled O
air O
. O

Topical O
1 O
percent O
isoproterenol O
in O
the O
presence O
of O
the O
phosphodiesterase B-GENE
inhibitor O
theophylline O
was O
tested O
for O
its O
ability O
to O
stimulate O
the O
rate O
of O
aqueous O
humor O
flow O
through O
the O
anterior O
chamber O
of O
the O
normal O
and O
the O
partially O
adrenergically O
denervated O
human O
eye O
( O
Horner's O
syndrome O
) O
. O

Copyright O
2000 O
Academic O
Press O
. O

Some O
mutations O
affected O
Dhfr B-GENE
in O
a O
qualitative O
manner O
, O
such O
as O
by O
changing O
the O
startpoint O
of O
one O
of O
the O
major O
Dhfr B-GENE
transcripts I-GENE
or O
changing O
the O
relative O
abundance O
of O
the O
two O
major O
Dhfr B-GENE
transcripts I-GENE
. O

The O
sequencing O
of O
Stellate B-GENE
copies O
located O
along O
the O
discontinuous O
cluster O
revealed O
a O
complex O
pattern O
of O
diversification O
. O

These O
results O
suggest O
that O
the O
phenotype O
of O
XLP O
may O
result O
from O
perturbed O
signaling O
not O
only O
through O
SLAM B-GENE
, O
but O
also O
other O
cell O
surface O
molecules O
that O
utilize O
SAP B-GENE
as O
a O
signaling O
adaptor O
protein O
. O

Only O
one O
ADR O
was O
related O
definitely O
to O
ciprofloxacin O
therapy O
. O

Here O
, O
a O
case O
of O
Sjogren's O
syndrome O
is O
presented O
that O
was O
initially O
diagnosed O
because O
of O
dental O
complaints O
, O
and O
long-term O
treatment O
of O
Sjogren's O
patients O
is O
discussed O
. O

The O
12S B-GENE
E1A I-GENE
product I-GENE
does O
not O
activate O
a O
TRE B-GENE
sequence I-GENE
, O
but O
cotransfection O
with O
c-jun B-GENE
circumvents O
this O
lack O
of O
stimulation O
. O

Second O
, O
the O
wild-type B-GENE
m8 I-GENE
3' I-GENE
UTR I-GENE
strongly O
reduces O
accumulation O
of O
heterologous O
transcripts O
in O
vivo O
, O
an O
activity O
that O
requires O
its O
K O
box O
sequences O
. O

Thus O
it O
appears O
that O
insertion O
of O
a O
transposable O
element O
near O
the O
5' O
terminus O
of O
the O
structural O
gene O
can O
produce O
constitutive O
expression O
of O
a O
normally O
glucose-repressed O
enzyme O
. O

The O
IE13 O
. O
1 O
cell O
line O
was O
able O
to O
complement O
a O
recombinant O
virus O
in O
which O
both O
copies O
of O
the O
IE B-GENE
gene I-GENE
were O
replaced O
by O
insertion O
of O
the O
Escherichia B-GENE
coli I-GENE
lacZ I-GENE
gene I-GENE
. O

After O
taking O
smears O
from O
lesions O
of O
the O
oral O
mucosa O
( O
tongue O
, O
cheeks O
, O
palate O
) O
and O
the O
contiguous O
denture O
surface O
by O
cotton O
wool O
swabs O
and O
inoculating O
them O
onto O
Sabouraud O
glucose O
agar O
and O
CHROMagar O
Candida O
, O
individual O
yeast O
species O
were O
identified O
by O
a O
germ O
tube O
, O
filamentous O
, O
and O
assimilation O
tests O
employing O
the O
commercial O
kit O
AuxaColor O
. O

[ O
18F O
] O
( O
+ O
) O
-4-fluorobenzyltrozamicol O
( O
FBT O
) O
, O
which O
selectively O
binds O
to O
the O
vesicular O
acetylcholine B-GENE
transporter I-GENE
in O
the O
presynaptic O
cholinergic O
neuron O
, O
has O
previously O
been O
shown O
to O
be O
a O
useful O
ligand O
for O
the O
study O
of O
cholinergic O
terminal O
density O
in O
the O
basal O
ganglia O
with O
PET O
. O

A O
genomic O
clone O
was O
isolated O
that O
contained O
12 O
. O
5 O
kb O
of O
the O
5'-flanking O
region O
and O
the O
first O
exon O
of O
the O
p69 B-GENE
71 I-GENE
2-5A I-GENE
synthetase I-GENE
gene I-GENE
. I-GENE

Here O
we O
report O
the O
cloning O
and O
characterization O
of O
Xenopus B-GENE
Pax-5 I-GENE
and O
Pax-8 B-GENE
, O
two O
orthologues O
of O
the O
Pax-2 B-GENE
5 I-GENE
8 I-GENE
gene I-GENE
family I-GENE
. I-GENE

However O
, O
cotransfection O
studies O
indicate O
that O
RVR B-GENE
does O
not O
activate O
transcription O
when O
this O
hormone B-GENE
response I-GENE
element I-GENE
is O
linked O
to O
a O
reporter O
gene O
but O
rather O
acts O
as O
a O
potent O
competitive O
repressor O
of O
ROR B-GENE
alpha I-GENE
function O
. O

The O
level O
of O
carboxyl-terminal B-GENE
parathyroid I-GENE
hormone I-GENE
in O
the O
patients O
with O
thyroid O
carcinoma O
was O
higher O
than O
that O
in O
the O
patients O
without O
thyroid O
carcinoma O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

The O
prothrombin B-GENE
gene I-GENE
G20210A I-GENE
mutation I-GENE
is O
not O
found O
among O
Japanese O
patients O
with O
deep O
vein O
thrombosis O
and O
healthy O
individuals O
. O

The O
correct O
termination O
of O
retroviral O
transcripts O
at O
the O
3' O
LTR B-GENE
R I-GENE
U5 I-GENE
junction I-GENE
is I-GENE
primarily O
dependent O
on O
the O
canonical O
AAUAAA O
polyadenylation B-GENE
signal O
, O
so O
we O
have O
analyzed O
the O
effect O
of O
mutating O
the O
polyadenylation O
signal O
sequences O
on O
the O
properties O
of O
a O
selectable O
murine O
retroviral O
vector O
. O

When O
the O
coronary O
sinus O
pressure O
reached O
15 O
torr O
, O
there O
was O
a O
significant O
decrease O
in O
cardiac O
index O
( O
3 O
. O
60 O
+ O
- O
0 O
. O
5 O
to O
2 O
. O
70 O
+ O
- O
0 O
. O
6 O
L O
min O
m2 O
, O
p O
less O
than O
0 O
. O
001 O
) O
, O
coronary O
blood O
flow O
( O
13 O
. O
7 O
+ O
- O
3 O
. O
1 O
to O
7 O
. O
0 O
+ O
- O
2 O
. O
1 O
ml O
min O
, O
p O
less O
than O
0 O
. O
001 O
) O
, O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
1 O
, O
567 O
+ O
- O
275 O
to O
1 O
, O
331 O
+ O
- O
314 O
, O
p O
less O
than O
0 O
. O
05 O
) O
, O
and O
an O
increase O
in O
coronary O
arteriovenous O
difference O
( O
62 O
. O
8% O
+ O
- O
9 O
. O
3% O
to O
70 O
. O
5% O
+ O
- O
5 O
. O
4% O
saturation O
, O
p O
less O
than O
0 O
. O
03 O
) O
. O

These O
results O
suggest O
that O
ULK2 B-GENE
is O
involved O
in O
a O
previously O
uncharacterized O
signaling O
pathway O
in O
mammalian O
cells O
. O

We O
compared O
previously O
the O
methylation O
status O
between O
normal O
liver O
and O
liver O
tumors O
in O
SV40 B-GENE
T I-GENE
t I-GENE
antigen I-GENE
transgenic I-GENE
mice O
( O
MT-D2 O
mice O
) O
using O
Restriction O
Landmark O
Genomic O
Scanning O
for O
Methylation O
( O
RLGS-M O
) O
and O
identified O
several O
loci O
spots O
that O
appeared O
to O
be O
methylated O
frequently O
in O
liver O
tumors O
. O

The O
5'-flanking O
region O
of O
the O
human B-GENE
lactoferrin I-GENE
gene I-GENE
was O
isolated O
from O
a O
human O
placental O
genomic O
library O
. O

Additionally O
, O
observations O
that O
patients O
with O
mitral O
versus O
aortic O
regurgitation O
respond O
differently O
to O
valve O
replacement O
suggest O
that O
differences O
exist O
preoperatively O
between O
these O
two O
types O
of O
volume O
overload O
. O

GH B-GENE
deficiency O
may O
be O
absolute O
, O
but O
often O
is O
not O
and O
the O
diagnosis O
may O
be O
complicated O
by O
a O
constellation O
of O
physical O
and O
hormonal O
findings O
that O
are O
along O
a O
spectrum O
from O
low O
normal O
GH B-GENE
sufficiency O
to O
absent O
GH B-GENE
secretion O
. O

The O
bovine B-GENE
PGHS-2 I-GENE
cDNA I-GENE
was O
cloned O
by O
a O
combination O
of O
reverse O
transcription-polymerase O
chain O
reaction O
and O
cDNA O
library O
screening O
. O

Previous O
studies O
have O
suggested O
that O
moderate O
cooling O
increases O
the O
responsiveness O
of O
vascular B-GENE
alpha2-adrenoceptors I-GENE
. O

Copyright O
2002 O
American O
Cancer O
Society O
. O
DOI O
10 O
. O
1002 O
cncr O
. O
10318 O

Stable O
association O
of O
U2 B-GENE
snRNP I-GENE
with O
the O
branchpoint O
sequence O
of O
mammalian O
pre-mRNAs O
requires O
binding O
of O
a O
non-snRNP B-GENE
protein I-GENE
to O
the O
polypyrimidine O
tract O
. O

Patterns O
defined O
by O
combinations O
of O
normal O
and O
abnormal O
laboratory O
results O
had O
decreased O
the O
likelihood O
of O
PEM O
from O
an O
all-2 O
to O
all-0 O
pattern O
. O

Nucleotide O
sequencing O
indicates O
that O
this O
E1 B-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
1821 O
base O
pairs O
( O
bp O
) O
in O
length O
with O
an O
open O
reading O
frame O
of O
1365 O
bp O
and O
a O
3'-untranslated O
region O
of O
356 O
bp O
. O

Retinoblastoma O
: O
a O
study O
of O
natural O
history O
and O
prognosis O
of O
268 O
cases O
. O

We O
have O
recently O
identified O
a O
mouse O
enzyme O
termed O
gamma-glutamyl B-GENE
leukotrienase I-GENE
( O
GGL B-GENE
) O
that O
converts O
leukotriene O
C4 O
( O
LTC4 O
) O
to O
leukotriene O
D4 O
( O
LTD4 O
) O
. O

The O
results O
suggest O
that O
the O
role O
of O
S O
. O
argyrostoma O
in O
the O
dissemination O
of O
Trichinella O
larvae O
in O
nature O
is O
limited O
in O
comparison O
to O
the O
role O
played O
by O
mammals O
with O
scavenger O
and O
cannibalistic O
behavior O
. O

Karger O
AG O
, O
Basel O

Proceedings O
: O
Reversible O
complete O
heart O
block O
following O
surgery O
of O
congenital O
heart O
defects O
. O

GABA B-GENE
( I-GENE
B I-GENE
) I-GENE
R1g I-GENE
was O
expressed O
in O
both O
brain O
and O
peripheral O
tissues O
. O

A O
malignant O
true O
teratoma O
of O
liver O
in O
childhood O
. O

To O
assess O
the O
health O
significance O
of O
the O
early O
renal O
changes O
after O
chronic O
exposure O
to O
cadmium O
, O
23 O
workers O
removed O
from O
exposure O
because O
of O
the O
discovery O
of O
an O
increased O
urinary O
excretion O
of O
beta B-GENE
2-microglobulin I-GENE
or O
retinol B-GENE
binding I-GENE
protein I-GENE
, O
or O
both O
, O
have O
been O
examined O
once O
a O
year O
for O
five O
years O
. O

We O
have O
examined O
reporter O
gene O
( O
beta-gal B-GENE
) O
expression O
directed O
by O
human B-GENE
heat I-GENE
shock I-GENE
transcription I-GENE
factors I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
HSF1 B-GENE
and O
HSF2 B-GENE
) O
in O
HeLa O
cells O
and O
in O
yeast O
( O
Saccharomyces O
cerevisiae O
) O
. O

Therefore O
, O
use O
of O
presaturation O
is O
recommended O
for O
myocardial O
motion O
studies O
using O
cine O
PC O
velocity O
data O
. O

The O
histological O
grading O
was O
certified O
in O
68 O
cases O
: O
12 O
G1 O
, O
39 O
G2 O
, O
17 O
G3 O
; O
extracapsular O
spread O
was O
found O
in O
20 O
54 O
cases O
( O
37% O
) O
. O

( O
3 O
) O
. O

Expression O
of O
Msp B-GENE
was O
toxic O
to O
E O
. O
coli O
when O
the O
entire O
msp B-GENE
gene I-GENE
was O
present O
. O

High-mobility-group B-GENE
protein I-GENE
I I-GENE
can O
modulate O
binding O
of O
transcription O
factors O
to O
the O
U5 B-GENE
region I-GENE
of O
the O
human B-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
proviral I-GENE
promoter I-GENE
. O

There O
was O
a O
significant O
correlation O
between O
tubular O
diameter O
and O
spg O
( O
r O
= O
0 O
. O
68 O
, O
P O
less O
than O
0 O
. O
001 O
) O
suggesting O
that O
tubular O
diameter O
measurements O
in O
histological O
sections O
could O
be O
used O
to O
predict O
sperm O
production O
. O

The O
rho B-GENE
genes I-GENE
comprise O
an O
evolutionarily O
conserved O
family O
with O
significant O
homology O
to O
the O
ras B-GENE
oncogene I-GENE
family I-GENE
. O

The O
effect O
of O
ICRF-187 O
on O
the O
antitumor O
response O
induced O
by O
the O
combination O
of O
ADR O
and O
WBH O
was O
also O
investigated O
in O
order O
to O
assess O
alterations O
in O
the O
therapeutic O
index O
of O
this O
combined O
therapeutic O
modality O
treatment O
. O

The O
syndrome O
of O
resistance O
to O
thyroid O
hormone O
is O
characterized O
by O
elevated O
serum O
free O
thyroid O
hormones O
, O
failure O
to O
suppress O
pituitary B-GENE
thyrotropin I-GENE
secretion O
, O
and O
variable O
peripheral O
refractoriness O
to O
hormone O
action O
. O

Survival O
rates O
for O
the O
original O
treatment O
group O
were O
84 O
. O
5% O
and O
57 O
. O
6% O
at O
12 O
and O
21 O
months O
, O
respectively O
; O
for O
the O
delayed O
treatment O
group O
, O
78 O
. O
8% O
and O
64 O
. O
6% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
and O
78 O
. O
8% O
and O
47 O
. O
5% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
for O
77 O
subjects O
with O
AIDS O
and O
93 O
. O
0% O
and O
71 O
. O
8% O
, O
respectively O
, O
for O
50 O
subjects O
with O
AIDS-related O
complex O
in O
the O
original O
treatment O
group O
. O

The O
signalling O
molecules O
Wnt1 B-GENE
and O
Sonic B-GENE
hedgehog I-GENE
, O
implicated O
in O
the O
activation O
of O
Myf5 B-GENE
in O
myogenic O
progenitor O
cells O
in O
the O
somite O
, O
are O
also O
produced O
in O
the O
viscinity O
of O
the O
Myf5 B-GENE
expression I-GENE
domain I-GENE
in O
the O
mesencephalon O
. O

Sequence O
analysis O
of O
this O
100-bp O
Col2a1 B-GENE
enhancer I-GENE
revealed O
several O
sequence O
motifs O
similar O
to O
motifs O
present O
within O
the O
regulatory O
region O
of O
the O
link B-GENE
protein I-GENE
gene I-GENE
, O
another O
cartilage O
gene O
. O

This O
is O
in O
contrast O
with O
the O
classical O
'oxygen O
debt O
hypothesis' O
, O
which O
states O
that O
the O
oxygen O
debt O
and O
lactate O
clearance O
are O
linked O
. O

Mental O
development O
is O
generally O
normal O
. O

Reactivities O
to O
horse B-GENE
anti-lymphocyte I-GENE
globulin I-GENE
. O

Further O
studies O
in O
T-24 O
cells O
demonstrated O
that O
HA O
fragments O
also O
induced O
I B-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
phosphorylation O
and O
degradation O
, O
kappa B-GENE
B-linked I-GENE
reporter I-GENE
gene I-GENE
expression O
, O
and O
ICAM-1 B-GENE
promoter I-GENE
activity O
in O
an O
NF-kappa O
B-dependent O
manner O
. O

Acetoin O
can O
be O
reused O
by O
the O
bacteria O
during O
stationary O
phase O
when O
other O
carbon O
sources O
have O
been O
depleted O
. O

An O
epidemic O
of O
hepatitis O
B O
virus O
infection O
among O
intravenous O
drug O
users O
in O
Iceland O
. O

Transformations O
in O
the O
morphine O
series O
. O

Morphology O
of O
bacteriophages O
of O
Klebsiella O
bacilli O
. O

During O
the O
biosynthesis O
of O
all O
three O
mutant O
polypeptides O
, O
the O
signal O
peptide O
is O
efficiently O
and O
accurately O
cleaved O
from O
the O
nascent O
protein O
, O
even O
though O
in O
mutants O
X2 O
and O
X3 O
the O
cleavage O
site O
itself O
has O
been O
altered O
. O

Influence O
of O
cyclo-oxygenase B-GENE
inhibition O
and O
of O
leukotriene B-GENE
receptor I-GENE
blockade O
on O
pulmonary O
vascular O
pressure O
cardiac O
index O
relationships O
in O
hyperoxic O
and O
in O
hypoxic O
dogs O
. O

Of O
the O
remaining O
seven O
, O
five O
reacted O
either O
with O
immediate O
and O
strong O
symptoms O
or O
had O
spontaneously O
reduced O
gluten B-GENE
intake O
, O
or O
had O
an O
acquired O
IgA B-GENE
deficiency O
. O

Polysorbate O
80 O
did O
not O
have O
a O
direct O
stimulant O
or O
relaxant O
effect O
on O
either O
guinea O
pig O
ileum O
or O
rat O
uterus O
, O
however O
, O
it O
antagonised O
the O
contractions O
induced O
by O
acetylcholine O
, O
histamine O
, O
barium O
, O
5-hydroxytryptamine O
and O
carbachol O
in O
a O
dose-dependent O
manner O
. O

The O
molecular O
mechanism O
by O
which O
Gle2p B-GENE
and O
the O
Gle2p-Nup116p B-GENE
interaction O
function O
in O
mRNA O
export O
is O
unknown O
. O

The O
C4BP B-GENE
alpha I-GENE
gene I-GENE
is O
organized O
as O
follows O
: O
the O
first O
exon O
codes O
for O
the O
first O
198 O
nucleotides O
of O
the O
5' O
UTR O
. O

EXERCISE O
IN O
THE O
TERRESTRIAL O
CHRISTMAS O
ISLAND O
RED O
CRAB O
GECARCOIDEA O
NATALIS O
- O
ENERGETICS O
OF O
LOCOMOTION O
. O

We O
have O
now O
located O
the O
5' O
ends O
of O
the O
two O
remaining O
late O
mRNAs O
. O

Acta O
572 O
, O
113-120 O
] O
. O

The O
RNA B-GENE
polymerase I-GENE
III-recruiting I-GENE
factor I-GENE
TFIIIB I-GENE
induces O
a O
DNA O
bend O
between O
the O
TATA O
box O
and O
the O
transcriptional O
start O
site O
. O

To O
search O
for O
genes O
that O
interact O
with O
the O
SLK1-SLT2 B-GENE
pathway O
, O
a O
synthetic O
lethal O
suppression O
screen O
was O
carried O
out O
. O

Scotchbond O
2 O
showed O
the O
least O
dye O
penetration O
but O
not O
statistically O
less O
than O
the O
XR O
bond O
Silus O
Plus O
combination O
. O

The O
consequences O
of O
intensive O
swine O
production O
on O
the O
environment O
and O
possible O
solutions O
by O
means O
of O
nutrition O
are O
outlined O
. O

Pitx2 B-GENE
rescues O
the O
GABAergic O
differentiation O
defect O
and O
partially O
rescues O
the O
axon O
guidance O
and O
behavioral O
phenotypes O
of O
unc-30 B-GENE
mutants I-GENE
, O
indicating O
a O
high O
degree O
of O
functional O
conservation O
between O
these O
evolutionarily O
related O
genes O
. O

These O
data O
strongly O
implicate O
the O
normal O
product O
of O
the O
int-2 B-GENE
gene I-GENE
, O
which O
is O
related O
to O
the O
fibroblast B-GENE
growth I-GENE
factor I-GENE
family I-GENE
, O
as O
a O
contributory O
factor O
in O
virally O
induced O
mammary O
tumors O
. O

Similarity O
of O
DNA O
binding O
and O
transcriptional O
regulation O
by O
Caenorhabditis B-GENE
elegans I-GENE
MAB-3 I-GENE
and O
Drosophila B-GENE
melanogaster I-GENE
DSX I-GENE
suggests O
conservation O
of O
sex O
determining O
mechanisms O
. O

Serum O
gastrin B-GENE
and O
AFP B-GENE
levels O
had O
the O
same O
evolution O
and O
appear O
to O
have O
the O
same O
interest O
to O
follow O
the O
course O
of O
the O
disease O
. O

Pokeweed B-GENE
mitogen I-GENE
( O
PWM B-GENE
) O
or O
anti-CD3 B-GENE
significantly O
increases O
c-jun B-GENE
messenger I-GENE
RNA I-GENE
( I-GENE
mRNA I-GENE
) I-GENE
levels O
in O
T O
cells O
. O

The O
same O
trend O
was O
noted O
between O
YG O
4 O
. O
5 O
heifers O
and O
YG O
5 O
. O
5 O
steers O
, O
indicating O
a O
sex-related O
deposition O
of O
seam O
fat O
in O
fed O
cattle O
. O

Nucleoprotein O
( O
N O
) O
expressed O
by O
both O
recombinant O
vaccinia O
virus O
and O
TGEV O
had O
a O
relative O
molecular O
mass O
( O
Mr O
) O
of O
47 O
, O
000 O
and O
was O
susceptible O
to O
degradation O
at O
the O
C-terminus O
yielding O
discrete O
breakdown O
products O
. O

A O
herpesvirus B-GENE
proteinase I-GENE
activity O
has O
been O
identified O
and O
partially O
characterized O
by O
using O
the O
cloned O
enzyme O
and O
substrate O
genes O
in O
transient O
transfection O
assays O
. O

Molecular O
cloning O
and O
expression O
of O
human B-GENE
UDP-d-Xylose I-GENE
: I-GENE
proteoglycan I-GENE
core I-GENE
protein I-GENE
beta-d-xylosyltransferase B-GENE
and O
its O
first O
isoform B-GENE
XT-II I-GENE
. O

Microwave O
hyperthermia-induced O
blood-brain O
barrier O
alterations O
. O

These O
results O
suggest O
that O
less O
antidopaminergic O
activity O
of O
RHAL O
in O
this O
neuroleptic O
test O
might O
be O
explained O
by O
the O
lesser O
conversion O
of O
RHAL O
to O
HAL O
. O

All O
patients O
had O
the O
CA B-GENE
125 I-GENE
assay O
performed O
within O
one O
week O
before O
their O
second-look O
operation O
. O

Early O
disagnosis O
of O
cancer--50 O
per O
cent O
of O
all O
patients O
could O
be O
cured O
. O

Thiopentone O
sodium O
administered O
at O
30 O
and O
10 O
min O
before O
or O
5 O
, O
10 O
and O
15 O
min O
after O
exposure O
to O
NOC-5 O
, O
but O
not O
thereafter O
, O
significantly O
attenuated O
NO-induced O
neurotoxicity O
compared O
with O
controls O
. O

Essentially O
, O
2'- O
O O
-methyl O
oligoribonucleotides O
( O
2'OMeRNA O
) O
were O
delivered O
to O
the O
nuclei O
of O
primary O
mdx O
myoblasts O
in O
culture O
. O

Microscopic O
anatomy O
and O
cell O
population O
dynamics O
. O

Angina O
( O
Q O
) O
persistence O
showed O
marked O
associations O
with O
previous O
myocardial O
infarction O
, O
diagnosed O
angina O
, O
electrocardiogram O
ischemia O
, O
and O
subsequent O
major O
ischemic O
heart O
disease O
events O
from O
Q5 O
onward O
. O

We O
propose O
that O
Mad B-GENE
and O
Medea B-GENE
encode O
rate-limiting O
components O
integral O
to O
dpp B-GENE
pathways I-GENE
throughout O
development O
. O

Furthermore O
, O
we O
demonstrate O
that O
transcription O
from O
the O
MMTV B-GENE
5' I-GENE
LTR I-GENE
is O
highly O
active O
in O
the O
absence O
of O
Stat5a B-GENE
, O
a O
transcription O
factor O
that O
had O
been O
shown O
previously O
to O
be O
required O
for O
transcription O
from O
the O
MMTV B-GENE
LTR I-GENE
. O

Functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
has O
been O
increasingly O
used O
in O
studying O
human O
brain O
function O
given O
its O
non-invasive O
feature O
and O
good O
spatial O
resolution O
. O

Viral O
infections O
have O
long O
been O
suspected O
to O
be O
causative O
agents O
in O
a O
number O
of O
inner O
ear O
dysfunctions O
. O

Microdetermination O
of O
adrenocortical O
steroids O
by O
double O
isotope O
method O
. O

STUDY O
DESIGN O
: O
Salivary B-GENE
immunoglobulin I-GENE
A I-GENE
levels O
of O
each O
of O
20 O
subjects O
were O
determined O
on O
3 O
occasions O
: O
first O
, O
while O
the O
subject O
was O
still O
smoking O
; O
second O
, O
7 O
days O
after O
cessation O
of O
smoking O
; O
third O
, O
on O
the O
14th O
day O
after O
cessation O
. O

Practical O
interest O
of O
such O
studies O
is O
limited O
since O
the O
pharmacokinetic O
parameters O
are O
systematically O
evaluated O
in O
man O
during O
phase O
I O
trials O
. O

Martin O
Luther O
and O
his O
physicians O
. O

40 O
, O
000 O
) O
. O

These O
results O
also O
suggest O
the O
involvement O
of O
additional O
elements O
in O
the O
UPR O
. O

RESULTS O
: O
Abnormal O
color O
perception O
was O
found O
in O
32% O
of O
the O
epilepsy O
patients O
treated O
with O
vigabatrin O
monotherapy O
and O
28% O
of O
the O
epilepsy O
patients O
treated O
with O
carbamazepine O
monotherapy O
. O

Cramps O
in O
extrapyramidal O
disorders O
. O

Interestingly O
, O
the O
similarities O
with O
the O
endophilin B-GENE
proteins I-GENE
cover O
the O
entire O
sequence O
of O
the O
SH3GLB B-GENE
family I-GENE
, O
suggesting O
a O
common O
fold O
and O
presumably O
a O
common O
mode O
of O
action O
. O

Each O
of O
these O
spliced O
mRNAs O
has O
an O
untranslated O
leader O
sequence O
of O
249 O
bases O
and O
a O
single O
intron O
of O
approximately O
540 O
bases O
which O
are O
contained O
entirely O
within O
TRs O
IRs O
sequences O
. O

We O
previously O
described O
the O
purification O
of O
an O
83-kDa B-GENE
phosphatidic I-GENE
acid I-GENE
phosphatase I-GENE
( O
PAP B-GENE
) O
from O
the O
porcine O
thymus O
membranes O
( O
Kanoh O
, O
H O
. O
, O
Imai O
, O
S O
. O
-i O
. O
, O
Yamada O
, O
K O
. O
and O
Sakane O
, O
F O
. O
( O
1992 O
) O
J O
. O

Tilmicosin O
is O
a O
novel O
macrolide O
antibiotic O
developed O
for O
exclusive O
use O
in O
veterinary O
medicine O
. O

TSC1 B-GENE
mutations I-GENE
include O
two O
nonsense O
mutations O
, O
four O
insertions O
, O
and O
three O
splice O
mutations O
. O

We O
have O
now O
tested O
all O
known O
mammalian B-GENE
Groucho I-GENE
family I-GENE
members I-GENE
for O
their O
ability O
to O
interact O
specifically O
with O
individual O
Tcf B-GENE
Lef I-GENE
family I-GENE
members I-GENE
. I-GENE

Fenfluramine O
( O
in O
doses O
ranging O
from O
0 O
. O
0625-4 O
. O
0 O
mg O
kg O
infusion O
) O
did O
not O
maintain O
self-administration O
behavior O
at O
or O
above O
the O
minimum O
requirement O
( O
FR O
30 O
) O
. O

No O
difference O
in O
telomere O
length O
was O
seen O
in O
mutants O
affected O
in O
the O
regulation O
of O
Cdc2 B-GENE
, O
whereas O
some O
of O
the O
DNA O
repair O
mutants O
examined O
had O
slightly O
longer O
telomeres O
than O
did O
the O
wild O
type O
. O

Using O
an O
opsonophagocytic O
bacterial O
assay O
and O
a O
suckling O
rat O
model O
of O
GBS O
sepsis O
, O
we O
analyzed O
a O
modified O
human B-GENE
immunoglobulin I-GENE
for O
opsonic O
and O
protective O
antibody O
. O

Near O
term O
, O
under O
experimental O
conditions O
, O
maternal O
and O
fetal O
blood O
gases O
, O
pH O
, O
uterine O
and O
umbilical O
blood O
flows O
were O
measured O
or O
calculated O
. O

Translation O
of O
the O
coding O
segment O
, O
which O
was O
designated O
MsPRP2 B-GENE
, O
suggested O
it O
encodes O
a O
chimeric O
40 O
, O
569 O
Da O
cell O
wall O
protein O
with O
an O
amino-terminal O
signal O
sequence O
, O
a O
repetitive O
proline-rich O
sequence O
, O
and O
a O
cysteine-rich O
carboxyl-terminal O
sequence O
homologous O
to O
nonspecific O
lipid O
transfer O
proteins O
. O

Cloning O
, O
expression O
, O
and O
nucleotide O
sequence O
of O
rat B-GENE
liver I-GENE
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
cDNAs I-GENE
. O

Just O
before O
inserting O
on O
the O
anterior O
margin O
and O
apex O
of O
the O
iliac O
crest O
it O
widens O
, O
assuming O
the O
aspect O
of O
a O
small O
cone O
. O

Integrated O
mapping O
analysis O
of O
the O
Werner B-GENE
syndrome I-GENE
region I-GENE
of O
chromosome O
8 O
. O

The O
cis-acting O
regulatory O
properties O
of O
an O
872 O
bp O
promoter O
fragment O
of O
a O
B O
. O
napus O
oleosin B-GENE
gene I-GENE
were O
examined O
by O
analysis O
of O
beta-glucuronidase B-GENE
( O
GUS B-GENE
) O
expression O
in O
transgenic O
tobacco O
plants O
containing O
an O
oleosin B-GENE
promoter-GUS I-GENE
transcriptional I-GENE
fusion I-GENE
. O

Plasma O
DHE O
concentration O
rose O
promptly O
above O
5 O
ng O
ml O
after O
the O
application O
of O
the O
PSA O
tape O
onto O
the O
damaged O
skin O
in O
hairless O
rat O
. O

39-47 O
. O

In O
the O
first O
group O
, O
0 O
. O
02% O
Prazosin O
( O
0 O
. O
5 O
mg O
kg O
) O
was O
administered O
intravenously O
for O
1 O
. O
5 O
hours O
before O
the O
application O
of O
Oxy-Hb O
or O
PGF2 O
alpha B-GENE
. I-GENE

Based O
on O
previous O
mapping O
of O
the O
G B-GENE
beta I-GENE
gamma I-GENE
binding I-GENE
region I-GENE
of O
beta B-GENE
ARK I-GENE
, O
and O
conserved O
residues O
within O
the O
PH B-GENE
domain I-GENE
, O
we O
have O
constructed O
a O
series O
of O
mutants O
in O
the O
carboxyl O
terminus O
of O
beta B-GENE
ARK I-GENE
in O
order O
to O
determine O
important O
residues O
involved O
in O
G B-GENE
beta I-GENE
gamma I-GENE
and O
PIP2 O
binding O
. O

Altogether O
, O
the O
results O
demonstrate O
that O
the O
two O
isoforms O
elicit O
similar O
responses O
in O
vivo O
despite O
differences O
in O
their O
regulation O
. O

An O
InlC B-GENE
deletion I-GENE
mutant I-GENE
shows O
reduced O
virulence O
when O
tested O
in O
an O
intravenous O
mouse O
model O
, O
but O
intracellular O
replication O
of O
the O
mutant O
in O
Caco-2 O
and O
J774 O
cells O
appears O
to O
be O
comparable O
with O
that O
of O
the O
wild-type O
strain O
. O

Zinc O
fingers O
( O
Zf O
) O
are O
a O
common O
structural O
motif O
found O
in O
many O
nucleic O
acid-binding O
proteins O
. O

When O
normalized O
for O
imaging O
time O
, O
all O
parameters O
are O
significantly O
higher O
with O
RASE O
, O
with O
a O
C O
A O
per O
unit O
time O
that O
was O
338% O
higher O
. O

The O
levels O
of O
NPY-ir B-GENE
in O
the O
rat O
vas O
deferens O
were O
not O
affected O
by O
either O
surgical O
or O
pharmacological O
treatment O
. O

Gimpl O
, O
F O
. O

A O
transparent O
overlay O
for O
assessing O
amplitude O
of O
ECG O
wave O
forms O
. O

Mono-ADP-ribosylation O
is O
a O
reversible O
modification O
of O
proteins O
, O
with O
NAD O
: O
arginine B-GENE
ADP-ribosyltransferases I-GENE
( O
EC B-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
31 I-GENE
) O
and O
ADP-ribosylarginine B-GENE
hydrolases I-GENE
( O
EC B-GENE
3 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
19 I-GENE
) O
catalyzing O
the O
opposing O
reactions O
in O
an O
ADP-ribosylation O
cycle O
. O

A O
single O
nucleotide O
polymorphism O
( O
SNP O
) O
in O
exon O
2 O
, O
which O
is O
tightly O
liked O
to O
another O
SNP O
( O
GTG83 O
ATG83 O
) O
, O
creates O
an O
additional O
alternative O
in-frame O
AUG O
in O
B-type O
MTH1 B-GENE
mRNAs I-GENE
yielding I-GENE
the O
fourth O
MTH1 O
polypeptide B-GENE
, I-GENE
p26 O
that B-GENE
possesses O
an O
additional O
mitochondrial O
targeting O
signal O
. O

Ovulation O
was O
induced O
in O
8 O
( O
56 O
. O
7% O
) O
patients O
who O
conceived O
. O

In O
contrast O
, O
despite O
external O
radiation O
therapy O
, O
brain O
metastases O
proved O
fatal O
. O

As O
determined O
in O
a O
modified O
yeast O
two-hybrid O
system O
, O
mIRS3 B-GENE
bound O
strongly O
to O
the O
p85 B-GENE
subunit I-GENE
of O
phosphatidylinositol B-GENE
3-kinase I-GENE
. O

Analysis O
of O
liver O
biopsy O
specimens O
from O
patients O
with O
hepatitis O
showed O
a O
large O
variation O
in O
the O
mean O
iron O
content O
of O
the O
liver O
ferritin B-GENE
molecules O
. O

Electrical O
activity O
was O
evaluated O
by O
monitoring O
the O
general O
electrocorticogram O
( O
ECoG O
) O
as O
well O
as O
local O
DC O
steady O
potential O
( O
two O
sites O
) O
. O

The O
antigen-specific B-GENE
IgG4 I-GENE
antibody I-GENE
seems O
to O
be O
an O
index O
in O
evaluating O
immunotherapy O
objectively O
. O

BACKGROUND O
: O
The O
c-myc B-GENE
proto-oncogene I-GENE
has O
been O
suggested O
to O
play O
key O
roles O
in O
cell O
proliferation O
, O
differentiation O
, O
transformation O
and O
apoptosis O
. O

Simultaneous O
, O
bilateral O
and O
permanent O
ventilation O
with O
a O
diaphragm O
pacing O
in O
childhood O
: O
the O
implantation O
technique O
and O
indications O
. O

T7 O
transcription O
could O
be O
manipulated O
to O
achieve O
different O
levels O
of O
constitutive O
expression O
, O
through O
the O
use O
of O
promoter O
mutations O
. O

Interferon B-GENE
beta I-GENE
therapy O
was O
discontinued O
for O
4 O
weeks O
. O

Deletion O
analysis O
indicates O
that O
TBP B-GENE
and O
hTAFII18 B-GENE
bind O
to O
distinct O
domains O
of O
hTAFII28 B-GENE
. O
hTAFII18 B-GENE
also O
interacts O
with O
TBP B-GENE
, O
but O
it O
interacts O
more O
strongly O
with O
hTAFII28 B-GENE
and O
hTAFII30 B-GENE
. O

The O
coding O
region O
of O
mkh1 B-GENE
is O
contained O
within O
a O
single O
exon O
encoding O
a O
1 O
, O
116-amino-acid O
protein O
. O

The O
outer O
diameter O
and O
the O
thickness O
of O
the O
rotor O
are O
60 O
mm O
and O
8 O
mm O
, O
respectively O
. O

Clinical O
research O
of O
non-A O
, O
non-B O
post-transfusion O
hepatitis O
. O

The O
highest O
postoperative O
CK-MB B-GENE
level O
was O
less O
after O
BC O
( O
BC O
, O
31 O
+ O
- O
17 O
U O
L O
; O
CC O
, O
56 O
+ O
- O
13 O
U O
L O
; O
p O
less O
than O
0 O
. O
05 O
) O
. O

The O
current O
study O
defines O
the O
vinculin- B-GENE
and O
FAK-interaction B-GENE
domains I-GENE
on O
paxillin B-GENE
and O
identifies O
the O
principal O
paxillin B-GENE
focal B-GENE
adhesion I-GENE
targeting I-GENE
motif I-GENE
. O

In O
44 O
evaluable O
patients O
the O
response O
rate O
was O
50% O
, O
with O
one O
complete O
response O
. O

The O
effect O
of O
treatment O
may O
thus O
be O
divided O
into O
two O
main O
phases--an O
initial O
phase O
with O
a O
reduction O
in O
LV O
mass O
and O
a O
reduction O
in O
cardiac O
output O
and O
no O
change O
in O
total O
peripheral O
resistance--and O
a O
second O
phase O
with O
a O
constant O
LV O
mass O
but O
an O
increase O
in O
cardiac O
output O
to O
the O
pretreatment O
level O
again O
and O
a O
concomitant O
decrease O
in O
total O
peripheral O
resistance O
. O

NF-kappaB B-GENE
, O
which O
is O
probably O
important O
for O
basal O
activity O
of O
the O
human B-GENE
NOS I-GENE
II I-GENE
promoter I-GENE
, O
is O
unlikely O
to O
function O
as O
a O
major O
effector O
of O
CM O
in O
DLD-1 O
cells O
. O

A O
false O
positive O
marker O
screen O
was O
associated O
with O
the O
occurrence O
of O
hand-foot O
syndrome O
even O
when O
the O
effect O
of O
regimen O
was O
accounted O
for O
by O
stratification O
( O
p O
= O
. O
01 O
) O
. O

With O
the O
exception O
of O
virus O
assay O
and O
quantitation O
, O
these O
methods O
are O
simple O
and O
inexpensive O
enough O
to O
be O
done O
in O
typical O
shellfish O
microbiology O
laboratories O
. O

Pulmonary O
vascular O
resistance O
was O
not O
altered O
, O
ejection O
fraction O
remained O
unchanged O
and O
isovolumic O
relaxation O
period O
was O
lengthened O
( O
119 O
+ O
- O
20 O
. O
1 O
to O
147 O
. O
39 O
+ O
- O
21 O
. O
15 O
, O
P O
less O
than O
0 O
. O
05 O
) O
. O

Presently O
four O
unique O
variants O
carrying O
distinct O
GAF B-GENE
sequences I-GENE
in O
the O
N-terminal O
region O
have O
been O
identified O
. O

Through O
a O
stretch O
of O
56 O
amino O
acids O
, O
constituting O
the O
MADS B-GENE
domain I-GENE
, O
the O
two O
proteins O
are O
identical O
except O
for O
two O
conservative O
amino O
acid O
substitutions O
. O

The O
ability O
of O
SMRT B-GENE
to O
associate O
with O
these O
transcription O
factors O
and O
thereby O
to O
mediate O
repression O
is O
strongly O
inhibited O
by O
activation O
of O
tyrosine B-GENE
kinase I-GENE
signaling O
pathways O
, O
such O
as O
that O
represented O
by O
the O
epidermal B-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

Finally O
, O
we O
determined O
that O
the O
P68 B-GENE
amino O
terminus O
was O
both O
necessary O
and O
sufficient O
for O
binding O
dsRNA O
as O
we O
were O
able O
to O
transfer O
dsRNA-binding O
properties O
to O
a O
reporter O
gene O
product O
previously O
unable O
to O
bind O
RNA O
. O

METHODS O
: O
A O
total O
of O
15 O
pigs O
were O
randomised O
to O
ligation O
of O
left O
marginal O
arteries O
( O
infarction O
group O
, O
n O
= O
5 O
) O
, O
to O
TMLR O
of O
the O
left O
lateral O
wall O
using O
a O
holmium O
: O
yttrium-aluminium O
garnet O
( O
Ho O
: O
YAG O
) O
laser O
( O
laser O
group O
, O
n O
= O
5 O
) O
, O
and O
to O
both O
( O
laser-infarction O
group O
, O
n O
= O
5 O
) O
. O

Moreover O
, O
promoters O
containing O
a O
TATA O
box O
in O
the O
absence O
of O
Sp1 B-GENE
sites I-GENE
or O
Sp1 B-GENE
sites I-GENE
in O
the O
absence O
of O
a O
TATA O
box O
were O
equally O
inducible O
in O
vitro O
, O
as O
was O
an O
RNA B-GENE
polymerase I-GENE
III I-GENE
promoter I-GENE
. O

Further O
research O
is O
recommended O
to O
identify O
the O
coping O
styles O
associated O
with O
the O
high O
EE O
low O
EE O
research O
classification O
. O

Curiously O
, O
testololactone O
was O
earlier O
and O
more O
widely O
used O
than O
aminoglutethimide O
in O
treating O
advanced O
breast O
carcinoma O
. O

Responses O
to O
the O
Plowright O
Rinderpest O
vaccine O
by O
43 O
calves O
and O
70 O
adult O
cattle O
in O
Uganda O
in O
1990 O
, O
through O
the O
production O
of O
IgG B-GENE
antibodies I-GENE
, O
were O
monitored O
for O
4 O
weeks O
using O
the O
ELISA O
assay O
. O

Fifty-one O
patients O
with O
primary O
refractory O
or O
relapsed O
malignant O
lymphoma O
( O
47 O
non-Hodgkin's O
lymphoma O
and O
four O
Hodgkin's O
disease O
) O
were O
treated O
with O
a O
new O
chemotherapeutic O
regimen O
( O
cisplatinum O
, O
methyl O
GAG O
, O
bleomocyin O
, O
methyl O
prednisolon O
) O
. O

In O
addition O
, O
marked O
hypertension O
accompanied O
this O
disorder O
and O
all O
abnormalities O
, O
including O
the O
hypertension O
, O
responded O
to O
1-desamino-8-D-arginine B-GENE
vasopressin I-GENE
therapy O
. O

These O
two O
contigs O
contain O
a O
total O
of O
163 O
open O
reading O
frames O
( O
ORFs O
) O
in O
26-29 O
putative O
operons O
; O
56 O
ORFs O
could O
be O
identified O
with O
reasonable O
certainty O
. O

Toxicity O
was O
significant O
in O
selected O
cases O
; O
three O
patients O
developed O
WBC O
counts O
less O
than O
1 O
, O
000 O
mm3 O
and O
one O
of O
these O
patients O
died O
with O
sepsis O
. O

Over-expression O
of O
the O
cofactor O
p300 B-GENE
, O
which O
functions O
as O
a O
coactivator O
of O
myoD-mediated O
transcription O
, O
alleviated O
repression O
by O
COUP-TF B-GENE
II I-GENE
. O

Interaction O
of O
the O
Fur B-GENE
repressor I-GENE
with O
a O
150-bp O
fragment O
encompassing O
the O
pvdS B-GENE
promoter I-GENE
was O
demonstrated O
in O
vivo O
by O
the O
Fur B-GENE
titration O
assay O
and O
confirmed O
in O
vitro O
by O
gel O
retardation O
experiments O
with O
a O
partially O
purified O
Fur B-GENE
preparation O
. O

The O
selective O
5-HT3 B-GENE
receptor I-GENE
antagonists O
ramosetron O
( O
YM060 O
) O
, O
YM114 O
( O
KAE-393 O
) O
, O
granisetron O
and O
ondansetron O
, O
and O
the O
substituted O
benzamides O
( O
5-HT4 B-GENE
receptor I-GENE
agonist O
5-HT3 O
receptor O
antagonists O
) O
cisapride O
mosapride O
and O
SC-53116 O
dose-dependently O
enhanced O
gastric O
emptying O
in O
normal O
rats O
. O

IFN B-GENE
alpha I-GENE
and O
IFN B-GENE
gamma I-GENE
inducibility O
is O
mediated O
by O
a O
single O
element O
: O
a O
high O
affinity O
, O
nearly O
palindromic O
version O
of O
the O
IFN B-GENE
gamma I-GENE
activation I-GENE
site I-GENE
( O
GAS B-GENE
) O
. O

In O
the O
present O
study O
, O
we O
characterized O
cis-elements O
of O
the O
human B-GENE
PCI I-GENE
gene I-GENE
required O
for O
expression O
in O
the O
hepatoma-derived O
cell O
line O
, O
HepG2 O
cells O
, O
and O
also O
evaluated O
rat B-GENE
PCI I-GENE
mRNA I-GENE
expression O
, O
particularly O
on O
the O
effect O
of O
androgen O
in O
rat O
reproductive O
tissues O
. O

The O
transcription B-GENE
factor I-GENE
CHOP I-GENE
( O
C B-GENE
EBP I-GENE
homologous I-GENE
protein I-GENE
10 I-GENE
) I-GENE
is O
a O
bZIP O
protein B-GENE
induced I-GENE
by O
a O
variety O
of O
stimuli O
that O
evoke O
cellular O
stress O
responses O
and O
has O
been O
shown O
to O
arrest O
cell O
growth O
and O
to O
promote O
programmed O
cell O
death O
. O

All O
ribosomal B-GENE
protein I-GENE
( O
rp B-GENE
) O
gene O
promoters O
from O
Saccharomyces O
cerevisiae O
studied O
so O
far O
contain O
either O
( O
usually O
two O
) O
binding O
sites O
for O
the O
global O
gene O
regulator O
Rap1p B-GENE
or O
one O
binding O
site O
for O
another O
global O
factor O
, O
Abf1p B-GENE
. O

Therefore O
, O
this O
study O
has O
demonstrated O
that O
prenatal O
disturbance O
can O
induce O
a O
lasting O
change O
in O
cytokine O
biology O
, O
which O
persists O
well O
beyond O
the O
fetal O
and O
infant O
stage O
. O

Seventeen O
of O
them O
were O
on O
treatment O
with O
systemic O
steroids O
. O

In O
contrast O
, O
c-Src B-GENE
activated O
by O
isoproterenol O
led O
to O
tyrosine O
phosphorylation O
of O
Shc B-GENE
and O
subsequent O
Erk B-GENE
activation O
, O
but O
not O
tyrosine O
phosphorylation O
of O
cortactin B-GENE
or O
Stat3 B-GENE
. O

Identity O
of O
GABP B-GENE
with O
NRF-2 B-GENE
, O
a O
multisubunit O
activator O
of O
cytochrome B-GENE
oxidase I-GENE
expression O
, O
reveals O
a O
cellular O
role O
for O
an O
ETS B-GENE
domain I-GENE
activator O
of O
viral O
promoters O
. O

Thus O
it O
appears O
that O
the O
management O
of O
blood O
, O
including O
washing O
is O
of O
great O
importance O
. O

In O
order O
to O
investigate O
the O
blood O
compatibility O
of O
autogenous O
vein O
graft O
( O
AVG O
) O
, O
changes O
in O
prostacyclin O
( O
PGI2 O
) O
production O
following O
harvesting O
and O
arterial O
implantation O
were O
studied O
experimentally O
. O

MAIN O
OUTCOME O
MEASURES O
: O
Associations O
of O
factor O
analysis-derived O
syndromes O
with O
risk O
factors O
for O
chemical O
interactions O
that O
inhibit O
butyrylcholinesterase B-GENE
and O
neuropathy O
target O
esterase B-GENE
. O

State O
of O
the O
body O
in O
disorders O
of O
diurnal O
physiological O
rhythms O
and O
long-term O
hypokinesia O
. O

OsBBPI B-GENE
was O
found O
to O
be O
rapidly O
induced O
in O
rice O
seedling O
leaf O
in O
response O
to O
cut B-GENE
, O
exogenous O
jasmonic O
acid O
( O
JA O
) O
, O
and O
two O
potent O
protein B-GENE
phosphatase I-GENE
2A I-GENE
( O
PP2A B-GENE
) O
inhibitors O
, O
cantharidin O
( O
CN O
) O
and O
endothall O
( O
EN O
) O
, O
in O
a O
light O
dark- O
, O
time- O
and O
dose-dependent O
manner O
; O
this O
induction O
was O
completely O
inhibited O
by O
cycloheximide O
( O
CHX O
) O
, O
indicating O
a O
requirement O
for O
de O
novo O
protein O
synthesis O
in O
its O
induction O
. O

Moreover O
, O
a O
high O
proportion O
of O
blood O
samples O
from O
a O
random O
sample O
of O
the O
rest O
of O
the O
suspects O
tested O
positive O
for O
trypanosome-specific O
DNA O
by O
PCR O
( O
79 O
. O
9% O
for O
T O
. O
b O
. O
gambiense O
and O
13 O
. O
9% O
for O
T O
. O
b O
. O
rhodesiense O
) O
. O

Mutations O
in O
the O
small O
subunit O
of O
ribulosebisphosphate B-GENE
carboxylase I-GENE
affect O
subunit O
binding O
and O
catalysis O
. O

Increased O
dietary O
energy O
decreased O
PAB O
and O
the O
use O
of O
added O
dietary O
CO O
rather O
than O
PF O
decreased O
PSHL O
in O
broiler O
breeders O
between O
26 O
and O
47 O
wk O
of O
age O
. O

Our O
data O
showed O
that O
activation O
of O
the O
raf-ERK B-GENE
pathway O
led O
to O
activation O
of O
TF B-GENE
expression O
in O
breast O
carcinoma O
cells O
and O
suggested O
that O
constitutive O
activation O
of O
this O
pathway O
leads O
to O
high O
TF B-GENE
expression O
in O
MDA-MB-231 O
cells O
. O

As O
expected O
, O
homologous B-GENE
loxP I-GENE
sequences I-GENE
efficiently O
underwent O
Cre-mediated O
recombination O
. O

IL-1beta B-GENE
was O
significantly O
higher O
in O
endometrioma O
than O
in O
lesions O
of O
other O
localizations O
. O

Evolution O
of O
lesions O
did O
not O
necessarily O
follow O
a O
regular O
progression O
through O
the O
later O
stages O
of O
the O
vitelliform O
classification O
. O

To O
get O
further O
insights O
into O
the O
molecular O
mechanisms O
that O
control O
tal-1 B-GENE
expression O
, O
we O
have O
isolated O
5' O
sequences O
of O
the O
murine O
gene O
and O
compared O
them O
to O
their O
human O
counterparts O
. O

Serum O
antibody O
titre O
was O
not O
significantly O
associated O
with O
the O
recurrence O
rate O
or O
the O
duration O
of O
infection O
. O

A O
series O
of O
5'-deletions O
revealed O
that O
the O
fragment O
-218 O
to O
+4 O
from O
the O
TSS O
had O
the O
highest O
promoter O
activity O
, O
nearly O
1000-fold O
greater O
than O
the O
promoterless O
chloramphenicol B-GENE
acetyltransferase I-GENE
construct I-GENE
. O

Areas O
with O
significantly O
greater O
rCBF O
for O
targeting O
were O
the O
left O
motor O
cortex O
, O
left O
intraparietal O
sulcus O
, O
and O
left O
caudate O
. O

A O
v-erbB-related B-GENE
protooncogene I-GENE
, O
c-erbB-2 B-GENE
, O
is O
distinct O
from O
the O
c-erbB-1 B-GENE
epidermal I-GENE
growth I-GENE
factor-receptor I-GENE
gene I-GENE
and I-GENE
is O
amplified O
in O
a O
human O
salivary O
gland O
adenocarcinoma O
. O

Finally O
, O
using O
in O
vitro O
binding O
studies O
, O
we O
showed O
that O
SREBP2 B-GENE
was O
able O
to O
displace O
ADD1 B-GENE
SREBP1 I-GENE
binding I-GENE
from O
the O
sterol O
regulatory B-GENE
element I-GENE
( I-GENE
SRE O
) B-GENE
site O
. O

Chronic O
nutritional O
diseases O
of O
infectious O
origin O
: O
an O
assessment O
of O
a O
nascent O
field O
. O

Isolation O
and O
characterization O
of O
the O
rat O
chromosomal O
gene O
for O
a O
polypeptide O
( O
pS1 B-GENE
) O
antigenically O
related O
to O
statin B-GENE
. O

Deformities O
of O
the O
tip O
of O
the O
olecranon O
and O
of O
the O
coronoid O
process O
are O
also O
described O
( O
De O
Palma O
1956 O
, O
Jordan O
1958 O
, O
Ahlberg O
1965 O
, O
Weseloh O
1973 O
) O
. O

Deletion O
of O
both O
prfA B-GENE
and O
ponA B-GENE
resulted O
in O
extremely O
slow O
growth O
and O
a O
reduction O
in O
sporulation O
efficiency O
. O

Secretion O
of O
interleukin-8 B-GENE
, O
RANTES B-GENE
, O
macrophage B-GENE
inflammatory I-GENE
protein I-GENE
1alpha I-GENE
, O
and O
10-kappaDa B-GENE
IFN-gamma-inducible I-GENE
protein I-GENE
were O
increased O
in O
differentiating O
keratinocytes O
by O
E6 B-GENE
. O

Stimulation O
of O
the O
caudate O
nucleus' O
dophamine-reactive O
system O
in O
dogs O
by O
means O
of O
administration O
of O
dophamine O
( O
60 O
micrograms O
) O
and O
phenamine O
led O
to O
deterioration O
of O
conditioned O
and O
unconditioned O
components O
of O
feeding O
behaviour O
. O

Binding O
to O
sulphatides O
and O
the O
alpha-dystroglycan B-GENE
receptor I-GENE
was O
much O
stronger O
and O
required O
at O
least O
two O
LG B-GENE
modules I-GENE
. O

The O
immune O
response O
of O
past-infection O
of O
cytomegalovirus O
in O
the O
patients O
of O
RTID O
is O
rather O
remarkable O
. O

The O
effect O
of O
CBZ O
and O
DPH O
can O
be O
explained O
by O
interference O
with O
thyroid O
hormone O
binding O
to O
TBG B-GENE
combined O
with O
enzyme-induced O
increased O
metabolic O
clearance O
rate O
of O
thyroid O
hormones O
without O
homeostatic O
maintenance O
of O
premedication O
levels O
of O
FT4 O
and O
FT3 O
. O

Reverse B-GENE
transcriptase I-GENE
and O
protease B-GENE
activities O
of O
avian O
leukosis O
virus O
Gag-Pol B-GENE
fusion I-GENE
proteins I-GENE
expressed O
in O
insect O
cells O
. O

Erythrocytic O
stages O
of O
mammalian O
malarial O
parasites O
contain O
acristate O
mitochondria O
whose O
functions O
are O
not O
well O
understood O
. O

New O
techniques O
for O
the O
mass O
spectrometry O
of O
natural O
products O
. O

Thromboxane B-GENE
B2 I-GENE
increased O
( O
97 O
+ O
- O
105 O
versus O
40 O
+ O
- O
26 O
pg O
ml O
) O
and O
was O
significantly O
higher O
during O
heparin O
free O
hemodialysis O
than O
during O
hemodialysis O
with O
heparin O
( O
p O
= O
0 O
. O
01 O
, O
Wilcoxon O
matched O
pairs O
signed O
rank O
test O
) O
. O

None O
were O
restricted O
from O
clinical O
duties O
, O
were O
given O
varicella-zoster B-GENE
immune I-GENE
globulin I-GENE
, O
or O
developed O
disease O
. O

D O
. O

This O
0 O
. O
74 O
kb O
cDNA O
contains O
an O
open O
reading O
frame O
( O
ORF O
) O
of O
477 O
bp O
encoding O
a O
polypeptide O
of O
159 O
amino O
acids O
( O
aa O
) O
which O
differs O
at O
only O
one O
position O
( O
position O
65 O
) O
from O
the O
human B-GENE
U1-C I-GENE
protein I-GENE
. O

Our O
results O
demonstrated O
that O
50% O
of O
the O
hepatic O
artery-alone O
ALT O
graft O
showed O
almost O
normal O
structure O
histologically O
at O
1 O
month O
after O
grafting O
, O
with O
bile O
secretion O
preserved O
. O

Human B-GENE
bcl3 I-GENE
protein I-GENE
specifically O
displaces O
( B-GENE
p50 I-GENE
) I-GENE
2-DNA I-GENE
complexes I-GENE
. O

Observations O
on O
saccules O
of O
rats O
exposed O
to O
long-term O
hypergravity O
. O

Videonystagmoscopy O
has O
been O
used O
to O
subjectively O
observe O
the O
responses O
of O
the O
vestibular O
system O
in O
a O
population O
of O
patients O
with O
vestibular O
deficits O
. O

In O
conclusion O
, O
these O
studies O
indicate O
that O
LiCl O
( O
1 O
) O
decreases O
histamine-stimulated O
gastric O
acid O
secretion O
, O
and O
( O
2 O
) O
diminishes O
bile-induced O
disruption O
of O
the O
gastric O
mucosal O
barrier O
in O
the O
canine O
Heidenhain O
pouch O
. O

We O
have O
previously O
reported O
that O
high O
level O
human B-GENE
desmin I-GENE
expression O
depends O
on O
a O
280-base O
pair O
muscle-specific O
enhancer O
which O
can O
function O
not O
only O
in O
myotubes O
, O
but O
can O
also O
activate O
gene O
expression O
in O
myoblasts O
. O

Treatment O
of O
human O
myeloid O
cell O
lines O
HL-60 O
and O
U937 O
with O
phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
increased O
within O
2 O
h O
cellular O
levels O
of O
the O
RNA O
hybridizable O
to O
LD78 B-GENE
cDNA I-GENE
. O

Analysis O
of O
intron O
exon O
boundaries O
of O
the O
genomic O
BAC O
clones O
demonstrate O
that O
junctin O
, B-GENE
junctate O
, B-GENE
and O
aspartyl O
beta-hydroxylase B-GENE
result I-GENE
from O
alternative O
splicing O
of O
the O
same O
gene O
. O

We O
have O
examined O
the O
regulation O
of O
the O
FGFR-1 B-GENE
gene I-GENE
( O
cek-1 B-GENE
) O
in O
avian O
myogenic O
cultures O
by O
immunocytochemistry O
and O
Northern O
blot O
analysis O
. O

A O
low O
aspirin B-GENE
esterase I-GENE
activity O
may O
be O
a O
contributory O
factor O
in O
precipitating O
these O
aspirin O
sensitive O
reactions O
. O

On O
the O
character O
of O
changes O
in O
the O
enzyme O
activity O
in O
the O
brain O
tissue O
during O
reflex O
epilepsy O
. O

Localized O
fluorescence O
was O
detectable O
only O
in O
cells O
containing O
a O
visible O
midcell O
constriction O
, O
suggesting O
that O
FtsK B-GENE
targeting O
normally O
occurs O
only O
at O
a O
late O
stage O
of O
septation O
. O

The O
NarX B-GENE
and O
NarQ B-GENE
proteins I-GENE
with O
amino O
acid O
substitutions O
at O
the O
first O
conserved O
histidine O
position O
were O
also O
unable O
to O
dephosphorylate O
NarL-phosphate O
in O
vitro O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Chloramphenicol B-GENE
acetyltransferase I-GENE
assays O
examining O
the O
ability O
of O
IE86 B-GENE
to O
repress O
activity O
from O
the O
HCMV O
major O
IE B-GENE
promoter I-GENE
or O
activate O
the O
HCMV B-GENE
early I-GENE
promoter I-GENE
for O
the O
2 O
. O
2-kb O
class O
of O
RNAs O
demonstrated O
the O
functional O
integrity O
of O
the O
IE86 B-GENE
protein I-GENE
. O

Piroximone O
is O
a O
new O
phosphodiesterase B-GENE
III I-GENE
inhibitor O
that O
combines O
inotropic O
and O
vasodilator O
properties O
. O

This O
enzyme O
is O
designated O
( B-GENE
1-- I-GENE
> I-GENE
4 I-GENE
) I-GENE
-beta-xylan I-GENE
endohydrolase I-GENE
isoenzyme I-GENE
X-I I-GENE
. O

Because O
the O
number O
of O
parameters O
required O
by O
a O
Volterra O
series O
grows O
rapidly O
with O
both O
the O
length O
of O
its O
memory O
and O
the O
order O
of O
its O
nonlinearity O
, O
methods O
for O
identifying O
these O
models O
from O
measurements O
of O
input O
output O
data O
are O
limited O
to O
low-order O
systems O
with O
relatively O
short O
memories O
. O

In O
macrophages O
, O
LPS-inducible O
HIV-1 O
gene O
expression O
is O
mediated O
in O
part O
by O
binding O
of O
NF-kappa B-GENE
B I-GENE
to O
identical O
tandem O
binding O
sites O
located O
within O
the O
long B-GENE
terminal I-GENE
repeat I-GENE
( O
LTR B-GENE
) O
. O

Both O
normal O
and O
transforming O
PCPH B-GENE
proteins I-GENE
have O
guanosine B-GENE
diphosphatase I-GENE
activity O
but O
only O
the O
oncoprotein O
cooperates O
with O
Ras B-GENE
in O
activating O
extracellular B-GENE
signal-regulated I-GENE
kinase I-GENE
ERK1 B-GENE
. O

New O
Langevin O
equations O
for O
a O
translating O
and O
simultaneously O
rotating O
asymmetric O
top O
. O

The O
early O
dg O
. O
of O
rejection O
and O
especially O
acute O
rejection O
, O
it's O
adequate O
management O
, O
decreased O
risk O
for O
the O
future O
chronic O
rejection O
nephropathy O
. O

Improvement O
of O
the O
CRT O
display O
of O
an O
averager O
. O

The O
half-life O
of O
the O
serum-induced O
CBP B-GENE
tk I-GENE
binding I-GENE
activity O
was O
estimated O
to O
be O
less O
than O
1 O
h O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Seventy-two O
of O
73 O
negative O
controls O
and O
all O
positive O
blocks O
as O
seen O
on O
soft O
tissue O
radiographs O
( O
STRs O
) O
were O
correctly O
coded O
( O
specificity O
98 O
. O
6% O
, O
sensitivity O
100% O
) O
. O

The O
method O
requires O
a O
reversed-phase O
column O
and O
a O
paired-ion O
technique O
to O
separate O
docusate O
sodium O
from O
other O
components O
. O

This O
study O
was O
aimed O
at O
assessing O
whether O
c-DDP O
administration O
immediately O
before O
radiotherapy O
could O
increase O
frequency O
and O
duration O
of O
objective O
responses O
, O
as O
well O
as O
survival O
, O
in O
patients O
affected O
with O
locally O
advanced O
stages O
of O
squamous O
carcinomas O
of O
the O
head O
and O
neck O
. O

Chem O
. O

In O
contrast O
, O
in O
LL O
patients O
during O
ENL O
the O
ConA-induced O
suppressor O
response O
was O
markedly O
reduced O
. O

In O
contrast O
, O
cotransfection O
of O
TFIIB B-GENE
and O
IRF-1 B-GENE
into O
NIH O
3T3 O
cells O
resulted O
in O
a O
dose-dependent O
repression O
of O
promoter O
activation O
which O
occurred O
in O
a O
TATA-dependent O
manner O
. O

Fetal O
lung O
volume O
: O
estimation O
at O
MR O
imaging-initial O
results O
. O

It O
contains O
three O
putative O
binding O
sites O
for O
transcription B-GENE
factor I-GENE
Sp1 I-GENE
as O
well O
as O
several O
short O
sequences O
that O
are O
similar O
to O
known O
cis-acting O
enhancers O
or O
binding O
sites O
for O
transcription O
factors O
. O

Thus O
, O
the O
system O
can O
be O
used O
to O
detect O
and O
study O
dynamic O
perfusion O
changes O
from O
the O
brain O
surface O
with O
minimal O
tissue O
damage O
. O

No O
'TATA' O
motif O
was O
identified O
near O
either O
the O
GABPalpha B-GENE
or O
ATPsynCF6 B-GENE
transcription O
start O
sites O
. O

Addition O
of O
soluble O
recombinant B-GENE
human I-GENE
SLF I-GENE
to O
SI4-h220 O
cultures O
enhanced O
reduction O
of O
cell-surface O
c-kit B-GENE
expression O
and O
its O
protein O
degradation O
. O

Transcription O
factors O
containing O
a O
basic B-GENE
helix-loop-helix I-GENE
( I-GENE
bHLH I-GENE
) I-GENE
motif I-GENE
regulate O
the O
expression O
of O
tissue-specific O
genes O
in O
a O
number O
of O
mammalian O
and O
insect O
systems O
. O

Also O
, O
transient O
overexpression O
of O
this O
protein O
in O
C2C12 O
cells O
reduced O
the O
transcription O
of O
a O
CAT-reporter B-GENE
regulated O
by O
an O
E12 B-GENE
MyoD I-GENE
driven I-GENE
enhancer I-GENE
. I-GENE

Two O
patients O
were O
treated O
with O
both O
regimens O
. O

271 O
: O
31290-31295 O
, O
1996 O
) O
. O

A O
1 O
. O
8-kb O
cDNA O
clone O
( O
designed O
hKID O
, O
gene B-GENE
symbol I-GENE
AQP2L I-GENE
) O
with O
homology O
to O
the O
aquaporins B-GENE
was O
isolated O
from O
a O
human O
kidney O
cDNA O
library O
. O

The O
Lm O
increased O
and O
the O
alveoli O
mm2 O
and O
elastic O
recoil O
pressure O
decreased O
. O

Serum-ferritin O
in O
diagnosis O
of O
haemochromatosis O
. O

Comparison O
of O
1 O
. O
5 O
Tesla O
and O
0 O
. O
35 O
Tesla O
field O
strength O
magnetic O
resonance O
imaging O
scans O
in O
the O
morphometric O
evaluation O
of O
the O
lumbar O
intervertebral O
foramina O
. O

Plasmid O
pAL618 O
contains O
the O
genetic O
determinants O
for O
H2 O
uptake O
( O
hup B-GENE
) O
from O
Rhizobium O
leguminosarum O
bv O
. O
viciae O
, O
including O
a O
cluster O
of O
17 O
genes O
named O
hupSLCDEFGHIJK-hypABFCDE B-GENE
. O

Chronic O
endotoxemia O
appears O
to O
be O
associated O
with O
an O
elevated O
pulmonary O
microvascular O
permeability O
and O
a O
tendency O
toward O
a O
hyperdynamic O
circulation O
but O
with O
an O
appreciable O
degree O
of O
refractoriness O
associated O
with O
regional O
hemodynamics O
and O
eicosanoid O
biosynthesis O
. O

These O
rearrangements O
result O
in O
the O
formation O
of O
chimeric O
genes O
showing O
the O
tyrosine B-GENE
kinase I-GENE
domain I-GENE
of O
ret B-GENE
fused O
with O
the O
5' O
end O
sequences O
of O
different O
genes O
. O

The O
TATA B-GENE
box-binding I-GENE
protein I-GENE
( O
TBP B-GENE
) O
plays O
an O
essential O
role O
in O
transcription O
by O
all O
three O
eukaryotic O
nuclear B-GENE
RNA I-GENE
polymerases I-GENE
, O
polymerases B-GENE
( I-GENE
Pol I-GENE
) I-GENE
I I-GENE
, I-GENE
II I-GENE
, I-GENE
and I-GENE
III I-GENE
. O

Mutation O
of O
nucleotides O
adjacent O
to O
the O
AP-1 B-GENE
cis-response I-GENE
elements I-GENE
had O
no O
effect O
on O
trans-activation O
. O

Endurance O
training O
resulted O
in O
an O
increase O
of O
stiffness O
associated O
with O
a O
decrease O
of O
type O
II O
fibers O
. O

Dual O
innervation O
of O
fast O
fibers O
in O
trunk O
muscles O
of O
lamprey O
larvae O
. O

Mucolipidosis O
type O
IV O
: O
clinical O
spectrum O
and O
natural O
history O
. O

At O
necropsy O
28 O
days O
post-inoculation O
, O
F344 O
rats O
had O
no O
gross O
lung O
lesions O
, O
even O
those O
given O
the O
maximum O
dose O
of O
1 O
. O
4 O
X O
10 O
( O
9 O
) O
colony-forming O
units O
of O
M O
. O
pulmonis O
. O

The O
Epstein-Barr B-GENE
virus I-GENE
transactivator I-GENE
Zta I-GENE
triggers O
lytic O
gene O
expression O
and O
is O
essential O
for O
replication O
of O
the O
lytic O
origin O
, O
oriLyt B-GENE
. O

Simple O
reaction O
time O
( O
RT O
) O
to O
a O
peripheral O
visual O
target O
( O
S2 O
) O
is O
shortened O
when O
a O
non-informative O
cue O
( O
S1 O
) O
is O
flashed O
at O
the O
S2 O
location O
100-150 O
ms O
before O
target O
onset O
( O
early O
facilitation O
) O
. O

We O
have O
determined O
the O
molecular O
lesions O
of O
nine O
Scm B-GENE
mutant I-GENE
alleles I-GENE
, O
which O
identify O
functional O
requirements O
for O
specific O
domains O
. O

MATERIAL O
AND O
METHODS O
: O
Of O
the O
17 O
men O
and O
17 O
women O
, O
who O
were O
21 O
to O
80 O
years O
of O
age O
, O
27 O
had O
hereditary O
motor O
and O
sensory O
neuropathy O
type O
I O
and O
7 O
had O
acquired O
demyelinating O
polyneuropathy O
. O

Anti-B B-GENE
. I-GENE
burgdorferi I-GENE
, O
anti-B B-GENE
. I-GENE
turicatae I-GENE
and O
anti-B B-GENE
. I-GENE
parkeri I-GENE
antibodies I-GENE
, O
tested O
by O
the O
indirect O
immunofluorescent O
assay O
( O
IFA O
) O
, O
were O
detected O
in O
10 O
. O
8 O
, O
16 O
. O
1 O
and O
8 O
. O
2% O
of O
the O
serum O
samples O
tested O
, O
and O
confirmed O
by O
IFA-ABS O
in O
1 O
. O
3 O
, O
1 O
. O
3 O
and O
1 O
. O
0% O
, O
respectively O
. O

Tobramycin O
60 O
mg O
did O
not O
show O
any O
remarkable O
effect O
, O
but O
dibecacin O
100 O
mg O
produced O
a O
slight O
potentiating O
effect O
on O
the O
action O
of O
d-tubocurarine O
. O

Ventricular O
volume O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
LVH O
shifted O
upward O
, O
whereas O
the O
normalized O
wall O
muscle O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
LVH O
showed O
a O
smaller O
slope O
. O

OBJECTIVE O
: O
1998 O
Surveillance O
, O
Epidemiology O
, O
and O
End O
Results O
( O
SEER O
) O
data O
estimate O
an O
83 O
. O
1% O
5-year O
survival O
rate O
for O
corpus O
uteri O
adenocarcinoma O
FIGO O
stage O
II O
. O

Intron O
K1 B-GENE
cox1 I-GENE
. I-GENE
2 I-GENE
is O
not O
found O
in O
S O
. O
cerevisiae O
and O
appears O
at O
an O
unique O
location O
in O
K O
. O
lactis O
. O

In O
B O
cells O
, O
HEF1 B-GENE
is O
phosphorylated O
by O
a O
cytoskeleton-dependent O
mechanism O
that O
is O
triggered O
by O
integrin B-GENE
ligation O
. O

Attenuation O
from O
the O
vit B-GENE
A2 I-GENE
consensus O
ERE B-GENE
is O
not O
necessarily O
dependent O
on O
DNA O
binding O
as O
the O
TR B-GENE
alpha I-GENE
DNA O
binding O
mutant O
was O
still O
able O
to O
inhibit O
E-dependent O
transactivation O
. O

We O
conclude O
that O
this O
new O
measurement O
technique O
provides O
an O
easy O
and O
accurate O
P0 O
. O
1 O
measurement O
using O
standard O
respiratory O
equipment O
when O
tested O
in O
a O
lung O
model O
. O

The O
data O
indicate O
that O
the O
minimal O
catalytic O
domain O
of O
Nmt1p B-GENE
is O
located O
between O
Ile59-- O
> O
Phe96 O
and O
Gly451-- O
> O
Leu455 O
. O

This O
family O
of O
proteins O
binds O
GC-rich O
motifs O
widely O
distributed O
in O
gene O
promoters O
, O
resulting O
in O
distinct O
activation O
or O
repression O
of O
transcriptional O
activities O
. O

Rare O
neurogenic O
tumor O
with O
metastasis O
to O
mouth O
, O
jaw O
and O
face O
regions O
. O

Studies O
using O
an O
inhibitor O
or O
a O
mutant B-GENE
Lb I-GENE
proteinase I-GENE
indicated O
that O
stimulation O
of O
IRES-driven O
translation O
is O
mediated O
via O
proteolysis O
of O
some O
cellular O
component O
( O
s O
) O
. O

The O
subjects O
were O
diagnosed O
on O
the O
basis O
of O
DSM-IV O
pathological O
gambling O
criteria O
and O
completed O
the O
Turkish O
Version O
of O
South O
Oaks O
Gambling O
Screen O
( O
SOGS O
) O
. O

The O
newly O
defined O
region O
contains O
an O
intron O
that O
may O
be O
alternatively O
spliced O
and O
seven O
polyadenylation O
signal O
sequences O
. O

The O
psaD B-GENE
, O
psaF B-GENE
, O
psaH B-GENE
, O
and O
psaL B-GENE
products I-GENE
have O
two O
isoforms O
each O
that O
are O
distinguished O
by O
different O
mobilities O
in O
polyacrylamide O
gel O
electrophoresis O
, O
and O
the O
psaE B-GENE
product I-GENE
has O
four O
isoforms O
. O

Fans O
in O
tunnels O
and O
open O
windows O
at O
aboveground O
locations O
appeared O
to O
greatly O
reduce O
the O
likelihood O
of O
high O
PH3 O
concentrations O
in O
enclosed O
areas O
. O

These O
well-characterized O
brain O
regions O
may O
provide O
a O
basis O
for O
future O
studies O
of O
RPTP-kappa B-GENE
function O
. O

The O
crystal O
structure O
of O
the O
VP16 B-GENE
core I-GENE
has O
been O
determined O
at O
2 O
. O
1 O
A O
resolution O
. O

A O
sequence O
representing O
about O
50% O
of O
the O
expected O
complete O
sequence O
was O
obtained O
by O
translation O
of O
the O
two O
open O
reading O
frames O
present O
on O
a O
1 O
. O
6 O
kb O
DNA O
genomic O
fragment O
. O

Drosophila B-GENE
UbcD1 I-GENE
encodes O
a O
highly O
conserved O
ubiquitin-conjugating O
enzyme O
involved O
in O
selective O
protein O
degradation O
. O

In O
vitro O
expression O
of O
four O
different O
naturally O
occurring O
nonsense O
and O
missense O
mutations O
revealed O
a O
dramatically O
altered O
subcellular O
location O
of O
the O
protein O
in O
cultured O
cells O
. O

Five O
of O
these O
eight O
patients O
in O
group O
II O
also O
received O
8-in-1 O
chemotherapy O
. O

What O
young O
people O
think O
and O
do O
when O
the O
option O
for O
cystic O
fibrosis O
carrier O
testing O
is O
available O
. O

The O
controversy O
of O
significance O
testing O
: O
misconceptions O
and O
alternatives O
. O

These O
results O
indicate O
that O
the O
p33 B-GENE
subunit I-GENE
of O
eIF3 B-GENE
plays O
an O
important O
role O
in O
the O
initiation O
phase O
of O
protein O
synthesis O
and O
that O
its O
RNA-binding O
domain O
is O
required O
for O
optimal O
activity O
. O

It O
has O
been O
shown O
in O
experiments O
in O
vitro O
that O
the O
hepatotrophic O
organic O
anions O
, O
the O
radiographic O
contrast O
agent O
( O
RCA O
) O
bilignost O
used O
in O
cholecystography O
and O
Bengal O
pink O
, O
have O
an O
affinity O
, O
unlike O
the O
urographic O
RCA O
triombrin O
and O
renotrophic O
dye O
indigo-carmine O
, O
for O
the O
plasmatic O
membranes O
( O
PM O
) O
of O
liver O
cells O
. O

The O
alpha B-GENE
7A I-GENE
form I-GENE
RNA I-GENE
contains O
an O
additional O
113 O
nucleotides O
compared O
to O
the O
B O
form O
, O
and O
a O
common O
coding O
region O
in O
the O
A O
and O
B O
form O
RNAs O
is O
used O
in O
alternate O
reading O
frames O
. O

The O
across-fiber O
pattern O
of O
the O
responses O
to O
hypotonic O
NaCl O
solutions O
correlated O
strongly O
to O
that O
elicited O
by O
distilled O
H2O O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

A O
Bub2p-dependent O
spindle O
checkpoint O
pathway O
regulates O
the O
Dbf2p B-GENE
kinase I-GENE
in I-GENE
budding I-GENE
yeast I-GENE
. O

All O
six O
ARF B-GENE
cDNAs I-GENE
are O
more O
similar O
to O
each O
other O
than O
to O
other O
approximately O
20-kDa B-GENE
guanine I-GENE
nucleotide-binding I-GENE
proteins I-GENE
. O

We O
have O
subcloned O
into O
pBR322 O
deoxyribonucleic O
acid O
( O
DNA O
) O
sequences O
mapping O
either O
in O
the O
coding O
region O
, O
the O
5' O
spacer O
, O
or O
the O
3' O
spacer O
of O
the O
H2B B-GENE
histone I-GENE
gene I-GENE
. O

The O
rrd1 B-GENE
, I-GENE
2delta I-GENE
mutant I-GENE
was O
partially O
rescued O
by O
inactivation O
of O
HOG1 B-GENE
or O
PBS2 B-GENE
, O
suggesting O
an O
interaction O
between O
the O
RRD B-GENE
genes I-GENE
and O
the O
Hog1p B-GENE
signal I-GENE
transduction I-GENE
pathway I-GENE
. O

Oscilloscope O
triggering O
circuit O
for O
recording O
long O
transients O
at O
fast O
sweep O
speeds O
. O

The O
negative O
predictive O
value O
is O
92% O
, O
vs O
80% O
for O
the O
NCEP O
I O
. O

The O
matrix O
surrounding O
the O
clusters O
either O
showed O
a O
normal O
morphology O
or O
a O
homogeneous O
appearance O
, O
within O
which O
faint O
cross O
striations O
but O
no O
distinctly O
fibrillar O
outlines O
could O
be O
identified O
. O

The O
muskox O
is O
a O
new O
host O
record O
for O
T O
. O
gondii O
. O

The O
patient's O
role O
, O
organized O
by O
the O
prerequisites O
of O
expressive O
freedom O
, O
is O
counter O
posed O
with O
the O
psychoanalyst's O
, O
which O
is O
structured O
to O
empower O
listening O
and O
understanding O
. O

Fas-resistant O
DT-40 O
lymphoma O
B-cells O
rendered O
BTK-deficient O
through O
targeted O
disruption O
of O
the O
btk B-GENE
gene I-GENE
by O
homologous O
recombination O
knockout O
underwent O
apoptosis O
after O
Fas B-GENE
ligation O
, O
but O
wild-type O
DT-40 O
cells O
or O
BTK-deficient O
DT-40 O
cells O
reconstituted O
with O
wild-type B-GENE
human I-GENE
btk I-GENE
gene I-GENE
did O
not O
. O

Immunoreactive O
AR B-GENE
content O
in O
transfected O
COS-1 O
cells O
was O
not O
influenced O
by O
exposure O
to O
8-Br-cAMP O
. O

Erythrocyte O
protoporphyrin O
concentration O
increased O
significantly O
( O
P O
less O
than O
0 O
. O
05 O
) O
by O
14 O
days O
in O
dogs O
fed O
the O
basal O
diet O
, O
and O
remained O
significantly O
high O
relative O
to O
that O
in O
dogs O
of O
the O
other O
dietary O
groups O
for O
the O
remainder O
of O
the O
study O
. O

A O
case O
of O
Goodpasture's O
syndrome O
. O

RXR-gamma B-GENE
expression O
produced O
significant O
reduction O
in O
levels O
of O
RA-responsive O
genes O
including O
the O
cyclin-dependent B-GENE
kinase I-GENE
inhibitors I-GENE
p21Cip1 B-GENE
WAF1 I-GENE
and I-GENE
p27Kip1 O
, B-GENE
resulting O
in O
increased O
cdc2 O
and B-GENE
cdk2 O
kinase B-GENE
activity I-GENE
and O
RB O
phosphorylation B-GENE
. O

Lower O
limits O
( O
to O
10 O
micrograms O
kg O
) O
were O
detectable O
, O
but O
with O
lower O
reliability O
( O
60% O
) O
. O

Insulin-like B-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
IGFII B-GENE
) O
is O
a O
mitogenic O
polypeptide O
, O
the O
mRNAs O
of O
which O
are O
present O
in O
multiple O
forms O
, O
despite O
derivation O
from O
a O
single O
gene O
. O

The O
more O
traditional O
SERMS O
, O
clomiphene O
citrate O
and O
tamoxifen O
, O
will O
be O
reviewed O
along O
with O
such O
modern O
drugs O
as O
raloxifene O
and O
faslodex O
, O
with O
emphasis O
upon O
their O
actions O
on O
breast O
, O
uterus O
, O
bone O
and O
lipids O
. O

We O
have O
cloned O
cDNA O
and O
genomic O
DNA O
for O
a O
mouse O
gene O
encoding O
a O
protein O
with O
significant O
sequence O
similarity O
to O
conserved O
domains O
found O
in O
proteins O
of O
the O
Spo11p B-GENE
family I-GENE
. O

If O
E O
. O
coli O
is O
present O
in O
any O
source O
water O
sample O
, O
the O
borehole O
and O
any O
directly O
connected O
borehole O
should O
be O
embargoed O
. O

One O
of O
these O
is O
surrounded O
by O
an O
adenine-uridine O
rich O
region O
that O
can O
form O
an O
11-base O
pair O
stem O
structure O
. O

An O
important O
mechanism O
by O
which O
the O
tumor O
suppressor O
p53 B-GENE
maintains O
genomic O
stability O
is O
to O
induce O
cell O
cycle O
arrest O
through O
activation O
of O
the O
cyclin-dependent B-GENE
kinase I-GENE
inhibitor I-GENE
p21 I-GENE
( I-GENE
WAF1 I-GENE
Cip1 I-GENE
) I-GENE
gene I-GENE
. I-GENE

However O
, O
the O
mouse O
has O
previously O
been O
shown O
to O
possess O
only O
three O
forms O
of O
ADH B-GENE
. O

The O
effect O
of O
antilymphocyte O
sera O
on O
formation O
of O
transplantation O
and O
anti-infection O
immunity O
in O
mice O
. O

The O
quantity O
of O
each O
population O
( O
L O
. O
bulgaricus O
, O
S O
. O
thermophilus O
) O
was O
then O
estimated O
in O
the O
pellet O
by O
PyMS O
, O
and O
the O
data O
were O
analysed O
by O
artificial O
neural O
networks O
( O
ANNs O
) O
. O

LysR B-GENE
proteins I-GENE
have O
been O
shown O
to O
regulate O
urease B-GENE
in I-GENE
Klebsiella I-GENE
aerogenes I-GENE
( O
NAC B-GENE
) O
, O
and O
catalase B-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
( O
OxyR B-GENE
) O
, O
which O
offers O
the O
intracellular O
bacterium O
protection O
from O
phagolysosome O
damage O
. O

Experiments O
on O
narcotized O
cats O
demonstrated O
that O
the O
derivatives O
of O
2-mercaptobenzimidazole O
possessing O
the O
properties O
of O
specific O
bradycardic O
agents O
and O
coded O
as O
CM-251 O
, O
CM-266 O
, O
and O
CM-345 O
, O
reduce O
the O
mean O
rise O
of O
segment O
ST O
on O
numerous O
leads O
of O
the O
epicardial O
electrogram O
during O
5-min O
occlusion O
of O
the O
anterior O
descending O
branch O
of O
the O
left O
coronary O
artery O
. O

Ten O
weeks O
after O
reconstruction O
, O
the O
regenerating O
nerves O
already O
resembled O
normal O
nerves O
. O

Franz O
Schubert--his O
life O
, O
music O
and O
diseases O
. O

The O
emerging O
view O
based O
on O
studies O
in O
yeast O
is O
that O
each O
class O
of O
snoRNPs B-GENE
is O
composed O
of O
a O
unique O
set O
of O
proteins O
. O

Conclusion O
: O
inlet O
type O
VSD O
and O
perimembranous O
type O
TOF O
have O
anatomic O
features O
in O
which O
the O
proximal O
His O
bundle O
tends O
to O
be O
jeopardized O
by O
suturing O
for O
VSD O
closure O
. O

Svensson O
et O
al O
. O

This O
study O
suggests O
that O
BSPMs O
are O
useful O
in O
the O
assessment O
of O
AMI O
in O
terms O
of O
diagnosis O
, O
location O
and O
extent O
of O
myocardial O
infarct O
. O

Erratum O
: O
Absence O
of O
precursor O
effects O
above O
the O
martensitic O
transformation O
in O
a O
virgin O
crystal O
of O
Li O
metal O
[ O
Phys O
. O

B-myb B-GENE
is O
essential O
for O
G1 O
S O
transition O
and O
has O
been O
shown O
to O
be O
phosphorylated O
by O
the O
cyclin O
A2 B-GENE
cdk2 I-GENE
complex I-GENE
. I-GENE

Movement O
programming O
depends O
on O
understanding O
of O
behavioral O
requirements O
. O

Its O
neuromuscular O
effects O
are O
similar O
to O
a O
single O
ED90 O
dose O
of O
vecuronium O
. O

The O
hp55 B-GENE
gamma I-GENE
protein I-GENE
interacts O
strongly O
with O
the O
activated O
IGFIR B-GENE
but O
not O
with O
the O
kinase-negative O
mutant O
receptor O
. O
hp55 B-GENE
gamma I-GENE
also O
interacts O
with O
the O
insulin B-GENE
receptor I-GENE
( O
IR B-GENE
) O
in O
the O
yeast O
two-hybrid O
system O
. O

In O
humans O
, O
four O
AMP B-GENE
deaminase I-GENE
variants I-GENE
, O
termed O
M O
( O
muscle O
) O
, O
L O
( O
liver O
) O
, O
E1 B-GENE
, O
and O
E2 B-GENE
( O
erythrocyte O
) O
can O
be O
distinguished O
by O
a O
variety O
of O
biochemical O
and O
immunological O
criteria O
. O

In O
a O
longitudinal O
study O
, O
14 O
low-risk O
fetuses O
were O
studied O
at O
2-week O
intervals O
from O
32 O
weeks O
of O
gestation O
onward O
. O

However O
the O
sequence O
surrounding O
the O
transcription O
start O
site O
CTCA O
( O
+1 O
) O
TTCC O
was O
similar O
to O
the O
consensus O
CTCA O
( O
+1 O
) O
NTCT O
( O
N O
is O
any O
nucleoside O
) O
for O
an O
initiator O
element O
found O
in O
terminal B-GENE
deoxynucleotidyltransferase I-GENE
and O
a O
number O
of O
other O
highly O
regulated O
genes O
. O

C B-GENE
. I-GENE
elegans I-GENE
KLP-11 I-GENE
OSM-3 I-GENE
KAP-1 I-GENE
: I-GENE
orthologs I-GENE
of O
the O
sea O
urchin O
kinesin-II B-GENE
, I-GENE
and I-GENE
mouse O
KIF3A O
KIFB B-GENE
KAP3 I-GENE
kinesin I-GENE
complexes I-GENE
. I-GENE

Increase O
in O
blood O
NEFA O
was O
further O
augmented O
by O
fat O
plus O
AA O
supplementation O
, O
but O
no O
changes O
in O
concentrations O
of O
Lys O
or O
Met O
in O
blood O
were O
found O
. O

Most O
eukaryotic O
mRNAs O
are O
translated O
by O
a O
"scanning O
ribosome" O
mechanism O
. O

According O
to O
the O
biochemical O
tests O
, O
high O
activity O
( O
over O
200 O
U O
l O
) O
of O
alkaline O
phosphatase B-GENE
was I-GENE
recorded O
exclusively O
in O
patients O
with O
the O
lymphogranulomatosis-induced O
liver O
damage O
. O

During O
sub-maximal O
exercise O
, O
DCR O
in O
the O
UT O
dogs O
decreased O
from O
a O
resting O
value O
of O
4 O
. O
08 O
+ O
- O
0 O
. O
18 O
mm O
Hg O
X O
ml-1 O
X O
min-1 O
to O
1 O
. O
91 O
+ O
- O
0 O
. O
17 O
mm O
Hg O
X O
ml-1 O
X O
min-1 O
at O
a O
workload O
of O
6 O
. O
4 O
kph O
( O
speed O
) O
16% O
( O
grade O
) O
. O

The O
incidence O
of O
HSV-2 O
positive O
subjects O
( O
HSV-2 B-GENE
HSV-1 I-GENE
antibody I-GENE
ratio I-GENE
> O
or O
= O
1 O
) O
was O
low O
in O
the O
Jewish O
Israeli O
population O
, O
compared O
to O
other O
demographic O
areas O
. O

The O
sorption O
mechanisms O
changed O
from O
adsorption O
to O
partition O
in O
the O
process O
of O
repetitious O
sorption O
. O

According O
to O
their O
staining O
affinity O
for O
anti-T B-GENE
antibodies I-GENE
, O
the O
glandular O
tissue O
cells O
were O
classified O
as O
T- O
, O
T+ O
, O
T++ O
, O
and O
T O
and O
the O
annual O
changes O
in O
the O
numbers O
of O
these O
cell O
populations O
, O
as O
well O
as O
in O
the O
volume O
occupied O
by O
the O
glandular O
tissue O
, O
were O
calculated O
. O

Cardiac O
preservation O
. O

A O
new O
method O
for O
the O
in O
vitro O
transfer O
of O
delayed O
hypersensitivity O
by O
dialysed O
transfer B-GENE
factor I-GENE
. O

Karger O
AG O
, O
Basel O

The O
cloned O
alcR B-GENE
gene I-GENE
provided O
in O
trans O
restored O
these O
siderophore O
system O
activities O
to O
the O
mutants O
. O

Study O
of O
bacterial O
motility O
and O
rate O
of O
movement O
using O
a O
closed O
circuit O
television O
. O

Analysis O
of O
lacZ B-GENE
transcriptional I-GENE
fusions I-GENE
shows O
that O
the O
KdgR-binding B-GENE
sites I-GENE
negatively O
affect O
the O
expression O
of O
rsmB B-GENE
. O

Extramedullary O
plasmacytoma O
of O
the O
parotid O
gland O
. O

In O
addition O
, O
a O
21-mer O
subrepeat O
structure O
is O
also O
present O
in O
each O
unit O
. O

Intravenous O
glucose O
tolerance O
tests O
were O
performed O
before O
operation O
, O
before O
starting O
CyA O
and O
after O
3 O
weeks O
. O

Modulation O
of O
AUUUA B-GENE
response I-GENE
element I-GENE
binding O
by O
heterogeneous B-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
in O
human O
T O
lymphocytes O
. O

The O
data O
provide O
strong O
evidence O
that O
ThlA B-GENE
is O
involved O
in O
the O
metabolism O
of O
both O
acid O
and O
solvent O
formation O
, O
whereas O
the O
physiological O
function O
of O
ThlB B-GENE
has O
yet O
to O
be O
elucidated O
. O

Selection O
of O
the O
22 O
items O
of O
the O
Clinical O
Institute O
Withdrawal O
Assessment-Benzodiazepines O
( O
CIWA-B O
) O
was O
based O
on O
statistically O
significant O
differences O
between O
baseline O
and O
critical O
withdrawal O
periods O
in O
high-dose O
subjects O
and O
between O
symptoms O
associated O
with O
placebo O
and O
diazepam O
in O
low-dose O
subjects O
, O
using O
contingency O
tables O
and O
logistic O
regression O
analysis O
. O

We O
also O
observed O
that O
cell B-GENE
surface I-GENE
CD4 I-GENE
( I-GENE
- I-GENE
) I-GENE
CD8 I-GENE
( I-GENE
- I-GENE
) I-GENE
CD3 I-GENE
( I-GENE
- I-GENE
) I-GENE
cells O
with O
rearranged B-GENE
TCR I-GENE
genes I-GENE
developed O
from O
Id3-transduced O
but O
not O
from O
control-transduced O
pre-T O
cells O
in O
an O
FTOC O
. O

In O
order O
to O
define O
potential O
candidate O
genes O
for O
inherited O
disorders O
characterized O
by O
aberrant O
gene O
expression O
, O
we O
utilized O
Kruppel-related B-GENE
sequences I-GENE
to O
isolate O
zinc O
finger-containing O
cDNAs O
. O

Praziquantel O
and O
Albendazole O
were O
found O
effective O
in O
the O
treatment O
of O
neurocysticercosis O
, O
but O
because O
of O
serious O
side O
effects O
encountered O
in O
some O
cases O
, O
the O
drugs O
should O
be O
used O
cautiously O
in O
selected O
cases O
only O
. O

The O
results O
raise O
the O
possibility O
that O
pH O
induced O
post-translational O
modifications O
of O
DdRPA B-GENE
are O
involved O
in O
events O
that O
halt O
cell O
proliferation O
and O
induce O
differentiation O
in O
Dictyostelium O
. O

However O
, O
activation O
of O
the O
cAMP O
pathway O
, O
which O
is O
known O
to O
regulate O
inhibin B-GENE
alpha I-GENE
expression O
, O
greatly O
enhanced O
the O
actions O
of O
SF-1 B-GENE
. O

At O
different O
times O
of O
the O
surgical O
procedures O
( O
thorax O
opening O
and O
closure O
, O
period O
of O
cardiopulmonary O
bypass O
) O
67 O
to O
100% O
of O
the O
patients O
in O
group O
1 O
had O
vancomycin O
concentrations O
in O
the O
studied O
tissues O
above O
the O
MIC O
90 O
for O
Staphylococcus O
aureus O
( O
1 O
microgram O
g O
) O
and O
Staphylococcus O
epidermidis O
( O
2 O
micrograms O
g O
) O
. O

Ent-kaurene B-GENE
synthase I-GENE
from I-GENE
the I-GENE
fungus I-GENE
Phaeosphaeria I-GENE
sp O
. O

Data O
Management O
in O
Practice-based O
Research O
. O

The O
incidence O
of O
cardiac O
death O
( O
one O
per O
group O
) O
, O
Q O
wave O
MI O
( O
propofol O
, O
n O
= O
7 O
; O
midazolam O
, O
n O
= O
3 O
; O
P O
= O
0 O
. O
27 O
) O
, O
or O
non O
Q O
wave O
MI O
( O
propofol O
, O
n O
= O
16 O
; O
midazolam O
, O
n O
= O
18 O
; O
P O
= O
0 O
. O
81 O
) O
did O
not O
differ O
between O
treatment O
groups O
. O

Evidence O
is O
presented O
that O
Leber's O
military O
aneurysm O
retinitis O
is O
not O
a O
separate O
entity O
but O
a O
special O
form O
of O
Coats' O
disease O
. O

Here O
, O
we O
alter O
the O
dimerization O
specificity O
of O
Fos B-GENE
by O
precisely O
replacing O
its O
leucine O
zipper O
with O
that O
from O
GCN4 B-GENE
. O

We O
confirmed O
the O
interaction O
between O
TLS B-GENE
and O
p65 B-GENE
by O
the O
pull-down O
assay O
in O
vitro O
and O
by O
a O
coimmunoprecipitation O
experiment O
followed O
by O
Western O
blot O
of O
the O
cultured O
cell O
in O
vivo O
. O

The O
cycle O
length O
of O
induced O
VT O
( O
n O
= O
10 O
VTs O
) O
was O
380 O
+ O
- O
41 O
msec O
. O

Nucleotide O
sequence O
, O
genome O
organization O
and O
phylogenetic O
analysis O
of O
pineapple O
mealybug O
wilt-associated O
virus-2 O
. O

Observations O
on O
the O
flight O
activities O
of O
Chrysops O
caecutiens O
L O
. O

Stimulation O
of O
[ O
3H O
] O
PA O
production O
upon O
CD3 B-GENE
cross-linking O
was O
77% O
lower O
in O
permeabilized O
CD45- B-GENE
cells O
than O
in O
CD45+ B-GENE
cells O
, O
consistent O
with O
the O
reduced O
activity O
of O
p59fyn B-GENE
in O
CD45- B-GENE
cells O
. O

In O
a O
series O
of O
402 O
consecutive O
autopsies O
, O
parietal O
pleural O
plaques O
( O
PP O
) O
were O
found O
in O
68 O
individuals O
above O
40 O
years O
of O
age O
. O

In O
contrast O
, O
high O
COUP-TFI B-GENE
expression O
impeded O
the O
neuronal O
differentiation O
of O
P19 O
cells O
induced O
with O
RA O
, O
resulting O
in O
cell O
cultures O
lacking O
neurons O
. O

We O
show O
that O
several O
heme-responsive O
mechanisms O
combine O
to O
regulate O
DAN B-GENE
TIR I-GENE
gene I-GENE
expression I-GENE
. O

NGF B-GENE
, O
but O
not O
EGF B-GENE
, O
enhances O
the O
upper O
bands O
, O
corresponding O
to O
phosphorylated B-GENE
Fra-2 I-GENE
. O

The O
FFA O
levels O
were O
not O
affected O
( O
P O
greater O
than O
. O
1 O
) O
by O
meal O
interval O
. O

A O
survey O
is O
given O
of O
the O
pharmacological O
backgrounds O
that O
are O
relevant O
for O
the O
drug O
treatment O
of O
essential O
hypertension O
in O
the O
elderly O
. O

Our O
results O
indicate O
that O
the O
minimal O
requirements O
for O
induction O
of O
PEPCK B-GENE
by O
PKA B-GENE
and O
inhibition O
by O
insulin B-GENE
include O
: O
1 O
) O
the O
CREB B-GENE
activation I-GENE
domain I-GENE
, O
2 O
) O
the O
PEPCK B-GENE
TATA I-GENE
sequence I-GENE
, O
and O
3 O
) O
insulin-responsive O
hepatoma O
cells O
. O

The O
Drosophila B-GENE
melanogaster I-GENE
Gart I-GENE
gene I-GENE
encodes O
three O
enzymatic O
activities O
in O
the O
pathway O
for O
purine O
de O
novo O
synthesis O
. O

In O
contrast O
, O
we O
did O
not O
detect O
a O
significant O
correlation O
between O
plasma B-GENE
TNFalpha I-GENE
and O
radiation O
pneumonitis O
. O

Unlike O
the O
mammalian O
proteins O
, O
XFGF3 B-GENE
is O
efficiently O
secreted O
as O
a O
Mr O
31 O
, O
000 O
glycoprotein O
, O
gp31 B-GENE
, O
which O
undergoes O
proteolytic O
cleavage O
to O
produce O
an O
NH2-terminally O
truncated O
product O
, O
gp27 B-GENE
. O

Enhancement O
of O
the O
immune O
response O
by O
aspecific O
action O
of O
vaccine O
additives O
in O
the O
aerogenic O
immunization O
of O
swine O
against O
swine O
plague O
. O

The O
effect O
of O
six O
arginine O
mutations O
of O
oxidative O
phosphorylation O
and O
AAC B-GENE
expression O
. O

Neuregulin B-GENE
stimulates O
ErbB2 B-GENE
, O
ErbB3 B-GENE
, O
and O
ErbB4 B-GENE
, O
members O
of O
the O
ErbB B-GENE
family I-GENE
of O
receptor B-GENE
tyrosine I-GENE
kinases I-GENE
. O

Previous O
studies O
have O
demonstrated O
that O
the O
TATA O
element O
is O
critical O
for O
basal O
and O
Tat-induced O
HIV-1 O
gene O
expression O
. O

Furthermore O
, O
cpxA* B-GENE
mutations O
suppress O
the O
toxicity O
conferred O
by O
the O
LamB-LacZ B-GENE
hybrid I-GENE
protein I-GENE
, O
which O
exerts O
its O
effects O
in O
the O
cytoplasm O
, O
sequestered O
from O
DegP B-GENE
. O

They O
include O
genes O
encoding O
three O
subunits O
of O
the O
cytochrome B-GENE
oxidase I-GENE
( O
cox1 B-GENE
to I-GENE
3 I-GENE
) O
, O
apocytochrome B-GENE
b I-GENE
( O
cob B-GENE
) O
, O
seven O
subunits O
of O
the O
NADH B-GENE
dehydrogenase I-GENE
complex I-GENE
( O
nad1 B-GENE
to I-GENE
6 I-GENE
, O
nad4L B-GENE
) O
, O
two O
ATPase B-GENE
subunits O
( O
atp6 B-GENE
and O
atp9 B-GENE
) O
, O
three O
ribosomal O
RNAs O
( O
rrn5 B-GENE
, O
srn B-GENE
and O
lrn B-GENE
) O
, O
23 O
tRNAs O
and O
four O
ribosomal B-GENE
proteins I-GENE
( O
rps3 B-GENE
, O
rps11 B-GENE
, O
rps12 B-GENE
and O
rpl16 B-GENE
) O
. O

OUTCOME O
: O
Acetylcholine B-GENE
receptor I-GENE
antibodies I-GENE
and O
single-fibre O
electromyogram O
were O
useful O
in O
the O
diagnosis O
of O
myasthenia O
gravis O
. O

In O
the O
PMR O
target O
area O
but O
not O
in O
the O
nontreated O
area O
an O
improvement O
in O
regional O
myocardial O
flow O
reserve O
occurs O
in O
wall O
segments O
with O
initially O
severely O
or O
moderately O
reduced O
stress O
perfusion O
. O

Therefore O
, O
ICSBP B-GENE
may O
be O
involved O
in O
maintaining O
submaximal O
transcriptional O
activity O
of O
IFN-inducible O
genes O
in O
hematopoietic O
cells O
. O

Blood O
eosinophils O
in O
patients O
with O
Taenia O
saginata O
taeniasis O
. O

Our O
results O
suggest O
that O
WASP B-GENE
activates O
transcription O
following O
TCR B-GENE
stimulation O
in O
a O
manner O
that O
is O
independent O
of O
its O
role O
in O
Arp2 B-GENE
3-directed O
actin O
polymerization B-GENE
. O

O2 O
and O
CO2 O
in O
the O
tracheostomy O
tube O
were O
continuously O
monitored O
by O
mass O
spectrometry O
using O
a O
special O
sample-hold O
phase-locked O
sampling O
technique O
. O

Removal O
of O
the O
carboxyl O
region O
severely O
reduced O
transcriptional O
activation O
. O

Aortic O
diameters O
in O
infants O
and O
young O
children O
: O
normative O
angiographic O
data O
. O

Using O
a O
3'-rapid O
amplification O
of O
cDNA O
ends O
strategy O
, O
we O
have O
cloned O
cDNAs O
representing O
the O
3'-termini O
of O
both O
the O
native O
and O
mutant O
transcripts O
from O
both O
P388 O
ADR O
3 O
and O
P388 O
ADR O
7 O
cells O
. O

Mutations O
at O
three O
sites O
have O
larger O
effects O
in O
muscle O
than O
nonmuscle O
cells O
; O
an O
A O
T-rich O
site O
mutation O
has O
a O
pronounced O
effect O
in O
both O
striated O
muscle O
types O
, O
mutations O
at O
the O
MEF1 O
( B-GENE
Right I-GENE
E-box I-GENE
) I-GENE
site I-GENE
are I-GENE
relatively O
specific O
to O
expression O
in O
skeletal O
muscle O
, O
and O
mutations O
at O
the O
CArG O
site O
are O
relatively O
specific O
to O
expression O
in O
cardiac O
muscle O
. O

Therefore O
, O
in O
our O
in O
vitro O
model O
, O
the O
localization O
of O
the O
mutation O
in O
the O
K-ras B-GENE
gene I-GENE
predisposes O
to O
a O
different O
level O
of O
aggressiveness O
in O
the O
transforming O
phenotype O
. O

Induction O
of O
anaesthesia O
was O
standardised O
: O
fentanyl O
( O
3 O
micrograms O
kg O
) O
, O
thiopentone O
( O
5 O
mg O
kg O
) O
, O
atracurium O
( O
0 O
. O
4 O
mg O
kg O
) O
. O

Moreover O
, O
Western O
blots O
demonstrated O
at O
least O
six O
types O
of O
Ypt B-GENE
in O
both O
Cr O
and O
Vc O
, O
suggesting O
that O
these O
Ypt B-GENE
are O
used O
for O
household O
functions O
responsible O
for O
vesicle O
transport O
rather O
than O
for O
cellular O
differentiation O
. O

In O
on-going O
screening O
programmes O
, O
the O
Haemoccult O
test O
consists O
of O
six O
slides O
and O
a O
test O
is O
considered O
positive O
if O
at O
least O
one O
slide O
is O
coloured O
. O

The O
results O
obtained O
were O
as O
follows O
: O
The O
mitral O
valve O
orifice O
area O
( O
MVA O
) O
was O
significantly O
smaller O
in O
patients O
with O
type O
III O
of O
the O
LVIT O
flow O
velocity O
pattern O
than O
in O
patients O
with O
type O
I O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

Our O
data O
indicate O
that O
SIP1 B-GENE
is O
required O
to O
confine O
XBra B-GENE
gene I-GENE
expression O
to O
the O
mesoderm O
. O

Menstrual-cycle O
phase O
did O
not O
significantly O
affect O
personality O
variables O
in O
either O
group O
. O

Here O
we O
show O
that O
these O
synthetic O
binding O
sites O
have O
a O
more O
restricted O
and O
specific O
ability O
to O
enhance O
transcription O
when O
assayed O
in O
transformed O
embryos O
. O

Administration O
of O
anticoagulants O
, O
i O
. O
e O
. O
, O
heparin O
, O
prostaglandin O
E1 O
and O
ticlopidine O
seems O
to O
be O
effective O
in O
alleviating O
symptoms O
and O
might O
prevent O
further O
deterioration O
. O

Both O
tear O
volume O
and O
tear O
flow O
were O
found O
to O
be O
significantly O
( O
P O
less O
than O
0 O
. O
001 O
) O
decreased O
up O
to O
6 O
h O
after O
instillation O
, O
reaching O
a O
minimum O
90 O
min O
after O
application O
( O
tear O
volume O
: O
-63% O
; O
tear O
flow O
: O
-71% O
) O
. O

Experimental O
reproduction O
of O
malignant O
catarrhal O
fever O
in O
Bali O
cattle O
. O

Deletion O
analysis O
was O
carried O
out O
within O
a O
part O
of O
the O
5'-flanking O
region O
showing O
homology O
to O
the O
upstream O
region O
of O
the O
yeast B-GENE
CYC1 I-GENE
gene I-GENE
. O

The O
fusion O
proteins O
were O
tested O
by O
ELISA O
for O
reactivity O
with O
a O
panel O
of O
human B-GENE
anti-La I-GENE
sera I-GENE
in O
order O
to O
define O
the O
nature O
of O
the O
epitopes O
. O

Class B-GENE
I I-GENE
alpha1 I-GENE
, I-GENE
2-mannosidases I-GENE
play O
an O
essential O
role O
in O
the O
elaboration O
of O
complex O
and O
hybrid O
N O
-glycans O
in O
mammalian O
cells O
. O

Recent O
developments O
in O
drugs O
antagonistic O
to O
factors O
causing O
peptic O
ulcer--clinical O
efficacy O
and O
problems O
; O
gastrin B-GENE
receptor I-GENE
blockaders O
. O

SCOB O
testing O
of O
food-restricted O
animals O
, O
using O
a O
multiple O
fixed O
ratio O
( O
FR O
) O
fixed O
interval O
( O
FI O
) O
schedule O
( O
FR20 O
: O
FI120 O
) O
, O
was O
conducted O
prior O
to O
each O
exposure O
to O
maintain O
the O
operant O
behavior O
; O
the O
data O
from O
Weeks O
-1 O
, O
4 O
, O
8 O
, O
and O
13 O
were O
evaluated O
for O
evidence O
of O
neurotoxicity O
. O

Two O
overlapping O
clones O
contained O
the O
complete O
Adh-2 B-GENE
gene I-GENE
composed O
of O
nine O
exons O
in O
a O
12-kb O
region O
, O
with O
the O
placement O
of O
introns O
matching O
that O
observed O
in O
other O
mammalian B-GENE
ADH I-GENE
genes I-GENE
. O

The O
imprinted O
expression O
of O
the O
endogenous O
gene O
can O
be O
recapitulated O
in O
mice O
by O
using O
a O
14-kb O
transgene O
encompassing O
4 O
kb O
of O
5'-flanking O
sequence O
, O
8 O
kb O
of O
3'-flanking O
sequence O
, O
which O
includes O
the O
two O
endoderm-specific O
enhancers O
, O
and O
an O
internally O
deleted O
structural O
gene O
. O

The O
strong O
conservation O
of O
the O
inverted O
terminal O
repeat O
sequence O
may O
reflect O
a O
common O
integration O
mechanism O
for O
VL30 B-GENE
elements I-GENE
and O
MuLV O
proviruses O
. O

A O
method O
of O
three-station O
three-dimensional O
magnetic O
resonance O
( O
MR O
) O
angiography O
of O
the O
lower O
extremities O
with O
segmented O
volume O
acquisition O
is O
presented O
. O

The O
presence O
of O
unidentified O
macroscopic O
or O
microscopic O
clusters O
of O
neoplastic O
cells O
, O
lying O
around O
, O
more O
or O
less O
close O
to O
, O
the O
line O
of O
insertion O
of O
lesion O
, O
could O
render O
any O
attempt O
to O
gain O
a O
"radical" O
excision O
useless O
. O

Psychological O
examinations O
in O
patients O
with O
chronic O
kidney O
insufficiency O
. O

Pathological O
processes O
in O
the O
cervix O
uteri O
. O

After O
the O
first O
cycle O
, O
18 O
cases O
were O
treated O
at O
dose O
level O
1 O
, O
after O
a O
second O
cycle O
, O
13 O
cases O
were O
treated O
at O
dose O
level O
2 O
. O

Their O
hydropathic O
plots O
are O
very O
similar O
and O
both O
possess O
three O
hydrophobic O
segments O
that O
are O
likely O
alpha-helical O
transmembrane O
segments O
. O

We O
propose O
that O
Mnt B-GENE
: O
Max B-GENE
: O
Sin3 B-GENE
complexes O
normally O
function O
to O
restrict O
Myc B-GENE
: O
Max B-GENE
activities O
associated O
with O
cell O
proliferation O
. O

We O
recently O
characterized O
a O
single O
yeast B-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
HMT1 B-GENE
) O
. O

The O
factor O
which O
binds O
to O
the O
TR B-GENE
promoter I-GENE
co-sedimented O
with O
SV40 O
chromosomes O
extracted O
late O
in O
infection O
. O

Complexes O
of O
qTBP42 B-GENE
with O
each O
complementary O
strand O
of O
telomeric O
DNA O
and O
with O
quadruplex O
forms O
of O
the O
guanine-rich O
strand O
had O
3 O
. O
7-14 O
. O
6 O
nM O
dissociation O
constants O
, O
Kd O
, O
whereas O
complexes O
with O
double-stranded O
telomeric O
DNA O
had O
up O
to O
100-fold O
higher O
Kd O
values O
. O

Between O
the O
subgroups O
of O
dementia O
disorders O
there O
were O
no O
significant O
differences O
in O
basal O
cortisol O
levels O
. O

Certain O
characteristics O
of O
eye O
changes O
in O
patients O
with O
pheochromocytoma O
including O
Sipple's O
syndrome O
. O

Proteomic O
patterns O
of O
nipple O
aspirate O
fluids O
obtained O
by O
SELDI-TOF O
: O
potential O
for O
new O
biomarkers O
to O
aid O
in O
the O
diagnosis O
of O
breast O
cancer O
. O

Correlation O
of O
skin O
disorders O
with O
CD4 B-GENE
lymphocyte O
counts O
in O
patients O
with O
HIV O
AIDS O
. O

An O
intact O
5 O
. O
7-kb O
provirus O
of O
the O
avian O
erythroblastosis O
virus O
E26 O
has O
been O
molecularly O
cloned O
for O
comparisons O
with O
avian O
myeloblastosis O
virus O
( O
AMV O
) O
and O
other O
avian O
tumor O
viruses O
. O

RESULTS O
: O
For O
E1 O
, O
itraconazole O
plasma O
drug O
concentration O
extrapolated O
to O
time O
zero O
( O
IV O
dose O
) O
was O
5 O
. O
2 O
+ O
- O
1 O
. O
4 O
micrograms O
ml O
, O
and O
mean O
residence O
time O
( O
MRT O
) O
was O
37 O
+ O
- O
16 O
hours O
. O

It O
was O
shown O
that O
administration O
of O
immunomodulator O
neurotropin B-GENE
( O
NSP B-GENE
) O
results O
in O
more O
steady O
consolidation O
and O
retention O
of O
feeding O
and O
avoidance O
behavior O
, O
and O
some O
neurophysiological O
mechanisms O
of O
that O
phenomena O
were O
revealed O
. O

Intriguingly O
, O
three O
hypomorphic O
Scm B-GENE
mutations O
, O
which O
map O
within O
an O
mbt B-GENE
repeat I-GENE
, O
interact O
with O
PcG B-GENE
mutations I-GENE
more O
strongly O
than O
do O
Scm B-GENE
null O
alleles O
. O

Serial O
measurements O
of O
total O
serum O
IgE B-GENE
appears O
to O
be O
a O
useful O
index O
of O
disease O
activity O
in O
ABPA O
. O

Dynamic O
decision O
making O
: O
human O
control O
of O
complex O
systems O
. O

Autopsy O
demonstrated O
good O
survival O
of O
the O
transplanted O
cells O
with O
good O
integration O
with O
the O
brain O
of O
the O
recipient O
and O
traces O
of O
positive O
immunocytochemical O
reaction O
for O
tyrosine B-GENE
hydroxylase I-GENE
. O

After O
profound O
normovolemic O
hemodilution O
( O
Hct O
9% O
) O
superiority O
of O
LV O
MC O
and O
LV O
diastolic O
properties O
was O
found O
, O
when O
myocardial O
oxygenation O
was O
supported O
by O
i O
. O
v O
. O
perflubron O
emulsion O
, O
a O
temporary O
O2 O
carrier O
. O

The O
inner O
ears O
were O
exposed O
by O
microdissection O
, O
and O
the O
vestibular O
sensory O
regions O
were O
either O
sectioned O
and O
studied O
with O
light O
or O
electron O
microscopy O
, O
or O
prepared O
and O
studied O
with O
the O
surface O
specimen O
technique O
. O

One O
of O
these O
fragments O
shows O
the O
highest O
amino O
acid O
sequence O
homology O
to O
the O
insect O
ecdysone O
inducible O
gene B-GENE
E75 I-GENE
. O

The O
domain O
structure O
of O
bovine B-GENE
LTBP-2 I-GENE
is O
very O
similar O
to O
that O
of O
the O
human B-GENE
LTBP-2 I-GENE
, O
containing O
20 O
examples O
of O
6-cysteine O
epidermal B-GENE
growth I-GENE
factor-like I-GENE
repeats I-GENE
, O
16 O
of O
which O
have O
the O
consensus O
sequence O
for O
calcium O
binding O
, O
together O
with O
4 O
examples O
of O
8-cysteine B-GENE
motifs I-GENE
characteristic O
of O
fibrillins B-GENE
and O
LTBP-1 B-GENE
. O

Stat B-GENE
activation O
in O
response O
to O
GH B-GENE
and O
IL-6 B-GENE
was O
determined O
by O
reporter O
gene O
induction O
. O

During O
early O
neurogenesis O
, O
Vnd B-GENE
protein I-GENE
is O
restricted O
to O
ventral O
column O
neuroectoderm O
and O
neuroblasts O
; O
later O
it O
is O
detected O
in O
a O
complex O
pattern O
of O
neurons O
. O

The O
median O
post-treatment O
, O
pre-operative O
serum B-GENE
PSA I-GENE
was O
0 O
. O
4 O
ng O
ml O
. O

The O
growth B-GENE
factor I-GENE
receptor-bound I-GENE
protein I-GENE
2 I-GENE
( O
Grb2 B-GENE
) O
adaptor O
when O
complexed O
with O
Sos B-GENE
( O
Son B-GENE
of I-GENE
sevenless I-GENE
) O
, O
the O
exchange O
factor O
of O
Ras B-GENE
, O
conveys O
the O
signal O
induced O
by O
tyrosine B-GENE
kinase-activated I-GENE
receptor I-GENE
to O
Ras B-GENE
by O
recruiting O
Sos B-GENE
to O
the O
membrane O
, O
allowing O
activation O
of O
Ras B-GENE
. O

Thus O
, O
despite O
the O
potential O
for O
common O
regulatory O
mechanisms O
, O
the O
available O
evidence O
indicates O
that O
the O
Mtx B-GENE
minimal I-GENE
promoter I-GENE
does O
not O
significantly O
affect O
Thbs3 B-GENE
gene I-GENE
expression O
. O

Phosphatidylinositol B-GENE
3-kinase I-GENE
potentiates O
, O
but O
does O
not O
trigger O
, O
T O
cell O
proliferation O
mediated O
by O
the O
IL-2 B-GENE
receptor I-GENE
. O

Value O
of O
the O
EMG O
in O
the O
diagnosis O
of O
a O
cardiomyopathy O
associated O
with O
a O
myotonic O
myopathy O
. O

As O
a O
result O
of O
alternative O
splicing O
, O
the O
BGP B-GENE
gene I-GENE
is O
transcribed O
into O
at O
least O
seven O
distinct O
mRNA O
species O
. O

Finally O
, O
some O
point O
mutations O
in O
the O
Gag-Pol B-GENE
PR B-GENE
domain I-GENE
inhibited O
activation O
of O
RT B-GENE
in O
trans O
by O
a O
wild-type B-GENE
PR I-GENE
, O
suggesting O
that O
the O
correct O
conformation O
of O
the O
PR B-GENE
domain I-GENE
in O
Gag-Pol B-GENE
is O
prerequisite O
for O
activation O
of O
RT O
. O

Three O
different O
site-directed O
mutations O
of O
the O
cyclic B-GENE
AMP I-GENE
response I-GENE
element I-GENE
each O
reduced O
the O
nerve B-GENE
growth I-GENE
factor I-GENE
effect O
by O
> O
90% O
. O

Significant O
GMBF O
reductions O
occurred O
in O
early O
shock O
in O
both O
treatment O
groups O
. O

HBB O
concentration O
in O
the O
fetuses O
indicated O
little O
, O
if O
any O
accumulation O
. O

SPP B-GENE
also O
induced O
transient O
tyrosine O
phosphorylation O
of O
focal B-GENE
adhesion I-GENE
kinase I-GENE
( O
p125 B-GENE
( O
FAK B-GENE
) O
) O
, O
a O
cytosolic B-GENE
tyrosine I-GENE
kinase I-GENE
that O
localizes O
in O
focal O
adhesions O
, O
and O
of O
the O
cytoskeleton-associated B-GENE
protein I-GENE
paxillin I-GENE
. O

Unlike O
the O
introns O
of O
other O
duplicated O
ribosomal O
protein O
genes O
which O
are O
highly O
diverged O
, O
the O
duplicated O
S13 B-GENE
genes I-GENE
have O
two O
nearly O
identical O
DNA O
sequences O
of O
25 O
and O
31 O
bp O
in O
length O
within O
their O
introns O
. O

Changes O
induced O
in O
the O
gills O
of O
milkfish O
( O
Chanos O
chanos O
Forsskal O
) O
fingerlings O
after O
acute O
exposure O
to O
nifurpirinol O
( O
Furanace O
; O
P-7138 O
) O
. O

In O
agreement O
with O
these O
data O
, O
western O
blot O
experiments O
using O
an O
antibody O
directed O
against O
the O
carboxy-terminal O
portion O
of O
the O
mouse O
c-kit B-GENE
protein I-GENE
showed O
that O
a O
polypeptide O
, O
of O
the O
size O
predicted O
by O
the O
open O
reading O
frame O
of O
the O
spermatid-specific B-GENE
c-kit I-GENE
cDNA I-GENE
, O
accumulates O
in O
the O
latest O
stages O
of O
spermatogenesis O
and O
in O
epididymal O
spermatozoa O
. O

Both O
the O
presence O
of O
arginine O
and O
anaerobiosis O
are O
needed O
to O
trigger O
induction O
of O
the O
pathway O
. O

The O
relatively O
mild O
defects O
observed O
in O
Rpd3 B-GENE
mutants I-GENE
suggest O
that O
the O
recently O
identified O
Groucho B-GENE
and O
dCtBP B-GENE
corepressor I-GENE
proteins I-GENE
do O
not O
function O
solely O
through O
the O
recruitment O
of O
histone B-GENE
deacetylases I-GENE
. O

Since O
September O
1980 O
to O
June O
1983 O
we O
have O
treated O
32 O
patients O
with O
ovarian O
cancer O
. O

Nonreturn O
rates O
can O
be O
used O
to O
derive O
more O
elementary O
biological O
measures O
for O
reproductive O
efficiency O
, O
such O
as O
conception O
rate O
and O
calving O
rate O
, O
which O
separately O
might O
be O
more O
reliable O
than O
nonreturn O
rate O
itself O
to O
evaluate O
the O
fertility O
of O
a O
bull O
or O
the O
performance O
of O
an O
AI O
technician O
. O

Waves O
N1 O
, O
P3 O
and O
CNV O
were O
recorded O
during O
a O
CNV O
paradigm O
in O
a O
simple O
reaction O
time O
task O
with O
a O
constant O
interstimulus O
interval O
( O
ISI O
) O
of O
1 O
sec O
. O

In O
the O
B6-derived O
Db B-GENE
mutant I-GENE
B6 I-GENE
. I-GENE
CH-2bm13 I-GENE
( I-GENE
bm13 I-GENE
) I-GENE
strain O
, O
part O
of O
the O
class B-GENE
I I-GENE
Db I-GENE
antigen-presenting I-GENE
groove I-GENE
is O
shaped O
by O
a O
class B-GENE
I I-GENE
Kb-encoded I-GENE
sequence I-GENE
. O

The O
stability O
of O
isoniazid O
solutions O
increases O
markedly O
with O
increasing O
NTA O
or O
EDTA O
concentration O
up O
to O
1 O
mmol O
l O
. O

Prolonged O
suspension O
induced O
a O
significant O
change O
in O
the O
geometric O
configuration O
of O
the O
femur O
middiaphysis O
by O
increasing O
the O
minimum O
diameter O
( O
12% O
) O
without O
any O
significant O
alterations O
in O
cortical O
area O
, O
density O
, O
mineral O
, O
and O
collagen B-GENE
concentrations O
. O

The O
dynamic O
properties O
of O
this O
protein O
fragment O
were O
measured O
and O
analyzed O
using O
both O
isotropic O
and O
anisotropic O
models O
of O
molecular O
motion O
. O

The O
original O
technique O
was O
developed O
in O
the O
1960's O
to O
analyze O
the O
inner O
ear O
fluid O
as O
a O
diagnostic O
procedure O
( O
i O
. O
e O
. O
, O
diagnostic O
labyrinthotomy O
) O
in O
acoustic O
neuroma O
suspects O
. O

This O
study O
utilizes O
the O
mammalian O
two-hybrid O
system O
to O
examine O
the O
role O
of O
ligand O
in O
the O
dimerization O
of O
human B-GENE
progesterone I-GENE
receptor I-GENE
( O
hPR B-GENE
) O
. O

No O
mutation O
of O
the O
NRL B-GENE
gene I-GENE
was O
found O
in O
any O
of O
the O
two O
families O
. O

The O
Nmd3 B-GENE
protein I-GENE
sequence I-GENE
does O
not O
contain O
readily O
recognizable O
motifs O
of O
known O
function O
. O

Several O
distinct O
apoptotic O
stimuli O
induce O
the O
expression O
and O
caspase-dependent O
cleavage O
of O
hTAF B-GENE
( I-GENE
II I-GENE
) I-GENE
80 I-GENE
delta I-GENE
. O
hTAF B-GENE
( I-GENE
II I-GENE
) I-GENE
80 I-GENE
delta I-GENE
, O
unlike O
hTAF B-GENE
( I-GENE
II I-GENE
) I-GENE
80 I-GENE
, O
forms O
a O
TFIID-like B-GENE
complex I-GENE
lacking O
hTAF B-GENE
( I-GENE
II I-GENE
) I-GENE
31 I-GENE
. O

A O
computed O
tomographic O
scan O
obtained O
after O
EOE-13 O
infusion O
accurately O
showed O
the O
perfusion O
pattern O
of O
the O
implanted O
catheter O
. O

Therefore O
, O
in O
conjunction O
with O
a O
positive O
pregnancy O
test O
and O
the O
patient's O
clinical O
history O
, O
a O
severely O
depressed O
or O
absent O
serum O
PAPP-A B-GENE
level O
may O
aid O
in O
the O
diagnosis O
of O
extrauterine O
pregnancy O
. O

Aneurysmal O
bone O
cyst O
of O
the O
jaws O
: O
analysis O
of O
11 O
cases O
. O

An O
8-bp O
sequence O
( O
ATTTCAAA B-GENE
) O
within O
the O
protected O
region O
shares O
significant O
homology O
with O
promoter O
sequences O
required O
for O
ethylene O
responsiveness O
from O
the O
tomato O
fruit-ripening O
E4 B-GENE
gene I-GENE
. O

However O
, O
the O
a1 B-GENE
isoform I-GENE
is O
expressed O
most O
heavily O
in O
brain O
and O
heart O
, O
a2 B-GENE
in O
liver O
and O
kidney O
, O
and O
a3 B-GENE
in O
liver O
, O
lung O
, O
heart O
, O
brain O
, O
spleen O
, O
and O
kidney O
. O

The O
R2 B-GENE
region I-GENE
within O
the O
class B-GENE
I I-GENE
enhancer I-GENE
acts O
as O
a O
negative O
element O
in O
Ad12-transformed O
cells O
and O
exhibits O
a O
stronger O
binding O
activity O
than O
is O
observed O
in O
nontumorigenic O
Ad5-transformed O
cells O
, O
which O
are O
not O
reduced O
in O
class B-GENE
I I-GENE
expression O
. O

Diverse O
endogenous O
light O
chains O
contribute O
to O
basement O
membrane O
reactivity O
in O
nonautoimmune O
mice O
transgenic O
for O
an O
anti-laminin B-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
. O

UF-021 O
ophthalmic O
solution O
( O
0 O
. O
03 O
to O
0 O
. O
24% O
) O
, O
when O
topically O
applied O
to O
the O
eyes O
of O
rabbits O
, O
caused O
dose-dependent O
IOP O
reduction O
( O
2 O
. O
8 O
to O
5 O
. O
2 O
mmHg O
) O
, O
without O
transient O
IOP O
rise O
. O

All O
9 O
untreated O
patients O
underwent O
laparoscopy O
, O
which O
identified O
3 O
intra-abdominal O
, O
3 O
vanished O
and O
2 O
peeping O
testes O
, O
and O
1 O
atrophic O
testis O
in O
the O
inguinal O
canal O
. O

This O
slope O
tended O
to O
be O
higher O
( O
approximately O
1 O
. O
6 O
dB O
dB O
) O
for O
L1 O
= O
L2 O
greater O
than O
80 O
dB O
. O

Another O
stem-loop O
called O
structure O
III O
near O
the O
3'-end O
of O
repY B-GENE
sequesters O
both O
the O
5'-rCGCC-3' B-GENE
sequence I-GENE
and O
the O
repZ B-GENE
ribosome-binding I-GENE
site I-GENE
. O

We O
further O
studied O
the O
effects O
of O
SIE-1 B-GENE
hypermethylation O
on O
p21WAF1 B-GENE
induction O
by O
STAT B-GENE
activation O
. O

Tumor B-GENE
necrosis I-GENE
factor-alpha I-GENE
( O
TNF B-GENE
alpha I-GENE
) O
, O
a O
proinflammatory O
cytokine O
, O
inhibits O
cAMP-stimulated O
testosterone O
production O
in O
mouse O
Leydig O
cells O
. O

Positive O
shifts O
of O
basal O
skin O
potentials O
during O
human O
sleep O
. O

To O
explore O
the O
functional O
properties O
of O
the O
protein O
encoded O
by O
neu B-GENE
, O
we O
created O
a O
fusion O
gene O
that O
joins O
the O
cytoplasmic O
domain O
of O
neu B-GENE
to O
the O
extracellular O
portion O
of O
an O
immunoglobulin B-GENE
heavy I-GENE
chain I-GENE
. O

Dermal O
toxicity O
and O
carcinogenicity O
of O
4-vinyl-1-cyclohexene O
diepoxide O
in O
Fischer O
rats O
and O
B6C3F1 O
mice O
. O

Radiogallium O
imaging O
is O
thus O
of O
limited O
use O
in O
evaluation O
of O
suspected O
giant O
cell O
tumors O
of O
bone O
. O

In O
vivo O
epiluminescence O
microscopy O
of O
pigmented O
skin O
lesions O
. O

In O
invertebrates O
, O
Fhit B-GENE
is O
encoded O
as O
a O
fusion O
protein O
with O
Nit B-GENE
, O
a O
member O
of O
the O
nitrilase B-GENE
superfamily I-GENE
. O

Here O
we O
localize O
a O
transferable O
40-amino O
acid O
region O
within O
the O
LBDs B-GENE
of O
RXR B-GENE
, O
RAR B-GENE
, O
TR B-GENE
, O
and O
chicken B-GENE
ovalbumin I-GENE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
that O
is O
critical O
for O
determining O
identity O
in O
the O
heterodimeric O
interaction O
and O
for O
high-affinity O
DNA O
binding O
. O

Recently O
, O
the O
3 B-GENE
. I-GENE
6-kb I-GENE
full-length I-GENE
alpha-GalNAc I-GENE
cDNA I-GENE
sequence I-GENE
was O
isolated O
and O
found O
to O
have O
remarkable O
nucleotide O
and O
predicted O
amino O
acid O
homology O
( O
55 O
. O
8 O
and O
46 O
. O
9% O
, O
respectively O
) O
with O
the O
human B-GENE
alpha-galactosidase I-GENE
A I-GENE
( O
alpha-Gal B-GENE
A I-GENE
) O
cDNA O
. O

Re-examination O
of O
the O
ED01 O
study O
. O

In O
the O
treatment O
of O
opioid O
naive O
patients O
who O
underwent O
surgery O
and O
received O
opioids O
for O
acute O
pain O
, O
oral O
ADL O
8-2698 O
( O
6 O
. O
0 O
mg O
) O
improved O
the O
management O
of O
postoperative O
ileus O
( O
POI O
) O
by O
shortening O
the O
time O
to O
achieve O
normal O
bowel O
function O
and O
, O
ultimately O
, O
hospital O
stay O
. O

The O
CPK-MB B-GENE
isoenzyme I-GENE
showed O
no O
percentage O
increase O
of O
total O
CPK B-GENE
higher O
than O
5% O
, O
measured O
at O
6 O
, O
12 O
, O
and O
24 O
h O
after O
the O
shock O
, O
independent O
of O
the O
number O
of O
attempts O
of O
cardioversion O
. O

Latanoprost O
produces O
an O
additional O
reduction O
of O
intraocular O
pressure O
( O
IOP O
) O
when O
used O
in O
combination O
with O
timolol O
, O
pilocarpine O
, O
acetazolamide O
and O
dipivefrin O
. O

The O
inhibitory O
response O
to O
taps O
is O
essentially O
a O
protective O
reflex O
which O
probably O
serves O
to O
reduce O
the O
activity O
of O
the O
jaw-closing O
muscles O
when O
one O
bites O
unexpectedly O
on O
hard O
objects O
. O

A O
flow O
rate O
of O
at O
least O
5 O
mL O
h O
is O
required O
through O
the O
receptor O
( O
volume O
, O
0 O
. O
4 O
mL O
) O
for O
accurate O
results O
. O

We O
conclude O
that O
Hansel's O
stain O
substantially O
improves O
the O
recognition O
of O
eosinophiluria O
as O
compared O
with O
Wright's O
stain O
. O

Histopathologically O
, O
a O
cystic O
lymphangioma O
was O
diagnosed O
because O
of O
the O
morphological O
features O
and O
the O
immunohistochemical O
stainings O
of O
CD34 B-GENE
and O
Factor B-GENE
VIII I-GENE
related I-GENE
antigen I-GENE
which O
were O
observed O
positive O
reactions O
in O
endothelial O
cells O
of O
the O
cysts O
. O

These O
changes O
in O
virus O
entry O
features O
may O
result O
in O
coronaviruses O
with O
novel O
pathogenic O
properties O
. O

Allelic O
variation O
in O
HLA-B B-GENE
and O
HLA-C B-GENE
sequences I-GENE
and O
the O
evolution O
of O
the O
HLA-B B-GENE
alleles I-GENE
. O

Nephrectomy O
applied O
to O
cattle O
. O

Structure O
and O
localization O
of O
the O
human B-GENE
gene I-GENE
encoding I-GENE
SR-BI I-GENE
CLA-1 I-GENE
. I-GENE

Rhesus O
macaques O
and O
BALB O
c O
mice O
inoculated O
with O
the O
Mengo O
virus O
SIV O
recombinants O
failed O
to O
develop O
CTL O
responses O
against O
the O
SIV O
gene O
products O
, O
while O
one O
of O
the O
HIV-Nef O
recombinants B-GENE
induced I-GENE
a O
weak O
CTL O
response O
in O
mice O
directed O
to O
an O
HIV1 O
Nef B-GENE
peptide I-GENE
spanning I-GENE
positions O
182-198 O
. O

We O
cloned O
and O
sequenced O
the O
cDNAs O
against O
genomic O
RNA O
and O
mRNA O
for O
phosphoprotein O
( O
P O
) O
of O
human O
parainfluenza O
type O
2 O
virus O
( O
PIV-2 O
) O
. O
cDNA O
clone O
from O
genomic O
RNA O
was O
1439 O
nucleotides O
in O
length O
excluding O
poly O
( O
A O
) O
and O
was O
found O
to O
have O
two O
small O
open O
reading O
frames O
encoding O
proteins O
of O
233 O
and O
249 O
amino O
acids O
. O

Also O
, O
samples O
of O
serum O
were O
absorbed O
with O
the O
various O
solid-phase O
allergens O
and O
the O
reactivity O
of O
the O
remaining O
IgE B-GENE
antibodies I-GENE
was O
determined O
. O

This O
study O
demonstrates O
that O
alteration O
of O
CDKN2 B-GENE
is O
one O
of O
the O
most O
frequent O
genetic O
abnormalities O
in O
prostate O
cancer O
and O
may O
contribute O
to O
prostate O
carcinogenesis O
. O

The O
chick O
axon-associated O
surface O
glycoprotein O
neurofascin B-GENE
is O
implicated O
in O
axonal O
growth O
and O
fasciculation O
as O
revealed O
by O
antibody O
perturbation O
experiments O
. O

In O
contrast O
, O
overproduction O
of O
Der3p B-GENE
is O
lethal O
in O
a O
sec61-2 B-GENE
strain O
at O
the O
permissive O
temperature O
of O
25 O
degrees O
C O
. O

The O
unilateral O
vestibular O
hypofunction O
. O

The O
lysozyme B-GENE
FEF I-GENE
site I-GENE
is O
immediately O
5' O
to O
a O
PU B-GENE
. O

The O
authors O
have O
tested O
the O
interference O
of O
the O
hemoglobin B-GENE
by O
two O
routine O
methods O
( O
Berthelot O
classic O
and O
Berthelot O
modified O
) O
for O
the O
determination O
of O
plasmatic O
urea O
. O

The O
nit-3 B-GENE
gene I-GENE
of I-GENE
the I-GENE
filamentous I-GENE
fungus I-GENE
Neurospora I-GENE
crassa I-GENE
encodes O
nitrate B-GENE
reductase I-GENE
, O
the O
enzyme O
which O
catalyzes O
the O
first O
step O
in O
nitrate O
assimilation O
. O

IgG B-GENE
and O
IgM B-GENE
antibody O
activity O
was O
determined O
by O
adding O
a O
1 O
: O
100 O
dilution O
of O
serum O
to O
plates O
coated O
with O
A60 B-GENE
antigen I-GENE
. O

GAL4-VP16-mediated O
antirepression O
required O
an O
auxiliary O
factor O
, O
denoted O
as O
a O
co-antirepressor O
, O
which O
was O
partially O
purified O
from O
Drosophila O
embryos O
. O

A O
consensus O
binding O
site O
for O
the O
transcription O
factor O
SP1 B-GENE
was O
identified O
in O
intron O
As O
downstream O
of O
the O
proenkephalin B-GENE
germ I-GENE
cell I-GENE
cap I-GENE
site I-GENE
region I-GENE
. O

The O
isolation O
of O
this O
gene O
was O
based O
on O
the O
identification O
of O
the O
Y-231 O
cosmid O
that O
contains O
CpG O
rich O
sequences O
( O
HTF B-GENE
islands I-GENE
) O
in O
its O
human O
insert O
. O

Sulfuric O
acid O
concentration O
in O
the O
catalyzed O
breathalyzer O
ampules O
. O

Additionally O
, O
a O
CaCO3-CO2 O
N2 O
buffered O
solution O
was O
necessary O
to O
maintain O
a O
pH O
of O
8 O
. O

For O
this O
reason O
, O
the O
particle O
forming O
capacity O
of O
derivatives O
of O
the O
HIV-1 B-GENE
group I-GENE
specific I-GENE
core I-GENE
antigen I-GENE
p55 I-GENE
gag I-GENE
was O
assayed O
and O
compared O
dependent O
on O
various O
expression O
systems O
: O
recombinant O
bacteria O
, O
vaccinia- O
and O
baculoviruses O
were O
established O
encoding O
the O
entire O
core B-GENE
protein I-GENE
p55 I-GENE
either O
in O
its O
authentic O
sequence O
or O
lacking O
the O
myristylation O
consensus O
signal O
. O

Ketanserin O
, O
a O
hypotensive O
drug O
with O
5-HT2 B-GENE
receptor I-GENE
antagonism O
, O
when O
administered O
by O
topical O
infusion O
of O
a O
0 O
. O
25% O
w O
v O
solution O
by O
corneal O
and O
scleral O
applications O
, O
was O
found O
to O
lower O
intraocular O
pressure O
with O
four O
times O
more O
activity O
than O
its O
metabolite O
, O
ketanserinol O
. O

The O
starting O
point O
is O
the O
consideration O
that O
the O
conceptions O
underlying O
the O
ICIDH O
are O
not O
suitable O
to O
serve O
as O
a O
mainstay O
of O
a O
model O
for O
diagnostics O
in O
rehabilitation O
because O
they O
do O
not O
reflect O
essential O
characteristics O
of O
the O
diagnostic O
process O
which O
is O
the O
basis O
for O
intervention O
. O

Analysis O
of O
the O
entire O
16 O
. O
7-kb O
mt O
genome O
determined O
that O
a O
MDP1 B-GENE
mediates O
cleavage O
of O
chick O
mtDNA O
in O
vitro O
at O
three O
H- O
and O
two O
L-strand O
sequence-specific O
target O
sites O
located O
within O
a O
90-bp O
A O
+ O
T-rich O
genomic O
tract O
, O
theoretically O
capable O
of O
forming O
stable O
secondary O
structures O
, O
approximately O
200 O
bases O
upstream O
from O
the O
H-strand O
origin O
( O
OH O
) O
of O
replication O
. O

Utility O
of O
OAE O
screener O
( O
GSI O
70 O
) O
for O
the O
evaluation O
of O
distortion O
product O
otoacoustic O
emissions O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
ability O
of O
the O
OAE O
screener O
GSI O
70 O
to O
evaluate O
of O
cochlea O
function O
in O
neonates O
, O
infants O
and O
adults O
. O

The O
3' O
UTR O
has O
several O
stable O
hairpins O
that O
are O
flanked O
by O
single-stranded B-GENE
( I-GENE
A I-GENE
U I-GENE
) I-GENE
UGC I-GENE
sequences I-GENE
. I-GENE

Terazosin O
, O
a O
structural O
analog O
of O
prazosin O
, O
also O
inhibits O
alpha B-GENE
1 I-GENE
adrenoceptors I-GENE
and O
is O
recommended O
as O
once O
or O
twice-daily O
therapy O
. O

The O
extraction O
measurements O
were O
used O
to O
test O
for O
extracerebral O
contamination O
of O
venous O
outflow O
. O

The O
patients O
are O
two O
healthy O
adult O
males O
. O

Supplementation O
was O
stopped O
when O
pl-ALB B-GENE
reached O
2 O
. O
0 O
g O
dL O
. O

Treatment O
of O
recurrent O
FSGS O
has O
included O
high-dose O
steroids O
, O
high-dose O
cyclosporine O
( O
CSA O
) O
, O
plasmapheresis O
, O
and O
ACE B-GENE
inhibitors O
with O
mixed O
results O
. O

Effect O
of O
proteolytic O
enzymes O
and O
polypeptides O
on O
the O
antacid O
activity O
of O
almagate O
and O
other O
antacids O
. O

We O
propose O
that O
the O
ambiguous O
discrimination O
required O
a O
greater O
time O
for O
simulus O
evaluation O
and O
that O
this O
was O
reflected O
in O
the O
delayed O
P3 O
latencies O
. O

The O
median O
preoperative O
best-corrected O
visual O
acuity O
of O
0 O
. O
08 O
( O
range O
hand O
motions O
0 O
. O
003 O
to O
0 O
. O
4 O
) O
, O
improved O
by O
5 O
lines O
to O
a O
median O
final O
postoperative O
best-corrected O
visual O
acuity O
of O
0 O
. O
25 O
( O
range O
0 O
. O
025-0 O
. O
5 O
) O
( O
P O
= O
0 O
. O
001 O
) O
. O

In O
the O
second O
case O
, O
an O
epidermal O
cyst O
was O
diagnosed O
. O

The O
colony-stimulating B-GENE
factors I-GENE
( O
CSFs B-GENE
) O
principally O
involved O
in O
the O
production O
of O
neutrophils O
and O
monocytes O
are O
granulocyte B-GENE
CSF I-GENE
, O
granulocyte-macrophage B-GENE
CSF I-GENE
, O
macrophage B-GENE
CSF I-GENE
, O
and O
interleukin B-GENE
3 I-GENE
( O
sometimes O
called O
multi-CSF B-GENE
) O
. O

By O
treating O
monkey O
COS O
cells O
with O
oligonucleotides O
linked O
to O
psoralen O
, O
we O
have O
generated O
targeted O
mutations O
in O
a O
simian O
virus O
40 O
( O
SV40 O
) O
vector O
contained O
within O
the O
cells O
via O
intracellular O
triple O
helix O
formation O
. O

Deltamethrin O
was O
most O
effective O
on O
the O
thatched O
surface O
and O
produced O
100% O
mortality O
of O
An O
. O
culicifacies O
adults O
up O
to O
12 O
weeks O
, O
even O
when O
exposed O
at O
the O
lowest O
dose O
12 O
. O
5 O
mg O
m2 O
. O

The O
DNA O
sequence O
adjacent O
to O
the O
lacZ B-GENE
gene I-GENE
has O
been O
determined O
for O
91 O
vegetative O
fusion O
genes O
whose O
products O
have O
been O
localized O
and O
for O
43 O
meiotically O
induced O
fusions O
. O

This O
study O
proposes O
an O
estimator O
for O
such O
global O
synchronizing O
effects O
upon O
unit-pair O
correlations O
based O
on O
local O
field O
potentials O
( O
LFPs O
) O
. O

RESULTS O
: O
Neither O
basal O
FSH B-GENE
level O
nor O
stimulated O
FSH B-GENE
level O
alone O
were O
statistically O
significant O
predictors O
of O
IVF O
success O
; O
however O
, O
no O
patient O
with O
a O
day O
3 O
FSH B-GENE
level O
> O
11 O
. O
1 O
mIU O
ml O
or O
a O
stimulated O
day O
10 O
FSH O
level B-GENE
> O
13 O
. O
5 O
mIU O
ml O
conceived O
and O
carried O
a O
pregnancy O
. O

The O
serum B-GENE
insulin I-GENE
response O
cannot O
. O

Significant O
correlations O
were O
obtained O
between O
changes O
in O
SSEP O
in O
response O
to O
AS O
and O
the O
presence O
of O
not O
deep O
residual-organic O
disturbances O
, O
so-called O
"ground" O
in O
psychogenic O
disorders O
. O

In O
rats O
, O
we O
examined O
the O
effect O
of O
an O
omentum O
wrapping O
on O
the O
vascularization O
of O
the O
trachea O
and O
on O
regeneration O
of O
the O
mucosal O
epithelium O
in O
the O
very O
early O
stage O
after O
free O
tracheal O
grafting O
. O

To O
evaluate O
the O
hepatic O
regenerative O
response O
in O
patients O
with O
alcoholic O
liver O
disease O
, O
sera O
from O
263 O
patients O
with O
severe O
alcoholic O
hepatitis O
and O
or O
cirrhosis O
were O
analyzed O
for O
hepatocyte O
growth B-GENE
factor I-GENE
( I-GENE
HGF O
) B-GENE
and O
alpha-fetoprotein O
( B-GENE
AFP O
) B-GENE
. O

Composites O
as O
restoration O
materials O
. O

The O
high O
selectivity O
of O
arrestins B-GENE
for O
this O
particular O
functional O
form O
of O
receptor O
ensures O
their O
timely O
binding O
and O
dissociation O
. O

Primary O
invasive O
Haemophilus O
influenzae O
type O
b O
disease O
: O
a O
population-based O
assessment O
of O
risk O
factors O
. O

However O
, O
while O
the O
sequence O
similarity O
between O
the O
membrane O
exons O
of O
avian B-GENE
mIgY I-GENE
and O
mammalian B-GENE
mIgG I-GENE
and I-GENE
IgE I-GENE
is O
striking O
, O
the O
overall O
similarity O
with O
Xenopus B-GENE
mIgY I-GENE
is O
very O
low O
. O

The O
same-sized O
EBNA B-GENE
protein I-GENE
( I-GENE
approximately I-GENE
78 I-GENE
, I-GENE
000 I-GENE
) I-GENE
was O
made O
after O
transfection O
with O
BamHI-K B-GENE
( I-GENE
5 I-GENE
. I-GENE
2 I-GENE
kilobase I-GENE
pairs I-GENE
[ I-GENE
kbp I-GENE
] I-GENE
) I-GENE
or O
the O
I1f B-GENE
subfragment I-GENE
( I-GENE
2 I-GENE
. I-GENE
9 I-GENE
kbp I-GENE
) I-GENE
. O

VP5 B-GENE
, O
which O
encodes O
the O
major B-GENE
capsid I-GENE
protein I-GENE
, O
each O
fused O
to O
the O
chloramphenicol B-GENE
acetyltransferase I-GENE
gene I-GENE
. O

Alternative O
splicing O
of O
RNA O
transcripts O
encoded O
by O
the O
murine B-GENE
p105 I-GENE
NF-kappa I-GENE
B I-GENE
gene I-GENE
generates O
I B-GENE
kappa I-GENE
B I-GENE
gamma I-GENE
isoforms I-GENE
with O
different O
inhibitory O
activities O
. O

Elevation O
of O
the O
tissues O
of O
the O
face O
is O
essentially O
vertical O
and O
acts O
on O
the O
forehead O
, O
temporal O
region O
, O
gaze O
and O
cheekbones O
. O

If O
facilities O
for O
measurements O
of O
O2 O
consumption O
and O
hence O
metabolic O
rate O
are O
available O
, O
these O
should O
be O
utilized O
. O

The O
P165 O
component O
, O
however O
, O
could O
be O
differentiated O
from O
the O
two O
later O
components O
since O
it O
increased O
in O
amplitude O
with O
increased O
task O
demands O
while O
the O
N2 O
and O
P3 O
amplitudes O
remained O
constant O
. O

Patients O
with O
moderate O
PDDAT O
were O
impaired O
on O
all O
serial O
positions O
for O
both O
spatial O
order O
and O
spatial O
recognition O
memory O
. O

At O
the O
time O
of O
the O
13 O
latest O
BPVs O
, O
age O
ranged O
from O
three O
days O
to O
13 O
. O
1 O
years O
( O
mean O
5 O
. O
7 O
+ O
- O
SD O
4 O
. O
8 O
years O
) O
. O

Stably O
transfected O
human O
kidney O
293 O
cells O
expressing O
the O
wild B-GENE
type I-GENE
rat I-GENE
LH I-GENE
CG I-GENE
receptor I-GENE
( I-GENE
rLHR O
) B-GENE
or O
receptors O
with O
C-terminal O
tails O
truncated O
at O
residues O
653 O
, O
631 O
, O
or O
628 O
( O
designated O
rLHR-t653 O
, B-GENE
rLHR-t631 O
, B-GENE
and O
rLHR-t628 O
) B-GENE
were O
used O
to O
probe O
the O
importance O
of O
this O
region O
on O
the O
regulation O
of O
hormonal O
responsiveness O
. O

We O
examined O
the O
hypothesis O
that O
the O
coronary O
vasomotor O
responses O
to O
etomidate O
( O
ETO O
) O
, O
propofol O
( O
PRO O
) O
, O
and O
sodium O
thiopental O
( O
STP O
) O
are O
mediated O
through O
contrasting O
effects O
on O
the O
resting O
nitric O
oxide O
( O
NO O
) O
-dependent O
vasodilator O
tone O
that O
opposes O
adrenergic O
vasoconstrictor O
activity O
in O
the O
intact O
dog O
. O

Here O
we O
have O
examined O
the O
ability O
of O
the O
cellular O
protein O
YB-1 B-GENE
to O
modulate O
transcription O
of O
the O
HIV-1 B-GENE
promoter I-GENE
in O
a O
human O
astrocytic O
cell O
line O
( O
U-87MG O
) O
, O
a O
neuronal O
cell O
line O
( O
SK-N-MC O
) O
and O
lymphoid O
cells O
( O
Jurkat O
) O
by O
transfection O
assay O
. O

In O
this O
study O
we O
examined O
hepatic O
stellate O
cell O
regulation O
of O
M6P B-GENE
IGFIIR I-GENE
expression I-GENE
and O
found O
that O
M6P O
IGFIIR B-GENE
mRNA I-GENE
transcript I-GENE
levels I-GENE
increased I-GENE
in O
stellate O
cells O
from O
rats O
exposed O
to O
carbon O
tetrachloride O
( O
CCl4 O
) O
, O
a O
potent O
fibrogenic O
stimulant O
. O

However O
, O
other O
regions O
of O
the O
plasmid O
are O
also O
efficiently O
repaired O
. O

Lack O
of O
effect O
of O
the O
appetite O
stimulant O
pizotifen O
( O
BC O
105 O
) O
on O
the O
absorption O
of O
isonicotinylhydrazine O
. O

We O
have O
improved O
our O
system O
for O
nuclear O
contour O
digitization O
and O
determined O
its O
theoretical O
limitations O
by O
digitizing O
standardized O
objects O
. O

To O
evaluate O
the O
comparative O
safety O
of O
U-P O
and O
D&E O
, O
we O
analyzed O
2 O
, O
805 O
U-P O
and O
9 O
, O
572 O
D&E O
abortions O
at O
13 O
to O
24 O
menstrual O
weeks' O
gestation O
. O

2 O
. O

These O
corrections O
do O
not O
involve O
sequences O
predicted O
to O
function O
as O
transcription O
factor O
binding O
sites O
. O

Our O
results O
showed O
that O
compared O
to O
the O
primary O
photon O
fluence O
, O
the O
extra-focal O
photon O
fluence O
from O
the O
primary O
collimator O
and O
the O
flattening O
filter O
was O
11%-16% O
at O
the O
isocenter O
, O
among O
which O
70% O
was O
contributed O
by O
the O
flattening O
filter O
. O

In O
men O
with O
BMI O
< O
30 O
, O
the O
OR O
was O
1 O
. O
83 O
for O
postprandial O
TG O
( O
P O
= O
. O
041 O
) O
and O
2 O
. O
77 O
for O
postprandial O
RP O
( O
P O
= O
. O
032 O
) O
in O
models O
that O
included O
fasting O
TG O
, O
LDL-C O
, O
and O
hypertension O
. O

The O
kinase B-GENE
inhibitor O
staurosporine O
( O
1 O
microM O
) O
blocks O
LPA-induced O
, O
but O
not O
epidermal O
growth O
factor-induced O
, O
activation O
of O
p21ras B-GENE
and O
MAP B-GENE
kinase I-GENE
, O
consistent O
with O
an O
intermediate B-GENE
protein I-GENE
kinase I-GENE
linking O
the O
LPA B-GENE
receptor I-GENE
to O
p21ras B-GENE
activation O
. O

The O
histochemistry O
and O
ultrastructure O
of O
calcified O
cerebellar O
deposits O
described O
by O
Tonge O
et O
al O
. O

Three O
of O
these O
subunits O
are O
also O
homologous O
to O
the O
dimeric O
POR B-GENE
from O
a O
mesophilic O
archaeon O
, O
Halobacterium O
halobium O
( O
21% O
identity O
) O
. O

The O
RNA O
transcripts O
structurally O
equivalent O
to O
I B-GENE
( I-GENE
2 I-GENE
) I-GENE
sgRNAs I-GENE
of O
TMV O
U1 O
and O
crTMV B-GENE
, O
but O
containing O
a O
hairpin O
structure O
( O
H O
) O
immediately O
upstream O
of O
IRES B-GENE
( I-GENE
MP I-GENE
, I-GENE
75 I-GENE
) I-GENE
( I-GENE
HIRES I-GENE
( I-GENE
MP I-GENE
) I-GENE
, I-GENE
( I-GENE
75 I-GENE
) I-GENE
( I-GENE
CR I-GENE
) I-GENE
-MP-CP-3'UTR I-GENE
; O
HIRES B-GENE
( I-GENE
MP I-GENE
, I-GENE
75 I-GENE
) I-GENE
( I-GENE
U1 I-GENE
) I-GENE
-MP-CP-3'UTR I-GENE
) O
, O
were O
able O
to O
express O
the O
MP B-GENE
gene I-GENE
in O
vitro O
. O

In O
addition O
a O
greater O
proportion O
of O
women O
in O
the O
sweeping O
group O
had O
a O
cervical O
dilatation O
of O
4 O
cm O
or O
more O
at O
the O
first O
vaginal O
examination O
in O
the O
labour O
ward O
( O
16 O
33 O
( O
49% O
) O
vs O
5 O
32 O
( O
16% O
) O
; O
OR O
4 O
. O
39 O
; O
95% O
CI O
1 O
. O
56 O
to O
12 O
. O
32 O
; O
P O
= O
0 O
. O
005 O
) O
. O

Exposure O
of O
endothelium O
to O
pulsatile O
shear O
stresses O
that O
followed O
a O
tape O
recording O
of O
physiological O
flow O
waveforms O
( O
electromagnetic O
flowmeter O
) O
did O
not O
cause O
gross O
injury O
or O
denudation O
even O
when O
peak O
shear O
exceeded O
1500 O
dyne O
cm2 O
. O

We O
report O
the O
preliminary O
biochemical O
characterization O
of O
the O
T B-GENE
antigens I-GENE
encoded O
by O
three O
SV40 O
mutants O
, O
5030 O
, O
5031 O
, O
and O
5061 O
, O
each O
of O
which O
have O
altered O
residues O
within O
or O
near O
the O
ATP O
binding O
pocket O
. O

Site-directed O
mutagenesis O
showed O
that O
two O
adjacent O
SP1 B-GENE
sites I-GENE
proximal O
to O
exon O
1 O
were O
equally O
important O
in O
sustaining O
basal O
promoter O
activity O
. O

Taken O
together O
, O
these O
results O
are O
consistent O
with O
the O
possibility O
that O
p202 B-GENE
protein I-GENE
contributes O
to O
the O
cell O
growth O
retardation O
activity O
of O
the O
IFNs B-GENE
, O
at O
least O
in O
part O
, O
by O
modulating O
p21 B-GENE
protein I-GENE
levels O
. O

Genomic O
organization O
of O
the O
human O
phosphodiesterase B-GENE
PDE11A I-GENE
gene I-GENE
. O

To O
modulate O
transcription O
, O
regulatory O
factors O
communicate O
with O
basal O
transcription O
factors O
and O
or O
RNA O
polymerases B-GENE
in I-GENE
a O
variety O
of O
ways O
. O

In O
Mv1Lu O
lung O
epithelial O
cells O
, O
ActR-IB B-GENE
and O
T B-GENE
beta I-GENE
R-I I-GENE
signal O
a O
common O
set O
of O
growth-inhibitory O
and O
transcriptional O
responses O
in O
association O
with O
their O
corresponding O
ligands O
and O
type B-GENE
II I-GENE
receptors I-GENE
. O

The O
observed O
phenotypes O
may O
be O
explained O
by O
( O
i O
) O
a O
selective O
disruption O
of O
very-low-density B-GENE
lipoprotein I-GENE
secretion O
due O
to O
decreased O
expression O
of O
genes O
encoding O
apolipoprotein B-GENE
B I-GENE
and O
microsomal B-GENE
triglyceride I-GENE
transfer I-GENE
protein I-GENE
, O
( O
ii O
) O
an O
increase O
in O
hepatic O
cholesterol O
uptake O
due O
to O
increased O
expression O
of O
the O
major O
high-density B-GENE
lipoprotein I-GENE
receptor I-GENE
, O
scavenger B-GENE
receptor I-GENE
BI I-GENE
, O
and O
( O
iii O
) O
a O
decrease O
in O
bile O
acid O
uptake O
to O
the O
liver O
due O
to O
down-regulation O
of O
the O
major O
basolateral B-GENE
bile I-GENE
acid I-GENE
transporters I-GENE
sodium B-GENE
taurocholate I-GENE
cotransporter I-GENE
protein I-GENE
and O
organic B-GENE
anion I-GENE
transporter I-GENE
protein I-GENE
1 O
. O

Two O
estrogen B-GENE
receptor I-GENE
( O
ER B-GENE
) O
isoforms O
with O
different O
estrogen O
dependencies O
are O
generated O
from O
the O
trout B-GENE
ER I-GENE
gene I-GENE
. O

In O
the O
context O
of O
the O
ADH2 B-GENE
upstream I-GENE
regulatory I-GENE
region I-GENE
, O
including O
UAS1 B-GENE
, O
working O
in O
concert O
with O
the O
ADH2 B-GENE
basal I-GENE
promoter I-GENE
elements I-GENE
, O
UAS2-dependent O
gene O
activation O
was O
dependent O
on O
orientation O
, O
copy O
number O
, O
and O
helix O
phase O
. O

Measurements O
were O
done O
with O
a O
commercial O
haematofluorometer O
Buchler O
ZF O
which O
was O
calibrated O
to O
the O
average O
haematocrit O
value O
of O
0 O
. O
42 O
. O

Paracrine O
activation O
of O
the O
HIV-1 B-GENE
LTR I-GENE
promoter I-GENE
by O
the O
viral B-GENE
Tat I-GENE
protein I-GENE
is O
mechanistically O
similar O
to O
trans-activation O
within O
a O
cell O
. O

Furthermore O
, O
binding O
of O
recombinant B-GENE
Myb I-GENE
and O
Ets-2 B-GENE
protein I-GENE
to O
these O
fragments O
could O
be O
competed O
with O
an O
excess O
of O
double O
stranded O
oligodeoxynucleotides O
containing O
canonical O
, O
but O
not O
mutated O
, O
Myb- O
or O
Ets-binding B-GENE
sites I-GENE
. O

A O
total O
of O
117 O
EVS O
treatments O
were O
performed O
on O
34 O
patients O
. O

O B-GENE
. I-GENE
novo-ulmi I-GENE
RNA-7 I-GENE
, O
previously O
believed O
to O
be O
a O
satellite-like O
RNA O
, O
is O
shown O
to O
be O
a O
defective O
RNA O
, O
derived O
from O
OnuMV4-Ld B-GENE
RNA I-GENE
by O
multiple O
internal O
deletions O
. O

Diffuse O
myalgias O
were O
more O
frequent O
in O
patients O
with O
than O
without O
an O
MMF O
lesion O
at O
deltoid O
muscle O
biopsy O
( O
P O
< O
0 O
. O
0001 O
) O
. O

Successful O
treatment O
with O
nasal O
continuous O
positive O
airway O
pressure O
( O
8 O
. O
3 O
+ O
- O
1 O
. O
5 O
cmH2O O
) O
for O
3 O
days O
caused O
a O
significant O
decrease O
in O
mean O
blood O
pressure O
in O
OSAS O
. O

DNA O
binding O
assays O
confirmed O
the O
interference O
of O
p30 B-GENE
( I-GENE
II I-GENE
) I-GENE
with O
the O
assembly O
of O
CREB-Tax-p300 B-GENE
CBP I-GENE
multiprotein I-GENE
complexes I-GENE
on I-GENE
21-bp O
repeat O
oligonucleotides O
in O
vitro O
. O

Full-length B-GENE
AT-PHH1 I-GENE
, O
and O
both O
AT-PHH1 B-GENE
and O
AT-PHH1 B-GENE
delta I-GENE
C-513 I-GENE
( O
truncated O
to O
be O
approximately O
the O
size O
of O
microbial B-GENE
photolyase I-GENE
genes I-GENE
) O
cDNAs O
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast O
and O
Escherichia O
coli O
mutants O
hypersensitive O
to O
ultraviolet O
light O
. O

GAP-N B-GENE
bound O
constitutively O
to O
p190 B-GENE
in O
both O
serum-deprived O
and O
growth O
factor-stimulated O
cells O
. O

Binding O
activity O
in O
rat O
liver O
nuclear O
extracts O
includes O
these O
orphan B-GENE
receptors I-GENE
as O
judged O
from O
electromobility O
supershift O
experiments O
and O
from O
results O
obtained O
with O
expressed O
receptors O
, O
although O
the O
element O
in O
CYP2C11 B-GENE
did O
not O
bind O
HNF-4 B-GENE
. O

Muscular O
pathology O
. O

Further O
, O
the O
ORFs O
of O
components O
3 O
and O
5 O
potentially O
encoded O
proteins O
of O
about O
20 O
kDa O
, O
the O
size O
of O
the O
BBTV B-GENE
coat I-GENE
protein I-GENE
. O

This O
computation O
is O
performed O
by O
a O
parallel O
network O
of O
locally O
connected O
neuron-like O
elements O
. O

SFP O
was O
significantly O
elevated O
in O
Hn O
( O
s O
) O
. O

Neither O
the O
p42 B-GENE
44 I-GENE
nor I-GENE
the O
JNK O
pathway B-GENE
was O
involved O
in O
the O
action O
of O
IL-1beta O
. B-GENE

Linkage O
studies O
have O
shown O
locus O
heterogeneity O
with O
one O
TSC B-GENE
gene I-GENE
mapped O
to O
chromosome O
9q34 O
and O
a O
second O
to O
16p13 O
. O
3 O
. O

These O
results O
suggest O
KCC3 B-GENE
is O
a O
new O
member O
of O
the O
KCC B-GENE
family I-GENE
that O
is O
under O
distinct O
regulation O
from O
KCC1 B-GENE
. O

The O
primary O
structure O
of O
a O
2671 O
bp O
DNA O
fragment O
between O
the O
pla B-GENE
gene I-GENE
( O
encoding O
plasminogen B-GENE
activator I-GENE
) O
and O
the O
origin O
of O
replication O
of O
the O
wild-type O
Yersinia O
pestis O
plasmid O
pYP358 O
was O
determined O
. O

A O
single O
amino O
acid O
difference O
in O
the O
C-terminal O
region O
influences O
dominant O
negative O
activity O
and O
receptor O
dimer O
formation O
. O

Progressive O
study O
and O
robustness O
test O
of O
QSAR O
model O
based O
on O
quantum O
chemical O
parameters O
for O
predicting O
BCF O
of O
selected O
polychlorinated O
organic O
compounds O
( O
PCOCs O
) O
. O

EEA1 B-GENE
is O
a O
conserved O
alpha-helical O
peripheral O
membrane O
protein O
flanked O
by O
cysteine O
"fingers" O
and O
contains O
a O
calmodulin-binding B-GENE
IQ I-GENE
motif I-GENE
. O

In O
a O
series O
of O
16 O
full-scale O
fire O
tests O
, O
investigators O
at O
the O
IIT O
Research O
Institute O
have O
concluded O
that O
automatic O
door O
control O
in O
the O
room O
of O
fire O
origin O
can O
significantly O
reduce O
the O
spread O
of O
toxic O
smoke O
and O
gases O
. O

Two O
studies O
on O
the O
relationship O
between O
taking O
a O
commercial O
coaching O
course O
and O
performance O
on O
the O
Medical O
College O
Admission O
Test O
( O
MCAT O
) O
are O
reported O
. O

However O
, O
in O
some O
of O
them O
either O
pattern O
may O
predominate O
or O
be O
exclusively O
present O
. O

The O
consensus O
gene O
order O
deduced O
by O
combining O
data O
from O
both O
crosses O
is O
D2Mit1- B-GENE
( O
Dbh B-GENE
, O
Notch1 B-GENE
) O
- O
( O
Col5a1 B-GENE
, O
Rxra B-GENE
) O
-Spna2-Ab B-GENE
l- I-GENE
( O
Ak1 B-GENE
, O
Fpgs B-GENE
) O
- O
( O
Grp78 B-GENE
, O
Pbx3 B-GENE
) O
- O
( O
Epb7 B-GENE
. I-GENE
2 I-GENE
, I-GENE
Hc I-GENE
, I-GENE
Gsn I-GENE
) O
-Acra B-GENE
. O

One O
form O
of O
the O
SBEI B-GENE
gene I-GENE
transcript I-GENE
in O
12-day O
old O
kernels O
contained O
the O
exon O
I+II+III O
combination O
at O
the O
5' O
end O
, O
whereas O
other O
forms O
differed O
by O
inclusion O
of O
intron O
1 O
or O
exclusion O
of O
exon O
II O
sequences O
. O

CHAP O
and O
the O
Department O
of O
Veterans O
Affairs O
. O

The O
remainder O
( O
18 O
. O
4% O
) O
was O
with O
IgA B-GENE
nephropathy O
, O
which O
was O
histologically O
mild O
. O

Cardiac O
output O
( O
CO O
) O
was O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
0005 O
) O
in O
the O
MBBF O
group O
. O

The O
presence O
of O
AS-oligo O
had O
no O
further O
effect O
on O
the O
FSH-mediated O
activation O
of O
the O
EB*-mTf-CAT B-GENE
construct I-GENE
but O
reduced O
cAMP-mediated O
activation O
. O

Among O
eight O
graminaceous O
species O
tested O
, O
Ids3 B-GENE
expression O
was O
observed O
only O
in O
Fe-deficient O
roots O
of O
H O
. O
vulgare O
and O
Secale O
cereale O
. O
which O
not O
only O
secrete O
2'-deoxymugineic O
acid O
( O
DMA O
) O
, O
but O
also O
mugineic O
acid O
( O
MA O
) O
and O
3-epihydroxymugineic O
acid O
( O
epiHMA O
, O
H O
. O
vulgare O
) O
, O
and O
3-hydroxymugineic O
acid O
( O
HMA O
, O
S O
. O
cereale O
) O
. O

We O
also O
found O
that O
environmental O
conditions O
for O
meiosis O
finely O
regulate O
the O
transcript O
levels O
of O
KIN28 B-GENE
and O
CCL1 B-GENE
, O
such O
that O
nitrogen O
starvation O
first O
elevates O
them O
but O
subsequent O
alkalization O
of O
medium O
decreases O
them O
. O

PURPOSE O
: O
To O
determine O
the O
effects O
of O
hypercholesterolemia O
and O
atherosclerosis-induced O
chronic O
cavernosal O
arterial O
insufficiency O
on O
cavernosal O
smooth O
muscle O
tone O
, O
nitric B-GENE
oxide I-GENE
synthase I-GENE
( O
NOS B-GENE
) O
activity O
and O
cavernosal O
tissue O
synthesis O
of O
constrictor O
eicosanoids O
. O

The O
multiple O
factors O
affecting O
plasma O
renin B-GENE
activity O
in O
essential O
hypertension O
. O

Transient O
co-transfection O
assays O
involving O
NFKB2 B-GENE
expression O
vectors O
and O
kappa O
B-driven O
reporter O
plasmids O
indicate O
that O
NFKB2 B-GENE
p85 B-GENE
has O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
NFKB2 B-GENE
p52 B-GENE
. O

We O
suggest O
that O
ventriculopleural O
shunting O
should O
be O
considered O
as O
the O
preferred O
alternative O
to O
peritoneal O
drainage O
in O
children O
with O
intra-abdominal O
adhesions O
or O
with O
a O
history O
of O
recent O
peritoneal O
infection O
. O

We O
have O
obtained O
the O
human B-GENE
EP4 I-GENE
receptor I-GENE
gene I-GENE
sequence I-GENE
and O
determined O
its O
structure O
relative O
to O
EP4R B-GENE
cDNA I-GENE
synthesized O
from O
peripheral O
blood O
lymphocytes O
. O

Model O
IV O
: O
primary O
abutments O
with O
the O
lateral O
incisor O
and O
the O
second O
molar O
as O
secondary O
abutments O
. O

Skeletal O
muscle O
metaboreceptor O
exercise O
responses O
are O
attenuated O
in O
heart O
failure O
. O

We O
use O
the O
term O
corticosteroid-dependent O
IA O
to O
refer O
to O
the O
serious O
problem O
of O
chronic O
IA O
requiring O
maintenance O
prednisone O
therapy O
. O

The O
maximum O
amplitude O
of O
evoked O
responses O
in O
the O
cervical O
sympathetic O
trunk O
was O
obtained O
when O
the O
T2 O
white O
ramus O
was O
stimulated O
and O
decreased O
gradually O
when O
followed O
by O
the O
stimulation O
of O
T1 O
, O
T3 O
, O
T4 O
and O
T5 O
white O
rami O
. O

CONCLUSION O
: O
Local O
control O
was O
highest O
with O
Preop O
in O
patients O
presenting O
primarily O
with O
gross O
disease O
, O
and O
with O
Postop O
in O
patients O
presenting O
primarily O
following O
gross O
total O
excision O
. O

Studies O
of O
lipoprotein-X B-GENE
( O
LP-X B-GENE
) O
and O
bile O
acids O
in O
familial O
LCAT B-GENE
deficiency O
. O

Oligonucleotide O
mutagenesis O
of O
these O
binding O
domains O
indicated O
their O
importance O
in O
the O
transcriptional O
regulation O
of O
the O
E3 B-GENE
promoter I-GENE
in O
yeast O
cells O
. O

Residual O
amphotericin O
B O
was O
detected O
in O
the O
feces O
of O
the O
mice O
only O
while O
they O
were O
receiving O
the O
0 O
. O
3 O
mg O
ml O
dose O
level O
. O

Neither O
Ha-Ras B-GENE
( O
G12V O
, O
T35S O
) O
( O
Ha-RasV12S35 B-GENE
) O
, O
which O
activates O
the O
Rafl B-GENE
signaling O
pathway O
, O
nor O
Ha-Ras B-GENE
( I-GENE
G12V I-GENE
, I-GENE
E37G I-GENE
) I-GENE
( O
Ha-RasV12G37 B-GENE
) O
, O
which O
stimulates O
the O
RalGDS B-GENE
pathway O
, O
did O
not O
have O
significant O
effects O
on O
factor-withdrawal O
apoptosis O
of O
myeloid O
cells O
. O

Effects O
of O
ionizing O
radiation O
in O
the O
human O
oral O
cavity O
and O
oropharynx O
: O
results O
of O
a O
survey O
. O

This O
report O
describes O
the O
identification O
of O
a O
gene O
of O
related O
function O
, O
SMD1 B-GENE
, O
located O
immediately O
3' O
to O
PRP38 B-GENE
. O

Preventive O
effect O
of O
ONO-3708 O
on O
thrombosis O
and O
vasospasms O
in O
vitro O
and O
in O
vivo O
. O

CONCLUSION O
: O
Rheumatic O
fever O
in O
the O
Nazareth O
area O
is O
still O
manifest O
. O

Water O
content O
and O
equilibrium O
water O
partition O
in O
immature O
cartilage O
. O

A O
novel O
cDNA O
clone O
termed O
R2 O
was O
isolated O
by O
subtractive O
hybridization O
of O
a O
cDNA O
library O
of O
phytohemagglutinin B-GENE
( O
PHA B-GENE
) O
phorbol O
myristate O
acetate-stimulated O
Jurkat O
cells O
and O
by O
rescreening O
a O
cDNA O
library O
of O
PHA-stimulated O
peripheral O
blood O
lymphocytes O
. O

Diltiazem O
decreased O
the O
total O
body O
clearance O
from O
34 O
. O
0 O
+ O
- O
8 O
. O
0 O
to O
28 O
. O
6 O
+ O
- O
6 O
. O
1 O
mL O
min O
( O
P O
less O
than O
. O
01 O
) O
, O
and O
prolonged O
the O
elimination O
half-life O
from O
12 O
. O
6 O
+ O
- O
3 O
. O
0 O
to O
14 O
. O
3 O
+ O
- O
2 O
. O
5 O
hours O
( O
P O
less O
than O
. O
01 O
) O
of O
antipyrine O
without O
any O
changes O
in O
volume O
of O
distribution O
. O

The O
yeast B-GENE
RER2 I-GENE
gene I-GENE
, O
identified O
by O
endoplasmic O
reticulum O
protein O
localization O
mutations O
, O
encodes O
cis-prenyltransferase B-GENE
, O
a O
key O
enzyme O
in O
dolichol O
synthesis O
. O

In O
electromobility O
shift O
assays O
, O
EWS-FLI-1 B-GENE
binding O
to O
the O
SRE B-GENE
is O
detectable O
in O
the O
absence O
of O
SRF B-GENE
whereas O
the O
binding O
of O
FLI-1 B-GENE
is O
not O
, O
suggesting O
that O
the O
interaction O
with O
DNA O
is O
the O
step O
which O
limits O
ternary O
complex O
formation O
by O
FLI-1 B-GENE
. O

We O
characterized O
three O
Arabidopsis O
thaliana O
cDNA O
clones O
that O
could O
rescue O
the O
sterile O
phenotype O
of O
the O
Schizosaccharomyces B-GENE
pombe I-GENE
pde1 I-GENE
mutant I-GENE
, O
which O
is O
defective O
in O
cAMP B-GENE
phosphodiesterase I-GENE
. O

Cortical O
afferents O
to O
the O
entorhinal O
cortex O
of O
the O
Rhesus O
monkey O
. O

In O
this O
study O
, O
we O
report O
the O
isolation O
and O
characterization O
of O
the O
entire O
rat B-GENE
GSTA3 I-GENE
( O
rGST B-GENE
Yc1 I-GENE
) O
subunit O
gene O
. O

Ras2p B-GENE
activates O
invasive O
growth O
using O
either O
of O
two O
downstream O
signaling O
pathways O
, O
the O
filamentation O
MAPK B-GENE
( O
Cdc42p B-GENE
Ste20p I-GENE
MAPK I-GENE
) I-GENE
cascade I-GENE
or O
the O
cAMP-dependent O
protein O
kinase B-GENE
( I-GENE
Cyr1p I-GENE
cAMP O
PKA B-GENE
) I-GENE
pathway I-GENE
. I-GENE

Gamma B-GENE
glutamyl I-GENE
transpeptidase I-GENE
activity O
was O
increased O
up O
to O
15 O
times O
above O
the O
upper O
normal O
limit O
in O
children O
, O
who O
received O
aminopyrine O
for O
two O
weeks O
or O
longer O
. O

CONCLUSIONS O
: O
Use O
of O
the O
first O
method O
was O
associated O
with O
a O
reduction O
in O
the O
time O
patients O
remained O
in O
the O
ICU O
before O
transfer O
to O
another O
unit O
and O
savings O
in O
nursing O
time O
, O
but O
the O
two O
methods O
did O
not O
differ O
according O
to O
clinical O
outcomes O
. O

In O
part O
as O
a O
result O
of O
its O
inability O
to O
sustain O
radiative O
loses O
, O
the O
BB O
resonator O
has O
extremely O
low O
RF O
power O
requirements O
. O

Hypoxic O
ventilatory O
responses O
were O
-1 O
. O
99 O
+ O
- O
0 O
. O
37 O
L O
min O
% O
SaO2 O
in O
the O
relatives O
and O
-1 O
. O
54 O
+ O
- O
0 O
. O
25 O
L O
min O
% O
SaO2 O
in O
the O
control O
subjects O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

They O
also O
discuss O
the O
existing O
nomenclature O
. O

These O
data O
indicate O
that O
the O
interaction O
of O
eIF4A B-GENE
with O
the O
middle O
region O
of O
eIF4GI B-GENE
is O
necessary O
for O
translation O
, O
whereas O
the O
interaction O
of O
eIF4A B-GENE
with O
the O
C-terminal O
region O
plays O
a O
modulatory O
role O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
hGCN5 B-GENE
is O
also O
an O
HAT B-GENE
and O
has O
the O
same O
substrate O
specificity O
as O
yGCN5 B-GENE
. O

Instead O
, O
some O
small O
negative O
effects O
are O
observed O
, O
particularly O
involving O
effects O
of O
husbands' O
retirement O
on O
the O
marital O
satisfaction O
of O
employed O
wives O
. O

We O
previously O
described O
two O
alanine O
cluster O
mutations O
, O
R77 O
to O
A O
( O
R77A O
) O
-K79A O
and O
E192A-E194A O
, O
which O
selectively O
inactivated O
the O
triphosphatase B-GENE
component I-GENE
. O

CKII B-GENE
as O
a O
CD44-associated B-GENE
serine I-GENE
kinase I-GENE
therefore O
may O
serve O
as O
an O
important O
molecule O
in O
a O
signaling O
cascade O
that O
produces O
a O
variety O
of O
cellular O
responses O
in O
MDA231 O
breast O
cancer O
cells O
. O

This O
is O
the O
first O
example O
of O
a O
eukaryotic O
transcription O
factor O
complex O
containing O
both O
a O
MADS-box B-GENE
and O
a O
forkhead B-GENE
protein I-GENE
, O
and O
it O
has O
important O
implications O
for O
the O
regulation O
of O
mammalian O
gene O
expression O
. O

To O
investigate O
the O
requirements O
for O
CBF2 B-GENE
binding O
, O
we O
synthesized O
a O
series O
of O
oligonucleotides O
carrying O
double O
transversion O
mutations O
spanning O
both O
the O
conserved O
core O
sequence O
and O
outside O
flanking O
sequences O
. O

Biol O
. O

Replacement O
of O
the O
wild-type O
5'-regulatory O
region O
with O
either O
of O
the O
mutants' O
cis-acting O
regulatory O
element O
resulted O
in O
the O
anaerobic O
expression O
of O
active B-GENE
Mn-superoxide I-GENE
dismutase I-GENE
. O

To O
study O
the O
functional O
differences O
between O
cutaneous O
HPV5 O
and O
HPV8 O
E7s B-GENE
and O
genital B-GENE
HPV16 I-GENE
E7 I-GENE
, O
we O
cloned O
each O
of O
the O
E7 B-GENE
open O
reading O
frames O
and O
tested O
their O
immortalizing O
and O
transforming O
activities O
, O
the O
binding O
ability O
of O
their O
products O
with O
retinoblastoma B-GENE
protein I-GENE
( O
RB B-GENE
) O
and O
their O
complementation O
activity O
of O
a O
RB-nonbinding B-GENE
adenovirus I-GENE
E1A I-GENE
mutant I-GENE
. O

Immunohistochemical O
staining O
was O
positive O
for O
S-100 B-GENE
in O
all O
9 O
cases O
stained O
, O
positive O
for O
HMB-45 B-GENE
in O
9 O
( O
90% O
) O
of O
10 O
, O
and O
negative O
for O
cytokeratin B-GENE
in O
all O
9 O
cases O
in O
which O
myxoid O
melanoma O
remained O
in O
the O
block O
after O
previous O
sections O
. O

Pneumothorax O
complicated O
by O
chronic O
steroid O
treatment O
. O

The O
response O
of O
the O
plasma B-GENE
fibrinogen I-GENE
level O
to O
the O
subucutaneous O
injection O
of O
turpentine O
and O
to O
the O
intravenous O
injection O
of O
endotoxin O
was O
measured O
in O
normal O
rabbits O
and O
in O
rabbits O
made O
granulocytopenic O
and O
thrombocytopenic O
with O
busulfan O
. O

The O
spleen O
rate O
of O
about O
600 O
villagers O
of O
RK O
I O
examined O
was O
54 O
. O
3% O
and O
the O
parasite O
rate O
13 O
. O
2% O
before O
the O
drug O
intervention O
. O

A O
thermal O
Kubo-Martin-Schwinger O
condition O
arises O
due O
to O
the O
coupling O
of O
a O
computer O
to O
a O
strong O
periodic O
source O
, O
namely O
, O
the O
daily O
and O
weekly O
usage O
patterns O
of O
the O
system O
. O

This O
region O
binds O
two O
ubiquitous O
nuclear O
factors O
, O
USF B-GENE
MLTF I-GENE
and I-GENE
the O
CAAT-binding O
transcription B-GENE
factor I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
( I-GENE
CTF I-GENE
NF1 O
) B-GENE
. I-GENE

Among O
the O
LE6 B-GENE
deletions O
, O
only O
one O
had O
a O
reduced O
transformation O
efficiency O
, O
while O
seven O
transformed O
cells O
at O
least O
as O
efficiently O
as O
wild-type B-GENE
LE6 I-GENE
. O

Changes O
of O
plasma O
cortisol O
level O
in O
late O
asthmatic O
responses O
. O

All O
patients O
with O
deterioriation O
in O
mental O
status O
showed O
a O
marked O
increase O
in O
liver O
enzymes O
( O
aspartate B-GENE
and I-GENE
alanine I-GENE
aminotransaminases I-GENE
) O
and O
severe O
coagulopathy O
. O

The O
results O
also O
showed O
that O
although O
oyster O
shell O
supplementation O
generally O
increased O
alkaline B-GENE
phosphatase I-GENE
activity O
, O
bone O
mineralization O
was O
relatively O
uninfluenced O
as O
judged O
by O
the O
low O
coefficients O
of O
variation O
( O
CV O
) O
of O
3 O
. O
14-3 O
. O
51% O
and O
3 O
. O
39-4 O
. O
82% O
for O
calcium O
and O
phosphorus O
content O
in O
the O
femur O
and O
tibia O
respectively O
. O

1 O
A O
colonic O
delivery O
system O
is O
described O
to O
deliver O
orally O
ingested O
drugs O
to O
the O
colon O
and O
release O
them O
at O
that O
site O
by O
coating O
with O
an O
acrylic O
based O
resin O
( O
Eudragit O
S O
) O
. O

Treating O
renal O
anaemia O
with O
recombinant O
human O
erythropoietin B-GENE
. O

The O
resulting O
clone O
pKB11 B-GENE
, O
which O
has O
a O
1369-base O
pair O
( O
bp O
) O
cDNA O
insert O
, O
overlapping O
pCAD142 B-GENE
by O
781 O
bp O
, O
was O
identified O
by O
hybridization O
methods O
and O
sequence O
analysis O
and O
found O
to O
contain O
the O
entire O
cDNA O
sequence O
for O
the O
amino O
end O
of O
the O
CAD B-GENE
polypeptide I-GENE
. O

Treatment O
of O
unstable O
angina O
: O
role O
of O
antithrombotic O
therapy O
. O

Acad O
. O

Biochemical O
studies O
revealed O
the O
expected O
loss O
of O
ChAT B-GENE
activity O
in O
the O
dorsal O
and O
ventral O
hippocampi O
of O
lesioned O
animals O
along O
with O
elevated O
levels O
of O
norepinephrine O
( O
NE O
) O
in O
the O
dorsal O
hippocampus O
of O
MS O
HSI O
animals O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Recognition O
of O
emphysema O
was O
poor O
when O
radiographs O
of O
inadequate O
quality O
were O
included O
( O
anteroposterior O
films O
or O
films O
from O
patients O
with O
acute O
or O
chronic O
lung O
disease O
) O
. O

Vasopressin B-GENE
( O
AVP B-GENE
) O
, O
the O
antidiuretic O
hormone O
, O
is O
a O
cyclic O
nonapeptide O
that O
acts O
through O
binding O
to O
G B-GENE
protein-coupled I-GENE
specific I-GENE
membrane I-GENE
receptors I-GENE
pharmacologically O
divided O
into O
three O
subtypes O
( O
V1a B-GENE
, O
V1b B-GENE
, O
and O
V2 B-GENE
) O
linked O
to O
distinct O
second O
messengers O
. O

Immunofluorescence O
studies O
in O
C2C12 O
myotubes O
show O
that O
Smad2 B-GENE
and O
MEF2A B-GENE
co-localise O
in O
the O
nucleus O
of O
multinuclear O
myotubes O
during O
differentiation O
. O

Homozygous O
mutation O
in O
two O
children O
led O
to O
amputation O
of O
legs O
due O
to O
purpura O
fulminans O
. O

The O
effect O
of O
salmon B-GENE
calcitonin I-GENE
nasal O
spray O
in O
women O
with O
established O
osteoporosis O
has O
also O
been O
studied O
. O

Studies O
in O
mammalian O
cells O
have O
correlated O
induction O
of O
inhibitory O
tyrosine O
15 O
( O
Y15 O
) O
phosphorylation O
on O
p34cdc2 B-GENE
with O
the O
response O
to O
DNA O
damage O
. O

Altogether O
46 O
phase O
III O
activities O
were O
recorded O
. O

Using O
a O
battery O
of O
I B-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
mutants I-GENE
, O
we O
show O
that O
( O
i O
) O
a O
dimer O
binds O
a O
single O
I B-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
molecule I-GENE
, O
( O
ii O
) O
the O
acidic O
C-terminal O
region O
of O
I B-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
is O
not O
required O
for O
protein-protein O
binding O
and O
does O
not O
mask O
the O
nuclear O
localization O
signal O
of O
the O
dimer O
, O
( O
iii O
) O
the O
same O
C-terminal O
region O
is O
required O
for O
inhibition O
of O
DNA O
binding O
, O
and O
( O
iv O
) O
this O
inhibition O
may O
be O
accomplished O
by O
direct O
interaction O
between O
the O
PEST-like B-GENE
region I-GENE
and O
the O
DNA-binding O
region O
of O
one O
of O
the O
subunits O
of O
the O
dimer O
. O

Activation O
mediated O
by O
Cat8p B-GENE
was O
no O
longer O
detectable O
in O
a O
cat1 B-GENE
mutant I-GENE
. O

EGF B-GENE
acts O
primarily O
by O
means O
of O
transactivation O
domain O
AF-1 B-GENE
, O
whereas O
cAMP O
acts O
via O
transactivation O
domain O
AF-2 B-GENE
of O
the O
ER O
. O

Of O
those O
injuries O
, O
143 O
cases O
were O
snowboard O
related O
and O
158 O
cases O
were O
ski O
related O
. O

Diacylglycerol B-GENE
kinase I-GENE
( O
DGK B-GENE
) O
attenuates O
levels O
of O
second O
messenger O
diacylglycerol O
in O
cells O
and O
produces O
another O
( O
putative O
) O
messenger O
, O
phosphatidic O
acid O
. O

Unusual O
course O
of O
plasmocytosis O
. O

4 O
) O
PU B-GENE
and O
PD B-GENE
lacked O
the O
canonical O
TATA O
or O
CAAT O
motifs O
, O
and O
are O
AT-rich O
. O

Their O
use O
established O
that O
the O
BrAAP O
activity O
catalyzed O
both O
a O
postproline O
and O
a O
postglutamate O
cleavage O
and O
therefore O
has O
a O
broader O
specificity O
than O
previously O
recognized O
. O

We O
have O
found O
that O
PEA2 B-GENE
is O
also O
required O
for O
the O
bipolar O
budding O
pattern O
and O
that O
it O
encodes O
a O
novel O
protein O
with O
a O
predicted O
coiled-coil O
domain O
. O

The O
most O
important O
finding O
, O
however O
, O
was O
that O
IMT O
values O
were O
related O
with O
24 O
h O
SBP O
or O
PP O
standard O
deviation O
( O
P O
< O
0 O
. O
001 O
) O
, O
a O
measure O
of O
overall O
SBP O
or O
PP O
variability O
. O

We O
recently O
found O
that O
the O
p72syk B-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
is O
physically O
associated O
with O
the O
TCR B-GENE
CD3 I-GENE
complex I-GENE
and I-GENE
is O
rapidly O
tyrosine O
phosphorylated O
and O
activated O
by O
receptor O
triggering O
also O
in O
T O
cells O
lacking O
p56lck O
. B-GENE

Similar O
synergistic O
activation O
was O
observed O
in O
the O
IL-8 B-GENE
promoter I-GENE
, O
which O
also O
contains O
both O
NF-IL6 B-GENE
and O
NF-kappa B-GENE
B I-GENE
binding I-GENE
sites I-GENE
. O

To O
identify O
the O
DNA O
sequences O
that O
cis-regulate O
the O
expression O
of O
the O
rat B-GENE
liver I-GENE
pyruvate I-GENE
kinase I-GENE
( O
L-PK B-GENE
) O
genes O
, O
a O
series O
of O
constructs O
in O
which O
the O
chloramphenicol B-GENE
acetyltransferase I-GENE
reporter I-GENE
genes I-GENE
is O
driven O
by O
various O
deleted O
fragments O
of O
the O
3200 O
base O
pairs O
( O
bp O
) O
upstream O
of O
the O
L-PK B-GENE
gene I-GENE
cap I-GENE
site I-GENE
have O
been O
assayed O
for O
transient O
expression O
after O
introduction O
into O
hepatoma O
HepG2 O
cells O
, O
rat O
hepatocytes O
in O
primary O
culture O
, O
fibroblast O
LTK- O
cells O
, O
myogenic O
C2C12 O
cells O
, O
and O
CHO O
cells O
. O

Stable O
transfection O
of O
the O
truncated O
reduced B-GENE
folate I-GENE
carrier I-GENE
cDNA I-GENE
into O
mouse O
L1210 O
leukemia O
cells O
: O
increased O
folate O
accumulation O
, O
decreased O
their O
leucovorin O
and O
folic O
acid O
growth O
requirements O
, O
and O
increased O
their O
sensitivity O
to O
methotrexate O
. O

Instead O
, O
TRPS1 B-GENE
potently O
and O
specifically O
represses O
transcriptional O
activation O
mediated O
by O
other O
GATA B-GENE
factors I-GENE
. O

Hyaluronan O
treatment O
stimulated O
collagen B-GENE
remodeling O
in O
the O
peripheral O
region O
and O
inhibited O
swelling O
of O
the O
meniscus O
repaired O
in O
the O
inner O
region O
. O

Recombinant B-GENE
human I-GENE
TFIID I-GENE
supported O
weak O
basal O
transcription O
in O
heat-treated O
nuclear O
extracts O
whereas O
a O
partially O
purified O
TFIID B-GENE
fraction O
from O
HeLa O
cells O
reconstituted O
a O
maximal O
level O
of O
transcription O
. O

We O
can O
classify O
antibiotics O
into O
two O
groups O
based O
on O
initial O
bactericidal O
activity O
against O
P O
. O
aeruginosa O
; O
one O
class O
is O
antibiotics O
having O
rapid O
initial O
killing O
such O
as O
AMK O
, O
IPM O
and O
PAPM O
, O
the O
other O
is O
CAZ O
, O
MEPM O
showing O
slow O
initial O
killing O
. O

X-ray O
crystallographic O
data O
show O
that O
the O
PLZF B-GENE
BTB B-GENE
POZ I-GENE
domain I-GENE
forms I-GENE
an O
obligate O
homodimer O
via O
an O
extensive O
interface O
. O

We O
have O
previously O
identified O
mouse B-GENE
and I-GENE
human I-GENE
cDNAs I-GENE
encoding I-GENE
UNC-51-like I-GENE
kinase I-GENE
( O
ULK1 B-GENE
) O
. O

Sequencing O
of O
zebrafish O
( O
Danio O
rerio O
) O
bacterial O
artificial O
chromosome O
and O
P1 O
artificial O
chromosome O
genomic O
clone O
fragments O
and O
of O
cDNA O
clones O
has O
led O
to O
the O
identification O
of O
five O
new O
loci O
coding O
for O
beta B-GENE
subunits I-GENE
of I-GENE
proteasomes I-GENE
( O
PSMB B-GENE
) O
. O

Penicillin B-GENE
acylase I-GENE
( O
PA B-GENE
) O
from O
Escherichia O
coli O
ATCC11105 O
is O
a O
periplasmic O
heterodimer O
consisting O
of O
a O
24 O
kDa O
small O
subunit O
and O
a O
65 O
kDa O
large O
subunit O
. O

Hepatocellular O
injury O
during O
preservation O
of O
human O
livers O
with O
UW O
and O
HTK O
solution O
. O

There O
was O
a O
significant O
but O
similar O
elevation O
of O
mean O
O2 O
uptake O
during O
40 O
min O
postexercise O
by O
13 O
. O
6% O
in O
both O
the O
fasted O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
fed O
state O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

Intracellular O
localization O
studies O
using O
the O
mDAP-3 B-GENE
EGFP I-GENE
fusion I-GENE
protein I-GENE
, I-GENE
cell O
fractionation O
and O
protease O
protection O
experiments O
localized O
mDAP-3 O
to B-GENE
the O
mitochondrial O
matrix O
. O

CONCLUSION O
: O
The O
study O
demonstrates O
that O
transvaginal O
ultrasonography O
has O
an O
efficiency O
of O
88% O
in O
differentiating O
endometriomas O
from O
other O
ovarian O
masses O
with O
a O
specificity O
of O
90% O
. O

Two O
polyadenylation O
sites O
were O
used O
, O
one O
at O
the O
end O
of O
the O
early B-GENE
( I-GENE
E I-GENE
) I-GENE
region I-GENE
of O
the O
viral O
DNA O
, O
the O
other O
at O
the O
end O
of O
the O
late B-GENE
( I-GENE
L I-GENE
) I-GENE
region I-GENE
. O

We O
concluded O
that O
Ga-fbg O
scintigraphy O
is O
a O
very O
simple O
method O
and O
sufficiently O
useful O
for O
detecting O
active O
left O
ventricular O
thrombi O
and O
for O
monitoring O
the O
effect O
of O
anticoagulant O
therapy O
. O

The O
carcass O
of O
a O
great O
horned O
owl O
( O
Bubo O
virginianus O
) O
, O
which O
had O
been O
found O
moribund O
in O
southern O
Ontario O
, O
was O
presented O
for O
necropsy O
. O

NGF B-GENE
elicits O
a O
more O
delayed O
and O
sustained O
ERK B-GENE
phosphorylation O
than O
EGF B-GENE
, O
consistent O
with O
previous O
reports O
. O

Compound O
1 O
is O
either O
21-O-angeloyl O
, O
22-O-tigloyl O
R1-barrigenol O
, O
or O
21-O-tigloyl O
, O
22-O-angeloyl O
R1-barrigenol O
. O

The O
enhancer O
region O
of O
Akv O
murine O
leukemia O
virus O
contains O
the O
sequence B-GENE
motif I-GENE
ACAGATGG I-GENE
. O

We O
show O
that O
in O
contrast O
to O
SRC1 B-GENE
, O
direct O
binding O
of O
CBP B-GENE
to O
the O
estrogen B-GENE
receptor I-GENE
is O
weak O
, O
suggesting O
that O
SRC1 B-GENE
functions O
primarily O
as O
an O
adaptor O
to O
recruit O
CBP B-GENE
and O
p300 B-GENE
. O

Immuno-cytochemistry O
, O
using O
antisera O
against O
Campylobacter O
jejuni O
, O
showed O
that O
the O
positive O
staining O
in O
altered O
epithelial O
cells O
were O
restricted O
to O
intracellular O
organisms O
having O
a O
structure O
resembling O
Campylobacter O
spp O
. O

The O
translation O
products O
of O
both O
clones O
are O
highly O
homologous O
to O
APS1 B-GENE
( O
66 O
and O
86% O
identity O
, O
respectively O
) O
over O
their O
entire O
lengths O
, O
including O
amino O
terminal O
sequences O
resembling O
transit O
peptides O
for O
plastid O
localization O
. O

Organization O
of O
the O
human B-GENE
LU I-GENE
gene I-GENE
and O
molecular O
basis O
of O
the O
Lu B-GENE
( I-GENE
a I-GENE
) I-GENE
Lu I-GENE
( I-GENE
b I-GENE
) I-GENE
blood I-GENE
group I-GENE
polymorphism I-GENE
. I-GENE

The O
MCA O
and O
UA O
PI O
values O
showed O
the O
greatest O
deviation O
for O
any O
single-vessel O
parameter O
. O

A O
decrease O
of O
erythrocyte O
Mn O
with O
age O
, O
expressed O
in O
nmol O
L O
, O
was O
noted O
( O
p O
< O
0 O
. O
02 O
) O
. O

Progressive O
100-mmHg O
stepwise O
decreases O
in O
superfusate O
oxygen O
partial O
pressure O
( O
PO2 O
) O
from O
control O
( O
95% O
O2 O
aeration O
, O
PO2 O
, O
620-650 O
mmHg O
) O
were O
produced O
, O
and O
subsequent O
changes O
in O
isometric O
active O
and O
resting O
tension O
were O
measured O
. O

Results O
of O
the O
long-term O
observation O
and O
treatment O
of O
patients O
with O
arterial O
hypertension O
. O

Jean O
Klig O
reviews O
recent O
literature O
about O
lower O
respiratory O
tract O
infection O
in O
children O
. O

In O
particular O
, O
the O
highly O
expressed O
ADH1 B-GENE
gene I-GENE
is O
represented O
in O
this O
database O
by O
no O
less O
than O
20 O
EST O
sequences O
. O

Transient O
expression O
of O
human B-GENE
and I-GENE
chicken I-GENE
progesterone I-GENE
receptors I-GENE
does O
not O
support O
alternative O
translational O
initiation O
from O
a O
single O
mRNA O
as O
the O
mechanism O
generating O
two O
receptor O
isoforms O
. O

In O
some O
cases O
, O
factor-induced O
Rac B-GENE
activation O
results O
in O
Rho B-GENE
activation O
, O
and O
factor-induced O
Cdc42 B-GENE
activation O
leads O
to O
Rac B-GENE
activation O
, O
as O
determined O
by O
specific O
morphological O
changes O
. O

A O
sequence O
comparison O
reveals O
two O
CCAAT B-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C O
EBP B-GENE
) I-GENE
consensus I-GENE
sequences O
, O
basic O
DNA O
binding O
region O
and O
leucine O
zippers O
1 O
and O
2 O
( O
bZIP1 O
and O
bZIP2 O
) O
, O
within O
this O
region O
. O

In O
the O
lattice O
, O
23% O
of O
the O
sites O
are O
occupied O
, O
95% O
of O
the O
atoms O
are O
in O
the O
lowest O
energy O
magnetic O
sublevel O
, O
and O
37% O
are O
in O
the O
lowest O
3D O
vibrational O
state O
. O

Arsenic O
contents O
in O
native O
copper O
. O

Complexes O
containing O
wild-type O
and O
either O
his175 B-GENE
or I-GENE
his273 I-GENE
mutant I-GENE
p53 I-GENE
proteins I-GENE
are O
completely O
unable O
to O
bind O
to O
the O
RGC B-GENE
DNA I-GENE
sequence I-GENE
. O

Analysis O
of O
human O
genomic O
DNA O
reveals O
an O
intronless O
sequence O
with O
strong O
homology O
to O
human B-GENE
G I-GENE
alpha I-GENE
q I-GENE
cDNA I-GENE
. O

The O
risk O
factors O
studied O
were O
male O
sex O
, O
hypertension O
, O
diabetes O
mellitus O
, O
hypercholesterolemia O
, O
cigarette O
smoking O
, O
sedentary O
life-style O
, O
and O
family O
history O
. O

CONCLUSIONS O
: O
Pretreatment O
with O
OCs O
prior O
to O
pituitary O
suppression O
in O
the O
early O
follicular O
phase O
decreases O
ovarian O
cyst O
formation O
, O
without O
an O
apparent O
effect O
on O
subsequent O
follicular O
recruitment O
or O
pregnancy O
rates O
. O

SV1 B-GENE
has O
a O
33-amino O
acid O
insert O
in O
the O
S1 B-GENE
transmembrane I-GENE
domain I-GENE
that O
does O
not O
alter O
S1 B-GENE
overall O
hydrophobicity O
, O
but O
makes O
the O
S0-S1 B-GENE
linker I-GENE
longer O
. O

Four O
transcription O
initiation O
sites O
have O
been O
identified O
by O
full-length O
RNA O
ligase-mediated O
rapid O
amplification O
of O
cDNA O
ends O
( O
RLM-RACE O
) O
between O
-61 O
and O
-32 O
bp O
from O
the O
translation O
initiation O
codon O
. O
Reverse O
transcription-PCR O
analysis O
revealed O
that O
PFK-A B-GENE
, O
PFK-B B-GENE
and O
PFK-C B-GENE
genes I-GENE
were O
expressed O
, O
in O
all O
mouse O
tissues O
tested O
, O
at O
varying O
levels O
. O

The O
small O
size O
and O
placement O
of O
the O
mutagenesis O
marker O
( O
the O
supF B-GENE
suppressor I-GENE
tRNA I-GENE
gene I-GENE
from I-GENE
Escherichia I-GENE
coli I-GENE
) O
within O
the O
vector O
substantially O
reduced O
the O
frequency O
of O
spontaneous O
mutations O
normally O
observed O
after O
transfection O
of O
mammalian O
cells O
with O
plasmid O
DNA O
; O
hence O
, O
UV-induced O
mutations O
were O
easily O
identified O
above O
the O
spontaneous O
background O
. O

Although O
not O
consistently O
identified O
in O
all O
samples O
, O
secondary O
Academic O
, O
Personal O
Responsibility O
, O
and O
Community O
Vocational O
dimensions O
were O
also O
identified O
. O

It O
can O
be O
concluded O
that O
in O
normotensive O
subjects O
, O
uric O
acid O
and O
xanthine B-GENE
oxidase I-GENE
have O
significant O
association O
with O
blood O
pressure O
and O
thus O
are O
one O
of O
the O
many O
factors O
which O
are O
involved O
in O
the O
cause O
or O
effect O
of O
hypertension O
. O

Hybridization O
analysis O
showed O
that O
the O
size O
of O
the O
mRNA O
is O
about O
1 O
. O
4 O
kilobases O
. O

The O
heterogeneous O
nuclear B-GENE
ribonucleoprotein I-GENE
C I-GENE
protein I-GENE
tetramer I-GENE
binds O
U1 B-GENE
, O
U2 B-GENE
, O
and O
U6 B-GENE
snRNAs I-GENE
through O
its O
high O
affinity O
RNA O
binding O
domain O
( O
the O
bZIP-like B-GENE
motif I-GENE
) O
. O

Canadian O
survey O
reveals O
widespread O
dissatisfaction O
among O
physicians O
. O

Topoisomerase B-GENE
II I-GENE
is O
a O
major O
target O
of O
the O
protein B-GENE
kinase I-GENE
casein I-GENE
kinase I-GENE
2 I-GENE
( O
PK B-GENE
CK2 I-GENE
) O
in O
vivo O
. O

Its O
transcription O
product O
, O
a O
1 O
. O
3 O
kb O
mRNA O
, O
is O
polyadenylated O
at O
a O
site O
containing O
consensus O
eukaryotic O
polyadenylation O
signals O
and O
mapping O
87 O
bp O
downstream O
of O
the O
translation O
termination O
codon O
for O
CG30 B-GENE
. O

The O
AL-R8 O
SI O
: O
the O
next O
generation O
staging O
container O
for O
plutonium O
pits O
at O
the O
USDOE O
Pantex O
Plant O
. O

The O
rad9 B-GENE
. I-GENE
192 I-GENE
DNA I-GENE
repair I-GENE
mutant I-GENE
from I-GENE
the I-GENE
fission I-GENE
yeast I-GENE
, I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
, O
is O
sensitive O
to O
both O
UV O
and O
ionising O
radiation O
. O

Seven O
patients O
( O
8 O
. O
3 O
percent O
) O
had O
latent O
hypothyroidism O
only O
discovered O
by O
hormonal O
determinations O
. O

In O
contrast O
to O
other O
known O
retroviruses O
, O
the O
FV B-GENE
pol I-GENE
genes I-GENE
are O
expressed O
via O
spliced O
transcripts O
. O

Two O
basic O
patterns O
of O
locomotor O
behavior O
and O
corresponding O
torso O
morphology O
exist O
among O
extant O
anthropoids O
. O

Collagen B-GENE
was O
extracted O
from O
the O
skin O
, O
and O
the O
lack O
of O
type B-GENE
III I-GENE
collagen I-GENE
was O
determined O
by O
means O
of O
sodium O
dodecyl O
sulfate-polyacrylamide O
gel O
electrophoresis O
( O
SDS-PAGE O
) O
. O

High O
fibrinogen B-GENE
levels O
could O
thus O
be O
a O
risk O
for O
perioperative O
thrombosis O
. O

Cooperative O
roles O
of O
Bozozok B-GENE
Dharma I-GENE
and I-GENE
Nodal-related O
proteins B-GENE
in I-GENE
the O
formation O
of O
the O
dorsal O
organizer O
in O
zebrafish O
. O

Newcastle O
disease O
virus O
surveillance O
in O
Hong O
Kong O
on O
local O
and O
imported O
poultry O
. O

RESULTS O
: O
Auditory O
thresholds O
collected O
during O
audiometric O
tests O
increased O
gradually O
in O
proportion O
with O
age O
, O
especially O
in O
the O
hypertensive O
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

In O
this O
case O
the O
degree O
of O
promoter O
methylation O
, O
which O
could O
extend O
beyond O
the O
T-DNA O
borders O
, O
was O
not O
correlated O
with O
the O
reduction O
in O
steady-state O
poly O
( O
A O
) O
+ O
mRNA O
levels O
, O
the O
silenced O
state O
was O
transmitted O
through O
meiosis O
and O
reactivation O
lasted O
several O
generations O
. O

Specimens O
were O
assayed O
for O
alpha-fetoprotein B-GENE
, O
unconjugated O
estriol O
, O
free O
alpha B-GENE
hCG I-GENE
, O
and O
total O
hCG B-GENE
. O

We O
report O
the O
use O
of O
a O
new O
technetium-99m-albumin O
colloid O
white O
blood O
cell O
( O
TAC-WBC O
) O
scan O
in O
the O
evaluation O
of O
appendicitis O
. O

Thus O
, O
SOX8 B-GENE
is O
a O
good O
candidate O
gene O
contributing O
to O
the O
mental O
retardation O
phenotype O
seen O
in O
ATR-16 O
patients O
. O

The O
concentrations O
of O
C4 B-GENE
and O
C1-INH B-GENE
increased O
with O
advancing O
stage O
of O
disease O
and O
were O
above O
normal O
mean O
values O
in O
all O
stages O
. O

We O
measured O
serum B-GENE
hepatocyte I-GENE
growth I-GENE
factor I-GENE
( O
HGF B-GENE
) O
in O
patients O
with O
acute O
myocardial O
infarction O
, O
angina O
pectoris O
, O
and O
other O
heart O
diseases O
. O

The O
Man9-mannosidase B-GENE
specificity O
of O
the O
cDNA O
construct O
was O
verified O
by O
the O
observation O
that O
all O
peptide O
sequences O
derived O
from O
a O
previously O
purified O
, O
catalytically O
active O
49-kDa O
fragment O
were O
found O
within O
the O
coding O
region O
. O

Cranio-caudal O
differences O
in O
granulation O
tissue O
formation O
: O
an O
experimental O
study O
in O
the O
rat O
. O

Here O
we O
show O
that O
for O
expression O
of O
snRNA O
genes O
in O
maize O
, O
a O
monocotyledonous O
plant O
, O
the O
USE O
and O
TATA O
elements O
are O
essential O
, O
but O
not O
sufficient O
, O
for O
transcription O
. O

The O
PETCO2 O
measurement O
during O
precordial O
compression O
predicted O
the O
success O
of O
defibrillation O
with O
return O
of O
spontaneous O
circulation O
. O

RESULTS O
: O
The O
binding O
of O
99mTc O
d O
, O
1-HMPAO O
to O
human O
placenta O
ranged O
from O
2 O
. O
95% O
+ O
- O
1 O
. O
5% O
to O
5 O
. O
82% O
+ O
- O
0 O
. O
3% O
per O
1 O
ml O
standard O
solution O
. O

Low O
NA O
and O
A O
may O
participate O
in O
lowering O
the O
plasma B-GENE
renin I-GENE
activity O
which O
in O
PA O
in O
suppressed O
, O
sometimes O
disproportionately O
to O
the O
actual O
body O
sodium O
content O
. O

These O
results O
suggest O
that O
indoramin O
may O
have O
Class O
III O
antiarrhythmic O
activity O
. O

A O
9 B-GENE
. I-GENE
5-kb I-GENE
KpnI-SalI I-GENE
fragment I-GENE
, O
where O
all O
the O
DNA O
changes O
associated O
with O
su B-GENE
( I-GENE
Hw I-GENE
) I-GENE
mutations I-GENE
were O
mapped O
, O
was O
able O
to O
rescue O
the O
su B-GENE
( I-GENE
Hw I-GENE
) I-GENE
mutant I-GENE
phenotype O
after O
P-element-mediated O
germ-line O
transformation O
. O

A O
panel O
of O
pharmacologic O
inhibitors O
was O
used O
to O
investigate O
the O
signal O
transduction O
pathways O
involved O
in O
TRAIL B-GENE
gene I-GENE
induction O
following O
T O
lymphocyte O
activation O
. O

Scanning O
electron O
microscopic O
investigations O
on O
the O
formation O
of O
Reissner's O
fiber O
in O
Rattus O
rattus O
. O

Changes O
in O
dopamine B-GENE
receptor I-GENE
sensitivity O
in O
humans O
after O
heavy O
alcohol O
intake O
. O

The O
sample O
is O
deproteinized O
and O
after O
centrifugation O
valproic O
acid O
in O
the O
supernatant O
is O
measured O
in O
the O
free O
form O
by O
direct O
injection O
into O
the O
gas O
chromatograph O
. O

Further O
, O
intracerebroventricular O
injections O
of O
KA O
resulted O
in O
the O
substantial O
loss O
of O
pyramidal O
cells O
in O
the O
whole O
CA3 O
field O
of O
the O
hippocampus O
. O

Gabapentin O
for O
opiod-related O
myoclonus O
in O
cancer O
patients O
. O

Heterogeneous O
electron O
transfer O
of O
cytochrome B-GENE
c I-GENE
facilitated O
by O
polypyrrole O
and O
methylene O
blue O
polypyrrole O
film O
modified O
electrodes O
. O

Sequence O
analysis O
revealed O
: O
1 O
) O
a O
kinase B-GENE
catalytic I-GENE
domain I-GENE
most O
characteristic O
of O
serine B-GENE
threonine I-GENE
kinases I-GENE
but I-GENE
hybrid O
between O
members O
of O
the O
family O
of O
microtubule-associated O
protein B-GENE
kinase I-GENE
kinase I-GENE
kinases I-GENE
and I-GENE
the O
fibroblast O
growth B-GENE
factor I-GENE
receptor I-GENE
family I-GENE
; I-GENE
2 O
) O
two O
putative O
alpha-helical O
leucine O
zipper O
motifs O
separated O
by O
a O
25-amino O
acid O
charged O
intermediate O
segment O
but O
lacking O
an O
NH2-terminal O
basic O
domain O
; O
and O
3 O
) O
COOH-terminal O
and O
NH2-terminal O
proline-rich O
domains O
suggestive O
of O
src O
homology B-GENE
3 I-GENE
( I-GENE
SH3 O
) B-GENE
domain O
binding O
regions O
. O

Epithelial O
damage O
was O
not O
observed O
in O
any O
controls O
but O
was O
in O
all O
tissues O
exposed O
to O
SO2 O
. O

Distribution O
and O
correlations O
of O
serum O
uric-acid O
in O
two O
French O
adult O
populations O
: O
13 O
, O
885 O
men O
and O
6 O
, O
861 O
women O
. O

Effects O
of O
cortisone O
, O
starvation O
, O
and O
rickets O
on O
oxidative O
enzyme O
activities O
of O
epiphyseal O
cartilage O
from O
rats O
. O

Transient O
overexpression O
of O
mutant B-GENE
EphB1 I-GENE
receptors I-GENE
( O
Y594F B-GENE
) O
blocked O
Nck B-GENE
recruitment O
to O
EphB1 B-GENE
, O
attenuated O
downstream O
JNK B-GENE
activation O
, O
and O
blocked O
cell O
attachment O
responses O
. O

Analysis O
of O
the O
upstream O
untranslated O
region O
of O
CHL15 B-GENE
revealed O
the O
presence O
of O
the O
hexamer O
element O
, O
ACGCGT B-GENE
( O
an O
MluI B-GENE
restriction I-GENE
site I-GENE
) O
controlling O
both O
the O
periodic O
expression O
and O
coordinate O
regulation O
of O
the O
DNA O
synthesis O
genes O
in O
budding O
yeast O
. O

Our O
results O
indicate O
that O
the O
expression O
of O
Cktsf1b1 B-GENE
, O
a O
gene O
associated O
with O
early O
development O
and O
cell O
transformation O
, O
is O
sensitive O
to O
MKK B-GENE
levels O
and O
may O
be O
regulated O
via O
multiple O
transcription O
factor O
complexes O
. O

Drugs O
suppressed O
> O
or O
= O
75% O
of O
the O
total O
premature O
ventricular O
contractions O
in O
all O
patients O
who O
had O
both O
use-dependent O
QRS O
prolongation O
and O
reverse O
use-dependent O
QT O
prolongation O
, O
in O
79% O
of O
patients O
with O
use-dependent O
QRS O
prolongation O
alone O
, O
in O
70% O
with O
reverse O
use-dependent O
QT O
prolongation O
alone O
, O
and O
in O
11% O
with O
neither O
use-dependent O
QRS O
prolongation O
nor O
reverse O
use-dependent O
QT O
prolongation O
. O

CONCLUSION O
: O
NBP O
pre-treatment O
or O
post-treatment O
markedly O
enhanced O
the O
rCBF O
to O
striatum O
in O
RMCAO O
rats O
. O

Thioredoxin B-GENE
( O
TR B-GENE
) O
is O
a O
small O
ubiquitous O
dithiol-reductase B-GENE
enzyme I-GENE
first O
identified O
in O
bacteria O
and O
plants O
. O

4 O
Five O
patients O
died O
within O
one O
month O
of O
captopril O
and O
five O
between O
four O
and O
seven O
months O
, O
three O
of O
whom O
had O
improved O
to O
class O
IIM O
and O
one O
to O
IIS O
before O
death O
. O

We O
have O
partially O
sequenced O
the O
RAP74 B-GENE
protein I-GENE
from O
purified O
HeLa O
cells O
, O
cloned O
its O
complementary O
DNA O
and O
shown O
that O
its O
translation O
product O
can O
interact O
with O
RAP30 B-GENE
in O
vitro O
as O
well O
as O
in O
vivo O
. O

Regulation O
of O
the O
human B-GENE
p21 I-GENE
WAF1 I-GENE
Cip1 I-GENE
promoter I-GENE
in I-GENE
hepatic I-GENE
cells O
by O
functional O
interactions O
between O
Sp1 O
and O
Smad B-GENE
family O
members B-GENE
. I-GENE

Nonetheless O
, O
that O
ventricular O
afferents O
, O
in O
certain O
special O
settings O
, O
are O
able O
to O
induce O
e O
. O
g O
. O
generalised O
vasodilation O
and O
hypotension O
cannot O
be O
excluded O
. O

A O
comparison O
of O
the O
nucleotide O
and O
deduced O
amino O
acid O
sequences O
of O
the O
core O
regions O
of O
the O
RNA-dependent B-GENE
RNA I-GENE
polymerase I-GENE
domains I-GENE
found O
in O
these O
three O
dsRNAs B-GENE
suggested O
that O
these O
dsRNAs B-GENE
probably O
evolved O
independently O
within O
each O
host O
plant O
from O
a O
common O
ancestor O
. O

CASE O
REPORT O
: O
We O
observed O
a O
congenital O
skin O
defect O
located O
exclusively O
on O
the O
trunk O
. O

The O
small B-GENE
GTPase I-GENE
Rho B-GENE
is O
implicated O
in O
physiological O
functions O
associated O
with O
actin-myosin O
filaments O
such O
as O
cytokinesis O
, O
cell O
motility O
, O
and O
smooth O
muscle O
contraction O
. O

Canine O
reproduction O
: O
effects O
of O
a O
single O
injection O
of O
medroxyprogesterone O
acetate O
on O
the O
reproductive O
organs O
of O
the O
bitch O
. O

The O
size O
of O
the O
infarct O
was O
determined O
using O
the O
creatine B-GENE
kinase I-GENE
integral O
method O
. O

The O
identified O
isolates O
of O
CSF O
( O
20 O
of O
29 O
) O
were O
: O
ECHO O
30 O
( O
9 O
) O
, O
ECHO O
11 O
( O
7 O
) O
, O
ECHO O
9 O
( O
3 O
) O
and O
ECHO O
7 O
( O
1 O
) O
. O

The O
cDNA O
clone O
was O
used O
as O
a O
homologous O
probe O
to O
isolate O
a O
truncated O
genomic O
clone O
encoding O
H2A1 B-GENE
. O

RESULTS O
: O
Plasma B-GENE
AVP I-GENE
responses O
to O
osmotic O
stimulation O
, O
and O
non-osmotic O
inhibition O
by O
drinking O
, O
were O
normal O
in O
patients O
with O
compulsive O
water O
drinking O
. O

Moreover O
, O
in O
rats O
allowed O
to O
choose O
in O
a O
T-maze O
between O
immediate-but-small O
vs O
. O
delayed-but-large O
reward O
, O
BZP O
significantly O
decreased O
the O
frequency O
with O
which O
the O
delayed O
reward O
was O
chosen O
, O
with O
5-HT O
uptake O
blockers O
producing O
opposite O
effects O
. O

Both O
the O
intact B-GENE
A1 I-GENE
protein I-GENE
and O
its O
proteolytic O
fragment O
, O
the O
UP1 B-GENE
protein I-GENE
, O
can O
be O
cleaved O
by O
Staphylococcus B-GENE
aureus I-GENE
V-8 I-GENE
protease I-GENE
to O
produce O
two O
polypeptides O
of O
92 O
amino O
acids O
. O

The O
human B-GENE
p100 I-GENE
protein I-GENE
was O
recently O
identified O
as O
a O
coactivator O
of O
the O
Epstein-Barr B-GENE
virus I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
. O

OBJECTIVES O
: O
To O
measure O
coagulation B-GENE
factor I-GENE
VIII I-GENE
: O
coagulant O
( O
F B-GENE
. I-GENE
VIII I-GENE
: O
C O
) O
and O
C1-esterase B-GENE
inhibitor I-GENE
( O
C1-INH B-GENE
) O
, O
hemostasis-associated O
acute-phase O
reactant O
proteins O
and O
coagulation B-GENE
factors I-GENE
VII I-GENE
( I-GENE
F I-GENE
. I-GENE
VII I-GENE
) I-GENE
, I-GENE
IX I-GENE
( I-GENE
F I-GENE
. I-GENE
IX I-GENE
) I-GENE
, I-GENE
and I-GENE
X I-GENE
( I-GENE
F I-GENE
. I-GENE
X I-GENE
) I-GENE
, O
hemostasis O
proteins O
not O
associated O
with O
an O
acute-phase O
response O
, O
in O
a O
select O
population O
of O
horses O
with O
colic O
and O
hemostasis O
abnormalities O
, O
and O
presumed O
to O
have O
acute-phase O
changes O
. O

SAM-TR-68-54 O
. O

Consistent O
with O
the O
hypothesis O
that O
it O
acts O
as O
transcriptional O
regulator O
, O
wild-type B-GENE
p53 I-GENE
protein I-GENE
binds O
DNA O
and O
activates O
transcription O
of O
several O
promoters O
. O

Critique O
of O
"Interactive O
Effects O
of O
Test O
Anxiety O
and O
Credit O
No O
Credit O
or O
A-F O
Grade O
Condition O
upon O
Short-term O
and O
Long-term O
Recall O
of O
Course O
Information O
. O

The O
distribution O
of O
red O
rice O
cultivation O
in O
Sri O
Lanka O
is O
coincident O
with O
the O
HIDD O
villages O
. O

It O
was O
not O
possible O
to O
study O
the O
basis O
for O
tissue-specific O
expression O
of O
this O
gene O
, O
because O
the O
beta B-GENE
3 I-GENE
gene I-GENE
promoter I-GENE
had O
not O
been O
isolated O
previously O
. O

The O
E1 B-GENE
replication I-GENE
protein I-GENE
of O
bovine O
papillomavirus O
type O
1 O
contains O
an O
extended O
nuclear O
localization O
signal O
that O
includes O
a O
p34cdc2 B-GENE
phosphorylation O
site O
. O

Stoichiometric O
phosphorylation O
of O
human B-GENE
p53 I-GENE
at O
Ser315 O
stimulates O
p53-dependent O
transcription O
. O
p53 B-GENE
protein I-GENE
activity O
as O
a O
transcription O
factor O
can O
be O
activated O
in O
vivo O
by O
antibodies O
that O
target O
its O
C-terminal O
negative O
regulatory O
domain O
suggesting O
that O
cellular O
enzymes O
that O
target O
this O
domain O
may O
play O
a O
role O
in O
stimulating O
p53-dependent O
gene O
expression O
. O

Commutative O
saccadic O
generator O
is O
sufficient O
to O
control O
a O
3-D O
ocular O
plant O
with O
pulleys O
. O

Measurements O
in O
the O
LWS O
p O
. O
a O
. O
, O
LWS O
lat O
. O
and O
at O
Ward's O
triangle O
were O
made O
in O
a O
total O
of O
100 O
patients O
. O

This O
suggests O
that O
helicase-like B-GENE
genes I-GENE
may O
be O
involved O
in O
the O
biosynthesis O
of O
nucleic O
acids O
and O
proteins O
, O
and O
that O
the O
genes O
can O
be O
transcriptionally O
activated O
by O
heat O
shock O
to O
compensate O
for O
the O
repressed O
synthesis O
of O
mRNA O
and O
protein O
. O

Elledge O
, O
P O
. O

With O
the O
modified O
fingertip-to-floor O
( O
MFTF O
) O
method O
, O
patients O
stand O
on O
a O
stool O
and O
forward O
bend O
so O
that O
measurements O
can O
be O
taken O
on O
patients O
who O
are O
able O
to O
touch O
the O
floor O
or O
reach O
beyond O
the O
level O
of O
the O
floor O
. O

Clicking O
on O
"Examples O
and O
Explanations O
of O
APA O
Form" O
provides O
a O
help O
system O
with O
examples O
of O
the O
various O
sections O
of O
a O
review O
article O
, O
journal O
article O
that O
has O
one O
experiment O
, O
or O
journal O
article O
that O
has O
two O
or O
more O
experiments O
. O

This O
proposed O
method O
is O
similar O
in O
principle O
to O
the O
sets O
technique O
but O
is O
shown O
to O
have O
much O
better O
expected O
time O
to O
alarm O
properties O
. O

After O
phosphorylation O
, O
STAT B-GENE
proteins I-GENE
are O
transported O
into O
the O
nucleus O
and O
exhibit O
transcriptional O
activity O
. O

Morphine O
produced O
a O
dose-dependent O
bradycardia O
followed O
by O
tachycardia O
. O

For O
the O
first O
30 O
min O
following O
insulin B-GENE
administration O
, O
the O
rate O
of O
change O
in O
glucose O
levels O
was O
significantly O
less O
among O
the O
patients O
with O
major O
depressive O
disorder O
than O
among O
either O
the O
patients O
with O
dysthymic O
disorder O
or O
the O
normal O
control O
subjects O
. O

The O
expression O
of O
chloramphenicol B-GENE
acetyltransferase I-GENE
was O
detected O
within O
1 O
h O
after O
infection O
of O
cells O
with O
recombinant O
virus O
, O
reflecting O
the O
early O
nature O
of O
the O
promoters O
used O
. O

Bioplastique O
granuloma O
presents O
with O
irregularly O
shaped O
cystic O
spaces O
of O
varying O
size O
containing O
jagged O
, O
translucent O
, O
nonbirefringent O
foreign O
bodies O
whereas O
Artecoll O
granuloma O
shows O
numerous O
round O
vacuoles O
nearly O
identical O
in O
size O
and O
shape O
enclosing O
round O
and O
sharply O
circumscribed O
, O
translucent O
, O
nonbirefringent O
foreign O
bodies O
. O

Pharmacokinetics O
of O
Carbamazepine O
in O
man O
: O
a O
review O
. O

Two O
transcripts O
of O
1 O
. O
6 O
kb O
and O
5 O
. O
8 O
kb O
are O
5' O
coterminal O
and O
may O
both O
encode O
the O
novel O
glycoprotein B-GENE
gene I-GENE
EUS4 I-GENE
. O

A O
randomised O
, O
controlled O
trial O
was O
undertaken O
in O
40 O
patients O
with O
active O
Crohn's O
disease O
to O
evaluate O
clinical O
and O
nutritional O
outcomes O
after O
an O
amino O
acid O
based O
diet O
containing O
3% O
fat O
was O
given O
by O
a O
feeding O
tube O
compared O
with O
a O
peptide O
based O
diet O
containing O
33% O
fat O
. O

Recombinant B-GENE
human I-GENE
erythropoietin I-GENE
( O
epoetin B-GENE
) O
is O
approved O
to O
be O
administered O
by O
the O
intravenous O
( O
i O
. O
v O
. O
) O
or O
subcutaneous O
( O
SC O
) O
route O
. O

We O
speculate O
that O
mast O
cell O
degranulation O
may O
be O
involved O
in O
the O
pathogenesis O
of O
necrobiosis O
by O
altering O
fibroblast O
enzyme O
activity O
and O
or O
producing O
prolonged O
inflammatory O
reactions O
. O

Hypomorphic O
dSLBP B-GENE
alleles I-GENE
support O
zygotic O
development O
but O
cause O
female O
sterility O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA O
, O
CHEMR1 B-GENE
, O
encoding O
a O
chemokine B-GENE
receptor I-GENE
with O
a O
homology O
to O
the O
human B-GENE
C-C I-GENE
chemokine I-GENE
receptor I-GENE
, O
CCR-4 B-GENE
. O

To O
achieve O
complete O
dissection O
of O
the O
anterior O
vitreous O
, O
we O
remove O
even O
a O
clear O
lens O
during O
the O
first O
surgical O
intervention O
in O
selected O
cases O
. O

Suggestive O
evidence O
was O
obtained O
that O
cstA B-GENE
is O
involved O
in O
peptide O
utilization O
. O

QBMDs O
for O
a O
5% O
change O
in O
response O
( O
QBMD05 O
) O
were O
6-fold O
lower O
, O
on O
average O
, O
than O
the O
corresponding O
NOAEL O
. O

Recombinant B-GENE
FVIIa I-GENE
was O
stable O
in O
the O
infusion O
pump O
for O
several O
days O
at O
room O
temperature O
and O
for O
24 O
h O
at O
body O
temperature O
. O

Using O
the O
polymerase B-GENE
chain O
reaction O
, O
Whipple-specific B-GENE
DNA I-GENE
fragments I-GENE
of O
284 O
base O
pairs O
from O
the O
genome O
of O
the O
Whipple O
bacterium O
( O
Tropheryma O
whippelii O
) O
were O
demonstrated O
. O

We O
have O
previously O
reported O
that O
depletion O
of O
protein B-GENE
kinase I-GENE
C I-GENE
by O
long-term O
treatment O
of O
B16 O
mouse O
melanoma O
cells O
with O
phorbol O
dibutyrate O
( O
PDBu O
) O
prevented O
cell O
density-dependent O
melanogenesis O
. O

PM O
12 O
or O
18 O
mg O
kg O
daily O
plus O
a O
standard O
dose O
of O
SB O
for O
21 O
days O
was O
statistically O
more O
effective O
than O
SB O
in O
producing O
a O
final O
cure O
for O
patients O
with O
VL O
in O
Bihar O
, O
India O
. O

Visidex O
I O
is O
unsuitable O
for O
storage O
and O
re-reading O
. O

A O
pathway O
for O
regulation O
of O
B B-GENE
lymphocyte I-GENE
antigen I-GENE
receptor-induced O
calcium O
flux O
. O

Silicosis O
mortality O
. O

Rats O
with O
one O
olfactory O
bulb O
removed O
and O
the O
contralateral O
naris O
closed O
can O
detect O
odors O
. O

Specimen O
mass O
reduction O
increased O
with O
irradiance O
from O
19 O
to O
72% O
of O
the O
initial O
mass O
for O
9--31 O
W O
cm O
( O
2 O
) O
, O
respectively O
. O

The O
transcription O
factor O
Jun B-GENE
( O
c-Jun B-GENE
) O
functions O
as O
a O
recipient O
of O
extracellular O
growth O
signals O
and O
converts O
them O
into O
patterns O
of O
gene O
expression O
. O

The O
encoded O
polypeptide O
is O
similar O
in O
sequence O
to O
the O
ABA-1 B-GENE
allergen I-GENE
of I-GENE
Ascaris I-GENE
, O
the O
gp15 B-GENE
400 I-GENE
'ladder' I-GENE
protein I-GENE
of I-GENE
Brugia I-GENE
malayi I-GENE
, I-GENE
Brugia I-GENE
pahangi I-GENE
and I-GENE
Wuchereria I-GENE
bancrofti I-GENE
, I-GENE
and O
a O
15-kDa O
antigen B-GENE
of I-GENE
Dirofilaria I-GENE
immitis I-GENE
. I-GENE

We O
now O
describe O
the O
identification O
of O
DEK B-GENE
as O
this O
43-kDa B-GENE
pets I-GENE
factor I-GENE
. O

TH-SH3 B-GENE
binding O
in O
vitro O
is O
abolished O
by O
specific O
, O
single O
amino O
acid O
substitutions O
within O
the O
Btk B-GENE
TH B-GENE
domain I-GENE
or O
the O
Fyn B-GENE
SH3 B-GENE
domain I-GENE
. O

Nuclear O
extracts O
prepared O
from O
both O
neural O
and O
non-neural O
cell O
lines O
, O
mouse O
brain O
, O
and O
mouse O
liver O
contain O
proteins O
that O
recognize O
and O
bind O
to O
the O
PROX B-GENE
and O
PAL B-GENE
sequences I-GENE
indicating O
that O
proteins O
which O
bind O
to O
these O
target O
sequences O
are O
widespread O
. O

The O
exon-intron O
distribution O
of O
Cdebp B-GENE
appears O
strikingly O
similar O
to O
that O
of O
the O
App B-GENE
gene I-GENE
in O
the O
regions O
encoding O
the O
conserved O
domains O
, O
with O
a O
divergent O
structure O
in O
the O
other O
parts O
. O

A O
region O
in O
the O
C-terminus O
of O
adenovirus B-GENE
2 I-GENE
5 I-GENE
E1a I-GENE
protein I-GENE
is I-GENE
required O
for O
association O
with O
a O
cellular O
phosphoprotein O
and O
important O
for O
the O
negative O
modulation O
of O
T24-ras O
mediated B-GENE
transformation O
, O
tumorigenesis O
and O
metastasis O
. O

We O
also O
review O
the O
role O
of O
grains O
in O
the O
formation O
of O
complex O
molecules O
in O
interstellar O
molecular O
clouds O
. O

Identification O
of O
an O
enhancer O
and O
an O
alternative O
promoter O
in O
the O
first O
intron O
of O
the O
alpha-fetoprotein B-GENE
gene I-GENE
. O

Spontaneous O
burst O
firing O
in O
cat O
primary O
auditory O
cortex O
: O
age O
and O
depth O
dependence O
and O
its O
effect O
on O
neural O
interaction O
measures O
. O

Second O
, O
plasmid-derived O
transgenes O
and O
gene O
targeting O
of O
the O
endogenous B-GENE
Hnf3g I-GENE
gene I-GENE
locus I-GENE
were O
used O
to O
demonstrate O
that O
the O
3'-flanking O
region O
of O
the O
gene O
is O
necessary O
and O
sufficient O
to O
direct O
reporter O
gene O
expression O
in O
liver O
, O
pancreas O
, O
stomach O
and O
small O
intestine O
. O

Polysome O
analyses O
in O
a O
temperature-sensitive O
fal1-1 B-GENE
mutant I-GENE
and O
a O
Fal1p-depleted O
strain O
reveal O
a O
decrease O
in O
the O
number O
of O
40S B-GENE
ribosomal I-GENE
subunits I-GENE
. O

Consistent O
with O
a O
possible O
role O
in O
transcription O
, O
Paf1p B-GENE
is O
localized O
to O
the O
nucleus O
. O

However O
, O
if O
the O
spatial O
resolution O
is O
not O
critical O
and O
interest O
is O
to O
compare O
a O
pathologic O
area O
with O
a O
contralateral O
VOI O
, O
then O
the O
acquisition O
of O
two O
single-voxel O
spectra O
may O
be O
preferred O
. O

Angiographic O
work-up O
in O
a O
patient O
with O
late O
vaginal O
metastasis O
from O
a O
renal O
carcinoma O
. O

Adaptation O
of O
taurocholate O
transport O
maximum O
to O
increased O
secretory O
load O
in O
the O
rat O
. O

The O
molecular O
mechanism O
of O
Tax-mediated O
trans-activation O
has O
been O
well O
investigated O
. O

This O
suggested O
that O
delta O
6 O
and O
delta O
5 O
desaturation O
activities O
are O
normal O
in O
these O
conditions O
with O
this O
C18 O
: O
2w6 O
supply O
. O

The O
mean O
values O
of O
the O
first O
three O
components O
were O
not O
significantly O
different O
in O
ARVD O
patients O
and O
control O
subjects O
. O

Additional O
information O
including O
echocardiographic O
sequences O
, O
perioperative O
video O
sequences O
, O
x-ray O
analysis O
, O
angiograms O
, O
etc O
. O
is O
represented O
in O
the O
program O
. O

Classification O
according O
to O
the O
ILAR O
criteria O
was O
possible O
in O
321 O
patients O
; O
290 O
patients O
had O
a O
disease O
duration O
> O
or O
= O
3 O
months O
and O
were O
classified O
according O
to O
the O
EULAR O
criteria O
. O

METHODS O
: O
109 O
suspected O
cases O
with O
SS O
underwent O
the O
biopsies O
. O

In O
order O
to O
delineate O
structural O
motifs O
regulating O
substrate O
affinity O
and O
recognition O
for O
the O
human B-GENE
dopamine I-GENE
transporter I-GENE
( O
DAT B-GENE
) O
, O
we O
assessed O
[ O
3H O
] O
dopamine O
uptake O
kinetics O
and O
[ O
3H O
] O
CFT O
binding O
characteristics O
of O
COS-7 O
cells O
transiently O
expressing O
mutant B-GENE
DATs I-GENE
in O
which O
the O
COOH O
terminus O
was O
truncated O
or O
substituted O
. O

Thus O
, O
methylation O
of O
Pph21p B-GENE
is O
important O
for O
formation O
of O
PP2A B-GENE
trimeric I-GENE
and I-GENE
dimeric I-GENE
complexes I-GENE
, O
and O
consequently O
, O
for O
PP2A B-GENE
function O
. O

157 O
+ O
- O
16 O
mg O
dl O
; O
NS O
) O
, O
glucose O
levels O
, O
and O
basal O
( O
17 O
+ O
- O
4 O
vs O
. O

Collectively O
, O
these O
experiments O
demonstrate O
that O
CFTR's B-GENE
NBF1+R I-GENE
region I-GENE
and O
its O
NBF2 B-GENE
domain I-GENE
, O
after O
folding O
separately O
as O
distinct O
units O
, O
have O
a O
strong O
propensity O
to O
interact O
and O
that O
this O
interaction O
is O
stable O
in O
the O
absence O
of O
added O
nucleotides O
or O
exogenously O
induced O
phosphorylation O
. O

Recurrent O
acute O
rhinosinusitis O
was O
common O
in O
both O
groups O
of O
patients O
, O
but O
the O
development O
of O
chronic O
rhinosinusitis O
was O
only O
found O
in O
patients O
with O
CVID O
, O
indicating O
the O
more O
severe O
nature O
of O
this O
condition O
compared O
with O
selective O
IgA B-GENE
deficiency O
. O

In O
patients O
who O
were O
not O
vented O
, O
there O
was O
overall O
significant O
depression O
of O
function O
( O
67 O
+ O
- O
5% O
of O
control O
; O
range O
, O
91--45% O
, O
p O
less O
than O
0 O
. O
01 O
) O
. O

Value O
of O
the O
method O
of O
passive O
hemagglutination O
with O
polysaccharide O
C O
in O
detecting O
C-reactive B-GENE
protein I-GENE
as O
compared O
to O
precipitation O
in O
capillaries O
and O
slide O
latex O
test O
with O
anti-CRP B-GENE
serum O
. O

2 O
new O
Algerian O
cases O
. O

Expression O
of O
the O
src B-GENE
homology I-GENE
3 I-GENE
( O
SH3 B-GENE
) O
-encoding O
, O
expressed O
in O
tumorigenic O
astrocytes O
( O
SETA O
) O
gene O
is O
associated O
with O
astrocyte O
transformation O
in O
culture O
and O
tumors O
in O
the O
adult O
brain O
. O

AIM O
: O
To O
understand O
the O
role O
of O
nutritional O
status O
in O
cirrhotic O
patients O
without O
clinical O
porto-systemic O
encephalopathy O
( O
PSE O
) O
. O
METHODS O
: O
Fifty-one O
non-alcoholic O
patients O
with O
cirrhosis O
without O
PSE O
were O
studied O
prospectively O
and O
compared O
with O
20 O
healthy O
volunteers O
. O

We O
have O
recently O
detected O
high O
levels O
of O
CKB B-GENE
mRNA I-GENE
in O
HeLa O
cells O
and O
, O
in O
this O
study O
, O
have O
tested O
whether O
this O
may O
be O
due O
to O
the O
extremely O
low O
amounts O
of O
p53 B-GENE
protein I-GENE
present O
in O
HeLa O
cells O
. O

Video O
images O
of O
the O
nostrils O
were O
captured O
and O
then O
analyzed O
for O
area O
, O
perimeter O
, O
centroid O
, O
principal O
axis O
, O
moments O
about O
the O
major O
and O
minor O
axes O
( O
I11 O
, O
I22 O
) O
, O
anisometry O
, O
bulkiness O
, O
lateral O
offset O
, O
internostril O
angle O
, O
and O
rotational O
angle O
. O

A O
randomized O
mix O
of O
180 O
sections O
( O
10 O
samples O
x O
3 O
tissues O
x O
3 O
stains O
x O
2 O
) O
gave O
90 O
matched O
pairs O
. O

Four O
out O
of O
10 O
patients O
showed O
clinical O
improvement O
according O
to O
Ritchie-Index O
, O
pain O
score O
, O
ESR O
and O
CRP O
. O

The O
results O
of O
these O
analyses O
indicate O
that O
the O
proteinase B-GENE
cleaves O
at O
amino O
acid O
residues O
E960-A961 O
, O
E1071-S1072 O
, O
E1345-T1346 O
, O
and O
E1419-G1420 O
; O
however O
, O
the O
cleavage O
efficiency O
is O
varied O
. O

Experiments O
with O
recombinant O
proteins O
showed O
that O
p50 B-GENE
p65 I-GENE
and I-GENE
high-mobility-group O
I B-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
cooperatively I-GENE
facilitated O
the O
binding O
of O
IRF-1 O
to B-GENE
the O
VCAM1 O
IRF B-GENE
binding B-GENE
site I-GENE
and I-GENE
that O
IRF-1 O
physically B-GENE
interacted O
with O
p50 O
and B-GENE
with O
high-mobility-group O
I B-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
. I-GENE

Control O
intact O
rats O
were O
age-matched O
to O
the O
different O
treated O
groups O
. O

Platelet O
function O
and O
platelet-polymorphonuclear-neutrophil O
interaction O
in O
patients O
with O
deficient O
platelet B-GENE
lipoxygenase I-GENE
activity O
. O

This O
machine O
drift O
, O
which O
was O
not O
associated O
with O
a O
rise O
in O
water O
phantom O
temperature O
and O
did O
not O
consistently O
correlate O
with O
estimated O
x-ray O
tube O
heat O
, O
could O
result O
in O
a O
significant O
overestimation O
of O
regional O
cerebral O
blood O
flow O
( O
rCBF O
) O
for O
a O
xenon O
CT O
rCBF O
protocol O
involving O
5-7 O
sequential O
scans O
obtained O
at O
1-min O
interscan O
intervals O
. O

In O
addition O
, O
negatively O
regulatory O
region O
may O
exist O
from O
-1782 O
to O
-1295 O
bp O
. O

In O
this O
report O
, O
we O
present O
two O
lines O
of O
evidence O
that O
all O
ribosomes O
which O
synthesize O
GCN4 B-GENE
have O
previously O
translated O
uORF1 B-GENE
, O
resumed O
scanning O
, O
and O
reinitiated O
at O
the O
GCN4 B-GENE
start O
site O
. O

A O
36 O
year-old O
woman O
was O
given O
Ergotamine O
Tartrate O
4 O
. O
5 O
mg O
p O
. O
d O
. O
during O
seven O
days O
, O
after O
an O
abortion O
( O
a O
still O
birth O
) O
. O

An O
economic O
analysis O
using O
West O
of O
Scotland O
Coronary O
Prevention O
Study O
( O
WOSCOPS O
) O
findings O
indicates O
that O
statin O
treatment O
would O
have O
prevented O
318 O
events O
per O
10 O
, O
000 O
patients O
in O
a O
population O
similar O
to O
that O
in O
WOSCOPS O
( O
average O
1 O
. O
5% O
annual O
risk O
of O
a O
cardiovascular O
event O
) O
at O
a O
discounted O
cost O
per O
life-year O
gained O
of O
pound20 O
, O
375 O
( O
$31 O
, O
818 O
) O
. O

The O
titer O
of O
TSH B-GENE
binding I-GENE
inhibitor I-GENE
immunoglobulin I-GENE
( O
TBII B-GENE
) O
, O
which O
had O
been O
8 O
. O
6% O
at O
initial O
presentation O
, O
rose O
to O
14 O
. O
9% O
in O
2 O
weeks O
. O

Y O
. O

A O
possible O
decrease O
in O
theophylline's O
volume O
of O
distribution O
at O
4 O
days O
, O
but O
not O
immediately O
, O
after O
administration O
of O
chloroquine O
was O
suggested O
, O
although O
this O
just O
failed O
to O
achieve O
statistical O
significance O
( O
p O
= O
0 O
. O
055 O
) O
. O

There O
was O
no O
correlation O
between O
secretor O
status O
and O
clinical O
status O
, O
spirometry O
measurements O
, O
salivary B-GENE
and I-GENE
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
tract O
colonization O
with O
P O
. O
aeruginosa O
and O
S O
. O
aureus O
. O

The O
results O
presented O
in O
this O
report O
suggest O
that O
the O
SV40 O
G-C-rich O
sequences O
can O
function O
as O
independent O
RNA B-GENE
polymerase I-GENE
II I-GENE
transcriptional-control O
elements O
. O

To O
determine O
if O
signing O
, O
when O
established O
, O
would O
compete O
with O
SIB O
when O
both O
were O
reinforced O
, O
extinction O
was O
then O
withdrawn O
. O

The O
structure O
of O
the O
calcineurin B-GENE
A I-GENE
gene I-GENE
was O
determined O
by O
comparison O
of O
the O
genomic O
and O
cDNA O
sequences O
. O

Fructokinase B-GENE
activity O
is O
elevated O
up O
to O
twofold O
when O
Z O
. O
mobilis O
was O
grown O
on O
fructose O
instead O
of O
glucose O
, O
and O
there O
was O
a O
parallel O
increase O
in O
frk B-GENE
mRNA I-GENE
levels O
. O

Mycoplasma O
pneumoniae O
was O
isolated O
from O
the O
pleural O
fluid O
of O
this O
patient O
. O

We O
found O
that O
T3 B-GENE
( O
10 O
( O
-8 O
) O
M O
) O
selectively O
stimulates O
transcription O
from O
rGH-TRE- O
and O
TREpal- O
, O
but O
not O
ME-TRE- O
and O
F2-TRE- O
, O
containing O
templates O
in O
which O
these O
TREs O
are O
linked O
in O
front O
of O
the O
rGH B-GENE
minimal I-GENE
promoter I-GENE
containing O
only O
the O
TATA B-GENE
box I-GENE
binding I-GENE
protein I-GENE
, O
but O
not O
any O
other O
proximal O
binding O
protein O
, O
sequence O
. O

On O
the O
basis O
of O
a O
patient's O
report O
of O
one O
inaccurate O
Clinitemp O
, O
we O
undertook O
to O
investigate O
the O
accuracy O
of O
this O
thermometer O
. O

Oligonucleotide-directed O
mutagenesis O
was O
used O
to O
create O
an O
NdeI B-GENE
restriction I-GENE
site I-GENE
at O
the O
natural O
ATG O
of O
the O
yeast O
R O
. O

However O
, O
three O
Hm1 B-GENE
mutants I-GENE
that O
were O
moderately O
deficient O
in O
stimulating O
PI O
turnover O
displayed O
normal O
sequestration O
, O
suggesting O
distinct O
mechanisms O
. O

Therefore O
, O
it O
would O
be O
advantageous O
to O
identify O
such O
persons O
and O
treat O
them O
preferentially O
. O

Large O
scale O
electronic O
structure O
calculations O
. O

Southern O
blot O
hybridization O
experiments O
suggest O
the O
presence O
of O
one O
copy O
of O
Atcys1 B-GENE
, O
Athyp1 B-GENE
and O
AKin10 B-GENE
per O
haploid O
genome O
, O
and O
Northern O
blot O
analysis O
demonstrates O
that O
the O
three O
genes O
are O
differentially O
expressed O
in O
roots O
, O
shoots O
and O
leaves O
. O

The O
results O
obtained O
are O
similar O
to O
those O
described O
with O
the O
previous O
Cremophor O
formulation O
although O
greater O
variability O
in O
induction O
and O
recovery O
times O
was O
noted O
with O
the O
emulsion O
formulation O
. O

Indeed O
the O
predicted O
folding O
of O
the O
5' O
and O
3'-untranslated O
regions O
revealed O
patterns O
of O
stem O
and O
loop O
structures O
conserved O
for O
all O
tick-borne O
flaviviruses O
suggesting O
a O
purifying O
selection O
for O
preservation O
of O
essential O
RNA O
secondary O
structures O
which O
could O
be O
involved O
in O
translational O
control O
and O
replication O
. O

Taurine O
deficiency O
significantly O
depressed O
the O
amplitude O
of O
OP1 O
and O
OP4 O
. O

The O
promoter O
region O
showed O
no O
consensus O
TATA O
box O
but O
it O
contains O
CCAAT O
and O
CreA B-GENE
boxes I-GENE
known O
to O
be O
involved O
in O
both O
stress O
and O
carbon-catabolite O
regulation O
of O
fungal O
promoters O
. O

We O
remain O
convinced O
that O
antilymphocyte B-GENE
globulin I-GENE
( O
ALG B-GENE
) O
is O
a O
potent O
immunosuppressive O
agent O
in O
humans O
. O

According O
to O
out O
field O
research O
, O
the O
tick O
fauna O
was O
very O
rich O
throughout O
that O
area O
, O
and O
it O
was O
permissible O
enough O
to O
determine O
ticks O
as O
the O
vectors O
, O
based O
on O
arising O
of O
anti-SF B-GENE
group I-GENE
rickettsiae I-GENE
( O
SFGR B-GENE
) O
antibody O
in O
mice O
inoculated O
with O
some O
tick O
emulsions O
, O
findings O
of O
rickettsiae O
reactive O
to O
patient O
sera O
or O
a O
species-specific O
monoclonal O
antibody O
to O
JSFR B-GENE
in O
the O
hemolymph O
cells O
of O
some O
ticks O
, O
and O
electron O
microscopical O
observations O
of O
SFGR B-GENE
in O
various O
internal O
organs O
including O
the O
salivary O
gland O
of O
ticks O
. O

An O
increase O
in O
hypothalamic O
expression O
of O
at O
least O
two O
of O
the O
erbB B-GENE
receptors I-GENE
is O
initiated O
before O
the O
pubertal O
augmentation O
of O
gonadal O
steroid O
secretion O
and O
is O
completed O
on O
the O
day O
of O
the O
first O
preovulatory O
surge O
of O
gonadotropins B-GENE
. O

These O
data O
indicate O
that O
phosphorylation O
of O
M B-GENE
protein I-GENE
at O
the O
major O
in O
vivo O
sites O
is O
not O
essential O
for O
virus O
assembly O
. O

Aviators O
from O
the O
Light O
Attack O
Wing O
, O
Pacific O
were O
surveyed O
and O
the O
results O
were O
categorized O
by O
aircraft O
type O
. O

Identification O
of O
mutations O
in O
the O
coding O
sequence O
of O
the O
proto-oncogene B-GENE
c-kit I-GENE
in O
a O
human O
mast O
cell O
leukemia O
cell O
line O
causing O
ligand-independent O
activation O
of O
c-kit B-GENE
product I-GENE
. O

Deletion O
from O
either O
the O
N- O
or O
C-terminal O
ends O
of O
repA B-GENE
( O
28 O
and O
69 O
codons O
, O
respectively O
, O
out O
of O
the O
286-codon O
open O
reading O
frame O
) O
affected O
the O
initiator O
but O
not O
the O
inhibitory O
activity O
. O

73 O
: O
658-666 O
, O
1999 O
) O
. O

A O
patient O
is O
described O
with O
skin O
lesions O
resembling O
Kaposi's O
sarcoma O
( O
KS O
) O
. O

Such O
mutations O
are O
thought O
to O
exert O
their O
dominant O
phenotype O
by O
sequestration O
of O
the O
guanine B-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
GNEF B-GENE
) O
. O

Induction O
of O
AtP5CS1 B-GENE
mRNA I-GENE
accumulation O
in O
salt-treated O
seedlings O
involves O
an O
immediate O
early O
transcriptional O
response O
regulated O
by O
ABA B-GENE
signalling O
that O
is O
not O
inhibited O
by O
cycloheximide O
, O
but O
abolished O
by O
the O
deficiency O
of O
ABA B-GENE
biosynthesis O
in O
the O
aba1 B-GENE
Arabidopsis I-GENE
mutant I-GENE
. O

NF-kappaB B-GENE
pathway O
activation O
occurs O
during O
transformation O
induced O
by O
a O
number O
of O
classical O
oncogenes O
, O
including O
Bcr B-GENE
Abl I-GENE
, I-GENE
Ras O
and B-GENE
Rac O
, B-GENE
and O
is O
necessary O
for O
full O
transforming O
potential O
. O

L-canavanine O
, O
a O
selective O
inhibitor O
of O
the O
inducible O
nitric B-GENE
oxide I-GENE
synthase I-GENE
, O
increases O
the O
mean O
systemic O
filling O
pressure O
, O
thereby O
improving O
venous O
return O
, O
under O
these O
conditions O
. O

One O
of O
these O
SEBPs B-GENE
, O
SEBP2 B-GENE
, O
was O
shown O
to O
be O
the O
product O
of O
the O
homeotic B-GENE
gene I-GENE
fork B-GENE
head I-GENE
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
using O
purified O
glucocorticoid B-GENE
receptor I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
( O
DBD O
) O
demonstrated O
that O
both O
GRE-2 B-GENE
and I-GENE
-3 I-GENE
motifs I-GENE
interact O
with O
DBD O
and O
oligonucleotide O
competition O
experiments O
established O
that O
these O
have O
different O
affinities O
for O
DBD O
. O

Human B-GENE
T-cell I-GENE
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
( I-GENE
HTLV-I I-GENE
) I-GENE
Tax I-GENE
is O
a O
potent O
transcriptional O
regulator O
that O
can O
activate O
or O
repress O
specific O
cellular O
genes O
and O
that O
has O
been O
proposed O
to O
contribute O
to O
leukemogenesis O
in O
adult O
T-cell O
leukemia O
. O

The O
major O
inserted O
DNA O
has O
no O
significant O
homology O
to O
published O
human O
nucleic O
acid O
sequences O
. O

CONCLUSION O
: O
Presence O
of O
APOE B-GENE
epsilon4 I-GENE
* I-GENE
seems I-GENE
to O
increase O
the O
risk O
for O
dementia O
and O
AD O
independently O
of O
its O
effect O
on O
dyslipidemia O
and O
atherogenesis O
. O

Experimental O
pancreatitis O
in O
pigs O
. O

These O
IgG B-GENE
antibodies I-GENE
in O
the O
babies O
diminished O
rapidly O
after O
delivery O
, O
and O
were O
detectable O
only O
in O
3 O
cases O
at O
2 O
, O
3 O
, O
and O
5 O
months O
of O
ages O
out O
of O
38 O
babies O
up O
to O
21 O
months O
. O

PATIENTS O
AND O
METHODS O
: O
One O
hundred O
eighty-four O
chemotherapy-naive O
patients O
receiving O
high-dose O
cisplatin O
( O
81 O
to O
120 O
mg O
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
granisetron O
doses O
( O
5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms O
kg O
) O
administered O
before O
chemotherapy O
. O

The O
O2 O
deficit O
was O
not O
related O
to O
blood O
lactate O
during O
submaximal O
exercise O
, O
muscle O
enzyme O
activity O
( O
citrate B-GENE
synthase I-GENE
, O
3-hydroxyacyl-CoA-dehydrogenase B-GENE
, O
lactate B-GENE
dehydrogenase I-GENE
) O
, O
number O
of O
muscle O
capillaries O
, O
%ST O
fibres O
or O
muscle O
buffer O
capacity O
. O

Subtraction O
hybridization O
identified O
melanoma B-GENE
differentiation I-GENE
associated I-GENE
gene-7 I-GENE
( O
mda-7 B-GENE
) O
, O
as O
a O
gene O
induced O
during O
these O
physiological O
changes O
in O
human O
melanoma O
cells O
. O

The O
euglobulin O
clot O
lysis O
time O
was O
slightly O
longer O
in O
the O
smokers O
than O
in O
the O
non-smokers O
in O
all O
three O
experimental O
situations O
, O
but O
the O
differences O
were O
not O
significant O
. O

The O
two O
IL6 B-GENE
mRNA I-GENE
species O
are O
generated O
by O
alternative O
polyadenylation O
at O
sites O
separated O
by O
a O
distance O
of O
1 O
. O
2 O
kilobases O
. O

We O
previously O
reported O
that O
Tax B-GENE
induced O
cell O
cycle O
progression O
from O
G0 O
G1 O
phase O
to O
S O
and O
G2 O
M O
phases O
in O
human O
T-cell O
line O
Kit O
225 O
cells O
. O

The O
variations O
were O
caused O
by O
opposite O
shifts O
in O
TSH B-GENE
frequency O
distribution O
in O
mothers O
and O
neonates O
. O

In O
the O
last O
20 O
years O
, O
the O
therapeutic O
uses O
of O
botulinum B-GENE
toxin I-GENE
, O
a O
potent O
neurotoxin O
, O
have O
been O
investigated O
. O

Obstruction O
of O
the O
ERF B-GENE
repressor I-GENE
function O
by O
the O
transactivating O
members O
of O
the O
ets B-GENE
family I-GENE
of O
genes O
( O
i O
. O
e O
. O
gag-myb-ets O
) O
may O
be O
essential O
for O
the O
control O
of O
genes O
involved O
in O
cell O
proliferation O
and O
may O
also O
underlie O
their O
tumorigenic O
effects O
. O

Intraventricular O
injection O
of O
( O
2S O
, O
1'R O
, O
2'R O
, O
3'R O
) O
-2- O
( O
2 O
, O
3-dicarboxycyclopropyl O
) O
glycine O
( O
DCG-IV O
) O
, O
a O
potent O
agonist O
for O
metabotropic O
glutamate B-GENE
receptors I-GENE
, O
to O
rats O
retarded O
dose-dependently O
the O
recovery O
from O
halothane O
anesthesia O
at O
a O
dose O
range O
from O
30 O
to O
300 O
pmol O
rat O
. O

The O
single O
most O
important O
element O
, O
by O
linker-scanning O
analysis O
, O
is O
a O
10-bp O
region O
that O
contains O
a O
CCAAT O
motif O
. O

An O
FP B-GENE
mutant I-GENE
, O
AcFP875-2 B-GENE
, O
had O
a O
1 O
. O
6-kbp O
insertion O
of O
S O
. O
frugiperda O
DNA O
near O
the O
5' O
end O
of O
these O
transcripts O
which O
by O
S1 O
analysis O
were O
shown O
to O
initiate O
within O
the O
host O
cell O
sequence O
. O

We O
took O
advantage O
of O
the O
high O
degree O
of O
aa O
sequence O
homology O
between O
DAHPSs B-GENE
from O
several O
species O
to O
isolate O
ARO3 B-GENE
homologues I-GENE
from O
the O
pathogenic O
yeast O
Candida O
albicans O
. O

The O
serum O
levels O
of O
beta-human B-GENE
chorionic I-GENE
gonadotropin I-GENE
( O
HCG B-GENE
) O
and O
placental B-GENE
alkaline I-GENE
phosphatase I-GENE
( O
PLAP B-GENE
) O
were O
not O
elevated O
. O

Effects O
of O
aging O
and O
beta-adrenergic-blockade O
on O
standing-induced O
QT O
QS2 O
changes O
. O

Several O
nuclear O
factors O
that O
interact O
with O
sequences O
in O
the O
5' O
flanking O
region O
of O
the O
mouse B-GENE
tyrosinase I-GENE
gene I-GENE
were O
identified O
using O
band O
shift O
and O
methylation O
interference O
assays O
. O

Only O
one O
of O
these O
bands O
was O
supershifted O
by O
antibody O
to O
p50 B-GENE
, O
whereas O
antibodies O
to O
p65 B-GENE
or O
other O
NF-kappaB B-GENE
proteins I-GENE
had O
no O
effect O
. O

All O
corneal O
buttons O
were O
processed O
for O
histopathologic O
and O
electron O
microscopic O
studies O
. O

In O
gel O
mobility O
shift O
assays O
, O
we O
found O
no O
evidence O
for O
VDR-TR B-GENE
heterodimer I-GENE
interaction O
with O
any O
tested O
element O
. O

A O
combined O
series O
of O
patients O
experienced O
a O
TOL O
after O
two O
or O
more O
previous O
cesarean O
deliveries O
; O
the O
rate O
of O
vaginal O
delivery O
was O
66% O
, O
and O
there O
was O
virtually O
no O
morbidity O
. O

The O
two O
drugs O
increase O
the O
rate O
of O
early O
diastolic O
filling O
. O

Furthermore O
, O
p150 B-GENE
suppresses O
actin B-GENE
gelation O
, O
which O
is O
induced O
by O
smooth B-GENE
muscle I-GENE
alpha-actinin I-GENE
. O

3--It O
is O
necessary O
to O
think O
about O
cosmetic O
consequences O
of O
the O
chinese O
flap O
and O
consider O
other O
possibilities O
of O
the O
flap O
choice O
. O

The O
HPLC O
method O
involves O
an O
octadecylsilane O
column O
at O
55 O
degrees O
C O
, O
a O
mixture O
of O
water-acetonitrile-orthophosphoric O
acid O
( O
779 O
: O
220 O
: O
1 O
, O
v O
v O
) O
as O
mobile O
phase O
and O
detection O
at O
226 O
nm O
. O

The O
results O
indicate O
that O
hrpRS B-GENE
and O
hrpL B-GENE
are O
part O
of O
a O
regulatory O
cascade O
in O
which O
HrpR B-GENE
and O
HrpS B-GENE
activate O
expression O
of O
hrpL B-GENE
and O
HrpL B-GENE
, O
a O
putative O
sigma B-GENE
factor I-GENE
, O
induces O
expression O
of O
HrpL-responsive B-GENE
genes I-GENE
. O

In O
Xenopus O
embryos O
, O
the O
engineered B-GENE
PDGF I-GENE
receptor I-GENE
protein I-GENE
induced O
the O
formation O
of O
mesoderm O
from O
animal-pole O
explants O
in O
an O
FK1012-dependent O
manner O
. O

Mutations O
within O
human O
UTR1 O
modulate O
NRF-1 B-GENE
expression O
by O
interfering O
with O
mRNA O
translational O
efficiency O
in O
transfected O
cells O
and O
in O
an O
in O
vitro O
translation O
system O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT B-GENE
enhancer-binding I-GENE
protein-beta I-GENE
( I-GENE
C O
EBP-beta B-GENE
) I-GENE
binding I-GENE
site O
between O
-2010 O
and O
-1954 O
in O
regulating O
transcription O
of O
collagenase-1 O
in O
monocytic B-GENE
cells O
. O

Mus81p B-GENE
also O
shares O
homology O
with O
motifs O
found O
in O
the O
XPF B-GENE
endonuclease I-GENE
superfamily I-GENE
. O

In O
the O
Rett O
syndrome O
we O
, O
therefore O
, O
suspect O
there O
are O
disturbances O
in O
the O
brain O
stem O
functions O
especially O
in O
the O
ascending O
reticular O
activating O
system O
which O
is O
related O
to O
elevation O
of O
the O
conscious O
level O
. O

Multistep O
transformation O
by O
defined O
fragments O
of O
herpes B-GENE
simplex I-GENE
virus I-GENE
type I-GENE
2 I-GENE
DNA I-GENE
: I-GENE
oncogenic I-GENE
region I-GENE
and O
its O
gene O
product O
. O

The O
gcd2-503 B-GENE
mutation O
also O
results O
in O
polysome O
runoff O
, O
accumulation O
of O
inactive O
80S B-GENE
ribosomal I-GENE
couples I-GENE
, O
and O
accumulation O
of O
at O
least O
one O
of O
the O
subunits O
of O
the O
general B-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
( O
eIF-2 B-GENE
alpha I-GENE
) O
in O
43S-48S B-GENE
particles I-GENE
following O
a O
shift O
to O
the O
restrictive O
temperature O
. O

Similarly O
, O
the O
DNA-binding O
activity O
of O
activator B-GENE
protein I-GENE
1 I-GENE
( O
AP-1 B-GENE
) O
is O
modified O
by O
a O
DNA B-GENE
repair I-GENE
enzyme I-GENE
, O
redox B-GENE
factor I-GENE
1 I-GENE
( O
Ref-1 B-GENE
) O
, O
which O
is O
identical O
to O
a O
DNA B-GENE
repair I-GENE
enzyme I-GENE
, O
AP B-GENE
endonuclease I-GENE
. O

Stereotactic O
radiofrequency O
lesioning O
of O
the O
hamartoma O
resulted O
in O
seizure O
remission O
without O
complications O
20 O
months O
after O
surgery O
. O

Gastric O
CO2 O
HCO3 O
was O
determined O
in O
absence O
of O
simultaneous O
inhibition O
of O
acid O
secretion O
by O
intra- O
and O
extragastric O
pCO2 O
pH O
measurements O
in O
23 O
persons O
and O
calculated O
using O
the O
equation O
of O
Henderson-Hasselbalch O
. O
pCO2 O
was O
measured O
with O
use O
of O
a O
new O
electrode O
. O

The O
microdensitometric O
scores O
and O
their O
side-to-side O
differences O
in O
patients O
correlated O
negatively O
with O
the O
serum O
25-OHD O
concentration O
and O
positively O
with O
the O
degree O
of O
paralysis O
. O

The O
investigation O
was O
thereafter O
continued O
in O
an O
open O
fashion O
by O
administering O
a O
single O
10 O
mg O
dose O
of O
the O
MAO-B B-GENE
inhibitor O
deprenyl O
to O
the O
same O
subjects O
. O

Immunofluoresence O
data O
indicated O
that O
once O
bound O
to O
the O
mutant O
receptor O
, O
fluorescent-labeled O
RAP B-GENE
co-localized O
with O
markers O
of O
the O
endosomal O
pathway O
, O
whereas O
, O
in O
cells O
expressing O
the O
wild-type O
receptor O
, O
RAP B-GENE
fluorescence O
co-localized O
with O
lysosomal O
markers O
. O

In O
14 O
patients O
whose O
PaCO2 O
was O
greater O
than O
or O
equal O
to O
39 O
torr O
( O
range O
39 O
to O
58 O
torr O
) O
and O
clinical O
asthma O
score O
was O
6 O
or O
greater O
, O
PaCO2 O
decreased O
a O
mean O
of O
11 O
. O
7 O
torr O
during O
a O
mean O
of O
8 O
. O
1 O
hours O
. O

Deletion O
analysis O
revealed O
that O
the O
essential O
domain O
of O
this O
promoter O
, O
termed O
the O
ORF5 B-GENE
deltaX I-GENE
transcript I-GENE
promoter I-GENE
, I-GENE
mapped O
to O
nucleotides O
1525-1625 O
. O

The O
need O
for O
including O
forensic O
medical O
expertise O
in O
the O
list O
of O
urgent O
criminal O
investigative O
actions O
. O

Expression O
of O
thymidine B-GENE
kinase I-GENE
gene I-GENE
in O
normal O
human O
diploid O
cells O
is O
both O
cell O
cycle- O
and O
age-dependent O
and O
appears O
to O
be O
transcriptionally O
regulated O
. O

By O
using O
interleukin-3-dependent O
cells O
that O
ectopically O
express O
the O
three O
ErbB B-GENE
proteins I-GENE
or O
their O
combinations O
, O
we O
found O
that O
ErbB-3 B-GENE
is O
devoid O
of O
any O
biological O
activity O
but O
both O
ErbB-1 B-GENE
and O
ErbB-2 B-GENE
can O
reconstitute O
its O
extremely O
potent O
mitogenic O
activity O
. O

This O
suggests O
that O
while O
underpredictions O
of O
pain O
do O
not O
hurt O
more O
, O
disruption O
on O
primary O
tasks O
and O
physiological O
impact O
are O
higher O
. O

Marine O
oils O
and O
cardiovascular O
reactivity O
. O

Psychiatry O
and O
the O
skin O
. O

The O
entire O
human B-GENE
teneurin-1 I-GENE
( O
TEN1 B-GENE
) O
gene O
is O
contained O
in O
eight O
PAC O
clones O
representing O
part O
of O
the O
chromosomal O
locus O
Xq25 O
. O

In O
the O
present O
study O
, O
we O
identified O
a O
strong O
positive O
cis-regulatory O
element O
at O
-70 O
bp O
to O
-75 O
bp O
in O
the O
LpS1 B-GENE
beta I-GENE
promoter I-GENE
with O
the O
sequence O
( O
G O
) O
6 O
and O
a O
similar O
, O
more O
distal O
cis-element O
at O
-721 O
bp O
to O
-726 O
bp O
. O

Several O
artifacts O
occurred O
that O
interfered O
with O
visualization O
of O
the O
diaphragm O
. O

Developmental O
follow-up O
at O
age O
2 O
years O
was O
performed O
. O

On O
the O
third O
occasion O
water O
( O
W O
) O
was O
ingested O
throughout O
the O
run O
. O

The O
JS78 O
mutation O
changes O
Gln243 O
in O
gp0 O
. O
7 O
to O
an O
amber O
codon O
, O
which O
explains O
the O
production O
of O
the O
truncated O
, O
30-kDa B-GENE
gp0 I-GENE
. I-GENE
7-related I-GENE
polypeptide I-GENE
, O
and O
implicates O
the O
11-kDa O
C-terminal O
domain O
in O
host O
transcription O
shut-off O
. O

Both O
pancreatic O
and O
intestinal O
cell O
lines O
were O
found O
to O
express O
a O
number O
of O
POU B-GENE
( O
OCT O
binding O
) O
homeodomain B-GENE
proteins I-GENE
examined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

Sequencing O
of O
the O
16p O
11 O
. O
1 O
Xq28 O
duplication O
breakpoints O
has O
revealed O
the O
presence O
of O
repetitive O
immunoglobulin-like O
CAGGG B-GENE
pentamer I-GENE
sequences I-GENE
at I-GENE
or O
near O
the O
paralogy O
boundaries O
. O

Thus O
, O
the O
synergistic O
effects O
of O
HNF-1beta B-GENE
and O
the O
GR B-GENE
on O
dexamethasone-stimulated O
promoter O
activity O
require O
that O
they O
are O
bound O
to O
the O
HNF-1 B-GENE
site I-GENE
and O
the O
GRE B-GENE
, O
respectively O
, O
and O
may O
involve O
protein-protein O
interactions O
between O
the O
transcription O
factors O
, O
or O
between O
them O
and O
the O
basal O
transcription O
machinery O
or O
a O
steroid B-GENE
receptor I-GENE
coactivator I-GENE
. O

In O
the O
control O
preparation O
before O
weight O
was O
allowed O
to O
increase O
, O
isogravimetric O
capillary O
pressure O
( O
Pci O
) O
averaged O
8 O
mmHg O
lower O
than O
colloid O
osmotic O
pressure O
of O
the O
plasma O
( O
IIp O
) O
. O

Construction O
of O
human O
cell O
lines O
which O
contain O
and O
express O
the O
adenovirus B-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
by O
cotransformation O
with O
the O
HSV-1 B-GENE
tk I-GENE
gene I-GENE
. O

The O
occurrence O
, O
maintenance O
and O
possible O
involvement O
of O
these O
repeated O
sequences O
, O
capable O
of O
forming O
stable O
secondary O
structures O
, O
are O
discussed O
in O
relation O
to O
their O
location O
in O
the O
region O
of O
control O
signals O
. O

This O
subfamily O
of O
genes O
all O
have O
a O
single O
ATP-binding O
domain O
at O
the O
N-terminus O
and O
a O
single O
C-terminal O
set O
of O
transmembrane O
segments O
. O

Approximately O
65% O
of O
the O
total O
cAMP-dependent B-GENE
phosphotransferase I-GENE
activity O
is O
recovered O
in O
particulate O
fractions O
of O
homogenates O
prepared O
from O
asynchronous O
populations O
of O
C O
. O
elegans O
. O

The O
various O
available O
data O
strongly O
suggesting O
an O
environmental O
toxic O
origin O
for O
the O
"sperm O
fall" O
will O
be O
presented O
as O
well O
as O
the O
most O
frequently O
suspected O
class O
of O
substances O
, O
the O
xenoestrogens O
. O

The O
predicted O
Pay4p B-GENE
sequence I-GENE
contains O
two O
putative O
ATP-binding O
domains O
and O
shows O
structural O
relationships O
to O
other O
potential O
ATP-binding O
proteins O
involved O
in O
biological O
processes O
as O
diverse O
as O
peroxisome O
biogenesis O
, O
vesicle-mediated O
protein O
transport O
, O
cell O
cycle O
control O
, O
and O
transcriptional O
regulation O
. O

DNA O
recognition O
by O
F B-GENE
factor I-GENE
TraI36 B-GENE
: O
highly O
sequence-specific O
binding O
of O
single-stranded O
DNA O
. O

We O
have O
followed O
37 O
phenytoin-treated O
patients O
with O
reduced O
serum B-GENE
IgA I-GENE
concentrations O
for O
2-7 O
years O
. O

Erythema O
exsudativum O
multiforme O
induced O
by O
granulocyte B-GENE
colony-stimulating I-GENE
factor I-GENE
in O
an O
allogeneic O
peripheral O
blood O
stem O
cell O
donor O
. O

The O
expression O
of O
the O
first O
two O
genes O
located O
in O
this O
unit O
( O
c-gvpD B-GENE
and O
c-gvpE B-GENE
) O
was O
also O
monitored O
by O
Western O
blot O
( O
immunoblot O
) O
analyses O
using O
antisera O
raised O
against O
these O
proteins O
synthesized O
in O
Escherichia O
coli O
. O

This O
region O
also O
contains O
a O
gene O
specifying O
a O
Leu-tRNA B-GENE
precursor I-GENE
and O
a O
remnant O
of O
a O
tau B-GENE
element I-GENE
. O

In O
summary O
, O
at O
equianesthetic O
concentrations O
, O
desflurane O
and O
isoflurane O
produced O
similar O
hemodynamic O
effects O
; O
however O
, O
in O
the O
absence O
of O
drugs O
that O
inhibit O
autonomic O
reflexes O
, O
desflurane O
had O
less O
negative O
inotropic O
activity O
and O
produced O
less O
decrease O
in O
arterial O
pressure O
. O

Sparfloxacin O
and O
clinafloxacin O
were O
evaluated O
against O
Enterococcus O
faecium O
SF2149 O
and O
Enterococcus O
faecalis O
WH245 O
, O
respectively O
. O

A O
330-kb O
YAC O
, O
A148A7 O
, O
spanned O
from O
the O
HLA-DQA1 B-GENE
locus I-GENE
through O
the O
Y3 B-GENE
Ring I-GENE
4 I-GENE
locus I-GENE
and I-GENE
extended O
at O
least O
130 O
kb O
centromeric O
of O
YAC O
B1D12 O
. O

Modification O
of O
dopamine B-GENE
D2 I-GENE
receptor I-GENE
activity O
by O
pergolide O
in O
Parkinson's O
disease O
: O
an O
in O
vivo O
study O
by O
PET O
. O

The O
highest O
doses O
were O
found O
for O
drivers O
who O
transported O
large O
numbers O
of O
99Mo O
generators O
. O

National O
certification O
: O
a O
vital O
component O
of O
quality O
assurance O
. O

Effects O
of O
dopamine O
and O
of O
a O
dopaminergic O
blocker O
, O
haloperidol O
, O
on O
the O
responses O
of O
carotid O
body O
chemoreceptors O
to O
hypoxia O
and O
hypercapnia O
were O
investigated O
in O
16 O
anesthetized O
cats O
. O

Mutational O
analysis O
of O
a O
DNA O
sequence O
involved O
in O
linking O
gene O
expression O
to O
the O
cell O
cycle O
. O

PCR O
Southern O
blot O
analysis O
of O
human O
kidney O
cDNA O
using O
primers O
flanking O
the O
hKID O
coding B-GENE
sequence I-GENE
revealed I-GENE
expression O
of O
a O
full-length O
mRNA O
and O
short O
transcripts O
with O
partial O
exon O
1 O
and O
partial O
exon O
4 O
deletions O
. O

E O
. O
, O
Hession O
, O
C O
. O
, O
Goff O
, O
D O
. O
, O
Griffiths O
, O
B O
. O
, O
Tizard O
, O
R O
. O
, O
Newman O
, O
B O
. O
, O
Chi-Rosso O
, O
G O
. O
, O
and O
Lobb O
, O
R O
. O
, O
( O
1990 O
) O
Cell O
63 O
, O
1349-1356 O
) O
. O

The O
NF-kappaB B-GENE
responsive O
reporter O
construct O
, O
( B-GENE
PRDII I-GENE
) I-GENE
( I-GENE
4 I-GENE
) I-GENE
-CAT I-GENE
, O
was O
used O
to O
explore O
transcription O
resulting O
from O
NF-kappaB B-GENE
activated O
by O
Tat B-GENE
. O

Transcriptional O
regulation O
of O
fbp1 B-GENE
promoter I-GENE
constructs I-GENE
containing O
only O
UAS1 B-GENE
or O
UAS2 B-GENE
confirms O
that O
the O
PKA B-GENE
and O
MAPK B-GENE
regulation O
is O
targeted O
to O
both O
sites O
. O

Furthermore O
, O
formation O
of O
foci O
of O
transformed O
RECs O
by O
the O
c-jun B-GENE
ras I-GENE
combination I-GENE
was I-GENE
augmented O
3-fold O
by O
the O
tumor O
promoter O
phorbol O
12-tetradecanoate O
13-acetate O
. O

Commonly O
used O
stressors O
are O
mental O
arithmetics O
, O
speech O
tasks O
, O
the O
Stroop O
test O
, O
videogame O
playing O
, O
films O
or O
videotapes O
and O
interviews O
. O

The O
highly O
restrained O
girls O
had O
a O
significantly O
higher O
EAT O
score O
than O
the O
low-restrained O
girls O
, O
and O
shared O
with O
their O
mothers O
a O
susceptibility O
to O
the O
disinhibitory O
effects O
of O
negative O
mood O
states O
on O
their O
eating O
behaviour O
. O

It O
was O
proposed O
that O
the O
synthetase-related O
sequences O
of O
GCN2 B-GENE
stimulate O
the O
activity O
of O
the O
kinase O
by O
interacting O
directly O
with O
uncharged O
tRNA O
that O
accumulates O
during O
amino O
acid O
limitation O
. O

99mTc O
phytate O
, O
198Au O
colloid O
, O
and O
99mTc O
antimony O
sulfide O
have O
been O
used O
; O
the O
last O
appears O
to O
have O
been O
the O
most O
satisfactory O
. O

Invited O
editorial O
on O
"Acute O
and O
chronic O
effects O
of O
exercise O
on O
leptin B-GENE
levels O
in O
humans" O
. O

Pharmacologic O
properties O
of O
serotonergic O
agents O
and O
antidepressant O
drugs O
. O

LCBF O
in O
normal O
and O
hypoxic O
puppies O
was O
correlated O
with O
local O
cerebral O
glucose O
utilization O
( O
LCGU O
) O
obtained O
under O
the O
same O
experimental O
conditions O
( O
Duffy O
et O
al O
, O
1982 O
) O
. O

Retinoids O
participate O
in O
the O
onset O
of O
differentiation O
, O
apoptosis O
and O
the O
inhibition O
of O
growth O
in O
a O
wide O
variety O
of O
normal O
and O
cancerous O
cells O
. O

The O
results O
revealed O
a O
hierarchy O
of O
ligand O
affinities O
that O
mirrored O
their O
adhesive O
activity O
( O
rsVCAM-1 B-GENE
> O
fibronectin B-GENE
variants I-GENE
containing O
CS1 B-GENE
> O
> O
other O
fibronectin B-GENE
variants I-GENE
) O
. O

The O
diagnosis O
of O
miliary O
tuberculosis O
should O
be O
systematically O
considered O
in O
ARDS O
of O
unknown O
origin O
. O

After O
giving O
a O
survey O
on O
the O
situation O
of O
antibiotic O
resistance O
in O
the O
region O
of O
Northern O
Bavaria O
during O
1973 O
74 O
and O
comparing O
the O
activity O
of O
a O
sulfamethoxazole O
( O
SMZ O
) O
trimethoprim O
( O
TMP O
) O
combination O
to O
other O
commonly O
used O
antibiotics O
and O
chemotherapeutic O
agents O
, O
the O
results O
of O
tests O
with O
the O
new O
combination O
of O
N1- O
( O
4 O
, O
5-dimethyl-2-oxazolyl O
) O
-sulfanilamide O
) O
( O
sulfamoxole O
) O
and O
2 O
, O
4-diamino-5- O
( O
3 O
, O
4 O
, O
5-trimethoxy-benzyl O
) O
-pyrimidine O
( O
trimethoprim O
) O
at O
a O
ratio O
of O
5 O
: O
1 O
( O
CN O
3123 O
; O
Nevin O
, O
Supristol O
) O
are O
compared O
to O
those O
of O
tests O
with O
TMP O
SMZ O
. O

The O
psychological O
tests O
consisted O
of O
a O
free-recall O
task O
, O
a O
test O
for O
visuomotor O
coordination O
and O
a O
recognition O
task O
. O

Coronary O
vasoconstriction O
caused O
by O
endothelin-1 B-GENE
is O
enhanced O
by O
ischemia-reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

The O
plasmid O
shuffle O
technique O
was O
used O
to O
replace O
the O
wild-type O
gene O
with O
the O
mutant O
form O
, O
resulting O
in O
failure O
of O
the O
yeast O
cells O
to O
grow O
. O

Late O
mRNA O
selected O
by O
a O
cDNA O
homologous O
to O
the O
HindIII-P B-GENE
EcoRI-B I-GENE
region I-GENE
of I-GENE
the O
AcNPV O
map O
directed O
the O
synthesis O
of O
31K O
and O
30K O
proteins O
which O
comigrated O
with O
the O
31K O
and O
30K O
proteins O
translated O
from O
RNA O
selected O
by O
the O
HindIII-A O
EcoRI-C B-GENE
SstI-G I-GENE
cDNA I-GENE
. I-GENE

To O
determine O
whether O
the O
NTP-binding O
motif O
is O
important O
for O
Rad24 B-GENE
function O
, O
we O
mutated O
the O
conserved O
lysine O
( O
115 O
) O
residue O
in O
this O
motif O
. O

Copper O
and O
ceruloplasmin B-GENE
content O
in O
pregnant O
women O
and O
in O
women O
with O
certain O
gynecological O
diseases O
. O

Constitutive O
activation O
of O
Rac1 B-GENE
and O
RhoA B-GENE
causes O
tumorigenic O
transformation O
of O
NIH O
3T3 O
cells O
, O
and O
their O
functions O
may O
be O
required O
for O
full O
Ras B-GENE
transformation O
. O

Proposals O
on O
authorization O
; O
by O
a O
group O
of O
nurses O
from O
psychiatric O
hospitals O
. O

RESULTS O
: O
The O
cardiac O
index O
significantly O
changed O
with O
varying O
PaCO2 O
levels O
( O
hypocapnia O
, O
- O
9% O
; O
hypercapnia O
, O
13% O
) O
. O

The O
DNA O
sequence O
of O
the O
sulfate B-GENE
activation I-GENE
locus I-GENE
from O
Escherichia O
coli O
K-12 O
has O
been O
determined O
. O

Transforming B-GENE
growth I-GENE
factor-beta I-GENE
( O
TGF-beta B-GENE
) O
induced O
growth O
arrest O
of O
cells O
involves O
regulation O
of O
the O
activities O
of O
both O
D- B-GENE
and I-GENE
E-type I-GENE
cyclin I-GENE
kinase I-GENE
complexes I-GENE
thought O
to O
be O
mediated O
primarily O
by O
the O
regulation O
of O
p15 B-GENE
( I-GENE
Ink4b I-GENE
) I-GENE
and O
p27 B-GENE
( I-GENE
Kip1 I-GENE
) I-GENE
cyclin I-GENE
kinase I-GENE
inhibitors I-GENE
. O

Epstein-Barr B-GENE
virus-encoded I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
activates O
the O
JNK B-GENE
pathway O
through O
its O
extreme O
C O
terminus O
via O
a O
mechanism O
involving O
TRADD B-GENE
and O
TRAF2 B-GENE
. O

WA O
constructs O
afforded O
relaxed O
and O
positive O
topoisomers O
, O
and O
cyclization O
kinetics O
indicated O
slow O
interconversion O
of O
precursors O
to O
the O
two O
topoisomers O
. O

These O
changes O
may O
be O
the O
result O
of O
, O
on O
the O
one O
hand O
, O
an O
increased O
sensitivity O
of O
the O
neuromuscular O
transmission O
and O
or O
decreased O
muscle O
contractility O
and O
, O
on O
the O
other O
hand O
, O
the O
result O
of O
a O
reduced O
plasma O
clearance O
during O
hypothermia O
. O

G-box-directed O
expression O
in O
leaves O
required O
the O
presence O
of O
an O
enhancer O
region O
from O
the O
cauliflower O
mosaic O
virus O
( O
CaMV O
) O
35S B-GENE
promoter I-GENE
. O

Binding O
specificity O
and O
modulation O
of O
the O
ApoA-I B-GENE
promoter I-GENE
activity O
by O
homo- O
and O
heterodimers O
of O
nuclear O
receptors O
. O

Different O
thermoluminescent O
detectors O
( O
TLD O
) O
have O
been O
used O
to O
measure O
the O
contribution O
of O
the O
low O
linear O
energy O
transfer O
component O
( O
LET O
< O
10 O
keV O
micrometer O
) O
and O
plastic O
nuclear O
track O
detectors O
( O
PNTD O
) O
for O
the O
high O
linear O
energy O
tranfer O
( O
LET O
) O
component O
. O

Deletion O
mapping O
experiments O
determined O
that O
the O
sequences O
required O
for O
full O
activity O
in O
MSC-1 O
cells O
were O
included O
within O
619 O
bp O
of O
the O
start O
site O
and O
identified O
several O
regions O
that O
demonstrated O
increased O
luciferase B-GENE
activity O
: O
the O
-583 O
bp O
to O
-564 O
bp O
, O
-503 O
bp O
to O
-484 O
bp O
, O
and O
-114 O
bp O
to O
-65 O
regions O
. O

Like O
the O
p190-B B-GENE
exon O
, O
the O
first O
exon O
of O
p190-A B-GENE
is O
extremely O
large O
( O
3 O
. O
7 O
kb O
in O
length O
) O
, O
encoding O
both O
the O
GTPase B-GENE
and O
middle O
domains O
( O
residues O
1-1228 O
) O
, O
but O
not O
the O
remaining O
GAP B-GENE
domain I-GENE
, O
suggesting O
a O
high O
conservation O
of O
genomic O
structure O
between O
two O
p190 B-GENE
genes I-GENE
. O

We O
have O
cloned O
a O
novel O
mouse O
protein O
, O
TAF B-GENE
( I-GENE
II I-GENE
) I-GENE
140 I-GENE
, O
containing O
an O
HFD B-GENE
and O
a O
plant B-GENE
homeodomain I-GENE
( O
PHD B-GENE
) O
finger O
, O
which O
we O
demonstrated O
by O
immunoprecipitation O
to O
be O
a O
mammalian B-GENE
TFIID I-GENE
component I-GENE
. O

The O
eukaryotic O
cell O
cycle O
is O
governed O
in O
part O
by O
the O
periodic O
transcription O
of O
cyclin B-GENE
genes I-GENE
, O
whose O
protein O
products O
associate O
with O
and O
positively O
regulate O
the O
cyclin-dependent B-GENE
kinases I-GENE
. O

Dopamine B-GENE
beta-hydroxylase I-GENE
( O
DBH B-GENE
) O
catalyzes O
the O
conversion O
of O
dopamine O
to O
noradrenaline O
and O
is O
selectively O
expressed O
in O
noradrenergic O
and O
adrenergic O
neurons O
and O
neuroendocrine O
cells O
. O

Cooperative O
dimerization O
of O
paired O
class O
homeo O
domains O
on O
DNA O
. O

G O
. O
, O
and O
Hyde O
, O
C O
. O

The O
cellular O
part O
of O
the O
third O
chimeric O
clone O
shows O
significant O
homology O
to O
an O
exon O
of O
the O
human B-GENE
tyrosine I-GENE
phosphatase I-GENE
1 I-GENE
gene I-GENE
, O
although O
oriented O
in O
the O
antisense O
direction O
compared O
to O
the O
adjacent O
LTR O
. O

Mobilization O
with O
cyclophosphamide O
and O
granulocyte-colony B-GENE
stimulating I-GENE
factor I-GENE
was O
effective O
in O
terms O
of O
CD34+ B-GENE
cell O
shift O
to O
peripheral O
blood O
and O
the O
good O
quality O
autograft O
reliaebly O
led O
to O
haematopoetic O
recovery O
after O
megachemotherapy O
. O

Both O
parents O
are O
clinically O
normal O
and O
unrelated O
. O

The O
results O
show O
that O
the O
structure O
of O
the O
decorin B-GENE
gene I-GENE
promoter I-GENE
is O
different O
from O
that O
of O
any O
other O
proteoglycan O
promoter O
characterized O
so O
far O
and O
indicate O
that O
the O
pur O
pyr O
segment O
plays O
a O
role O
in O
the O
regulation O
of O
gene O
transcription O
. O

Ammonia O
concentration O
dropped O
significantly O
in O
all O
treatments O
, O
a O
finding O
which O
suggests O
a O
protective O
effect O
on O
protein O
nitrogen O
degradation O
to O
non-protein O
nitrogen O
( O
NH3 O
) O
. O

Thus O
, O
IRF-7 B-GENE
exhibits O
functional O
similarity O
to O
IRF-3 B-GENE
; O
however O
, O
the O
preferential O
expression O
of O
IRF-7 B-GENE
in O
lymphoid O
cells O
( O
the O
cell O
type O
that O
expresses O
IFNA B-GENE
) O
suggests O
that O
IRF-7 B-GENE
may O
play O
a O
critical O
role O
in O
regulating O
the O
IFNA B-GENE
gene I-GENE
expression O
. O

Rather O
, O
complete O
skipping O
of O
exon O
V O
and O
subsequent O
joining O
of O
exon O
IV O
to O
exon O
VI O
caused O
a O
shift O
in O
the O
open O
reading O
frame O
, O
which O
remodeled O
GPHe B-GENE
( I-GENE
P2 I-GENE
) I-GENE
with O
an O
elongated O
new O
hydrophobic O
sequence O
for O
membrane O
anchoring O
. O

All O
stimulations O
were O
down-regulated O
with O
GnRH-a B-GENE
commenced O
on O
day O
21 O
in O
a O
long O
protocol O
before O
gonadotropin B-GENE
stimulation O
. O

The O
consensus O
highlights O
the O
importance O
of O
residues O
other O
than O
the O
eight O
motifs O
that O
are O
often O
associated O
with O
DEAD-box B-GENE
RNA I-GENE
helicases I-GENE
, O
as O
well O
as O
de-emphasising O
the O
importance O
of O
the O
"A" O
residue O
within O
the O
"DEAD" B-GENE
motif I-GENE
. O

Fortunately O
DDT- O
, O
HCH- O
and O
HCB-levels O
decreased O
in O
breast O
milk O
during O
the O
last O
years O
. O

Two O
other O
peptides O
, O
either O
partially O
or O
totally O
lacking O
the O
basic O
region O
, O
but O
containing O
the O
intact O
leucine O
zipper O
domain O
, O
readily O
form O
dimers O
but O
do O
not O
bind O
to O
the O
CRE B-GENE
. O

The O
duration O
of O
diabetes O
mellitus O
in O
these O
patients O
was O
from O
5 O
months O
to O
6 O
years O
, O
and O
in O
all O
patients O
this O
was O
the O
first O
myocardial O
infarction O
. O

We O
detected O
mos B-GENE
transcripts I-GENE
by O
Northern O
( O
RNA O
) O
analyses O
in O
RNA O
prepared O
from O
chicken O
and O
quail O
ovaries O
and O
testes O
. O

Nursing O
home O
discharges O
in O
clinical O
practice O
. O

Seven O
clones O
encoding O
interferon B-GENE
response I-GENE
element I-GENE
binding I-GENE
factors I-GENE
have O
been O
isolated O
from O
a O
mouse O
fibroblast O
lambda O
gt11 O
cDNA O
library O
by O
using O
a O
32P O
end-labeled O
tandem O
trimer O
of O
the O
mouse B-GENE
( I-GENE
2'-5' I-GENE
) I-GENE
oligoadenylate I-GENE
synthetase I-GENE
gene I-GENE
interferon B-GENE
response I-GENE
element I-GENE
as O
a O
probe O
. O

The O
patient O
initially O
attained O
complete O
remission O
( O
CR1 O
) O
with O
conventional O
chemotherapy O
and O
then O
relapsed O
14 O
months O
later O
. O

Truncation O
variants O
of O
peptides O
isolated O
from O
MHC B-GENE
class I-GENE
II I-GENE
molecules I-GENE
suggest O
sequence O
motifs O
. O

Recombinant B-GENE
I-kappa I-GENE
B I-GENE
alpha I-GENE
inhibited O
kappa B-GENE
B I-GENE
motif I-GENE
binding O
by O
nuclear B-GENE
factor-kappa I-GENE
B1 I-GENE
, O
RelA B-GENE
, O
and O
c-Rel B-GENE
as O
indicated O
by O
studies O
using O
UV O
radiation-induced O
covalent O
cross-linking O
to O
a O
bromodeoxyuridine-substituted O
kappa B-GENE
B I-GENE
oligonucleotide I-GENE
. O

Cells O
lacking O
p116 B-GENE
exhibit O
a O
striking O
defect O
in O
the O
formation O
of O
these O
macropinocytic O
structures O
, O
a O
concomitant O
reduction O
in O
the O
rate O
of O
fluid O
phase O
pinocytosis O
, O
a O
significant O
decrease O
in O
the O
efficiency O
of O
chemotactic O
aggregation O
, O
and O
a O
decrease O
in O
cellular O
F-actin B-GENE
content O
. O

Promoter O
region O
of O
the O
transcriptional O
unit O
for O
human B-GENE
alpha I-GENE
1-chimaerin I-GENE
, O
a O
neuron-specific B-GENE
GTPase-activating I-GENE
protein I-GENE
for O
p21rac B-GENE
. O
alpha B-GENE
1-chimaerin I-GENE
is O
a O
neuron-specific B-GENE
GTPase-activating I-GENE
protein I-GENE
for O
p21rac B-GENE
, O
a O
protein O
involved O
in O
morphological O
events O
. O

Surprisingly O
, O
the O
COOH-terminal O
domain O
of O
RanGAP1 B-GENE
was O
also O
found O
to O
harbor O
a O
nuclear O
localization O
signal O
. O

Thus O
, O
the O
anti-interferon O
functions O
of O
vIRF-2 B-GENE
may O
contribute O
to O
the O
establishment O
of O
a O
chronic O
or O
latent O
infection O
. O

For O
EPV O
3 O
, O
10 O
, O
or O
40 O
, O
the O
bias O
exceeded O
25% O
for O
7 O
, O
3 O
, O
and O
1 O
in O
the O
8-predictor O
model O
respectively O
, O
when O
a O
conventional O
selection O
criterion O
was O
used O
( O
alpha O
= O
0 O
. O
05 O
) O
. O

Position O
22 O
is O
an O
isoleucine O
in O
the O
complete B-GENE
SsoL12 I-GENE
protein I-GENE
sequence I-GENE
, O
coded O
by O
an O
AUA O
codon O
. O

Plasma O
concentrations O
of O
ANF B-GENE
( O
pANF B-GENE
) O
, O
aldosterone O
( O
PAC O
) O
and O
renin B-GENE
( O
PRC B-GENE
) O
were O
measured O
daily O
, O
as O
were O
hemodynamic O
parameters O
. O

Immunochemical O
studies O
with O
filarial O
antigens O
. O

RPM B-GENE
RGL3 I-GENE
resembled I-GENE
AF-6 O
and B-GENE
Nore1 O
in B-GENE
interacting O
strongly O
with O
constitutively O
active O
M-Ras O
and B-GENE
p21 O
Ras B-GENE
. B-GENE

To O
our O
knowledge O
this O
is O
the O
first O
case O
in O
which O
a O
probable O
association O
between O
cholelithiasis O
and O
Wildervanck's O
syndrome O
has O
been O
recorded O
. O

The O
results O
are O
discussed O
in O
relation O
to O
acoustical O
models O
of O
sound O
propagation O
and O
physiology O
, O
and O
it O
is O
suggested O
that O
height-dependent O
degradation O
within O
a O
forest O
is O
an O
important O
selection O
pressure O
for O
transmissibility O
in O
avian O
communication O
. O

To O
identify O
the O
important O
cis-DNA O
regulatory O
element O
( O
s O
) O
involved O
in O
the O
tissue- O
, O
region- O
, O
and O
cell-specific O
expression O
of O
the O
mE-RABP B-GENE
gene I-GENE
, O
the O
5-kb O
DNA O
fragment O
was O
sequenced O
. O

The O
two O
larger O
peptides O
, O
one O
containing O
amino O
acids O
1-228 O
and O
the O
other O
containing O
amino O
acids O
85-228 O
, O
formed O
dimers O
in O
solution O
and O
bound O
DNA O
specifically O
as O
a O
dimer O
. O

Here O
the O
cloning O
and O
molecular O
analysis O
of O
the O
Zm-ERabp1 B-GENE
, O
Zm-ERabp4 B-GENE
, O
and O
Zm-ERabp5 B-GENE
genes I-GENE
is O
presented O
. O

Mechanism O
of O
enhancement O
of O
DNA O
expression O
consequent O
to O
cointernalization O
of O
a O
replication-deficient O
adenovirus O
and O
unmodified O
plasmid O
DNA O
. O

Using O
this O
method O
, O
VLPs O
were O
obtained O
in O
quantities O
sufficient O
for O
further O
characterization O
. O

Lactate O
accumulation O
peak O
was O
unaffected O
by O
supplementation O
( O
HMB O
, O
8 O
. O
1 O
+ O
- O
1 O
. O
1 O
mM O
; O
LEU O
, O
6 O
. O
2 O
+ O
- O
0 O
. O
8 O
mM O
; O
CON O
, O
7 O
. O
5 O
+ O
- O
1 O
. O
3 O
mM O
) O
. O

W O
. O

Tissue O
pressure O
, O
rCBF O
, O
and O
water O
content O
were O
measured O
from O
gray O
matter O
in O
the O
central O
core O
and O
the O
peripheral O
margin O
of O
the O
MCA O
territory O
over O
6 O
h O
after O
MCAO O
. O

Exons O
III O
to O
VIII O
, O
which O
cover O
the O
coding O
region O
and O
the O
3' O
untranslated O
region O
, O
are O
almost O
identical O
in O
all O
types O
of O
PST B-GENE
or O
AST B-GENE
cDNAs I-GENE
. O

Alena O
is O
a O
nurse O
in O
Prague--she O
dreams O
of O
higher O
wages O
and O
a O
trip O
across O
the O
ocean O
. O

An O
experiment O
examined O
the O
effects O
of O
treatment O
with O
gonadotrophin O
releasing O
hormone O
( O
100 O
micrograms O
GnRH B-GENE
injected O
24 O
h O
after O
progestagen O
sponge O
removal O
) O
, O
season O
of O
treatment O
( O
autumn O
v O
. O
spring O
) O
, O
the O
effect O
of O
supplementary O
feeding O
with O
lupin O
grain O
( O
in O
autumn O
only O
, O
from O
12 O
days O
before O
until O
8 O
days O
after O
sponge O
removal O
) O
on O
the O
time O
of O
ovulation O
in O
182 O
mature O
Merino O
ewes O
superovulated O
with O
a O
combination O
of O
400 O
I O
. O
U O
. O
pregnant B-GENE
mare I-GENE
serum I-GENE
gonadotrophin I-GENE
( O
PMSG B-GENE
) O
and O
12 O
mg O
follicle B-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH-P B-GENE
) O
. O

The O
early O
lethality O
of O
the O
left-sided O
resectio O
was O
0% O
and O
the O
postoperative O
survival--5-10 O
months O
. O

EIAV B-GENE
LTR I-GENE
sequence I-GENE
variability O
is O
confined O
mostly O
to O
a O
small O
portion O
of O
the O
enhancer O
within O
the O
U3 B-GENE
segment I-GENE
of O
the O
LTR B-GENE
. O

In O
the O
context O
of O
liver O
allograft O
shortage O
, O
our O
results O
suggest O
that O
an O
ELT O
should O
not O
be O
performed O
in O
patients O
with O
cardiac O
failure O
, O
more O
than O
two O
OSF O
, O
or O
an O
APACHE O
II O
score O
higher O
than O
30 O
. O

If O
no O
alloantibodies O
are O
detected O
, O
further O
analysis O
to O
define O
a O
role O
of O
drug- O
related O
or O
autoantibodies O
is O
required O
. O

The O
protein O
mixtures O
of O
sesame O
flour O
and O
soybean O
flour O
were O
well O
accepted O
. O

The O
site O
of O
autophosphorylation O
is O
Tyr397 O
which O
corresponds O
to O
the O
consensus O
autophosphorylation O
site O
of O
other O
Src B-GENE
family I-GENE
tyrosine B-GENE
kinases I-GENE
. O

Our O
results O
favor O
the O
possibility O
that O
the O
Drosophila B-GENE
EGF I-GENE
receptor I-GENE
DER B-GENE
Egfr I-GENE
expressed I-GENE
by O
the O
EMA O
cells O
functions O
as O
a O
receptor O
for O
Vein O
. B-GENE

Infrared O
measurements O
of O
temperature O
changes O
and O
estimates O
of O
the O
heating O
produced O
at O
the O
mical O
. O

Northern O
blot O
and O
reverse O
transcription-PCR O
analyses O
of O
human O
mRNA O
samples O
demonstrate O
that O
RNR B-GENE
is O
expressed O
exclusively O
in O
the O
retina O
, O
with O
transcripts O
of O
approximately O
7 O
. O
5 O
kb O
, O
approximately O
3 O
. O
0 O
kb O
, O
and O
approximately O
2 O
. O
3 O
kb O
by O
Northern O
blot O
analysis O
. O

One O
group O
of O
six O
cDNA O
clones O
was O
derived O
from O
a O
2 O
. O
9-kilobase O
early O
transcript O
encoded O
by O
the O
IR2 B-GENE
repeat I-GENE
element I-GENE
and O
showed O
restriction O
site O
polymorphism O
for O
the O
enzyme B-GENE
SmaI I-GENE
. O

Compared O
to O
controls O
, O
both O
UB O
and O
OCS O
rats O
showed O
a O
small O
but O
significant O
post-operative O
reduction O
in O
the O
nocturnality O
of O
drinking O
. O

Recombinant B-GENE
human I-GENE
serum I-GENE
albumin I-GENE
( O
rHSA B-GENE
) O
produced O
by O
cultured O
fermentation O
has O
been O
prepared O
in O
the O
form O
of O
microcapsules O
nominally O
3-5 O
microns O
in O
diameter O
and O
radiolabelled O
with O
technetium-99m O
following O
reduction O
with O
stannous O
chloride O
. O

These O
data O
suggest O
that O
proper O
direct O
binding O
of O
Nhp2p B-GENE
to O
H B-GENE
ACA I-GENE
snoRNAs I-GENE
is I-GENE
required O
for O
the O
assembly O
of O
H O
ACA B-GENE
snoRNPs I-GENE
and I-GENE
hence I-GENE
for O
the O
stability O
of O
some O
of O
their O
components O
. O

This O
mode O
of O
ternary O
complex O
formation O
is O
in O
contrast O
to O
the O
one O
seen O
in O
the O
promoter O
of O
the O
c-fos B-GENE
protooncogene I-GENE
, O
where O
formation O
of O
the O
ternary O
complex O
is O
dependent O
on O
the O
prior O
assembly O
of O
the O
serum B-GENE
response I-GENE
factor-DNA I-GENE
binary I-GENE
complex I-GENE
. O

Bile O
bilirubin O
did O
not O
rise O
within O
12 O
h O
after O
haem O
infusion O
a O
finding O
which O
warrants O
further O
investigation O
. O

Following O
intravenous O
administration O
, O
the O
myocardial O
concentration O
of O
tracer O
thallium-201 O
, O
potassium-43 O
, O
and O
rubidium-81 O
were O
determined O
in O
mice O
; O
thallium O
was O
present O
in O
the O
greatest O
concentration O
in O
the O
myocardium O
( O
2 O
. O
08% O
compared O
1 O
. O
25% O
for O
potassium O
and O
1 O
. O
15% O
for O
rubidium O
at O
10 O
minutes O
) O
. O

It O
acts O
on O
Cdks B-GENE
in O
the O
G1 O
and O
S O
phases O
of O
the O
cell O
cycle O
, O
and O
also O
binds O
to O
proliferating B-GENE
cell I-GENE
nuclear I-GENE
antigen I-GENE
( O
PCNA B-GENE
) O
, O
blocking O
DNA O
replication O
in O
vitro O
. O

The O
mutation O
within O
the O
asgB480 B-GENE
allele I-GENE
was O
identified O
as O
an O
A-to-G O
transition O
that O
results O
in O
a O
threonine-to-alanine O
substitution O
in O
the O
predicted O
protein O
product O
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
polyhedrin B-GENE
gene I-GENE
of O
Spodoptera O
exigua O
nuclear O
polyhedrosis O
virus O
. O

In O
12 O
cases O
( O
3 O
. O
1% O
) O
, O
a O
change O
in O
stage O
resulted O
. O

Inherent O
hematology O
of O
old O
age O
. O

We O
couldn't O
detect O
any O
effect O
of O
n-3 O
FA O
supplementation O
on O
total O
cholesterol O
, O
HDL O
cholesterol O
, O
LDL B-GENE
cholesterol O
, O
apo B-GENE
A1 I-GENE
, O
Lp B-GENE
( I-GENE
a I-GENE
) I-GENE
, O
HbA1C B-GENE
, O
glucose O
, O
fibrinogen B-GENE
, O
factor B-GENE
VIII I-GENE
, O
antithrombin B-GENE
III I-GENE
, O
plasminogen B-GENE
activator I-GENE
inhibitor I-GENE
, O
tissue B-GENE
plasminogen I-GENE
activator I-GENE
and O
von B-GENE
Willebrand I-GENE
factor I-GENE
concentration O
, O
on O
bleeding O
time O
or O
on O
systolic O
or O
diastolic O
blood O
pressure O
. O

A O
multi-centre O
evaluation O
of O
the O
card O
indirect O
agglutination O
test O
for O
trypanosomiasis O
( O
TrypTect O
CIATT O
) O
. O

Indeed O
, O
A-MuLV O
pseudotyped O
with O
some O
viruses O
, O
such O
as O
the O
Moloney O
MuLV O
, O
has O
been O
shown O
to O
be O
highly O
lymphogenic O
, O
whereas O
A-MuLV O
pseudotyped O
with O
other O
viruses O
, O
such O
as O
the O
BALB O
c O
endogenous O
N-tropic O
MuLV O
, O
has O
been O
shown O
to O
be O
devoid O
of O
lymphogenic O
potential O
( O
N O
. O

Whole-mount O
in O
situ O
hybridization O
to O
early O
mouse O
embryos O
of O
9 O
. O
5-10 O
. O
5 O
days O
indicated O
a O
complex O
pattern O
of O
Arp1 B-GENE
expression O
spatially O
overlapping O
with O
the O
expression O
of O
All1 B-GENE
. O

Conjugated O
estrogens O
shorten O
bleeding O
time O
in O
uraemia O
: O
a O
possible O
role O
of O
serotonin O
? O

The O
subunit-a B-GENE
gene I-GENE
is O
preceded O
by O
a O
gene O
coding O
for O
a O
small O
hydrophobic O
protein O
, O
as O
has O
been O
observed O
previously O
in O
the O
atp B-GENE
operons I-GENE
in O
E O
. O
coli O
, O
bacterium O
PS3 O
and O
cyanobacteria O
. O

US-Doppler O
has O
recently O
gained O
attention O
as O
a O
noninvasive O
method O
for O
the O
functional O
evaluation O
of O
arteriovenous O
fistulas O
( O
FAV O
) O
. O

The O
physical O
and O
chemical O
stability O
of O
a O
combination O
of O
drugs O
commonly O
administered O
into O
the O
epidural O
or O
intrathecal O
space O
for O
the O
treatment O
of O
chronic O
pain O
was O
investigated O
. O

Are O
low O
P300 O
amplitudes O
a O
marker O
for O
schizophrenia O
. O

The O
human O
pathogenic O
bacterium O
group O
A O
Streptococcus O
produces O
an O
extracellular B-GENE
cysteine I-GENE
protease I-GENE
[ B-GENE
streptococcal I-GENE
pyrogenic I-GENE
exotoxin I-GENE
B I-GENE
( O
SpeB B-GENE
) O
] O
that O
is O
a O
critical O
virulence O
factor O
for O
invasive O
disease O
episodes O
. O

Restriction O
analysis O
and O
Southern O
hybridization O
revealed O
the O
presence O
of O
Tn5422 B-GENE
in O
all O
the O
plasmid-mediated O
cadmium-resistant O
L O
. O
monocytogenes O
strains O
tested O
but O
not O
in O
strains O
encoding O
cadmium O
resistance O
on O
the O
chromosome O
. O

Another O
full O
ORF O
was O
found O
on O
the O
opposite O
strand O
downstream O
from O
the O
nspC B-GENE
gene I-GENE
. O

These O
two O
mAbs O
used O
the O
same O
V B-GENE
( I-GENE
H I-GENE
) I-GENE
and O
J B-GENE
( I-GENE
H I-GENE
) I-GENE
gene I-GENE
segments I-GENE
, O
but O
different O
D B-GENE
, O
Vkappa B-GENE
, O
and O
Jkappa B-GENE
genes I-GENE
. O

Similarity O
is O
most O
striking O
in O
the O
zinc B-GENE
knuckle I-GENE
region I-GENE
, O
a O
region O
characteristic O
of O
gag B-GENE
genes I-GENE
of O
most O
replication-competent O
retroelements O
. O

The O
up-regulation O
of O
E-selectin B-GENE
, O
one O
of O
the O
adhesion O
molecules O
on O
the O
endothelium O
, O
is O
an O
important O
event O
in O
the O
mediation O
of O
the O
inflammatory O
response O
. O

IGF B-GENE
I I-GENE
and O
insulin B-GENE
receptors I-GENE
are O
homologous O
proteins O
that O
function O
in O
distinct O
physiological O
pathways O
. O

Side O
effect O
including O
subjective O
and O
objective O
symptoms O
were O
strictly O
evaluated O
in O
163 O
cases O
( O
KS-R1 O
group O
in O
83 O
cases O
, O
oral O
group O
in O
80 O
cases O
) O
, O
but O
the O
incidence O
rate O
which O
was O
22 O
. O
9% O
for O
the O
KS-R1 O
group O
and O
23 O
. O
8% O
for O
the O
oral O
group O
showed O
no O
significant O
difference O
. O

Increased O
plasma O
IgE B-GENE
was O
also O
confirmed O
in O
the O
NC O
mice O
, O
and O
treatment O
with O
FK506 O
ointment O
reduced O
the O
plasma O
IgE B-GENE
level O
. O

We O
found O
that O
the O
amplitude O
of O
the O
cortical O
evoked O
potentials O
( O
amplitude O
of O
the O
N2 O
P2 O
peak O
) O
increased O
from O
5 O
. O
1 O
+ O
- O
0 O
. O
7 O
microV O
at O
5 O
mA O
to O
16 O
. O
3 O
+ O
- O
1 O
. O
1 O
microV O
at O
20 O
mA O
. O

Disruption O
of O
RB B-GENE
E2F-1 I-GENE
interaction I-GENE
by O
single O
point O
mutations O
in O
E2F-1 O
enhances B-GENE
S-phase O
entry O
and O
apoptosis O
. O

Ventilatory O
management O
casebook O
. O

Plots O
of O
RV O
, O
LV O
+ O
S O
and O
2A O
weight O
vs O
real O
hematocrit O
showed O
sharp O
upward O
inflections O
at O
real O
hematocrit O
65% O
, O
suggesting O
a O
possible O
role O
of O
increased O
viscosity O
in O
CO O
cardiomegaly O
at O
the O
higher O
hematocrit O
. O

We O
conclude O
that O
DNA O
ploidy O
is O
a O
major O
objective O
prognostic O
factor O
and O
therapeutic O
determinant O
for O
endometrial O
carcinoma O
. O

When O
phosphorylation O
of O
exogenous O
peptide O
substrates O
was O
measured O
as O
a O
function O
of O
receptor O
self-phosphorylation O
, O
tyrosine B-GENE
kinase I-GENE
activity O
was O
found O
to O
be O
enhanced O
two O
to O
threefold O
at O
1-2 O
mol O
of O
phosphate O
per O
mol O
of O
receptor O
. O

It O
is O
exclusively O
observed O
in O
smooth O
muscle O
cells O
by O
Northern O
blotting O
and O
immunohistochemical O
analysis O
and O
therefore O
designated O
"smoothelin B-GENE
. I-GENE
" I-GENE
A O
human O
smooth O
muscle O
cDNA O
library O
was O
screened O
with O
the O
monoclonal B-GENE
antibody I-GENE
R4A I-GENE
, O
and O
a O
full-size O
cDNA O
of O
the O
protein O
was O
selected O
. O

The O
native O
enzyme O
purified O
from O
protease-B-deficient O
URA2-transformed O
cells O
, O
was O
phosphorylated O
in O
vitro O
using O
catalytic O
subunits O
of O
pure O
cAMP-dependent B-GENE
protein I-GENE
kinase I-GENE
. O

Sodium O
polystyrene O
sulfonate O
treatment O
for O
lithium O
toxicity O
: O
effects O
on O
serum O
potassium O
concentrations O
. O

BACKGROUND O
: O
We O
conducted O
a O
phase O
I O
study O
with O
MDL O
73 O
, O
147EF O
, O
a O
new O
5 B-GENE
hydroxytryptamine I-GENE
3 I-GENE
( I-GENE
5-HT3 I-GENE
) I-GENE
receptor I-GENE
antagonist O
, O
in O
25 O
patients O
requiring O
emetogenic O
chemotherapy O
. O

We O
examined O
Akt B-GENE
activation O
in O
Lyn- O
, O
Syk- O
and O
Btk-deficient O
DT40 O
cells O
and O
B O
cells O
from O
Lyn B-GENE
( I-GENE
- I-GENE
- I-GENE
) I-GENE
mice I-GENE
. O

Large O
strain O
differences O
were O
found O
for O
all O
variables O
recorded O
, O
i O
. O
e O
. O
, O
the O
proportion O
of O
attacking O
males O
, O
the O
time O
spent O
in O
the O
brightly O
lit O
box O
, O
and O
the O
number O
of O
transitions O
between O
the O
lit O
and O
the O
dark O
boxes O
. O

During O
ISO+AT O
infusion O
, O
abdominal O
fat O
blood O
flow O
was O
still O
significantly O
increased O
as O
compared O
with O
control O
values O
in O
lean O
and O
obese O
subjects O
. O

Twenty-two O
of O
the O
24 O
patients O
had O
a O
rise O
in O
the O
total O
serum O
amylase B-GENE
following O
ERCP O
. O

MCh O
infusion O
caused O
a O
concentration-dependent O
increase O
in O
airway O
resistance O
at O
constant O
QBA O
. O

We O
obtained O
the O
prevalence O
of O
IgG B-GENE
antibodies I-GENE
against O
Trypanosoma O
cruzi O
among O
1076 O
blood O
donors O
at O
the O
Instituto O
Nacional O
de O
Cardiologia O
"Ignacio O
Chavez" O
in O
Mexico O
City O
. O

In O
particular O
, O
the O
potential O
for O
prostate O
cancer O
chemoprevention O
using O
nonsteroidal O
anti-inflammatory O
drugs O
( O
cyclo-oxygenase B-GENE
inhibitors O
; O
NSAIDs O
) O
has O
received O
little O
attention O
. O

Both O
TRE-like B-GENE
elements I-GENE
were O
capable O
of O
binding O
AP1 B-GENE
. O

Anamnestic O
data O
were O
obtained O
from O
case O
history O
, O
smoking O
habits O
were O
not O
known O
in O
collective O
A O
and O
C O
. O

Using O
a O
conditional-lethal O
mutant O
allele O
of O
SUP45 B-GENE
( O
sup45-2 B-GENE
) O
and O
a O
combination O
of O
in O
vivo O
and O
in O
vitro O
approaches O
, O
we O
demonstrate O
that O
the O
product O
of O
the O
SUP45 B-GENE
gene I-GENE
( O
Sup45p B-GENE
or O
eRF1 B-GENE
) O
is O
a O
factor O
required O
for O
translation O
termination O
in O
yeast O
. O

Large O
differences O
between O
the O
groups O
were O
not O
observed O
in O
HA-synthesizing O
enzyme O
activity O
, O
but O
degradative O
enzyme O
activity O
was O
much O
higher O
in O
aspirin-induced O
asthma-related O
polyps O
than O
in O
other O
types O
of O
nasal O
polyps O
tested O
. O

The O
progression O
of O
non-A O
, O
non-B O
hepatitis O
to O
chronic O
diseases O
, O
and O
the O
transformation O
to O
hepatocellular O
carcinoma O
. O

This O
study O
investigated O
the O
degree O
to O
which O
racial O
identity O
influences O
Mexican-Americans' O
performance O
on O
the O
L O
, O
K O
, O
and O
MF O
scales O
of O
the O
MMPI-2 O
. O

The O
results O
show O
that O
both O
the O
amino O
and O
carboxy O
termini O
of O
the O
NS1 B-GENE
protein I-GENE
molecule I-GENE
and O
the O
cysteines O
at O
residues O
337 O
and O
340 O
are O
essential O
for O
tubule O
formation O
. O

Several O
cytokines O
exhibit O
a O
high O
degree O
of O
temporal O
regulation O
as O
well O
as O
somnogenic O
potency O
( O
e O
. O
g O
. O
, O
interleukin-1 B-GENE
[ B-GENE
IL-1 I-GENE
] I-GENE
, O
tumor B-GENE
necrosis I-GENE
factor-alpha I-GENE
[ B-GENE
TNF-alpha I-GENE
] I-GENE
) O
. O

Effects O
of O
single O
and O
combined O
maltose O
tetrapalmitate O
immunotherapy O
, O
cyclophosphamide O
chemotherapy O
and O
radiotherapy O
on O
ethyl O
carbamate O
accelerated O
primary O
lung O
cancer O
in O
A O
J O
mice O
. O

The O
authors O
evaluate O
the O
clinical O
efficacy O
of O
EMB O
AZS O
in O
recurrent O
ulcer O
after O
operation O
on O
the O
stomach O
caused O
by O
a O
high O
level O
of O
acid O
production O
and O
ulcerative O
gastroduodenal O
bleeding O
. O

Vacuum O
Rabi O
splitting O
as O
a O
feature O
of O
linear-dispersion O
theory O
: O
Analysis O
and O
experimental O
observations O
. O

Successive O
abdominal O
scintillation O
with O
131-I-tagged O
BSP--description O
of O
the O
thyroid O
gland O
, O
kidney O
and O
spleen O
( O
comparison O
with O
131-I-RB O
) O
. O

The O
operation O
recommended O
is O
excision O
of O
3 O
mm O
of O
central O
slip O
followed O
by O
end-to-end O
repair O
of O
the O
tendon O
. O

The O
Scales O
of O
Cognitive O
Impairment O
Rated O
From O
Institutional O
Records O
( O
SCIRFIR O
) O
, O
a O
battery O
based O
on O
commonly O
used O
dementia O
rating O
instruments O
, O
was O
tested O
on O
the O
records O
of O
26 O
chronically O
institutionalized O
, O
elderly O
schizophrenia O
patients O
, O
for O
the O
purpose O
of O
retrospectively O
evaluating O
the O
long-term O
course O
of O
cognitive O
change O
in O
schizophrenia O
and O
relating O
it O
to O
available O
autopsy O
materials O
. O

We O
report O
an O
odd O
case O
of O
marked O
enlargement O
of O
suprapineal O
recess O
in O
a O
patient O
with O
triventricular O
hydrocephalus O
. O

Molecular O
cloning O
and O
characterization O
of O
OsPSK B-GENE
, O
a O
gene O
encoding O
a O
precursor O
for O
phytosulfokine-alpha B-GENE
, O
required O
for O
rice O
cell O
proliferation O
. O

Cross-talking O
among O
Drosophila B-GENE
nuclear I-GENE
receptors I-GENE
at O
the O
promiscuous B-GENE
response I-GENE
element I-GENE
of O
the O
ng-1 B-GENE
and O
ng-2 B-GENE
intermolt I-GENE
genes I-GENE
. O

The O
results O
of O
supershift O
analysis O
using O
specific O
antibodies O
against O
transcription O
factors O
suggested O
that O
both O
binding O
complexes O
contained O
the O
NF-kappaB B-GENE
components O
p50 B-GENE
and O
p65 B-GENE
, O
and O
did O
not O
contain O
other O
NF-kappaB B-GENE
proteins I-GENE
( O
p52 B-GENE
, O
c-Rel B-GENE
, O
Rel B-GENE
B I-GENE
) O
, O
AP-1 B-GENE
proteins I-GENE
( O
c-Fos B-GENE
, O
C-Jun B-GENE
) O
, O
CREB B-GENE
or O
C B-GENE
EBPbeta I-GENE
( I-GENE
NF-IL6 O
) B-GENE
. O

The O
COOH-terminal O
46 O
codons O
of O
slyD B-GENE
encode O
a O
remarkable O
histidine-rich O
peptide O
sequence O
which O
is O
at O
least O
partly O
dispensable O
for O
slyD B-GENE
function O
in O
E-mediated O
lysis O
. O

These O
results O
confirmed O
that O
cleavage O
of O
the O
leader O
peptide O
is O
the O
last O
step O
in O
nisin B-GENE
maturation O
and O
is O
necessary O
to O
generate O
a O
biologically O
active O
peptide O
. O

It O
is O
concluded O
that O
axillo-axillary O
by-pass O
is O
a O
simple O
solution O
for O
a O
complex O
haemodynamic O
, O
clinical O
and O
therapeutic O
problem O
. O

Under O
these O
conditions O
, O
transfections O
with O
cDNAs O
of O
the O
NF-kappa B-GENE
B I-GENE
p50 I-GENE
and O
serum B-GENE
response I-GENE
factor I-GENE
( O
SRF B-GENE
) O
produced O
a O
factor O
( O
s O
) O
that O
mediated O
Tax B-GENE
binding O
to O
the O
NF-kappa B-GENE
B I-GENE
site I-GENE
and O
the O
CArG B-GENE
box I-GENE
respectively O
. O

Here O
we O
report O
that O
Dbp5p B-GENE
and O
Rat7p B-GENE
interact O
through O
their O
Nterminal O
domains O
. O

Comparisons O
with O
the O
available O
amino O
acid O
residue O
( O
aa O
) O
sequence O
information O
from O
the O
complete O
CPMV B-GENE
RNA I-GENE
1 I-GENE
sequence I-GENE
and O
the O
partial O
sequence O
of O
red B-GENE
clover I-GENE
mottle I-GENE
virus I-GENE
RNA I-GENE
1 I-GENE
suggest O
that O
CPSMV B-GENE
RNA I-GENE
1 I-GENE
specifies O
the O
expected O
set O
of O
five O
mature O
proteins O
: O
32K B-GENE
proteinase I-GENE
cofactor I-GENE
, O
58K B-GENE
presumed I-GENE
helicase I-GENE
, O
VPg B-GENE
5'-linked I-GENE
protein I-GENE
of O
the O
genomic O
RNAs O
, O
24K B-GENE
proteinase I-GENE
, O
and O
87K B-GENE
presumed I-GENE
polymerase I-GENE
, O
separated O
by O
four O
cleavage O
sites O
. O

Reverse O
transcriptase-polymerase O
chain O
reaction O
assays O
showed O
that O
PKRDeltaE7 B-GENE
is O
expressed O
in O
a O
broad O
range O
of O
human O
tissues O
at O
variable O
levels O
. O

Two O
mammalian O
enzymes O
, O
the O
haem-controlled B-GENE
repressor I-GENE
( O
HCR B-GENE
) O
and O
the O
double-stranded B-GENE
RNA-activated I-GENE
inhibitor I-GENE
( O
dsI B-GENE
) O
, O
phosphorylate O
Ser-51 O
of O
the O
alpha O
subunit O
, O
thereby O
inhibiting O
the O
exchange O
of O
bound O
nucleotides O
on O
, O
and O
thus O
the O
recycling O
of O
, O
eIF-2 B-GENE
. O

The O
mean O
serum O
creatinine O
levels O
were O
similar O
at O
one O
year O
( O
SPK O
1 O
. O
8 O
, O
KTA O
1 O
. O
9 O
mg O
d O
) O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Urinary O
excretion O
of O
oestrone O
, O
oestradiol-17 O
beta O
and O
oestriol O
in O
pregnancies O
complicated O
by O
steroid B-GENE
sulphatase I-GENE
deficiency O
. O

Although O
a O
great O
deal O
is O
understood O
about O
how O
bHLH B-GENE
factors I-GENE
activate O
gene O
transcription O
via O
E-box O
DNA O
consensus O
sequences O
, O
studies O
of O
bHLH B-GENE
factor I-GENE
function O
in O
higher O
eukaryotes O
often O
have O
been O
hindered O
by O
the O
presence O
of O
multiple O
family O
members O
. O

However O
these O
search O
engines O
respond O
with O
such O
cumbersome O
results O
that O
domain O
specific O
experts O
can O
not O
tolerate O
. O

Previous O
genetic O
studies O
led O
to O
the O
conclusion O
that O
nitrate O
and O
nitrite O
induction O
of O
nasF B-GENE
operon I-GENE
expression O
is O
determined O
by O
a O
transcriptional O
antitermination O
mechanism O
. O

According O
to O
symptoms O
, O
signs O
, O
imaging O
features O
, O
operation O
findings O
, O
the O
original O
places O
and O
the O
expansive O
directions O
of O
the O
tumor O
, O
they O
were O
divided O
into O
four O
clinical O
types O
: O
sellar O
, O
clival O
, O
occipito-temporal O
and O
extent O
. O

ID-PaGIA O
diphtheria B-GENE
toxin I-GENE
polymer O
particle O
diagnostic O
agent O
manufactured O
by O
DiaMed O
AG O
, O
Switzerland O
, O
was O
tried O
at O
bacteriological O
laboratory O
of O
Institute O
of O
Childhood O
Infections O
in O
St O
. O

The O
localization O
of O
ZAP-70 B-GENE
to O
the O
cell O
cortex O
is O
, O
therefore O
, O
regulated O
by O
the O
activity O
of O
SRC-family B-GENE
kinases I-GENE
, O
independently O
of O
their O
ability O
to O
phosphorylate O
immunoreceptor O
tyrosine-based O
activation O
motifs O
of O
the O
TCR B-GENE
. O

Revascularization O
after O
anterior O
maxillary O
and O
mandibular O
osteotomy O
. O

Short-course O
amphotericin O
B O
therapy O
for O
candidemia O
in O
pediatric O
patients O
. O

RESULTS O
: O
Fournier's O
gangrene O
occurs O
worldwide O
. O

Kindling O
of O
the O
primary O
visual O
cortex O
( O
VC O
) O
was O
compared O
with O
that O
of O
the O
amygdala O
in O
cats O
. O

To O
study O
the O
regulation O
of O
its O
expression O
, O
the O
human B-GENE
aldehyde I-GENE
reductase I-GENE
gene I-GENE
and O
promoter O
were O
cloned O
and O
characterized O
. O

Serodiagnosis O
of O
trypanosomiasis O
in O
dromedary O
camels O
using O
a O
card O
agglutination O
test O
set O
( O
Testryp O
CATT O
) O
. O

The O
impact O
of O
social O
support O
on O
the O
relationships O
of O
gay O
male O
couples O
is O
examined O
. O

RESULTS O
: O
The O
bilinear O
model O
provided O
a O
significantly O
better O
fit O
to O
the O
acuity O
outcome O
data O
. O

Atherosclerosis O
. O

Tobacco O
mosaic O
virus-infected O
tobacco O
( O
Nicotiana O
tabacum O
var O
. O

The O
long-term O
prediction O
is O
based O
on O
an O
algorithm O
for O
R-R O
interval O
estimation O
. O

Despite O
these O
limitations O
the O
CHIME O
monitor O
provides O
an O
opportunity O
to O
record O
physiological O
data O
previously O
unavailable O
in O
the O
home O
. O

Diffuse O
white O
matter O
injury O
can O
be O
attributed O
to O
radiation O
and O
associated O
with O
neurological O
deficits O
, O
but O
leukoencephalopathy O
is O
rarely O
observed O
in O
the O
absence O
of O
chemotherapy O
. O

The O
biology O
of O
Hyostrongylus O
ruidus O
. O

This O
observation O
cannot O
be O
explained O
by O
the O
scanning O
model O
for O
ribosomal O
initiation O
and O
suggests O
that O
ribosomes O
may O
be O
binding O
directly O
at O
an O
internal O
mRNA O
site O
at O
or O
near O
the O
initiator O
AUG O
codon O
for O
the O
C B-GENE
protein I-GENE
. O

Several O
new O
techniques O
are O
available O
for O
monitoring O
control O
of O
diabetes O
. O

Static O
and O
dynamic O
compliance O
was O
measured O
after O
induction O
of O
anesthesia O
, O
before O
and O
immediately O
after O
filtration O
in O
the O
operating O
theater O
, O
1 O
hour O
after O
return O
to O
the O
pediatric O
intensive O
care O
unit O
, O
and O
24 O
hours O
after O
the O
operation O
. O

Large O
ones O
were O
similar O
in O
size O
to O
the O
main O
lobe O
and O
small O
ones O
were O
approximately O
1 O
4 O
of O
the O
length O
of O
the O
main O
lobe O
. O

Two O
families O
with O
concordant O
inheritance O
of O
DNAH9 B-GENE
alleles I-GENE
in O
affected O
individuals O
were O
observed O
. O

Serum B-GENE
IgM I-GENE
and O
IgE B-GENE
concentrations O
, O
allergen-specific B-GENE
IgE I-GENE
scores O
, O
and O
the O
tumor O
E2R B-GENE
status O
were O
combined O
to O
construct O
a O
three-level O
risk O
classification O
that O
was O
more O
prognostic O
than O
any O
of O
the O
individual O
components O
. O

Hyperprolactinaemia O
, O
moderate O
hypogonadism O
, O
infraclinical O
neuropathies O
, O
arterial O
stenoses O
and O
moderate O
venous O
leakages O
seem O
to O
play O
a O
partial O
role O
of O
organic O
starter O
or O
cofactor O
, O
the O
sexual O
consequences O
of O
which O
are O
amplified O
by O
psychological O
factors O
, O
partly O
secondary O
to O
the O
initial O
sexual O
failures O
. O

The O
resurgence O
of O
drug-resistant O
malaria O
makes O
urgent O
the O
evaluation O
of O
new O
antimalarial O
agents O
. O

The O
spectrum O
of O
phenotypes O
caused O
by O
these O
mutations O
was O
strikingly O
different O
than O
mutations O
in O
the O
adaptor O
for O
the O
VP16 B-GENE
activation I-GENE
domain I-GENE
. O

CONCLUSIONS O
: O
Congenital O
horizontal O
tarsal O
kink O
is O
rare O
and O
its O
cause O
is O
unknown O
. O

The O
transforming O
gene O
of O
the O
avian B-GENE
sarcoma I-GENE
virus I-GENE
CT10 I-GENE
encodes O
a O
fusion O
protein O
( O
p47gag-crk B-GENE
or O
v-Crk B-GENE
) O
containing O
viral B-GENE
Gag I-GENE
sequences I-GENE
fused O
to O
cellular O
sequences O
consisting O
primarily O
of O
Src B-GENE
homology I-GENE
regions I-GENE
2 I-GENE
and I-GENE
3 I-GENE
( O
SH2 B-GENE
and O
SH3 B-GENE
sequences I-GENE
) O
. O

It O
is O
likely O
that O
other O
pathways O
involve O
alternate O
signal O
transduction O
events O
( O
e O
. O
g O
. O
, O
calcium O
mobilization O
) O
and O
promoter O
response O
elements O
( O
e O
. O
g O
. O
, O
SRE O
) O
. O

Their O
studies O
have O
revealed O
a O
considerable O
increase O
of O
CSF B-GENE
AP I-GENE
activity O
in O
purulent O
meningitides O
whereas O
in O
serous O
meningitides O
it O
grows O
negligibly O
. O

The O
ORF3 O
probe O
also O
hybridized O
to O
a O
540 O
bp O
transcript O
consistent O
with O
the O
size O
of O
ORF3 O
alone O
and O
supportive O
of O
the O
mutagenesis O
data O
of O
non-linkage O
. O

In O
these O
cases O
, O
greatly O
increased O
human B-GENE
chorionic I-GENE
gonadotropin I-GENE
( O
hCG B-GENE
) O
levels O
and O
suppressed O
TSH B-GENE
levels O
suggest O
that O
hCG B-GENE
has O
thyrotropic O
activity O
. O

Disturbance O
of O
regeneration O
in O
the O
above O
pathological O
condition O
results O
from O
the O
damage O
to O
tunica O
propria O
and O
loss O
of O
its O
function O
for O
the O
support O
of O
structural O
homeostasis O
. O

However O
, O
a O
correlation O
was O
observed O
between O
SF O
levels O
of O
IL-8 B-GENE
with O
those O
of O
lactate O
, O
LDH B-GENE
, O
beta B-GENE
2-microglobulin I-GENE
and O
glucose O
. O

The O
recently O
developed O
gamma-interferon B-GENE
( O
IFN-gamma B-GENE
) O
assay O
system O
for O
the O
diagnosis O
of O
bovine O
tuberculosis O
in O
cattle O
has O
been O
accredited O
by O
the O
Standing O
Committee O
on O
Agriculture O
for O
use O
in O
Australia O
. O

Substrates O
for O
p210 B-GENE
( I-GENE
bcr-abl I-GENE
) I-GENE
are O
likely O
to O
be O
involved O
in O
the O
pathogenesis O
of O
CML O
. O

Comparison O
of O
cDNA O
sequences O
revealed O
that O
the O
two O
mRNA O
species O
arise O
as O
a O
result O
of O
alternate O
use O
of O
poly O
( O
A O
) O
-addition O
sites O
. O

Polyprotein O
processing O
in O
Southampton O
virus O
: O
identification O
of O
3C-like B-GENE
protease I-GENE
cleavage O
sites O
by O
in O
vitro O
mutagenesis O
. O

Assay O
of O
serum B-GENE
immunoreactive I-GENE
trypsin I-GENE
in O
dried O
blood O
spots O
and O
the O
early O
detection O
of O
cystic O
fibrosis O
. O

Reliability O
of O
cervical O
range O
of O
motion O
using O
the O
OSI O
CA O
6000 O
spine O
motion O
analyser O
on O
asymptomatic O
and O
symptomatic O
subjects O
. O

Implications O
of O
this O
observation O
for O
pediatrics O
are O
discussed O
. O

At O
some O
sites O
, O
%T O
is O
greatly O
increased O
by O
Cl- O
concentrations O
up O
to O
1 O
M O
, O
while O
at O
other O
sites O
%T O
is O
reduced O
or O
unaffected O
by O
these O
conditions O
. O

Northern O
blot O
analysis O
demonstrated O
the O
ubiquitous O
expression O
of O
2 O
. O
9 O
kb O
and O
3 O
. O

Objective O
responses O
also O
occurred O
in O
studies O
that O
explored O
sequential O
use O
of O
exemestane O
after O
failure O
of O
aminoglutethimide O
( O
26% O
with O
exemestane O
200 O
mg O
day O
) O
or O
other O
nonsteroidal O
aromatase O
inhibitors B-GENE
( O
6 O
. O
6% O
with O
exemestane O
25 O
mg O
day O
) O
. O

Thus O
, O
sgRNA2 B-GENE
has O
the O
3'TE B-GENE
in O
its O
5' O
UTR O
. O

Such O
a O
concept O
is O
crucial O
to O
our O
understanding O
of O
the O
pathology O
of O
ageing O
in O
general O
. O

After O
the O
application O
of O
RS O
86 O
, O
REM O
latency O
was O
shortened O
in O
all O
groups O
under O
investigation O
. O

Two O
additional O
cis-acting O
sequences O
, O
conserved O
in O
both O
the O
region O
1 O
and O
3 O
promoters O
, O
were O
identified O
, O
suggesting O
a O
role O
for O
these O
sequences O
in O
the O
coordinate O
regulation O
of O
transcription O
from O
these O
promoters O
. O

BRCA1 B-GENE
, O
a O
familial O
breast O
and O
ovarian O
cancer O
susceptibility O
gene O
encodes O
nuclear O
phosphoproteins O
that O
function O
as O
tumor O
suppressors O
in O
human O
breast O
cancer O
cells O
. O

A O
high O
efficacy O
of O
the O
combined O
use O
of O
nontoxic O
doses O
of O
two O
pharmaceuticals O
: O
cystamine O
( O
50 O
mg O
kg O
) O
and O
mexamine O
( O
25 O
mg O
kg O
) O
under O
the O
conditions O
of O
short-term O
exogenous O
hypoxia O
( O
7 O
. O
5% O
O2 O
) O
was O
found O
in O
( O
CBA O
X O
C57Bl O
) O
F1 O
mice O
. O

In O
contrast O
, O
both O
Sp1 B-GENE
and O
ETS B-GENE
proteins I-GENE
are O
required O
to O
bring O
about O
full O
promoter O
activity O
in O
the O
Surf-1 B-GENE
direction O
. O

The O
epidemic O
occurred O
in O
a O
group O
of O
26 O
community O
members O
( O
23 O
men O
and O
3 O
women O
, O
mean O
age O
, O
28 O
. O
9--3 O
years O
) O
living O
and O
working O
together O
, O
who O
underwent O
acute O
and O
convalescent O
serologic O
tests O
for O
Mycoplasma O
pneumoniae O
, O
Legionella O
pneumophila O
, O
cytomegalovirus O
, O
adenovirus O
, O
Coxiella O
burnetii O
, O
and O
Chlamydia O
pneumoniae O
. O

We O
found O
strand O
selective O
repair O
in O
DNA O
fragments O
within O
two O
active O
genes O
, O
DHFR B-GENE
and O
an O
unknown O
gene O
adjacent O
to O
DHFR B-GENE
. O

Six O
( O
four O
FAP O
; O
two O
primary O
amyloidosis O
) O
also O
had O
diffusely O
positive O
myocardial O
uptakes O
, O
but O
the O
intensity O
was O
less O
than O
that O
of O
the O
sternum O
. O

The O
minimum O
inhibitory O
concentrations O
( O
MICs O
) O
of O
ketoconazole O
, O
miconazole O
, O
itraconazole O
, O
fluconazole O
, O
and O
amphotericin O
B O
were O
significantly O
influenced O
by O
the O
inoculum O
size O
, O
regardless O
of O
the O
techniques O
used O
. O

The O
major O
phenotypes O
resulting O
from O
Fab1p B-GENE
kinase I-GENE
inactivation O
include O
temperature-sensitive O
growth O
, O
vacuolar O
acidification O
defects O
, O
and O
dramatic O
increases O
in O
vacuolar O
size O
. O

These O
results O
demonstrate O
Ras- O
and O
Raf-independent O
ERK B-GENE
MAPK I-GENE
activation O
maintains O
cell O
viability O
following O
heat O
shock O
. O

Initial O
control O
of O
bleeding O
is O
similar O
, O
but O
eradication O
is O
achieved O
in O
fewer O
sessions O
with O
EVL O
. O

Naloxone O
( O
2 O
mg O
kg O
bolus O
+ O
2 O
mg O
X O
kg-1 O
X O
h-1 O
) O
was O
given O
with O
one O
of O
the O
two O
doses O
of O
the O
lipopolysaccharide O
. O

Moreover O
, O
a O
complex O
containing O
PTP B-GENE
phi I-GENE
, O
paxillin B-GENE
, O
and O
a O
paxillin-associated B-GENE
tyrosine I-GENE
kinase I-GENE
, O
Pyk2 B-GENE
, O
can O
be O
immunoprecipitated O
from O
macrophage O
lysates O
, O
and O
the O
catalytic O
domain O
of O
PTP B-GENE
phi I-GENE
selectively O
binds O
paxillin B-GENE
and O
Pyk2 B-GENE
in O
vitro O
. O

Action O
of O
strontium-90 O
and O
metaphos O
on O
Cyprinus O
carpio O
. O

In O
the O
pRb B-GENE
( I-GENE
- I-GENE
) I-GENE
SAOS-2 O
cell O
line O
transiently O
transfected O
with O
a O
reporter O
plasmid O
containing O
six O
tal-1 B-GENE
binding I-GENE
site I-GENE
, O
pRb B-GENE
enhances O
the O
transcriptional O
activity O
of O
tal-1-E12-Lmo2 B-GENE
and O
tal-1-E12-Lmo2-Ldb1 B-GENE
complexes I-GENE
but O
not O
that O
of O
a O
tal-1-E12 B-GENE
heterodimer I-GENE
. O

The O
flux O
rates O
of O
p-toluidine O
decreased O
as O
the O
pH O
value O
in O
the O
donor O
solution O
increased O
. O

Using O
immunochemical O
co-precipitation O
methods O
, O
we O
also O
found O
that O
the O
two O
proteins O
are O
bound O
in O
vivo O
. O

Transcription O
start O
site O
mapping O
identified O
the O
presence O
of O
an O
aphidicolin-sensitive O
late O
transcript O
arising O
from O
a O
TAAG B-GENE
motif I-GENE
located O
at O
-352 O
nucleotides O
and O
an O
aphidicolin-insensitive O
early O
transcript O
originating O
from O
a O
TTGT B-GENE
motif I-GENE
located O
35 O
nucleotides O
downstream O
to O
a O
TATA O
box O
at O
-312 O
nucleotides O
, O
with O
respect O
to O
the O
+1 O
ATG O
of O
lef2 B-GENE
. O

Anesthesiologists O
often O
use O
more O
than O
one O
drug O
in O
a O
patient O
to O
achieve O
a O
target O
response O
, O
such O
as O
a O
desired O
blood O
pressure O
. O

Aneurysmectomy O
and O
the O
performance O
of O
CABG O
were O
not O
significantly O
associated O
with O
postoperative O
ECG O
changes O
, O
but O
more O
bypass O
grafts O
per O
patient O
grafted O
appeared O
in O
the O
group O
with O
postoperative O
ECG O
changes O
, O
suggesting O
that O
coronary O
artery O
disease O
may O
be O
more O
severe O
in O
that O
group O
. O

The O
average O
values O
were O
199 O
and O
424 O
revertants O
g O
for O
the O
hamburgers O
and O
hot O
dogs O
, O
respectively O
. O

Of O
208 O
eligible O
subjects O
, O
82 O
received O
supervised O
IPT O
at O
a O
dose O
of O
900 O
mg O
twice O
weekly O
for O
6 O
mo O
( O
Regimen O
A O
) O
, O
73 O
received O
unsupervised O
IPT O
900 O
mg O
twice O
weekly O
for O
6 O
mo O
( O
Regimen O
B O
) O
, O
and O
53 O
received O
unsupervised O
IPT O
300 O
mg O
daily O
for O
6 O
mo O
( O
Regimen O
C O
) O
. O

We O
demonstrate O
that O
a O
VT+ O
peptide O
was O
specifically O
phosphorylated O
by O
protein B-GENE
kinase I-GENE
C I-GENE
( O
PKC B-GENE
) O
in O
vitro O
, O
but O
not O
by O
protein B-GENE
kinase I-GENE
A I-GENE
( O
PKA B-GENE
) O
. O

Plasma O
and O
erthrocyte O
lipid O
profile O
and O
lipoprotein B-GENE
lipase I-GENE
activity O
in O
postheparin O
plasma O
on O
vasectomized O
rabbits O
were O
studied O
and O
also O
the O
incidence O
of O
atherosclerosis O
in O
different O
arterial O
beds O
. O

Treatment O
of O
meat O
muscle O
800 O
V O
for O
45 O
s O
reduced O
weeping O
but O
increased O
slightly O
the O
rate O
of O
autoxidation O
of O
lipids O
. O

The O
single-stranded O
DNA O
Pur B-GENE
alpha I-GENE
recognition I-GENE
element I-GENE
disrupts O
these O
complexes O
. O

Our O
data O
provide O
a O
biochemical O
explanation O
for O
the O
similarity O
in O
phenotype O
between O
A-T O
and O
NBS O
. O

The O
role O
of O
calcitonin B-GENE
, O
and O
other O
agonists O
which O
activate O
the O
cAMP O
pathway O
, O
in O
regulating O
transcription O
of O
the O
human B-GENE
parathyroid I-GENE
hormone-related I-GENE
protein I-GENE
( O
PTHrP B-GENE
) O
gene O
was O
investigated O
in O
a O
human O
lung O
cancer O
cell O
line O
( O
BEN O
) O
. O

The O
extended O
rat B-GENE
SP-A I-GENE
isoforms I-GENE
were O
enriched O
in O
the O
more O
fully O
glycosylated O
and O
multimeric O
SP-A B-GENE
species O
separated O
on O
SDS-PAGE O
gels O
. O

PATIENTS O
AND O
METHODS O
: O
We O
report O
our O
experience O
with O
seven O
children O
with O
active O
small O
bowel O
Crohn's O
disease O
given O
a O
casein-based O
, O
polymeric O
feed O
rich O
in O
TGF-beta B-GENE
2 I-GENE
( O
Specific O
Polymeric O
Diet O
; O
Nestle-Clintec O
; O
Vevey O
, O
Switzerland O
) O
as O
complete O
nutrition O
for O
8 O
weeks O
. O

The O
action O
of O
nef O
was O
specific O
to O
the O
LTR O
, O
as O
expression O
of O
nef B-GENE
had O
no O
effect O
on O
the O
activity O
of O
the O
simian O
virus O
40 O
, O
c-fms B-GENE
, O
urokinase B-GENE
plasminogen I-GENE
activator I-GENE
, O
or O
type B-GENE
5 I-GENE
acid I-GENE
phosphatase I-GENE
promoter I-GENE
. O
trans-activating O
activity O
was O
also O
manifested O
by O
a O
frameshift O
mutant O
expressing O
only O
the O
first O
35 O
amino O
acids O
of O
the O
protein O
. O

Kf O
, O
c O
and O
CT O
( O
referenced O
to O
the O
initial O
lung O
mass O
) O
decreased O
linearly O
with O
reductions O
in O
lung O
mass O
% O
delta O
Kf O
, O
c O
= O
1 O
. O
26-0 O
. O
98% O
mass O
removed O
( O
r O
= O
0 O
. O
90 O
, O
P O
less O
than O
0 O
. O
01 O
) O
and O
% O
delta O
CT O
= O
-3 O
. O
99-0 O
. O
98% O
mass O
removed O
( O
r O
= O
0 O
. O
82 O
, O
P O
less O
than O
0 O
. O
01 O
) O
relationships O
that O
were O
not O
altered O
by O
blocker O
pretreatment O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

During O
1985 O
, O
1990 O
, O
and O
1995 O
, O
respectively O
, O
11 O
. O
7 O
, O
11 O
. O
3 O
, O
and O
11 O
. O
4 O
infants O
per O
100 O
, O
000 O
live O
births O
had O
a O
diagnosis O
of O
HSV O
( O
P O
= O
. O
98 O
) O
. O

The O
Wilms' B-GENE
tumour I-GENE
suppressor I-GENE
protein I-GENE
( O
WT1 B-GENE
) O
is O
a O
putative O
transcriptional O
regulatory O
protein O
with O
four O
zinc O
fingers O
, O
the O
last O
three O
of O
which O
have O
extensive O
sequence O
homology O
to O
the O
early B-GENE
growth I-GENE
response-1 I-GENE
( O
EGR-1 B-GENE
) O
protein O
. O

This O
study O
demonstrates O
secretion O
of O
bicarbonate O
by O
the O
human O
stomach O
in O
vivo O
at O
a O
rate O
equivalent O
to O
10--20% O
of O
basal O
acid O
secretion O
. O

Commonly O
observed O
systemic O
toxic O
effects O
( O
bone O
marrow O
, O
gastrointestinal O
tract O
, O
and O
heart O
) O
were O
not O
seen O
in O
this O
study O
. O

Correlating O
with O
the O
previous O
observation O
that O
CBF B-GENE
binding O
to O
the O
78C1 O
site O
is O
enhanced O
by O
EGTA O
and O
EDTA O
, O
these O
divalent O
cation O
chelators O
specifically O
stimulate O
78C1-directed O
transcription O
. O

At O
pH O
6 O
. O
9 O
, O
the O
same O
lidocaine O
concentrations O
significantly O
reduced O
resting O
potential O
( O
3-10% O
) O
, O
action O
potential O
amplitude O
( O
3-8% O
) O
and O
Vmax O
( O
14-22% O
) O
. O

The O
methylation O
of O
nuclear O
and O
chloroplast O
DNAs O
has O
been O
examined O
in O
relation O
to O
the O
known O
differential O
expression O
of O
C4 B-GENE
photosynthesis I-GENE
genes I-GENE
in O
the O
bundle O
sheath O
and O
mesophyll O
cells O
of O
etiolated O
, O
greening O
, O
and O
fully O
green O
maize O
leaves O
. O

Marinol O
marijuana O
usage O
was O
associated O
with O
depressed O
CD4+ O
counts B-GENE
and O
elevated O
amylase O
levels B-GENE
within O
the O
DDI O
subgroup O
. O

Two O
Pax2 B-GENE
5 I-GENE
8-binding I-GENE
sites I-GENE
in I-GENE
Engrailed2 I-GENE
are O
required B-GENE
for O
proper O
initiation O
of O
endogenous O
mid-hindbrain O
expression O
. O

The O
SH3 B-GENE
domains I-GENE
of O
Grb2 B-GENE
bound O
in O
vitro O
to O
specific O
proline-rich O
motifs O
in O
the O
HPK1 B-GENE
tail O
and O
functioned O
synergistically O
to O
direct O
the O
stable O
binding O
of O
Grb2 B-GENE
to O
HPK1 B-GENE
in O
transfected O
Cos1 O
cells O
. O

An O
approximately O
37-kDa O
cytoplasmic O
protein O
is O
rapidly O
tyrosine-phosphorylated O
in O
the O
response O
of O
mouse O
BAC1 O
. O
2F5 O
macrophages O
to O
colony B-GENE
stimulating I-GENE
factor-1 I-GENE
( O
CSF-1 B-GENE
) O
. O
pp37 B-GENE
was O
purified O
from O
the O
cytosolic O
fraction O
by O
anti-Tyr B-GENE
( I-GENE
P I-GENE
) I-GENE
affinity O
chromatography O
, O
size O
exclusion O
chromatography O
, O
and O
C4 O
reverse O
phase O
high O
pressure O
liquid O
chromatography O
. O

The O
immunophilin B-GENE
, O
which O
can O
be O
of O
the O
FK506- O
or O
cyclosporin O
A-binding O
class O
, O
binds O
to O
hsp90 B-GENE
via O
its O
tetratricopeptide O
repeat O
( O
TPR O
) O
domain O
, O
and O
different O
receptor O
heterocomplexes O
exist O
depending O
upon O
which O
immunophilin B-GENE
occupies O
the O
TPR-binding B-GENE
region I-GENE
of O
hsp90 B-GENE
. O

Cocaine-treated O
rats O
acquired O
a O
preference O
for O
cocaine-associated O
contextual O
stimuli O
( O
CS O
) O
relative O
to O
saline-injected O
control O
rats O
. O

Primer O
extension O
and O
S1 B-GENE
nuclease I-GENE
mapping O
experiments O
were O
used O
to O
locate O
the O
transcription O
initiation O
site O
of O
Nramp1 B-GENE
and O
revealed O
the O
presence O
of O
one O
major O
and O
several O
minor O
initiation O
sites O
. O

Feeding O
behavior O
, O
circannual O
body O
weight O
and O
hibernation O
rhythms O
in O
European O
hamsters O
lesioned O
in O
the O
noradrenergic O
ascending O
bundles O
. O

Double-blind O
, O
placebo-controlled O
trial O
. O

We O
have O
identified O
two O
overlapping O
expressed O
sequence O
tag O
clones O
, O
which O
contain O
the O
missing O
4 O
. O
4-kb O
3'-UTR O
of O
the O
human B-GENE
D2 I-GENE
( O
hD2 B-GENE
) O
cDNA O
. O

Eight O
induced O
cDNA O
sequences O
were O
identified O
and O
designated O
message B-GENE
up-regulated I-GENE
during I-GENE
death I-GENE
( O
mud B-GENE
) O
-1-8 O
. O

Several O
highly O
conserved O
regions O
were O
identified O
at O
the O
near O
N O
terminus O
, O
middle O
and O
C O
terminus O
. O

S O
. O
, O
K O
. O

Aryl B-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
translocator I-GENE
( O
ARNT B-GENE
) O
is O
a O
component O
of O
the O
transcription O
factors O
, O
aryl B-GENE
hydrocarbon I-GENE
receptor I-GENE
( O
AhR B-GENE
) O
and O
hypoxia-inducible B-GENE
factor I-GENE
1 I-GENE
, O
which O
transactivate O
their O
target O
genes O
, O
such O
as O
CYP1A1 B-GENE
and O
erythropoietin B-GENE
, O
in O
response O
to O
xenobiotic O
aromatic O
hydrocarbons O
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

Deletion O
and O
mutational O
analyses O
revealed O
two O
positive O
cis-regulatory O
elements O
in O
this O
region O
that O
are O
essential O
for O
CSX1 B-GENE
expression O
in O
cardiomyocytes O
. O

This O
mechanism O
is O
in O
contrast O
to O
other O
cases O
of O
splicing O
regulation O
by O
PTB B-GENE
, O
in O
which O
the O
protein O
represses O
the O
splice O
site O
to O
which O
it O
binds O
. O

Time O
shifts O
increase O
growth B-GENE
hormone I-GENE
release O
. O

The O
pharmacological O
effects O
of O
the O
novel O
compound O
WEB O
1881 O
FU O
( O
4-amino-methyl-1-benzyl-pyrrolidine-2-one-fumarate O
) O
were O
investigated O
. O

Phenazone O
potentiates O
the O
local O
anaesthetic O
effect O
of O
lidocaine O
in O
mice O
. O

Salzburg O
, O
9-12 O
September O
1987 O
. O

There O
was O
a O
trend O
in O
all O
studies O
favouring O
PVI O
. O

Estimation O
of O
L-alanine O
in O
serum O
or O
plasma O
using O
the O
LKB O
reaction O
rate O
analyser O
. O

We O
have O
carried O
out O
a O
comprehensive O
and O
systematic O
mutagenesis O
of O
the O
Cse4p B-GENE
N I-GENE
terminus I-GENE
to O
analyze O
its O
function O
. O

On O
the O
diagnosis O
of O
bovine O
leucosis O
and O
its O
control O
in O
southern O
Lower O
Saxony O
. O

HL-A B-GENE
antibodies I-GENE
in O
polytransfused O
patients O
. O

Analysis O
of O
cell O
cycle O
regulation O
in O
the O
budding O
yeast O
Saccharomyces O
cerevisiae O
has O
shown O
that O
a O
central O
regulatory O
protein B-GENE
kinase I-GENE
, O
Cdc28 B-GENE
, O
undergoes O
changes O
in O
activity O
through O
the O
cell O
cycle O
by O
associating O
with O
distinct O
groups O
of O
cyclins B-GENE
that O
accumulate O
at O
different O
times O
. O

Ischaemia O
was O
induced O
by O
a O
low O
flow O
rate O
of O
0 O
. O
8 O
mL O
min-1 O
for O
30 O
min O
, O
and O
was O
followed O
by O
a O
40-minute O
reperfusion O
. O

They O
also O
indicate O
that O
direct O
interactions O
between O
C B-GENE
EBPs I-GENE
and I-GENE
specific O
Ets O
family B-GENE
members O
, O
together O
with O
GATA-1 O
, B-GENE
are O
important O
for O
eosinophil O
lineage O
determination O
. O

To O
understand O
the O
molecular O
regulation O
of O
these O
genes O
in O
thyroid O
cells O
, O
the O
effect O
of O
thyroid B-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
TTF-1 B-GENE
) O
and O
the O
paired B-GENE
domain-containing I-GENE
protein I-GENE
8 I-GENE
( O
Pax-8 B-GENE
) O
on O
the O
transcriptional O
activity O
of O
the O
deiodinase B-GENE
promoters I-GENE
were O
studied O
. O

To O
begin O
to O
understand O
this O
role O
, O
we O
overexpressed O
ATF-2 B-GENE
in O
a O
human O
cancer O
cell O
line O
. O

CD O
was O
determined O
using O
the O
Farnsworth O
D-15 O
method O
. O

During O
insulin B-GENE
infusion O
, O
a O
20% O
dextrose O
solution O
was O
infused O
by O
a O
Biostator O
in O
order O
to O
maintain O
the O
patient's O
glycemia O
at O
90 O
mg O
dl O
. O

An O
approximately O
2-kilobase O
B2 O
transcript O
was O
expressed O
in O
all O
alfalfa O
organs O
tested O
. O

Doxorubicin O
, O
dacarbazine O
, O
vincristine O
, O
and O
cyclophosphamide O
in O
the O
treatment O
of O
advanced O
gastrointestinal O
leiomyosarcoma O
. O

A O
cohort O
of O
Swedish O
children O
was O
monitored O
from O
6 O
months O
to O
11 O
years O
of O
age O
. O

We O
provide O
community O
metabolic O
data O
that O
indicate O
that O
large O
changes O
in O
CO2 O
concentration O
can O
occur O
in O
coral O
reef O
waters O
via O
biogeochemical O
processes O
not O
directly O
associated O
with O
photosynthesis O
, O
respiration O
, O
calcification O
, O
and O
CaCO3 O
dissolution O
. O

Effect O
of O
aging O
on O
respiratory O
skeletal O
muscles O
. O

Mutational O
analysis O
of O
yeast B-GENE
CEG1 I-GENE
demonstrated O
that O
four O
of O
the O
five O
conserved O
motifs O
are O
essential O
for O
capping O
enzyme O
function O
in O
vivo O
. O

Chronic O
hypophosphatemia O
is O
the O
most O
common O
type O
of O
"resistant" O
rickets O
. O

Abbreviations O
: O
CAS B-GENE
, O
CRK-associated B-GENE
substrate I-GENE
; O
CH B-GENE
, O
calponin-homology B-GENE
domain I-GENE
; O
CSK B-GENE
, O
C-terminal B-GENE
SRC I-GENE
kinase I-GENE
; O
E6 B-GENE
, O
Papillomavirus B-GENE
E6 I-GENE
protein I-GENE
; O
FAK B-GENE
, O
focal B-GENE
adhesion I-GENE
kinase I-GENE
; O
GIT B-GENE
, O
GRK B-GENE
interacter I-GENE
; O
GPCR B-GENE
, O
heterotrimeric-G-protein-coupled B-GENE
receptor I-GENE
; O
GRK B-GENE
, O
G-protein-coupled-receptor B-GENE
kinase I-GENE
; O
MAPK B-GENE
, O
mitogen-activated B-GENE
protein I-GENE
kinase I-GENE
( O
ERK B-GENE
, O
p38 B-GENE
, O
JNK B-GENE
) O
; O
PAK B-GENE
, O
p21-activated B-GENE
kinase I-GENE
; O
PBS B-GENE
, O
paxillin-binding B-GENE
subdomain I-GENE
; O
PIX B-GENE
, O
PAK-interacting B-GENE
exchange I-GENE
factor I-GENE
; O
PKL B-GENE
, O
paxillin B-GENE
kinase I-GENE
linker I-GENE
; O
POR1 B-GENE
, O
partner B-GENE
of I-GENE
Rac I-GENE
; O
PS O
, O
phosphoserine O
; O
PT O
, O
phosphothreonine O
; O
PY O
, O
phosphotyrosine O
; O
RTK B-GENE
, O
growth B-GENE
factor I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
; O
SH B-GENE
, O
SRC-homology B-GENE
domain I-GENE
. O

We O
have O
identified O
SWI5's O
nuclear O
localization O
signal O
( O
NLS O
) O
and O
show O
that O
it O
can O
confer O
cell O
cycle-dependent O
nuclear O
entry O
to O
a O
heterologous O
protein O
. O

We O
found O
that O
PML B-GENE
was O
expressed O
at O
a O
lower O
level O
in O
S O
, O
G2 O
, O
and O
M O
phases O
and O
at O
a O
significantly O
higher O
level O
in O
G1 O
phase O
. O

Electroglottography O
is O
a O
useful O
, O
non-invasive O
technique O
that O
can O
assist O
in O
the O
assessment O
of O
vocal O
fold O
dysfunction O
. O

The O
three-dimensional O
structure O
of O
RT B-GENE
shows O
that O
it O
is O
a O
strikingly O
asymmetric O
heterodimer O
consisting O
of O
two O
differently O
folded O
subunits O
( O
molecular O
weights O
66 O
kDa O
and O
51 O
kDa O
) O
with O
identical O
amino-terminal O
amino O
acid O
sequences O
( O
residues O
1-428 O
) O
. O

Metformin O
plasma O
concentrations O
remained O
unchanged O
except O
for O
patients O
transferred O
from O
1 O
. O
5 O
to O
2 O
. O
0 O
g O
daily O
to O
850 O
mg O
twice O
daily O
; O
in O
these O
patients O
plasma O
concentrations O
increased O
from O
1 O
. O
83 O
+ O
- O
0 O
. O
87 O
to O
2 O
. O
50 O
+ O
- O
0 O
. O
89 O
micrograms O
l O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

From O
the O
National O
Institutes O
of O
Health O
. O

The O
TYAC O
P1 O
resource O
, O
derivative O
STSs O
, O
and O
polymorphisms O
constitute O
an O
enabling O
resource O
to O
further O
studies O
of O
telomere O
structure O
and O
function O
and O
a O
means O
for O
physical O
and O
genetic O
map O
integration O
and O
closure O
. O

One O
complex O
most O
likely O
contained O
Sp1 B-GENE
, O
and O
another O
complex O
showed O
S-phase-specific O
binding O
, O
suggesting O
a O
direct O
role O
in O
the O
cell-cycle-dependent O
R1 B-GENE
gene I-GENE
expression O
. O

This O
points O
to O
a O
specific O
interference O
with O
HSV-induced O
DNA O
amplification O
. O

The O
cell O
cycle-regulated O
transcription O
factor O
E2F B-GENE
is O
also O
known O
to O
bend O
DNA O
upon O
binding O
. O

In O
11 O
patients O
with O
Horton's O
headache O
morphological O
investigations O
( O
differential O
white O
blood O
cell O
count O
) O
, O
cytoenzymatic O
determinations O
( O
alkaline B-GENE
and I-GENE
acid I-GENE
phosphatase I-GENE
, O
non-specific B-GENE
esterase I-GENE
) O
and O
cytoimmunological O
tests O
( O
IgM B-GENE
and O
IgG B-GENE
binding O
) O
were O
carried O
out O
on O
capillary O
blood O
neutrophils O
obtained O
from O
the O
area O
of O
pain O
, O
non-painful O
area O
of O
the O
skin O
on O
the O
head O
on O
the O
contralateral O
side O
, O
and O
from O
the O
finger O
. O

The O
oxygen O
uptake O
( O
VO2 O
) O
, O
carbon O
dioxide O
output O
( O
VCO2 O
) O
, O
respiratory O
rate O
( O
fR O
) O
, O
minute O
ventilation O
( O
VE O
) O
, O
alveolar O
ventilation O
( O
VA O
) O
, O
alveolar O
oxygen O
pressure O
( O
PAO2 O
) O
, O
and O
VE O
VO2 O
ratio O
were O
higher O
in O
the O
cows O
, O
while O
the O
tidal O
volume O
( O
VT O
) O
and O
physiological O
dead O
space O
( O
VD O
) O
were O
larger O
in O
the O
horses O
. O

Two O
cDNAs O
encoding O
casein B-GENE
kinase-1 I-GENE
have O
been O
isolated O
from O
a O
yeast O
cDNA O
library O
and O
termed O
CKI1 B-GENE
and O
CKI2 B-GENE
. O

The O
RAP74 B-GENE
subunit I-GENE
of O
TFIIF B-GENE
alone O
contained O
the O
stimulatory O
activity O
and O
the O
minimal O
region O
sufficient O
for O
stimulation O
corresponds O
to O
COOH-terminal O
residues O
358-517 O
. O

These O
observations O
of O
elevated O
serum B-GENE
lipase I-GENE
and O
serum O
CA B-GENE
19-9 I-GENE
in O
Sjogren's O
syndrome O
without O
evidence O
of O
malignancy O
may O
reflect O
pancreatic O
involvement O
in O
this O
disorder O
. O

These O
results O
confirming O
the O
high O
validity O
of O
NOM O
inhibiting O
test O
in O
the O
diagnosis O
of O
tumoural O
hyperprolactinemic O
states O
, O
reveal O
contradictory O
responses O
to O
CD O
LD O
, O
LD O
and O
DOM O
, O
with O
sustain O
the O
existence O
of O
2 O
sub-group O
of O
Prolactinomas O
: O
with O
or O
without O
a O
maintained O
DA O
central O
tonus O
supporting O
the O
possibility O
of O
different O
etiopathogenetical O
factors O
in O
inducing O
a O
tumoural O
hyperprolactinemic O
states O
. O

Efficacy O
of O
first-generation O
Cavermap O
to O
verify O
location O
and O
function O
of O
cavernous O
nerves O
during O
radical O
prostatectomy O
: O
a O
multi-institutional O
evaluation O
by O
experienced O
surgeons O
. O

In O
order O
to O
characterize O
the O
functional O
elements O
of O
the O
promoter O
that O
in O
some O
way O
must O
respond O
to O
these O
regulatory O
signals O
, O
a O
number O
of O
promoter O
mutations O
were O
constructed O
, O
including O
a O
set O
of O
linker-scanning O
mutations O
across O
the O
entire O
promoter O
region O
. O

Skn-1a B-GENE
lacking O
the O
C-terminal O
region O
completely O
lost O
transactivation O
ability O
, O
irrespective O
of O
the O
promoter O
tested O
, O
and O
was O
able O
to O
block O
transactivation O
by O
normal O
Skn-1a B-GENE
in O
competition O
assays O
. O

Structural O
basis O
for O
activation O
of O
human B-GENE
lymphocyte I-GENE
kinase I-GENE
Lck B-GENE
upon O
tyrosine O
phosphorylation O
. O

Among O
them O
, O
26 O
cases O
were O
benign O
and O
34 O
malignant O
. O

Such O
transgenic O
plants O
should O
enable O
not O
only O
the O
mutational O
analysis O
of O
sequence O
elements O
within O
the O
replication O
origin O
region O
, O
but O
also O
the O
construction O
of O
a O
new O
generation O
of O
vectors O
for O
gene O
amplification O
in O
plants O
, O
based O
on O
a O
minimal O
virus O
replicon O
. O

Site-directed O
mutagenesis O
revealed O
that O
two O
clusters O
of O
basic O
amino O
acids O
within O
a O
conserved O
basic O
region O
and O
two O
amphipathic O
helices O
within O
the O
adjacent O
HLH B-GENE
domain I-GENE
are O
essential O
for O
sequence-specific O
DNA O
binding O
and O
hetero-oligomerization O
, O
respectively O
. O

OBJECTIVE O
: O
To O
determine O
the O
impact O
of O
the O
introduction O
of O
clarithromycin O
and O
azithromycin O
on O
the O
treatment O
and O
survival O
of O
patients O
with O
AIDS O
and O
disseminated O
Mycobacterium O
avium O
complex O
( O
DMAC O
) O
. O

At O
this O
stage O
, O
the O
eventual O
high O
mortality O
of O
acute O
ischemia O
is O
established O
whatever O
the O
urgency O
of O
the O
operation O
or O
the O
skill O
with O
which O
it O
is O
performed O
. O

The O
relation O
between O
VE O
VO2 O
and O
Q O
VO2 O
showed O
a O
significant O
negative O
correlation O
( O
r O
= O
-0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
01 O
) O
. O

Indoor O
concentrations O
were O
only O
weakly O
correlated O
with O
outdoor O
concentrations O
, O
however O
, O
and O
personal O
exposures O
were O
even O
more O
poorly O
correlated O
with O
outdoor O
concentrations O
. O

However O
, O
when O
a O
second O
, O
upstream B-GENE
IRE-like I-GENE
sequence I-GENE
was O
evaluated O
by O
EMSA O
, O
a O
DNA O
binding O
pattern O
distinct O
from O
that O
seen O
following O
exposure O
to O
IFN-gamma B-GENE
alone O
was O
observed O
after O
prolonged O
stimulation O
with O
both O
IFN-alpha B-GENE
and O
IFN-gamma B-GENE
. O

Growth B-GENE
factor I-GENE
allows O
effective O
dose-intensive O
regimen O
in O
advanced O
breast O
cancer O
patients O
. O

Clone O
4c O
( O
2681 O
bp O
) O
had O
a O
coding O
region O
identical O
to O
that O
of O
clone O
22c O
but O
it O
included O
a O
putative O
intron O
of O
959 O
bp O
. O

These O
results O
indicate O
that O
an O
internal O
short O
element O
located O
at O
the O
very O
5' O
terminal O
of O
L1 B-GENE
sequence I-GENE
and O
the O
nuclear O
factor O
binding O
to O
the O
element O
play O
a O
crucial O
role O
in O
the O
transcription O
of O
human B-GENE
L1 O
. O

E47 B-GENE
protein I-GENE
levels O
remain O
high O
until O
the O
double O
positive O
developmental O
stage O
, O
at O
which O
point O
they O
drop O
to O
relatively O
moderate O
levels O
, O
and O
are O
further O
downregulated O
upon O
transition O
to O
the O
single O
positive O
stage O
. O

Laboratory O
aspects O
with O
particular O
reference O
to O
chemotherapy O
and O
control O
. O

The O
transcriptional O
unit O
spans O
a O
chromosomal O
region O
of O
about O
55 O
kilobase O
pairs O
( O
kbp O
) O
. O

The O
plant O
protein O
maintains O
all O
the O
functional O
domains O
found O
in O
the O
other O
proteins O
, O
including O
nuclear O
localization O
signal O
, O
DNA-binding O
domain O
and O
helicase B-GENE
motifs I-GENE
, O
suggesting O
that O
it O
might O
also O
act O
as O
part O
of O
the O
RNA O
transcription O
apparatus O
, O
as O
well O
as O
nucleotide O
excision O
repair O
in O
plant O
cells O
. O

SELECTION O
CRITERIA O
: O
All O
controlled O
trials O
where O
adults O
with O
schizophrenia O
or O
similar O
illnesses O
were O
randomised O
to O
quetiapine O
, O
placebo O
or O
other O
neuroleptic O
drugs O
and O
where O
clinically O
relevant O
outcomes O
were O
reported O
. O

Transcriptional O
control O
signals O
of O
a O
herpes B-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
late I-GENE
( I-GENE
gamma I-GENE
2 I-GENE
) I-GENE
gene I-GENE
lie O
within O
bases O
-34 O
to O
+124 O
relative O
to O
the O
5' O
terminus O
of O
the O
mRNA O
. O

Although O
it O
has O
been O
shown O
that O
it O
is O
possible O
to O
use O
orally O
administered O
testosterone O
to O
maintain O
se-T O
levels O
in O
the O
normal O
male O
range O
, O
the O
convenience O
to O
the O
patient O
must O
be O
balanced O
against O
the O
cost O
and O
possible O
side O
effects O
of O
the O
large O
doses O
required O
. O

The O
congenital O
forms O
( O
7 O
cases O
) O
all O
occurred O
in O
female O
infants O
and O
involved O
the O
mucosa O
overlying O
either O
the O
anterior O
ridge O
of O
the O
maxilla O
or O
the O
mandible O
. O

The O
recovery O
value O
of O
systolic O
pressure O
was O
higher O
than O
diastolic O
pressure O
and O
pulse O
pressure O
increased O
. O

Human O
T-cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
encodes O
a O
40-kDa O
nuclear O
protein O
, O
Tax B-GENE
, O
which O
stimulates O
transcription O
from O
three O
21-base O
pair O
( O
bp O
) O
repeats O
in O
its O
U3 B-GENE
region I-GENE
. O

The O
effect O
of O
ligustrazine O
hydrochloride O
( O
LTH O
) O
on O
depressing O
pulmonary O
artery O
hypertension O
has O
been O
proved O
in O
recent O
studies O
. O

Band-shift O
assays O
were O
performed O
using O
the O
LPS-and B-GENE
IL-1-responsive I-GENE
element I-GENE
( O
LILRE B-GENE
) O
oligonucleotide O
, O
a O
gamma B-GENE
interferon I-GENE
activation I-GENE
site-like I-GENE
site I-GENE
that O
is O
present O
in O
the O
human B-GENE
IL-1beta I-GENE
promoter I-GENE
. O

Here O
we O
suggest O
that O
uvrA B-GENE
and O
the O
nucleotide O
excision O
repair O
pathway O
are O
involved O
in O
the O
repair O
of O
acid-induced O
DNA O
damage O
and O
are O
associated O
with O
successful O
adaptation O
of O
S O
. O
mutans O
to O
low O
pH O
. O

A O
protein O
footprint O
also O
was O
identified O
for O
a O
GC O
box O
element O
at O
nucleotides O
-59 O
to O
-45 O
. O

Thus O
, O
we O
have O
identified O
a O
GRE B-GENE
sufficient O
to O
account O
for O
full O
glucocorticoid O
inducibility O
and O
an O
HNF-1 B-GENE
site I-GENE
close O
to O
the O
promoter O
that O
are O
major O
determinants O
of O
transcriptional O
control O
of O
the O
Xenopus B-GENE
fibrinogen I-GENE
B I-GENE
beta I-GENE
subunit I-GENE
gene I-GENE
in O
cells O
from O
normal O
liver O
tissue O
. O

Here O
we O
present O
genetic O
evidence O
suggesting O
that O
PP2A B-GENE
functions O
downstream O
of O
Ras1 B-GENE
in O
the O
Sevenless B-GENE
receptor B-GENE
tyrosine I-GENE
kinase I-GENE
( O
RTK B-GENE
) O
signal O
transduction O
pathway O
that O
specifies O
R7 O
photoreceptor O
cell O
fate O
in O
the O
developing O
Drosophila O
eye O
. O

CONCLUSION O
: O
In O
our O
animal O
model O
, O
blood-brain O
barrier O
disruption O
was O
a O
reproducible O
, O
integral O
finding O
of O
single-fraction O
, O
high-dose O
irradiation O
injury O
. O

Three O
radiologists O
without O
knowledge O
of O
patients' O
data O
and O
treatment O
analyzed O
30 O
angiograms O
with O
and O
30 O
examinations O
without O
PGF O
. O

Mean O
Hg O
concentrations O
in O
the O
livers O
of O
mice O
at O
some O
sites O
in O
Isle O
Royale O
are O
not O
significantly O
lower O
( O
P O
= O
0 O
. O
62 O
) O
than O
Hg O
concentrations O
considered O
by O
some O
government O
agencies O
to O
be O
unhealthy O
for O
human O
consumption O
. O

axl O
, O
a O
transforming O
gene O
isolated O
from O
primary O
human O
myeloid O
leukemia O
cells O
, O
encodes O
a O
novel O
receptor B-GENE
tyrosine I-GENE
kinase I-GENE
. O

In O
E O
. O
coli O
, O
CheW B-GENE
mediates O
the O
physical O
coupling O
of O
the O
receptors O
to O
the O
kinase B-GENE
CheA B-GENE
. O

We O
argue O
that O
this O
is O
the O
general O
property O
of O
QSAR O
models O
developed O
using O
LOO O
cross-validation O
. O

Expression O
in O
established O
LCLs O
, O
occurring O
irrespective O
of O
virus O
producer O
status O
, O
was O
not O
a O
consequence O
of O
continued O
in O
vitro O
passage O
; O
thus O
, O
appropriately O
spliced O
BamHI-A B-GENE
transcripts I-GENE
could O
be O
amplified O
from O
normal O
B O
cells O
within O
1 O
day O
of O
their O
experimental O
infection O
in O
vitro O
, O
along O
with O
BamHI-C B-GENE
W I-GENE
promoter-initiated I-GENE
but O
not O
BamHI-F O
promoter-initiated B-GENE
mRNAs I-GENE
. I-GENE

The O
equivalent O
of O
the O
third O
ligand O
, O
H-87 B-GENE
, O
is O
T-47 O
in O
the O
PSTAIRE B-GENE
sequence I-GENE
motif I-GENE
. O

In O
all O
eight O
cases O
, O
neither O
FL O
nor O
DLL O
cells O
showed O
alterations O
of O
bcl-2 B-GENE
gene I-GENE
sequences I-GENE
in O
the O
breakpoint O
region O
, O
suggesting O
high O
conservation O
of O
the O
bcl-2 B-GENE
gene I-GENE
during O
both O
t O
( O
14 O
; O
18 O
) O
translocation O
and O
morphologic O
transformation O
of O
the O
FL O
cells O
. O

The O
transcriptional O
activity O
of O
PPARgamma B-GENE
is O
positively O
modulated O
by O
ligand O
binding O
and O
negatively O
regulated O
by O
phosphorylation O
mediated O
by O
the O
MEK B-GENE
ERK I-GENE
signaling I-GENE
pathway I-GENE
. I-GENE

Furthermore O
, O
the O
insertion O
of O
the O
ColE1 B-GENE
cer I-GENE
site I-GENE
into O
the O
RK2 O
plasmid O
deleted O
for O
the O
par O
region O
failed O
to O
stabilize O
the O
plasmid O
in O
the O
MC1061K O
strain O
, O
indicating O
that O
the O
multimer O
resolution O
activity O
encoded O
by O
parCBA B-GENE
is O
not O
by O
itself O
responsible O
for O
the O
stabilization O
activity O
observed O
for O
this O
operon O
. O

19F O
NMR O
studies O
in O
ABF4-type O
layered O
antiferromagnets O
. O

No O
local O
destruction O
by O
tumor O
or O
infection O
could O
be O
demonstrated O
apart O
from O
HIV O
infection O
. O

We O
have O
identified O
three O
binding O
sites O
for O
protein O
complexes O
: O
a O
palindrome O
, O
a O
direct O
repeat O
, O
and O
a O
C+T O
sequence O
that O
corresponds O
to O
seven O
GAGA B-GENE
motifs I-GENE
on O
the O
transcribed O
strand O
. O

These O
results O
indicate O
that O
the O
sulfhydryl O
group O
of O
certain O
angiotensin B-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
can O
potentiate O
their O
effect O
on O
the O
endogenous O
nitrovasodilator O
EDRF B-GENE
. O

Selenium O
, O
as O
a O
constituent O
of O
glutathione B-GENE
peroxidase I-GENE
, O
plays O
a O
role O
in O
the O
antioxidant O
defense O
systems O
of O
the O
body O
, O
but O
other O
metabolic O
roles O
for O
selenium O
may O
yet O
be O
discovered O
. O

Since O
the O
UfAP B-GENE
and O
UTMP B-GENE
share O
many O
biosynthetic O
and O
structural O
features O
that O
include O
site O
of O
biosynthesis O
in O
the O
endometrium O
, O
P4-responsiveness O
, O
the O
presence O
of O
the O
mannose O
6-phosphate O
lysosomal O
recognition O
marker O
, O
and O
considerable O
sequence O
similarity O
, O
the O
UfAP B-GENE
and O
the O
UTMP B-GENE
may O
have O
homologous O
function O
which O
for O
both O
still O
remains O
obscure O
. O

HVH2 B-GENE
mRNA I-GENE
showed O
an O
expression O
pattern O
distinct O
from O
CL100 B-GENE
( O
human B-GENE
homologue I-GENE
of I-GENE
mouse I-GENE
MKP1 I-GENE
) O
and O
PAC1 B-GENE
, O
two O
previously O
identified O
MAP B-GENE
kinase I-GENE
phosphatases I-GENE
. O

In O
ciliates O
, O
both O
mechanisms O
are O
readily O
observed O
. O

We O
have O
studied O
the O
biokinetics O
of O
BLM O
labeled O
with O
indium-111 O
( O
In-111 O
) O
. O

Exon O
A O
is O
located O
approximately O
7 O
kb O
5' O
to O
the O
HSL B-GENE
translation I-GENE
start I-GENE
site I-GENE
. O

In O
contrast O
, O
transiently O
transfected O
cells O
expressing O
EBNA-3 B-GENE
revealed O
a O
sixfold O
increase O
in O
EBNA-3 B-GENE
protein I-GENE
expression O
from O
the O
genomic O
EBNA-3 B-GENE
gene I-GENE
compared O
to O
EBNA-3 B-GENE
cDNA I-GENE
. O

SETTING O
: O
A O
division O
of O
a O
large O
tea O
plantation O
in O
Kandy O
. O

Imaging O
features O
of O
splenic O
epidermoid O
cyst O
with O
pathologic O
correlation O
. O

One O
of O
these O
genes O
, O
REC114 B-GENE
, O
is O
described O
here O
, O
and O
the O
data O
confirm O
that O
REC114 B-GENE
is O
a O
meiosis-specific O
recombination O
gene O
with O
no O
detectable O
function O
in O
mitosis O
. O

2 O
) O
The O
time-sharing O
principle O
was O
applied O
to O
gain O
high O
stability O
. O

The O
corresponding O
genotype O
was O
determined O
with O
a O
restriction O
enzyme-based O
assay O
. O

In O
patients O
with O
limited O
disease O
, O
the O
survival O
in O
the O
alternating O
arm O
was O
significantly O
superior O
to O
the O
survival O
in O
the O
CAV O
arm O
( O
P O
= O
. O
014 O
) O
or O
the O
survival O
in O
the O
PE O
arm O
( O
P O
= O
. O
023 O
) O
. O

Analysis O
of O
disassociation O
rates O
indicates O
that O
the O
Grf10-Swi5-DNA B-GENE
complex I-GENE
has O
a O
longer O
half-life O
than O
protein-DNA O
complexes O
that O
contain O
only O
Swi5 B-GENE
or O
Grf10 B-GENE
. O

Constructs O
were O
made O
in O
which O
an O
AATAAA O
and O
the O
GT-rich O
region O
were O
separated O
by O
various O
distances O
ranging O
from O
7 O
to O
43 O
bp O
. O

The O
prevalence O
of O
hepatitis B-GENE
B I-GENE
surface I-GENE
antigen I-GENE
( O
HBsAg B-GENE
) O
and O
anti-HBs B-GENE
was O
determined O
by O
a O
sensitive O
double-antibody O
radio-immunoassay O
technique O
in O
a O
series O
of O
patients O
with O
chronic O
liver O
diseases O
. O

GCD10 B-GENE
binds O
RNA O
in O
vitro O
and O
we O
present O
strong O
biochemical O
evidence O
that O
it O
is O
identical O
to O
the O
RNA-binding O
subunit O
of O
yeast B-GENE
initiation I-GENE
factor-3 I-GENE
( O
eIF-3 B-GENE
) O
. O
eIF-3 B-GENE
is O
a O
multisubunit O
complex O
that O
stimulates O
translation O
initiation O
in O
vitro O
at O
several O
different O
steps O
. O

Based O
on O
these O
results O
the O
minimal O
control O
element O
( O
AX B-GENE
470 I-GENE
) O
specifying O
the O
anterior O
boundary O
of O
Hox B-GENE
expression O
was O
designated O
as O
Hoxa-7 B-GENE
enhancer I-GENE
. O

There O
have O
been O
five O
problems O
( O
extravasation O
2 O
, O
suspected O
sepsis O
1 O
, O
and O
hematoma O
2 O
) O
during O
a O
total O
of O
2 O
, O
927 O
days O
of O
exposure O
. O

Plasma O
lipid O
and O
lipoprotein O
profiles O
were O
compared O
in O
elderly O
female O
runners O
( O
RU O
: O
n O
= O
15 O
, O
aged O
66 O
+ O
- O
5 O
years O
, O
body O
fat O
20 O
+ O
- O
4% O
, O
training O
distance O
35 O
+ O
- O
15 O
km O
week-1 O
, O
VO2max O
36 O
+ O
- O
4 O
ml O
kg-1 O
min-1 O
, O
mean O
+ O
- O
SD O
) O
and O
age-matched O
untrained O
women O
( O
UT O
: O
n O
= O
28 O
, O
66 O
+ O
- O
4 O
years O
, O
body O
fat O
26 O
+ O
- O
6% O
, O
VO2max O
26 O
+ O
- O
3 O
ml O
kg-1 O
min-1 O
) O
. O

Dementia O
is O
being O
avoided O
in O
NHS O
and O
social O
care O
. O

The O
cDNA O
has O
an O
open O
reading O
frame O
of O
900 O
amino O
acids O
capable O
of O
encoding O
a O
97-kDa O
protein O
. O

Two O
independent O
transgenic O
lines O
were O
produced O
, O
and O
both O
showed O
expression O
of O
the O
Gus B-GENE
gene I-GENE
specifically O
in O
the O
endosperm O
during O
mid-development O
( O
first O
detected O
10-12 O
d O
after O
anthesis O
) O
. O

The O
second O
complex O
, O
when O
purified O
, O
contained O
four O
protein O
components O
including O
the O
36-kDa O
protein O
. O

Histopathologic O
observations O
showed O
that O
both O
somatostatin B-GENE
and O
triamcinolone O
acetonide O
reduced O
the O
inflammatory O
signs O
in O
the O
joint O
structures O
, O
although O
triamcinolone O
acetonide O
appeared O
to O
be O
more O
effective O
. O

Induction O
in O
AP-1 B-GENE
DNA O
binding O
correlates O
with O
a O
concomitant O
GH B-GENE
trans-activation O
of O
c-jun B-GENE
and O
c-fos B-GENE
genes I-GENE
described O
previously O
. O

HDL-cholesterol O
( O
+6% O
, O
P O
less O
than O
. O
01 O
) O
and O
apolipoprotein B-GENE
A-I I-GENE
( O
+6% O
, O
P O
less O
than O
. O
01 O
) O
concentrations O
increased O
significantly O
only O
in O
the O
young O
. O

We O
have O
generated O
a O
computer O
model O
of O
the O
C-terminal O
domain O
of O
the O
434 O
repressor O
based O
on O
the O
crystal O
structure O
of O
the O
homologous B-GENE
UmuD' I-GENE
protein I-GENE
. O

Activation O
of O
a O
CRE-dependent B-GENE
junB I-GENE
promoter I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( I-GENE
CAT O
) B-GENE
reporter O
gene O
by O
the O
BCR O
was B-GENE
also O
blocked O
by O
SB203580 O
. O

Oxygen O
delivery O
and O
consumption O
and O
P50 O
in O
patients O
with O
acute O
myocardial O
infarction O
. O

The O
tyrosine B-GENE
hydroxylase I-GENE
gene I-GENE
( O
TH B-GENE
) O
contains O
a O
single O
copy O
of O
a O
consensus O
CRE B-GENE
at O
-45 O
to O
-38 O
base O
pair O
( O
bp O
) O
upstream O
of O
the O
transcription O
initiation O
site O
. O

Adrenergic O
system O
activation O
, O
indicated O
by O
metanephrine O
epinephrine O
ratio O
, O
increased O
with O
time O
in O
losing O
males O
, O
except O
that O
after O
one O
month O
of O
cohabitation O
, O
turnover O
returned O
to O
levels O
that O
equaled O
those O
of O
control O
animals O
. O

In O
C O
. O
albicans O
, O
HST6 B-GENE
is O
expressed O
constitutively O
at O
high O
levels O
in O
the O
different O
cell O
types O
analysed O
( O
yeast O
, O
hyphae O
, O
white O
and O
opaque O
) O
, O
demonstrating O
that O
HST6 B-GENE
transcription O
is O
not O
repressed O
in O
this O
diploid O
yeast O
, O
unlike O
in O
diploid O
S O
. O
cerevisiae O
, O
and O
suggesting O
a O
basic O
biological O
function O
for O
the O
Hst6p B-GENE
transporter O
in O
C O
. O
albicans O
. O

Ketamine O
in O
the O
treatment O
of O
bronchospasm O
during O
mechanical O
ventilation O
. O

It O
is O
concluded O
that O
the O
plasma B-GENE
prolactin I-GENE
response O
to O
12 O
. O
5 O
micrograms O
i O
. O
v O
. O

But O
no O
influence O
was O
observed O
at O
lower O
concentrations O
than O
1 O
4 O
MIC O
of O
AMK O
. O

Three O
patients O
with O
four O
renoureteral O
units O
have O
undergone O
single-stage O
reconstruction O
involving O
ureteroureterostomy O
and O
ipsilateral O
ureteroneocystostomy O
following O
temporary O
loop O
cutaneous O
ureterostomy O
. O

Oxygen O
tension O
of O
the O
small O
lymph O
vessels O
( O
PLO2 O
) O
of O
the O
rabbit O
hind O
limb O
was O
measured O
with O
both O
a O
flow-through O
micro O
chamber O
and O
a O
polarographic O
catheter-tip O
oxygen O
electrode O
to O
obtain O
experimental O
data O
on O
the O
source O
of O
oxygen O
in O
the O
lymph O
. O

The O
smaller O
uptake O
rate O
and O
faster O
clearance O
rate O
resulted O
in O
the O
lower O
BCF O
for O
SWA O
killifish O
. O

The O
second O
functional O
pair O
of O
CreA B-GENE
sites I-GENE
is O
located O
between O
the O
two O
transcription O
initiation O
sites O
. O

Six O
out O
of O
ten O
hearts O
from O
macerated O
stillborn O
infants O
showed O
varying O
degrees O
of O
positive O
staining O
. O

The O
proliferation-specific O
HNF-3 B-GENE
fork I-GENE
head I-GENE
homolog-11B I-GENE
protein I-GENE
( I-GENE
HFH-11B O
; B-GENE
also O
known O
as O
Trident O
and B-GENE
Win O
) B-GENE
is O
a O
family O
member O
of O
the O
winged O
helix B-GENE
fork I-GENE
head I-GENE
transcription I-GENE
factors I-GENE
and I-GENE
in I-GENE
regenerating O
liver O
its O
expression O
is O
reactivated O
prior O
to O
hepatocyte O
entry O
into O
DNA O
replication O
( O
S O
phase O
) O
. O

In O
vitro O
transcription O
results O
indicate O
that O
this O
5' O
structure O
functions O
in O
the O
attenuation O
mechanism O
, O
since O
deletion O
of O
the O
stem-loop O
caused O
an O
increase O
in O
transcription O
readthrough O
. O

Northern O
blotting O
showed O
that O
MDMX B-GENE
, O
like O
MDM2 B-GENE
, O
is O
expressed O
in O
all O
tissues O
tested O
, O
and O
that O
several O
mRNAs O
for O
MDMX B-GENE
can O
be O
detected O
. O

The O
mean O
serum O
creatinine O
level O
did O
not O
change O
during O
the O
first O
6 O
months O
after O
withdrawal O
of O
MMF O
. O

Control O
subjects' O
evoked O
potentials O
( O
EPs O
) O
were O
characterized O
by O
an O
initial O
positivity O
in O
the O
90-140 O
ms O
range O
( O
P1 O
) O
at O
the O
temporo-occipital O
site O
. O

The O
diagnostic O
value O
of O
blood O
serum O
and O
urinary B-GENE
amylase I-GENE
, O
lipase B-GENE
, O
and O
trypsin B-GENE
in O
exacerbations O
of O
chronic O
relapsing O
pancreatitis O
is O
discussed O
. O

Gel O
filtration O
, O
sedimentation O
velocity O
, O
and O
immunoprecipitation O
experiments O
revealed O
that O
beta4 B-GENE
is O
a O
component O
of O
a O
multisubunit O
complex O
( O
AP-4 B-GENE
) O
that O
also O
contains O
the O
sigma4 B-GENE
polypeptide I-GENE
and O
two O
additional O
adaptor O
subunit O
homologs O
named O
mu4 B-GENE
( O
mu-ARP2 B-GENE
) O
and O
epsilon B-GENE
. O

Hexsyn O
is O
the O
Goodyear O
Tire O
and O
Rubber O
Company O
tradename O
for O
a O
polyolefin O
rubber O
synthesized O
from O
1-hexene O
with O
3-5% O
methylhexadiene O
as O
the O
source O
of O
residual O
double O
bonds O
for O
vulcanization O
. O

The O
recessive O
hos1 B-GENE
mutation O
causes O
enhanced O
induction O
of O
the O
CBF B-GENE
transcription I-GENE
factors I-GENE
by O
low O
temperature O
as O
well O
as O
of O
their O
downstream O
cold-responsive O
genes O
. O

This O
mutant O
was O
identified O
by O
screening O
with O
a O
TGF-beta-inducible O
vector O
a O
series O
of O
mink O
lung O
epithelial O
cell O
clones O
that O
have O
normal O
TGF-beta B-GENE
binding O
activity O
but O
have O
lost O
antiproliferative O
and O
transcriptional O
responses O
to O
TGF-beta B-GENE
. O

Regulation O
of O
ASN1 B-GENE
and O
ASN2 B-GENE
expression O
was O
studied O
using O
lacZ B-GENE
fusions I-GENE
and O
both O
genes O
were O
found O
to O
be O
several O
times O
less O
expressed O
in O
the O
absence O
of O
the O
transcription O
activator O
Gcn4p B-GENE
. O

GlcNAc- O
and O
GlcNAc2-PP-Dolichol B-GENE
biosynthesis O
could O
be O
shown O
with O
isolated O
S O
. O
cerevisiae O
membranes O
from O
cells O
harboring O
the O
recombinant O
plasmid O
and O
grown O
on O
glucose O
thus O
suppressing O
transcription O
of O
the O
endogenous O
gene O
. O

The O
predicted O
domain O
structures O
of O
FkbB B-GENE
and O
FkbC B-GENE
are O
analogous O
to O
that O
of O
FkbA B-GENE
and O
comprise O
30 O
fatty-acid-synthase B-GENE
( I-GENE
FAS I-GENE
) I-GENE
-like I-GENE
domains I-GENE
arranged O
in O
6 O
modules O
. O

The O
observation O
that O
beta B-GENE
2m I-GENE
with O
covalently O
attached O
peptide O
can O
effectively O
create O
CTL O
target O
structures O
in O
vitro O
offers O
new O
possibilities O
for O
the O
in O
vivo O
induction O
of O
epitope-specific O
CTL O
responses O
by O
either O
DNA O
immunization O
or O
injection O
of O
the O
purified O
epitope-linked O
beta B-GENE
2m O
. O

The O
mechanistic O
implications O
of O
aromatic O
non-responsiveness O
of O
autonomously O
expressed O
A-domain O
, O
despite O
its O
demonstrated O
ability O
to O
bind O
phenol O
, O
are O
discussed O
. O

No O
systematic O
L-R O
differences O
were O
observed O
. O

Computerized O
detection O
of O
abnormal O
asymmetry O
in O
digital O
chest O
radiographs O
. O

When O
pollen O
allergen O
from O
three O
grass O
species O
were O
used O
, O
The O
RAST-test O
results O
did O
not O
differ O
from O
duplicate O
values O
either O
. O

In O
1990 O
, O
an O
International O
Commission O
for O
the O
Certification O
of O
Eradication O
of O
Poliomyelitis O
Eradication O
( O
ICCPE O
) O
was O
established O
by O
the O
Pan O
American O
Health O
Organization O
to O
eventually O
determine O
if O
transmission O
was O
interrupted O
. O

New O
diagnostic O
strategies O
for O
lupus O
anticoagulants O
and O
antiphospholipid B-GENE
antibodies I-GENE
. O

A O
genetic O
and O
molecular O
analysis O
of O
non-inducible O
qutA B-GENE
mutants I-GENE
showed O
that O
all O
23 O
mutations O
analysed O
map O
within O
the O
N-terminal O
half O
of O
the O
encoded O
QUTA B-GENE
protein I-GENE
. O

To O
the O
best O
of O
our O
knowledge O
, O
SNTCS O
is O
highly O
malignant O
. O

Motile O
nocardoid O
Actinomycetales O
. O

Our O
data O
complement O
other O
studies O
of O
circumpolar O
populations O
and O
reinforce O
the O
reported O
high O
prevalences O
of O
SPA O
and O
HLA-B27 B-GENE
among O
those O
populations O
. O

Here O
, O
we O
report O
that O
a O
transfected O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cell O
line O
expressing O
a O
murine B-GENE
CD4 I-GENE
fragment I-GENE
containing O
the O
first O
two O
N-terminal O
domains O
secretes O
both O
monomeric O
molecules O
and O
disulfide-linked O
multimers O
. O

